TW202528335A - Capsid polypeptides and methods of use thereof - Google Patents

Abstract

The disclosure is directed in part to dependoparvovirus capsid polypeptides that can be used to deliver payloads.

Description

Capsid polypeptides and methods of use thereof (I)

Cross-reference to related applications

This application claims priority to U.S. Provisional Application No. 63/535,716, filed on August 31, 2023, the contents of which are incorporated herein by reference in their entirety.

Sequence Listing

This application contains a sequence listing, which has been submitted electronically in XML format and is incorporated herein by reference in its entirety. The XML sequence listing, created on August 29, 2024, is named DYN-002WO_SL.xml and is 853,159 bytes in size.

Dependoparvoviruses, such as adeno-associated dependoparvoviruses (AAV), have attracted attention as vectors for delivering various payloads into cells, including cells in humans.

This disclosure relates, in part, to improved dependency parvovirus coat polypeptides, such as VP1, VP2, and/or VP3 coat polypeptides; methods for producing dependency parvoviruses comprising the coat polypeptides; compositions for use therewith; and viral particles produced therefrom. In certain aspects, this disclosure relates to viral particles comprising the improved dependency parvovirus coat polypeptides that exhibit increased central nervous system (CNS) biodistribution and/or transduction compared to, for example, viral particles lacking mutations in the modified dependency parvovirus coat polypeptides. In certain aspects, the present disclosure relates to viral particles comprising a modified parvovirus capsid polypeptide that exhibit increased skeletal muscle biodistribution and/or transduction compared to, for example, a non-modified parvovirus capsid polypeptide.

Thus, provided herein are the capsid polypeptides described herein. Typically, the capsid polypeptides herein comprise two or three mutations at positions corresponding to Q592, T593, and G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. In some embodiments, the capsid polypeptides herein comprise two or three mutations selected from the following: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine or alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1 and serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. Optionally, the capsid polypeptide may comprise methionine, threonine, or glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1 and alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. Optionally, the capsid polypeptide may comprise methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1 and methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Optionally, the capsid polypeptide may comprise serine, alanine, threonine, or glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1 and methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Optionally, the capsid polypeptide may comprise valine or glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise an alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1 and a methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Optionally, the capsid polypeptide may comprise a valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1.

Exemplary VP1 capsid polypeptides herein comprise the amino acid sequences set forth in SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, the capsid polypeptide comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VP1 polypeptide of any one of SEQ ID NO: 12 to SEQ ID NO: 158, or the VP2 or VP3 portion thereof.

Other exemplary capsid polypeptides are disclosed in Section 6.2 and in numbered Examples 1-986.

Further provided herein is a nucleic acid comprising a nucleotide sequence encoding a capsid polypeptide provided herein (e.g., a capsid polypeptide disclosed in Section 6.2 or any of Numbered Examples 1 to 986). In some embodiments, the nucleic acid molecule comprises a nucleotide sequence of any one of SEQ ID NO: 159 to SEQ ID NO: 305, a fragment thereof (e.g., a fragment thereof encoding a VP2 or VP3 polypeptide), or a variant thereof having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some embodiments, the percent sequence identity is calculated excluding any nucleotide sequence encoding an insertion of a targeting peptide sequence. In some embodiments, the percent sequence identity is calculated including any nucleotide sequence encoding an insertion of a targeting peptide sequence. In some embodiments, the nucleic acid is a vector, such as a plasmid. Exemplary nucleic acids are disclosed in Section 6.2 and in Examples 987 to 1006.

Further provided herein are dependency parvovirus particles comprising a capsid polypeptide (e.g., a capsid polypeptide disclosed in Section 6.2 or any of Examples 1 to 986) and/or a nucleic acid described herein (e.g., a nucleic acid disclosed in Section 6.2 or any of Examples 987 to 1006, or a nucleic acid comprising a transgene/payload disclosed in Section 6.6.1). In some embodiments, the dependency parvovirus is an adeno-associated dependency parvovirus (AAV). In some embodiments, the AAV is AAV9, e.g., a variant AAV9. Exemplary viral particles are disclosed in Section 6.3 and Examples 1007 to 1165. In some embodiments, the viral particles have one or more of the features disclosed in Section 6.4 and Examples 1018 to 1165.

In some embodiments, this disclosure is directed, in part, to a cell, cell-free system, or other translation system comprising a nucleic acid or vector described herein, e.g., comprising a sequence encoding a capsid polypeptide having one or more mutations described herein (e.g., a capsid polypeptide disclosed in Section 6.2 or any one of numbered Examples 1-986). In some embodiments, the cell, cell-free system, or other translation system comprises a dependent microviral particle described herein, e.g., wherein the particle comprises a nucleic acid comprising a sequence encoding a capsid polypeptide (e.g., a capsid polypeptide disclosed in Section 6.2 or any of Examples 1 to 986) and/or a nucleic acid described herein, e.g., a nucleic acid disclosed in Section 6.2 or any of Examples 987 to 1006, or a nucleic acid comprising a transgene disclosed in Section 6.6.1. Exemplary cell, cell-free, and other translation systems and their use for producing dependent microviral particles are disclosed in Section 6.5 and Example 1166.

Further provided herein are methods for using the dependency-dependent microviruses disclosed herein, for example, to deliver a payload to cells or to treat a disease or condition in a subject. These methods generally comprise contacting a cell with a dependency-dependent microvirus particle described herein or administering to a subject an amount effective to treat the disease or condition. Exemplary methods are disclosed in Section 6.6 and Examples 1167 to 2685 and 2687 to 2688. The dependency-dependent microviral particles can be in the form of a composition, such as a pharmaceutical composition comprising the dependency-dependent microviral particles and a pharmaceutically acceptable carrier or excipient, such as the pharmaceutical compositions described in Section 6.6.2 and Example 2686.

Other features, advantages, and applications of the capsid polypeptides, nucleic acids, and dependent parvoviral particles described herein, as well as methods for producing and using the same, are described in more detail below.

6.1. Definition

Unless otherwise defined herein, scientific and technical terms used in connection with this document shall have the meanings commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein may be used to practice or test the present invention, exemplary methods and materials are described below. In the event of conflict, the present specification (including definitions) will control. Generally, nomenclature used in connection with and techniques of cell and tissue culture, molecular biology, immunology, microbiology, genetics, analytical chemistry, synthetic organic chemistry, medicine and pharmaceutical chemistry, and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. Enzymatic reactions and purification techniques are performed according to the manufacturer's instructions as commonly accomplished in the art or as described herein. Furthermore, unless the context requires otherwise, singular terms shall include the plural and plural terms shall include the singular. Throughout the specification and examples, the words "have" and "comprise" or variations such as "has," "having," "comprises," or "comprising" shall be understood to imply the inclusion of the stated integer or group of integers but not the exclusion of any other integer or group of integers. All publications and other references mentioned herein are incorporated herein by reference in their entirety. Although various documents are cited herein, such citation does not constitute an admission that any of these documents form part of the general knowledge in the art.

A , an , the : As used herein, the singular forms "a,""an," and "the" include plural referents unless the context clearly dictates otherwise.

About , Approximately : As used herein, the terms " about" and "approximately" generally mean an acceptable degree of error in the measured quantity, given the nature or precision of the measurement. An exemplary degree of error is within 15 percent (%) of a given value or range of values, typically within 10%, and more typically within 5%. Any disclosure herein preceded by the term "about" or "approximately" also discloses the value itself. For example, a disclosure of "about 10 μg/ml" discloses the value "10 μg/ml."

CNS : As used herein, "CNS" means one or more regions of the central nervous system. In embodiments, the CNS includes one or more of the following: the brain and the spinal cord.

Corresponds to : As used herein, the term "corresponds to," as used with respect to a position in a sequence (e.g., an amino acid or nucleic acid sequence), can be used with respect to an entire capsid polypeptide or polynucleotide sequence (e.g., the full-length sequence of a capsid polypeptide comprising VP1, VP2, and VP3 polypeptides, or a nucleic acid molecule encoding the same). In some embodiments, the term "corresponds to" can be used with respect to a region or domain of a capsid polypeptide. For example, a position that corresponds to a position in the VP1 portion of a reference capsid polypeptide can correspond to the VP1 portion of a variant capsid polypeptide. Thus, when aligning two sequences to determine whether a position corresponds to another position, the full-length polypeptide can be used, or a domain (region) can be used to determine whether a position corresponds to a particular position. In some embodiments, the region is the VP1 polypeptide. In some embodiments, the region is the VP2 polypeptide. In some embodiments, the region is the VP3 polypeptide. In some embodiments, when the reference polypeptide is a wild-type sequence (e.g., full-length or region) of an AAV of a certain serotype, the variant polypeptide may be of the same serotype, having a mutation at the corresponding position compared to the reference sequence (e.g., full-length or region). In some embodiments, the variant capsid polypeptide is of a different serotype than the reference sequence.

Dependency Virus Capsid : As used herein, the term "dependency virus capsid" refers to an assembled viral capsid comprising a dependency virus polypeptide. In some embodiments, the dependency virus capsid is a functional dependency virus capsid, e.g., fully folded and/or assembled, capable of infecting a target cell, or remains stable (e.g., folded/assembled and/or capable of infecting a target cell) for at least a temporary period of time.

Dependency Viral Particles : As used herein, the term "dependency viral particle" refers to an assembled viral capsid comprising a dependency viral polypeptide and encapsulated nucleic acid (e.g., comprising one or more components of a payload, a dependency viral genome (e.g., the entire dependency viral genome), or both). In some embodiments, the dependency viral particle is a functional dependency viral particle, e.g., comprising a desired payload, that is fully folded and/or assembled, capable of infecting a target cell, or that remains stable (e.g., folded/assembled and/or capable of infecting a target cell) for at least a temporary period of time.

Dependency parvovirus X particles / capsids : As used herein, the term "dependency parvovirus X particles/capsids" refers to dependency parvovirus particles/capsids that comprise at least one polypeptide, or a nucleic acid sequence encoding a polypeptide, derived from a naturally occurring species or serotype of dependency parvovirus X. For example, a dependency parvovirus B particle refers to a dependency parvovirus particle that comprises at least one polypeptide, or a nucleic acid sequence encoding a polypeptide, derived from a naturally occurring dependency parvovirus B sequence. As used in this context, derived from means having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence in question. Correspondingly, as used herein, an AAVX particle/capsid refers to an AAV particle/capsid that comprises at least one polypeptide or polypeptide-encoding nucleic acid sequence derived from a naturally occurring AAV serotype X. For example, an AAV9 particle refers to an AAV particle that comprises at least one polypeptide or polypeptide-encoding nucleic acid sequence derived from a naturally occurring AAV9 sequence. Sometimes, a parvovirus X capsid is referred to as "wild-type" or "wt" when it comprises a capsid polypeptide from a designated sequence identifier associated with the parvovirus X capsid. Thus, for example, the terms wild-type AAV9 capsid or wtAAV9 capsid (or simply wtAAV9) are used interchangeably and refer to a capsid comprising the capsid polypeptide of SEQ ID NO: 1 (e.g., the VP1 capsid and the VP2 and VP3 portions thereof of SEQ ID NO: 1).

Edit distance : Sequences disclosed herein can be described in terms of "edit distance." The minimum number of sequence edits (i.e., the addition, substitution, or deletion of a single amino acid (for amino acid sequences) or a single nucleotide (for nucleotide sequences)) that transforms one sequence into another is the edit distance between the two sequences. The term "edit distance" is often used interchangeably with the term "Levenshtein distance."

Exogenous : As used herein, the term "exogenous" refers to the presence in a situation (e.g., in a nucleic acid, polypeptide, or cell) of a feature, sequence, or component that does not naturally occur in that situation. For example, a nucleic acid sequence encoding a polypeptide can include exogenous codons as provided herein (e.g., a codon encoding an amino acid that does not naturally occur at that position (e.g., in a reference sequence)). The term exogenous is used in this manner to mean that the codon in question at that position does not naturally occur, e.g., is not present in AAV9, e.g., is not present in SEQ ID NO: 1. In some embodiments, the codon replaces an endogenous codon. In some embodiments, the exogenous codon is inserted into a nucleic acid sequence, e.g., relative to a reference sequence. Those skilled in the art will readily understand that a sequence (e.g., a codon) may be exogenous when provided in a particular sequence (e.g., one that does not naturally contain the codon at the site in question), but may not be exogenous in a second sequence (e.g., one that naturally contains the particular codon at the site in question).

Functional : As used herein with respect to a polypeptide component of an avian dependent parvoviral capsid (e.g., Cap (e.g., VP1, VP2, and/or VP3) or Rep), the term "functional" refers to a polypeptide that provides at least 50%, 60%, 70%, 80%, 90%, or 100% of the activity of the naturally occurring form of the polypeptide component (e.g., when present in a host cell). For example, a functional VP1 polypeptide can stably fold and assemble into an avian dependent parvoviral capsid (e.g., capable of encapsulation and/or secretion). As used herein with respect to dependent parvoviral capsids or particles, "functional" refers to capsids or particles that comprise one or more of the following production characteristics: contain the desired payload, are fully folded and/or assembled, are capable of infecting target cells, or remain stable (e.g., folded/assembled and/or capable of infecting target cells) for at least a threshold time.

Mutational difference : As used herein with respect to a polypeptide sequence, a single amino acid mutation (e.g., a substitution, insertion, or deletion) present in a subject polypeptide sequence relative to a reference polypeptide sequence. In various embodiments, the reference polypeptide sequence is a polypeptide of any one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, and SEQ ID NOs: 12-158, or a VP2 or VP3 portion thereof. In some embodiments, the reference polypeptide is a polypeptide of any one of SEQ ID NO: 1 and SEQ ID NOs: 12-158, or a VP2 or VP3 portion thereof. In a preferred embodiment, the reference polypeptide is a polypeptide of SEQ ID NO: 1. In various embodiments, the subject polypeptide is a polypeptide of any one of SEQ ID NOs: 12 to SEQ ID NOs: 158, or a VP2 or VP3 portion thereof.

Mutation set : As used herein, the term "mutation set" refers to a complete collection of single amino acid mutations (substitutions, deletions, and/or insertions) in a variant capsid polypeptide sequence (e.g., a polypeptide sequence of any one of SEQ ID NO: 12 to SEQ ID NO: 158, or the VP2 or VP3 portion thereof) relative to a reference sequence (e.g., a wild-type reference sequence). In some embodiments, the reference sequence is the wild-type AAV9 VP1 capsid polypeptide (SEQ ID NO: 1) or the VP2 or VP3 portion thereof. In some cases, a portion of a mutagen set (i.e., more than one single amino acid mutation) is collectively labeled, however, it should be understood that even when referred to in this manner, a mutagen set is a collection of single amino acid mutations. For example, the insertion of amino acids 1, 2, and 3 between amino acid N at position nn and amino acid W at position ww of the reference sequence can be labeled "Nnn_3aa_Www_123", and it should be understood that each of amino acids 1, 2, and 3 represents a separate single amino acid mutation within the mutation set. Mutation sets for certain variant capsid polypeptides described herein can be found, for example, in Table 1.

Nucleic Acid : As used herein, the term "nucleic acid" in its broadest sense refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via phosphodiester linkages. As will be apparent from the context, in some embodiments, " nucleic acid " refers to individual nucleic acid monomers (e.g., nucleotides and/or nucleosides); in some embodiments, " nucleic acid " refers to an oligonucleotide chain comprising individual nucleic acid monomers or a longer polynucleotide chain comprising many individual nucleic acid monomers. In some embodiments, a " nucleic acid " is or comprises RNA; in some embodiments, a "nucleic acid" is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is one or more nucleic acid analogs, comprises one or more nucleic acid analogs, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid is one or more modified synthetic or non-naturally occurring nucleotides, comprises one or more modified synthetic or non-naturally occurring nucleotides, or consists of one or more modified synthetic or non-naturally occurring nucleotides. In some embodiments, a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. For example, in some embodiments, a nucleic acid is one or more "peptide nucleic acids," comprises one or more "peptide nucleic acids," or consists of one or more "peptide nucleic acids," which are known in the art and have peptide bonds in their backbone rather than phosphodiester bonds and are considered within the scope of the present invention. Alternatively or additionally, in some embodiments, the nucleic acid has one or more phosphorothioate linkages and/or 5'-N-phosphoamidate linkages rather than phosphodiester linkages. In some embodiments, the nucleic acid has a nucleotide sequence that encodes a functional gene product (e.g., RNA or protein). In some embodiments, the nucleic acid is partially or completely single-stranded; in some embodiments, the nucleic acid is partially or completely double-stranded.

Or : Unless otherwise indicated, the conjunction "or" is intended to be used in its proper sense as a Boolean logical operator, encompassing both selections that are alternatives (A or B, where the selection of A is mutually exclusive with B) and selections that are conjunctive (A or B, where both A and B are selected). In some places herein, the term "and/or" is used for the same purpose, which should not be interpreted as implying that "or" is used with reference to mutually exclusive alternatives.

Percent Identity : Sequences disclosed herein may be described in terms of "percent identity" (% identity). To calculate the percent identity between two amino acid sequences or two nucleic acid sequences, the two sequences to be compared were aligned using the EMBOSS Needle pairwise alignment software tool (available at www.ebi.ac.uk/Tools/psa/emboss_needle/) based on the Needleman and Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48(3):443-53) using the following parameters: matrix: BLOSUM62 (for amino acid sequences) or DNAfull (for DNA sequences); gap opening: 10; gap extension: 0.5; terminal gap penalty: false; terminal gap opening: 10; and terminal gap extension: 0.5. Percent identity is determined by dividing the number of amino acid or nucleotide matches in the alignment by the length of the alignment and multiplying by 100. For example, if two amino acid sequences are aligned with 95 matching amino acids and an alignment length of 100 amino acids, then the two sequences are 95% identical.

When calculating percent identity between two capsid polypeptides, one or both of which contain one or more targeting peptide insertions, the percent identity can be determined without removing the targeting peptide insertion sequence from the capsid polypeptide sequence, or the percent identity can be determined after removing the targeting peptide insertion sequence from the capsid polypeptide sequence. For example, if a first capsid polypeptide has the same sequence as a second capsid polypeptide, except that the first capsid polypeptide has a 7-mer targeting peptide insertion, then when the percent identity is determined without removing the targeting peptide insertion sequence from the first capsid polypeptide sequence, the two capsid polypeptides have less than 100% sequence identity, while when the targeting peptide insertion sequence is removed from the first capsid polypeptide sequence before calculating the percent identity, the two capsid polypeptides have 100% sequence identity. Unless the context requires otherwise, references herein to percent identity of a capsid polypeptide without reference to a targeting peptide refer to the percent identity of the capsid polypeptide determined after removal of the targeting peptide insertion sequence, if any, present in both capsid polypeptides. References herein to percent identity calculated "taking into account the targeting peptide insertion" mean that the percent identity is calculated without removal of the targeting peptide insertion sequence, if any, present in both capsid polypeptides. References herein to percent identity calculated "without taking into account the targeting peptide insertion" mean that the percent identity is calculated after removal of the targeting polypeptide insertion sequence, if any, present in both capsid polypeptides.

PNS : As used herein, "PNS" means one or more regions of the peripheral nervous system excluding the CNS. In embodiments, the PNS includes the dorsal root ganglion. In embodiments, the PNS includes sensory neurons and motor neurons.

Polypeptides, Peptides, and Proteins : The terms "polypeptide,""peptide," and "protein" are used interchangeably herein to refer to amino acid polymers of any length. The polymers may be linear or branched chains, may contain modified amino acids, and may be interspersed with non-amino acids.

Targeting peptide : As used herein, "targeting peptide" refers to a peptide that is inserted into or linked to a capsid polypeptide to alter its tropism. Targeting peptides can be inserted into the AAV capsid sequence to enhance targeting to a desired cell type, tissue, or organ, for example, to enhance CNS targeting. Targeting peptides are typically 3 to 20 amino acids in length, for example, 3 to 12 amino acids, 5 to 12 amino acids, 5 to 10 amino acids, or 7 to 10 amino acids in length.

Treatment : As used herein, the term "treating a disease or condition" refers to treating a manifest disease or condition, e.g., where a subject already has one or more symptoms of the disease or condition, or treating a pre-manifest disease or condition, e.g., where a subject has been identified as having the disease or condition but has not yet developed one or more symptoms of the disease or condition. Pre-manifest conditions can be identified, for example, by genetic testing.

Variant : As used herein, "variant capsid polypeptide" refers to a polypeptide that differs from a reference sequence (e.g., SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11, preferably SEQ ID NO: 1, or a subunit thereof, such as the VP2 or VP3 portion thereof). A variant capsid polypeptide can, for example, comprise a mutation (e.g., a substitution, deletion, or insertion). In some embodiments, the variant is about or at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the reference sequence. As will be apparent to those skilled in the art, any capsid polypeptide, such as any of the capsid polypeptides disclosed herein, such as any of SEQ ID NO: 12 to SEQ ID NO: 158, is a variant capsid polypeptide with respect to another capsid polypeptide having a different amino acid sequence, such as another capsid polypeptide having a reference sequence as described above. Thus, the term "variant capsid polypeptide" herein means and is used interchangeably with "capsid polypeptide," and does not require any comparison to a specific reference sequence. In some embodiments, the reference sequence is a polypeptide comprising SEQ ID NO: 1. In some embodiments, the reference sequence comprises or consists of, for example, a VP1, VP2, or VP3 polypeptide of SEQ ID NO: 1. In some cases as used herein, the term "variant" refers to a viral particle comprising a variant capsid polypeptide, such as those described herein. 6.2. Capsid polypeptides and nucleic acids encoding the same

This disclosure is directed, in part, to a variant capsid polypeptide and a nucleic acid comprising a sequence encoding the variant capsid polypeptide, wherein the variant capsid polypeptide comprises a mutation (insertion, deletion, or substitution) compared to the wild-type sequence. In some embodiments, the wild-type sequence is SEQ ID NO: 1. This disclosure is directed, in part, to a variant capsid polypeptide comprising SEQ ID NO: 1 having one or more mutations compared to SEQ ID NO: 1, and a nucleic acid molecule encoding the variant capsid polypeptide. The mutation can be, for example, an insertion, deletion, or substitution compared to the wild-type sequence. In some embodiments, the wild-type sequence is SEQ ID NO: 1.

In some embodiments, the variant capsid polypeptide comprises a mutation at a position corresponding to a mutation present in any one of SEQ ID NO: 12 to SEQ ID NO: 158, as compared to SEQ ID NO: 1. VP1 capsid polypeptides comprising the amino acid sequence of SEQ ID NO: 12 to SEQ ID NO: 158 are referred to herein as variant 1 (V1) to variant 147 (V147), respectively. Mutations associated with V1 to V147 with respect to the VP1 polypeptide of SEQ ID NO: 1 are shown in Table 1 below. Table 1 : Mutation groups from V1 to V147 variants Mutation group compared with SEQ ID NO: 1 V1 [『H584A』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596I』] V2 [『Q579S』, 『H584T』, 『A587I』, 『Q592V』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V3 [『M559A』, 『H584L』, 『Q592V』, 『T593S』, 『G594M』, 『W595Q』, 『V596I』] V4 [『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』、『Q597N』、『G600S』] V5 [『S576P』、『Q579S』、『T582V』、『A587T』、『Q592V』、『T593S』、『G594M』、『W595S』、『V596N』、『N598S』] V6 [『T569V』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V7 [『Q579L』、『A581S』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596I』] V8 [『N562V』,『H584T』,『Q592V』,『T593S』,『G594M』,『W595I』,『V596I』,『N598A』] V9 [『G549K』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V10 [『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V11 [『M559A』, 『S576P』, 『Q592V』, 『T593S』, 『G594M』, 『W595T』, 『V596W』] V12 [『K557N』、『H584T』、『Q592V』、『T593S』、『G594M』、『W595K』、『V596I』] V13 [『S576M』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596Q』] V14 [『S576P』、『Q579Y』、『A587T』、『Q592V』、『T593S』、『G594M』、『W595S』、『V596L』、『N598S』] V15 [『M559C』, 『N583S』, 『H584T』, 『Q592V』, 『T593S』, 『G594M』, 『W595K』, 『V596I』] V16 [『M559I』, 『N583S』, 『H584T』, 『Q592V』, 『T593S』, 『G594M』, 『W595K』, 『V596I』] V17 [『A587T』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V18 [『G549N』, 『M559N』, 『T582V』, 『Q592V』, 『T593S』, 『G594M』, 『W595A』, 『V596I』] V19 [『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』、『I601V』] V20 [『A587N』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V21 [『A589V』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V22 [『N583S』, 『H584T』, 『Q588V』, 『A589T』, 『Q592V』, 『T593S』, 『G594M』, 『W595K』, 『V596I』] V23 [『R550V』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V24 [『T582V』, 『Q592V』, 『T593S』, 『G594M』, 『W595S』, 『V596G』, 『N598S』] V25 [『Q588N』、『A589T』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596W』] V26 [『R550G』,『H584L』,『Q592V』,『T593S』,『G594M』,『W595Q』,『V596W』] V27 [『A589T』、『Q592V』、『T593S』、『G594M』、『W595T』、『V596M』、『Q597L』] V28 [『A587P』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V29 [『G549H』,『N552D』,『V580C』,『H584N』,『Q592V』,『T593S』,『G594M』,『W595K』,『V596W』] V30 [『K557N』、『M559F』、『N583S』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596W』] V31 [『Q592V』、『T593A』、『G594M』、『W595Q』、『V596M』] V32 [『H584N』、『Q592V』、『T593S』、『G594M』、『W595T』、『V596M』、『Q599V』] V33 [『H584T』,『Q592V』,『T593S』,『G594M』,『W595T』,『V596M』] V34 [『Q579C』、『H584I』、『Q592V』、『T593S』、『G594M』、『W595K』、『V596W』] V35 [『H584T』,『Q592V』,『T593S』,『G594M』,『W595M』,『V596M』] V36 [『M559N』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V37 [『N552H』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V38 [『K557L』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V39 [『M559C』, 『Y577W』, 『H584L』, 『Q592V』, 『T593S』, 『G594M』, 『W595K』, 『V596L』] V40 [『A587T』, 『A589S』, 『Q592V』, 『T593S』, 『G594M』, 『W595Q』, 『V596M』] V41 [『R550K』、『S576P』、『Q592V』、『T593S』、『G594M』、『W595T』、『V596W』] V42 [『V553A』,『N562T』,『Q592V』,『T593S』,『G594M』,『W595Q』,『V596M』] V43 [『N583S』,『H584A』,『Q592V』,『T593S』,『G594M』,『W595M』,『V596I』] V44 [『Q592V』、『T593S』、『G594M』、『W595Q』、『V596N』、『Q599L』] V45 [『N583S』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596Q』、『Q599C』] V46 [『M559Y』, 『Y577W』, 『Q579N』, 『H584T』, 『Q592V』, 『T593S』, 『G594M』, 『W595M』, 『V596M』] V47 [『A589T』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596M』] V48 [『S576P』、『H584M』、『A587T』、『Q592V』、『T593S』、『G594M』、『W595S』、『V596L』、『N598S』] V49 [『H584F』、『Q592V』、『T593S』、『G594M』、『W595T』、『V596L』] V50 [『S576P』, 『H584A』, 『A587T』, 『Q592V』, 『T593S』, 『G594M』, 『W595S』, 『V596L』, 『N598S』] V51 [『Q592V』、『T593S』、『G594M』、『W595T』、『V596L』、『N598S』] V52 [『Q592V』、『T593S』、『G594M』、『W595Q』、『V596G』、『Q597T』] V53 [『R550G』、『S576P』、『Q592V』、『T593S』、『G594M』、『W595T』、『V596W』] V54 [『H584N』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596W』] V55 [『M559A』, 『N583S』, 『H584A』, 『Q592V』, 『T593S』, 『G594M』, 『W595Q』, 『V596I』, 『Q599C』] V56 [『K557N』、『M559V』、『N583S』、『Q592V』、『T593S』、『G594M』、『W595Q』、『V596W』] V57 [『R550G』,『H584N』,『Q592V』,『T593S』,『G594M』,『W595Q』,『V596W』] V58 [『H584M』、『Q592V』、『T593S』、『G594M』、『W595V』、『V596M』] V59 [『H584I』、『Q592V』、『T593S』、『G594M』、『W595T』、『Q599L』] V60 [『M559A』, 『N583S』, 『H584T』, 『Q592V』, 『T593S』, 『G594M』, 『W595F』] V61 [『Q579T, Q592V, T593S, G594M, W595Q, V596W, N598T, I601V』] V62 [『E563T』、『N583S』、『H584L』、『Q592V』、『T593S』、『G594M』、『W595K』] V63 [『T582V』, 『N583S』, 『A589N』, 『Q592V』, 『T593S』, 『G594M』, 『W595T』, 『V596L』] V64 [『M559C』, 『H584M』, 『Q592V』, 『T593S』, 『G594M』, 『W595K』, 『V596W』, 『I601V』] V65 [『Q592V』、『T593A』、『G594M』、『W595T』、『V596I』] V66 [『Q592V』、『T593A』、『G594M』、『W595Q』] V67 [『G549D』,『N583S』,『Q592V』,『T593A』,『G594M』,『W595T』,『V596M』] V68 [『Q592V』、『T593A』、『G594M』、『W595T』、『V596M』] V69 [『N583S』、『Q592V』、『T593A』、『G594M』、『W595T』、『V596L』] V70 [『A589T』、『Q592V』、『T593A』、『G594M』、『W595T』、『V596M』] V71 [『Q579M』、『Q592V』、『T593A』、『G594M』、『W595N』、『V596A』] V72 [『S576W』、『Q592V』、『T593A』、『G594M』、『W595T』、『V596M』] V73 [『A589T』、『Q592V』、『T593A』、『G594M』、『W595S』、『V596M』] V74 [『Q579S』、『Q592V』、『T593A』、『G594M』、『W595N』、『V596M』] V75 [『A589Q』,『A591S』,『Q592V』,『T593A』,『G594M』,『W595N』] V76 [『S586Q』、『A587T』、『A589T』、『Q592V』、『T593A』、『G594M』、『W595N』] V77 [『H584T』,『Q592V』,『T593S』,『G594T』,『W595Q』,『V596M』] V78 [『Q592V』、『T593S』、『G594T』、『W595Q』、『V596N』、『Q597N』] V79 [『A589T』,『Q592V』,『T593S』,『G594T』,『W595Q』,『V596M』,『N598A』] V80 [『A587T』、『Q592V』、『T593S』、『G594T』、『W595T』、『V596A』、『N598S』] V81 [『H584N』、『Q592V』、『T593S』、『G594T』、『W595Q』、『V596M』] V82 [『H584M』、『A589T』、『Q592V』、『T593S』、『G594T』、『W595S』、『V596M』] V83 [『A589T』、『Q592V』、『T593S』、『G594T』、『W595Q』、『V596M』] V84 [『Q588N』、『A589T』、『Q592V』、『T593S』、『G594T』、『W595T』、『V596N』、『Q597N』、『N598S』] V85 [『Q579S』、『H584N』、『Q592V』、『T593S』、『G594T』、『W595G』] V86 [『A589T』、『Q592V』、『T593S』、『G594T』、『W595Q』、『V596N』、『Q597N』] V87 [『Q579S』,『H584L』,『Q592V』,『T593S』,『G594T』,『W595G』,『V596I』] V88 [『A587S』, 『Q588T』, 『A589T』, 『Q592V』, 『T593S』, 『G594T』, 『W595Q』, 『V596H』, 『N598S』] V89 [『A589T』、『Q592V』、『T593S』、『G594T』、『W595Q』、『V596I』] V90 [『Q579S』,『H584L』,『Q592V』,『T593S』,『G594T』,『W595G』] V91 [『N583S』、『Q592V』、『T593S』、『G594T』、『W595E』、『V596M』] V92 [『Q592V』、『T593S』、『G594T』、『W595S』、『V596M』、『I601V』] V93 [『A587T』、『Q592V』、『T593S』、『G594T』、『W595Q』、『V596M』] V94 [『Q588G』,『A589T』,『Q592V』,『T593S』,『G594T』,『W595Q』,『V596M』,『N598S』] V95 [『Q592V』、『T593S』、『G594T』、『W595Q』、『V596N』、『I601V』] V96 [『M559N』、『Q579S』、『A587T』、『A589S』、『T593S』、『G594M』、『W595T』、『V596L』、『N598S』] V97 [『Y577M』、『Q579S』、『N583S』、『A587T』、『T593S』、『G594M』、『W595T』、『V596L』、『N598S』] V98 [『R550L』、『M559S』、『Q579S』、『T593S』、『G594M』、『W595T』、『V596L』、『N598S』] V99 [『Q579S』, 『S586Q』, 『T593S』, 『G594M』, 『W595T』, 『V596M』, 『Q597N』, 『N598S』] V100 [『Q579S』、『Q588N』、『T593S』、『G594M』、『W595N』、『V596N』] V101 [『Q579S』、『T593S』、『G594M』、『W595T』、『V596N』、『N598S』] V102 [『G549V』,『Q579V』,『A587T』,『T593S』,『G594M』,『W595A』,『V596L』,『N598S』] V103 [『R550S』, 『Q579S』, 『A581C』, 『A587I』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V104 [『T593S』, 『G594M』, 『W595Q』, 『V596G』, 『N598S』] V105 [『Q579N』、『A587S』、『T593S』、『G594M』、『W595N』、『V596M』、『N598S』] V106 [『G549M』,『M559S』,『T593S』,『G594M』,『W595N』,『V596M』,『N598S』] V107 [『A555I』, 『M559S』, 『Q579S』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V108 [『Y577F』、『Q579S』、『T593S』、『G594M』、『W595Q』、『V596M』、『N598S』] V109 [『A589T』, 『T593S』, 『G594M』, 『W595N』, 『V596M』, 『N598S』] V110 [『A589T』,『T593S』,『G594M』,『W595V』,『V596M』,『N598S』] V111 [『M559S』, 『Q579S』, 『T593S』, 『G594M』, 『W595Q』, 『V596M』, 『N598S』] V112 [『A589T』, 『T593S』, 『G594M』, 『W595S』, 『V596M』, 『N598A』] V113 [『M559Y』, 『Q579S』, 『A587T』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V114 [『G549S』, 『Q579S』, 『T582Q』, 『A587I』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V115 [『Q579S』, 『A581C』, 『T582M』, 『A587I』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V116 [『R550A』, 『M559Y』, 『Q579S』, 『A587I』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V117 [『T561S』, 『Q579S』, 『A581C』, 『H584N』, 『A587I』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V118 [『M559S』, 『Q579T』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V119 [『A587S』、『Q588N』、『T593S』、『G594M』、『W595Q』、『V596N』] V120 [『M559F』、『Q579S』、『T593S』、『G594M』、『W595N』、『V596M』、『N598S』] V121 [『N552L』、『M559S』、『Q579S』、『T593S』、『G594M』、『W595T』、『V596L』、『N598S』] V122 [『S576Q』、『Q579S』、『T593S』、『G594M』、『W595T』、『V596M』、『N598T』] V123 [『G549D』,『Q579S』,『T593S』,『G594M』,『W595Q』,『V596M』,『N598S』] V124 [『A587T』, 『Q588N』, 『Q592V』, 『T593Q』, 『G594M』, 『W595A』, 『V596M』, 『N598S』] V125 [『Q592V』、『T593Q』、『G594M』、『W595T』、『V596L』、『N598S』] V126 [『A587T』、『Q592V』、『T593Q』、『G594M』、『W595A』、『V596M』、『N598S』] V127 [『H584T』、『Q592V』、『T593Q』、『G594M』、『W595A』、『V596M』、『N598S』] V128 [『S576W』、『Q592V』、『T593Q』、『G594M』、『W595T』、『V596I』、『N598S』] V129 [『Q592V』,『T593S』,『W595K』] V130 [Q592V, T593S] V131 [『N583S』,『Q592V』,『T593S』,『W595K』] V132 [『Q579T』、『Q592V』、『G594M』、『W595S』、『V596M』] V133 [『Q579S』,『S586Q』,『A589T』,『Q592V』,『G594M』,『W595N』] V134 [『A591S』,『Q592V』,『G594M』,『W595N』,『V596N』] V135 [『Q579T』、『Q592V』、『G594M』、『W595N』、『V596N』] V136 [『Q579T』、『Q592V』、『G594M』、『W595N』、『V596L』] V137 [『Q579S』、『Q592V』、『G594M』、『W595N』、『V596N』] V138 [『Y577W』, 『Q579N』, 『H584A』, 『A587T』, 『A589T』, 『Q592V』, 『T593S』, 『G594M』, 『W595K』, 『V596L』, 『I601V』] V139 [『R550G』, 『Y577W』, 『Q579N』, 『H584N』, 『A587T』, 『A589T』, 『Q592V』, 『T593S』, 『G594M』, 『W595K』, 『V596L』, 『I601V』] V140 [『Y577W』, 『Q579N』, 『H584N』, 『A587T』, 『A589T』, 『Q592V』, 『T593S』, 『G594M』, 『W595K』, 『V596L』, 『I601V』] V141 [『I566L』, 『S576P』, 『Q579S』, 『A587T』, 『Q592V』, 『T593S』, 『G594M』, 『W595S』, 『V596N』, 『N598S』] V142 [『D551E』, 『S576P』, 『Q579S』, 『A587T』, 『Q592V』, 『T593S』, 『G594M』, 『W595S』, 『V596N』, 『N598S』] V143 [『S576Q』, 『Q579S』, 『A581S』, 『A587G』, 『Q592V』, 『T593S』, 『G594M』, 『W595S』, 『V596M』, 『I601V』] V144 [『S576P』、『Q579S』、『A587T』、『Q588G』、『Q592V』、『T593S』、『G594M』、『W595S』、『V596N』、『N598S』] V145 [『M559T』, 『Q579S』, 『A587T』, 『A589S』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V146 [『M559S』, 『Q579S』, 『A587T』, 『A589S』, 『T593S』, 『G594M』, 『W595T』, 『V596L』, 『N598S』] V147 [『Q579T, H584N, Q592V, T593S, G594M, W595M, V596L, N598S, I601V』]

In some embodiments, provided herein are variant coccus polypeptides (and nucleic acids encoding the same) comprising at least one of the mutational differences associated with any of the variant coccus polypeptides of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least one mutation corresponding to a mutational difference associated with any of the variant coccus polypeptides of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant capsid polypeptide (and nucleic acid encoding the same) comprising at least two mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least two mutations corresponding to two mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant capsid polypeptide (and nucleic acid encoding the same) comprising at least three mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least three mutations corresponding to three mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant coa polypeptide (and nucleic acid encoding the same) comprising at least four mutational differences relative to any variant coa polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least four mutations corresponding to four mutational differences relative to any variant coa polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant capsid polypeptide (and nucleic acid encoding the same) comprising at least five mutational differences relative to any of the variant capsid polypeptides of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least five mutations corresponding to five mutational differences relative to any of the variant capsid polypeptides of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant capsid polypeptide (and nucleic acid encoding the same) comprising at least six mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least six mutations corresponding to six mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant coa polypeptide (and nucleic acid encoding the same) comprising at least seven mutational differences relative to any variant coa polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least seven mutations corresponding to seven mutational differences relative to any variant coa polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant capsid polypeptide (and nucleic acid encoding the same) comprising at least 8 mutational differences relative to any of the variant capsid polypeptides of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least 8 mutations corresponding to 8 mutational differences relative to any of the variant capsid polypeptides of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant capsid polypeptide (and nucleic acid encoding the same) comprising at least 9 mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least 9 mutations corresponding to 9 mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158. In some embodiments, provided herein is a variant capsid polypeptide (and nucleic acid encoding the same) comprising at least 10 mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising at least 10 mutations corresponding to 10 mutational differences relative to any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158.

In some embodiments, the capsid polypeptides herein comprise a capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-A below shows representative variant capsid polypeptides comprising (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-A variants G549 R550 D551 N552 V553 K557 M559 N562 E563 I566 T569 S576 Y577 Q579 V580 A581 T582 N583 H584 A587 Q588 A589 Q592 T593 G594 W595 V596 Q597 N598 Q599 G600 I601 Editing distance from SEQ ID NO:1 V1 - - - - - - - - - - - - - - - - - - A - - - V S M Q I - - - - - 6 V2 - - - - - - - - - - - - - S - - - - T I - - V S M T L - S - - - 9 V3 - - - - - - A - - - - - - - - - - - L - - - V S M Q I - - - - - 7 V4 - - - - - - - - - - - - - - - - - - - - - - V S M Q M N - - S - 7 V5 - - - - - - - - - - - P - S - - V - - T - - V S M S N - S - - - 10 V6 - - - - - - - - - - V - - - - - - - - - - - V S M Q M - - - - - 6 V7 - - - - - - - - - - - - - L - S - - - - - - V S M Q I - - - - - 7 V8 - - - - - - - V - - - - - - - - - - T - - - V S M I I - A - - - 8 V9 K - - - - - - - - - - - - - - - - - - - - - V S M Q M - - - - - 6 V10 - - - - - - - - - - - - - - - - - - - - - - V S M Q M - - - - - 5 V11 - - - - - - A - - - - P - - - - - - - - - - V S M T W - - - - - 7 V12 - - - - - N - - - - - - - - - - - - T - - - V S M K I - - - - - 7 V13 - - - - - - - - - - - M - - - - - - - - - - V S M Q Q - - - - - 6 V14 - - - - - - - - - - - P - Y - - - - - T - - V S M S L - S - - - 9 V15 - - - - - - C - - - - - - - - - - S T - - - V S M K I - - - - - 8 V16 - - - - - - I - - - - - - - - - - S T _ - - V S M K I - - - - - 8 V17 - - - - - - - - - - - - - - - - - - - T - - V S M Q M - - - - - 6 V18 N - - - - - N - - - - - - - - - V - - - - - V S M A I - - - - - 8 V19 - - - - - - - - - - - - - - - - - - - - - - V S M Q M - - - - V 6 V20 - - - - - - - - - - - - - - - - - - - N - - V S M Q M - - - - - 6 V21 - - - - - - - - - - - - - - - - - - - - - V V S M Q M - - - - - 6 V22 - - - - - - - - - - - - - - - - - S T - V T V S M K I - - - - - 9 V23 - V - - - - - - - - - - - - - - - - - - - - V S M Q M - - - - - 6 V24 - - - - - - - - - - - - - - - - - V - - - - V S M S G - S - - - 7 V25 - - - - - - - - - - - - - - - - - - - - N T V S M Q W - - - - - 7 V26 - G - - - - - - - - - - - - - - - - L - - - V S M Q W - - - - - 7 V27 - - - - - - - - - - - - - - - - - - - - - T V S M T M L - - - - 7 V28 - - - - - - - - - - - - - - - - - - - P - - V S M Q M - - - - - 6 V29 H - - D - - - - - - - - - - C - - - N - - - V S M K W - - - - - 9 V30 - - - - - N F - - - - - - - - - - S - - - - V S M Q W - - - - - 8 V32 - - - - - - - - - - - - - - - - - - N - - - V S M T M - - V - - 7 V33 - - - - - - - - - - - - - - - - - - T - - - V S M T M - - - - - 6 V34 - - - - - - - - - - - - - C - - - - I - - - V S M K W - - - - - 7 V35 - - - - - - - - - - - - - - - - - - T - - - V S M M M - - - - - 6 V36 - - - - - - N - - - - - - - - - - - _ - - - V S M Q M - - - - - 6 V37 - - - H - - - - - - - - - - - - - - - - - - V S M Q M - - - - - 6 V38 - - - - - L - - - - - - - - - - - - - - - - V S M Q M - - - - - 6 V39 - - - - - - C - - - - - W - - - - - L - - - V S M K L - - - - - 8 V40 - - - - - - - - - - - - - - - - - - - T - S V S M Q M - - - - - 7 V41 - K - - - - - - - - - P - - - - - - - - - - V S M T W - - - - - 7 V42 - - - - A - - T - - - - - - - - - - - - - - V S M Q M - - - - - 7 V43 - - - - - - - - - - - - - - - - - S A - - - V S M M I - - - - - 7 V44 - - - - - - - - - - - - - - - - - - - - - - V S M Q N - - L - - 6 V45 - - - - - - - - - - - - - - - - - S - - - - V S M Q Q - - C - - 7 V46 - - - - - - Y - - - - - W N - - - - T - - - V S M M M - - - - - 9 V47 - - - - - - - - - - - - - - - - - - - - - T V S M Q M - - - - - 6 V48 - - - - - - - - - - - P - - - - - - M T - - V S M S L - S - - - 9 V49 - - - - - - - - - - - - - - - - - - F - - - V S M T L - - - - - 6 V50 - - - - - - - - - - - P - - - - - - A T - - V S M S L - S - - - 9 V51 - - - - - - - - - - - - - - - - - - - - - - V S M T L - S - - - 6 V52 - - - - - - - - - - - - - - - - - - - - - - V S M Q G T - - - - 6 V53 - G - - - - - - - - - P - - - - - - - - - - V S M T W - - - - - 7 V54 - - - - - - - - - - - - - - - - - - N - - - V S M Q W - - - - - 6 V55 - - - - - - A - - - - - - - - - - S A - - - V S M Q I - - C - - 9 V56 - - - - - N V - - - - - - - - - - S - - - - V S M Q W - - - - - 8 V57 - G - - - - - - - - - - - - - - - - N - - - V S M Q W - - - - - 7 V58 - - - - - - - - - - - - - - - - - - M - - - V S M V M - - - - - 6 V59 - - - - - - - - - - - - - - - - - - I - - - V S M T - - - L - - 6 V60 - - - - - - A - - - - - - - - - - S T - - - V S M F - - - - - - 7 V61 - - - - - - - - - - - - - T - - - - - - - - V S M Q W T - - V 8 V62 - - - - - - - - T - - - - - - - - S L - - - V S M K - - - - - - 7 V63 - - - - - - - - - - - - - - - - V S - - - N V S M T L - - - - - 8 V64 - - - - - - C - - - - - - - - - - - M - - - V S M K W - - - - V 8 V138 - - - - - - - - - - - - W N - - - - A T - T V S M K L - - - - V 11 V139 - G - - - - - - - - - - W N - - - - N T - T V S M K L - - - - V 12 V140 - - - - - - - - - - - - W N - - - - N T - T V S M K L - - - - V 11 V141 - - - - - - - - - L - P - S - - - - - T - - V S M S N - S - - - 10 V142 - - E - - - - - - - - P - S - - - - - T - - V S M S N - S - - - 10 V143 - - - - - - - - - - - Q - S - S - - - G - - V S M S M - - - - V 10 V144 - - - - - - - - - - - P - S - - - - - T G - V S M S N - S - - - 10 V147 - - - - - - - - - - - - - T - - - - N - - - V S M M L - S - - V 9

In some embodiments, the capsid polypeptides herein comprise a capsid polypeptide containing: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-B below shows representative variant capsid polypeptides comprising (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-B variants G549 S576 Q579 N583 S586 A587 A589 A591 Q592 T593 G594 W595 V596 Editing distance from SEQ ID NO:1 V31 - - - - - - - - V A M Q M 5 V65 - - - - - - - - V A M T I 5 V66 - - - - - - - - V A M Q - 4 V67 D - - S - - - - V A M T M 7 V68 - - - - - - - - V A M T M 5 V69 - - - S - - - - V A M T L 6 V70 - - - - - - T - V A M T M 6 V71 - - M - - - - - V A M N A 6 V72 - W - - - - - - V A M T M 6 V73 - - - - - - T - V A M S M 6 V74 - - S - - - - - V A M N M 6 V75 - - - - - - Q S V A M N - 6 V76 - - - - Q T T - V A M N - 7

In some embodiments, the capsid polypeptides herein comprise a capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-C below shows representative variant capsid polypeptides comprising (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-C variants Q579 N583 H584 A587 Q588 A589 Q592 T593 G594 W595 V596 Q597 N598 I601 Editing distance from SEQ ID NO:1 V77 - - T - - - V S T Q M - - - 6 V78 - - - - - - V S T Q N N - - 6 V79 - - - - - T V S T Q M - A - 7 V80 - - - T - - V S T T A - S - 7 V81 - - N - - - V S T Q M - - - 6 V82 - - M - - T V S T S M - - - 7 V83 - - - - - T V S T Q M - - - 6 V84 - - - - N T V S T T N N S - 9 V85 S - N - - - V S T G - - - - 6 V86 - - - - - T V S T Q N N - - 7 V87 S - L - - - V S T G I - - - 7 V88 - - - S T T V S T Q H - S - 9 V89 - - - - - T V S T Q I - - - 6 V90 S - L - - - V S T G - - - - 6 V91 - S - - - - V S T E M - - - 6 V92 - - - - - - V S T S M - - V 6 V93 - - - T - - V S T Q M - - - 6 V94 - - - - G T V S T Q M - S - 8 V95 - - - - - - V S T Q N - - V 6

In some embodiments, the capsid polypeptides herein comprise a capsid polypeptide comprising: (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-D below shows representative variant capsid polypeptides comprising (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-D variants G549 R550 N552 A555 M559 T561 S576 Y577 Q579 A581 T582 N583 H584 S586 A587 Q588 A589 T593 G594 W595 V596 Q597 N598 Editing distance from SEQ ID NO:1 V96 - - - - N - - - S - - - - - T - S S M T L - S 9 V97 - - - - - - - M S - - S - - T - - S M T L - S 9 V98 - L - - S - - - S - - - - - - - - S M T L - S 8 V99 - - - - - - - - S - - - - Q - - - S M T M N S 8 V100 - - - - - - - - S - - - - - - N - S M N N - - 6 V101 - - - - - - - - S - - - - - - - - S M T N - S 6 V102 V - - - - - - - V - - - - - T - - S M A L - S 8 V103 - S - - - - - - S C - - - - I - - S M T L - S 9 V104 - - - - - - - - - - - - - - - - - S M Q G - S 5 V105 - - - - - - - - N - - - - - S - - S M N M - S 7 V106 M - - - S - - - - - - - - - - - - S M N M - S 7 V107 - - - I S - - - S - - - - - - - - S M T L - S 8 V108 - - - - - - - F S - - - - - - - - S M Q M - S 7 V109 - - - - - - - - - - - - - - - - T S M N M - S 6 V110 - - - - - - - - - - - - - - - - T S M V M - S 6 V111 - - - - S - - - S - - - - - - - - S M Q M - S 7 V112 - - - - - - - - - - - - - - - - T S M S M - A 6 V113 - - - - Y - - - S - - - - - T - - S M T L - S 8 V114 S - - - - - - - S - Q - - - I - - S M T L - S 9 V115 - - - - - - - - S C M - - - I - - S M T L - S 9 V116 - A - - Y - - - S - - - - - I - - S M T L - S 9 V117 - - - - - S - - S C - - N - I - - S M T L - S 10 V118 - - - - S - - - T - - - - - - - - S M T L - S 7 V119 - - - - - - - - - - - - - - S N - S M Q N - - 6 V120 - - - - F - - - S - - - - - - - - S M N M - S 7 V121 - - L - S - - - S - - - - - - - - S M T L - S 8 V122 - - - - - - Q - S - - - - - - - - S M T M - T 7 V123 D - - - - - - - S - - - - - - - - S M Q M - S 7 V145 - - - - T - - - S - - - - - T - S S M T L - S 9 V146 - - - - S - - - S - - - - - T - S S M T L - S 9

In some embodiments, the capsid polypeptides herein comprise a capsid polypeptide containing: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-E below shows representative variant capsid polypeptides comprising (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-E variants S576 H584 A587 Q588 Q592 T593 G594 W595 V596 N598 Editing distance from SEQ ID NO:1 V124 - - T N V Q M A M S 8 V125 - - - - V Q M T L S 6 V126 - - T - V Q M A M S 7 V127 - T - - V Q M A M S 7 V128 W - - - V Q M T I S 7

In some embodiments, the capsid polypeptides herein comprise a capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-F below shows representative variant capsid polypeptides comprising (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-F variants N583 Q592 T593 W595 Editing distance from SEQ ID NO:1 V129 - V S K 3 V130 - V S - 2 V131 S V S K 4

In some embodiments, the capsid polypeptides herein comprise a capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-G below shows representative variant capsid polypeptides comprising (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. Table 1-G variants Q579 S586 A589 A591 Q592 G594 W595 V596 Editing distance from SEQ ID NO:1 V132 T - - - V M S M 5 V133 S Q T - V M N - 6 V134 - - - S V M N N 5 V135 T - - - V M N N 5 V136 T - - - V M N L 5 V137 S - - - V M N N 5

Optionally, the capsid polypeptide herein comprises tryptophan, glutamine, serine, threonine, valeric acid, asparagine, alanine, phenylalanine, lysine, isoleucine, or methionine at a position corresponding to position W595 of the VP1 capsid polypeptide of SEQ ID NO: 1.

Optionally, the capsid polypeptide herein comprises valine, methionine, tryptophan, isoleucine, asparagine, leucine, glutamine, alanine, or glycine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise glutamine at a position corresponding to W595 and methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise glutamine at a position corresponding to W595 and isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise threonine at a position corresponding to W595 and leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise serine at a position corresponding to W595 and asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise glutamine at a position corresponding to W595 and asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise an alanine at a position corresponding to W595 and a methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1 and asparagine at a position corresponding to V596.

In some embodiments, the capsid polypeptides herein comprise a threonine at a position corresponding to W595 and an isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise glutamine at a position corresponding to W595 and valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise a threonine at a position corresponding to W595 and an alanine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise a lysine at a position corresponding to W595 and a valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise tryptophan at a position corresponding to W595 and valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise a serine at a position corresponding to W595 and a methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise asparagine at a position corresponding to W595 and valeric acid at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, the capsid polypeptides herein comprise asparagine at a position corresponding to W595 and leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) serine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) alanine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) alanine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) alanine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) lysine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) tryptophan at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) serine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In certain embodiments, the capsid polypeptide herein comprises: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1; (d) asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1; and (e) leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1.

In some embodiments, provided herein is a variant capsid polypeptide (and nucleic acid encoding the same) comprising all mutational differences associated with any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158, or comprising mutations corresponding to all mutational differences associated with any variant capsid polypeptide of SEQ ID NO: 12 to SEQ ID NO: 158.

Within any of the above categories, it is understood that in the variant coccus polypeptides described above specifying a plurality of mutational differences associated with or corresponding to any of the variant coccus polypeptides of SEQ ID NO: 12 to SEQ ID NO: 158, the mutation can be selected from any of the mutational differences associated with the variant coccus polypeptide. Thus, for example, with respect to a variant having mutational differences #1, #2, #3, and #4 relative to a reference polypeptide, wherein the variant capsid polypeptide comprises one of the mutational differences, it is #1 or #2 or #3 or #4; similarly, wherein the variant capsid comprises two of the mutational differences, two of those are #1 and #2, #1 and #3, #1 and #4, #2 and #3, #2 and #4, or #3 and #4; similarly, wherein the variant comprises three of the mutational differences, three of those are #1 and #2 and #3, #1 and #2 and #4, #1 and #3 and #4, or #2 and #3 and #4; similarly, wherein the variant comprises all four of the mutational differences, four of those are #1, #2, #3, and #4. Those skilled in the art will appreciate that all possible combinations of the number of mutational differences for each variant capsid polypeptide of any one of SEQ ID NO: 12 to SEQ ID NO: 158 (up to the total number of mutational differences for the variant capsid polypeptide) can be generated using conventional techniques, and each such table for each of SEQ ID NO: 12 to SEQ ID NO: 158 is incorporated herein in its entirety. Such tables can be generated, for example, using the "combinations" method from the "itertools" package in the Python programming language, which is hereby incorporated by reference in its entirety.

In some embodiments, the variant capsid polypeptide comprises one or more mutational differences related to a capsid polypeptide described herein (e.g., related to any one of SEQ ID NO: 12 to SEQ ID NO: 158) and has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to a reference AAV serotype (e.g., described herein, e.g., to SEQ ID NO: 1). In embodiments, the variant capsid polypeptide comprises one or more mutational differences associated with a capsid polypeptide described herein (e.g., associated with any one of SEQ ID NO: 12 to SEQ ID NO: 158) or corresponding to one or more mutational differences associated with a capsid polypeptide described herein (e.g., associated with any one of SEQ ID NO: 12 to SEQ ID NO: 158). In embodiments, the variant capsid polypeptide is at least 90%, at least 95%, 96%, 97%, 98%, 99%, or 100% identical to a reference AAV serotype described herein, except for the mutational differences described or corresponding to the mutational differences associated with a capsid polypeptide described herein (e.g., associated with any one of SEQ ID NO: 12 to SEQ ID NO: 158). In embodiments, the variant coagulant polypeptides described herein are at least 90%, at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the coagulant polypeptide of SEQ ID NO: 1 (e.g., the VP1, VP2, or VP3 sequence of SEQ ID NO: 1), except for the mutational difference contained within the variant coagulant polypeptide relative to a coagulant polypeptide described herein (e.g., relative to any one of SEQ ID NO: 12 to SEQ ID NO: 158) or corresponding to a mutational difference relative to a coagulant polypeptide described herein (e.g., relative to any one of SEQ ID NO: 12 to SEQ ID NO: 158). In embodiments, the variant coagulant polypeptides described herein are at least 90%, at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the coagulant polypeptide of SEQ ID NO: 3 (e.g., the VP1, VP2, or VP3 sequence of SEQ ID NO: 3), except for the mutational difference contained within the variant coagulant polypeptide relative to a coagulant polypeptide described herein (e.g., relative to any one of SEQ ID NO: 12 to SEQ ID NO: 158) or corresponding to a mutational difference relative to a coagulant polypeptide described herein (e.g., relative to any one of SEQ ID NO: 12 to SEQ ID NO: 158). In embodiments, the variant capsid polypeptides described herein are at least 90%, at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the capsid polypeptide of SEQ ID NO: 5 (e.g., the VP1, VP2, or VP3 sequence of SEQ ID NO: 5), except for the mutational difference contained within the variant capsid polypeptide (associated with or corresponding to any one of SEQ ID NO: 12 to SEQ ID NO: 158). In embodiments, the variant capsid polypeptides described herein are at least 90%, at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the capsid polypeptide of SEQ ID NO: 7 (e.g., the VP1, VP2, or VP3 sequence of SEQ ID NO: 7), except for the mutational difference contained within the variant capsid polypeptide (associated with or corresponding to a mutational difference associated with any one of SEQ ID NO: 12 to SEQ ID NO: 158). In embodiments, the variant capsid polypeptides described herein are at least 90%, at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the capsid polypeptide of SEQ ID NO: 9 (e.g., the VP1, VP2, or VP3 sequence of SEQ ID NO: 9), except for the mutational difference contained within the variant capsid polypeptide (associated with or corresponding to a mutational difference associated with any one of SEQ ID NO: 12 to SEQ ID NO: 158). In embodiments, the variant capsid polypeptides described herein are at least 90%, at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the capsid polypeptide of SEQ ID NO: 11 (e.g., the VP1, VP2, or VP3 sequence of SEQ ID NO: 1), except for the mutational difference contained within the variant capsid polypeptide (associated with or corresponding to a mutational difference associated with any one of SEQ ID NO: 12 to SEQ ID NO: 158).

In some embodiments, a variant capsid polypeptide is provided that comprises a variant capsid polypeptide that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a variant capsid polypeptide provided herein.

In some embodiments, a variant capsid polypeptide is provided that comprises a variant capsid polypeptide that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a variant capsid polypeptide provided herein (excluding the targeting peptide insertion).

In some embodiments, the variant capsid polypeptide comprises VP1, VP2, VP3, or any combination thereof, each of which is at least or about 95%, 96%, 97%, 98%, or 99% identical to the polypeptide of any one of SEQ ID NO: 12 to SEQ ID NO: 158, and optionally comprises at least one (e.g., all) mutational differences of these SEQ ID NO: 12 to SEQ ID NO: 158.

In some embodiments, the variant capsid polypeptide comprises VP1, VP2, VP3, or any combination thereof, each of which is at least or about 95%, 96%, 97%, 98%, or 99% identical to the polypeptide of any one of SEQ ID NO: 12 to SEQ ID NO: 158 (excluding the target peptide insertion), and optionally comprises at least one (e.g., all) mutational differences from these SEQ ID NO: 12 to SEQ ID NO: 158.

In some embodiments, the variant capsid polypeptide comprises VP1, VP2, VP3, or any combination thereof, each having about 1 to about 20 mutations compared to the polypeptide of any one of SEQ ID NO: 12 to SEQ ID NO: 158, and optionally comprising at least one (e.g., all) mutational differences from these SEQ ID NO: 12 to SEQ ID NO: 158.

In some embodiments, the variant capsid polypeptide comprises VP1, VP2, VP3, or any combination thereof, each having about 1 to about 10 mutations compared to the polypeptide of any one of SEQ ID NO: 12 to SEQ ID NO: 158, and optionally comprising at least one (e.g., all) mutational differences from these SEQ ID NO: 12 to SEQ ID NO: 158.

In some embodiments, the variant capsid polypeptide comprises VP1, VP2, VP3, or any combination thereof, each having 1 to 5 mutations compared to the polypeptide of any one of SEQ ID NO: 12 to SEQ ID NO: 158, and optionally comprising at least one (e.g., all) mutational differences from these SEQ ID NO: 12 to SEQ ID NO: 158.

In one embodiment, nucleic acid molecules encoding variant capsid polypeptides provided herein are provided. In one embodiment, the nucleic acid molecule comprises a sequence encoding a variant capsid polypeptide (e.g., a VP1, VP2, or VP3 capsid polypeptide) of any one of SEQ ID NO: 12 to SEQ ID NO: 158, or a fragment thereof. In one embodiment, the nucleic acid molecule comprises a sequence encoding a variant capsid polypeptide (e.g., a VP1, VP2, or VP3 capsid polypeptide) of any one of SEQ ID NO: 159 to SEQ ID NO: 305, or a fragment thereof (e.g., a VP1-encoding, VP2-encoding, or VP3-encoding fragment thereof).

In some embodiments, the nucleic acid molecule encodes a variant capsid polypeptide that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a variant capsid polypeptide provided herein.

In some embodiments, the nucleic acid molecule or the nucleic acid molecule encoding a reference polypeptide for % identity purposes comprises the nucleotide sequence of SEQ ID NO: 159 to SEQ ID NO: 305, respectively.

In some embodiments, a nucleic acid molecule or a nucleic acid molecule encoding a reference polypeptide for purposes of % identity comprises a nucleotide sequence encoding a variant capsid polypeptide sequence, such as described herein, such as a nucleotide sequence encoding any one of SEQ ID NO: 12 to SEQ ID NO: 158.

In some embodiments, a variant capsid polypeptide or a reference polypeptide for purposes of % identity comprises the sequence of any one of SEQ ID NO: 12 to SEQ ID NO: 158, which are encoded by the nucleotide sequences of SEQ ID NO: 159 to SEQ ID NO: 305, respectively.

In some embodiments, the variant capsid polypeptide comprises a sequence including all mutational differences associated with any one of SEQ ID NO: 12 to SEQ ID NO: 158, for example, relative to SEQ ID NO: 1.

In some embodiments, the variant capsid polypeptide is a VP1 capsid polypeptide. In some embodiments, the variant capsid polypeptide is a VP2 capsid polypeptide. In some embodiments, the variant capsid polypeptide is a VP3 capsid polypeptide. With reference to the sequence of SEQ ID NO: 1, the VP1 capsid polypeptide comprises amino acids 1-737 of SEQ ID NO: 1. With reference to the sequence of SEQ ID NO: 1, the VP2 capsid polypeptide comprises amino acids 138-737 of SEQ ID NO: 1. With reference to the sequence of SEQ ID NO: 1, the VP3 capsid polypeptide comprises amino acids 203-737 of SEQ ID NO: 1.

With respect to variant capsid polypeptide sequences of any one of SEQ ID NO: 12 to SEQ ID NO: 158, the VP1 capsid polypeptide comprises all of the amino acids of any one of SEQ ID NO: 12 to SEQ ID NO: 158. With respect to variant capsid polypeptides of any one of SEQ ID NO: 12 to SEQ ID NO: 158, the VP2 capsid polypeptide comprises, for example, consists of, a sequence beginning with the threonine corresponding to the threonine at position 138 of SEQ ID NO: 1 and continuing to the C-terminus of any one of SEQ ID NO: 12 to SEQ ID NO: 158. With respect to the sequence of any one of SEQ ID NO:12 to SEQ ID NO:158, the VP3 capsid polypeptide comprises, for example, consists of, a sequence starting with a methionine corresponding to the methionine at position 203 of SEQ ID NO:1 and continuing to the C-terminus of any one of SEQ ID NO:12 to SEQ ID NO:158.

Exemplary sequences of variant capsid polypeptides are provided in SEQ ID NO: 12 to SEQ ID NO: 158, respectively, and exemplary nucleic acid molecules encoding the same are provided in SEQ ID NO: 159 to SEQ ID NO: 305, respectively.

In some embodiments, the nucleic acid molecule encodes a variant capsid polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the VP1, VP2 or VP3 sequence of any one of SEQ ID NO: 12 to SEQ ID NO: 158.

In some embodiments, the nucleic acid molecule encodes a variant chalcanth polypeptide that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VP1, VP2, or VP3 sequence of any one of SEQ ID NO:12 to SEQ ID NO:158 (excluding the targeting peptide insertion). 6.2.1. Variant Chalcanth polypeptides (corresponding positions)

Mutations in the capsid polypeptide sequences described herein are described with respect to positions and/or amino acids at positions within a reference sequence (e.g., SEQ ID NO: 1). Thus, in some embodiments, the capsid polypeptides described herein are variant capsid polypeptides of a reference sequence (e.g., SEQ ID NO: 1), including, for example, capsid polypeptides comprising at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a reference capsid polypeptide sequence (e.g., a reference capsid polypeptide VP1, VP2, and/or VP3 sequence), e.g., SEQ ID NO: 1 (or a VP2 or VP3 sequence contained therein), and comprising one or more mutations described herein.

It will be understood by those skilled in the art, without theoretical limitation, that each amino acid position within a reference sequence corresponds to a position within the sequence of another reference capsid polypeptide (e.g., a capsid polypeptide derived from a parvovirus of a different serotype). Such corresponding positions are identified using sequence alignment tools known in the art. A particularly preferred sequence alignment tool is the EMBOSS Needle pairwise sequence alignment software tool (available at www.ebi.ac.uk/Tools/psa/emboss_needle/), which is based on the Needleman and Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48(3):443-53). An alignment of exemplary reference capsid polypeptides is shown in Figures 1A to 1C. Thus, in some embodiments, variant capsid polypeptides of the invention include variants of reference capsid polypeptides that include one or more mutations described herein at positions in the reference capsid polypeptides that correspond to positions of mutations described herein for different reference capsid polypeptides. Thus, for example, relative to a mutation described as XnnnY in SEQ ID NO: 1 (wherein X is the amino acid present at position nnn in SEQ ID NO: 1 and Y is an amino acid mutation at that position, e.g., as described herein), provided herein are variant capsid polypeptides comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a reference capsid polypeptide sequence other than SEQ ID NO: 1 (e.g., a reference capsid polypeptide VP1, VP2, and/or VP3 sequence) and further comprising a disclosed mutation at a position corresponding to position nnn of SEQ ID NO: 1 (e.g., a position corresponding to position nnn in the new variant capsid polypeptide sequence). (The corresponding position is determined as described above using a sequence alignment tool, such as the clustal omega tool described above. Examples of corresponding amino acid positions for exemplary known AAV serotypes are provided in Figures 1A to 1C. In some embodiments, the variant is a variant of an AAV9 capsid polypeptide, which can be referred to as an "AAV9 variant capsid polypeptide" or "variant AAV9 capsid polypeptide.")

Thus, in embodiments, provided herein are variant capsid polypeptide sequences that are variants of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence other than SEQ ID NO: 1 described herein), wherein the variants include one or more mutations corresponding to the mutations described herein. In embodiments, these variants include mutations corresponding to all mutations associated with any one of SEQ ID NO: 12 to SEQ ID NO: 158.

The variant capsid polypeptides described herein are optionally variants of reference capsid serotypes known in the art. Non-limiting examples of such reference AAV serotypes include AAV1, AAVrh10, AAV-DJ, AAV-DJ8, AAV5, AAVPHP.B (PHP.B), AAVPHP.A (PHP.A), AAVG2B-26, AAVG2B-13, AAVTH1.1-32, AAVTH1.1-35, AAVPHP.B2 (PHP.B2), AAVPHP.B3 (PHP.B3), AAVPHP.N/PHP.B-DGT, AAVPHP.B-EST, AAVPHP.B-GGT, AAVPHP.B-ATP, AAVPHP.B-ATT-T, AAVPHP.B-DGT-T, AAVPHP.B-G GT-T, AAVPHP.B-SGS, AAVPHP.B-AQP, AAVPHP.B-QQP, AAVPHP.B-SNP(3), AAVPHP.B-SNP, AAVPHP.B-QGT, AAVPHP.B-NQT, AAVPHP.B- EGS, AAVPHP.B-SGN, AAVPHP.B-EGT, AAVPHP.B-DST, AAVPHP.B-DST, AAVPHP.B-STP, AAVPHP.B-PQP, AAVP HP.B-SQP, AAVPHP.B-QLP, AAVPHP.B-TMP, AAVPHP.B-TTP, AAVPHP.eB, AAVPHP.S/G2A12, AAVG2A15/G2A3 (G2A3), AAVG2B4 (G2B4), AAVG2B5 (G2B5), PHP.S, AAV2, AAV2G9, AAV3, AAV3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2, AAV8, AAV9.11, AAV9.13, AAV9, AAV9 K449R (or K449R AAV9), AAV9.16, AAV9.24, AAV9.45, AAbiodisV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV12, AAV16.3, AAV24.1, AAV27.3, AAV42.12, AAV42- 1b, AAV42-2, AAV42-3a, AAV42-3b, AAV42-4, AAV42-5a, AAV42-5b, AAV42-6b, AAV42-8, AAV42-10, AAV42-11, AAV42-12, A AV42-13, AAV42-15, AAV42-aa, AAV43-1, AAV43-12, AAV43-20, AAV43-21, AAV43-23, AAV43-25, AAV43-5, AAV44.1, AAV44 .2, AAV44.5, AAV223.1, AAV223.2, AAV223.4, AAV223.5, AAV223.6, AAV223.7, AAV1-7/rh.48, AAV1-8/rh.49, AAV2-15/r h.62, AAV2-3/rh.61, AAV2-4/rh.50, AAV2-5/rh.51, AAV3.1/hu.6, AAV3.1/hu.9, AAV3-9/rh.52, AAV3-11/rh.53, AAV4- 8/r11.64, AAV4-9/rh.54, AAV4-19/rh.55, AAV5-3/rh.57, AAV5-22/rh.58, AAV7.3/hu.7, AA V16.8/hu.10, AAV16.12/hu.11, AAV29.3/bb.1, AAV29.5/bb.2, AAV106.1/hu.37, AAV114.3/h u.40, AAV127.2/hu.41, AAV127.5/hu.42, AAV128.3/hu.44, AAV130.4/hu.48, AAV145.1/hu.5 3. AAV145.5/hu.54, AAV145.6/hu.55, AAV161.10/hu.60, AAV161.6/hu.61, AAV33.12/hu.17, AAV33.4/hu.15, AAV33.8/hu.16, AAV52/hu.19, AAV52.1/hu.20, AAV58.2/hu.25, AAVA3.3, AA VA3.4, AAVA3.5, AAVA3.7, AAVC1, AAVC2, AAVC5, AAVF3, AAVF5, AAVH2, AAVrh.72, AAVhu.8, AAV rh.68, AAVrh.70, AAVpi.1, AAVpi.3, AAVpi.2, AAVrh.60, AAVrh.44, AAVrh.65, AAVrh.55, AAV rh.47, AAVrh.69, AAVrh.45, AAVrh.59, AAVhu.12, AAVH6, AAVH-1/hu.1, AAVH-5/hu.3, AAVLG- 10/rh.40, AAVLG-4/rh.38, AAVLG-9/hu.39, AAVN721-8/rh.43, AAVCh.5, AAVCh.5R1, AAVcy.2, AAVcy.3, AA Vcy.4, AAVcy.5, AAVCy.5R1, AAVCy.5R2, AAVCy.5R3, AAVCy.5R4, AAVcy.6, AAVhu.1, AAVhu.2, AAVhu.3, AAVh u.4, AAVhu.5, AAVhu.6, AAVhu.7, AAVhu.9, AAVhu.10, AAVhu.11, AAVhu.13, AAVhu.15, AAVhu.16, AAVhu.17 , AAVhu.18, AAVhu.20, AAVhu.21, AAVhu.22, AAVhu.23.2, AAVhu.24, AAVhu.25, AAVhu.27, AAVhu.28, AAVhu. 29. AAVhu.29R, AAVhu.31, AAVhu.32, AAVhu.34, AAVhu.35, AAVhu.37, AAVhu.39, AAVhu.40, AAVhu.41, AAVh u.42, AAVhu.43, AAVhu.44, AAVhu.44R1, AAVhu.44R2, AAVhu.44R3, AAVhu.45, AAVhu.46, AAVhu.47, AAVhu.4 8. AAVhu.48R1, AAVhu.48R2, AAVhu.48R3, AAVhu.49, AAVhu.51, AAVhu.52, AAVhu.54, AAVhu.55, AAVhu.56, AAVhu.57, AAVhu.58, AAVhu.60, AAVhu.61, AAVhu.63, AAVhu.64, AAVhu.66, AAVhu.67, AAVhu.14/9, AAVhu.t 19. AAVrh.2, AAVrh.2R, AAVrh.8, AAVrh.8R, AAVrh.10, AAVrh.12, AAVrh.13, AAVrh.13R, AAVrh.14, AAVrh.17, AAVrh.18, AAVrh.19, AAVr h.20, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, A AAVrh.37R2, AAVrh.38, AAVrh.39, AAVrh.40, AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49, AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54, AAVrh.56, AAVrh.57, AAVrh.58, AAVrh.61, AAVrh.64, AAVrh.64R1, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74 (also known as AAVrh74), AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV, BAAV, goat AAV, bovine AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14, AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhEr1.35, AAVhEr1.7, AAVhEr1.36, AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36, AAVhER1.23, AAVhEr3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV- LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV- LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-LK16, AAV- LK17, AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7, AAV-PAEC8, AAV-PAEC11, AAV-PAEC12, AAV-2-pre-miRNA-101, AAV-8h, AAV-8b, AAV-h, AAV-b, AAV SM 10-2. AAV Shuffle 100-1, AAV reshuffled 100-3, AAV reshuffled 100-7, AAV reshuffled 10-2, AAV reshuffled 10-6, AAV reshuffled 10-8, AAV reshuffled 100-2, AAV SM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10, BNP61 AAV, BNP62 AAV, BNP63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.11, AAVhu.53, AAV4-8/rh.64, AAVLG-9/hu.39, AAV54.5/hu.23 , AAV54.2/hu.22, AAV54.7/hu.24, AAV54.1/hu.21, AAV54.4R/hu.27, AAV46.2/hu.28, AAV46.6/hu.29, AAV128.1/hu.43, true type AAV (ttAAV), UPENN AAV 10, Japanese AAV 10 serotype, AAV CBr-7.1, AAV CBr-7.10, AAV CBr-7.2, AAV CBr-7.3, AAV CBr-7.4, AAV CBr-7.5, AAV CBr-7.7, AAV CBr-7.8, AAV CBr-B7.3, AAV CBr-B7.4, AAV CBr-E1, AAV CBr-E2, AAV CBr-E3, AAV CBr-E4, AAV CBr-E5, AAV CBr-e5, AAV CBr-E6, AAV CBr-E7, AAV CBr-E8, AAV CHt-1, AAV CHt-2, AAV CHt-3, AAV CHt-6.1, AAV CHt-6.10, AAV CHt-6.5, AAV CHt-6.6, AAV CHt-6.7, AAV CHt-6.8, AAV CHt-P1, AAV CHt-P2, AAV CHt-P5, AAV CHt-P6, AAV CHt-P8, AAV CHt-P9, AAV CKd-1, AAV CKd-10, AAV CKd-2, AAV CKd-3, AAV CKd-4, AAV CKd-6, AAV CKd-7, AAV CKd-8, AAV CKd-B1, AAV CKd-B2, AAV CKd-B3, AAV CKd-B4, AAV CKd-B5, AAV CKd-B6, AAV CKd-B7, AAV CKd-B8, AAV CKd-H1, AAV CKd-H2, AAV CKd-H3, AAV CKd-H4, AAV CKd- H5, AAV CKd-H6, AAV CKd-N3, AAV CKd-N4, AAV CKd-N9, AAV CLg-F1, AAV CLg-F2, AAV CLg-F3, AAV CLg-F4, AAV CLg-F5, AAV CLg-F6, AAV CLg-F7, AAV CLg-F8, AAV CLv-1, AAV CLv1-1, AAV Clv1-10, AAV CLv1-2, AAV CLv-12, AAV CLv1-3, AAV CLv-13, AAV CLv1-4, AAV Clv1-7, AAV Clv1-8, AAV Clv1-9, AAV CLv-2, AAV CLv-3, AAV CLv-4, AAV CLv-6, AAV CLv-8, AAV CLv-D1, AAV CLv-D2, AAV CLv-D3, AAV CLv-D4, AAV CLv-D5, AAV CLv-D6,AAV CLv-D7, AAV CLv-D8, AAV CLv-E1, AAV CLv-K1, AAV CLv-K3, AAV CLv-K6, AAV CLv-L4, AAV CLv-L5, AAV CLv-L6, AAV CLv-M1, AAV CLv-M11, AAV CLv-M2, AAV CLv-M5, AAV CLv-M6, AAV CLv-M7, AAV CLv-M8, AAV CLv-M9, AAV CLv-R1, AAV CLv-R2, AAV CLv-R3, AAV CLv-R4, AAV CLv-R5, AAV CLv-R6, AAV CLv-R7, AAV CLv-R8, AAV CLv-R9, AAV CSp-1, AAV AAV CSp-8.8, AAV CSp-8.9, AAV CSp-9, AAV.hu.48R3, AAV.VR-355, AAV3B, AAV4, AAV5, AAVF1/HSC1, AAVF11/HSC11, AAVF12/HSC12, AAVF13/HSC13, AAVF14/HSC14, AAVF15/HSC15, AAVF16/HSC16, AAVF17/HSC17, AAVF2/HSC2, AAVF3/HSC3, AAVF4/HSC4, AAVF5/HSC5, AAVF6/HSC6, AAVF7/HSC7, AAVF8/HSC8 and/or AAVF9/HSC9, 7m8, Spark100, AAVMYO and variants thereof.

In some embodiments, the reference AAV capsid sequence comprises an AAV2 sequence. In some embodiments, the reference AAV capsid sequence comprises an AAV5 sequence. In some embodiments, the reference AAV capsid sequence comprises an AAV8 sequence. In some embodiments, the reference AAV capsid sequence comprises an AAV9 sequence. In some embodiments, the reference AAV capsid sequence comprises an AAVrh74 sequence. Although not theoretically bound, it should be understood that the reference AAV capsid sequence comprises the VP1 region. In certain embodiments, the reference AAV capsid sequence comprises the VP1, VP2, and/or VP3 regions, or any combination thereof. The reference VP1 sequence can be considered synonymous with the reference AAV capsid sequence.

The wild-type reference sequence of AAV9, SEQ ID NO: 1, is as follows: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAK TAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLT MASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO: 1)

Unless otherwise indicated, SEQ ID NO: 1 is the reference sequence. In the above sequences, sequences found in VP1, VP2, and VP3 are underlined (e.g., the VP3 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 203 to 737 of SEQ ID NO: 1), sequences found in both VP1 and VP2 are bolded (e.g., the VP2 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 138 to 737 of SEQ ID NO: 1), and sequences that are not underlined or bolded are found only in VP1 (e.g., the VP1 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 1 to 737 of SEQ ID NO: 1).

The wild-type reference sequence of SEQ ID NO: 1 can be encoded by the reference nucleic acid sequence of SEQ ID NO: 2.

An exemplary reference sequence of wild-type AAV2, SEQ ID NO: 3 (wild-type AAV2), is as follows: MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPPKPAERHKDDSRGLVLPGYKYLGPFNGLDKGEPVNEADAAALEHDKAYDRQLDSGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRVLEPLGLVEEPVKTAPGKKRPVEHSPVEPDSSSGTGKAGQQPARKRLNFGQTGDADSVPDPQPLGQPPAAPSGLGTNT MATGSGAPMADNNEGADGVGNSSGNWHCDSTWMGDRVITTSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTNTPSGTTTQSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHLNGRDSLVNPGPAMASHKDDEEKFFPQSGVLIFGKQGSEKTNVDIEKVMITDEEEIRTTNPVATEQYGSVSTNLQRGNRQAATADVNTQGVLPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTTFSAAKFASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSVNVDFTVDTNGVYSEPRPIGTRYLTRNL (SEQ ID NO: 3)

In the above sequences, sequences found in VP1, VP2, and VP3 are underlined (e.g., the VP3 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 203-735 of SEQ ID NO: 3), sequences found in both VP1 and VP2 are bolded (e.g., the VP2 capsid polypeptide comprises, e.g., consists of, sequences corresponding to amino acids 138 to 735 of SEQ ID NO: 3), and sequences that are not underlined or bolded are found only in VP1 (e.g., the VP1 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 1 to 735 of SEQ ID NO: 3).

An exemplary nucleic acid sequence encoding SEQ ID NO:3 is SEQ ID NO:4.

An exemplary reference sequence of wild-type AAV5, SEQ ID NO: 5 (wild-type AAV5), is as follows: MSFVDHPPDWLEEVGEGLREFLGLEAGPPKPKPNQQHQDQARGLVLPGYNYLGPGNGLDRGEPVNRADEVAREHDISYNEQLEAGDNPYLKYNHADAEFQEKLADDTSFGGNLGKAVFQAKKRVLEPFGLVEEGAK TAPTGKRIDDHFPKRKKARTEEDSKPSTSSDAEAGPSGSQQLQIPAQPASSLGADT MSAGGGGPLGDNNQGADGVGNASGDWHCDSTWMGDRVVTKSTRTWVLPSYNNHQYREIKSGSVDGSNANAYFGYSTPWGYFDFNRFHSHWSPRDWQRLINNYWGFRPRSLRVKIFNIQVKEVTVQDSTTTIANNLTSTVQVFTDDDYQLPYVVGNGTEGCLPAFPPQVFTLPQYGYATLNRDNTENPTERSSFFCLEYFPSKMLRTGNNFEFTYNFEEVPFHSSFAPSQNLFKLANPLVDQYLYRFVSTNNTGGVQFNKNLAGRYANTYKNWFPGPMGRTQGWNLGSGVNRASVSAFATTNRMELEGASYQVPPQPNGMTNNLQGSNTYALENTMIFNSQPANPGTTATYLEGNMLITSESETQPVNRVAYNVGGQMATNNQSSTTAPATGTYNLQEIVPGSVWMERDVYLQGPIWAKIPETGAHFHPSPAMGGFGLKHPPPMMLIKNTPVPGNITSFSDVPVSSFITQYSTGQVTVEMEWELKKENSKRWNPEIQYTNNYNDPQFVDFAPDSTGEYRTTRPIGTRYLTRPL (SEQ ID NO:5)

In the above sequences, sequences found in VP1, VP2, and VP3 are underlined (e.g., the VP3 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 193 to 725 of SEQ ID NO:5), sequences found in both VP1 and VP2 are bolded (e.g., the VP2 capsid polypeptide comprises, e.g., consists of, sequences corresponding to amino acids 137-725 of SEQ ID NO:5), and sequences that are not underlined or bolded are found only in VP1 (e.g., the VP1 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 1 to 725 of SEQ ID NO:5).

An exemplary nucleic acid sequence encoding SEQ ID NO:5 is SEQ ID NO:6.

An exemplary reference sequence of wild-type AAV8, SEQ ID NO: 7 (wild-type AAV8), is as follows: MAADGYLPDWLEDNLSEGIREWWALKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEPSPQRSPDSSTGIGKKGQQPARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGPNT MAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGATNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLSFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFQFTYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTGGTANTQTLGFSQGGPNTMANQAKNWLPGPCYRQQRVSTTTGQNNNSNFAWTAGTKYHLNGRNSLANPGIAMATHKDDEERFFPSNGILIFGKQNAARDNADYSDVMLTSEEEIKTTNPVATEEYGIVADNLQQQNTAPQIGTVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQSKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTSVDFAVNTEGVYSEPRPIGTRYLTRNL (SEQ ID NO:7)

In the above sequences, sequences found in VP1, VP2, and VP3 are underlined (e.g., the VP3 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 204-739 of SEQ ID NO:7), sequences found in both VP1 and VP2 are bolded (e.g., the VP2 capsid polypeptide comprises, e.g., consists of, sequences corresponding to amino acids 138 to 735 of SEQ ID NO:7), and sequences that are not underlined or bolded are found only in VP1 (e.g., the VP1 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 1 to 739 of SEQ ID NO:7).

An exemplary nucleic acid sequence encoding SEQ ID NO:7 is SEQ ID NO:8.

An exemplary reference sequence of wild-type AAVrh74, SEQ ID NO: 9 (wild-type AAVrh74), is as follows: MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDNGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVESPVKTAPGKKRPVEPSPQRSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVPDPQPIGEPPAGPSGLGSGT MAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEERFFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNAAPIVGAVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQAKLASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLTRNL (SEQ ID NO:9)

An alternative exemplary reference sequence to SEQ ID NO: 11 (instead of wild-type AAVrh74 ) is as follows: MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDNGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVESPVKTAPGKKRPVEPSPQRSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVPDPQPIGEPPAGPSGLGSGT MAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEERFFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNAAPIVGAVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFTKAKLASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLTRNL (SEQ ID NO: 11)

In the above sequences (SEQ ID NO:9 or SEQ ID NO:11), sequences found in VP1, VP2, and VP3 are underlined (e.g., the VP3 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 204 to 739 of SEQ ID NO:9), sequences found in both VP1 and VP2 are bolded (e.g., the VP2 capsid polypeptide comprises, e.g., consists of, sequences corresponding to amino acids 137 to 739 of SEQ ID NO:9), and sequences that are not underlined or bolded are found only in VP1 (e.g., the VP1 capsid polypeptide comprises, e.g., consists of, amino acids corresponding to amino acids 1 to 739 of SEQ ID NO:9).

An exemplary nucleic acid sequence encoding SEQ ID NO:9 is SEQ ID NO:10.

This article is about the structural capsid proteins (including VP1, VP2, and VP3) encoded by the capsid (Cap) gene. These capsid proteins form the proteinaceous outer shell (i.e., the capsid) of viral vectors such as AAV. VP capsid proteins synthesized from Cap polynucleotides typically include methionine as the first amino acid (Met1) in the peptide sequence, associated with the start codon (AUG or ATG) in the corresponding Cap nucleotide sequence. However, the first methionine (Met1) residue, or substantially any first amino acid (AA1), is typically cleaved off after or during polypeptide synthesis by protein processing enzymes such as Met-aminopeptidases. This "Met/AA-clipping" process is typically associated with the corresponding acetylation of the second amino acid in the polypeptide sequence (e.g., alanine, valine, serine, threonine, etc.). Met-clipping is typically performed by the VP1 and VP3 coat proteins, but can also be performed by the VP2 coat protein. Incomplete Met/AA-clipping results in a mixture of one or more (one, two, or three) VP coat proteins comprising the viral capsid, some of which contain the Met1/AA1 amino acid sequence (Met+/AA+) and some of which lack the Met1/AA1 amino acid sequence due to Met/AA-clipping (Met-/AA-). For further discussion of Met/AA-depletion in capsid proteins, see Jin et al., Direct Liquid Chromatography/Mass Spectrometry Analysis for Complete Characterization of Recombinant Adeno-Associated Virus Capsid Proteins. Hum Gene Ther Methods. 2017 Oct 28(5):255-267; Hwang et al., N-Terminal Acetylation of Cellular Proteins Creates Specific Degradation Signals. Science. 2010 Feb 19. 327(5968):973-977; the contents of each of these references are incorporated herein by reference in their entirety. According to the present invention, references to capsid polypeptides are not limited to those that are depleted (Met-/AA-) or those that are not depleted (Met+/AA+), and in the context also refer to individual capsid polypeptides, viral capsids composed of a mixture of capsid proteins, and/or polynucleotide sequences (or fragments thereof) that encode, describe, produce, or generate the capsid polypeptides described herein. Direct references to "capsid polypeptides" (such as VP1, VP2, or VP3) also include VP capsid proteins that include the Met1/AA1 amino acids (Met+/AA+), as well as the corresponding VP capsid polypeptides that lack the Met1/AA1 amino acids due to Met/AA- depletion (Met-/AA-). Further herein, reference to a specific SEQ ID NO: (whether protein or nucleic acid) that comprises or encodes one or more capsid polypeptides including Met1/AA1 amino acids (Met+/AA+) is to be understood as teaching VP capsid polypeptides that lack the Met1/AA1 amino acids, as any sequence lacking only the first listed amino acid (whether Met1/AA1) is readily apparent upon inspection of the sequence. As a non-limiting example, reference to a VP1 polypeptide sequence that is 736 amino acids in length and includes the "Met1" amino acid (Met+) encoded by the AUG/ATG start codon is also to be understood as teaching a VP1 polypeptide sequence that is 735 amino acids in length and does not include the "Met1" amino acid (Met-) of the 736 amino acid Met+ sequence. As a second non-limiting example, reference to a VP1 polypeptide sequence that is 736 amino acids in length and includes the "AA1" amino acid encoded by any NNN start codon (AA1+) can also be understood to teach a VP1 polypeptide sequence that is 735 amino acids in length and does not include the "AA1" amino acid of the 736-amino acid AA1+ sequence (AA1-). References to viral capsids formed by VP capsid proteins (e.g., references to specific AAV capsid serotypes) can include VP capsid proteins that include the Met1/AA1 amino acids (Met+/AA1+), the corresponding VP capsid proteins that lack the Met1/AA1 amino acids due to Met/AA1- deletion (Met-/AA1-), and combinations thereof (Met+/AA1+ and Met-/AA1-). As a non-limiting example, an AAV capsid serotype may include VP1 (Met+/AA1+), VP1 (Met-/AA1-), or a combination of VP1 (Met+/AA1+) and VP1 (Met-/AA1-). An AAV capsid serotype may also include VP3 (Met+/AA1+), VP3 (Met-/AA1-), or a combination of VP3 (Met+/AA1+) and VP3 (Met-/AA1-); and may also include similar optional combinations of VP2 (Met+/AA1) and VP2 (Met-/AA1-).

In some embodiments, a reference AAV capsid sequence comprises an amino acid sequence that is 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of those described above.

In some embodiments, the reference AAV capsid sequence is encoded by a nucleotide sequence having 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any of those described above. In certain embodiments, the reference sequence is not an AAV capsid sequence and is actually a different vector (e.g., lentivirus, plasmid, etc.).

In some embodiments, the nucleic acid herein (e.g., encoding an AAV9 variant capsid protein) comprises a known control element or sequence that is operably linked to the nucleic acid molecule in a manner that allows transcription, translation, and/or expression in cells transfected with the nucleic acid (e.g., a plasmid vector comprising the nucleic acid) or infected with a virus comprising the nucleic acid. As used herein, "operably linked" sequences include both expression control sequences that are adjacent to the gene of interest and expression control sequences that act lateral to or at a distance to control the gene of interest.

Expression control sequences include efficient RNA processing signals, such as splicing and polyadenylation (polyA) signals; appropriate transcription initiation, termination, promoter, and enhancer sequences; sequences that stabilize cytoplasmic mRNA; sequences that enhance protein stability; sequences that enhance translation efficiency (e.g., Kozak consensus sequences); and, in some embodiments, sequences that enhance secretion of the encoded transgene product. Expression control sequences (including natural, constitutive, induced, and/or tissue-specific promoters) are known in the art and can be used with the compositions and methods disclosed herein.

In some embodiments, the transgene's native promoter is used. Without theoretical constraints, the native promoter can mimic the transgene's native expression, or provide temporal, developmental, or tissue-specific expression, or expression in response to a specific transcriptional stimulus. In some embodiments, the transgene is operably linked to other native expression control elements, such as enhancer elements, polyadenylation sites, or Kozak consensus sequences, for example, to mimic native expression.

In some embodiments, the transgene is operably linked to a tissue-specific promoter, such as a promoter that is particularly active in one or more CNS cell types. In some embodiments, the transgene is operably linked to a promoter that is active in skeletal muscle. A promoter active in skeletal muscle may be specific to skeletal muscle or more broadly expressed in other muscle types.

In some embodiments, the vector (e.g., a plasmid) carrying the transgene includes a selectable marker or reporter gene. Such selectable reporter or marker genes can be used to signal the presence of the vector (e.g., a plasmid) in the bacterial cell. Other components of the vector (e.g., a plasmid) include an origin of replication. The selection of these and other promoters and vector elements is known, and many such sequences are available (see, e.g., Sambrook et al. and references cited therein).

In some embodiments, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit increased CNS transduction compared to viral particles having a wild-type capsid polypeptide (SEQ ID NO: 1).

In some embodiments, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit increased skeletal muscle transduction compared to viral particles having a wild-type capsid polypeptide (SEQ ID NO: 1).

In some embodiments, the capsid polypeptide is an isolated or purified polypeptide (e.g., isolated or purified from cells, other biological components, or contaminants). In some embodiments, the variant polypeptide is present in a dependent parvovirus particle, such as described herein. In some embodiments, the variant capsid polypeptide is present in a cell, a cell-free system, or a translation system, such as described herein.

In some embodiments, the capsid polypeptide is present in an AAV9-dependent parvovirus B (e.g., AAV9) particle. In some embodiments, the capsid particle has increased CNS transduction. In some embodiments, the capsid particle has increased skeletal muscle transduction.

In some embodiments, the dependent microviral particles comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence provided herein (e.g., any one of SEQ ID NO: 12 to SEQ ID NO: 158). In some embodiments, the variant capsid polypeptide comprises an amino acid sequence that differs from the amino acid sequence of a variant capsid polypeptide provided herein by no more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid.

In some embodiments, the additional changes improve the production characteristics of the dependent microviral particles or their methods of preparation. In some embodiments, the additional changes improve or alter another characteristic of the dependent microviral particles, such as tropism. 6.2.1. Targeting Peptides

The capsid polypeptides described herein may (but need not) include a targeting peptide to alter the tropism of the capsid polypeptide, for example, to enhance targeting to the CNS or skeletal muscle. Thus, in some embodiments, the capsid polypeptides described herein include a targeting peptide. In other embodiments, the capsid polypeptides described herein do not include a targeting peptide. 6.2.1.1. CNS Targeting Peptides

Various targeting peptides for enhancing CNS tropism that may be included in the capsid polypeptides herein are described in the art, for example, in WO 2017/197355, WO 2019/006182, WO 2019/060454, WO 2012/145601, WO 2018/022905, WO 2021/243085, WO 2019/076856, WO 2015/038958, WO 2015/191508, WO 2020/068990, WO 2020/210655, WO 2020/198737, WO 2020/028751, WO 2019/028306, WO 2017/100671 A1, WO 2020/028751 A2, WO 2020/072683 A1, WO 2020/160337 A1, WO 2020/223280 A1, WO 2021/025995 A1, WO 2021/202651 A1, WO 2021/230987 A1, WO 2022/235702 A1、WO 2020/014471、WO 2018/189244、WO 2019/141765、WO 2019/207132、WO 2019/210267、WO 2018/156654、WO 2010/093784、WO 2015/048534、WO 2017/058892、WO 2019/169132、WO 2021/108468、WO 2021/102234、WO 2022/173847、WO 2021/077000、WO 2020/160337、WO 2021/050974、WO 2021/222831、WO 2022/020616、WO 2020/193799、WO 2021/072197、WO 2022/126188、WO 2022/126189、WO 2021/165544、WO 2021/084133、WO 2022/040527、WO 2022/221400, WO 2022/221404, WO 2022/221420, WO 2021/216456, WO 2021/009684, WO 2021/242909, WO 2019/158619, WO 2021/226267, WO 2023/283962, WO 2021/219762, WO 2022/226374, WO 2022/226375, WO 2022/229703 and WO 2022/229702, the contents of which are incorporated herein by reference in their entirety. Targeting peptides are typically 3 to 20 amino acids in length. In some embodiments, the targeting peptide is 3 to 12 amino acids long. In other embodiments, the targeting peptide is 5 to 12 amino acids long. In other embodiments, the targeting peptide is 5 to 10 amino acids long. In other embodiments, the targeting peptide is 7 to 10 amino acids long. In some embodiments, the targeting peptide is 7 amino acids long. In other embodiments, the targeting peptide is 9 amino acids long.

In some embodiments, the targeting peptide comprises at least 3, 4, 5, 6, 7, 8 or 9 consecutive amino acids from the amino acid sequence of PLNGAVHLY (SEQ ID NO: 308). In some embodiments, the targeting peptide comprises the amino acid sequence PLNGAVHLY (SEQ ID NO: 308). In some embodiments, the targeting peptide comprises at least 3, 4, 5, 6 or 7 consecutive amino acids from the amino acid sequence of IVMNSLK (SEQ ID NO: 309). In some embodiments, the targeting peptide comprises the amino acid sequence IVMNSLK (SEQ ID NO: 309). In some embodiments, the targeting peptide comprises at least 3, 4, 5, 6 or 7 consecutive amino acids from the amino acid sequence of RDSPKGW (SEQ ID NO: 310). In some embodiments, the targeting peptide comprises the amino acid sequence RDSPKGW (SEQ ID NO: 310). In some embodiments, the targeting peptide comprises at least 3, 4, 5, 6, or 7 consecutive amino acids from the amino acid sequence of YSTDVRM (SEQ ID NO: 311). In some embodiments, the targeting peptide comprises the amino acid sequence YSTDVRM (SEQ ID NO: 311). In some embodiments, the targeting peptide comprises at least 3, 4, 5, 6, or 7 consecutive amino acids from the amino acid sequence of RESPRGL (SEQ ID NO: 312). In some embodiments, the targeting peptide comprises the amino acid sequence RESPRGL (SEQ ID NO: 312). In some embodiments, the targeting peptide comprises 4, 5, 6, or 7 consecutive amino acids from GNNTRSV (SEQ ID NO: 313), GNNTRDT (SEQ ID NO: 314), or TNSTRPV (SEQ ID NO: 315). In some embodiments, the targeting peptide comprises the amino acid sequence GNNTRSV (SEQ ID NO: 313). In some embodiments, the targeting peptide comprises the amino acid sequence GNNTRDT (SEQ ID NO: 314). In some embodiments, the targeting peptide comprises the amino acid sequence TNSTRPV (SEQ ID NO: 315).

In some embodiments, the CNS targeting peptide is present in (e.g., inserted into) loop VIII of a capsid polypeptide. In some embodiments, the targeting peptide is inserted at any amino acid position corresponding to positions 586-592 (inclusive) of a wild-type capsid polypeptide (SEQ ID NO: 1). For example, the targeting peptide can be inserted between amino acids 588-589 (positions corresponding to a wild-type capsid polypeptide (SEQ ID NO: 1)). In some embodiments, the targeting peptide is present in (e.g., inserted into) immediately following positions 586, 588, or 589 of a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide further comprises a deletion at position 587 and/or a deletion at position 588 of a wild-type capsid polypeptide (SEQ ID NO: 1). 6.2.1.2. Muscle-targeted peptides

Various targeting peptides for enhancing skeletal muscle tropism that may be included in the capsid polypeptides herein are described in the art, for example, in WO 2020/206189 A1, WO 2022/226374 A1, WO 2022/053630 A1, and WO 2019/207132 A1.

In some embodiments, the muscle targeting peptide comprises at least 3, 4, 5, 6, or 7 consecutive amino acids from the amino acid sequence ASSLNIA (SEQ ID NO: 316).

In some embodiments, the targeting peptide targets the insulin receptor (INSR). In some embodiments, the peptide targeting INSR comprises an amino acid sequence having at least 80%, 87%, 91%, 94%, 97%, or 100% sequence identity to SLEEEWAQVECEVYGRGCPSGSLDESFYDWFERQL (SEQ ID NO: 317) or at least 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 consecutive amino acids from the amino acid sequence SLEEEWAQVECEVYGRGCPSGSLDESFYDWFERQL (SEQ ID NO: 317).

In some embodiments, the targeting peptide targets muscle-specific kinase (MUSK). In some embodiments, the inserted MUSK targeting peptide is derived from the acetylcholinesterase collagen tail peptide (ColQ), such as the C-terminal portion of ColQ (ColQ CTD). In some embodiments, the ColQ CTD peptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to TPFYPVGYTVKQPGTCGDGVLQPGEECDDGNPDVSDGCIDCHRAYCGDGYRHQGVEDCDGSDFGYLTCETYLPGSYGDLRCTQYCSIDSTPCRYFT (SEQ ID NO: 318) or at least 70, 80, 85, 90, 91, 92, 93, 94, 95, or 96 consecutive amino acids from the amino acid sequence TPFYPVGYTVKQPGTCGDGVLQPGEECDDGNPDVSDGCIDCHRAYCGDGYRHQGVEDCDGSDFGYLTCETYLPGSYGDLRCTQYCSIDSTPCRYFT (SEQ ID NO: 318).

In some embodiments, the targeting peptide targets integrins, for example, via an RGD motif. In some embodiments, the RGD peptide comprises a subsequence of Y or F amino acids to produce the RGDY (SEQ ID NO: 319) or _RGDF (SEQ ID NO: ₃₂₀ ) motif. In some embodiments, the integrin targeting peptide comprises the motif _RGDX1X2X3X4 (SEQ ID NO: 321), wherein each of _X1 to _X4 is any _amino acid. In various embodiments of SEQ ID NO: 319, _X1 , _X2 , and _X3 are each independently selected from L, G, V, and A, and/or _X4 is S, V, A, G, or L. In some embodiments, at least one of _X2 and _X3 is G. In some embodiments, the targeting peptide comprises the amino acid sequence RGDLGLS (SEQ ID NO: 322). In some embodiments, the targeting peptide comprises the amino acid sequence RGDLSTP (SEQ ID NO: 323). In some embodiments, the targeting peptide comprises the amino acid sequence SNSRGDYNSL (SEQ ID NO: 324). In some embodiments, the targeting peptide comprises the amino acid sequence ENRRGDFNNT (SEQ ID NO: 325). In some embodiments, the targeting peptide comprises the amino acid sequence SRGDYNSL (SEQ ID NO: 326). In some embodiments, the targeting peptide comprises the amino acid sequence RGDYNSL (SEQ ID NO: 327). In some embodiments, the targeting peptide comprises the amino acid sequence RGDLST (SEQ ID NO: 328). In some embodiments, the targeting peptide comprises the amino acid sequence RGDYVGL (SEQ ID NO: 329). In some embodiments, the targeting peptide comprises the amino acid sequence RGDAVGV (SEQ ID NO: 330). The RGD peptide can be inserted into a linker scaffold, such as a flexible linker, such as GGGS (SEQ ID NO: 331). Other suitable linker scaffolds can be found in WO 2022/226374 A1, pages 26-28 of which are incorporated herein by reference.

In some embodiments, the skeletal muscle targeting peptide is present (e.g., inserted) within loop VIII of a capsid polypeptide. In some embodiments, the targeting peptide is inserted at any amino acid position corresponding to positions 586-592 (inclusive) of a wild-type capsid polypeptide (SEQ ID NO: 1). For example, the targeting peptide can be inserted between amino acids 588-589 (positions corresponding to a wild-type capsid polypeptide (SEQ ID NO: 1)). In some embodiments, the targeting peptide is present (e.g., inserted) immediately following positions 586, 588, or 589 of a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide further comprises a deletion at position 587 and/or a deletion at position 588 of a wild-type capsid polypeptide (SEQ ID NO: 1). 6.2.2. Nucleic Acids and Peptides

This disclosure further relates, in part, to a nucleic acid comprising a sequence encoding a variant capsid polypeptide as provided herein. In embodiments, the nucleic acid encodes, for example, a VP1 variant capsid polypeptide as described herein. In embodiments, the nucleic acid encodes, for example, a VP2 variant capsid polypeptide as described herein. In embodiments, the nucleic acid encodes, for example, a VP3 variant capsid polypeptide as described herein. In embodiments, the nucleic acid encodes, for example, VP1, VP2, and VP3 variant capsid polypeptides as described herein. In some embodiments, the variant capsid polypeptide comprises the sequence of any one of SEQ ID NO:12 to SEQ ID NO:158. In some embodiments, the nucleic acid comprises SEQ ID NO:159 to SEQ ID NO:305, respectively. 6.3. Dependent Small Virus Particles

This document is also directed, in part, to dependency parvoviral particles (e.g., functional dependency parvoviral particles) comprising a nucleic acid or polypeptide described herein or produced by a method described herein.

Parvoviruses are single-stranded DNA viruses that grow only in cells where certain functions, such as those provided by co-infecting helper viruses, are required. Several species of parvoviruses are known, including parvovirus A and parvovirus B, which include serotypes known in the art as adeno-associated viruses (AAV). At least thirteen AAV serotypes have been characterized. General information and reviews of AAV can be found, for example, in Carter, Handbook of Parvoviruses , Vol. 1, pp. 169-228 (1989), and Berns, Virology , pp. 1743-1764, Raven Press, (New York, 1990). AAV serotypes, and to a certain extent, parvovirus species, are structurally and functionally related. (See, e.g., Blacklowe, Parvoviruses and Human Disease , ed. J.R. Pattison (1988), pp. 165-174; and Rose, Comprehensive Virology 3:1-61 (1974). For example, all AAV serotypes clearly display very similar replication properties mediated by homologous rep genes; and all possess three related capsid proteins. In addition, heteroduplex analysis reveals extensive cross-hybridization between serotypes along the length of the genome, further suggesting an interrelationship. The parvovirus genome also contains self-adhesive segments at the ends corresponding to the inverted terminal repeat sequences (ITRs).

The genome organization of naturally occurring dependent parvoviruses, such as the AAV serotypes, is very similar. For example, the AAV genome is a linear, single-stranded DNA molecule of approximately 5,000 nucleotides (nt) or less in length. Inverted terminal repeats (ITRs) flank unique nucleotide sequences encoding nonstructural replication (Rep) proteins and structural capsid (Cap) proteins. Three different viral particle (VP) proteins form the capsid. The terminal approximately 145 nt of the genome is self-complementary and organized to enable the formation of an energetically stable intramolecular double helix that forms a T-shaped hairpin. These hairpin structures serve as the starting point for viral DNA replication and as primers for the cellular DNA polymerase complex. The Rep gene encodes the Rep proteins: Rep78, Rep68, Rep52, and Rep40. Rep78 and Rep68 are transcribed from the p5 promoter, while Rep52 and Rep40 are transcribed from the p19 promoter. The cap gene encodes the VP proteins VP1, VP2, and VP3. The cap gene is transcribed from the p40 promoter.

In some embodiments, the dependent parvoviral particles herein comprise a nucleic acid comprising a variant capsid polypeptide provided herein. In some embodiments, the particles comprise a polypeptide provided herein.

In some embodiments, the dependent parvoviral particles described herein are AAV9 particles. In some embodiments, the AAV9 particles comprise a variant capsid polypeptide provided herein or a nucleic acid molecule encoding the same.

In some embodiments, the dependent microviral particles comprise a variant capsid comprising a variant capsid polypeptide described herein. In embodiments, the dependent microviral particles comprise a variant capsid polypeptide described herein and a nucleic acid molecule. In embodiments, the dependent microviral particles comprise a variant capsid polypeptide described herein and a nucleic acid molecule comprising one or more inverted terminal repeats (ITRs) (e.g., ITRs derived from AAV9 dependent microviruses or AAV2 dependent microviruses), one or more regulatory elements (e.g., a promoter), and a payload (e.g., as described herein, e.g., a heterologous transgene). In embodiments, at least one of the ITRs is modified. In embodiments, the nucleic acid molecule is single-stranded. In embodiments, the nucleic acid molecule is double-stranded, e.g., self-complementary. Various ITRs and their use in self-complementary AAV vectors are recognized in the art and include those described in U.S. Patent Nos. 7,465,583, 8,298,818, and 9,150,882; U.S. Patent Application Publication Nos. 2004/0029106 Al, 2023/0139985 Al, 2022/0175887 Al; and Wilmott et al., 2019, Hum. Gene. Ther. Methods , 30(6):206-213 and McCarty, 2008, Mol. Ther. , 16(10):1648-1656, each of which is incorporated herein by reference. 6.4. Improved biodistribution and transduction characteristics

This document is directed, in part, to nucleic acids, polypeptides, cells, cell-free systems, translation systems, viral particles, and methods related to their use and preparation for producing viral particles that have increased distribution to CNS tissues and cells and/or CNS transduction compared to viral particles comprising a reference sequence that does not otherwise comprise the mutations described herein (or mutations corresponding thereto), e.g., compared to viral particles comprising the capsid polypeptide sequence of SEQ ID NO: 1. In some embodiments, the use of viral particles comprising a variant capsid polypeptide described in Section 6.2 or any of Numbered Examples 1 to 986 (e.g., the viral particles described in Section 6.2 or any of Numbered Examples 1007 to 1165) results in increased CNS biodistribution of viral particles and/or increased transduction of transgenic viral particles broadly in cells of the CNS or specifically in the brain, and thus results in increased expression of the effective load (transgene) in the CNS or brain. In some embodiments, the use of viral particles comprising a variant capsid polypeptide described in Section 6.2 or any of Numbered Examples 1 to 986 (e.g., the viral particles described in Sections 6.3 and 6.4 or any of Numbered Examples 1007 to 1165) further results in reduced (or non-increased) biodistribution of viral particles and/or reduced (or non-increased) transduction of the transgene in one or more peripheral tissues (e.g., liver, spleen, dorsal root ganglion, or any combination of two or more of the foregoing peripheral tissue types). In some embodiments, the use of viral particles comprising a variant capsid polypeptide as described in Section 6.2 or any of Numbered Examples 1 to 986 (e.g., the viral particles described in Sections 5.3 and 5.4 or any of Numbered Examples 1007 to 1165) further results in increased skeletal muscle biodistribution of viral particles and/or increased transduction of transgenic viral particles in skeletal muscle cells, and thus results in increased expression of the effective load (transgene) in skeletal muscle.

In some embodiments, as described herein, for example, in Section 8 (e.g., Example 1 or Example 2), biodistribution and transduction (of the tissue types described in this section, for example) are measured, for example, by relative quantification (e.g., via qPCR) of transgene mRNA in one or more samples isolated from relevant tissue types (e.g., CNS or skeletal muscle). In some embodiments, biodistribution and/or transduction of viral particles harboring variant capsid polypeptides can be measured using viral particles harboring a transgene operably linked to a promoter active in the target cell or tissue type of interest. In some embodiments, the promoter is a ubiquitous promoter. In other embodiments, the promoter is selective or specific for a target cell or tissue type (e.g., CNS and/or muscle (generalized muscle expression or skeletal muscle)) and, optionally, has low (or no) activity in cell or tissue types where transgene expression is not desired (e.g., liver, spleen, PNS, or any combination of two or all of the foregoing). A promoter that is selective for a first cell or tissue type relative to a second cell or tissue type is active in the first cell or tissue type and has low activity or is silent in the second cell or tissue type. In some embodiments, the promoter is CNS-specific or CNS-selective. In some embodiments, the promoter is muscle-specific or muscle-selective. In some embodiments, the promoter is active in both the CNS and muscle tissues. In some embodiments, biodistribution and/or transduction of viral particles harboring variant capsid polypeptides can be measured using viral particles harboring a transgene operably linked to a ubiquitous promoter or a CNS-specific promoter. For example, biodistribution can be measured using viral particles harboring a transgene operably linked to the CBh promoter or the hSYN promoter. In various embodiments, the transgene is a transgene encoding a capsid polypeptide or any other suitable heterologous transgene, such as a nucleic acid encoding a synthetic, mammalian, or human therapeutic protein or nucleic acid (e.g., mRNA or RNAi) or a reporter gene sequence (e.g., encoding a GFP or mCherry reporter).

In embodiments, e.g., as described herein, viral particles comprising, e.g., variant capsid polypeptides described herein, are capable of crossing the blood-brain barrier. In embodiments, viral particles comprising, e.g., variant capsid polypeptides described herein, exhibit increased blood-brain barrier crossing relative to viral particles comprising a reference capsid polypeptide, e.g., a reference capsid polypeptide of SEQ ID NO: 1, e.g., as described herein. In embodiments, viral particles comprising, e.g., variant capsid polypeptides described herein, exhibit increased transduction of neurons, astrocytes, glial cells, or a combination thereof, relative to viral particles comprising a reference capsid polypeptide, e.g., a reference capsid polypeptide of SEQ ID NO: 1, e.g., as described herein.

In some embodiments, viral particles comprising variant capsid polypeptides, such as those described herein, exhibit improved properties, such as improved biodistribution, transduction, and/or production. Unless otherwise indicated, the rate of improvement is presented as a fold improvement compared to the rate exhibited by viral particles comprising the capsid polypeptide of SEQ ID NO: 1. In some embodiments, improvement means an increase, such as an increase in CNS biodistribution or CNS transduction. In other embodiments, improvement means a decrease, such as a decrease in liver biodistribution or liver transduction. Viral particles with increased biodistribution or transduction in target cells or target tissue types (e.g., CNS) and/or reduced biodistribution or transduction in off-target cells or off-target tissue types (e.g., liver) can have improved specificity for the target cells or target tissue types. This improvement can be beneficial for using viral particles to deliver therapeutic transgenes to target cells or target tissue types in individuals suffering from, for example, a disease affecting the target cells or target tissue types.

In some embodiments, one or more improved properties (e.g., increased or decreased biodistribution and/or transduction) are exhibited in mammals (e.g., primates, such as humans). In some embodiments, increased or decreased biodistribution and/or transduction is exhibited following administration of a viral particle or a pharmaceutical composition comprising the viral particle (e.g., as described herein, by systemic administration, such as intravenous administration).

In some embodiments, viral particles comprising variant capsid polypeptides exhibit improvements in one or more categories as defined below.

In some embodiments, the viral particles exhibit improvements in Class A (CNS biodistribution) and Class B (CNS transduction). These improvements can be beneficial for using viral particles to deliver therapeutic transgenes to the CNS of individuals suffering from, for example, diseases affecting the CNS. In some embodiments, the viral particles exhibit improvements in Class A (CNS biodistribution) and Class B (CNS transduction), as well as one or more of Class C (PNS biodistribution and/or transduction), Class D (liver biodistribution and/or transduction), and Class E (spleen biodistribution and/or transduction). In some embodiments, the viral particles exhibit improvements in Class A (CNS biodistribution), Class B (CNS transduction), and Class D (liver biodistribution and/or transduction), and optionally, Class C (PNS biodistribution and/or transduction) and/or Class E (spleen biodistribution and/or transduction). Optionally, viral particles may also demonstrate improvements in Class F (skeletal muscle biodistribution) and/or Class G (skeletal muscle transduction), for example to deliver therapeutic transgenes to patients with diseases affecting both the CNS and skeletal muscle tissue (e.g., SMA, multiple sclerosis, amyotrophic lateral sclerosis (ALS), ataxia, Becker muscular dystrophy, Charcot-Marie-Tooth disease, dystonia, Friedreich's ataxia, glycogen storage disease II, Kennedy disease, Lambert-Eaton Myasthenic syndrome, Both the central nervous system and muscles in individuals with schizophrenia, mitochondrial DNA depletion syndrome, myo-oculo-encephalopathy, neuromyotonia, periodic paralysis, juvenile primary lateral sclerosis, progressive external ophthalmoplegia, spastic paraplegia, congenital stiff-person syndrome, delayed akinesia, Werdnig-Hoffman disease, or X-linked spinal and bulbar muscular dystrophy.

In further embodiments, viral particles comprising variant capsid polypeptides exhibit improvements in Class F (skeletal muscle biodistribution) and/or Class G (skeletal muscle transduction). In some embodiments, viral particles exhibit improvements in both Class F (skeletal muscle biodistribution) and Class G (skeletal muscle transduction). These improvements may be beneficial for the use of viral particles to deliver therapeutic transgenes to skeletal muscle tissue in individuals suffering from, for example, diseases affecting skeletal muscle. In some embodiments, the virosomes exhibit improvements in one or more of Class F (skeletal muscle biodistribution) and/or Class G (skeletal muscle transduction), and Class C (PNS biodistribution and/or transduction), Class D (liver biodistribution and/or transduction), and Class E (spleen biodistribution and/or transduction). In some embodiments, the virosomes exhibit improvements in Class F (skeletal muscle biodistribution) and/or Class G (skeletal muscle transduction), as well as improvements in Class D (liver biodistribution and/or transduction), and, as appropriate, further exhibit improvements in Class C (PNS biodistribution and/or transduction) and/or Class E (spleen biodistribution and/or transduction).

Category A (CNS biodistribution ) : In some embodiments herein, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit increased CNS biodistribution compared to viral particles comprising a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased CNS biodistribution comprises increased brain biodistribution and/or spinal cord biodistribution. In some embodiments, the increased brain biodistribution is total brain biodistribution or biodistribution in a specific brain tissue (e.g., brainstem, basal ganglia, cerebellum, forebrain, hippocampus, midbrain, or temporal cortex), in each case measured using a CNS-specific promoter (e.g., hSyn), using a persistent promoter (e.g., Cbh), or using a combination of a CNS-specific promoter (e.g., hSyn) and a persistent promoter (e.g., Cbh). In some embodiments, the increased biodistribution is increased total brain biodistribution using the Cbh or hSyn promoter and/or as defined in any of Examples A1 to A3.

Embodiment A1 : In one embodiment of Class A, the biodistribution is about (or at least about) 3-fold better compared to a viral particle comprising a variant capsid polypeptide having a reference sequence, such as a wild-type capsid protein, such as a capsid polypeptide having SEQ ID NO: 1.

Embodiment A2 : In one embodiment of Class A, the biodistribution is about (or at least about) 10-fold better compared to viral particles comprising a variant capsid polypeptide having a reference sequence, such as a wild-type capsid protein, such as a capsid polypeptide having SEQ ID NO: 1.

Embodiment A3 : In one embodiment of Class A, the biodistribution is about (or at least about) 25-fold better relative to viral particles comprising a variant capsid polypeptide having a reference sequence, such as a wild-type capsid protein, such as a capsid polypeptide having SEQ ID NO: 1.

Category B (CNS transduction ) : In some embodiments herein, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit increased CNS transduction compared to viral particles comprising a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased CNS transduction comprises increased brain transduction and/or spinal cord transduction. In some embodiments, increased brain transduction is total brain transduction or transduction in a specific brain tissue (e.g., brainstem, basal ganglia, cerebellum, forebrain, hippocampus, midbrain, or temporal cortex), in each case measured with a CNS-specific promoter (e.g., hSyn), with a persistent promoter (e.g., Cbh), or with a combination of a CNS-specific promoter (e.g., hSyn) and a persistent promoter (e.g., Cbh). In some embodiments, increased transduction is increased total brain transduction using the Cbh or hSyn promoter and/or as defined in any of Examples B1 to B3.

Embodiment B1 : In one embodiment of Class B, the transduction is about (or at least about) 3-fold greater than that of a viral particle comprising a variant capsid polypeptide having a reference sequence, eg, a wild-type capsid protein, eg, a capsid polypeptide having SEQ ID NO: 1.

Embodiment B2 : In one embodiment of Class B, the transduction is about (or at least about) 10-fold better compared to a viral particle comprising a variant capsid polypeptide having a reference sequence, eg, a wild-type capsid protein, eg, a capsid polypeptide having SEQ ID NO: 1.

Embodiment B3 : In one embodiment of Class B, the transduction is about (or at least about) 25-fold better compared to a viral particle comprising a variant capsid polypeptide having a reference sequence, eg, a wild-type capsid protein, eg, a capsid polypeptide having SEQ ID NO: 1.

Category C ( Peripheral Nervous System ( " PNS " ) Biodistribution and / or Transduction ) : In some aspects herein, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit similar or reduced PNS biodistribution and/or transduction compared to viral particles comprising a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, PNS biodistribution and/or transduction is measured using a CNS-specific promoter (e.g., hSyn), using a persistent promoter (e.g., Cbh), or using a combination of a CNS-specific promoter (e.g., hSyn) and a persistent promoter (e.g., Cbh). In some embodiments, PNS biodistribution and/or transduction is DRG biodistribution and/or transduction and/or as defined in any one of Embodiments C1 to C3.

Embodiment C1 : In one embodiment of Class C, the PNS biodistribution and/or transduction is increased by about (or not more than about) 5-fold relative to a viral particle comprising a variant capsid polypeptide having a reference sequence, e.g., a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Embodiment C2 : In one embodiment of Class C, the PNS biodistribution and/or transduction is increased by about (or not more than about) 3-fold relative to a viral particle comprising a variant capsid polypeptide having a reference sequence, e.g., a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Embodiment C3 : In one embodiment of Class C, the PNS biodistribution and/or transduction is increased by about (or not more than about) 1.5-fold relative to a viral particle comprising a variant capsid polypeptide having a reference sequence, e.g., a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Category D ( liver biodistribution and / or transduction ) : In some aspects herein, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit similar or reduced liver biodistribution and/or transduction compared to viral particles comprising a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, liver biodistribution and/or transduction is measured using a CNS-specific promoter (e.g., hSyn), using a persistent promoter (e.g., Cbh), or using a combination of a CNS-specific promoter (e.g., hSyn) and a persistent promoter (e.g., Cbh). In some embodiments, liver biodistribution and/or transduction is as defined in any one of Embodiments D1 to D3.

Embodiment D1 : In one embodiment of Class D, the liver biodistribution and/or transduction is about (or no more than about) 1-fold greater than the liver biodistribution and/or transduction of a viral particle comprising a reference sequence, e.g., a variant capsid polypeptide having a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Embodiment D2 : In one embodiment of Class D, the liver biodistribution and/or transduction is about (or no more than about) 0.8 times the liver biodistribution and/or transduction of a viral particle comprising a reference sequence, e.g., a variant capsid polypeptide having a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Embodiment D3 : In one embodiment of Class D, the liver biodistribution and/or transduction is about (or no more than about) 0.6 times the liver biodistribution and/or transduction of a viral particle comprising a reference sequence, e.g., a variant capsid polypeptide having a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Category E ( Spleen Biodistribution and / or Transduction ) : In some aspects herein, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit similar or reduced spleen biodistribution and/or transduction compared to viral particles comprising a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, spleen biodistribution and/or transduction is measured using a CNS-specific promoter (e.g., hSyn), using a persister promoter (e.g., Cbh), or using a combination of a CNS-specific promoter (e.g., hSyn) and a persister promoter (e.g., Cbh). In some embodiments, spleen biodistribution and/or transduction is as defined in any one of Embodiments E1 to E3.

Embodiment E1 : In one embodiment of Class E, the spleen biodistribution and/or transduction is about (or no more than about) 5-fold greater than the spleen biodistribution and/or transduction of viral particles comprising a reference sequence, e.g., a variant capsid polypeptide having a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Embodiment E2 : In one embodiment of Class E, the spleen biodistribution and/or transduction is about (or no more than about) 3-fold greater than the spleen biodistribution and/or transduction of viral particles comprising a reference sequence, e.g., a variant capsid polypeptide having a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Embodiment E3 : In one embodiment of Class E, the spleen biodistribution and/or transduction is about (or no more than about) 1-fold greater than the spleen biodistribution and/or transduction of viral particles comprising a reference sequence, e.g., a variant capsid polypeptide having a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1.

Category F ( Skeletal Muscle Biodistribution ) : In some embodiments herein, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit increased skeletal muscle biodistribution compared to viral particles comprising a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased skeletal muscle biodistribution is measured using a constitutive promoter (e.g., Cbh). In some embodiments, the increased skeletal muscle biodistribution is as defined in any of Embodiments F1 to F3.

Embodiment F1 : In one embodiment of Class F, the biodistribution is about (or at least about) 1.5-fold better relative to a viral particle comprising a variant capsid polypeptide having a reference sequence, such as a wild-type capsid protein, such as a capsid polypeptide having SEQ ID NO: 1.

Embodiment F2 : In one embodiment of Class F, the biodistribution is about (or at least about) 2-fold better relative to a viral particle comprising a variant capsid polypeptide having a reference sequence, eg, a wild-type capsid protein, eg, a capsid polypeptide having SEQ ID NO: 1.

Embodiment F3 : In one embodiment of Class F, the biodistribution is about (or at least about) 3-fold better relative to a viral particle comprising a variant capsid polypeptide having a reference sequence, such as a wild-type capsid protein, such as a capsid polypeptide having SEQ ID NO: 1.

Category G ( Skeletal Muscle Transduction ) : In some embodiments herein, viral particles comprising a variant capsid polypeptide (e.g., a variant capsid polypeptide described herein) exhibit increased skeletal muscle transduction compared to viral particles comprising a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased skeletal muscle biodistribution is measured using a constitutive promoter (e.g., Cbh). In some embodiments, the increased skeletal muscle transduction is as defined in any of Embodiments G1 to G3.

Embodiment G1 : In one embodiment of Class G, the transduction is about (or at least about) 1.5-fold greater than that of a viral particle comprising a variant capsid polypeptide having a reference sequence, eg, a wild-type capsid protein, eg, a capsid polypeptide having SEQ ID NO: 1.

Embodiment G2 : In one embodiment of class G, the transduction is about (or at least about) 2-fold greater than that of a viral particle comprising a variant capsid polypeptide having a reference sequence, eg, a wild-type capsid protein, eg, a capsid polypeptide having SEQ ID NO: 1.

Embodiment G3 : In one embodiment of Class G, the transduction is about (or at least about) 3-fold greater than that of a viral particle comprising a variant capsid polypeptide having a reference sequence, e.g., a wild-type capsid protein, e.g., a capsid polypeptide having SEQ ID NO: 1. 6.5. Methods of Preparing the Compositions Described herein

This disclosure is directed, in part, to a method for producing dependent microviral particles, such as those described herein. In some embodiments, the method for producing dependent microviral particles comprises providing cells, a cell-free system, or other translation system comprising a nucleic acid encoding a variant capsid polypeptide or a polypeptide provided herein (e.g., a variant capsid polypeptide), and culturing the cells, the cell-free system, or other translation system under conditions suitable for producing the dependent microviral particles, thereby producing the dependent microviral particles.

In some embodiments, the nucleic acids or polypeptides described herein are produced by methods known to those skilled in the art. In some embodiments, the nucleic acids, polypeptides, and fragments thereof described herein are produced by any suitable means, including recombinant production, chemical synthesis, or other synthetic means. Such production methods are within the knowledge of those skilled in the art and are not limitations of the present invention. 6.5.1. Host Cells

The scope of the present invention is directed to a host cell comprising a nucleic acid herein (encoding a variant capsid polypeptide, such as described in Section 6.2).

Host cells herein (e.g., host cells useful for producing conventional AAV viral particles comprising variant AAV capsids as described herein) generally contain one or more nucleic acids encoding sequences encoding a variant capsid polypeptide as described herein (e.g., as described in Section 6.2) and a payload (e.g., a transgene), as well as one or more coding sequences encoding additional components that facilitate packaging of the payload into the receptive parvoviral capsid. Additional components include, for example, sequences encoding the rep protein and receptive parvoviral inverted terminal repeats (ITRs), as well as auxiliary sequences that facilitate production and/or secretion of receptive parvoviral particles. Examples of auxiliary sequences include E1a, E1b, E2a, E4, and VA. These helper sequences can be included endogenously in the host cell (e.g., the host cell can be engineered to express these helper sequences, e.g., integrated into the host cell genome), or can be provided exogenously (e.g., transduced on the same or different nucleic acid as the variant coat polypeptide, payload, rep and/or ITR).

In some embodiments, the helper sequence comprises an AdV5 helper sequence. An exemplary AdV5 genome is disclosed in the art as NCBI reference sequence AC_000008.1 (disclosed as SEQ ID NO: 1 of PCT Patent Application Publication No. WO/2022/079429 A1). In some embodiments, the host cells disclosed herein comprise a portion of the AdV5 genome encoding one or more helper protein sequences (e.g., E1a, E1b, E2a, E4) or RNA sequence (e.g., VA). In some embodiments, the host cells disclosed herein comprise a nucleic acid sequence encoding one or more AdV5 helper protein sequences. Certain exemplary AdV5 helper protein sequences are provided below.

AdV5 E1A :MRHIICHGGVITEEMAASLLDQLIEEVLADNLPPPSHFEPPTLHELYDLDVTAPEDPNEEAVSQIFPDSVMLAVQEGIDLLTFPPAPGSPEPPHLSRQPEQPEQRALGPVSMPNLVPEVIDLTCHEAGFPPSDDEDEEGEEFVL DYVEHPGHGCRSCHYHRRNTGDPDIMCSLCYMRTCGMFVYSPVSEPEPEPEPEPARPTRRPKMAPAILRRPTSPVSRECNSSTDSCDSGPSNTPPEIHPVVPLCPIKPVAVRVGGRRQAVECIEDLLNEPGQPLDLSCKRPRP (SEQ ID NO:424)

AdV5 E1B 19K : MEAWECLEDFSAVRNLLEQSSNSTSWFWRFLWGSSQAKLVCRIKEDYKWEFEELLKSCGELFDSLNLGHQALFQEKVIKTLDFSTPGRAAAAVAFLSFIKDKWSEETHLSGGYLLDFLAMHLWRAVVRHKNRLLLLSSVRPAIIPTEEQQQQQEEARRRRQEQSPWNPRAGLDPRE (SEQ ID NO:425)

AdV5 E1B 55K : MERRNPSERGVPAGFSGHASVESGCETQESPATVVFRPPGDNTDGGAAAAAGGSQAAAAGAEPMEPESRPGPSGMNVVQVAELYPELRRILTITEDGQGLKGVKRERGACEATEEARNLAFSLM TRHRPECITFQQIKDNCANELDLLAQKYSIEQLTTYWLQPGDDFEEAIRVYAKVALRPDCKYKISKLVNIRNCCYISGNGAEVEIDTEDRVAFRCSMINMWPGVLGMDGVVIMNVRFTGPNFSG TVFLANTNLILHGVSFYGFNNTCVEAWTDVRVRGCAFYCCWKGVVCRPKSRASIKKCLFERCTLGILSEGNSRVRHNVASDCGCFMLVKSVAVIKHNMVCGNCEDRASQMLTCSDGNCHLLKTI HVASHSRKAWPVFEHNILTRCSLHLGNRRGVFLPYQCNLSHTKILLEPESMSKVNLNGVFDMTMKIWKVLRYDETRTRCRPCECGGKHIRNQPVMLDVTEELRPDHLVLACTRAEFGSSDEDTD (SEQ ID NO:426)

AdV5 E3 12.5K : MLSGEAEQLRLKHLVHCRRHKCFARDSGEFCYFELPEDHIEGPAHGVRLTAQGELARSLIREFTQRPLLVERDRGPCVLTVICNCPNLGLHQDLCCHLCAEYNKYRN (SEQ ID NO:427)

AdV5 E3 CR1-α0 : MNNSSNSTGYSNSGFSRIGVGVILCLVILFIILILTLLCLRLAACCVHICIYCQLFKRWGRHPR (SEQ ID NO:428)

AdV5 E3 gp19K : MIRYIILGLLTLASAHGTTQKVDFKEPACNVTFAAEANECTTLIKCTTEHEKLLIRHKNKIGKYAVYAIWQPGDTTEYNVTVFQGKSHKTFMYTFPFYEMCDITMYMSKQYKLWPPQNCVENTGTFCCTAMLITVLALVCTLLYIKYKSRRSFIEEKKMP (SEQ ID NO:429)

AdV5 E3 CR1-β0 : MTNTTNAAAATGLTSTTNTPQVSAFVNNWDNLGMWWFSIALMFVCLIIMWLICCLKRKRARPPIYSPIIVLHPNNDGIHRLDGLKHMFFSLTV (SEQ ID NO:430)

AdV5 E3 RID-α : MIPRVFILLTLVALFCACSTLAAVSHIEVDCIPAFTVYLLYGFVTLTLICSLITVVIAFIQCIDWVCVRFAYLRHHPQYRDRTIAELLRIL (SEQ ID NO:431)

AdV5 E3 RID-β : MKFTVTFLLIICTLSAFCSPTSKPQRHISCRFTRIWNIPSCYNEKSDLSEAWLYAIISVMVFCSTILALAIYPYLDIGWKRIDAMNHPTFPAPAMLPLQQVVAGGFVPANQPRPTSPPTTEISYFNLTGGDD (SEQ ID NO:432)

AdV5 E3 14.7K : MTDTLDLEMDGIITEQRLLERRRAAAEQQRMNQELQDMVNLHQCKRGIFCLVKQAKVTYDSNTTGHRLSYKLPTKRQKLVVMVGEKPITITQHSVETEGCIHSPCQGPEDLCTLIKTLCGLKDLIPFN (SEQ ID NO:433)

AdV5 E4 ORF6/7 : MTTSGVPFGMTLRPTRSRLSRRTPYSRDRLPPFETETRATILEDHPLLPECNTLTMHNAWTSPSPPVKQPQVGQQPVAQQLDSDMNLSELPGEFINITDERLARQETVWNITPKNMSVTHDMMLFKASRGERTVYSVCWEGGGRLNTRVL (SEQ ID NO:434)

AdV5 E4 34K : MTTSGVPFGMTLRPTRSRLSRRTPYSRDRLPPFETETRATILEDHPLLPECNTLTMHNVSYVRGLPCSVGFTLIQEWVVPWDMVLTREELVILRKCMHVCLCCANIDIMTSMMIHGYESWALHCHCSSPGSLQCIAGGQVLASWFRM VVDGAMFNQRFIWYREVVNYNMPKEVMFMSSVFMRGRHLIYLRLWYDGHVGSVVPAMSFGYSALHCGILNNIVVLCCSYCADLSEIRVRCCARRTRRLMLRAVRIIAEETTAMLYSCRTERRRQQFIRALLQHHRPILMHDYDSTPM (SEQ ID NO:435)

AdV5 E4 ORF4 : MVLPALPAPPVCDSQNECVGWLGVAYSAVVDVIRAAAHEGVYIEPEARGRLDALREWIYYNYYTERSKRRDRRRRSVCHARTWFCFRKYDYVRRSIWHDTTTNTISVVSAHSVQ (SEQ ID NO:436)

AdV5 E4 ORF3 : MIRCLRLKVEGALEQIFTMAGLNIRDLLRDILRRWRDENYLGMVEGAGMFIEEIHPEGFSLYVHLDVRAVCLLEAIVQHLTNAIICSLAVEFDHATGGERVHLIDLHFEVLDNLLE (SEQ ID NO:437)

AdV5 E4 ORFB : MFERKMVSFSVVVPELTCLYLHEHDYDVLSFLREALPDFLSSTLHFISPPMQQAYIGATLVSIAPSMRVIISVGSFVMVPGGEVAALVRADLHDYVQLALRRDLRDRGIFVNVPLLNLIQVCEEPEFLQS (SEQ ID NO:438)

AdV5 E4 ORF1 : MAAAVEALYVVLEREGAILPRQEGFSGVYVFFSPINFVIPMGAVMLSLRVCIPPGYFGRFLALTDVNQPDVFTESYIMTPDMTEELSVVLFNHGDQFFYGHAGMAVVRLMLIRVVFPVVRQASNV (SEQ ID NO:439)

In some embodiments, the helper sequence comprises an AdV2 helper sequence. An exemplary AdV2 genome is disclosed in the art as NCBI reference sequence AC_000007.1 (disclosed as SEQ ID NO: 2 of PCT Patent Application Publication No. WO/2022/079429 A1). In some embodiments, the host cells disclosed herein comprise a portion of the AdV2 genome encoding one or more helper protein sequences (e.g., E1a, E1b, E2a, E4) or RNA sequence (e.g., VA). In some embodiments, the host cells disclosed herein comprise a nucleic acid sequence encoding one or more AdV2 helper protein sequences. Certain exemplary AdV2 helper protein sequences are provided below.

AdV2 E1A : MRHIICHGGVITEEMAASLLDQLIEEVLADNLPPPSHFEPPTLHELYDLDVTAPEDPNEEAVSQIFPESVMLAVQEGIDLFTFPPAPGSPEPPHLSRQPEQPEQRALGPVSMPNLVPEVIDLTCHEAGFPPSDDEDEEGEEFVL DYVEHPGHGCRSCHYHRRNTGDPDIMCSLCYMRTCGMFVYSPVSEPEPEPEPEPARPTRRPKLVPAILRRPTSPVSRECNSSTDSCDSGPSNTPPEIHPVVPLCPIKPVAVRVGGRRQAVECIEDLLNESGQPLDLSCKRPRP (SEQ ID NO:440)

AdV2 E1B 19K : MEAWECLEDFSAVRNLLEQSSNSTSWFWRFLWGSSQAKLVCRIKEDYKWEFEELLKSCGELFDSLNLGHQALFQEKVIKTLDFSTPGRAAAAVAFLSFIKDKWSEETHLSGGYLLDFLAMHLWRAVVRHKNRLLLLSSVRPAIIPTEEQQQEEARRRRRQEQSPWNPRAGLDPRE (SEQ ID NO:441)

AdV2 E1B 55K : MERRNPSERGVPAGFSGHASVESGGETQESPATVVFRPPGNNTDGGATAGGSQAAAAAGAEPMEPESRPGPSGMNVVQVAELFPELRRILTINEDGQGLKGVKRERGASEATEEARNLTFSLM TRHRPECVTFQQIKDNCANELDLLAQKYSIEQLTTYWLQPGDDFEEAIRVYAKVALRPDCKYKISKLVNIRNCCYISGNGAEVEIDTEDRVAFRCSMINMWPGVLGMDGVVIMNVRFTGPNFSG TVFLANTNLILHGVSFYGFNNTCVEAWTDVRVRGCAFYCCWKGVVCRPKSRASIKKCLFERCTLGILSEGNSRVRHNVASDCGCFMLVKSVAVIKHNMVCGNCEDRASQMLTCSDGNCHLLKTI HVASHSRKAWPVFEHNILTRCSLHLGNRRGVFLPYQCNLSHTKILLEPESMSKVNLNGVFDMTMKIWKVLRYDETRTRCRPCECGGKHIRNQPVMLDVTEELRPDHLVLACTRAEFGSSDEDTD (SEQ ID NO:442)

AdV2 E3 12.5K : MTSGEAERLRLTHLDHCRRHKCFARGSGEFCYFELPEEHIEGPAHGVRLTTQVELTRSLIREFTKRPLLVERERGPCVLTVVCNCPNPGLHQDLCCHLCAEYNKYRN (SEQ ID NO:443)

AdV2 E3 CR1-α0 : MSNSSNSTSLSNFSGIGVGVILTLVILFILILALLCLRVAACCTHVCTYCQLFKRWGQHPR (SEQ ID NO:444)

AdV2 E3 gp19K : MRYMILGLLALAAVCSAAKKVEFKEPACNVTFKSEANECTTLIKCTTEHEKLIIRHKDKIGKYAVYAIWQPGDTNDYNVTVFQGENRKTFMYKFPFYEMCDITMYMSKQYKLWPPQKCLENTGTFCSTALLITALALVCTLLYLKYKSRRSFIDEKKMP (SEQ ID NO:445)

AdV2 E3 CR1-β0 : MTGSTIAPTTDYRNTTATGLTSALNLPQVHAFVNDWASLDMWWFSIALMFVCLIIMWLICCLKRRRARPPIYRPIIVLNPHNEKIHRLDGLKPCSLLLQYD (SEQ ID NO:446)

AdV2 E3 RIDα : MIPRVLILLTLVALFCACSTLAAVAHIEVDCIPPFTVYLLYGFVTLILICSLVTVVIAFIQFIDWVCVRIAYLRHHPQYRDRTIADLLRIL (SEQ ID NO:447)

AdV2 E3 RIDβ : MKRSVIFVLLIFCALPVLCSQTSAPPKRHISCRFTQIWNIPSCYNKQSDLSEAWLYAIISVMVFCSTIFALAIYPYLDIGWNAIDAMNHPTFPVPAVIPLQQVIAPINQPRPPSPPTTEISYFNLTGGDD (SEQ ID NO:448)

AdV2 E3 14.7K : MTESLDLELDGINTEQRLLERRKAASERERLKQEVEDMVNLHQCKRGIFCVVKQAKLTYEKTTTGNRLSYKLPTQRQKLVLMVGEKPITVTQHSAETEGCLHFPYQGPEDLCTLIKTMCGIRDLIPFN (SEQ ID NO:449)

AdV2 E4 ORF6/7 : MTTSGVPFGMTLRPTRSRLSRRTPYSRDRLPPFETETRATILEDHPLLPECNTLTMHNAWTSPSPPVEQPQVGQQPVAQQLDSDMNLSELPGEFINITDERLARQETVWNITPKNMSVTHDMMLFKASRGERTVYSVCWEGGGRLNTRVL (SEQ ID NO:450)

AdV2 E4 34K : MTTSGVPFGMTLRPTRSRLSRRTPYSRDRLPPFETETRATILEDHPLLPECNTLTMHNVSYVRGLPCSVGFTLIQEWVVPWDMVLTREELVILRKCMHVCLCCANIDIMTSMMIHGYESWALHCHCSSPGSLQCIAGGQVLASWFRM VVDGAMFNQRFIWYREVVNYNMPKEVMFMSSVFMRGRHLIYLRLWYDGHVGSVVPAMSFGYSALHCGILNNIVVLCCSYCADLSEIRVRCCARRTRRLMLRAVRIIAEETTAMLYSCRTERRRQQFIRALLQHHRPILMHDYDSTPM (SEQ ID NO:451)

AdV2 E4 ORF4 : MVLPALPAPPVCDSQNECVGWLGVAYSAVVDVIRAAAHEGVYIEPEARGRLDALREWIYYNYYTERAKRRDRRRRSVCHARTWFCFRKYDYVRRSIWHDTTTNTISVVSAHSVQ (SEQ ID NO:452)

AdV2 E4 ORF3 : MIRCLRLKVEGALEQIFTMAGLNIRDLLRDILIRWRDENYLGMVEGAGMFIEEIHPEGFSLYVHLDVRAVCLLEAIVQHLTNAIICSLAVEFDHATGGERVHLIDLHFEVLDNLLE (SEQ ID NO:453)

AdV2 E4 ORF2 : MFERKMVSFSVVVPELTCLYLHEHDYDVLAFLREALPDFLSSTLHFISPPMQQAYIGATLVSIAPSMRVIISVGSFVMVPGGEVAALVRADLHDYVQLALRRDLRDRGIFVNVPLLNLIQVCEEPEFLQS (SEQ ID NO:454)

AdV2 E4 ORF1 : MAAAVEALYVVLEREGAILPRQEGFSGVYVFFSPINFVIPMGAVMLSLRVCIPPGYFGRFLALTDVNQPDVFTESYIMTPDMTEELSVVLFNHGDQFFYGHAGMAVVRLMLIRVVFPVVRQASNV (SEQ ID NO:455)

Additional AAV helper sequences are recognized in the art and include, for example, those described in U.S. Patent Application Publication Nos. 2004/0248288 A1 and 2022/0259572 A1, and PCT Patent Application Publication Nos. WO/1997/017458 A1, WO/2024/143429 A1, and WO/2020/208379 A1, each of which is incorporated herein by reference.

Expression control sequences include efficient RNA processing signals, such as splicing and polyadenylation (polyA) signals; appropriate transcription initiation, termination, promoter, and enhancer sequences; sequences that stabilize cytoplasmic mRNA; sequences that enhance protein stability; sequences that enhance translation efficiency (e.g., Kozak consensus sequences); and, in some embodiments, sequences that enhance secretion of the encoded transgene product. Expression control sequences (including natural, constitutive, induced, and/or tissue-specific promoters) are known in the art and can be used with the compositions and methods disclosed herein.

In some embodiments, the transgene's native promoter is used. Without theoretical constraints, the native promoter can mimic the transgene's native expression, or provide temporal, developmental, or tissue-specific expression, or expression in response to a specific transcriptional stimulus. In some embodiments, the transgene is operably linked to other native expression control elements, such as enhancer elements, polyadenylation sites, or Kozak consensus sequences, for example, to mimic native expression.

In some embodiments, the transgene is operably linked to a tissue-specific promoter, such as a promoter that is particularly active in one or more liver cell types.

In some embodiments, the vector (e.g., a plasmid) carrying the transgene includes a selectable marker or reporter gene. Such selectable reporter or marker genes can be used to signal the presence of the vector (e.g., a plasmid) in the bacterial cell. Other components of the vector (e.g., a plasmid) include an origin of replication. The selection of these and other promoters and vector elements is known, and many such sequences are available (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY, and references cited therein).

In some embodiments, insect cells can be used in the production of the compositions described herein or in the methods for making the dependent parvoviral particles described herein. For example, the insect cell lines used can be derived from the fall armyworm ( Spodoptera frugiperda ), such as Sf9, SF21, and SF900+; fruit fly cell lines; mosquito cell lines, such as Aedes albopictus -derived cell lines; domestic silkworm cell lines, such as Bombyx mori cell lines; Trichoplusia ni cell lines, such as High Five cells; or Lepidoptera cell lines, such as Ascalapha odorata cell lines. In some embodiments, insect cells are susceptible to bacillary viral infection and include High Five, Sf9, Se301, SeIZD2109, SeUCR1, SP900+, Sf21, BTI-TN-5B1-4, MG-1, Tn368, HzAml, BM-N, Ha2302, Hz2E5, and Ao38. The use of insect cells for expressing heterologous proteins is well-established in the art, as are methods for introducing nucleic acids (e.g., vectors, e.g., insect cell-compatible vectors) into such cells and methods for maintaining such cells in culture. See, e.g., O'Reilly et al., 1994, Baculovirus Expression Vectors, A Laboratory Manual. Oxford Univ. Press; Satnulski et al., 1989, J. Vir. 63:3822-8; Kajigaya et al., 1991 PNAS 88:4646-50; Ruffin et al., 1992, J. Vir. 66:6922-30; Kimbauer et al., 1996, Vir. 21. 9:37-44; Zhao et al., 2000, Vir. 272:382-93; and U.S. Patent No. 6,204,059, the contents of each of which are incorporated herein by reference in their entirety.

In certain embodiments, a combination of an insect host cell system and a bacillivirus system is used (e.g., as described in Luckow et al., 1988, Bio/Technology 6:47). In certain embodiments, the expression system is the Trichoplusia ni Tn 5B1-4 insect cell/bacillivirus system, which can be used to produce high levels of protein, as described in U.S. Patent No. 6,660,521, which is incorporated herein by reference in its entirety.

Insect cells can be expanded, cultured, transfected, infected, and stored in any cell culture medium, cell transfection medium, or storage medium known in the art. Non-limiting examples of culture media include Hyclone SFX Insect Cell Medium, Expression Systems ESF AF Insect Cell Medium, Basic IPL-41 Insect Cell Medium, ThermoFisher Sf90011 Medium, ThermoFisher Sf900111 Medium, and ThermoFisher Grace's Insect Cell Medium. The insect cell mixture and/or culture medium may also contain appropriate formulation additives or drugs, including but not limited to salts, acids, bases, buffers, and surfactants (such as Poloxamer 188/Pluronic F-68).

In some embodiments, the methods herein can be performed using mammalian cell types that allow for replication-dependent minivirus or biologic production and can be maintained in culture. Host cells include cells derived from mammalian species, including but not limited to humans, monkeys, mice, rats, rabbits, and hamsters. Host cells can be of any suitable cell type, including but not limited to cell lines, fibroblasts, hepatocytes, tumor cells, and transformed cells. Mammalian cells used can be HEK293, HEK293T, HeLa cells (HeLa), CHO, NS0, SP2/0, PER.C6, Vero, RD, BHK, HT 1080, A549, Cos-7, ARPE-19, MRC-5, WEH1, 3T3, 1.0T1/2, MDCK, COS 1, COS 7, BSC 1, BSC 40, BMT 10, W138, Saos, C2C12, HepG2, L cells, primary fibroblasts, hepatocytes, and myofibroblasts of mammalian origin, COS cells, C127, 3T3, CHO, HeLa cells, KB cells, BHK, and other mammalian cell lines described in U.S. Patent Nos. 6,156,303, 5,387,484, 5,741,683, 5,691,176, 6,428,988, 5,688,676, and 6,541,258, the contents of each of which are incorporated herein by reference.

In some embodiments, the host cell comprises a nucleic acid encoding a variant capsid polypeptide disclosed herein, wherein the nucleic acid is integrated into the host cell genome. Such host cells include adenoviral rep and cap genes integrated into the genome. Transcription of the integrated rep and cap genes can depend on the introduction of certain helper viral sequences (e.g., adenoviral E4, E2a, and/or VA RNA) into the cell by transduction or other suitable means. Example plasmid-free host cells are described in U.S. Patent Application Publication No. 2022/0025396 A1 and U.S. Patent No. 5,658,785, which are incorporated herein by reference.

In some embodiments, the host cell is a trans-complementing packaging cell line that provides a function that is lacking in a replication-deficient helper virus, such as HEK293 cells or other Ea trans-complementing cells. In some embodiments, the packaging cell line 293-10-3 is used as described in U.S. Patent No. 6,281,010, which is incorporated herein by reference.

In some embodiments, the mammalian host cells (e.g., 293T cells) can be in an adherent state (e.g., adhered/attached to a suitable surface such as a cell culture flask, vial, tray, well, tube, etc.). In other embodiments, the mammalian host cells can be in a suspended state (e.g., suspended in a culture medium). 6.5.2. Viral Particle Production

In some embodiments, the nucleic acids herein are located as part of any genetic element (vector) that can be delivered to a host cell, such as naked DNA, plasmids, phages, transposons, cosmids, episomal genomes, protein-containing non-viral delivery vehicles (e.g., lipid-based carriers), viruses, etc., to transfer the sequences carried thereon. Such vectors can be delivered to host cells by any suitable method, including transfection, liposome delivery, electroporation, membrane fusion techniques, viral infection, high-speed DNA-coated pellets, and protoplast fusion. Those skilled in the art have the knowledge and skills in nucleic acid manipulation to construct any embodiment of the present invention, including genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY.

In some embodiments, the vectors herein comprise a sequence encoding a dependent parvoviral variant capsid polypeptide or a fragment thereof provided herein. In some embodiments, the vectors herein comprise a sequence encoding a dependent parvoviral Rep protein or a fragment thereof. Such Rep coding regions encode at least AAV Rep78, Rep68, Rep52, and Rep40, or functional homologs thereof. The Rep coding region is not required to include all wild-type genes, but may be altered (e.g., by insertion, deletion, or mutation of one or more nucleotides) as long as the rep gene present provides sufficient replication function when expressed in recombinant cells. The Rep coding region may be derived from any AAV serotype. In some embodiments, the Rep coding region is or comprises a rep gene encoding an AAV2 Rep protein, exemplary sequences of which are provided below.

AAV2 Rep78 : MPGFYEIVIKVPSDLDGHLPGISDSFVNWVAEKEWELPPDSDMDLNLIEQAPLTVAEKLQRDFLTEWRRVSKAPEALFFVQFEKGESYFHMHVLVETTGVKSMVLGRFLSQIREKLIQRIYRGIEPTLPNWFAVTKTRNGAGGGNKVVDECYIPN YLLPKTQPELQWAWTNMEQYLSACLNLTERKRLVAQHLTHVSQTQEQNKENQNPNSDAPVIRSKTSARYMELVGWLVDKGITSEKQWIQEDQASYISFNAASNSRSQIKAALDNAGKIMSLTKTAPDYLVGQQPVEDISSNRIYKILELNGYDPQ YAASVFLGWATKKFGKRNTIWLFGPATTGKTNIAEAIAHTVPFYGCVNWTNENFPFNDCVDKMVIWWEEGKMTAKVVESAKAILGGSKVRVDQKCKSSAQIDPTPVIVTSNTNMCAVIDGNSTTFEHQQPLQDRMFKFELTRRLDHDFGKVTKQE VKDFFRWAKDHVVEVEHEFYVKKGGAKKRPAPSDADISEPKRVRESVAQPSTSDAEASINYADRYQNKCSRHVGMNLMLFPCRQCERMNQNSNICFTHGQKDCLECFPVSESQPVSVVKKAYQKLCYIHHIMGKVPDACTACDLVNVDLDDCIFEQ (SEQ ID NO:456)

AAV2 Rep68 : MPGFYEIVIKVPSDLDGHLPGISDSFVNWVAEKEWELPPDSDMDLNLIEQAPLTVAEKLQRDFLTEWRRVSKAPEALFFVQFEKGESYFHMHVLVETTGVKSMVLGRFLSQIREKLIQRIYRGIEPTLPNWFAV TKTRNGAGGGNKVVDECYIPNYLLPKTQPELQWAWTNMEQYLSACLNLTERKRLVAQHLTHVSQTQEQNKENQNPNSDAPVIRSKTSARYMELVGWLVDKGITSEKQWIQEDQASYISFNAASNSRSQIKAALD NAGKIMSLTKTAPDYLVGQQPVEDISSNRIYKILELNGYDPQYAASVFLGWATKKFGKRNTIWLFGPATTGKTNIAEAIAHTVPFYGCVNWTNENFPFNDCVDKMVIWWEEGKMTAKVVESAKAILGGSKVRVD QKCKSSAQIDPTPVIVTSNTNMCAVIDGNSTTFEHQQPLQDRMFKFELTRRLDHDFGKVTKQEVKDFFRWAKDHVVEVEHEFYVKKGGAKKRPAPSDADISEPKRVRESVAQPSTSDAEASINYADRLARGHSL (SEQ ID NO:457)

AAV2 Rep52 : MELVGWLVDKGITSEKQWIQEDQASYISFNAASNSRSQIKAALDNAGKIMSLTKTAPDYLVGQQPVEDISSNRIYKILELNGYDPQYAASVFLGWATKK FGKRNTIWLFGPATTGKTNIAEAIAHTVPFYGCVNWTNENFPFNDCVDKMVIWWEEGKMTAKVVESAKAILGGSKVRVDQKCKSSAQIDPTPVIVTSNT NMCAVIDGNSTTFEHQQPLQDRMFKFELTRRLDHDFGKVTKQEVKDFFRWAKDHVVEVEHEFYVKKGGAKKRPAPSDADISEPKRVRESVAQPSTSDAEASINYADRYQNKCSRHVGMNLMLFPCRQCERMNQNSNICFTHGQKDCLECFPVSESQPVSVVKKAYQKLCYIHHIMGKVPDACTACDLVNVDLDDCIFEQ (SEQ ID NO:458)

AAV2 Rep40 : MELVGWLVDKGITSEKQWIQEDQASYISFNAASNSRSQIKAALDNAGKIMSLTKTAPDYLVGQQPVEDISSNRIYKILELNGYDPQYAASVFLGWATKKFGKRNTIWLFGPATTGKTNIAEAIAHTVPFYGCVNWTNENFPFNDCVDKMVIWWEEG KMTAKVVESAKAILGGSKVRVDQKCKSSAQIDPTPVIVTSNTNMCAVIDGNSTTFEHQQPLQDRMFKFELTRRLDHDFGKVTKQEVKDFFRWAKDHVVEVEHEFYVKKGGAKKRPAPSDADISEPKRVRESVAQPSTSDAEASINYADRLARGHSL (SEQ ID NO:459)

In some embodiments, the Rep coding region encodes a Rep sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to one or more AAV2 Rep proteins. In some embodiments, the Rep coding region comprises a nucleotide sequence encoding a Rep78 protein having at least 80%, at least about 85%, at least about 90%, at least about 95%, at least 98%, at least 99%, or 100% sequence identity to AAV2 Rep78. In some embodiments, the Rep coding region comprises a nucleotide sequence encoding a Rep68 protein having at least 80%, at least about 85%, at least about 90%, at least about 95%, at least 98%, at least 99%, or 100% sequence identity to AAV2 Rep68. In some embodiments, the Rep coding region comprises a nucleotide sequence encoding a Rep52 protein having at least 80%, at least about 85%, at least about 90%, at least about 95%, at least 98%, at least 99%, or 100% sequence identity to AAV2 Rep52. In some embodiments, the Rep coding region comprises a nucleotide sequence encoding a Rep40 protein having at least 80%, at least about 85%, at least about 90%, at least about 95%, at least 98%, at least 99%, or 100% sequence identity to AAV2 Rep40.

In some embodiments, the Rep encoding sequence encodes a wild-type Rep protein. Alternatively, the Rep encoding sequence may encode one or more mutant Rep proteins having improved properties compared to the wild-type Rep protein. Examples of such mutant Rep proteins are described in U.S. Patent No. 11,060,070, which is incorporated herein by reference.

Additional exemplary Rep gene and protein sequences are disclosed as SEQ ID NOs: 7 to 15 and 20 to 22 of PCT Patent Application Publication No. WO/2022/079429 A1, which is incorporated herein by reference.

In some embodiments, these vectors contain both the epizootic parvoviral cap and rep proteins. In vectors providing both AAV rep and cap, in embodiments, both the epizootic parvoviral rep and cap sequences are derived from the same epizootic species or serotype. Alternatively, embodiments of the present invention also provide vectors in which the rep sequence is derived from a different epizootic species or serotype than the epizootic species or serotype providing the cap sequence (e.g., an AAV2 rep sequence and an AAV9 cap sequence). In some embodiments, the rep and cap sequences are expressed from separate sources (e.g., separate vectors, or a host cell genome and a vector). In some embodiments, the rep sequence is fused in frame to the cap sequence of a different receptive parvovirus species or serotype to form a chimeric receptive parvovirus vector.

In some embodiments, the vectors of the present invention further contain a payload, such as a minigene comprising a selected transgene, for example, flanked by a dependent parvoviral 5' ITR and a dependent parvoviral 3' ITR. In some embodiments, the ITRs are from the same serotype as the variant capsid polypeptide. In some embodiments, the ITRs are of a different serotype than the variant capsid polypeptide. In some embodiments, the viral genome comprises two ITR sequence regions, wherein the ITRs are of the same serotype as each other. In some embodiments, the viral genome comprises two ITR sequence regions, wherein the ITRs are of different serotypes. Non-limiting examples include zero, one, or two ITRs of the same serotype as the capsid. In one embodiment, both ITRs of the viral genome of the AAV particle are AAV2 ITRs. Independently, each ITR can be about 100 to about 150 nucleotides in length. An ITR can be about 100-105 nucleotides in length, 106-110 nucleotides in length, 111-115 nucleotides in length, 116-120 nucleotides in length, 121-125 nucleotides in length, 126-130 nucleotides in length, 131-135 nucleotides in length, 136-140 nucleotides in length, 141-145 nucleotides in length, or 146-150 nucleotides in length. In one embodiment, the ITR is 140-142 nucleotides in length. Non-limiting examples of ITR lengths are 102, 105, 130, 140, 141, 142, and 145 nucleotides in length.

The vectors described herein, such as plasmids, can be used for a variety of purposes, but are particularly suitable for producing recombinant dependent parvoviral particles comprising dependent parvoviral sequences or fragments thereof and, in some embodiments, a payload.

In one embodiment, the present invention provides a method for preparing a dependent parvoviral particle (e.g., a dependent parvoviral B particle, such as an AAV9 particle) or a portion thereof. In some embodiments, the method comprises culturing a host cell containing a nucleic acid sequence encoding a dependent parvoviral variant capsid protein or a fragment thereof provided herein; a functional rep gene (e.g., encoding a Rep protein described herein); a payload, such as a minigene comprising dependent parvoviral inverted terminal repeats (ITRs) and a transgene; and helper functions sufficient to facilitate packaging of the payload (e.g., minigene) into the dependent parvoviral capsid. In embodiments, the components necessary for packaging a payload (e.g., a minigene) into a dependent parvoviral capsid are provided in trans to the host cells cultured therein. In some embodiments, any one or more of the required components (e.g., payload (e.g., minigene), rep sequence, cap sequence, and/or auxiliary functions) are provided by a host cell that has been engineered using methods known to those skilled in the art to stably contain one or more of the required components. In some embodiments, the host cell that has been engineered to stably contain the required components contains the required components under the control of an inducible promoter. In some embodiments, the required components are under the control of a persistent promoter. Examples of suitable inducible promoters and perpetuating promoters are provided herein, and other examples are known to those skilled in the art. In some embodiments, a selected host cell that has been engineered to stably contain one or more components comprises a component under the control of a perpetuating promoter and another component under the control of one or more inducing promoters. For example, a host cell that has been engineered to stably contain the desired components is generated from a HEK 293 cell (e.g., comprising an auxiliary function under the control of a perpetuating promoter), the host cell comprising rep and/or cap proteins under the control of one or more inducing promoters.

In embodiments, the payload (e.g., minigene), rep sequence, cap sequence, and auxiliary functions required to produce the dependent small viral particles herein are delivered to the encapsulating host cell in the form of any genetic element (e.g., in a vector or vector combination) to transfer the sequences carried thereon. The genetic element can be delivered by any suitable method, including those described herein. Methods for constructing the genetic elements, vectors, and other nucleic acids herein are known to those skilled in the art and include genetic engineering, recombinant engineering, and synthetic techniques. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY. Similarly, methods for producing rAAV virions are well known, and the selection of a suitable method is not limiting of the present invention. See, e.g., K. Fisher et al., J. Virol, 70:520-532 (1993) and U.S. Patent No. 5,478,745. Unless otherwise specified, the dependent parvoviral ITRs and other selected dependent parvoviral components described herein are readily selected from any dependent parvoviral species and serotype, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh74, or AAV9.

ITRs or other dependent parvoviral components can be readily isolated from dependent parvoviral species or serotypes using techniques available to those skilled in the art. Dependent parvoviral species and serotypes can be isolated or obtained from academic, commercial, or public sources (e.g., the American Type Culture Collection, Manassas, VA). In some embodiments, dependent parvoviral sequences can be obtained by synthesis or other suitable means, such as by reference to published sequences available in the literature or databases such as GenBank or PubMed.

Methods for expressing proteins (e.g., recombinant or heterologous proteins, such as parvovirus-dependent polypeptides) in insect cells are well documented, as are methods for introducing nucleic acids (e.g., vectors, such as insect cell-compatible vectors) into such cells and methods for maintaining such cells in culture. See, e.g., METHODS IN MOLECULAR BIOLOGY , Richard, ed., Humana Press, NJ (1995); O'Reilly et al., BACULOVIRUS EXPRESSION VECTORS, A LABORATORY MANUAL , Oxford Univ. Press (1994); Samulski et al., J. Vir. 63:3822-8 (1989); Kajigaya et al., Proc. Nat'l. Acad. Sci. USA 88:4646-50 (1991); Ruffing et al., J. Vir. 66:6922-30 (1992); Kirnbauer et al., Vir. 219:37-44 (1996); Zhao et al., Vir. 272:382-93 (2000); Samulski et al. and U.S. Patent No. 6,204,059. In some embodiments, a nucleic acid construct encoding an insect cell-dependent parvoviral polypeptide (e.g., an insect cell-dependent parvoviral genome) is an insect cell-compatible vector. As used herein, an "insect cell-compatible vector" refers to a nucleic acid molecule that is capable of productively transforming or transfecting an insect or insect cell. Exemplary biological vectors include plasmids, linear nucleic acid molecules, and recombinant viruses. Any vector can be used as long as it is insect cell-compatible. The vector can be integrated into the genome of the insect cell or remain present extrachromosomally. The vector can exist permanently or transiently, for example, as an episomal vector. The vector may be introduced by any means known in the art. Such means include, but are not limited to, chemical treatment of cells, electroporation, or infection. In some embodiments, the vector is a bacillivirus, a viral vector, or a plasmid. Methods for producing dependent parvovirus capsids (e.g., AAV) in insect cells include, for example, those described in U.S. Patent Application Publication No. 2024/0093231 A1, U.S. Patent No. 11,306,291, Joshi et al., 2024, Methods Mol Biol , 2829:203-214, and Marwidi et al., 2024, Mol Ther Methods Clin Dev . , 32(2)101228, which are incorporated herein by reference.

In some embodiments, the nucleic acid sequence encoding the parvoviral polypeptide is operably linked to regulatory expression control sequences for expression in specific cell types, such as Sf9 or HEK cells. Techniques known to those skilled in the art for expressing foreign genes in insect or mammalian host cells can be used with the compositions and methods herein. Methods for molecular engineering and expressing polypeptides in insect cells are described, for example, in Summers and Smith. A Manual of Methods for Baculovirus Vectors and Insect Culture Procedures , Texas Agricultural Experimental Station Bull. No. 7555, College Station, Tex. (1986); Luckow. 1991. Prokop et al., Cloning and Expression of Heterologous Genes in Insect Cells with Baculovirus Vectors' Recombinant DNA Technology and Applications, 97-152 (1986); King, LA and RD Possee, The baculovirus expression system , Chapman and Hall, United Kingdom (1992); O'Reilly, DR, LK Miller, VA Luckow, Baculovirus Expression Vectors: A Laboratory Manual , New York (1992); WH Freeman and Richardson, CD, Baculovirus Expression Vectors: A Laboratory Manual , New York (1992). Protocols, Methods in Molecular Biology , Vol. 39 (1995) U.S. Patent No. 4,745,051; US2003148506; and WO 03/074714. Also contemplated are promoters suitable for transcription of nucleotide sequences encoding dependent parvovirus polypeptides, including the polyhedrin, p10, p35, or IE-1 promoters, and other promoters described in the aforementioned references.

In some embodiments, providing a cell comprising a nucleic acid described herein comprises obtaining a cell comprising the nucleic acid.

Methods for culturing host cells, cell-free systems, and other translation systems are known to those skilled in the art. In some embodiments, culturing the host cells comprises providing the cells with a suitable medium and incubating the cells and medium for a period of time suitable to achieve viral particle production.

In some embodiments, the method of preparing dependent parvoviral particles further comprises a purification step comprising separating the dependent parvoviral particles from one or more other components (e.g., from cells or culture medium components).

In some embodiments, the production of dependent parvoviral particles comprises one or more (e.g., all) of the following: expression of dependent parvoviral polypeptides, assembly of dependent parvoviral capsids, expression (e.g., replication) of dependent parvoviral genomes, and packaging of the dependent parvoviral genomes into dependent parvoviral capsids to produce dependent parvoviral particles. In some embodiments, the production of dependent parvoviral particles further comprises secretion of the dependent parvoviral particles into a culture medium. The dependent parvoviral particles can be isolated from the collected culture medium. In other embodiments, small, dependent viral particles are isolated from host cells. For example, adherent host cells can then be collected by scraping and/or pelleting, and suspended cells can be collected by pelleting and transferring to a container. The collection step can be repeated as needed to completely collect the resulting cells. If necessary, host cell lysis can be achieved by continuous freeze-thaw cycles (−80°C to 37°C), chemical lysis (e.g., addition of detergents such as triton), mechanical lysis, or by allowing the cell culture to degrade after reaching ~0% viability. Cellular debris can be removed by centrifugation and/or depth filtration.

In some embodiments, and as described elsewhere herein, nucleic acid molecules encoding variant capsid polypeptides are placed in the dependent miniviral genome. In some embodiments, and as described elsewhere herein, nucleic acid molecules encoding variant capsid polypeptides and the dependent miniviral genome are packaged into dependent miniviral particles as part of the methods for preparing the dependent miniviral particles described herein. In other embodiments, nucleic acid molecules encoding variant capsid polypeptides are not packaged into dependent miniviral particles prepared by the methods described herein.

In some embodiments, methods for preparing dependent microviral particles described herein produce dependent microviral particles comprising a payload (e.g., a payload described herein) and a variant capsid polypeptide. In some embodiments, the payload comprises a second nucleic acid (e.g., in addition to the dependent microviral genome), and the production of the dependent microviral particles comprises encapsulating the second nucleic acid into the dependent microviral particles. In some embodiments, the cells, cell-free systems, or other translation systems used in the methods for preparing dependent microviral particles comprise the second nucleic acid. In some embodiments, the second nucleic acid comprises an exogenous sequence (e.g., exogenous to the dependency virus, cell, or target cell or subject to which the dependency virus particles are to be administered). In some embodiments, the exogenous sequence encodes an exogenous polypeptide. In some embodiments, the exogenous sequence encodes a therapeutic product.

In some embodiments, the viral particles herein have a production efficiency similar to that of viral particles having a reference capsid polypeptide, e.g., a wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, for example, compared to viral particles having a reference capsid polypeptide, e.g., a wild-type capsid polypeptide (SEQ ID NO: 1), the production efficiency of the viral particles herein is (a) at least 0.1-fold, at least 0.2-fold, at least 0.3-fold, at least 0.4-fold, at least 0.5-fold, at least 0.6-fold, at least 0.7-fold, at least 0.8-fold, or at least 0.9-fold, and/or (b) at most 1-fold greater, or the production efficiency is within any range defined by the values in (a) and (b). In some embodiments, the production efficiency is at least 0.5-fold greater than that of viral particles having a wild-type capsid polypeptide (SEQ ID NO: 1).

Production efficiency can be assessed by transient triple transfection of adherent HEK293T cells followed by iodixanol gradient purification to produce viral particles with variant capsids and genomes encoding unique barcodes and fluorescent reporter genes under the control of ubiquitous promoters (e.g., CBh) or neuronal cell type-specific promoters (e.g., human synaptotagmin).

Various methods and systems for producing dependent parvoviruses in host cells are recognized in the art and are encompassed herein, including, for example, those described in U.S. Patent Application Publication Nos. 20220064671 A1, 20220259572 A1, and 20220025396 A1, and PCT Patent Application Publication Nos. WO/1999/011764 A2, WO/2023/178220 A1, WO/2020/208379 A1, WO/2023/143063 A1, WO/2023/239627 A2, WO/2021/156609 A1, and WO/2021/113767 A1, each of which is incorporated herein by reference in its entirety. 6.6. Application

This disclosure is directed, in part, to compositions comprising the nucleic acids, polypeptides, or particles described herein. This disclosure is further directed, in part, to methods utilizing the compositions, nucleic acids, polypeptides, or particles described herein. As will be apparent from this disclosure, the nucleic acids, polypeptides, particles, and methods disclosed herein have various utilities.

This document is directed, in part, to a vector comprising a nucleic acid described herein, e.g., a nucleic acid encoding a variant capsid polypeptide. Many types of vectors are known to those skilled in the art. In some embodiments, the vector comprises a plasmid. In some embodiments, the vector is an isolated vector, e.g., removed from a cell or other biological component.

This disclosure is directed, in part, to a cell, cell-free system, or other translation system comprising a nucleic acid or vector described herein, such as a nucleic acid molecule encoding a variant capsid polypeptide. In some embodiments, the cell, cell-free system, or other translation system is capable of producing dependent miniviral particles comprising the variant capsid polypeptide. In some embodiments, the cell, cell-free system, or other translation system comprises a nucleic acid comprising a dependent miniviral genome or a component of a dependent miniviral genome sufficient to facilitate the production of dependent miniviral particles comprising the variant capsid polypeptide.

In some embodiments, the cell, cell-free system or other translation system further comprises one or more independent parvoviral nucleic acid sequences that promote the production and/or secretion of dependent parvoviral particles. Such sequences are referred to herein as helper sequences. In some embodiments, the helper sequences comprise one or more genes from another virus (e.g., an adenovirus or herpes virus). In some embodiments, the presence of the helper sequences is essential for the production and/or secretion of dependent parvoviral particles. In some embodiments, the cell, cell-free system or other translation system comprises a vector, such as a plasmid, comprising one or more helper sequences.

In some embodiments, a cell, cell-free system, or other translation system comprises a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a sequence encoding one or more dependent parvoviral genes (e.g., a Cap gene, a Rep gene, or a complete dependent parvoviral genome) and an auxiliary sequence, and wherein the second nucleic acid comprises a payload. In some embodiments, a cell, cell-free system, or other translation system comprises a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a sequence encoding one or more dependent parvoviral genes (e.g., a Cap gene, a Rep gene, or a complete dependent parvoviral genome) and a payload, and wherein the second nucleic acid comprises an auxiliary sequence. In some embodiments, a cell, cell-free system, or other translation system comprises a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a helper sequence and a payload, and wherein the second nucleic acid comprises a sequence encoding one or more dependent parvoviral genes (e.g., a Cap gene, a Rep gene, or a complete dependent parvoviral genome). In some embodiments, a cell, cell-free system, or other translation system comprises a first nucleic acid, a second nucleic acid, and a third nucleic acid, wherein the first nucleic acid comprises a sequence encoding one or more dependent parvoviral genes (e.g., a Cap gene, a Rep gene, or a complete dependent parvoviral genome), the second nucleic acid comprises a helper sequence, and the third nucleic acid comprises a payload.

In some embodiments, the first nucleic acid, the second nucleic acid, and optionally the third nucleic acid are located in a single molecule, such as a single vector or a vector and genomic DNA. In some embodiments, one, two, or all of the first nucleic acid, the second nucleic acid, and optionally the third nucleic acid are integrated (e.g., stably integrated) into the genome of the cell.

In embodiments, the cells described herein are generated by transfecting suitable cells with a nucleic acid described herein. In some embodiments, methods for preparing dependent microviral particles comprising a variant capsid polypeptide provided herein, or methods for improving methods for preparing dependent microviral particles, comprise providing cells described herein. In some embodiments, providing cells comprises transfecting suitable cells with one or more nucleic acids described herein.

Various types and species of cells suitable for use with the nucleic acids and vectors described herein are known in the art. In some embodiments, the cells are human cells. In some embodiments, the cells are immortalized cells or cells from a cell line known in the art. In some embodiments, the cells are HEK293 cells. In some embodiments, the cells are HEK293T cells. 6.6.1. Methods of Delivery of Payloads

This disclosure is directed, in part, to a method for delivering a payload to a cell (e.g., a cell in an individual or a sample). In some embodiments, the method for delivering a payload to a cell comprises contacting the cell with a dependent microviral particle comprising a variant capsid polypeptide (e.g., as described herein) containing a payload. Also included herein are dependent microviral particles comprising a variant capsid polypeptide (e.g., as described herein) containing a payload described herein, the dependent microviral particles being used in the methods for delivering a payload described herein. In some embodiments, the dependent microviral particle is a dependent microviral particle described herein and comprises a payload described herein. In some embodiments, the cells are CNS cells. In some embodiments, the cells are skeletal muscle cells. Non-limiting examples of skeletal muscle include the biceps, triceps, quadriceps, tibialis, gastrocnemius, and diaphragm. In some embodiments, the method is performed in vitro. In some embodiments, the cells are obtained from an ex vivo sample from an individual.

In some embodiments, the payload comprises a transgene. In some embodiments, the transgene is a nucleic acid sequence heterologous to the vector sequence flanking the transgene, and the transgene encodes a polypeptide, RNA (e.g., miRNA or siRNA), or other product of interest. In some embodiments, the transgene nucleic acid is operably linked to a regulatory element in a manner sufficient to promote transcription, translation, and/or expression of the transgene in host cells.

Within the scope of the invention, a transgene is any polypeptide or RNA encoding sequence, and the transgene selected will depend on the intended use. In some embodiments, the transgene comprises a reporter sequence that generates a detectable signal upon expression. Such reporter sequences include, but are not limited to, DNA sequences encoding colorimetric reporters (e.g., β-lactamase, β-galactosidase (LacZ), alkaline phosphatases), cell division reporters (e.g., thymidine kinase), fluorescent or luminescent reporters (e.g., green fluorescent protein (GFP) or luciferase), resistance conveying sequences (e.g., chloromycin acetyltransferase (CAT)), or membrane-bound proteins (including those for which high-affinity antibodies exist or can be generated by known means, e.g., comprising antigenic tags such as hemagglutinin or Myc).

In some embodiments, the reporter sequence is operably linked to a regulatory element that drives its expression, providing a signal detectable by known means, including enzymatic assays, radiometric assays, colorimetric assays, fluorescent or other spectroscopic assays, fluorescence-activated cell sorting assays, and immunoassays, including enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and immunohistochemistry. In some embodiments, the transgene encodes a product useful in biology and medicine, such as RNA, a protein, a peptide, an enzyme, or a dominant negative mutant. In some embodiments, the RNA includes tRNA, ribosomal RNA, dsRNA, catalytic RNA, small hairpin RNA, siRNA, trans-splicing RNA, and antisense RNA. In some embodiments, the RNA inhibits or eliminates the expression of a targeted nucleic acid sequence in a treated subject (e.g., a human or animal subject).

In some embodiments, the transgene is used to correct or ameliorate a genetic defect. In some embodiments, the genetic defect includes a defect in which a normal gene is expressed at less than normal levels or a defect in which a functional gene product is not expressed. In some embodiments, the transgene encodes a therapeutic protein or polypeptide that is expressed in host cells. In some embodiments, the dependent parvoviral particles contain or deliver multiple transgenes, for example to correct or ameliorate a genetic defect caused by a multiunit protein. In some embodiments, different transgenes (e.g., each located in/delivered by a different dependent parvoviral particle or a single dependent parvoviral particle) are used to encode each subunit of a protein, or to encode different peptides or proteins, for example when the size of the DNA encoding the protein subunit is large, such as for immunoglobulins, platelet-derived growth factor, or muscular dystrophy. In some embodiments, different subunits of a protein are encoded by the same transgene, such as a single transgene encoding each subunit, wherein the DNA of each subunit is separated by an internal ribozyme entry site (IRES). In some embodiments, the DNA is separated by a sequence encoding a 2A peptide that is self-cleaved in a post-translational event. See, e.g., Donnelly et al., J. Gen. Virol. , 78(Pt 1):13-21 (January 1997); Furler et al., Gene Ther. , 8(11):864-873 (June 2001); Klump et al., Gene Ther 8(10):811-817 (May 2001) (incorporated herein by reference in their entirety).

In some embodiments, a viral particle is provided comprising a genome, wherein the genome comprises a nucleic acid expression construct. The nucleic acid expression construct may comprise a heterologous transgene and one or more regulatory elements.

In some embodiments, the regulatory element comprises a promoter, such as a promoter that is active in the target cell or tissue type of interest. In some embodiments, the promoter is a ubiquitous promoter. In other embodiments, the promoter is selective or specific for the target cell or tissue type (e.g., CNS and/or muscle (generalized muscle expression or skeletal muscle)) and, optionally, has low (or no) activity in cell or tissue types in which transgene expression is not desired (e.g., liver, spleen, PNS, or any combination of two or all of the foregoing). A promoter that is selective for a first cell or tissue type relative to a second cell or tissue type is active in the first cell or tissue type and less active or silent in the second cell or tissue type. In some embodiments, the promoter is CNS-specific or CNS-selective. In some embodiments, the promoter is muscle-specific or muscle-selective. In some embodiments, the promoter is active in both CNS and muscle tissue.

In some embodiments, the promoter is a ubiquitous or persistent promoter that is active in mammalian cells (e.g., human cells), for example, in a human cell type of interest. In some embodiments, the cell type is a CNS cell, such as a neuron, a glial cell, an endothelial cell, and the like. In some embodiments, the cell type is a skeletal muscle cell. Examples of ubiquitous promoters include, but are not limited to, the CAG promoter (a hybrid of the cytomegalovirus early enhancer element, the chicken β-actin promoter (e.g., the first exon and first intron of the chicken β-actin gene) and the splice acceptor of the rabbit β-globin gene), the chicken β-actin promoter, the CBA promoter, the CBh promoter, the CB6 promoter, the CMV promoter, the human EF1-α promoter, the PGK promoter, the ubiquitin C (UBC) promoter, and fragments thereof. In some embodiments, the promoter is tissue-specific, e.g., a promoter specific for CNS tissues or CNS cells. Examples of CNS-specific promoters include, but are not limited to, synaptobrevin (SYN or SYN1) promoter, neuron-specific enolase (NSE) promoter, Ca ²⁺ /calmodulin-dependent kinase subunit α ( ^CaMKII ) promoter, synaptobrevin I with minimal CMV sequence (SynI-minCMV) promoter, glial fibrillary acidic protein (GFAP) promoter, internexin neuronal intermediate filament protein alpha (INA) promoter, nestin (NES) promoter, neurofilament light chain (NF-IL) promoter, and mitochondrial isosterol (MIFR) promoter. chain (NfL) promoter, neurofilament heavy chain (NfH) promoter, myelin-associated oligodendrocyte basic protein (MOBP) promoter, myelin basic protein (MBP) promoter, tyrosine hydroxylase (TH) promoter, forkhead box A2 (FOXA2) promoter, aldehyde dehydrogenase 1 family member L1 (ALDH1L1) promoter, glutamate decarboxylase 2 (GAD2) promoter, riken gene A930098C07Rik (A93) promoter, somatostatin (SST) promoter, platelet-derived growth factor receptor alpha (PDGFRA) promoter, glutamate receptor metabotropic 1 (GRM1) promoter, C-type natriuretic peptide precursor (NPPC) promoter, adrenomedullin (ADM) promoter, type 2 lactosamine alpha-2,3-sialyltransferase (ST3GAL6) promoter, ras responsive element binding protein 1 (ras responsive element binding protein 1, RREB1) promoter, deiodinase iodothyronine type II (DIO2) promoter, excitatory amino acid transporter 2 (EAAT2) promoter, nuclear receptor subfamily 2 group F member 2 (NR2F2) promoter, platelet-derived growth factor (PDGF) promoter, methyl-CpG binding protein 2 (MeCP2) promoter, and mouse, primate, or human homologs of any of the foregoing, and fragments (e.g., active fragments) of any of the foregoing. In embodiments, the CNS-specific promoter is a neuron-specific promoter. In embodiments, the CNS-specific promoter is an astrocyte-specific promoter. In some embodiments, the promoter is a promoter specific for muscle tissue or muscle cells, such as the desmin, MCK, TNNT2, or smooth muscle 22 (SM22) promoter. Other exemplary muscle-specific promoters are described below.

In some embodiments, the promoter is a CBh promoter. An exemplary CBh promoter sequence is shown as SEQ ID NO: 306. In some embodiments, the CBh promoter comprises a nucleotide sequence having at least 90%, at least 95%, at least 96%, at least 97%, or at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 306.

In other embodiments, the promoter is a synapsin promoter, such as the human synapsin promoter (hSYN). An exemplary hSYN promoter sequence is shown as SEQ ID NO: 307. In some embodiments, the CBh promoter comprises a nucleotide sequence having at least 90%, at least 95%, at least 96%, at least 97%, or at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 307.

In some embodiments, the nucleic acid expression construct comprises an intron. In embodiments, the intron is positioned between a promoter and a heterologous transgene. In some embodiments, the intron is positioned 5' to the heterologous transgene on the expression construct, for example, immediately 5' to the heterologous transgene or 100 nucleotides or less 5' to the heterologous transgene. In some embodiments, the intron is a chimeric intron derived from human b-globulin and Ig heavy chain (also referred to as a b-globulin splice donor/immunoglobulin heavy chain splice acceptor intron, or a b-globulin/IgG chimeric intron; Reed, R. et al., Genes and Development, 1989, which is incorporated herein by reference in its entirety). In other embodiments, the intron is a VH4 intron or an SV40 intron.

As provided herein, in some embodiments, viral particles comprising a payload are provided, wherein the payload comprises a nucleic acid comprising a heterologous transgene. In some embodiments, the heterologous transgene encodes an RNA interferor, such as siRNA, shRNA, or other interfering nucleic acid.

In some embodiments, the payload comprises a heterologous transgene encoding a therapeutic polypeptide. In some embodiments, the heterologous transgene is a human gene or fragment thereof. In some embodiments, the therapeutic polypeptide is a human protein. In some embodiments, the heterologous transgene in the viral particle encodes a molecule that can be used to treat a disease, and the viral particle is administered to a patient in need thereof to treat the disease. In some embodiments, the payload comprises a molecule that is effective in treating chronic CNS diseases, such as an RNA interfering nucleotide (e.g., shRNA, siRNA, or miRNA that inhibits APOL-1). Examples of diseases according to the present invention (and heterologous transgenes or molecules encoded by such heterologous transgenes) include: MPS1 (alpha-L-iduronidase (IDUA)); MPS II - Hunter syndrome (iduronate-2-sulfatase (IDS)); ceratopsinosis - Batten disease (CLN1, CLN2, CLN10, CLN13, CLN5, CLN11, CLN4, CNL14, CLN3, CLN6, CLN7, CLN8, CLN12); MPS IIIa - Sanfilippo Type A syndrome (heparan sulfate sulfatase (also known as N-sulfoglucosamine sulfohydrolase)); MPS IIIB - Sanfilippo syndrome type b (N-acetyl-alpha-D-glucosaminidase (NAGLU)); MPS VI - Maroteaux-Lamy syndrome (arylsulfatase B); MPS IV A - Morquio syndrome type A (GALNS); MPS IV B Mauque syndrome type B (GLB1); chronic or neuropathic pain; osteogenesis imperfecta type I, II, III, or IV (COL1A1 and/or COL1A2); hereditary vascular edema (SERPING1, C1NH); osteogenesis imperfecta type V (IFITM5); osteogenesis imperfecta type VI (SERPINF1); osteogenesis imperfecta type VII (CRTAP); osteogenesis imperfecta type VIII (LEPRE1 and/or P3H1); osteogenesis imperfecta type IX (PPIB); Gaucher disease types I, II, and III (glucocerebrosidase; GBA1); Parkinson's disease (glucocerebrosidase; GBA1 and/or dopamine decarboxylase); Pompe disease (acid maltase; GAA; hGAA); heterochromatic leukodystrophy (arylsulfatase A); MPS VII - Sly syndrome (β-glucuronidase); MPS VIII (glucosamine-6-sulfate sulfatase); MPS IX (hyaluronidase); maple syrup urine disease (BCKDHA, BCKDHB, and/or DBT); Niemann-Pick disease (neurophospholipases); Parkinson's disease (anti-alpha-synuclein RNAi); Alzheimer's disease (anti-mutant APP RNAi); Niemann-Pick disease without neurophospholipase (NPC1 or NPC gene encoding cholesterol metabolites); Tay-Sachs disease (α-subunit of β-hexosidase); Sandhoff disease (both α and β subunits of β-hexosidase); Fabry disease (α-galactosidase); fucosylation (fucosidase (FUCA1)); α-mannosidosis (α-mannosidase); β-mannosidosis (β-mannosidase); Wolman disease (cholesterol ester hydrolase); Dravet syndrome (SCN1A, SCN1B, SCN2A, GABRG2); Parkinson's disease (neurotrophin); Parkinson's disease (neurocollagen-derived growth factor (GDGF)); Parkinson's disease (tyrosine hydroxylase); frontotemporal dementia (granulin pro-promoter); Angelman syndrome (ubiquitin protein ligase 3A (UBE3A) gene editing system targeting UBE3A inhibitory RNA (UBE3A-antisense transcript)); Parkinson's disease (glutamine decarboxylase; FGF-2; BDGF); Spinal Muscular Atrophy (Spinal Muscular Atrophy, SMN, including SMN1 or SMN2); Friedreich's ataxia (taxia); amyotrophic lateral sclerosis (ALS) (SOD1 inhibitors, such as anti-SOD1 RNAi); glycogenostasis la (glucose-6-phosphatase); XLMTM (MTM1); Crigler Najjar disease (UGT1A1); CPVT (CASQ2); spinocerebellar ataxia (ATXN2; ATXN3 or other ATXN genes; anti-mutant Machado-Joseph disease/SCA3 allele RNAi); Rett syndrome (MECP2 or fragments thereof); achromatopsia (CNGB3, CNGA3, GNAT2, PDE6C); choriocarcinomatosis (CDM); Danon disease (LAMP2); cystic fibrosis (CFTR or fragments thereof); Duchenne muscular dystrophy (mini/micromyosin gene); SARS-CoV-2 infection (anti-SARS-CoV-2 RNAi, SARS-CoV-2 genome fragments, or S protein (including variants)); limb-girdle muscular dystrophy type 2C-gamma-sarcoglycanopathy (human α-sarcoglycan); advanced heart failure (SERCA2a); rheumatoid arthritis (TNFR:Fc fusion; anti-TNF antibodies or fragments thereof); Leber congenital amaurosis (GAA); X-linked adrenoleukodystrophy (ABCD1); Limb-girdle muscular dystrophy type 2C-gamma-sarcoglycanopathy (gamma-sarcoglycan); Angelman syndrome (UBE3A); Retinitis pigmentosa (hMERTK); Age-related macular degeneration (sFLT01); Phelan-McDermid syndrome (SHANK3; 22q13.3 substitution); Becker muscular dystrophy and sporadic inclusion body myositis (huFollistatin344); Parkinson's disease (GDNF); Metachromatic leukodystrophy-MLD (cuARSA); Hepatitis C (anti-HCV RNAi); 2D limb-girdle muscular dystrophy (hSGCA); human immunodeficiency virus infection (PG9DP); acute intermittent porphyria (PBGD); Leber's hereditary optic neuropathy (PIND4v2); alpha-1 antitrypsin deficiency (αIAT); synoptic retinoschisis X (RS1); chorioretinopathy (hCHM); giant axonal neuropathy (GAN); hemophilia B (factor IX); homozygous FH (hLDLR); Dysferlinopathy (DYSF); achromatosis (CNGA3 or CNGB3); progressive supranuclear neuropathy (MAPT; anti-Tau; anti-MAPT RNAi); ornithine transaminase deficiency (OTC); hemophilia A (Factor VIII); Age-related macular degeneration (AMD), including wetAMD (anti-VEGF antibodies or RNAi); X-linked retinitis pigmentosa (RPGR); myotonic dystrophy type 1 (DMPK; anti-DMPK RNAi, including anti-CTG trinucleotide repeat RNAi); myotonic dystrophy type 2 (CNBP); facioscapulohumeral muscular dystrophy (D4Z4 DNA); oculopharyngeal muscular dystrophy (PABPN1; mutant PABPN1 inhibitors (e.g., RNAi)); mucopolysaccharidosis type VI (hARSB); Leber's hereditary optic neuropathy (ND4); myofascial microtubular myopathy (MTM1); Kogel-Najjar syndrome (UGT1A1); retinitis pigmentosa (hPDE6B); mucopolysaccharidosis type 3B (hNAGLU); Duchenne muscular dystrophy (GALGT2); Alzheimer's disease (NGF; ApoE4; ApoE2; ApoE3; anti-ApoE RNAi, MAPT, anti-tau antibodies, anti-β-amyloid antibodies (e.g., aducanumab); multiple system atrophy; familial lipoprotein lipase deficiency (LPL); alpha-1 antitrypsin deficiency (hAAT); Leber congenital amaurosis 2 (hRPE65v2); Batten disease; late infantile neuronal lipofuscinosis (CLN2); Huntington's disease (HTT; anti-HTT) RNAi); fragile X syndrome (FMR1); fragile X-related tremor/ataxia syndrome (FMR1), premature ovarian aging (FMR1), polycystic ovary syndrome (FMR1), Leber's hereditary optic neuropathy (PlND4v2); aromatic amino acid decarboxylase deficiency (hAADC); retinitis pigmentosa (hMERKTK); and retinitis pigmentosa (RLBB1). In some embodiments, the CNS disease is a tauopathy (e.g., Alzheimer's disease, progressive supranuclear neuropathy, frontotemporal dementia (Pick's disease) Disease), corticobasal degeneration, argyrophilic granulopathy, globuloneurocolloid tauopathy, neurofibrillary entanglement dementia, chronic traumatic encephalopathy (CTE), or age-related tauopathies), and the payload is an anti-tau antibody or an antisense oligonucleotide targeting MAPT. In some embodiments, the payload comprises a molecule effective for treating a muscle-related disease. Exemplary, non-limiting muscle-related diseases are described below.

In some embodiments, the heterologous transgene encodes a therapeutic polypeptide. In some embodiments, the heterologous transgene is a human gene or a fragment thereof. In some embodiments, the therapeutic polypeptide is a human protein. In some embodiments, the heterologous transgene encodes an antibody or a fragment thereof (e.g., an antibody light chain, an antibody heavy chain, a Fab, or a scFv). Examples of antibodies or fragments thereof encoded by heterologous transgenes include, but are not limited to, anti-Ab antibodies (e.g., solanezumab, GSK933776, and lecanemab), anti-sortin (e.g., AL-001), anti-Tau (e.g., ABBV-8E12, UCB-0107, and NI-105), anti-SEMA4D (e.g., VX15/2503), anti-α-synuclein (e.g., prasinezumab, NI-202, and MED-1341), anti-SOD1 (e.g., NI-204), anti-CGRP receptor (e.g., eptinezumab, fremanezumab, or galcanezumab), anti-VEGF (e.g., sevacizumab, ranibizumab, bevacizumab, and brolucizumab), anti-EpoR (e.g., LKA-651), anti-ALK1 (e.g., ascrinvacumab), anti-C5 (e.g., tesidolumab, ravulizumab, and eculizumab), anti-CD105 (e.g., carotuximab), anti-CC1Q (e.g., ANX-007), anti-TNFa (e.g., adalimumab, infliximab, and golimumab), anti-RGMa (e.g., elezanumab), anti-TTR (e.g., NI-301 and PRX-004), anti-CTGF (e.g., pamrevlumab), anti-IL6R (e.g., satralizumab, tocilizumab, and sarilumab), anti-IL6 (e.g., siltuximab, clazakizumab, sirukumab, olokizumab, and gerilimzumab), anti-IL4R (e.g., dupilumab), anti-IL17A (e.g., ixekizumab and secukinumab), anti-IL5R (e.g., reslizumab), anti-IL-5 (e.g., benralizumab and mepolizumab), anti-IL13 (e.g., tralokinumab), anti-IL12/IL23 (e.g., ustekinumab), anti-CD19 (e.g., inebilizumab), anti-IL31RA (e.g., nemolizumab), anti-ITGF7 mAb (e.g., etrolizumab), anti-SOST mAb (e.g., romosozumab), anti-IgE (e.g., omalizumab), anti-TSLP (e.g., nemolizumab), anti-pKal mAb (e.g., lanadelumab), anti-ITGA4 (e.g., natalizumab), anti-ITGA4B7 (e.g., vedolizumab), anti-BLyS (e.g., belimumab), anti-PD-1 (e.g., nivolumab and pembrolizumab), anti-RANKL (e.g., denosumab), anti-PCSK9 (e.g., alirocumab and evolocumab), anti-ANGPTL3 (e.g., evinacumab*), anti-OxPL (e.g., E06), anti-fD (e.g., lampalizumab), or anti-MMP9 (e.g., andecaliximab), as appropriate, wherein the heavy chain (Fab and Fc regions) and light chain are cleaved by furin. (F)/F2A or furin (F)/T2A, an IRES site, or a flexible linker to ensure, for example, equal expression of heavy and light chain polypeptides.

In some embodiments, the viral particles comprise a heterologous transgene encoding a genome editing system. Examples include a CRISPR genome editing system (e.g., one or more components of a CRISPR genome editing system, such as a guide RNA molecule and/or an RNA-guided nuclease, such as a Cas enzyme, such as Cas9, Cpf1, and the like), a zinc finger nuclease genome editing system, a TALEN genome editing system, or a meganuclease genome editing system. In embodiments, the genome editing system targets a mammalian (e.g., human) genomic target sequence. In embodiments, the viral particles comprise a heterologous transgene encoding a targetable transcriptional regulator. Examples include CRISPR-based transcriptional regulators (e.g., one or more components of a CRISPR-based transcriptional regulator, such as a guide RNA molecule and/or an enzymatically inactive RNA-guided nuclease/transcription factor ("TF") fusion protein, such as dCas9-TF fusions, dCpf1-TF fusions, and the like), zinc finger transcriptional factor fusion proteins, TALEN transcriptional regulators, or meganuclease transcriptional regulators.

In some embodiments, a therapeutic molecule or component of a therapeutic molecule or system is delivered by more than one unique viral particle (e.g., a population comprising more than one unique viral particle). In other embodiments, a therapeutic molecule or component of a therapeutic molecule or system is delivered by a single unique viral particle (e.g., a population comprising a single unique viral particle).

In embodiments, the transgene encodes any biologically active product or other product, such as a product of research interest. Suitable transgenes can be readily selected by those skilled in the art, such as, but not limited to, those described herein.

Other examples of proteins encoded by the transgene include, but are not limited to, colony stimulating factor (CSF); blood factors (such as β-globulin, hemoglobin, tissue fibroblast lysogenum activator or its analogs, such as reteplase, lanteplase or tenecteplase) and coagulation factors; interleukins; soluble receptors, such as soluble TNF-α receptor, soluble VEGF receptor, soluble interleukin receptors (e.g., soluble IL-1 receptor and soluble type II IL-1 receptor) or ligand-binding fragments of soluble receptors; growth factors, such as keratinocyte growth factor (KGF), stem cell factor (SCF) or fibroblast growth factor (fibroblast growth factor); factors, such as basic FGF and acidic FGF); enzymes; interleukins; enzyme activators, such as tissue fibroblast growth factor; angiogenic agents, such as vascular endothelial growth factor, neuroglioma-derived growth factor, angiopoietin, or angiopoietin-2; anti-angiogenic agents, such as soluble VEGF receptors; protein vaccines; neuroactive peptides, such as nerve growth factor (NGF) or oxytocin; thrombolytics; tissue factor; macrophage-activating factor; tissue inhibitors of metalloproteinases; or IL-1 receptor antagonists.

In embodiments, provided herein is a nucleotide sequence encoding a molecule for treating Alzheimer's disease. In embodiments, the molecule for treating Alzheimer's disease comprises an inhibitory nucleic acid molecule (e.g., an antisense oligonucleotide or an inhibitory RNA (e.g., an siRNA, miRNA, or shRNA molecule). In embodiments, the molecule for treating Alzheimer's disease comprises an inhibitory nucleic acid molecule (e.g., an antisense oligonucleotide or an inhibitory RNA (e.g., an siRNA, miRNA, or shRNA molecule)) that targets β-amyloid, α-synuclein, Tau, a TREM, such as TREM2, or an apolipoprotein E protein, such as APOE1, APOE2, APOE3, or APOE4.

In embodiments, molecules used to treat Alzheimer's disease comprise a genome editing system (e.g., zinc finger nucleases, meganucleases, TALENs, or RNA-guided genome editing systems (e.g., Cas polypeptides and guide RNA molecules). In embodiments, the genome editing system targets a gene region encoding β-amyloid or Tau protein. In embodiments, the genome editing system targets MSA4.

In some embodiments, the molecule used to treat Alzheimer's disease is an antibody or an antigen-binding fragment thereof (e.g., scFv). In some embodiments, the molecule used to treat Alzheimer's disease is a human protein or a fragment or variant thereof. In some embodiments, the molecule used to treat Alzheimer's disease is an inhibitor of β-amyloid aggregation. In some embodiments, the molecule used to treat Alzheimer's disease is an inhibitor of α-synuclein. In some embodiments, the molecule used to treat Alzheimer's disease is an anti-β-amyloid antibody, such as gantenerumab, crenezumab, aducanumab, lecanemab, bapineuzumab, solanezumab, donanemab, or trontinemab (an anti-β-amyloid/anti-transferrin receptor bispecific antibody). In some embodiments, the molecule used to treat Alzheimer's disease is a tau inhibitor, such as an anti-tau antibody (e.g., semorinemab). In an embodiment, the molecule used to treat Alzheimer's disease is an anti-TREM antibody or an antigen-binding fragment thereof. In an embodiment, the molecule used to treat Alzheimer's disease is human neural growth factor or a fragment or variant thereof. In an embodiment, the molecule used to treat Alzheimer's disease is human brain-derived neurotrophic factor or a fragment or variant thereof. In an embodiment, the molecule used to treat Alzheimer's disease is human synaptophysin-1 (SynCav1) or a fragment or variant thereof.

Thus, in certain aspects, provided herein is a viral particle comprising (a) a variant capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Alzheimer's disease, such as described herein, and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide as described in Section 6.2; (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Alzheimer's disease, such as described herein, and (ii) a promoter operably linked to the nucleotide sequence.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Alzheimer's disease (e.g., gentamicin or an antigen-binding fragment thereof), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In embodiments, described herein are viral particles comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Alzheimer's disease (e.g., cremizumab or an antigen-binding fragment thereof), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating myasthenia gravis (e.g., an anti-IL-6 antibody (e.g., satelizumab) or an antigen-binding fragment thereof), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In one embodiment, provided herein is a nucleotide sequence encoding a molecule for treating Parkinson's disease. In one embodiment, the molecule for treating Parkinson's disease comprises an inhibitory nucleic acid molecule (e.g., an antisense oligonucleotide or an inhibitory RNA (e.g., an siRNA, miRNA, or shRNA molecule). In one embodiment, the molecule for treating Parkinson's disease comprises an inhibitory nucleic acid molecule (e.g., an antisense oligonucleotide or an inhibitory RNA (e.g., an siRNA, miRNA, or shRNA molecule)) targeting SNCA. Exemplary accession numbers for human SNCA and exemplary antisense oligonucleotides targeting SNCA are described in Table 3.

In embodiments, molecules used to treat Parkinson's disease comprise a genome editing system (e.g., zinc finger nucleases, meganucleases, TALENs, or RNA-guided genome editing systems (e.g., Cas polypeptides and guide RNA molecules). In embodiments, the genome editing system targets a gene region encoding α-synuclein (e.g., the SNCA gene).

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Parkinson's disease (e.g., an anti-α-synuclein antibody (e.g., prazizumab or BIIB054) or an antigen-binding fragment thereof), and (ii) a promoter operably linked to the nucleotide sequence. In one embodiment, described herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Parkinson's disease (e.g., human β-glucocerebrosidase or a fragment thereof) (e.g., a human GBA1 gene or a fragment or variant thereof, such as a variant thereof having at least 90% or at least 95% sequence identity to human GBA1), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human GBA1 are set forth in Table 2. Exemplary human GBA1 variants (e.g., variants containing a single nucleotide polymorphism) are disclosed in PCT Patent Application Publication No. WO/2023/004370/A1, which is incorporated herein by reference in its entirety. In one embodiment, described herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Parkinson's disease (e.g., an inhibitor of LRRK2), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Parkinson's disease, such as a trophic factor (e.g., neuroglia cell line-derived neurotrophic factor (GDNF) or brain dopamine neurotrophic factor (CDNF), or a fragment thereof), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Parkinson's disease (e.g., an antisense RNA (e.g., an antisense RNA targeting the α-synuclein or SNCA gene) or a fragment thereof), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Gaucher's disease (e.g., a human glucocerebrosidase (GC enzyme, such as β-glucosylceramidase-1) or a fragment or variant thereof) (e.g., a human GBA gene, such as a human GBA1 gene), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises an ITR flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces the viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a protein encoding a molecule for treating multiple sclerosis (e.g., an anti-CD20 antibody (e.g., ocrelizumab, rituximab, ofatumumab), or RG6035/RO7121932 (anti-CD20 anti-transferrin receptor bispecific antibody, sometimes referred to as Brainshuttle (BS))). In one embodiment, the invention relates to a nucleotide sequence encoding CD20 (multiple sclerosis) or an antigen-binding fragment thereof, and (ii) a promoter operably linked to the nucleotide sequence. In an embodiment, the multiple sclerosis is relapsing remitting multiple sclerosis. In an embodiment, the multiple sclerosis is primary progressive multiple sclerosis. In an embodiment, the multiple sclerosis is secondary progressive multiple sclerosis. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) introns, (c) enhancer or suppressor sequences, (d) stuffer sequences, and (e) A polyA sequence. Preferably, the viral genome comprises ITRs flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell producing the viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Huntington's disease (e.g., an inhibitory nucleic acid against mutant Huntington's protein (HTT) (e.g., tominersen, WVE-120101, or WVE-120102)), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises an ITR flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces the viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, e.g., a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Phelan McDermid syndrome (e.g., human SHANK3 or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human SHANK3)), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising: (a) a capsid polypeptide described herein, e.g., a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Phelan-McCayd-Mead syndrome (e.g., a human growth hormone, e.g., human insulin-like growth factor 1 (IGF-1), or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human IGF-1)), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanked by the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating frontotemporal dementia (e.g., a human granulin proprotein or granulin, or a fragment or variant thereof), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, e.g., a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating frontotemporal dementia (e.g., an anti-tau antibody (e.g., ceranaemia) or a fragment or variant thereof), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating frontotemporal dementia (e.g., an inhibitory nucleic acid targeting SOD-1 (e.g., tofersen)), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating muscular dystrophy (ALS), such as an inhibitory nucleic acid targeting SOD-1 (e.g., tolfensen), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, e.g., a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating ALS (e.g., an inhibitory nucleic acid targeting C9orf72 (e.g., BIIB078)), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, e.g., a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating ALS (e.g., an inhibitory nucleic acid targeting ATXN2 (e.g., BIIB105)), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating ALS (e.g., an inhibitory nucleic acid targeting FUS), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating multiple systemic atrophy (e.g., an anti-α-synuclein antibody (e.g., pralidoxime)), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating multiple systemic atrophy (e.g., an antisense oligonucleotide targeting human SNCA), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating multiple systemic atrophy (e.g., human neuroglia-derived neurotrophic factor (GDNF) or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human GDNF)), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependency parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises an ITR flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces the viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, e.g., a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating progressive supranuclear palsy (PSP), e.g., an anti-tau antibody (e.g., ceruleanumab), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating progressive supranuclear palsy (PSP), such as an anti-α-synuclein antibody (e.g., pralidoxime), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises an ITR flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces the viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Friedreich's disease (e.g., human frataxin (FRXN) or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human FRXN)), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises an ITR flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces the viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a nucleotide sequence encoding a molecule for treating Angelman syndrome. In embodiments, the molecule for treating Angelman syndrome comprises an inhibitory nucleic acid molecule (e.g., an antisense oligonucleotide or an inhibitory RNA (e.g., an siRNA, miRNA, or shRNA molecule). In embodiments, the molecule for treating Angelman syndrome comprises an inhibitory nucleic acid molecule (e.g., an antisense oligonucleotide or an inhibitory RNA (e.g., an siRNA, miRNA, or shRNA molecule)) that targets UBE3A.

In embodiments, the molecule used to treat Angelman syndrome comprises a genome editing system (e.g., zinc finger nuclease, meganuclease, TALEN, or RNA-guided genome editing system (e.g., Cas polypeptide and guide RNA molecule). In embodiments, the genome editing system targets UBE3A.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Angelman syndrome (e.g., an inhibitor of UBE3A antisense nucleic acid (e.g., rugonersen) or human UBE3A or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human UBE3A)), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human UBE3A are set forth in Table 2. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanked by the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating fragile X syndrome (e.g., human fragile X mental retardation protein (FMRP) or a fragment or variant thereof) (e.g., a nucleotide sequence comprising the FMR1 gene or a fragment or variant thereof), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human FMRP are set forth in Table 2. In one embodiment, described herein is a viral particle comprising (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating fragile X syndrome (e.g., a transcriptional silencing inhibitor of FMRP), and (ii) a promoter operably linked to the nucleotide sequence. In one embodiment, described herein is a viral particle comprising (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating fragile X syndrome, such as human diacylglycerol kinase (DGKk) or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human DGKk), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human DGKk are set forth in Table 2. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanked by the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 4.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Rett syndrome (e.g., human MECP2 or a fragment or variant thereof, such as a variant thereof having at least 90% or at least 95% sequence identity to human MECP2), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human MECP2 are set forth in Table 2. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises an ITR flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces the viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Dravet syndrome (e.g., voltage-gated human sodium ion channel type 1-alpha (SCN1A or Nav1.1) or a fragment or variant thereof), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, e.g., a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Dravet syndrome (e.g., an inhibitory nucleic acid targeting a mutant SCN1A transcript), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, e.g., a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Dravet syndrome (e.g., an anti-tau antibody (e.g., cerulenzumab) or a fragment or variant thereof), and (ii) a promoter operably linked to the nucleotide sequence. In embodiments, described herein are viral particles comprising (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Dravet syndrome (e.g., human spike protein binding protein 1 (STXBP1) or a fragment or variant thereof), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Friedreich's ataxia (e.g., a human FXN gene or a fragment or variant thereof), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

Other exemplary diseases that can be treated and other exemplary heterologous transgenes that can be delivered via the viral particles herein are provided in Table 2. Table 2 Exemplary CNS indications and transgenic genes Indications genetically modified organisms UniProt accession number (human) Achromatopsia - color blindness Cyclic nucleotide-gated cation channel alpha-3 (CNGA3) Q16281 Cyclic nucleotide-gated cation channel beta-3 (CNGB3) Q9NQW8 Guanine nucleotide-binding protein G(t) subunit alpha-2 (GNAT2) P19087 Cone retinal cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha (PDE6C) P51160 Acute intermittent porphyria Bilichrome deaminase (PBGD) HMBS P08397 Adie syndrome-Adie's pupil MPZ P25189 Age-related macular degeneration vascular endothelial growth factor receptor 1 (FLT1) P17948 Vascular endothelial growth factor A (VEGFA) P15692 Agenesis of the corpus callosum (ACCPN) SLC12A6 Q9UHW9 Aicardi-Goutieres syndrome TREX1 Q9NSU2 Alexander disease GFAP P14136 Alpers syndrome POLG P54098 Alternating hemiplegia ATP1A2 P50993 ATP1A3 P13637 Alzheimer's disease NGF P01138 ApoE P02649 Presenilin (PSEN1) A0A024R6A3 Presenilin-2 (PSEN2) P49810 Amyloid-β proprotein (APP) P05067 ADAM10 O14672 MAPT (Tau) P10636 Amyotrophic Lateral Sclerosis (ALS) - Lou Gehrig's Disease Superoxide dismutase-1 (SOD1) P00441 Hereditary neuromuscular atrophy SEPT9 Q9UHD8 Angelman syndrome Ubiquitin-protein ligase E3A (UBE3A) Q05086 Aromatic L-amino acid decarboxylase deficiency (AADCD) DDC P20711 Ataxia APTX Q7Z2E3 KCNA1 Q09470 CACNA1A O00555 Ataxia with telangiectasia - Louis-Bar syndrome Serine protein kinase ATM (ATM) Q13315 Attention Deficit Hyperactivity Disorder (ADHD) DRD4 P21917 CDH2 P19022 Beck's muscular dystrophy Follistatin (FST) P19883 DMD P11532 Benign idiopathic eyelid spasm DRD5 P21918 Bradbury-Eggleston syndrome (Pure autonomic nervous system failure) COQ2 Q96H96 Bulbar palsy (BVVLS1) SLC52A3 Q9NQ40 Canavan disease-aminoacylase 2 deficiency ASPA P45381 carpal tunnel syndrome TTR P02766 Spongioma-Cavernomatous Hemangioma-Cavernomatous Malformation KRIT1 O00522 Cerebellar hypoplasia (CHEGDD) OXR1 Q8N573 Cerebellar ataxia (CAMRQ2) WDR81 Q562E7 Cerebral arteriovenous stenosis associated with SCI and leukoencephalopathy (CADASIL) NOTCH3 Q9UM47 Cerebral gigantism-Sotos syndrome 1 NSD1 Q96L73 Cerebro-oculofacial-skeletal syndrome (COFS) ERCC6 Q03468 Waxy lipofuscinosis-Baden disease CLN1 (PPT1) P50897 CLN2 (TPP1) O14773 CLN3 (battenin) Q13286 CLN4 Q9H3Z4 CLN5 O75503 CLN6 Q9NWW5 CLN7 (MFSD8) Q8NHS3 CLN8 Q9UBY8 CLN10 (Cathepsin D) P07339 CLN11 (granulin proprotein) P28799 CLN12 (ATP13A2) Q9NQ11 CLN13 (Cathepsin F) Q9UBX1 CLN14 (KCTD7) Q96MP8 Charcot-Marie-Tooth disease PMP22 Q01453 MPZ P25189 DNM2 P50570 MFN2 O95140 KIF1B O60333 SBF2 Q86WG5 PNKP Q96T60 GDAP1 Q8TB36 LMNA P02545 FGD4 Q96M96 MTMR2 Q13614 Chorea NKX2-1 P43699 Chorea acanthocytosis VPS13A Q96RL7 Achoroidal dysplasia Rab escort protein (Rep1) CHM P24386 Chronic inflammatory demyelinating polyneuropathy (CIDP) PMP22 Q01453 Cockayne syndrome B (CSB) ERCC6 Q03468 Coffin-Lowry syndrome RPS6KA3 P51812 Craniosynostosis MSX2 P35548 TWIST1 Q15672 SKI P12755 SMAD6 O43541 Creutzfeldt-Jakob disease PRNP P04156 HLA-DQB1 P01920 Kerger-Najjar syndrome-hyperbilirubinemia UDP-glucuronosyltransferase 1A1 (UGT1A1) P22309 Cushing Syndrome PRKACA P17612 Dentorubral atrophy (DRPLA) ATN1 P54259 Developmental and epileptic encephalopathy ARX Q96QS3 FGF12 P61328 PIGP P57054 GABRB3 P28472 NECAP1 Q8NC96 Developmental Dyspraxia-Speech-Language Disorder 1 (SPCH1) FOXP2 O15409 Dravet syndrome Sodium channel protein subunit type 1 alpha (SCN1A) P35498 SCN1B Q07699 SCN2A Q99250 GABA receptor subunit gamma-2 (GABRG2) P18507 Autonomic nervous system disorder - Day syndrome ELP1 O95163 Dystonia GCH1 P30793 TOR1A O14656 SGCE O43556 TUBB4A P04350 Encephalocele COL18A1 P39060 epilepsy GRIN2A Q12879 CSTB P04080 STARD7 Q9NQZ5 DEPDC5 O75140 PCDH19 Q8TAB3 Essential tremors DRD3 P35462 NOTCH2NLC P0DPK4 FUS P35637 Fabry disease α-Galactosidase A (GLA) P06280 Farber disease-neuramidase deficiency ASAH1 Q13510 Fahr disease SLC20A2 Q08357 febrile epilepsy GABRG2 P18507 ADGRV1 Q8WXG9 CPA6 P11509 SCN1A P35498 Fragile X syndrome FMR1 (FMRP) Q06787 Diglycerol kinase (DGKk) Q5KSL6 Friedreich ataxia FXN Q16595 Frontotemporal dementia Granular protein precursor (GRN) P28799 MAPT (tau) P10636 PSEN1 A0A024R6A3 Fucoseosis α-L-fucosidase (FUCA1) P04066 White spot fundus RLBP1 P12271 Gaucher disease types I, II, and III Glucocerebrosidase (GBA1) P04062 Systemic gangliosidosis (GM1, GM2, GM3) GLB1 P16278 Gerstmann-Straussler-Scheinker disease PRNP P04156 Giant axonal neuropathy Giant axonal neuropathic protein (GAN) Q9H2C0 Glycogen storage disease II-Pompe disease-acid maltase deficiency Acid maltase (lysosomal α-glucosidase) (LYAG, GAA) P10253 Guillain-Barré syndrome PMP22 Q01453 Hallervorden-Spatz disease-PKAN-NBIA1 PANK2 Q9BZ23 Alternating hemiplegia ATP1A2 P50993 ATP1A3 P13637 Hereditary neuropathy WNK1 Q9H4A3 MFN2 O95140 HK1 P19367 TFG Q92734 SPTLC1 O15269 Refsum disease PHYH O14832 Holoprosencephaly GLI2 P10070 TGIF1 Q15583 ZIC2 O95409 PTCH1 Q13635 SHH Q15465 Huntington's disease HTT P42858 hydrocephalus CCDC88C Q9P219 WDR81 Q562E7 TRIM71 Q2Q1W2 MPDZ O75970 pigmentation disorder IKBKG Q9Y6K9 Infantile hypotonia NALCN Q8IZF0 TBCK Q8TEA7 CCDC174 Q6PII3 UNC80 Q8N2C7 Childish axonal dystrophy PLA2G6 O60733 Juvenile phytanic acid storage disease (PBD1B) PEX1 O43933 Joubert Syndrome INPP5E Q9NRR6 Kennedy disease Androgen receptor (AR) P10275 Klippel-Feil Syndrome GDF6 Q6KF10 Krabbe disease - GALC deficiency GALC P54803 Lambert-Eaton Myasthenic Syndrome CACNA1A O00555 CACNB2 Q13936 Landau-Kleffner Syndrome GRIN2A Q12879 Late-stage juvenile neuronal lipofuscinosis (CLN2) TPP1 O14773 Lesch-Nyhan Syndrome HPRT1 P00492 Leiber's congenital amaurosis - retinal blindness Retinal guanylate cyclase 1 (GUCY2D) Q02846 Retinoid isohydrolase (RPE65) Q16518 290 kDa centrosomal protein (CEP290) O15078 Crumbs protein homolog 1 (CRB1) P82279 Leiber's hereditary optic neuropathy NADH-ubiquinone oxidoreductase chain 4 (ND4) P03905 White matter dystrophy ARSA P15289 Levine-Critchley Syndrome - Chorea acanthocytosis VPS13A Q96RL7 Lewy body dementia SNCA P37840 SNCB Q16143 Lipoproteinemia - Urbach-Wiethe disease ECM1 Q16610 Sphenoencephaly PAFAH1B1 Q9PTR5 NDE1 Q9NXR1 TUBA1A Q71U36 LAMB1 LAMB1 KATNB1 Q9BVA0 RELN P78509 Macrocephaly/megalencephaly TBC1D7 Q9P0N9 Menkes Disease ATP7A Q04656 Metachromatic Leukodystrophy - MLD Arylsulfatase A (ARSA) P15289 microcephaly KIF11 P52732 MCPH1 Q8NEM0 SLC25A19 Q9HC21 Familial hemiplegic migraine CACNA1A O00555 ATP1A2 P50993 SCN1A P35498 Mitochondrial DNA Deletion Syndrome RRM2B Q7LG56 DGUOK Q16854 POLG P54098 TYMP P19971 TK2 O00142 Morvan disease WNK1 Q9H4A3 Mucolipidosis GNPTAB Q3T906 MCOLN1 Q9GZU1 Mucopolysaccharidosis type I (MPS I) - Hurler syndrome α-L-Iduronidase (IDUA) P35475 MPS II - Hunter syndrome Iduronate-2-sulfatase (IDS) P22304 MPS IIIa - Sanfilippo syndrome type A Heparan sulfate sulfatase (HSS) or N-sulfoglucosamine sulfohydrolase (SGSH) P51688 MPS IIIB - Sanfilippo syndrome type B N-acetyl-α-D-aminoglucosidase (NAGLU) P54802 MPS VI - Maroteaux-Lamy syndrome Arylsulfatase B (ARSB) P15848 MPS IV A - Mauque syndrome type A N-acetylgalactosamine-6-sulfatase (GALNS) P34059 MPS IV B - Mauque syndrome type B β-Galactosidase 1 (GLB1) P16278 MPS VII - Seeley Syndrome β-glucuronidase P08236 MPS VIII Glucosamine-6-sulfate sulfatase P15586 MPS IX Hyaluronidase-1 (HYAL1) Q12794 Multiple sclerosis PDCD1 Q15116 Multisystem atrophy COQ2 Q96H96 Congenital presynaptic weakness syndrome CHAT P28329 muscle spasms NOL3 O60936 Myoclonus and leukocytosis (FAME2) STARD7 Q9NQZ5 Narcolepsy HCRT (OX) O43612 MOG Q16653 Neuroacanthocytosis-McLeod syndrome XK P51811 Neurodevelopmental disorder with cerebral atrophy and facial dysmorphism (NEDCAFD) TTC5 Q8N0Z6 Neurodevelopmental disorder with infantile epileptic seizures NCDN Q9UBB6 Neurofibroma NF1 P21359 Neuromyotonia HINT1 P49773 Neurogenic ceramide lipofuscinosis PPT1 P50897 TPP1 O14773 CLN5 O75503 CLN3 Q13286 CLN6 Q9NWW5 CLN8 Q9UBY8 DNAJC5 Q9H3Z4 MFSD8 Q8NHS3 CTSD P07339 Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP) MTATP6 P00846 Type II hereditary sensory and autonomic neuropathy WNK1 Q9H4A3 Hypomyelinating congenital neuropathy 1 EGR2 P11161 Niemann-Pick disease Sphingomyelin phosphodiesterase 1 (SMPD1) P17405 NPC intracellular cholesterol transporter 1 (NPC1) O15118 Ohtahara Syndrome - Developmental and Epileptic Encephalopathy 1 ARX Q96QS3 Ornithine aminoformyl transferase deficiency OTC P00480 Orthostatic intolerance SLC6A2 P23975 Parkinson's disease Glucocerebrosidase (GBA1) P04062 Dopamine decarboxylase (DDC) P20711 Neuronutrients Q99748 GDGF P39905 Tyrosine hydroxylase (TH) (tyrosine 3-monooxygenase) P07101 Glutamine decarboxylase (GAD) Q99259 Fibroblast Growth Factor 2 (FGF2) P09038 Brain-derived neurotrophic factor (BDNF) P23560 Chorea PNKD Q8N490 Pelizaeus-Merzbacher Disease PLP1 P60201 Pena-Shokeir Type II Syndrome ERCC6 Q03468 Periodic paralysis SCN4A P35499 Phelan-McCedar-Mead syndrome SH3 and multiple anchor repeat domain protein 3 (SHANK3) Q9BYB0 Phytanic Acid Storage Disease-Peroxisome Biogenesis Disorder 1B PEX1 O43933 Pick's disease PSEN1 A0A024R6A3 MAPT (tau) P10636 Pyrencephaly type 1 COL4A1 P02462 Juvenile primary lateral sclerosis ALS2 Q96Q42 Primary progressive aphasia GRN P28799 Progressive external ophthalmoplegia POLG P54098 POLG2 Q9UHN1 SLC25A4 P12235 TWNK Q96RR1 Progressive bulbar palsy SLC52A3 Q9NQ40 Progressive supranuclear neuropathy Microtubule-associated protein tau (MAPT) Tau P10636 Pseudo-Torch syndrome OCLN Q16625 STAT2 P52630 USP18 Q9UMW8 Retinitis Pigmentosa 38 - Rod-Cone malnutrition Meritogen tyrosine-protein kinase (MERTK) Q12866 Retinitis pigmentosa40 PDE6B P35913 Rett syndrome Methyl-CpG-binding protein 2 (MECP2) P51608 Sandhoff disease β-Hexosidase subunit α (HEXA) P06865 β-Hexosidase subunit β (HEXB) P07686 Schizencephaly SIX3 O95343 EMX2 Q04743 SHH Q15465 Seitelberger Disease PLA2G6 O60733 Septooptic dysplasia - De Morsier syndrome HESX1 Q9UBX0 Snijders Blok-Fisher syndrome POU3F3 P20264 Spastic paralysis SPG11 Q96JI7 SPAST Q9UBP0 KIF5A Q12840 NIPA1 Q7RTP0 CYP7B1 O75881 ATL1 Q8WXF7 Spinal Muscular Atrophy-Kugelberg-Welander Disease Survival motor neuron protein (SMN) SMN1 Q16637 Spinocerebellar ataxia Ataxan-1 (ATXN1) SCA1 P54253 Ataxan-2 (ATXN2) SCA2 Q99700 Ataxan-3 (ATXN3) SCA3 P54252 ZFHX3 Q15911 CACNA1A O00555 ATXN7 (SCA7) O15265 TMEM240 Q5SV17 sporadic inclusion body myositis Follistatin (FST) P19883 Steele-Richardson-Olszewski syndrome - Parkinson's disease-dementia syndrome MAPT(Tau) P10636 Congenital stiff-person syndrome GLRA1 P23415 GLRB P48167 Substantia nigra NUP62 P37198 PDE8B O95263 MTATP6 P00846 VAC14 Q08AM6 stroke Tissue-type fibroblast lysogeny activator (tPA) P00750 Neuronal differentiation factor 1 (NeuroD1) Q13562 Sturge-Weber Syndrome GNAQ P50148 Subcortical vascular encephalopathy-cerebral arteriovenous disease HTRA1 Q92743 Systemic lupus erythematosus DNASE1L3 Q13609 TLR7 Q9NYK1 Delayed akinesia CYP2D6 P10635 Tay-Sachs disease β-Hexosidase subunit α (HEXA) P06865 Tourette syndrome HDC P19113 SLITRK1 Q96PX8 Hereditary tremor type 1 DRD3 P35462 Troyer syndrome SPART Q8N0X7 Tuberous sclerosis TSC1 Q92574 TSC2 P49815 IFNG P01579 Von Hippel-Lindau Disease VHL P40337 CCND1 P24385 Von Recklinghausen Disease NF1 P21359 Wildnig-Hoffmann disease SMN1 Q16637 West Syndrome ARX Q96QS3 Wilson disease ATP7B P35670 Wolman's disease-acid lipase disease LIPA P38571 X-linked adrenoleukodystrophy ATP-binding cassette family D member 1 (ABCD1) P33897 X-linked retinoschisis Retinoschizine (RS1) O15537 X-linked retinitis pigmentosa X-linked retinitis pigmentosa GTPase regulator (RPGR) Q92834 X-linked spinal and bulbar muscular dystrophy UBA1 P22314

In some embodiments, the payload is an antisense oligonucleotide that is effective in treating CNS diseases, for example, by modulating target gene expression. Exemplary CNS diseases that can be treated using antisense oligonucleotides include amyotrophic lateral sclerosis, Huntington's disease, and Alzheimer's disease. Exemplary target genes for these antisense oligonucleotides for treating CNS diseases include SOD1, C9orf72, dysregulatory protein 2, huntingtin (HTT), sortin-associated receptor, microtubule-associated protein tau (MAPT), and neutral neurophospholipase (N-SMase). Various antisense oligonucleotides effective for treating CNS diseases are described in the art and include, for example, those described in Bennett et al., 2019 Annu Rev Neurosci . 42:385-406, Rinaldi et al., 2018, Nature Reviews Neurology, 14:9-21, and Rook et al., 2022, BioDrugs 36(2):105-119, each of which is incorporated herein by reference.

Non-limiting exemplary antisense oligonucleotides that can be delivered via the viral particles herein (as well as associated target genes and CNS tissue-related diseases that can be treated) are provided in Table 3. When these antisense oligonucleotides are indicated by reference to patents or patent application publications, these patents and patent applications are incorporated herein by reference in their entirety for their disclosure of antisense oligonucleotide structures and sequences. Table 3 Exemplary CNS indications, target genes, and antisense oligonucleotide transgenes Indications target gene Uniprot accession number (human) Exemplary transgenes Amyotrophic lateral sclerosis Superoxide dismutase 1 (SOD 1) P00441 Antisense oligonucleotides described in U.S. Patent Application Publication Nos. 2024/0182903 A1, 2022/0073930 A1, 2017/0152517 A1, 2020/0354723 A1, 2022/0315930 A1, and 2023/0193281 A1. C9orf72 Q96LT7 Antisense oligonucleotides described in U.S. Patent Application Publication Nos. 2018/0023077 A1, 2015/0267197 A1, 2020/0385723 A1, 2016/0237432 A1, 2023/0098111 A1, and 20190231808 A1. Huntington's disease Huntingtin protein (HTT) P42858 Antisense oligonucleotides described in U.S. Patent Application Publication Nos. 20140303238 A1, 2017/0253877 A1, and 2022/0098585 A1; and PCT Patent Application Publication No. WO/2024/035946 A1. Alzheimer's disease Sortilin-related receptor 1 (SORL1) Q92673 Antisense oligonucleotides described in PCT Patent Application Publication No. WO/2023/275376 A1. Neutral neurophospholipase (N-SMase), also known as sphingomyelin phosphodiesterase 2 (SMPD2) O60906 Antisense oligonucleotides described in U.S. Patent Application Publication No. 2014/0275210 A1. Spinocerebellar ataxia type 2 (SCA2) Ataxan-2 (ATXN2) Q99700 Antisense oligonucleotides described in U.S. Patent Application Publication No. 2020/0024600 A1 Parkinson's disease SNCA P37840 Antisense oligonucleotides described in U.S. Patent Application Publication Nos. 20050137155 A1, 20050186591 A1, 20200362347 A1, 20040219671 A1, 20220119811 A1, 20210180065 A1, and 20200392494 A1

This disclosure further relates, in part, to a method for delivering a payload to a subject (e.g., an animal or human subject). In some embodiments, the method for delivering a payload to a subject comprises administering to the subject a dependent microviral particle comprising a variant polypeptide (e.g., as described herein) comprising a payload, e.g., in an amount and for a time sufficient to deliver the payload. In some embodiments, the dependent microviral particle is a dependent microviral particle as described herein and comprises a payload as described herein. In some embodiments, the particle delivers the payload to the CNS. In some embodiments, delivery to the CNS is increased compared to particles without a variant coat polypeptide or compared to a wild-type coat polypeptide (e.g., a coat polypeptide having SEQ ID NO: 1). In some embodiments, the particles deliver an effective cargo to skeletal muscle tissue. In some embodiments, delivery to skeletal muscle tissue is increased compared to particles without a variant coat polypeptide or compared to a wild-type coat polypeptide (e.g., a coat polypeptide having SEQ ID NO: 1).

In some embodiments, a viral particle comprising a genome is provided, wherein the genome comprises a nucleic acid expression construct comprising a heterologous transgene and one or more regulatory elements, wherein the one or more regulatory elements comprise a muscle (e.g., skeletal muscle) specific promoter. Examples of muscle-specific promoters that can be used to drive expression of transgenes in skeletal muscle include, but are not limited to, desmin (DES), CAMK, Mb, myosin (e.g., myo-3), myotrophin, muscle creatine kinase (MCK), MHCK7, CK6, CK7, CK8, CK8e, dMCK, tMCK, MH, SPc-5-12 (also known as C5-12), alpha skeletal actin (ASKA), SP-301, E-syn, myosin light chain (MLC), myosin heavy chain (MHC), four and a half LIM domain protein 1 (FHL1), alpha 2 coactin (ACTN2), filament protein-C (FLNC), myoplasmic/endoplasmic reticulum calcium ATPase 1 (ATP2A1), type 1 troponin I (TNNI1), myosin-1 The MYH1, MYLPF, tropomyosin alpha-3 chain (TPM3), Pitx3, and ankyrin repeat domain-containing protein 2 (ANKRD2) promoters were expressed. Promoters capable of driving expression in skeletal muscle are further described in Skopenkova et al., 2021, Acta Naturae 13(1):47-58, Piekarowicz et al., 2019, Mol Ther Methods Clin Dev. 15:157-169, Wang, 2008 Gene Ther. 15:1489-1499, Coulon et al., 2007, JBC 282(45):33192-33200, WO 2021/127655 and WO 2023/006890, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiments, the payload comprises a molecule effective for treating muscle disease, such as a protein or an RNA interfering nucleotide (e.g., shRNA, siRNA, or miRNA).

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a protein encoding a molecule for treating Duchenne muscular dystrophy (DMD) (e.g., human muscular dystrophy protein (DMD)) or a fragment or variant thereof (e.g., a protein having at least 90% or at least 95% sequence identity with human DMD); The invention relates to a method for producing a viral genome comprising: (i) a nucleotide sequence having at least one residue of the first moiety of the invention and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human DMD are set forth in Table 4. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) introns, (c) enhancer or suppressor sequences, (d) stuffer sequences, and (e) polyA sequences. Preferably, the viral genome comprises ITRs flanking the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in host cells that produce viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating X-linked myotubular myopathy (e.g., human myotubularin (MTM1) or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human MTM1)), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human MTM1 are set forth in Table 4. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanked by the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating myotonic dystrophy type 1 (DM1), such as human myotonic protein kinase (DMPK) or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human DMPK), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human DMPK are set forth in Table 4. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanked by the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating limb-girdle muscular dystrophy (LGMD), such as human γ-sarcoglycan, α-sarcoglycan, β-sarcoglycan, or δ-sarcoglycan, or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human γ-sarcoglycan, α-sarcoglycan, β-sarcoglycan, or δ-sarcoglycan), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human γ-sarcoglycan, α-sarcoglycan, β-sarcoglycan, and δ-sarcoglycan are set forth in Table 4. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanked by the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating Pompe disease (e.g., human acid α-glucosidase (GAA) or a fragment (e.g., exon 2) or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human GAA or a portion thereof)), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human GAA are set forth in Table 4. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanked by the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces viral particles. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating facioscapulohumeral muscular dystrophy (FSHD) (e.g., an antisense oligonucleotide targeting human DUX4), and (ii) a promoter operably linked to the nucleotide sequence. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependency parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises the ITRs flanking the nucleotide sequence and the polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell where the viral particles are produced. In some embodiments, the viral genome is self-complementary.

In certain aspects, provided herein is a viral particle comprising: (a) a capsid polypeptide described herein, such as a capsid polypeptide described in Section 6.2; and (b) an engineered viral genome comprising (i) a nucleotide sequence encoding a molecule for treating facioscapulohumeral muscular dystrophy (FSHD), such as human SMCHD1 or a fragment or variant thereof (e.g., a variant thereof having at least 90% or at least 95% sequence identity to human SMCHD1 or a portion thereof), and (ii) a promoter operably linked to the nucleotide sequence. Exemplary accession numbers for human SMCHD1 are set forth in Table 4. The viral genome may further comprise one or more (e.g., two, three, four, or all five) of the following: (a) a pair of dependent parvoviral ITRs, (b) an intron, (c) an enhancer or suppressor sequence, (d) a stuffer sequence, and (e) a polyA sequence. Preferably, the viral genome comprises ITRs flanked by the nucleotide sequence and a polyA sequence operably linked to the nucleotide sequence. Typically, the viral genome lacks rep and cap sequences, which are in trans in the host cell that produces viral particles. In some embodiments, the viral genome is self-complementary.

Exemplary muscle tissue-related diseases that can be treated include, but are not limited to, acid maltase deficiency (AMD), amyotrophic lateral sclerosis (ALS), Anderson-Tawil Syndrome, Barthel syndrome (TAZ), Beck muscular dystrophy (BMD), Beck congenital myotonia, Bethlem myopathy, bulbar muscular dystrophy (spondylobula), carnitine deficiency, carnitine palmitoyltransferase deficiency (CPT deficiency), central core disease (CCD), centronuclear myopathy, Chuck-Marie-Duchesne disease (CMT), congenital muscular dystrophy (CMD), congenital myotonic syndrome (CMS), myotonic congenital dystrophy, and Cori disease. (Debrunase Deficiency), Danon's Disease, Debrunase Deficiency, Dejerine-Sottas Disease (DSD), Dermatomyositis (DM), Distal Muscular Dystrophy (DD), Distal Myopathy with Anterior Tibial Attack, Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (Myotonic Dystrophy), Emery-Dreifuss Muscular Dystrophy (EDMD), Endocrine Myopathies, Eulenberg Disease (Paronychia Congenita), Facioscapulohumeral Muscular Dystrophy (FSH or FSHD), Finnish Distal Myopathy (Tibia), Forbes Disease (debrachiatin deficiency), Friedreich's ataxia (FA), Fukuyama Congenital Muscular Dystrophy, Glycopathia Type 10, Glycopathia Type 11, Glycopathia Type 2, Glycopathia Type 3, Glycopathia Type 5, Glycopathia Type 7, Glycopathia Type 9, Gowers-Laing Distal Myopathy, Hauptmann-Thanheuser MD (Emery-Dreifuss Muscular Dystrophy), Dystrophy), hereditary inclusion body myositis, hereditary motor and sensory neuropathy (Chuck-Marie-Douglas disease), hyperthyroid myopathy, hypothyroid myopathy, inclusion body myositis (IBM), hereditary myopathies, integrin-deficient congenital muscular dystrophy, Kennedy disease (spondylobular atrophy), Kugelberg-Welander disease (spinal muscular atrophy), lactate dehydrogenase deficiency, Lambert-Eaton myasthenia syndrome (LEMS), limb-girdle muscular dystrophy (LGMD), Lou Gehrig's disease (muscular dystrophy), McArdle disease (phosphorylase deficiency), platelet-deficient congenital muscular dystrophy, muscle metabolic disease, mitochondrial myopathy, Miyoshi myopathy, Miyoshi distal myopathy, motor neuron disease, muscle-eye-encephalopathy, myasthenia gravis (MG), myoadenylate deaminase deficiency, myofibrillar myopathy, myophosphorylase deficiency, myotonia congenita (MC), myotonic muscular dystrophy (MMD), myomicrotubular myopathy (MTM or MM), nematode myopathy, Nonaka distal myopathy, oculopharyngeal muscular dystrophy (OPMD), paramyotonia congenita, Pearson syndrome Syndrome), periodic paralysis, Charcot-Marie-Tooth disease (Chucker-Marie-Tooth disease), phosphofructokinase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, phosphorylase deficiency, phosphorylase deficiency, polymyositis (PM), Pompe disease (acid maltase deficiency), lamina propria 2 deficiency (LAMA2), progressive external ophthalmoplegia (PEO), rod body disease (nematode myopathy), spinal muscular atrophy (SMA), spondylobular atrophy (SBMA), Steinert disease (myotonic dystrophy), Tarui disease (phosphofructokinase deficiency), Thomsen disease (myotonia congenita), Ullrich congenital muscular dystrophy (Ullrich congenital muscular dystrophy), Muscular Dystrophy, Walker-Warburg Syndrome (congenital muscular dystrophy), Welander Distal Myopathy, Werdnig-Hoffmann Disease (spinal muscular atrophy), and ZASP-related myopathies.

Suitable payloads for treating muscle-related diseases are known in the art and include the following disease (suitable payload) combinations: Barthel syndrome (TAZ), idiopathic laminarin deficiency (LAMA2), Duchenne muscular dystrophy (DMD), Beck muscular dystrophy (BMD), Danon's disease (LAMP2), limb-girdle muscular dystrophy (subtypes and affected genes: LGMD1A (TTID), LGMD1B (LMNA), LGMD1C (CAV3), LGMD1D (DNAJB6), LGMD1E (DES), LGMD1F (TNP03), LGMD1G (HNRPDL), LGMD1H, LGMD2A (CAPN3), LGMD2B (DYSF), LGMD2C (SGCG), LGMD2D (SGCA), LGMD2E (SGCB), LGMD2F (SGCD), LGMD2G (TCAP), LGMD2H (TRIM32), LGMD2I (FKRP), LGMD2J (TTN), LGMD2K (POMT1), LGMD2L (AN05), LGMD2M (FKTN), LGMD2N (POMT2), LGMD20 (POMGNT1), LGMD2Q (PLEC1)), Miyoshi myopathy (DYSF), distal myopathy with anterior tibial attack (DYSF), Wieland distal myopathy (TIA1), Gowers-Lane distal myopathy (MYH7), facioscapulohumeral muscular dystrophy (subtypes and affected genes: type 1 (DUX4), type 2 (SMCHD1)), oculopharyngeal muscular dystrophy (PABPN1), myotonic dystrophy (subtypes and affected genes: DM1 (DMPK) and DM2) (ZNF9), myotonia congenita (CLCN1), congenital myotonia flexorrhagic (SCN4A), myotubular myopathy (MTM1), and glycogenostasis type II (Pompe disease) (GAA).

In some embodiments, the payload is selected from: TAZ, LAMA2, DMD, LAMP2, CAPN3, DYSF, SGCA, SGCB, FKRP, PABPN1, MTM1, and GAA.

Certain exemplary muscle tissue-related diseases that can be treated and exemplary heterologous transgenes that can be delivered via the viral particles herein are provided in Table 4. Table 4 Exemplary muscle diseases and transgenic genes Indications genetically modified organisms UniProt accession number (human) Acid maltase deficiency-glycogenostasis II GAA P10253 Advanced heart failure SERCA2a (ATP2A2) P16615 Amyotrophic Lateral Sclerosis (ALS)-Lou Gehrig's Disease Superoxide dismutase-1 (SOD1) P00441 Anderson-Tavel syndrome KCNJ2 P63252 Barthel syndrome TAFAZZIN Q16635 Beck muscular dystrophy (BMD) DMD P11532 Baker's myotonia congenita CLCN1 P35523 Bethlem myopathy COL6A3 P12111 COL6A2 P12110 COL6A1 P12109 Bulbar muscle atrophy AR P10275 Systemic primary carnitine deficiency SLC22A5 O76082 Carnitine acyltransferase deficiency type 1 CPT1A P50416 Carnitine acyltransferase deficiency type 2 CPT2 P23786 Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) Calcium Sequestrant-2 (CASQ2) O14958 Central nuclear disease - congenital myopathy type 1A RYR1 P21817 Centronuclear myopathy type 1 MTMR14 Q8NCE2 DNM2 O14717 Chuck-Mary-Dew disease PMP22 Q01453 MPZ P25189 DNM2 P50570 MFN2 O95140 KIF1B O60333 SBF2 Q86WG5 PNKP Q96T60 GDAP1 Q8TB36 LMNA P02545 FGD4 Q96M96 MTMR2 Q13614 Congenital muscular dystrophy-Ulrich disease COL6A3 P12111 COL6A2 P12110 COL6A1 P12109 Myasthenia gravis COLQ Q9Y215 AGRN O00468 RAPSN Q13702 GFPT1 Q06210 SCN4A P35499 ALG2 Q9H553 ALG14 Q96F25 DPAGT1 Q9H3H5 CHRNE Q04844 CHRNA1 P02708 DOK7 Q18PE1 CHAT P28329 Congenital myopathy ACTA1 P68133 STAC3 Q96MF2 TPM3 P06753 Myotonic dystrophy congenita DMPK Q09013 Corey's disease-debrenning enzyme deficiency-Forbes disease AGL P35573 Danon disease LAMP2 P13473 Dezeen-Sotha disease MPZ P25189 EGR2 P11161 PMP22 Q01453 PRX Q9BXM0 Wieland's distal muscular dystrophy TIA1 P31483 Miyoshi's distal muscular dystrophy DYSF O75923 Distal myopathy with anterior tibialis attacks DYSF O75923 Duchenne muscular dystrophy Degenerative Disorders of Muscle (DMD) P11532 GALGT2 (B4GALNT2) Q8NHY0 Difflin's disease Deforin protein (DYSF) O75923 Emery-Dreyfus muscular dystrophy EMD P50402 SYNE1 Q8NF91 SYNE2 Q8WXH0 TMEM43 Q9BTV4 LMNA P02545 Ehrenberg disease-paramyotonia congenita SCN4A P35499 Facioscapulohumeral muscular dystrophy SMCHD1 A6NHR9 LRIF1 Q5T3J3 Friedreich ataxia FXN Q16595 Fukuyama congenital muscular dystrophy FKTN O75072 Type 10 Glycopathies - Glycogen Storage Disease X PGAM2 P15259 Type 11 Glycogenosis - Glycogen Storage Disease XI LDHA P00338 Type 2 glycogenopathies - Glycogen storage disease II - Pompe disease - Acid maltase deficiency GAA P10253 Type 3 glycogenopathies - Glycogen storage disease III AGL P35573 Type 5 glycogenopathies - Glycogen storage disease V - McArdle disease - Myophosphorylase deficiency PYGM P11217 Glycogenosis type 7 - Glycogen storage disease VII - Phosphofructokinase deficiency - Taurean disease PFKM P08237 Type 9 Glycogenosis - Glycogenosis IX PHKB Q93100 PHKA2 P46019 Hereditary inclusion body myositis GNE Q9Y223 Integrin-deficient congenital muscular dystrophy ITGA7 Q13683 Kennedy's disease-spondylobula-bulbar atrophy Androgen receptor (AR) P10275 Kugelberg-Wielander disease SMN1 Q16637 Lactate dehydrogenase A deficiency LDHA P00338 Lactate dehydrogenase B deficiency LDHB P07195 Lambert-Eaton myasthenia syndrome CACNB2 Q08289 Ryan distal myopathy MYH7 A7E2Y1 Limb-girdle muscular dystrophy type 2C (LGMD-2C) γ-sarcoglycan Q13326 Limb-girdle muscular dystrophy type 2D (LGMD-2D) α-sarcoglycan Q16586 Limb-girdle muscular dystrophy type 2E (LGMD-2E) β-sarcoglycan Q16585 Limb-girdle muscular dystrophy type 2F (LGMD-2F) δ-sarcoglycan Q92629 Platelet-deficient congenital muscular dystrophy LAMA2 P24043 Muscle-eye-brain disease POMGNT1 Q8WZA1 Mitochondrial myopathy CHCHD10 Q8WYQ3 Miyoshi myopathy DYSF O75923 Myoadenylate deaminase deficiency AMPD1 P23109 Myofibrillar myopathy 1 DES P17661 Myofibrillar myopathy 2 CRYAB P02511 Myofibrillar myopathy 3 MYOT Q9UBF9 Myofibril myopathy 4 - ZASP-related myopathy LDB3 (ZASP) O75112 Myofibrillar myopathy 5 FLNC Q14315 Myofibrillar myopathy 6 BAG3 O95817 Myofibrillar myopathy7 KY Q8NBH2 Myofibrillar myopathy8 PYROXD1 Q8WU10 Myofibrillar myopathy 9 TTN Q8WZ42 Myofibrillar myopathy10 SVIL O95425 Myofibrillar myopathy11 UNC45B Q8IWX7 Myofibrillar myopathy12 MYL2 Q99972 Myotonic dystrophy type 1-Steinert disease Myotonia dysplasia kinase (DMPK) Q09013 Myotonic dystrophy type 2 CNBP P62633 Myotubular myopathy MTM1 Q13496 Myopathy 1 TPM3 P06753 Myopathy 2 NEB P20929 Myopathy 5A, 5B, 5C TNNT1 P13805 Myopathy 3 ACTA1 P68133 Myopathy 6 KBTBD13 C9JR72 Myopathy 4 TPM2 P07951 Myopathy7 CFL2 Q9Y281 Myopathy8 KLHL40 Q2TBA0 Myopathy 9 KLHL41 O60662 Myopathy 10 LMOD3 Q0VAK6 distal myopathy in the wild GNE Q9Y223 Oculopharyngeal muscle atrophy PABPN1 Q86U42 Ornithine aminoformyl transferase deficiency OTC P00480 paramyotonia congenita SCN4A P35499 Hypokalemic periodic paralysis CACNA1S Q13698 Hyperkalemic periodic paralysis SCN4A P35499 Phosphoglycerate kinase deficiency PGK1 P00558 Polymyositis PMSCL2 Q01780 PMSCL1 Q06265 Progressive external ophthalmoplegia POLG P54098 POLG2 Q9UHN1 SLC25A4 P12235 TWNK Q96RR1 Spinal muscular atrophy type 3 - Kugelberg-Wieland disease Survival motor neuron protein (SMN) SMN1 Q16637 Thompson disease-myotonia congenita (autosomal dominant) CLCN1 P35523 Walker-Warburg syndrome POMT1 Q9Y6A1 X-synechiae microtubular myopathy Myotubularin (MTM1) Q13496 Wednig-Hoffmann disease - spinal muscular atrophy type 1 SMN1 Q16637

In some embodiments, the payload is human sarcoma protein.

In some embodiments, the payload is an antisense oligonucleotide that is effective in treating muscle diseases, for example, by modulating target gene expression. Exemplary target genes for such antisense oligonucleotides for treating muscle diseases include, for example, MSTN, INHBA, ACVR1B, MLCK1, ACVR1, FBXO32, TRIM63, MEF2D, KLF15, MED1, MED13, DUX4, LMNA, SMN, GAA, GYS2, DMD, DMPK, MSTN, and PPP1R3A.

Non-limiting exemplary antisense oligonucleotides that can be delivered via the viral particles herein (as well as the associated target genes and treatable muscle tissue-related diseases) are provided in Table 5. When such antisense oligonucleotides are indicated by reference to patents or patent application publications, these patents and patent applications are incorporated herein by reference in their entirety for their disclosure of antisense oligonucleotide structures and sequences. Table 5 Exemplary muscle diseases, target genes, and antisense oligonucleotide transgenes Indications target gene Uniprot accession number (human) Exemplary transgenes Hutchinson-Gilford progeria syndrome (HGPS) Lamina nuclear protein A (LMNA) P02545 Antisense oligonucleotides described in U.S. Patent No. 10,076,536 and U.S. Patent Application Publication Nos. 2017/0051278 A1 and 2018/0271893 A1 Spinal muscular atrophy (SMA) Survival motor neurons (SMN) Q16637 Antisense oligonucleotides described in U.S. Patent Application Publication No. 2019/0015440 A1 Glycogen storage disease type II (GSD-II) or Pompe disease Acid α-glucosidase (GAA) P10253 Antisense oligonucleotides described in U.S. Patent Application Publication No. 2018/0216111 A1 Glycogen synthase (GYS2) P54840 Antisense oligonucleotides described in U.S. Patent Application Publication No. 2017/0182189 A1 Duchenne muscular dystrophy Degenerative Disorders of Muscle (DMD) P11532 Antisense oligonucleotides described in: U.S. Patent Application Publication Nos. 2019/0177723 A1 and 20210261963 A1; and PCT Patent Application Publication Nos. WO 2017/062835 A2 and 2019/059973 A1 Myotonic dystrophy type 1-Steinert disease Myotonic dystrophy-protein kinase (DMPK) Q09013 Antisense oligonucleotides described in U.S. Patent Application Publication Nos. 2024/0117356 A1, 2010/0016215 A1, 2013/0237585 A1, 2015/0064181 A1, 2015/0238627 A1, and 2016/0304877 A1 muscle atrophy Myostatin (MSTN) O14793 Antisense oligonucleotides described in U.S. Patent Application Publication No. 2018/0327749 A1 Facioscapulohumeral muscular dystrophy Dual-Uniform Module 4 (DUX4) Q9UBX2 Antisense oligonucleotides described in U.S. Patent Application Publication No. 2023/0272065 A1 6.6.2. Treatment

This disclosure is directed, in part, to a method of treating a disease or condition in a subject (e.g., an animal or human subject). In some embodiments, the method of treating a disease or condition in a subject comprises administering to the subject a dependent microviral particle comprising a variant polypeptide described herein (e.g., comprising a payload described herein). In some embodiments, the dependent microviral particle comprising a variant polypeptide (comprising a payload described herein) is administered in an amount and/or for a time effective to treat the disease or condition. In some embodiments, the payload is a therapeutic product. In some embodiments, the payload is a nucleic acid (e.g., encoding an exogenous polypeptide). Also provided herein are dependent microviral particles comprising a variant polypeptide described herein (e.g., comprising a payload described herein) for use in the treatment methods described herein. Also provided herein are uses of dependent microviral particles comprising a variant polypeptide described herein (e.g., comprising a payload described herein) for the manufacture of a medicament for treating a disease or condition described herein.

Dependency-dependent parvoviral particles comprising the variant polypeptides described herein or produced by the methods described herein can be used to express one or more therapeutic proteins to treat various diseases or conditions. In some embodiments, the disease or condition is cancer, such as a carcinoma, sarcoma, leukemia, or lymphoma; or an autoimmune disease, such as multiple sclerosis. Non-limiting examples of cancer include esophageal cancer; bronchogenic cancer; colon cancer; colorectal cancer; gastric cancer; hepatocellular carcinoma; basal cell carcinoma; squamous cell carcinoma (of various tissues); bladder cancer, including transitional cell carcinoma; lung cancer, including small cell lung cancer and non-small cell lung cancer; adrenal cortical carcinoma; sweat gland carcinoma; sebaceous gland carcinoma; thyroid cancer; pancreatic cancer; breast cancer; ovarian cancer; prostate cancer; adenocarcinoma; papillary carcinoma; papillary adenocarcinoma; cystadenocarcinoma; medullary carcinoma; renal cell carcinoma; uterine cancer; testicular cancer; osteogenic carcinoma; ductal carcinoma in situ or bile duct carcinoma; chorionic carcinoma; seminoma; embryonal carcinoma; Wilms' tumor; tumor); cervical cancer; epithelial cancer; and nasopharyngeal carcinoma. Non-limiting examples of sarcomas include fibrosarcoma, myxosarcoma, liposarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, osteosarcoma, lymphoendotheliosarcoma, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas. Non-limiting examples of solid tumors include ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, neuroglioma, astrocytoma, medulloblastoma, craniopharyngioma, meningioma, melanoma, neuroblastoma, and retinoblastoma. Non-limiting examples of leukemia include chronic myeloproliferative syndrome; T-cell CLL prolymphocytic leukemia, acute myeloid leukemia; chronic lymphocytic leukemia, including B-cell CLL, hairy cell leukemia; and acute lymphoblastic leukemia. Examples of lymphoma include, but are not limited to, B-cell lymphomas, such as Burkitt's lymphoma; and Hodgkin's lymphoma. In some embodiments, the disease or condition is a genetic disorder. In some embodiments, the genetic disorder is sickle cell anemia, glycogen storage disease (GSD, such as type I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, and XIV GSD), cystic fibrosis, lysosomal acid lipase (LAL) deficiency 1, Tay-Sachs disease, phenylketonuria, mucopolysaccharidosis, galactosemia, muscular dystrophy (e.g., Duchenne muscular dystrophy), hemophilia (e.g., hemophilia A (classic hemophilia) or hemophilia B (Klinefelter's disease (Christmas Disease))), Wilson's disease, Fabry disease, Gaucher's disease, hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. Examples of other diseases or conditions are provided above in Section 6.6.1.

In some embodiments, the disease or condition is a CNS disease. Exemplary CNS diseases include: absence of the septum pellucidum, acid lipase disease, acid maltase deficiency, acquired epileptic aphasia, acute disseminated encephalomyelitis, attention deficit hyperactivity disorder (ADHD), Adie's pupil, Adie's syndrome, adrenoleukodystrophy, agenesis of the corpus callosum, agnosia, Aicardi syndrome, Aicardi-Goutieres syndrome, AIDS neurological complications, Alexander disease, Alpers' disease, Disease), alternating hemiplegia, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), anencephaly, aneurysm, Angelman's syndrome, angiomatosis, Angelman's syndrome, hypoxia, antiphospholipid syndrome, aphasia, psychokinesia, arachnoid cyst, arachnitis, Arnold-Chiari malformation, arteriovenous malformation, Asperger's syndrome Syndrome), ataxia, ataxia with telangiectasia, ataxia and cerebellar or spinocerebellar degeneration, atrial fibrillation and stroke, attention deficit hyperactivity disorder, autism spectrum disorder, autonomic dysfunction, back pain, Babinski syndrome, Batten disease, Becker's myotonia, Bechet's disease, Bell's Palsy, benign idiopathic eye spasm, benign focal muscular atrophy, benign intracranial hypertension, Bernhardt-Roth syndrome, Binswanger's Disease), eyelid spasm, Bloch-Sulzberger Syndrome, brachial nerve plexus lesion, brachial nerve plexus lesion, Bradbury-Eggleston Syndrome, brain and spinal tumors, brain artery tumors, brain injury, Brown-Sequard Syndrome, bulbar palsy, bulbar muscular atrophy, CADASIL, Canavan disease, carpal tunnel syndrome, causalgia, cavernous hemangiomas, cavernous hemangiomas Angioma), spongiosa, central cervical cord syndrome, central spinal cord syndrome, central pain syndrome, central pontine myelolysis, head disease, neuramidase deficiency, cerebellar degeneration, cerebellar hypoplasia, cerebral arteriovenous aneurysm, cerebral arteriosclerosis, brain atrophy, cerebral beriberi, spongiosa, cerebral gigantism, cerebral hypoxia, cerebral palsy, cerebro-oculofacial-skeletal syndrome (COFS), Chuck-Marie-Duchesne disease, Chiari malformation, Malformation), cholesterol ester storage disease, chorea, choreoacanthocytosis, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic orthostatic intolerance, chronic pain, Cockayne syndrome type II, Crohn's disease, syringomyelia, coma, complex regional pain syndrome, concentric sclerosis (Baló's sclerosis), congenital bilateral facial paralysis, congenital myasthenia, congenital myopathy, congenital angiospongiosus malformation, corticobasal degeneration, cranial arteritis, craniosynostosis, Cree encephalitis, Kujak disease, chronic progressive external ophthalmoplegia, cumulative trauma syndrome, Cushing's syndrome Syndrome), giant cell inclusion disease, giant cell virus infection, dancing eyes and feet syndrome, Dandy-Walker Syndrome, Dawson Disease, Demersier syndrome, Dejerine-Klumpke Palsy, dementia, multi-infarct dementia, semantic dementia, subcortical dementia, dementia with Lewy bodies, demyelination disease, odontocerebellar ataxia, odontorubral atrophy, dermatomyositis, developmental dyspraxia, Devic's syndrome Syndrome), diabetic neuropathy, diffuse sclerosis, distal hereditary motor neuropathy, Dravet syndrome, autonomic nervous system disorders, dysgraphia, dyslexia, dysphagia, dyspraxia, dyspraxia, myocerebellar dyssynergia, progressive cerebellar dystonia, dystonia, early infantile epileptic encephalopathy, nullopeptidylsine syndrome, encephalitis, encephalitis lethargica, encephalocele, encephalomyelitis, encephalopathy, encephalopathy (familial infantile form), encephalotrigeminal angiomatosis, epilepsy, epileptic hemiplegia, intermittent ataxia, Erb's palsy Palsy), Elb-Duchenne and Dejerin-Kromke palsy, essential tremor, extrapontine myelinolysis, Faber's disease, Fabry disease, Fahr's syndrome, syncope, familial autonomic nervous system dysfunction, familial hemangioma, familial idiopathic basal ganglia calcification, familial periodic palsy, familial spastic palsy, Farber's disease Disease), febrile epilepsy, fibromuscular dysplasia, Fisher syndrome, floppy infant syndrome, foot drop, fragile X syndrome, Friedreich's ataxia, frontotemporal dementia, Gaucher's disease, systemic gangliosidosis (GM1, GM2), Gerstmann's syndrome, Gerstmann-Straussler-Scheinker disease, giant axonal neuropathy, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, glossopharyngeal neuralgia, glycogen storage disease, Guillain-Barré syndrome, Hallervorden-Spatz disease Disease), head injury, headache, continuous hemifacial headache, hemifacial spasticity, alternating hemiplegia, hereditary neuropathy, hereditary spastic posterior fasciitis, polyneuritis-type hereditary ataxia, herpes zoster, herpes zoster oticus, Hirayama syndrome, Holmes-Adie syndrome, holoprosencephaly, HTLV-1 related myelopathy, Hughes syndrome Syndrome), Huntington's disease, Helleborus syndrome, hydrocephalus, hydrocephalus, normal pressure hydrocephalus, hydromyelia, hypercortisolism, lethargy, hypertonia, hypotonia, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinence pigmenti, infantile hypotonia, infantile axonal dystrophy, infantile phytanic acid storage disease, infantile Refsum disease, infantile spasticity, inflammatory myopathy, occipital exencephaly, intestinal lipid dystrophy, intracranial cysts, intracranial hypertension, Isaacs' syndrome, Joubert syndrome Syndrome), Kearns-Sayre Syndrome, Kennedy's disease, Kinsbourne syndrome, Kleine-Levin syndrome, Klippel-Feil syndrome, Klippel-Trenaunay syndrome (KTS), Klüver-Bucy syndrome, Korsakoff's amnesic syndrome, Krabbe disease, Kugelberg-Welander disease Disease), Kuru, Lambert-Eaton Syndrome, Landau-Kleffner Syndrome, Collateral femoral cutaneous nerve entrapment, Collateral medullary syndrome, learning disabilities, Leigh's Disease, Lennox-Gastaut Syndrome, Lesch-Nyhan Syndrome, Leukodystrophy, Levine-Critchley Syndrome, Lewy Body Dementia, Lichtheim's disease, lipid storage disease, lipoprotein deposition disease, flat brain syndrome, locked-in syndrome, Lou Gehrig's disease Disease), Lupus Neurological Sequelae, Lyme Disease Neurological Complications, Lysosomal Storage Disease, Machado-Joseph Disease, Megacephaly, Megacephaly, Melkersson-Rosenthal Syndrome, Meningitis, Meningitis and Encephalitis, Menkes Disease, Paresthesias Meralgia, Heterochromic Leukodystrophy, Microcephaly, Migraines, Miller Fisher Syndrome, Mini-Stroke, Mitochondrial Myopathy, Mitochondrial DNA Deletion Syndrome, Moebius Syndrome, Unilateral Muscular Atrophy, Morvan Syndrome, Motor Neuron Disease, Moyamoya Disease), mucolipidosis, mucopolysaccharidosis, multi-infarct dementia, multifocal motor neuropathy, multiple sclerosis, multisystem atrophy, multisystem atrophy with orthostatic hypotension, muscular dystrophy, myasthenia gravis, myelin-destructive diffuse sclerosis, myelitis, myositis infantile, myoclonic encephalopathy, myoclonic seizures, myopathy, congenital myopathy, thyrotoxic myopathy, myotonia, myotonia congenita, narcolepsy, NARP (neuropathy, ataxia and retinitis pigmentosa), neuroacanthocytosis, neuropathy with cerebral iron accumulation, neurodegenerative diseases, neurofibroma, antipsychotic malignant syndrome, neurological complications of AIDS, neurological complications of Lyme disease, neurological consequences of cytomegalovirus infection, neurological manifestations of Pompe disease, lupus Neurological sequelae, neuromyelitis optica, neuromyotonia, neuronal ceramide lipofuscinosis, neuronal migration disorder, neuropathic pain, hereditary neuropathy, neuropathy, neurosarcoidosis, neurosyphilis, neurotoxicity, cavernous nevus, Niemann-Pick disease, O'Sullivan-McLeod syndrome Syndrome), occipital neuralgia, Ohtahara Syndrome, olivopontine-cerebellar atrophy, strabismus, oculomotor convulsions, orthostatic hypotension, overuse syndrome, chronic pain, pantothenate kinase-related neuropathy, paraneoplastic syndrome, paresthesias, Parkinson's disease, choreoathetosis, hemicrania, Parry-Romberg disease, Pelizaeus-Merzbacher disease, Pena Shokeir II syndrome Syndrome), perineurial cyst, Charcot-Marie-Tooth atrophy, periodic palsy, peripheral neuropathy, periventricular leukomalacia, persistent vegetative state, generalized developmental disability, phytanic acid storage disease, Pick's disease, nerve compression, piriformis syndrome, pituitary tumor, polymyositis, Pompe disease, cerebral perforation, post-poliomyelitis, post-herpetic neuralgia, post-infectious encephalomyelitis, postural hypotension, postural orthostatic tachycardia syndrome, postural tachycardia syndrome, primary odontoid atrophy, primary lateral sclerosis, primary progressive aphasia, prion disease Diseases), progressive bulbar palsy, progressive hemifacial atrophy, progressive ataxia, progressive multifocal leukoencephalopathy, progressive muscular atrophy, progressive sclerotic gray matter dystrophy, progressive supranuclear neuropathy, prosopagnosia, pseudobulbar palsy, pseudo-Torch syndrome, pseudotoxoplasmosis syndrome, pseudotumor cerebri, psychogenic movement, Ramsay Hunt Syndrome I, Ramsay Hunt Syndrome II, Rasmussen's Encephalitis, reflex sympathetic dystrophy, Refsum disease Disease), Childish Refsum's Disease, Repetitive Movement Disorder, Repetitive Stress Injury, Restless Legs Syndrome, Retrovirus-Associated Myelopathy, Rett Syndrome, Reye's Syndrome, Rheumatic Encephalitis, Riley-Day Syndrome, Sacral Radiculocyst, Saint Vitus Dance, Salivary Gland Disease, Sandhoff Disease, Schilder's Disease, Schizencephaly, Seitelberger Disease, Epilepsy, Semantic Dementia, Septoseptal Dysplasia, Severe Myoclonic Epilepsy of Infancy Infancy (SMEI), shaken baby syndrome, herpes zoster, Shy-Drager syndrome, Sjögren's syndrome, sleep apnea, sleeping sickness, Sotos syndrome, seizures, spina bifida, spinal cord infarction, spinal cord injury, spinal cord tumor, spinal muscular atrophy, spinocerebellar ataxia, spinocerebellar atrophy, spinocerebellar degeneration, sporadic ataxia, Steele-Richardson-Olszewski syndrome, stiff-person syndrome, substantia nigra, stroke, Sturge-Weber syndrome Syndrome), subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, short-lasting unilateral neuralgic headache (SUNCT), dysphagia, Sydenham Chorea, syncope, syphilitic spondylosclerosis, syringomyelia, syringomyelia, systemic lupus erythematosus, myelopathy, delayed akinesia, Tarlov cysts, Tay-Sachs disease, temporal artery inflammation, thromboembolic cord syndrome, Thomsen's myotonia, thoracic outlet syndrome, thyrotoxic myopathy, trigeminal neuralgia, Todd's paralysis, Tourette syndrome Syndrome), transient ischemic attack, infectious spongiform encephalopathy, transverse myelitis, traumatic brain injury, tremors, trigeminal neuralgia, tropical spastic paralysis, Troyer syndrome, tuberous sclerosis, angioedema, vasculitis of the central and peripheral nervous systems, vitamin B12 deficiency, von Economo's disease, Van Hippel-Lindau disease (VHL), von Recklinghausen's disease, Wallenberg's syndrome, Weldnig-Hoffmann disease, Wernicke-Korsakoff syndrome Syndrome), Wester Syndrome, Whiplash, Whipple's Disease, Williams Syndrome, Wilson Disease, Wollman Disease, X-linked Spinal and Bulbous Muscular Atrophy. Examples of other diseases or conditions are provided above in Section 6.6.1.

In some cases, the disease or condition is a musculoskeletal disease. Exemplary diseases of skeletal muscle include acid maltase deficiency (AMD), amyotrophic lateral sclerosis (ALS), Anderson-Tawil syndrome, Beck muscular dystrophy (BMD), Beck congenital myotonia, Bethlem myopathy, bulbar muscular dystrophy (spondylobula), carnitine deficiency, carnitine palmitoyltransferase deficiency (CPT deficiency), central nuclear disease (CCD), central nuclear myopathy, Chuck-Mare-Duchesne disease (CMT), congenital muscular dystrophy (CMD), congenital myotonic syndrome (CMS), congenital myotonic dystrophy, Corey's disease (debrachial enzyme deficiency), debrachial enzyme deficiency, Dejerine-Sottas disease, and congenital myotonic dystrophy. Disease; DSD), dermatomyositis (DM), distal muscular dystrophy (DD), Duchenne muscular dystrophy (DMD), myotonic dystrophy (myotonic dystrophy), Emery-Dreyfus muscular dystrophy (EDMD), endocrine myopathy, Ehrenberg disease (congenital paramyotonia), facioscapulohumeral muscular dystrophy (FS H or FSHD), Finnish (tibia) distal myopathy, Forbes disease (debrachial enzyme deficiency), Friedreich's ataxia (FA), Fukuyama's congenital muscular dystrophy, glycogenotype 10, glycogenotype 11, glycogenotype 2, glycogenotype 3, glycogenotype 5, glycogenotype 7, glycogenotype 9, Galls-Lane distal myopathy, Hauptmann-Tanhauser MD Emery-Dreyfus muscular dystrophy, hereditary inclusion body myositis, hereditary motor and sensory neuropathy (Chuck-Marley-Doucet disease), hyperthyroid myopathy, hypothyroid myopathy, inclusion body myositis (IBM), hereditary myopathies, integrin-deficient congenital muscular dystrophy, Kennedy disease (spondylobular atrophy), Kugelberg-Wiland disease (spinal muscular atrophy), lactate dehydrogenase deficiency, Lambert-Eaton myasthenia syndrome (LEMS), limb girdle Lou Gehrig's disease (LGMD), Lou Gehrig's disease (muscular dystrophy), McArdle disease (phosphorylase deficiency), platelet-deficient congenital muscular dystrophy, muscle metabolic diseases, mitochondrial myopathy, Miyoshi's distal myopathy, motor neuron disease, myo-oculo-encephalopathy, myasthenia gravis (MG), myoadenylate deaminase deficiency, myofibrillar myopathy, myophosphorylase deficiency, myotonia congenita (MC), myotonic muscular dystrophy (MMD) , myotubular myopathy (MTM or MM), myopathy, distal Nonaka myopathy, oculopharyngeal muscle atrophy (OPMD), paramyotonia congenita, Pearson syndrome, periodic palsy, Charcot-Marie-Duchesne disease, phosphofructokinase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, phosphorylase deficiency, phosphorylase deficiency, polymyositis (PM), Pompe disease (acid maltase deficiency), progressive external ophthalmoplegia Paralysis (PEO), rod disease (nematode myopathy), spinal muscular atrophy (SMA), spondylobular muscular atrophy (SBMA), Steinert disease (myotonic dystrophy), Taret disease (phosphofructokinase deficiency), Thomson disease (myotonia congenita), Ulrich congenital muscular dystrophy, Walker-Warburg syndrome (congenital muscular dystrophy), Wieland distal myopathy, Wedniger-Hoffmann disease (spinal muscular atrophy), and ZASP-related myopathies.

In some categories, the disease or condition is a disease affecting the CNS and muscles, such as SMA, multiple sclerosis, amyotrophic lateral sclerosis (ALS), ataxia, Beck muscular dystrophy, Chuck-Marie-Dows disease, dystonia, Friedreich's ataxia, glycogen storage disease II, Kennedy disease, Lambert-Eaton myasthenia syndrome, mitochondrial DNA deletion syndrome, myo-oculo-encephalopathy, neuromyotonia, periodic paralysis, juvenile primary lateral sclerosis, progressive external ophthalmoplegia, spastic paralysis, congenital stiff-man syndrome, tarda ataxia, Wildnig-Hoffmann disease, or X-linked spinal and bulbar muscular dystrophy.

In some embodiments, administration of a dependent parvoviral particle comprising a variant polypeptide and a payload (e.g., a transgene described in Section 6.6.1 or its subsections) to a subject induces expression of the payload (e.g., a transgene) in the subject. In some embodiments, expression is induced in the CNS. In some embodiments, production in the CNS is similar compared to similar particles with wild-type capsid protein. In some embodiments, production in the CNS is increased compared to similar particles with wild-type capsid protein (e.g., particles with the capsid protein of SEQ ID NO: 1). In some embodiments, expression is induced in skeletal muscle. In some embodiments, production in muscle is similar compared to similar particles with wild-type capsid protein (e.g., particles with the capsid protein of SEQ ID NO: 1). In some embodiments, production in skeletal muscle is increased compared to similar particles with wild-type capsid protein (e.g., particles with the capsid protein of SEQ ID NO: 1). The amount of payload (e.g., a transgene, e.g., a heterologous protein, e.g., a therapeutic polypeptide) expressed in an individual (e.g., an individual's serum) can vary. For example, in some embodiments, the payload (e.g., the protein or RNA product of the transgene) can be expressed in the serum of an individual at an amount of at least about 9 μg/ml, at least about 10 μg/ml, at least about 50 μg/ml, at least about 100 μg/ml, at least about 200 μg/ml, at least about 300 μg/ml, at least about 400 μg/ml, at least about 500 μg/ml, at least about 600 μg/ml, at least about 700 μg/ml, at least about 800 μg/ml, at least about 900 μg/ml, or at least about 1000 μg/ml. In some embodiments, the payload (e.g., protein or RNA product of a transgene) is present in the serum of a subject at about 9 μg/ml, about 10 μg/ml, about 50 μg/ml, about 100 μg/ml, about 200 μg/ml, about 300 μg/ml, about 400 μg/ml, about 500 μg/ml, about 600 μg/ml, about 700 μg/ml, about 800 μg/ml, about 900 μg/ml, about 1000 μg/ml, about 1500 μg/ml, about 2000 μg/ml, about 2500 μg/ml, or a range between any two of these values.

In some embodiments, for therapeutic applications, viral particles comprising the capsid polypeptides described herein are prepared as pharmaceutical compositions. As used herein, the term "pharmaceutical composition" refers to a composition comprising at least one active ingredient (e.g., viral particle) and, optionally, one or more pharmaceutically acceptable carriers or excipients.

The relative amounts of the active ingredient, pharmaceutically acceptable carrier or excipient, and/or any additional ingredients in the pharmaceutical compositions herein may vary. The composition of the pharmaceutical composition may vary depending on the identity, size, and/or condition of the individual being treated, the route of administration of the composition, and/or any other factors. The composition may contain between 0.0001% and 99% (w/w) active ingredient. By way of example, the composition may contain between 0.0001% and 100%, e.g., between 0.5% and 50%, between 1% and 30%, between 5% and 80%, or at least 80% (w/w) active ingredient. Non-limiting examples of carriers and/or excipients include solvents, dispersion media, diluents or other liquid vehicles, dispersing or suspending aids, surfactants, isotonic agents, thickening or emulsifying agents, preservatives, or combinations thereof. 7. Numbered Examples

While various specific embodiments have been illustrated and described, it should be understood that various changes can be made without departing from the spirit and scope of the present disclosure. This disclosure is illustrated by the numbered embodiments described below. Unless otherwise specified, the features of any of the concepts, categories, and/or embodiments described in the above detailed description may be applied mutatis mutandis to any of the following numbered embodiments. 1. A capsid polypeptide comprising two or three of the following: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine or alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 2. The capsid polypeptide of Example 1, comprising valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1. 3. The capsid polypeptide of Example 1 or Example 2, comprising serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 4. The capsid polypeptide of Example 1 or Example 2, comprising alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 5. The capsid polypeptide of any one of Examples 1 to 4, comprising methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 6. A capsid polypeptide comprising valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1 and serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 7. The capsid polypeptide of Example 6, comprising methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 8. The capsid polypeptide of Example 6, comprising threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 9. The capsid polypeptide of Example 6, comprising glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 10. A capsid polypeptide comprising valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1 and alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 11. The capsid polypeptide of Example 10, comprising methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 12. A capsid polypeptide comprising valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1 and methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 13. The capsid polypeptide of Example 12, comprising serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 14. The capsid polypeptide of Example 12, comprising alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 15. The capsid polypeptide of Example 12, comprising threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 16. The capsid polypeptide of Example 12, comprising glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 17. A capsid polypeptide comprising serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1 and methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 18. The capsid polypeptide of Example 17, comprising valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1. 19. The capsid polypeptide of Example 17, comprising glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1. 20. A capsid polypeptide comprising alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1 and methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 21. The capsid polypeptide of Example 20, comprising valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1. 22. A capsid polypeptide comprising: (a) glutamine or glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine, alanine, glutamine, or threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) methionine, threonine, or glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1, wherein the capsid polypeptide does not comprise two or all three of the following: glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1, a methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1, Threonine at position T593 of the VP1 capsid polypeptide of SEQ ID NO:1 and glycine at position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 23. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine, alanine, or glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) methionine or threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 24. The capsid polypeptide of Example 22 or Example 23, comprising serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 25. The capsid polypeptide of Example 22 or Example 23, comprising alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 26. The capsid polypeptide of Example 22 or Example 23, comprising glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 27. The capsid polypeptide of any one of Examples 22 to 26, comprising methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 28. The capsid polypeptide of any one of Examples 22 to 26, comprising threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 29. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 30. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 31. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 32. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 33. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 34. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 35. A capsid polypeptide comprising: (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; and (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1. 36. The capsid polypeptide of any one of embodiments 1 to 35, comprising tryptophan, glutamine, serine, threonine, valine, asparagine, alanine, phenylalanine, lysine, isoleucine, or methionine at a position corresponding to position W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 37. The capsid polypeptide of any one of embodiments 1 to 35, comprising glutamine, serine, threonine, valine, asparagine, alanine, phenylalanine, lysine, isoleucine, or methionine at a position corresponding to position W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 38. The capsid polypeptide of any one of embodiments 1 to 35, comprising tryptophan at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 39. The capsid polypeptide of any one of embodiments 1 to 35, comprising glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 40. The capsid polypeptide of any one of Examples 1 to 35, comprising serine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 41. The capsid polypeptide of any one of Examples 1 to 35, comprising threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 42. The capsid polypeptide of any one of embodiments 1 to 35, comprising valine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 43. The capsid polypeptide of any one of embodiments 1 to 35, comprising asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 44. The capsid polypeptide of any one of Examples 1 to 35, comprising alanine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 45. The capsid polypeptide of any one of embodiments 1 to 35, comprising phenylalanine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 46. The capsid polypeptide of any one of embodiments 1 to 35, comprising a lysine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 47. The capsid polypeptide of any one of embodiments 1 to 35, comprising isoleucine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 48. The capsid polypeptide of any one of embodiments 1 to 35, comprising methionine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 49. The capsid polypeptide of any one of embodiments 1 to 48, comprising valine, methionine, tryptophan, isoleucine, asparagine, leucine, glutamine, alanine, or glycine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 50. The capsid polypeptide of any one of embodiments 1 to 48, comprising methionine, tryptophan, isoleucine, asparagine, leucine, glutamine, alanine, or glycine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 51. The capsid polypeptide of any one of embodiments 1 to 48, comprising valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 52. The capsid polypeptide of any one of Examples 1 to 48, comprising methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 53. The capsid polypeptide of any one of embodiments 1 to 48, comprising tryptophan at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 54. The capsid polypeptide of any one of embodiments 1 to 48, comprising isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 55. The capsid polypeptide of any one of embodiments 1 to 48, comprising asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 56. The capsid polypeptide of any one of embodiments 1 to 48, comprising leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 57. The capsid polypeptide of any one of Examples 1 to 48, comprising glutamine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 58. The capsid polypeptide of any one of Examples 1 to 48, comprising alanine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 59. The capsid polypeptide of any one of embodiments 1 to 48, comprising glycine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 60. The capsid polypeptide of any one of embodiments 1 to 35, comprising glutamine at a position corresponding to W595 and methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 61. The capsid polypeptide of any one of Examples 1 to 35, comprising glutamine at a position corresponding to W595 and isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 62. The capsid polypeptide of any one of embodiments 1 to 35, comprising threonine at a position corresponding to W595 and leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 63. The capsid polypeptide of any one of Examples 1 to 35, comprising serine at a position corresponding to W595 and asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 64. The capsid polypeptide of any one of Examples 1 to 35, comprising glutamine at a position corresponding to W595 and asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 65. The capsid polypeptide of any one of Examples 1 to 35, comprising alanine at a position corresponding to W595 and methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 66. The capsid polypeptide of any one of Examples 1 to 35, comprising asparagine at a position corresponding to W595 and asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 67. The capsid polypeptide of any one of embodiments 1 to 35, comprising threonine at a position corresponding to W595 and isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 68. The capsid polypeptide of any one of embodiments 1 to 35, comprising glutamine at a position corresponding to W595 and valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 69. The capsid polypeptide of any one of Examples 1 to 35, comprising threonine at a position corresponding to W595 and alanine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 70. The capsid polypeptide of any one of embodiments 1 to 35, comprising lysine at a position corresponding to W595 and valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 71. The capsid polypeptide of any one of embodiments 1 to 35, comprising tryptophan at a position corresponding to W595 and valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 72. The capsid polypeptide of any one of Examples 1 to 35, comprising serine at a position corresponding to W595 and methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 73. The capsid polypeptide of any one of embodiments 1 to 35, comprising asparagine at a position corresponding to W595 and valeric acid at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 74. The capsid polypeptide of any one of embodiments 1 to 35, comprising asparagine at a position corresponding to W595 and leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 75. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 76. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 77. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) serine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 78. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 79. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 80. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 81. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 82. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) alanine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 83. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 84. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) alanine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 85. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) threonine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) glutamine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 86. A capsid polypeptide comprising: (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 87. A capsid polypeptide comprising: (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 88. A capsid polypeptide comprising: (a) glutamine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 89. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) alanine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 90. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 91. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) alanine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 92. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) glutamine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) threonine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) isoleucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 93. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) lysine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 94. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) serine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) glycine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) tryptophan at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 95. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) serine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) methionine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 96. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) valine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 97. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) asparagine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 98. A capsid polypeptide comprising: (a) valine at a position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO:1; (b) threonine at a position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO:1; (c) methionine at a position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO:1; (d) asparagine at a position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO:1; and (e) leucine at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO:1. 99. The capsid polypeptide of any one of embodiments 1 to 98, comprising alanine, asparagine, serine, threonine, or valine at a position corresponding to A589 of the VP1 capsid polypeptide of SEQ ID NO: 1. 100. The capsid polypeptide of any one of Examples 1 to 98, comprising asparagine, serine, threonine, or valine of the VP1 capsid polypeptide of SEQ ID NO: 1 101. The capsid polypeptide of any one of Examples 1 to 98, comprising alanine at a position corresponding to A589 of the VP1 capsid polypeptide of SEQ ID NO: 1. 102. The capsid polypeptide of any one of Examples 1 to 98, comprising asparagine at a position corresponding to A589 of the VP1 capsid polypeptide of SEQ ID NO: 1. 103. The capsid polypeptide of any one of Examples 1 to 98, comprising serine at a position corresponding to A589 of the VP1 capsid polypeptide of SEQ ID NO: 1. 104. The capsid polypeptide of any one of Examples 1 to 98, comprising threonine at a position corresponding to A589 of the VP1 capsid polypeptide of SEQ ID NO: 1. 105. The capsid polypeptide of any one of Examples 1 to 98, comprising valine at a position corresponding to A589 of the VP1 capsid polypeptide of SEQ ID NO: 1. 106. The capsid polypeptide of any one of embodiments 1 to 105, comprising glutamine, leucine, asparagine, or threonine at a position corresponding to Q597 of the VP1 capsid polypeptide of SEQ ID NO: 1. 107. The capsid polypeptide of any one of embodiments 1 to 105, comprising leucine, asparagine, or threonine at a position corresponding to Q597 of the VP1 capsid polypeptide of SEQ ID NO: 1. 108. The capsid polypeptide of any one of embodiments 1 to 105, comprising glutamine at a position corresponding to Q597 of the VP1 capsid polypeptide of SEQ ID NO: 1. 109. The capsid polypeptide of any one of embodiments 1 to 105, comprising leucine at a position corresponding to Q597 of the VP1 capsid polypeptide of SEQ ID NO: 1. 110. The capsid polypeptide of any one of embodiments 1 to 105, comprising asparagine at a position corresponding to Q597 of the VP1 capsid polypeptide of SEQ ID NO: 1. 111. The capsid polypeptide of any one of Examples 1 to 105, comprising threonine at a position corresponding to Q597 of the VP1 capsid polypeptide of SEQ ID NO: 1. 112. The capsid polypeptide of any one of Examples 1 to 111, comprising glycine, lysine, histidine, or asparagine at a position corresponding to G549 of the VP1 capsid polypeptide of SEQ ID NO: 1. 113. The capsid polypeptide of any one of Examples 1 to 111, comprising lysine, histidine, or asparagine at a position corresponding to G549 of the VP1 capsid polypeptide of SEQ ID NO: 1. 114. The capsid polypeptide of any one of Examples 1 to 111, comprising glycine at a position corresponding to G549 of the VP1 capsid polypeptide of SEQ ID NO: 1. 115. The capsid polypeptide of any one of Examples 1 to 111, comprising a lysine at a position corresponding to G549 of the VP1 capsid polypeptide of SEQ ID NO: 1. 116. The capsid polypeptide of any one of Examples 1 to 111, comprising histidine at a position corresponding to G549 of the VP1 capsid polypeptide of SEQ ID NO: 1. 117. The capsid polypeptide of any one of Examples 1 to 111, comprising asparagine at a position corresponding to G549 of the VP1 capsid polypeptide of SEQ ID NO: 1. 118. The capsid polypeptide of any one of embodiments 1 to 117, comprising arginine, lysine, valine, or glycine at a position corresponding to R550 of the VP1 capsid polypeptide of SEQ ID NO: 1. 119. The capsid polypeptide of any one of embodiments 1 to 117, comprising lysine, valine, or glycine at a position corresponding to R550 of the VP1 capsid polypeptide of SEQ ID NO: 1. 120. The capsid polypeptide of any one of Examples 1 to 117, comprising arginine at a position corresponding to R550 of the VP1 capsid polypeptide of SEQ ID NO: 1. 121. The capsid polypeptide of any one of Examples 1 to 117, comprising a lysine at a position corresponding to R550 of the VP1 capsid polypeptide of SEQ ID NO: 1. 122. The capsid polypeptide of any one of Examples 1 to 117, comprising valine at a position corresponding to R550 of the VP1 capsid polypeptide of SEQ ID NO: 1. 123. The capsid polypeptide of any one of Examples 1 to 117, comprising glycine at a position corresponding to R550 of the VP1 capsid polypeptide of SEQ ID NO: 1. 124. The capsid polypeptide of any one of embodiments 1 to 123, comprising asparagine, aspartic acid, or histidine at a position corresponding to N552 of the VP1 capsid polypeptide of SEQ ID NO: 1. 125. The capsid polypeptide of any one of Examples 1 to 123, comprising aspartic acid or histidine at a position corresponding to N552 of the VP1 capsid polypeptide of SEQ ID NO: 1. 126. The capsid polypeptide of any one of Examples 1 to 123, comprising asparagine at a position corresponding to N552 of the VP1 capsid polypeptide of SEQ ID NO: 1. 127. The capsid polypeptide of any one of Examples 1 to 123, comprising aspartic acid at a position corresponding to N552 of the VP1 capsid polypeptide of SEQ ID NO: 1. 128. The capsid polypeptide of any one of Examples 1 to 123, comprising histidine at a position corresponding to N552 of the VP1 capsid polypeptide of SEQ ID NO: 1. 129. The capsid polypeptide of any one of embodiments 1 to 128, comprising valine or alanine at a position corresponding to V553 of the VP1 capsid polypeptide of SEQ ID NO: 1. 130. The capsid polypeptide of any one of embodiments 1 to 128, comprising valine at a position corresponding to V553 of the VP1 capsid polypeptide of SEQ ID NO: 1. 131. The capsid polypeptide of any one of Examples 1 to 128, comprising alanine at a position corresponding to V553 of the VP1 capsid polypeptide of SEQ ID NO: 1. 132. The capsid polypeptide of any one of Examples 1 to 131, comprising aspartic acid at a position corresponding to D554 of the VP1 capsid polypeptide of SEQ ID NO: 1. 133. The capsid polypeptide of any one of Examples 1 to 132, comprising alanine at a position corresponding to A555 of the VP1 capsid polypeptide of SEQ ID NO: 1. 134. The capsid polypeptide of any one of Examples 1 to 133, comprising aspartic acid at a position corresponding to D556 of the VP1 capsid polypeptide of SEQ ID NO: 1. 135. The capsid polypeptide of any one of embodiments 1 to 134, comprising lysine, leucine, or asparagine at a position corresponding to K557 of the VP1 capsid polypeptide of SEQ ID NO: 1. 136. The capsid polypeptide of any one of embodiments 1 to 134, comprising leucine or asparagine at a position corresponding to K557 of the VP1 capsid polypeptide of SEQ ID NO: 1. 137. The capsid polypeptide of any one of embodiments 1 to 134, comprising a lysine at a position corresponding to K557 of the VP1 capsid polypeptide of SEQ ID NO: 1. 138. The capsid polypeptide of any one of embodiments 1 to 134, comprising leucine at a position corresponding to K557 of the VP1 capsid polypeptide of SEQ ID NO: 1. 139. The capsid polypeptide of any one of Examples 1 to 134, comprising asparagine at a position corresponding to K557 of the VP1 capsid polypeptide of SEQ ID NO: 1. 140. The capsid polypeptide of any one of embodiments 1 to 139, comprising valine at a position corresponding to V558 of the VP1 capsid polypeptide of SEQ ID NO: 1. 141. The capsid polypeptide of any one of embodiments 1 to 140, comprising methionine, alanine, cysteine, isoleucine, asparagine, phenylalanine, tyrosine, or valine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 142. The capsid polypeptide of any one of embodiments 1 to 140, comprising alanine, cysteine, isoleucine, asparagine, phenylalanine, tyrosine, or valine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 143. The capsid polypeptide of any one of embodiments 1 to 140, comprising methionine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 144. The capsid polypeptide of any one of Examples 1 to 140, comprising alanine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 145. The capsid polypeptide of any one of embodiments 1 to 140, comprising cysteine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 146. The capsid polypeptide of any one of embodiments 1 to 140, comprising isoleucine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 147. The capsid polypeptide of any one of Examples 1 to 140, comprising asparagine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 148. The capsid polypeptide of any one of embodiments 1 to 140, comprising phenylalanine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 149. The capsid polypeptide of any one of embodiments 1 to 140, comprising tyrosine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 150. The capsid polypeptide of any one of embodiments 1 to 140, comprising valine at a position corresponding to M559 of the VP1 capsid polypeptide of SEQ ID NO: 1. 151. The capsid polypeptide of any one of Examples 1 to 140, comprising isoleucine at a position corresponding to I560 of the VP1 capsid polypeptide of SEQ ID NO: 1. 152. The capsid polypeptide of any one of Examples 1 to 151, comprising threonine at a position corresponding to T561 of the VP1 capsid polypeptide of SEQ ID NO: 1. 153. The capsid polypeptide of any one of embodiments 1 to 152, comprising asparagine, valeric acid, or threonine at a position corresponding to N562 of the VP1 capsid polypeptide of SEQ ID NO: 1. 154. The capsid polypeptide of any one of embodiments 1 to 152, comprising valine or threonine at a position corresponding to N562 of the VP1 capsid polypeptide of SEQ ID NO: 1. 155. The capsid polypeptide of any one of Examples 1 to 152, comprising asparagine at a position corresponding to N562 of the VP1 capsid polypeptide of SEQ ID NO: 1. 156. The capsid polypeptide of any one of embodiments 1 to 152, comprising valine at a position corresponding to N562 of the VP1 capsid polypeptide of SEQ ID NO: 1. 157. The capsid polypeptide of any one of Examples 1 to 152, comprising threonine at a position corresponding to N562 of the VP1 capsid polypeptide of SEQ ID NO: 1. 158. The capsid polypeptide of any one of embodiments 1 to 157, comprising glutamine or threonine at a position corresponding to E563 of the VP1 capsid polypeptide of SEQ ID NO: 1. 159. The capsid polypeptide of any one of Examples 1 to 157, comprising glutamine at a position corresponding to E563 of the VP1 capsid polypeptide of SEQ ID NO: 1. 160. The capsid polypeptide of any one of Examples 1 to 157, comprising threonine at a position corresponding to E563 of the VP1 capsid polypeptide of SEQ ID NO: 1. 161. The capsid polypeptide of any one of Examples 1 to 160, comprising glutamine at a position corresponding to E564 of the VP1 capsid polypeptide of SEQ ID NO: 1. 162. The capsid polypeptide of any one of Examples 1 to 161, comprising glutamine at a position corresponding to E565 of the VP1 capsid polypeptide of SEQ ID NO: 1. 163. The capsid polypeptide of any one of Examples 1 to 162, comprising isoleucine at a position corresponding to I566 of the VP1 capsid polypeptide of SEQ ID NO: 1. 164. The capsid polypeptide of any one of Examples 1 to 163, comprising a lysine at a position corresponding to K567 of the VP1 capsid polypeptide of SEQ ID NO: 1. 165. The capsid polypeptide of any one of Examples 1 to 164, comprising threonine at a position corresponding to T568 of the VP1 capsid polypeptide of SEQ ID NO: 1. 166. The capsid polypeptide of any one of Examples 1 to 165, comprising threonine or valine at a position corresponding to T569 of the VP1 capsid polypeptide of SEQ ID NO: 1. 167. The capsid polypeptide of any one of Examples 1 to 165, comprising threonine at a position corresponding to T569 of the VP1 capsid polypeptide of SEQ ID NO: 1. 168. The capsid polypeptide of any one of embodiments 1 to 165, comprising valine at a position corresponding to T569 of the VP1 capsid polypeptide of SEQ ID NO: 1. 169. The capsid polypeptide of any one of Examples 1 to 168, comprising asparagine at a position corresponding to N570 of the VP1 capsid polypeptide of SEQ ID NO: 1. 170. The capsid polypeptide of any one of embodiments 1 to 169, comprising a proline at a position corresponding to P571 of the VP1 capsid polypeptide of SEQ ID NO: 1. 171. The capsid polypeptide of any one of embodiments 1 to 170, comprising valine at a position corresponding to V572 of the VP1 capsid polypeptide of SEQ ID NO: 1. 172. The capsid polypeptide of any one of Examples 1 to 171, comprising alanine at a position corresponding to A573 of the VP1 capsid polypeptide of SEQ ID NO: 1. 173. The capsid polypeptide of any one of Examples 1 to 172, comprising threonine at a position corresponding to T574 of the VP1 capsid polypeptide of SEQ ID NO: 1. 174. The capsid polypeptide of any one of Examples 1 to 173, comprising glutamine at a position corresponding to E575 of the VP1 capsid polypeptide of SEQ ID NO: 1. 175. The capsid polypeptide of any one of embodiments 1 to 174, comprising serine, proline, or methionine at a position corresponding to S576 of the VP1 capsid polypeptide of SEQ ID NO: 1. 176. The capsid polypeptide of any one of embodiments 1 to 174, comprising proline or methionine at a position corresponding to S576 of the VP1 capsid polypeptide of SEQ ID NO: 1. 177. The capsid polypeptide of any one of embodiments 1 to 174, comprising a proline at a position corresponding to S576 of the VP1 capsid polypeptide of SEQ ID NO: 1. 178. The capsid polypeptide of any one of Examples 1 to 174, comprising methionine at a position corresponding to S576 of the VP1 capsid polypeptide of SEQ ID NO: 1. 179. The capsid polypeptide of any one of Examples 1 to 178, comprising tyrosine or tryptophan at a position corresponding to Y577 of the VP1 capsid polypeptide of SEQ ID NO: 1. 180. The capsid polypeptide of any one of Examples 1 to 178, comprising tyrosine at a position corresponding to Y577 of the VP1 capsid polypeptide of SEQ ID NO: 1. 181. The capsid polypeptide of any one of Examples 1 to 178, comprising tryptophan at a position corresponding to Y577 of the VP1 capsid polypeptide of SEQ ID NO: 1. 182. The capsid polypeptide of any one of Examples 1 to 181, comprising glycine at a position corresponding to G578 of the VP1 capsid polypeptide of SEQ ID NO: 1. 183. The capsid polypeptide of any one of embodiments 1 to 182, comprising glutamine, serine, leucine, tyrosine, cysteine, or asparagine at a position corresponding to Q579 of the VP1 capsid polypeptide of SEQ ID NO: 1. 184. The capsid polypeptide of any one of embodiments 1 to 182, comprising serine, leucine, tyrosine, cysteine, or asparagine at a position corresponding to Q579 of the VP1 capsid polypeptide of SEQ ID NO: 1. 185. The capsid polypeptide of any one of Examples 1 to 182, comprising glutamine at a position corresponding to Q579 of the VP1 capsid polypeptide of SEQ ID NO: 1. 186. The capsid polypeptide of any one of Examples 1 to 182, comprising serine at a position corresponding to Q579 of the VP1 capsid polypeptide of SEQ ID NO: 1. 187. The capsid polypeptide of any one of Examples 1 to 182, comprising leucine at a position corresponding to Q579 of the VP1 capsid polypeptide of SEQ ID NO: 1. 188. The capsid polypeptide of any one of Examples 1 to 182, comprising tyrosine at a position corresponding to Q579 of the VP1 capsid polypeptide of SEQ ID NO: 1. 189. The capsid polypeptide of any one of Examples 1 to 182, comprising cysteine at a position corresponding to Q579 of the VP1 capsid polypeptide of SEQ ID NO: 1. 190. The capsid polypeptide of any one of Examples 1 to 182, comprising asparagine at a position corresponding to Q579 of the VP1 capsid polypeptide of SEQ ID NO: 1. 191. The capsid polypeptide of any one of embodiments 1 to 190, comprising valine or cysteine at a position corresponding to V580 of the VP1 capsid polypeptide of SEQ ID NO: 1. 192. The capsid polypeptide of any one of Examples 1 to 190, comprising valine at a position corresponding to V580 of the VP1 capsid polypeptide of SEQ ID NO: 1. 193. The capsid polypeptide of any one of embodiments 1 to 190, comprising cysteine at a position corresponding to V580 of the VP1 capsid polypeptide of SEQ ID NO: 1. 194. The capsid polypeptide of any one of Examples 1 to 193, comprising alanine or serine at a position corresponding to A581 of the VP1 capsid polypeptide of SEQ ID NO: 1. 195. The capsid polypeptide of any one of Examples 1 to 193, comprising alanine at a position corresponding to A581 of the VP1 capsid polypeptide of SEQ ID NO: 1. 196. The capsid polypeptide of any one of Examples 1 to 193, comprising serine at a position corresponding to A581 of the VP1 capsid polypeptide of SEQ ID NO: 1. 197. The capsid polypeptide of any one of Examples 1 to 196, comprising threonine or valine at a position corresponding to T582 of the VP1 capsid polypeptide of SEQ ID NO: 1. 198. The capsid polypeptide of any one of Examples 1 to 196, comprising threonine at a position corresponding to T582 of the VP1 capsid polypeptide of SEQ ID NO: 1. 199. The capsid polypeptide of any one of Examples 1 to 196, comprising valine at a position corresponding to T582 of the VP1 capsid polypeptide of SEQ ID NO: 1. 200. The capsid polypeptide of any one of Examples 1 to 199, comprising asparagine or serine at a position corresponding to N583 of the VP1 capsid polypeptide of SEQ ID NO: 1. 201. The capsid polypeptide of any one of Examples 1 to 199, comprising asparagine at a position corresponding to N583 of the VP1 capsid polypeptide of SEQ ID NO: 1. 202. The capsid polypeptide of any one of Examples 1 to 199, comprising serine at a position corresponding to N583 of the VP1 capsid polypeptide of SEQ ID NO: 1. 203. The capsid polypeptide of any one of embodiments 1 to 202, comprising histidine, isoleucine, leucine, methionine, asparagine, alanine, threonine, or phenylalanine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 204. The capsid polypeptide of any one of embodiments 1 to 202, comprising isoleucine, leucine, methionine, asparagine, alanine, threonine, or phenylalanine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 205. The capsid polypeptide of any one of embodiments 1 to 202, comprising isoleucine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 206. The capsid polypeptide of any one of embodiments 1 to 202, comprising leucine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 207. The capsid polypeptide of any one of Examples 1 to 202, comprising methionine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 208. The capsid polypeptide of any one of embodiments 1 to 202, comprising asparagine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 209. The capsid polypeptide of any one of Examples 1 to 202, comprising alanine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 210. The capsid polypeptide of any one of embodiments 1 to 202, comprising threonine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 211. The capsid polypeptide of any one of embodiments 1 to 202, comprising phenylalanine at a position corresponding to H584 of the VP1 capsid polypeptide of SEQ ID NO: 1. 212. The capsid polypeptide of any one of Examples 1 to 211, comprising glutamine at a position corresponding to Q585 of the VP1 capsid polypeptide of SEQ ID NO: 1. 213. The capsid polypeptide of any one of Examples 1 to 212, comprising serine at a position corresponding to S586 of the VP1 capsid polypeptide of SEQ ID NO: 1. 214. The capsid polypeptide of any one of embodiments 1 to 213, comprising alanine, isoleucine, asparagine, proline, or threonine at a position corresponding to A587 of the VP1 capsid polypeptide of SEQ ID NO: 1. 215. The capsid polypeptide of any one of embodiments 1 to 213, comprising isoleucine, asparagine, proline, or threonine at a position corresponding to A587 of the VP1 capsid polypeptide of SEQ ID NO: 1. 216. The capsid polypeptide of any one of Examples 1 to 213, comprising alanine at a position corresponding to A587 of the VP1 capsid polypeptide of SEQ ID NO: 1. 217. The capsid polypeptide of any one of embodiments 1 to 213, comprising isoleucine at a position corresponding to A587 of the VP1 capsid polypeptide of SEQ ID NO: 1. 218. The capsid polypeptide of any one of Examples 1 to 213, comprising asparagine at a position corresponding to A587 of the VP1 capsid polypeptide of SEQ ID NO: 1. 219. The capsid polypeptide of any one of Examples 1 to 213, comprising a proline at a position corresponding to A587 of the VP1 capsid polypeptide of SEQ ID NO: 1. 220. The capsid polypeptide of any one of Examples 1 to 213, comprising threonine at a position corresponding to A587 of the VP1 capsid polypeptide of SEQ ID NO: 1. 221. The capsid polypeptide of any one of embodiments 1 to 220, comprising glutamine, asparagine, or valeric acid at a position corresponding to Q588 of the VP1 capsid polypeptide of SEQ ID NO: 1. 222. The capsid polypeptide of any one of embodiments 1 to 220, comprising asparagine or valine at a position corresponding to Q588 of the VP1 capsid polypeptide of SEQ ID NO: 1. 223. The capsid polypeptide of any one of embodiments 1 to 220, comprising glutamine at a position corresponding to Q588 of the VP1 capsid polypeptide of SEQ ID NO: 1. 224. The capsid polypeptide of any one of embodiments 1 to 220, comprising asparagine at a position corresponding to Q588 of the VP1 capsid polypeptide of SEQ ID NO: 1. 225. The capsid polypeptide of any one of embodiments 1 to 220, comprising valine at a position corresponding to Q588 of the VP1 capsid polypeptide of SEQ ID NO: 1. 226. The capsid polypeptide of any one of Examples 1 to 225, comprising alanine at a position corresponding to A589 of the VP1 capsid polypeptide of SEQ ID NO: 1. 227. The capsid polypeptide of any one of embodiments 1 to 226, comprising glutamine at a position corresponding to Q590 of the VP1 capsid polypeptide of SEQ ID NO: 1. 228. The capsid polypeptide of any one of Examples 1 to 227, comprising alanine at a position corresponding to A591 of the VP1 capsid polypeptide of SEQ ID NO: 1. 229. The capsid polypeptide of any one of embodiments 1 to 228, comprising asparagine, serine, or alanine at a position corresponding to N598 of the VP1 capsid polypeptide of SEQ ID NO: 1. 230. The capsid polypeptide of any one of embodiments 1 to 228, comprising serine or alanine at a position corresponding to N598 of the VP1 capsid polypeptide of SEQ ID NO: 1. 231. The capsid polypeptide of any one of embodiments 1 to 228, comprising asparagine at a position corresponding to N598 of the VP1 capsid polypeptide of SEQ ID NO: 1. 232. The capsid polypeptide of any one of Examples 1 to 228, comprising serine at a position corresponding to N598 of the VP1 capsid polypeptide of SEQ ID NO: 1. 233. The capsid polypeptide of any one of Examples 1 to 228, comprising alanine at a position corresponding to N598 of the VP1 capsid polypeptide of SEQ ID NO: 1. 234. The capsid polypeptide of any one of embodiments 1 to 233, comprising glutamine, valine, leucine, or cysteine at a position corresponding to Q599 of the VP1 capsid polypeptide of SEQ ID NO: 1. 235. The capsid polypeptide of any one of embodiments 1 to 233, comprising valine, leucine, or cysteine at a position corresponding to Q599 of the VP1 capsid polypeptide of SEQ ID NO: 1. 236. The capsid polypeptide of any one of embodiments 1 to 233, comprising glutamine at a position corresponding to Q599 of the VP1 capsid polypeptide of SEQ ID NO: 1. 237. The capsid polypeptide of any one of embodiments 1 to 233, comprising valine at a position corresponding to Q599 of the VP1 capsid polypeptide of SEQ ID NO: 1. 238. The capsid polypeptide of any one of embodiments 1 to 233, comprising leucine at a position corresponding to Q599 of the VP1 capsid polypeptide of SEQ ID NO: 1. 239. The capsid polypeptide of any one of embodiments 1 to 233, comprising cysteine at a position corresponding to Q599 of the VP1 capsid polypeptide of SEQ ID NO: 1. 240. The capsid polypeptide of any one of embodiments 1 to 239, comprising glycine or serine at the position corresponding to G600 of the VP1 capsid polypeptide of SEQ ID NO: 1. 241. The capsid polypeptide of any one of Examples 1 to 239, comprising glycine at a position corresponding to G600 of the VP1 capsid polypeptide of SEQ ID NO: 1. 242. The capsid polypeptide of any one of Examples 1 to 239, comprising serine at a position corresponding to G600 of the VP1 capsid polypeptide of SEQ ID NO: 1. 243. The capsid polypeptide of any one of embodiments 1 to 242, comprising isoleucine or valine at a position corresponding to I601 of the VP1 capsid polypeptide of SEQ ID NO: 1. 244. The capsid polypeptide of any one of embodiments 1 to 242, comprising isoleucine at a position corresponding to I601 of the VP1 capsid polypeptide of SEQ ID NO: 1. 245. The capsid polypeptide of any one of embodiments 1 to 242, comprising valine at a position corresponding to I601 of the VP1 capsid polypeptide of SEQ ID NO: 1. 246. The capsid polypeptide of any one of embodiments 1 to 245, comprising leucine at a position corresponding to L602 of the VP1 capsid polypeptide of SEQ ID NO: 1. 247. The capsid polypeptide of any one of embodiments 1 to 246, comprising a proline at a position corresponding to P603 of the VP1 capsid polypeptide of SEQ ID NO: 1. 248. The capsid polypeptide of any one of embodiments 1 to 247, comprising glycine at a position corresponding to G604 of the VP1 capsid polypeptide of SEQ ID NO: 1. 249. The capsid polypeptide of any one of embodiments 1 to 248, comprising methionine at a position corresponding to M605 of the VP1 capsid polypeptide of SEQ ID NO: 1. 250. The capsid polypeptide of any one of embodiments 1 to 249, comprising valine at a position corresponding to V606 of the VP1 capsid polypeptide of SEQ ID NO: 1. 251. The capsid polypeptide of any one of embodiments 1 to 250, comprising tryptophan at a position corresponding to W607 of the VP1 capsid polypeptide of SEQ ID NO: 1. 252. The capsid polypeptide of any one of embodiments 1 to 251, comprising glutamine at a position corresponding to Q608 of the VP1 capsid polypeptide of SEQ ID NO: 1. 253. The capsid polypeptide of any one of embodiments 1 to 252, comprising aspartic acid at a position corresponding to D609 of the VP1 capsid polypeptide of SEQ ID NO: 1. 254. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 70% sequence identity ((a) with or (b) without targeting peptide insertion) to the VP1 capsid polypeptide or VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 75% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide or the VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. 256. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 80% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) with the VP1 capsid polypeptide or the VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. 257. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 85% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) with the VP1 capsid polypeptide or the VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 90% sequence identity ((a) with or (b) without targeting peptide insertion) to the VP1 capsid polypeptide or VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 91% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide or the VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. 260. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 92% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide or VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 93% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide or the VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. 262. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 94% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide or VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 95% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide or VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 96% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide or the VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. 265. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 97% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide or VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 98% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide or the VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. 267. A capsid polypeptide according to any one of embodiments 1 to 253, comprising an amino acid sequence having at least 99% sequence identity ((a) with or (b) without targeting peptide insertion) to the VP1 capsid polypeptide or VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158. The capsid polypeptide of any one of embodiments 1 to 253, comprising a VP1 capsid polypeptide or a VP2 or VP3 portion thereof of any one of SEQ ID NOs: 12-158 having at least 99. Amino acid sequences with 5% sequence identity ((a) with or without targeting peptide insertion). 269. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 12 or its VP2 or VP3 portion. 270. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 13 or its VP2 or VP3 portion. 271. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 14 or its VP2 or VP3 portion. 272. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 15 or its VP2 or VP3 portion. 273. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 16 or its VP2 or VP3 portion. 274. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 17 or the VP2 or VP3 portion thereof. 275. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 18 or its VP2 or VP3 portion. 276. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 19 or the VP2 or VP3 portion thereof. 277. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 20 or the VP2 or VP3 portion thereof. 278. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 21 or the VP2 or VP3 portion thereof. 279. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 22 or the VP2 or VP3 portion thereof. 280. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 23 or its VP2 or VP3 portion. 281. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 24 or the VP2 or VP3 portion thereof. 282. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 25 or its VP2 or VP3 portion. 283. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 26 or the VP2 or VP3 portion thereof. 284. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 27 or the VP2 or VP3 portion thereof. 285. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 28 or its VP2 or VP3 portion. 286. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 29 or the VP2 or VP3 portion thereof. 287. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 30 or the VP2 or VP3 portion thereof. 288. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 31 or its VP2 or VP3 portion. 289. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 32 or the VP2 or VP3 portion thereof. 290. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 33 or its VP2 or VP3 portion. 291. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 34 or its VP2 or VP3 portion. 292. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 35 or its VP2 or VP3 portion. 293. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 36 or its VP2 or VP3 portion. 294. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 37 or the VP2 or VP3 portion thereof. 295. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 38 or its VP2 or VP3 portion. 296. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 39 or the VP2 or VP3 portion thereof. 297. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 40 or the VP2 or VP3 portion thereof. 298. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 41 or its VP2 or VP3 portion. 299. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 42 or the VP2 or VP3 portion thereof. 300. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 43 or its VP2 or VP3 portion. 301. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 44 or its VP2 or VP3 portion. 302. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 45 or its VP2 or VP3 portion. 303. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 46 or its VP2 or VP3 portion. 304. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 47 or the VP2 or VP3 portion thereof. 305. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 48 or its VP2 or VP3 portion. 306. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 49 or the VP2 or VP3 portion thereof. 307. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 50 or the VP2 or VP3 portion thereof. 308. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 51 or its VP2 or VP3 portion. 309. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 52 or the VP2 or VP3 portion thereof. 310. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 53 or its VP2 or VP3 portion. 311. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 54 or the VP2 or VP3 portion thereof. 312. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 55 or its VP2 or VP3 portion. 313. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 56 or its VP2 or VP3 portion. 314. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 57 or the VP2 or VP3 portion thereof. 315. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 58 or its VP2 or VP3 portion. 316. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 59 or the VP2 or VP3 portion thereof. 317. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 60 or its VP2 or VP3 portion. 318. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 61 or its VP2 or VP3 portion. 319. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 62 or its VP2 or VP3 portion. 320. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 63 or its VP2 or VP3 portion. 321. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 64 or the VP2 or VP3 portion thereof. 322. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 65 or its VP2 or VP3 portion. 323. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 66 or its VP2 or VP3 portion. 324. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 67 or the VP2 or VP3 portion thereof. 325. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 68 or its VP2 or VP3 portion. 326. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 69 or the VP2 or VP3 portion thereof. 327. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 70 or the VP2 or VP3 portion thereof. 328. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 71 or the VP2 or VP3 portion thereof. 329. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 72 or the VP2 or VP3 portion thereof. 330. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 73 or its VP2 or VP3 portion. 331. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 74 or the VP2 or VP3 portion thereof. 332. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 75 or its VP2 or VP3 portion. 333. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 76 or the VP2 or VP3 portion thereof. 334. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 77 or the VP2 or VP3 portion thereof. 335. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 78 or its VP2 or VP3 portion. 336. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 79 or the VP2 or VP3 portion thereof. 337. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 80 or the VP2 or VP3 portion thereof. 338. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 81 or its VP2 or VP3 portion. 339. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 82 or the VP2 or VP3 portion thereof. 340. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 83 or its VP2 or VP3 portion. 341. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 84 or the VP2 or VP3 portion thereof. 342. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 85 or its VP2 or VP3 portion. 343. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 86 or its VP2 or VP3 portion. 344. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 87 or the VP2 or VP3 portion thereof. 345. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 88 or the VP2 or VP3 portion thereof. 346. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 89 or the VP2 or VP3 portion thereof. 347. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 90 or the VP2 or VP3 portion thereof. 348. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 91 or its VP2 or VP3 portion. 349. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 92 or the VP2 or VP3 portion thereof. 350. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 93 or the VP2 or VP3 portion thereof. 351. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 94 or the VP2 or VP3 portion thereof. 352. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 95 or the VP2 or VP3 portion thereof. 353. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 96 or the VP2 or VP3 portion thereof. 354. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 97 or the VP2 or VP3 portion thereof. 355. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 98 or its VP2 or VP3 portion. 356. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 99 or the VP2 or VP3 portion thereof. 357. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 100 or the VP2 or VP3 portion thereof. 358. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 101 or the VP2 or VP3 portion thereof. 359. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 102 or the VP2 or VP3 portion thereof. 360. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 103 or the VP2 or VP3 portion thereof. 361. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 104 or the VP2 or VP3 portion thereof. 362. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 105 or the VP2 or VP3 portion thereof. 363. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 106 or the VP2 or VP3 portion thereof. 364. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 107 or the VP2 or VP3 portion thereof. 365. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 108 or its VP2 or VP3 portion. 366. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 109 or the VP2 or VP3 portion thereof. 367. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 110 or the VP2 or VP3 portion thereof. 368. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 111 or the VP2 or VP3 portion thereof. 369. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 112 or the VP2 or VP3 portion thereof. 370. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 113 or the VP2 or VP3 portion thereof. 371. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 114 or the VP2 or VP3 portion thereof. 372. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 115 or its VP2 or VP3 portion. 373. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 116 or the VP2 or VP3 portion thereof. 374. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 117 or the VP2 or VP3 portion thereof. 375. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 118 or its VP2 or VP3 portion. 376. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 119 or the VP2 or VP3 portion thereof. 377. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 120 or the VP2 or VP3 portion thereof. 378. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 121 or the VP2 or VP3 portion thereof. 379. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 122 or the VP2 or VP3 portion thereof. 380. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 123 or the VP2 or VP3 portion thereof. 381. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 124 or the VP2 or VP3 portion thereof. 382. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 125 or its VP2 or VP3 portion. 383. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 126 or the VP2 or VP3 portion thereof. 384. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 127 or the VP2 or VP3 portion thereof. 385. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 128 or the VP2 or VP3 portion thereof. 386. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 129 or the VP2 or VP3 portion thereof. 387. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 130 or the VP2 or VP3 portion thereof. 388. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 131 or the VP2 or VP3 portion thereof. 389. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 132 or its VP2 or VP3 portion. 390. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 133 or the VP2 or VP3 portion thereof. 391. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 134 or the VP2 or VP3 portion thereof. 392. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 135 or its VP2 or VP3 portion. 393. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 136 or the VP2 or VP3 portion thereof. 394. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 137 or the VP2 or VP3 portion thereof. 395. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 138 or its VP2 or VP3 portion. 396. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 139 or the VP2 or VP3 portion thereof. 397. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 140 or the VP2 or VP3 portion thereof. 398. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 141 or its VP2 or VP3 portion. 399. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 142 or the VP2 or VP3 portion thereof. 400. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 143 or the VP2 or VP3 portion thereof. 401. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 144 or the VP2 or VP3 portion thereof. 402. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 145 or its VP2 or VP3 portion. 403. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 146 or the VP2 or VP3 portion thereof. 404. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 147 or the VP2 or VP3 portion thereof. 405. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 148 or its VP2 or VP3 portion. 406. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 149 or the VP2 or VP3 portion thereof. 407. A capsid polypeptide, which is optionally the capsid polypeptide of any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 150 or the VP2 or VP3 portion thereof. 408. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 151 or the VP2 or VP3 portion thereof. 409. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 152 or the VP2 or VP3 portion thereof. 410. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 153 or the VP2 or VP3 portion thereof. 411. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 154 or the VP2 or VP3 portion thereof. 412. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 155 or its VP2 or VP3 portion. 413. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 156 or the VP2 or VP3 portion thereof. 414. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 157 or the VP2 or VP3 portion thereof. 415. A capsid polypeptide, which is optionally a capsid polypeptide according to any one of Examples 1 to 268, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 158 or the VP2 or VP3 portion thereof. 416. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V1; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:12 (or from the VP2 or VP3 portion thereof). 417. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V2; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:13 (or from the VP2 or VP3 portion thereof). 418. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the set of mutations of variant V3; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:14 (or from the VP2 or VP3 portion thereof). 419. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V4; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:15 (or from the VP2 or VP3 portion thereof). 420. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V5; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:16 (or from the VP2 or VP3 portion thereof). 421. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V6; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:17 (or from the VP2 or VP3 portion thereof). 422. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V7; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:18 (or from the VP2 or VP3 portion thereof). 423. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V8; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:19 (or from the VP2 or VP3 portion thereof). 424. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V9; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:20 (or from the VP2 or VP3 portion thereof). 425. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V10; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:21 (or from the VP2 or VP3 portion thereof). 426. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V11; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:22 (or from the VP2 or VP3 portion thereof). 427. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V12; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:23 (or from the VP2 or VP3 portion thereof). 428. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V13; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:24 (or from the VP2 or VP3 portion thereof). 429. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V14; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:25 (or from the VP2 or VP3 portion thereof). 430. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V15; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:26 (or from the VP2 or VP3 portion thereof). 431. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V16; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:27 (or from the VP2 or VP3 portion thereof). 432. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V17; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:28 (or from the VP2 or VP3 portion thereof). 433. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V18; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:29 (or from the VP2 or VP3 portion thereof). 434. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V19; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:30 (or from the VP2 or VP3 portion thereof). 435. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V20; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:31 (or from the VP2 or VP3 portion thereof). 436. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V21; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:32 (or from the VP2 or VP3 portion thereof). 437. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V22; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:33 (or from the VP2 or VP3 portion thereof). 438. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V23; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:34 (or from the VP2 or VP3 portion thereof). 439. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V24; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:35 (or from the VP2 or VP3 portion thereof). 440. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V25; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:36 (or from the VP2 or VP3 portion thereof). 441. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V26; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:37 (or from the VP2 or VP3 portion thereof). 442. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V27; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:38 (or from the VP2 or VP3 portion thereof). 443. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V28; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:39 (or from the VP2 or VP3 portion thereof). 444. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V29; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:40 (or from the VP2 or VP3 portion thereof). 445. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V30; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:41 (or from the VP2 or VP3 portion thereof). 446. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V31; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:42 (or from the VP2 or VP3 portion thereof). 447. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V32; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:43 (or from the VP2 or VP3 portion thereof). 448. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V33; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:44 (or from the VP2 or VP3 portion thereof). 449. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V34; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:45 (or from the VP2 or VP3 portion thereof). 450. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V35; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:46 (or from the VP2 or VP3 portion thereof). 451. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the set of mutations of variant V36 (or its VP2 or VP3 portion); and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:47 (or its VP2 or VP3 portion). 452. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V37; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:48 (or from the VP2 or VP3 portion thereof). 453. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V38; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:49 (or from the VP2 or VP3 portion thereof). 454. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V39; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:50 (or from the VP2 or VP3 portion thereof). 455. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V40; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:51 (or from the VP2 or VP3 portion thereof). 456. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V41; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:52 (or from the VP2 or VP3 portion thereof). 457. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V42; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:53 (or from the VP2 or VP3 portion thereof). 458. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V43; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:54 (or from the VP2 or VP3 portion thereof). 459. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V44; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:55 (or from the VP2 or VP3 portion thereof). 460. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V45; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:56 (or from the VP2 or VP3 portion thereof). 461. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V46; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:57 (or from the VP2 or VP3 portion thereof). 462. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V47; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:58 (or from the VP2 or VP3 portion thereof). 463. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V48; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:59 (or from the VP2 or VP3 portion thereof). 464. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V49; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:60 (or from the VP2 or VP3 portion thereof). 465. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V50; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:61 (or from the VP2 or VP3 portion thereof). 466. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V51; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:62 (or from the VP2 or VP3 portion thereof). 467. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V52; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:63 (or from the VP2 or VP3 portion thereof). 468. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V53; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:64 (or from the VP2 or VP3 portion thereof). 469. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V54; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:65 (or from the VP2 or VP3 portion thereof). 470. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V55; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:66 (or from the VP2 or VP3 portion thereof). 471. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V56; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:67 (or from the VP2 or VP3 portion thereof). 472. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V57; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:68 (or from the VP2 or VP3 portion thereof). 473. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V58; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:69 (or from the VP2 or VP3 portion thereof). 474. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V59; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:70 (or from the VP2 or VP3 portion thereof). 475. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V60; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:71 (or from the VP2 or VP3 portion thereof). 476. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V61; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:72 (or from the VP2 or VP3 portion thereof). 477. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V62; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:73 (or from the VP2 or VP3 portion thereof). 478. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V63; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:74 (or from the VP2 or VP3 portion thereof). 479. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V64; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:75 (or from the VP2 or VP3 portion thereof). 480. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V65; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:76 (or from the VP2 or VP3 portion thereof). 481. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V66; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:77 (or from the VP2 or VP3 portion thereof). 482. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V67; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:78 (or from the VP2 or VP3 portion thereof). 483. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V68; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:79 (or from the VP2 or VP3 portion thereof). 484. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V69; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:80 (or from the VP2 or VP3 portion thereof). 485. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V70; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:81 (or from the VP2 or VP3 portion thereof). 486. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V71; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:82 (or from the VP2 or VP3 portion thereof). 487. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V72; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:83 (or from the VP2 or VP3 portion thereof). 488. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V73; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:84 (or from the VP2 or VP3 portion thereof). 489. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V74; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:85 (or from the VP2 or VP3 portion thereof). 490. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V75; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:86 (or from the VP2 or VP3 portion thereof). 491. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V76; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:87 (or from the VP2 or VP3 portion thereof). 492. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V77; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:88 (or from the VP2 or VP3 portion thereof). 493. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V78; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:89 (or from the VP2 or VP3 portion thereof). 494. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V79; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:90 (or from the VP2 or VP3 portion thereof). 495. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V80; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:91 (or from the VP2 or VP3 portion thereof). 496. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V81; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:92 (or from the VP2 or VP3 portion thereof). 497. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V82; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:93 (or from the VP2 or VP3 portion thereof). 498. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V83; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:94 (or from the VP2 or VP3 portion thereof). 499. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V84; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:95 (or from the VP2 or VP3 portion thereof). 500. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V85; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:96 (or from the VP2 or VP3 portion thereof). 501. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V86; and (b) comprises an amino acid sequence that is 15 or fewer editing distances from the amino acid sequence of SEQ ID NO:97 (or from the VP2 or VP3 portion thereof). 502. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V87; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:98 (or from the VP2 or VP3 portion thereof). 503. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V88; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:99 (or from the VP2 or VP3 portion thereof). 504. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V89; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:100 (or from the VP2 or VP3 portion thereof). 505. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V90; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:101 (or from the VP2 or VP3 portion thereof). 506. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V91; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:102 (or from the VP2 or VP3 portion thereof). 507. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V92; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:103 (or from the VP2 or VP3 portion thereof). 508. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V93; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:104 (or from the VP2 or VP3 portion thereof). 509. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V94; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:105 (or from the VP2 or VP3 portion thereof). 510. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V95; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:106 (or from the VP2 or VP3 portion thereof). 511. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V96; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:107 (or from the VP2 or VP3 portion thereof). 512. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V97; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:108 (or from the VP2 or VP3 portion thereof). 513. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V98; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:109 (or from the VP2 or VP3 portion thereof). 514. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V99; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:110 (or from the VP2 or VP3 portion thereof). 515. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V100; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:111 (or from the VP2 or VP3 portion thereof). 516. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V101; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:112 (or from the VP2 or VP3 portion thereof). 517. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V102; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:113 (or from the VP2 or VP3 portion thereof). 518. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V103; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:114 (or from the VP2 or VP3 portion thereof). 519. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V104; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:115 (or from the VP2 or VP3 portion thereof). 520. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V105; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:116 (or from the VP2 or VP3 portion thereof). 521. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V106; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:117 (or from the VP2 or VP3 portion thereof). 522. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V107; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:118 (or from the VP2 or VP3 portion thereof). 523. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V108; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:119 (or from the VP2 or VP3 portion thereof). 524. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V109; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:120 (or from the VP2 or VP3 portion thereof). 525. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V110; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:121 (or from the VP2 or VP3 portion thereof). 526. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V111; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:122 (or from the VP2 or VP3 portion thereof). 527. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V112; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:123 (or from the VP2 or VP3 portion thereof). 528. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V113; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:124 (or from the VP2 or VP3 portion thereof). 529. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V114; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:125 (or from the VP2 or VP3 portion thereof). 530. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V115; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:126 (or from the VP2 or VP3 portion thereof). 531. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V116; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:127 (or from the VP2 or VP3 portion thereof). 532. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V117; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:128 (or from the VP2 or VP3 portion thereof). 533. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V118; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:129 (or from the VP2 or VP3 portion thereof). 534. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V119; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:130 (or from the VP2 or VP3 portion thereof). 535. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V120; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:131 (or from the VP2 or VP3 portion thereof). 536. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V121; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:132 (or from the VP2 or VP3 portion thereof). 537. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V122; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:133 (or from the VP2 or VP3 portion thereof). 538. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V123; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:134 (or from the VP2 or VP3 portion thereof). 539. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V124; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:135 (or from the VP2 or VP3 portion thereof). 540. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V125; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:136 (or from the VP2 or VP3 portion thereof). 541. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V126; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:137 (or from the VP2 or VP3 portion thereof). 542. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V127; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:138 (or from the VP2 or VP3 portion thereof). 543. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V128; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:139 (or from the VP2 or VP3 portion thereof). 544. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V129; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:140 (or from the VP2 or VP3 portion thereof). 545. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V130; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:141 (or from the VP2 or VP3 portion thereof). 546. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V131; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:142 (or from the VP2 or VP3 portion thereof). 547. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V132; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:143 (or from the VP2 or VP3 portion thereof). 548. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V133; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:144 (or from the VP2 or VP3 portion thereof). 549. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V134; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:145 (or from the VP2 or VP3 portion thereof). 550. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V135; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:146 (or from the VP2 or VP3 portion thereof). 551. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V136; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:147 (or from the VP2 or VP3 portion thereof). 552. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V137; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:148 (or from the VP2 or VP3 portion thereof). 553. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V138; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:149 (or from the VP2 or VP3 portion thereof). 554. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V139; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:150 (or from the VP2 or VP3 portion thereof). 555. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V140; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:151 (or from the VP2 or VP3 portion thereof). 556. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V141; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:152 (or from the VP2 or VP3 portion thereof). 557. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V142; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:153 (or from the VP2 or VP3 portion thereof). 558. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V143; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:154 (or from the VP2 or VP3 portion thereof). 559. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V144; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:155 (or from the VP2 or VP3 portion thereof). 560. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V145; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:156 (or from the VP2 or VP3 portion thereof). 561. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V146; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:157 (or from the VP2 or VP3 portion thereof). 562. A capsid polypeptide: (a) comprises at least 70%, at least 80%, or at least 90% (and preferably at least 70%) of the mutations in the mutation group of variant V147; and (b) comprises an amino acid sequence that has an editing distance of 15 or less from the amino acid sequence of SEQ ID NO:158 (or from the VP2 or VP3 portion thereof). 563. The capsid polypeptide of any one of Examples 416 to 562, which has the same amino acid as the capsid polypeptide whose amino acid sequence is shown in part (b) at the position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1. 564. The capsid polypeptide of any one of Examples 416 to 563, which has the same amino acid as the capsid polypeptide whose amino acid sequence is shown in part (b) at the position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 565. The capsid polypeptide of any one of Examples 416 to 564, which has the same amino acid as the capsid polypeptide whose amino acid sequence is shown in part (b) at the position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 566. The capsid polypeptide of any one of Examples 416 to 565, which has the same amino acid as the capsid polypeptide whose amino acid sequence is shown in part (b) at the position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 567. The capsid polypeptide of any one of Examples 416 to 566, which has the same amino acid as the capsid polypeptide whose amino acid sequence is shown in part (b) at the position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 568. The shell of any one of Examples 416 to 567, wherein the editing distance from the amino acid sequence shown in part (b) (or from the VP2 or VP3 portion thereof) is 14 or less. 569. The shell of any one of Examples 416 to 567, wherein the editing distance from the amino acid sequence shown in part (b) (or from the VP2 or VP3 portion thereof) is 13 or less. 570. The shell of any one of Examples 416 to 567, wherein the editing distance from the amino acid sequence shown in part (b) (or from the VP2 or VP3 portion thereof) is 12 or less. 571. The shell of any one of Examples 416 to 567, wherein the editing distance from the amino acid sequence shown in part (b) (or from the VP2 or VP3 portion thereof) is 11 or less. 572. The shell of any one of Examples 416 to 567, wherein the editing distance from the amino acid sequence shown in part (b) (or from the VP2 or VP3 portion thereof) is 10 or less. 573. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V1, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 574. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V2, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 575. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V3, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 576. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V4, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 577. A capsid polypeptide comprising 8, 9, or all 10 mutations from the set of mutations of variant V5, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 578. A capsid polypeptide comprising 4, 5, 6, or all 7 mutations from the set of mutations of variant V6, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 579. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V7, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 580. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V8, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 581. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V9, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 582. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V10, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 583. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V11, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 584. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V12, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 585. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V13, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 586. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V14, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 587. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V15, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 588. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V16, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 589. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V17, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 590. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V18, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 591. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V19, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 592. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V20, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 593. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V21, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 594. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V22, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 595. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V23, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 596. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V24, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 597. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V25, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 598. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V26, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 599. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V27, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 600. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V28, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 601. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V29, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 602. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V30, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 603. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V31, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 604. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V32, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 605. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V33, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 606. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V34, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 607. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V35, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 608. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V36, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 609. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V37, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 610. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V38, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 611. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V39, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 612. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V40, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 613. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V41, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 614. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V42, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 615. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V43, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 616. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V44, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 617. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V45, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 618. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V46, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 619. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V47, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 620. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V48, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 621. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V49, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 622. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V50, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 623. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V51, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 624. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V52, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 625. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V53, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 626. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V54, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 627. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V55, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 628. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V56, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 629. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V57, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 630. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V58, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 631. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V59, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 632. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V60, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 633. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V61, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 634. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V62, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 635. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V63, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 636. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V64, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 637. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V65, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 638. A capsid polypeptide comprising two, three, or all four mutations from the set of mutations of variant V66, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 639. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V67, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 640. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V68, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 641. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V69, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 642. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V70, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 643. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V71, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 644. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V72, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 645. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V73, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 646. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V74, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 647. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V75, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 648. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V76, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-B. 649. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V77, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 650. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V78, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 651. A capsid polypeptide comprising 5, 6, or 7 mutations selected from the group of mutations of variant V79, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 652. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V80, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 653. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V81, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 654. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V82, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 655. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V83, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 656. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V84, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 657. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V85, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 658. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V86, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 659. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V87, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 660. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V88, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 661. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V89, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 662. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V90, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 663. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V91, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 664. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V92, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 665. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V93, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 666. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V94, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 667. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V95, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-C. 668. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V96, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 669. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V97, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 670. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V98, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 671. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V99, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 672. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V100, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 673. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V101, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 674. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V102, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 675. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V103, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 676. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V104, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 677. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V105, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 678. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V106, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 679. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V107, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 680. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V108, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 681. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V109, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 682. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V110, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 683. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V111, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 684. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V112, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 685. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V113, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 686. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V114, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 687. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V115, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 688. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V116, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 689. A capsid polypeptide comprising 8, 9, or all 10 mutations from the set of mutations of variant V117, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 690. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V118, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 691. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V119, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 692. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V120, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 693. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V121, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 694. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V122, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 695. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V123, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 696. A capsid polypeptide comprising 6, 7, or all 8 mutations from the set of mutations of variant V124, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-E. 697. A capsid polypeptide comprising 4, 5, or all 6 mutations from the set of mutations of variant V125, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-E. 698. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V126, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-E. 699. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V127, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-E. 700. A capsid polypeptide comprising 5, 6, or all 7 mutations from the set of mutations of variant V128, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-E. 701. A capsid polypeptide comprising two or all three mutations from the set of mutations of variant V129, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-F. 702. A capsid polypeptide comprising two mutations from the set of mutations of variant V130, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-F. 703. A capsid polypeptide comprising two, three, or all four mutations from the set of mutations of variant V131, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-F. 704. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V132, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-G. 705. A capsid polypeptide comprising four, five, or all six mutations from the set of mutations of variant V133, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-G. 706. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V134, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-G. 707. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V135, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-G. 708. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V136, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-G. 709. A capsid polypeptide comprising three, four, or all five mutations from the set of mutations of variant V137, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-G. 710. A capsid polypeptide comprising 9, 10, or all 11 mutations from the set of mutations of variant V138, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 711. A capsid polypeptide comprising 10, 11, or all 12 mutations from the set of mutations of variant V139, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 712. A capsid polypeptide comprising 9, 10, or all 11 mutations from the set of mutations of variant V140, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 713. A capsid polypeptide comprising 8, 9, or all 10 mutations from the set of mutations of variant V141, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 714. A capsid polypeptide comprising 8, 9, or all 10 mutations from the set of mutations of variant V142, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 715. A capsid polypeptide comprising 8, 9, or all 10 mutations from the set of mutations of variant V143, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 716. A capsid polypeptide comprising 8, 9, or all 10 mutations from the set of mutations of variant V144, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 717. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V145, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 718. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V146, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-D. 719. A capsid polypeptide comprising 7, 8, or all 9 mutations from the set of mutations of variant V147, as compared to the VP1 capsid polypeptide of SEQ ID NO: 1, as described in Table 1-A. 720. The capsid polypeptide of any one of Examples 573 to 719, which has the same amino acid as the variant capsid polypeptide at the position corresponding to Q592 of the VP1 capsid polypeptide of SEQ ID NO: 1. 721. The capsid polypeptide of any one of Examples 573 to 720, which has the same amino acid as the variant capsid polypeptide at the position corresponding to T593 of the VP1 capsid polypeptide of SEQ ID NO: 1. 722. The capsid polypeptide of any one of Examples 573 to 721, which has the same amino acid as the variant capsid polypeptide at the position corresponding to G594 of the VP1 capsid polypeptide of SEQ ID NO: 1. 723. The capsid polypeptide of any one of Examples 573 to 722, which has the same amino acid as the variant capsid polypeptide at the position corresponding to W595 of the VP1 capsid polypeptide of SEQ ID NO: 1. 724. The capsid polypeptide of any one of Examples 573 to 723, which has the same amino acid as the variant capsid polypeptide at a position corresponding to V596 of the VP1 capsid polypeptide of SEQ ID NO: 1. 725. The capsid polypeptide of any one of Examples 1 to 724, wherein the sequence thereof has an editing distance of (a) 12 or less or (b) 10 or less from the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 726. The capsid polypeptide of any one of Examples 1 to 724, wherein its sequence has an editing distance of (a) 9 or less or (b) 8 or less from the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 727. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:12; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:12; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:12. 728. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:13; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:13; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:13. 729. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:14; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:14; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:14. 730. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:15; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:15; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:15. 731. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:16; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:16; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:16. 732. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:17; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:17; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:17. 733. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:18; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:18; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:18. 734. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:19; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:19; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:19. 735. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:20; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:20; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:20. 736. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:21; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:21; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:21. 737. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:22; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:22; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:22. 738. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:23; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:23; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:23. 739. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:24; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:24; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:24. 740. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:25; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:25; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:25. 741. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:26; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:26; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:26. 742. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:27; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:27; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:27. 743. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:28; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:28; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:28. 744. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:29; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:29; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:29. 745. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:30; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:30; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:30. 746. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:31; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:31; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:31. 747. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:32; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:32; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:32. 748. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:33; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:33; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:33. 749. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:34; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:34; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:34. 750. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:35; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:35; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:35. 751. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:36; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:36; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:36. 752. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:37; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:37; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:37. 753. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:38; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:38; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:38. 754. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:39; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:39; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:39. 755. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:40; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:40; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:40. 756. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:41; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:41; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:41. 757. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:42; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:42; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:42. 758. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:43; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:43; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:43. 759. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:44; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:44; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:44. 760. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:45; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:45; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:45. 761. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:46; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:46; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:46. 762. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:47; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:47; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:47. 763. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:48; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:48; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:48. 764. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:49; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:49; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:49. 765. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:50; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:50; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:50. 766. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:51; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:51; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:51. 767. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:52; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:52; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:52. 768. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:53; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:53; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:53. 769. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:54; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:54; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:54. 770. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:55; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:55; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:55. 771. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:56; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:56; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:56. 772. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:57; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:57; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:57. 773. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:58; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:58; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:58. 774. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:59; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:59; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:59. (d) 775. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:60; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:60; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:60. 776. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:61; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:61; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:61. 777. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:62; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:62; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:62. 778. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:63; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:63; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:63. 779. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:64; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:64; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:64. 780. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:65; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:65; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:65. 781. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:66; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:66; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:66. 782. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:67; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:67; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:67. 783. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:68; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:68; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:68. 784. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:69; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:69; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:69. 785. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:70; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:70; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:70. 786. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:71; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:71; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:71. 787. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:72; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:72; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:72. 788. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:73; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:73; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:73. 789. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:74; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:74; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:74. 790. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:75; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:75; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:75. 791. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:76; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:76; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:76. 792. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:77; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:77; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:77. 793. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:78; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:78; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:78. 794. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:79; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:79; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:79. 795. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:80; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:80; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:80. 796. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:81; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:81; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:81. 797. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:82; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:82; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:82. 798. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:83; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:83; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:83. 799. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:84; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:84; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:84. 800. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:85; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:85; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:85. 801. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:86; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:86; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:86. 802. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:87; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:87; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:87. 803. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:88; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:88; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:88. 804. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:89; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:89; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:89. 805. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:90; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:90; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:90. 806. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:91; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:91; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:91. 807. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:92; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:92; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:92. 808. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:93; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:93; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:93. 809. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:94; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:94; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:94. 810. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:95; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:95; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:95. 811. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:96; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:96; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:96. 812. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:97; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:97; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:97. 813. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:98; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:98; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:98. 814. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:99; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:99; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:99. 815. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:100; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:100; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:100. 816. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:101; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:101; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:101. 817. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:102; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:102; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:102. 818. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:103; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:103; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:103. 819. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:104; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:104; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:104. 820. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:105; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:105; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:105. 821. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:106; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:106; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:106. 822. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:107; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:107; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:107. 823. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:108; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:108; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:108. 824. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:109; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:109; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:109. 825. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:110; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:110; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:110. 826. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:111; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:111; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:111. 827. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:112; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:112; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:112. 828. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:113; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:113; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:113. 829. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:114; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:114; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:114. 830. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:115; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:115; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:115. 831. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:116; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:116; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:116. 832. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:117; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:117; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:117. 833. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:118; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:118; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:118. 834. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:119; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:119; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:119. 835. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:120; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:120; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:120. 836. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:121; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:121; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:121. 837. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:122; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:122; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:122. 838. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:123; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:123; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:123. 839. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:124; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:124; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:124. 840. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:125; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:125; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:125. 841. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:126; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:126; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:126. 842. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:127; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:127; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:127. 843. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:128; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:128; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:128. 844. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:129; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:129; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:129. 845. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:130; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:130; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:130. 846. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:131; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:131; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:131. 847. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:132; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:132; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:132. 848. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:133; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:133; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:133. 849. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:134; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:134; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:134. 850. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:135; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:135; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:135. 851. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:136; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:136; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:136. 852. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:137; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:137; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:137. 853. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:138; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:138; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:138. 854. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:139; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:139; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:139. 855. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:140; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:140; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:140. 856. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:141; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:141; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:141. 857. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:142; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:142; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:142. 858. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:143; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:143; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:143. 859. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:144; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:144; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:144. 860. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:145; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:145; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:145. 861. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:146; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:146; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:146. 862. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:147; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:147; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:147. 863. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:148; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:148; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:148. 864. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:149; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:149; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:149. 865. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:150; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:150; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:150. 866. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:151; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:151; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:151. 867. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:152; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:152; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:152. 868. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:153; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:153; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:153. 869. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:154; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:154; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:154. 870. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:155; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:155; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:155. 871. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:156; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:156; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:156. 872. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:157; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:157; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:157. 873. The capsid polypeptide of any one of Examples 1 to 726, wherein its sequence has an editing distance of (a) 12 or less or (b) 10 or less from: (a) the VP1 capsid polypeptide of SEQ ID NO:158; (b) the VP2 capsid polypeptide corresponding to the VP2 portion of SEQ ID NO:158; or (c) the VP3 capsid polypeptide corresponding to the VP3 portion of SEQ ID NO:158. 874. A capsid polypeptide engineered to include the amino acid sequence VSMM (SEQ ID NO:332), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO:1. 875. A capsid polypeptide engineered to include the amino acid sequence VSMMLQS (SEQ ID NO: 333), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 876. A capsid polypeptide engineered to include the amino acid sequence VSMMLQSQGV (SEQ ID NO: 334), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 877. A capsid polypeptide engineered to include the amino acid sequence NQSAQAQAVSMMLQSQGV (SEQ ID NO: 335), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 878. A capsid polypeptide engineered to include the amino acid sequence TVATNNQSAQAQAVSMML (SEQ ID NO: 336), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 879. A capsid polypeptide engineered to include the amino acid sequence TVATNNQSAQAQAVSMMLQSQGV (SEQ ID NO: 337), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 880. A capsid polypeptide engineered to include the amino acid sequence VSMQW (SEQ ID NO:338), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO:1. 881. A capsid polypeptide engineered to include the amino acid sequence VSMQWQT (SEQ ID NO: 339), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 882. A capsid polypeptide engineered to include the amino acid sequence VSMQWQTQGV (SEQ ID NO: 340), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 883. A capsid polypeptide engineered to include the amino acid sequence TVATNHQSAQAQAVSMQW (SEQ ID NO: 341), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 884. A capsid polypeptide engineered to include the amino acid sequence TVATNHQSAQAQAVSMQWQTQGV (SEQ ID NO: 342), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 885. A capsid polypeptide engineered to include the amino acid sequence VSMTML (SEQ ID NO: 343), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 886. A capsid polypeptide engineered to include the amino acid sequence TQAVSMTML (SEQ ID NO: 344), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 887. A capsid polypeptide engineered to include the amino acid sequence VSMTW (SEQ ID NO:345), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO:1. 888. A capsid polypeptide engineered to include the amino acid sequence PYGQVATNHQSAQAQAVSMTW (SEQ ID NO: 346), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 889. A capsid polypeptide engineered to include the amino acid sequence AITNEEEIKTTNPVATEPYGQVATNHQSAQAQAVSMTW (SEQ ID NO:347), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO:1. 890. A capsid polypeptide engineered to include the amino acid sequence VSMSN (SEQ ID NO:348), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO:1. 891. A capsid polypeptide engineered to include the amino acid sequence TQAQAVSMSNQS (SEQ ID NO: 349), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 892. A capsid polypeptide engineered to include the amino acid sequence PYGSVAVNHQSTQAQAVSMSNQS (SEQ ID NO: 350), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 893. A capsid polypeptide engineered to include the amino acid sequence VSMQI (SEQ ID NO:351), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO:1. 894. A capsid polypeptide engineered to include the amino acid sequence AQSAQAQAVSMQI (SEQ ID NO: 352), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 895. A capsid polypeptide engineered to include the amino acid sequence VSMQW (SEQ ID NO: 338), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 896. A capsid polypeptide engineered to include the amino acid sequence SAQAQAVSMQW (SEQ ID NO: 353), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO: 1. 897. A capsid polypeptide engineered to include the amino acid sequence NVFITNEEEIKTTNPVATESYGQVATSHQSAQAQAVSMQW (SEQ ID NO:354), optionally wherein the amino acid sequence is within the region of the capsid polypeptide corresponding to amino acids 550-620 of SEQ ID NO:1. 898. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 70% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 899. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 75% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 900. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 80% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 901. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 85% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 902. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 90% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 903. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 91% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 904. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 92% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 905. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 93% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 906. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 94% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 907. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 95% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 908. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 96% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 909. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 97% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 910. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 98% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 911. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 99% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide of SEQ ID NO: 1 or its VP2 or VP3 portion. 912. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 70% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) with the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 913. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 75% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 914. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 80% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 915. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 85% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 916. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 90% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 917. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 91% sequence identity to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion). 918. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 92% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 919. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 93% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 920. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 94% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 921. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 95% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 922. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 96% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 923. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 97% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 924. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 98% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 925. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 99% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide of SEQ ID NO: 3 or its VP2 or VP3 portion. 926. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 70% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 927. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 75% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 928. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 80% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 929. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 85% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 930. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 90% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 931. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 91% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 932. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 92% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 933. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 93% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 934. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 94% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 935. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 95% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 936. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 96% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 937. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 97% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 938. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 98% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 939. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 99% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO:5 or its VP2 or VP3 portion. 940. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 70% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 941. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 75% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 942. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 80% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 943. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 85% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 944. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 90% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 945. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 91% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 946. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 92% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 947. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 93% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 948. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 94% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 949. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 95% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 950. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 96% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 951. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 97% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 952. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 98% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 953. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 99% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 7 or its VP2 or VP3 portion. 954. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 70% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 955. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 75% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 956. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 80% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 957. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 85% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 958. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 90% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 959. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 91% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 960. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 92% sequence identity ((a) taking into account the insertion of the targeting peptide or (b) not taking into account the insertion of the targeting peptide) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 961. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 93% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 962. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 94% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 963. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 95% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 964. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 96% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 965. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 97% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 966. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 98% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 967. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 99% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 9 or its VP2 or VP3 portion. 968. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 70% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 969. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 75% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 970. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 80% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 971. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 85% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 972. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 90% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 973. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 91% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 974. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 92% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 975. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 93% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 976. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 94% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 977. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 95% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 978. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 96% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 979. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 97% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 980. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 98% sequence identity ((a) with or without targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 981. A capsid polypeptide according to any one of embodiments 1 to 897, comprising an amino acid sequence having at least 99% sequence identity ((a) taking into account the targeting peptide insertion or (b) not taking into account the targeting peptide insertion) to the VP1 capsid polypeptide of SEQ ID NO: 11 or its VP2 or VP3 portion. 982. The capsid polypeptide of any one of Examples 1 to 861, which is a VP1 capsid polypeptide. 983. The capsid polypeptide of any one of Examples 1 to 861, which is a VP2 capsid polypeptide. 984. The capsid polypeptide of any one of Examples 1 to 861, which is a VP3 capsid polypeptide. 985. The capsid polypeptide of any one of Examples 1 to 984, which lacks a targeting peptide. 986. The capsid polypeptide of any one of embodiments 1 to 984, comprising a targeting peptide, wherein (a) the targeting peptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 308-330; (b) the targeting peptide is inserted immediately after the position corresponding to 586, 588, or 589 of SEQ ID NO: 1; (c) the capsid polypeptide further comprises a deletion at the position corresponding to 587 and/or 588 of SEQ ID NO: 1; or (d) any combination of two or all three of (a), (b), and (c). 987. A nucleic acid molecule encoding a capsid polypeptide according to any one of Examples 1 to 986. 988. The nucleic acid molecule of embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 70% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 989. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 75% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 990. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 80% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 991. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 85% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 992. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 90% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 993. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 91% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 994. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 92% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 995. The nucleic acid molecule of embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 93% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 996. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 94% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 997. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 95% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 998. The nucleic acid molecule of embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 96% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 999. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 97% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 1000. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 98% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 1001. A nucleic acid molecule according to embodiment 987, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 99% sequence identity with the nucleic acid sequence of any one of SEQ ID NOs: 159-305, or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 1002. The nucleic acid molecule of Example 987, wherein the nucleic acid molecule comprises a nucleotide sequence of any one of SEQ ID NOs: 159-305 or a fragment thereof (e.g., a fragment encoding VP1, VP2, or VP3). 1003. The nucleic acid molecule of any one of embodiments 987 to 1002, wherein the nucleic acid molecule comprises the nucleotide sequence of any one of SEQ ID NOs: 159-305. 1004. The nucleic acid molecule of any one of embodiments 987 to 1002, wherein the nucleic acid molecule comprises a fragment encoding a VP2 capsid polypeptide of the nucleotide sequence of any one of SEQ ID NOs: 159-305. 1005. The nucleic acid molecule of any one of embodiments 987 to 1002, wherein the nucleic acid molecule comprises a fragment encoding a VP3 capsid polypeptide of the nucleotide sequence of any one of SEQ ID NOs: 159-305. 1006. A nucleic acid molecule according to any one of embodiments 987 to 1005, wherein the nucleic acid molecule is double-stranded or single-stranded, and wherein the nucleic acid molecule is linear or circular, for example wherein the nucleic acid molecule is a plasmid. 1007. A viral particle (e.g., an adeno-associated virus ("AAV") particle) comprising a capsid polypeptide according to any one of Examples 1 to 986 or a capsid polypeptide encoded by a nucleic acid molecule according to any one of Examples 987 to 1006. 1008. The viral particle of Example 1007 comprises a nucleic acid containing a payload (e.g., a heterologous transgene) and one or more regulatory elements. 1009. The viral particle of embodiment 1008, wherein the one or more regulatory elements comprise a promoter. 1010. The viral particle of Example 1009, wherein the promoter is a persistent promoter. 1011. The viral particle of Example 1010, wherein the promoter is a CBh promoter. 1012. The viral particle of Example 1011, wherein the CBh promoter comprises a nucleotide sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 306. 1013. The viral particle of Example 1009, wherein the promoter is a CNS-specific promoter. 1014. The viral particle of Example 1013, wherein the promoter is the hSYN promoter. 1015. The viral particle of Example 1014, wherein the hSYN promoter comprises a nucleotide sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 307. 1016. The viral particle of Example 1009, wherein the promoter is a muscle-specific promoter. 1017. The viral particle of Example 1016, wherein the muscle-specific promoter is a skeletal muscle-specific promoter. 1018. The viral particle of any one of Examples 1007 to 1017, wherein the viral particle is as shown in Section 6. 4, wherein, relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), the one or more features comprise: (a) an improvement in Class A (CNS biodistribution), such as described in any one of Examples A1 to A3; (b) an improvement in Class B (CNS transduction), such as described in any one of Examples B1 to B3; (c) an improvement in Class C (PNS biodistribution and/or transduction), such as described in any one of Examples C1 to C3; (d) an improvement in Class D (liver biodistribution and/or transduction), such as described in any one of Examples D1 to D3; (e) an improvement in Class E (liver biodistribution and/or transduction). (i) improvements in Class A (CNS biodistribution), such as those described in any one of Examples A1 to A3; (ii) improvements in Class B (CNS transduction), such as those described in any one of Examples B1 to B3; (iii) improvements in Class C (CNS biodistribution), such as those described in any one of Examples B1 to B3; (iv) improvements in Class D (liver biodistribution and/or transduction), for example, as described in any one of Examples C1 to C3; (v) improvements in Class E (spleen biodistribution and/or transduction), for example, as described in any one of Examples E1 to E3; (vi) improvements in Class F (skeletal muscle biodistribution), for example, as described in any one of Examples F1 to F3; and (vii) improvements in Class G (skeletal muscle transduction), for example, as described in any one of Examples G1 to G3. 1019. The viral particles of Example 1018 exhibit increased central nervous system (CNS) biodistribution relative to wild-type AAV9 (e.g., viral particles comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., in a mammal (e.g., in a mouse or in an NHP), e.g., as measured as described herein, wherein: (a) the increase in CNS biodistribution is 6. 4; (b) the viral particle has the characteristics as defined in any one of Examples A1 to A3; (c) the CNS biodistribution is increased using Section 6. 4; (d) exhibits increased CNS biodistribution following systemic (e.g., intravenous) administration of the viral particles; or (e) any combination of two or more, three or more, or all four of (a) to (d). 1020. The viral particle of any one of embodiments 1007 to 1018, wherein the viral particle exhibits increased brain biodistribution relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, optionally wherein the increased brain biodistribution (a) is as described in Section 6. 4, for example as described in any one of Examples A1 to A3 and/or (b) using Section 6. Measured using the method described in 4. 1021. The viral particle of embodiment 1020, wherein the viral particle exhibits increased brain biodistribution after systemic (e.g., intravenous) administration. 1022. The viral particle of embodiment 1020 or embodiment 1021, wherein the viral particle exhibits a brain biodistribution that is at least five times greater than the brain biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1023. The viral particle of embodiment 1020 or embodiment 1021, wherein the viral particle exhibits a brain biodistribution that is at least 10 times greater than the brain biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1024. The viral particle of embodiment 1020 or embodiment 1021, wherein the viral particle exhibits a brain biodistribution that is at least 20 times greater than the brain biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1025. The viral particle of embodiment 1020 or embodiment 1021, wherein the viral particle exhibits a brain biodistribution that is at least 30 times greater than the brain biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1026. The viral particle of embodiment 1020 or embodiment 1021, wherein the viral particle exhibits a brain biodistribution that is at least 40 times greater than the brain biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1027. The viral particle of any one of embodiments 1007 to 1026, wherein the viral particle exhibits reduced peripheral nervous system ("PNS") (e.g., dorsal root ganglion (DRG)) biodistribution relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., in a mammal (e.g., in a mouse or in an NHP), e.g., as measured as described herein, optionally wherein the reduced PNS (e.g., DRG) biodistribution (a) is as described in Section 6. 4, for example as described in any one of Examples C1 to C3 and/or (b) using Section 6. Measured using the method described in 4. 1028. The viral particle of Example 1027, wherein the viral particle exhibits reduced DRG biodistribution after systemic (e.g., intravenous) administration. 1029. The viral particle of Example 1027 or Example 1028, wherein the viral particle exhibits a DRG biodistribution that is less than 1-fold greater than the DRG biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1030. The viral particle of Example 1027 or Example 1028, wherein the DRG biodistribution exhibited by the viral particle is less than 0. 9 times. 1031. The viral particle of Example 1027 or Example 1028, wherein the DRG biodistribution exhibited by the viral particle is less than 0. 8 times. 1032. The viral particle of Example 1027 or Example 1028, wherein the DRG biodistribution exhibited by the viral particle is less than 0. 7 times. 1033. The viral particle of Example 1027 or Example 1028, wherein the DRG biodistribution exhibited by the viral particle is less than 0. 6 times. 1034. The viral particle of Example 1027 or Example 1028, wherein the DRG biodistribution exhibited by the viral particle is less than 0. 5 times. 1035. The viral particle of any one of embodiments 1027 to 1034, wherein the viral particle exhibits a DRG biodistribution that is at least 0.1% of the DRG biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 4 times. 1036. The viral particle of any one of embodiments 1027 to 1033, wherein the viral particle exhibits a DRG biodistribution that is at least 0.1% of the DRG biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 5 times. 1037. The viral particle of any one of embodiments 1027 to 1032, wherein the viral particle exhibits a DRG biodistribution that is at least 0.1% of the DRG biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 6 times. 1038. The viral particle of any one of embodiments 1027 to 1031, wherein the viral particle exhibits a DRG biodistribution that is at least 0.1% of the DRG biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 9 times. 1039. The viral particle of any one of embodiments 1007 to 1034, wherein the viral particle exhibits reduced liver biodistribution relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, optionally wherein the reduced liver biodistribution (a) is as described in Section 6. 4, for example as described in any one of Examples D1 to D3 and/or (b) using Section 6. Measured using the method described in 4. 1040. The viral particle of Example 1039, wherein the viral particle exhibits reduced liver biodistribution after systemic (e.g., intravenous) administration. 1041. The viral particle of Example 1039 or Example 1040, wherein the viral particle exhibits a liver biodistribution that is less than 1-fold greater than the liver biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1042. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 9 times. 1043. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 8 times. 1044. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 7 times. 1045. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 6 times. 1046. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 5 times. 1047. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 4 times. 1048. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 3 times. 1049. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 2 times. 1050. The viral particle of Example 1039 or Example 1040, wherein the liver biodistribution exhibited by the viral particle is less than 0. 1x. 1051. The viral particle of any one of embodiments 1039 to 1050, wherein the viral particle exhibits a liver biodistribution that is at least 0.1% of the liver biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 05 times. 1052. The viral particle of any one of embodiments 1039 to 1050, wherein the viral particle exhibits a liver biodistribution that is at least 0.1% of the liver biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 06 times. 1053. The viral particle of any one of embodiments 1039 to 1050, wherein the viral particle exhibits a liver biodistribution that is at least 0.1% of the liver biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 07 times. 1054. The viral particle of any one of embodiments 1039 to 1050, wherein the viral particle exhibits a liver biodistribution that is at least 0.1% of the liver biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 08 times. 1055. The viral particle of any one of embodiments 1039 to 1050, wherein the viral particle exhibits a liver biodistribution that is at least 0.1% of the liver biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 09 times. 1056. The viral particle of any one of embodiments 1039 to 1049, wherein the viral particle exhibits a liver biodistribution that is at least 0.1% of the liver biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1x. 1057. The viral particle of any one of embodiments 1039 to 1048, wherein the viral particle exhibits a liver biodistribution that is at least 0.1% of the liver biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 2 times. 1058. The viral particle of any one of embodiments 1039 to 1047, wherein the viral particle exhibits a liver biodistribution that is at least 0.1% of the liver biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 3 times. 1059. The viral particle of any one of embodiments 1007 to 1058, wherein the viral particle exhibits reduced spleen biodistribution relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, optionally wherein the reduced spleen biodistribution (a) is as described in Section 6. 4, for example as described in any one of Examples E1 to E3 and/or (b) using Section 6. Measured using the method described in 4. 1060. The viral particle of Example 1059, wherein the viral particle exhibits reduced spleen biodistribution after systemic (e.g., intravenous) administration. 1061. The viral particle of Example 1059 or Example 1060, wherein the viral particle exhibits a spleen biodistribution that is less than 1-fold that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1062. The viral particle of Example 1059 or Example 1060, wherein the spleen biodistribution exhibited by the viral particle is less than 0. 9 times. 1063. The viral particle of Example 1059 or Example 1060, wherein the spleen biodistribution exhibited by the viral particle is less than 0. 8 times. 1064. The viral particle of Example 1059 or Example 1060, wherein the spleen biodistribution exhibited by the viral particle is less than 0. 7 times. 1065. The viral particle of Example 1059 or Example 1060, wherein the spleen biodistribution exhibited by the viral particle is less than 0. 6 times. 1066. The viral particle of Example 1059 or Example 1060, wherein the spleen biodistribution exhibited by the viral particle is less than 0. 5 times. 1067. The viral particle of Example 1059 or Example 1060, wherein the spleen biodistribution exhibited by the viral particle is less than 0. 4 times. 1068. The viral particle of Example 1059 or Example 1060, wherein the spleen biodistribution exhibited by the viral particle is less than 0. 3 times. 1069. The viral particle of any one of embodiments 1059 to 1068, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 01 times. 1070. The viral particle of any one of embodiments 1059 to 1068, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 015 times. 1071. The viral particle of any one of embodiments 1059 to 1068, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 02 times. 1072. The viral particle of any one of embodiments 1059 to 1068, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 05 times. 1073. The viral particle of any one of embodiments 1059 to 1068, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 07 times. 1074. The viral particle of any one of embodiments 1059 to 1068, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 09 times. 1075. The viral particle of any one of embodiments 1059 to 1068, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1x. 1076. The viral particle of any one of embodiments 1059 to 1068, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 2 times. 1077. The viral particle of any one of embodiments 1059 to 1067, wherein the viral particle exhibits a spleen biodistribution that is at least 0.1% of the spleen biodistribution of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 3 times. 1078. The viral particle of any one of embodiments 1007 to 1077, wherein the viral particle exhibits increased CNS transduction relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, optionally wherein the increased CNS transduction (a) is as described in Section 6. 4, for example as described in any one of Examples B1 to B3 and/or (b) using Section 6. Measured using the method described in 4. 1079. The viral particle of any one of embodiments 1007 to 1078, wherein the viral particle exhibits increased brain transduction relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, optionally wherein the increased brain transduction (a) is as described in Section 6. 4, for example as described in any one of Examples A1 to A3 and/or (b) using Section 6. Measured using the method described in 4. 1080. The viral particle of Example 1079, wherein the viral particle exhibits increased brain transduction after systemic (e.g., intravenous) administration. 1081. The viral particle of Example 1079 or Example 1080, wherein the viral particle exhibits brain transduction that is at least twice that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1082. The viral particle of Example 1079 or Example 1080, wherein the viral particle exhibits brain transduction that is at least 4 times greater than that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1083. The viral particle of Example 1079 or Example 1080, wherein the viral particle exhibits brain transduction that is at least 10 times greater than that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1084. The viral particle of Example 1079 or Example 1080, wherein the viral particle exhibits brain transduction that is at least 20 times greater than that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1085. The viral particle of Example 1079 or Example 1080, wherein the viral particle exhibits brain transduction that is at least 25 times greater than that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1086. The viral particle of any one of embodiments 1079 to 1084, wherein the viral particle exhibits brain transduction that is at most 40 times greater than that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1087. The viral particle of any one of embodiments 1079 to 1084, wherein the viral particle exhibits brain transduction that is at most 50 times greater than that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1088. The viral particle of any one of embodiments 1007 to 1087, wherein the viral particle exhibits reduced DRG transduction relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, wherein the reduced PNS (e.g., reduced DRG) transduction (a) is as described in Section 6. 4, for example as described in any one of Examples C1 to C3 and/or (b) using Section 6. Measured using the method described in 4. 1089. The viral particle of Example 1088, wherein the viral particle exhibits reduced DRG transduction after systemic (e.g., intravenous) administration. 1090. The viral particle of Example 1088 or Example 1089, wherein the viral particle exhibits DRG transduction that is less than 1-fold that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1091. The viral particle of Example 1088 or Example 1089, wherein the DRG transduction exhibited by the viral particle is less than 0. 1x. 1092. The viral particle of Example 1088 or Example 1089, wherein the DRG transduction exhibited by the viral particle is less than 0. 05 times. 1093. The viral particle of Example 1088 or Example 1089, wherein the DRG transduction exhibited by the viral particle is less than 0. 03 times. 1094. The viral particle of Example 1088 or Example 1089, wherein the DRG transduction exhibited by the viral particle is less than 0. 02 times. 1095. The viral particle of any one of embodiments 1088 to 1094, wherein the DRG transduction exhibited by the viral particle is at least 0.1% of the DRG transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 01 times. 1096. The viral particle of any one of embodiments 1088 to 1094, wherein the DRG transduction exhibited by the viral particle is at least 0.1% of the DRG transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 015 times. 1097. The viral particle of any one of embodiments 1088 to 1094, wherein the DRG transduction exhibited by the viral particle is at least 0.1% of the DRG transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 016 times. 1098. The viral particle of any one of embodiments 1007 to 1097, wherein the viral particle exhibits reduced liver transduction relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, optionally wherein the reduced liver transduction (a) is as described in Section 6. 4, for example as described in any one of Examples D1 to D3 and/or (b) using Section 6. Measured using the method described in 4. 1099. The viral particle of Example 1098, wherein the viral particle exhibits reduced liver transduction after systemic (e.g., intravenous) administration. 1100. The viral particle of Example 1098 or Example 1099, wherein the liver transduction rate exhibited by the viral particle is less than 1-fold that of the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1101. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 9 times. 1102. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 8 times. 1103. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 7 times. 1104. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 6 times. 1105. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 5 times. 1106. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 4 times. 1107. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 3 times. 1108. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 2 times. 1109. The viral particle of Example 1098 or Example 1099, wherein the liver transduction exhibited by the viral particle is less than 0. 1x. 1110. The viral particle of any one of embodiments 1098 to 1109, wherein the liver transduction exhibited by the viral particle is at least 0.1% of the liver transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 01 times. 1111. The viral particle of any one of embodiments 1098 to 1109, wherein the liver transduction exhibited by the viral particle is at least 0.1% of the liver transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 03 times. 1112. The viral particle of any one of embodiments 1098 to 1109, wherein the liver transduction exhibited by the viral particle is at least 0.1% of the liver transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 05 times. 1113. The viral particle of any one of embodiments 1098 to 1108, wherein the liver transduction exhibited by the viral particle is at least 0.1% of the liver transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1x. 1114. The viral particle of any one of embodiments 1098 to 1107, wherein the liver transduction exhibited by the viral particle is at least 0.1% of the liver transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 2 times. 1115. The viral particle of any one of embodiments 1098 to 1106, wherein the liver transduction exhibited by the viral particle is at least 0.1% of the liver transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 3 times. 1116. The viral particle of any one of embodiments 1098 to 1104, wherein the liver transduction exhibited by the viral particle is at least 0.1% of the liver transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 5 times. 1117. The viral particle of any one of embodiments 1098 to 1102, wherein the liver transduction exhibited by the viral particle is at least 0.1% of the liver transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 7 times. 1118. The viral particle of any one of embodiments 1007 to 1117, wherein the viral particle exhibits reduced spleen transduction relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, optionally wherein the reduced spleen transduction (a) is as described in Section 6. 4, for example as described in any one of Examples E1 to E3 and/or (b) using Section 6. Measured using the method described in 4. 1119. The viral particle of Example 1118, wherein the viral particle exhibits reduced spleen transduction after systemic (e.g., intravenous) administration. 1120. The viral particle of Example 1118 or Example 1119, wherein the viral particle exhibits spleen transduction that is less than 1-fold that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1121. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 9 times. 1122. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 8 times. 1123. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 7 times. 1124. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 6 times. 1125. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 5 times. 1126. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 4 times. 1127. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 3 times. 1128. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 2 times. 1129. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 1x. 1130. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 05 times. 1131. The viral particles of Example 1118 or Example 1119, wherein the spleen transduction exhibited by the viral particles is less than 0. 02 times. 1132. The viral particle of any one of embodiments 1118 to 1131, wherein the spleen transduction exhibited by the viral particle is at least 0.1% of the spleen transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 01 times. 1133. The viral particle of any one of embodiments 1118 to 1130, wherein the spleen transduction exhibited by the viral particle is at least 0.1% of the spleen transduction exhibited by the viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 02 times. 1134. The viral particle of any one of embodiments 1007 to 1133, wherein the viral particle exhibits a production efficiency (e.g., as described herein) that is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 1x. 1135. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 05 times. 1136. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 1x. 1137. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 2 times. 1138. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 3 times. 1139. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 4 times. 1140. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 5 times. 1141. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 6 times. 1142. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 7 times. 1143. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 8 times. 1144. The viral particles of Example 1134, wherein the production efficiency of the viral particles is at least 0.1% of the production efficiency of wild-type AAV9 (e.g., viral particles comprising the capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 9 times. 1145. The viral particle of any one of Examples 1134 to 1144, wherein the production efficiency of the viral particle is at most 1-fold the production efficiency of wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2). 1146. The viral particle of any one of embodiments 1007 to 1145, wherein the viral particle exhibits increased skeletal muscle biodistribution relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, wherein the increased muscle biodistribution (a) is as described in Section 6. 4, for example as described in any one of Examples F1 to F3 and/or (b) using Section 6. Measured using the method described in 4. 1147. The viral particles of Example 1146 exhibit increased skeletal muscle biodistribution after systemic (e.g., intravenous) administration of the viral particles. 1148. The viral particle of Example 1146 or Example 1147, wherein the skeletal muscle biodistribution exhibited by the viral particle is at least 1. 5 times. 1149. The viral particle of Example 1148, wherein the viral particle exhibits a skeletal muscle biodistribution that is at least twice that of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1150. The viral particle of Example 1148, wherein the viral particle exhibits a skeletal muscle biodistribution that is at least three times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1151. The viral particle of Example 1148, wherein the viral particle exhibits a skeletal muscle biodistribution that is at least four times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1152. The viral particle of Example 1148, wherein the viral particle exhibits a skeletal muscle biodistribution that is at least 5 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1, optionally wherein the skeletal muscle biodistribution is: (a) at least 6 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1; (b) at least 7 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1; (c) at least 8 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1; (d) at least 9 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1; (e) at least 10 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1; (f) at least 11 times the skeletal muscle biodistribution of a virus particle comprising the capsid polypeptide of SEQ ID NO:1; (g) at least 12 times the skeletal muscle biodistribution of a virus particle comprising the capsid polypeptide of SEQ ID NO:1; (h) at least 13 times the skeletal muscle biodistribution of a virus particle comprising the capsid polypeptide of SEQ ID NO:1; (i) at least 14 times the skeletal muscle biodistribution of a virus particle comprising the capsid polypeptide of SEQ ID NO:1. 1153. The viral particle of Example 1148 or Example 1152, wherein the skeletal muscle biodistribution exhibited by the viral particle is 1. 5x to 14x. 1154. The viral particle of Example 1148, wherein the viral particle exhibits skeletal muscle biodistribution that is 2 to 14 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1155. The viral particle of Example 1148, wherein the viral particle exhibits skeletal muscle biodistribution that is 3 to 14 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1156. The viral particle of Example 1148, wherein the viral particle exhibits skeletal muscle biodistribution that is 5 to 14 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1157. The viral particle of Example 1148, wherein the viral particle exhibits skeletal muscle biodistribution that is 8 to 14 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1158. The viral particle of Example 1148, wherein the viral particle exhibits skeletal muscle biodistribution that is 10 to 14 times greater than the skeletal muscle biodistribution of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1159. The viral particle of any one of embodiments 1007 to 1158, wherein the viral particle exhibits increased skeletal muscle transduction relative to wild-type AAV9 (e.g., a viral particle comprising a capsid polypeptide encoded by SEQ ID NO: 1 or SEQ ID NO: 2), e.g., measured in a mammal (e.g., in a mouse or in an NHP), e.g., as described herein, optionally wherein the increased muscle transduction (a) is as described in Section 6. 4, for example as described in any one of Examples G1 to G3 and/or (b) using Section 6. Measured using the method described in 4. 1160. The viral particle of Example 1159, wherein the viral particle exhibits increased skeletal muscle transduction after systemic (e.g., intravenous) administration. 1161. The viral particle of Example 1159 or Example 1160, wherein the skeletal muscle transduction exhibited by the viral particle is at least 1. 5 times. 1162. The viral particle of Example 1161, wherein the viral particle exhibits skeletal muscle transduction that is at least twice as high as the skeletal muscle transduction of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1163. The viral particle of Example 1161, wherein the viral particle exhibits skeletal muscle transduction that is at least three times greater than the skeletal muscle transduction of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1164. The viral particle of Example 1161, wherein the viral particle exhibits skeletal muscle transduction that is at least 4 times greater than the skeletal muscle transduction of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. 1165. The viral particle of Example 1166, wherein the skeletal muscle transduction exhibited by the viral particle is 1. 5x to 5x. 1166. A method for producing viral particles comprising a capsid polypeptide, the method comprising introducing a nucleic acid molecule according to any one of Examples 987 to 1006 into cells (e.g., HEK293 cells) and collecting the viral particles therefrom. 1167. A method for delivering a payload (e.g., a nucleic acid) to a cell, the method comprising contacting the cell with a viral particle comprising a capsid polypeptide according to any one of Examples 1 to 986 and the payload, or contacting the cell with a viral particle according to any one of Examples 1007 to 1165. 1168. The method of embodiment 1167, wherein the cell is a CNS cell. 1169. The method of embodiment 1168, wherein the CNS cell is a neuron, a neural glial cell, an astrocyte, an oligodendrocyte, an endothelial cell, or any combination thereof. 1170. The method of Example 1167, wherein the cell is a skeletal muscle cell. 1171. A method for delivering a payload (e.g., a nucleic acid) to a subject, the method comprising administering to the subject a viral particle comprising a capsid polypeptide according to any one of Examples 1 to 986 and a payload, or administering to the subject a viral particle according to any one of Examples 1007 to 1165. 1172. The method of embodiment 1171, wherein the viral particle delivers the payload to the CNS. 1173. The method of embodiment 1171 or embodiment 1172, wherein the viral particle delivers the payload to skeletal muscle. 1174. The capsid polypeptide of any one of Examples 1 to 986, the viral particle of any one of Examples 1007 to 1165, or the method of any one of Examples 1166 to 1172, wherein the viral particle (e.g., a viral particle comprising the capsid polypeptide) delivers the payload to the CNS with: (a) increased biodistribution and/or transduction, e.g., biodistribution and/or transduction compared to a viral particle comprising the capsid polypeptide of SEQ ID NO: 1, optionally wherein the biodistribution is at least 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, or greater than the biodistribution and/or transduction of a viral particle comprising the capsid polypeptide of SEQ ID NO: 1; and optionally (b) increased biodistribution and/or transduction compared to a viral particle comprising the capsid polypeptide of SEQ ID NO: 1. Reduced liver, spleen, or DRG (or any combination of two or all three of the liver, spleen, and DRG) biodistribution of viral particles comprising the capsid polypeptide of SEQ ID NO:1, optionally wherein the biodistribution in the liver, spleen, or DRG is each independently selected from: (i) less than 1-fold, (ii) 0. 95 times or less, (iii) 0. 9 times or less, (iv) 0. 8 times or less; or (v) 0. 7 times or less. 1175. The capsid polypeptide, viral particle, or method of embodiment 1174, wherein the one or more CNS cells are selected from neurons, neural glial cells, astrocytes, oligodendrocytes, endothelial cells, or any combination thereof. 1176. A method for treating a disease or condition in a subject, the method comprising administering to the subject: (a) a viral particle: (i) comprising a capsid polypeptide according to any one of Examples 1 to 986 and a heterologous nucleic acid sequence encoding a therapeutic product suitable for treating the disease or condition; (ii) comprising a capsid polypeptide encoded by a nucleic acid molecule according to any one of Examples 987 to 1006 and a heterologous nucleic acid sequence encoding a therapeutic product suitable for treating the disease or condition; or (iii) a viral particle according to any one of Examples 1007 to 1165; or (b) a composition, such as a pharmaceutical composition, comprising the viral particle according to (a) and, optionally, a pharmaceutically acceptable carrier. 1177. The method of embodiment 1176, wherein the disease or condition is a disease or condition of the CNS. 1178. The method of embodiment 1177, wherein the disease or condition is selected from the group consisting of absent septum pellucidum, acid lipase disease, acid maltase deficiency, acquired epileptic aphasia, acute disseminated encephalomyelitis, attention deficit hyperactivity disorder (ADHD), Addison's pupil, Addison's syndrome, adrenoleukodystrophy, agenesis of the corpus callosum, agnosia, Acardi syndrome, Acardi-Guterres syndrome, AIDS neurological complications Alper's disease, Alexander's disease, Alpers' disease, alternating hemiplegia, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), anencephaly, aneurysm, Angelman syndrome, angiomatosis, Angelman syndrome, hypoxia, antiphospholipid syndrome, aphasia, psychokinetic ataxia, arachnoid cyst, arachnoid meningitis, Arnold-Chiari malformation, arteriovenous malformation, Asperger's syndrome, ataxia, ataxia telangiectasia Atonia and cerebellar or spinocerebellar degeneration, atrial fibrillation and stroke, attention deficit hyperactivity disorder, autism spectrum disorder, autonomic dysfunction, back pain, Babinski syndrome, Batten disease, Beck's myotonia, Behçet's disease, Berg's palsy, benign idiopathic eyelid spasm, benign focal muscular atrophy, benign intracranial hypertension, Bernhardt-Ross syndrome, Bevacizumab disease, eyelid spasm, Bloch-Sulzberg syndrome, brachial nerve plexus Birth injury, brachial nerve plexus injury, Bradbury-Eggleston syndrome, brain and spinal tumors (including but not limited to those that have metastasized to the brain, such as metastatic breast cancer), brain arterial tumors, brain injury, Brown-Strauss syndrome, bulbar palsy, bulbar muscular dystrophy, bulbar muscular dystrophy, cerebral somatic autosomal dominant arteriovenous artery disease with subcortical infarcts and leukoencephalopathy (CADASIL), Canavan disease, carpal tunnel syndrome, causalgia, Spongiomatous angioma, spongiomatous angioma, spongiomatous malformation, central cervical cord syndrome, central spinal cord syndrome, central pain syndrome, central pontine myelolysis, head disease, neuramidase deficiency, cerebellar degeneration, cerebellar hypoplasia, cerebral arteriovenous aneurysm, cerebral arteriosclerosis, brain atrophy, cerebral beriberi, spongiomatous malformation, cerebral gigantism, cerebral hypoxia, cerebral palsy, encephal-oculofacial-skeletal syndrome (COFS), Chuck-Marie- Duchenne disease, Chiari malformation, cholesterol storage disease, chorea, choreoacanthocytosis, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic orthostatic intolerance, chronic pain, Cockayne syndrome type II, Crohn's disease, syringomyelia, coma, complex regional pain syndrome, concentric sclerosis (Barlow's sclerosis), congenital bilateral facial paralysis, congenital myasthenia, congenital myopathy, congenital vascular cavernosal malformation craniofacial degeneration, craniosynostosis, craniosynostosis, Creutzfeldt-Jakob disease, chronic progressive external ophthalmoplegia, cumulative trauma syndrome, Cushing's syndrome, giant cell inclusion disease, giant cell virus infection, dancing eyes and feet syndrome, Dandy-Walker syndrome, Dawson's disease, Demersier syndrome, Djerin-Krompa palsy, dementia, multi-infarct dementia, semantic dementia, subcortical dementia , Lewy body dementia, demyelination disease, odontocerebellar ataxia, odontorubral atrophy, dermatomyositis, developmental dyspraxia, Deweker's syndrome, diabetic neuropathy, diffuse sclerosis, distal hereditary motor neuron disease, Dravet syndrome, autonomic nervous system disorders, dysgraphia, dyslexia, dysphagia, dyspraxia, myoclonic cerebellar coordination disorder, progressive cerebellar coordination disorder, dystonia, early infantile epileptic encephalopathy, Encephalitis, encephalitis lethargica, encephalocele, encephalomyelitis, encephalopathy, encephalopathy (familial infantile form), encephalotrigeminal angiomatosis, epilepsy, epileptic hemiplegia, intermittent ataxia, Elb's palsy, Elb-Duchenne and Dejerin-Kromke palsy, essential tremor, extrapontine myelinolysis, Farber's disease, Fabry disease, Farr's syndrome, syncope, familial autonomic nervous system disorders, familial hemangioma, familial Idiopathic basal ganglia calcification, familial periodic palsy, familial spastic paralysis, Farber disease, febrile seizures, fibromuscular dysplasia, Fisher syndrome, floppy infant syndrome, foot drop, fragile X disease, Friedreich ataxia, frontotemporal dementia, Gaucher disease, systemic gangliosidosis (GM1, GM2), Gerstmann-Stausler-Scheinker disease, giant axonal neuropathy degeneration, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, glossopharyngeal neuralgia, glycogen storage disease, Guillain-Barré syndrome, Holloway-Spatz disease, head injury, headache, hemifacial pain, hemifacial spasticity, alternating hemiparesis, hereditary neuropathy, hereditary spastic posterior limb palsy, polyneuritis-type hereditary ataxia, herpes zoster, herpes zoster oticus, Hirayama syndrome, Hodgkin-Ellison syndrome, Holoprosencephaly, HTLV-1-associated myelopathy, Hughes syndrome, Huntington's disease, Hearst syndrome, hydrocephalus, hydrocephalus, normal pressure hydrocephalus, hydromyelia, hypercortisolism, lethargy, hypertonia, hypotonia, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile hypotonia, infantile axonal dystrophy, infantile phytanic acid storage disease, infantile Refsum's disease, infantile spasticity, inflammation Myopathy, occipital exencephaly, intestinal lipid malnutrition, intracranial cysts, intracranial hypertension, Issacs syndrome, Joubert syndrome, Karns-Sayre syndrome, Kennedy disease, Kingsbrinner syndrome, Klein-Levine syndrome, Klein-Feigen syndrome, Klippel-Trenlaunay syndrome (KTS), Krul-Bucy syndrome, Korsakoff amnesia, Krabbe disease, Kugelberg-Wiland disease , kuru, Lambert-Eaton myasthenia syndrome, Landau-Klevner syndrome, collateral femoral cutaneous nerve entrapment, collateral medullary syndrome, learning disabilities, Lewy's disease, Lennox-Castos syndrome, Reich-Nyhen syndrome, leukodystrophy, Levine-Critchley syndrome, Lewy body dementia, Lischteheim's disease, lipid storage disease, lipoproteinemia, flat brain syndrome, locked-in syndrome, Lou Gehrig's disease, lupus erythematosus Heredity, Lyme disease-neurocomplications, lysosomal storage disease, Machado-Joseph disease, megalencephaly, megalencephaly, Mayer-Röhm syndrome, meningitis, meningitis and encephalitis, Menkes disease, melatonin, metachromatic leukodystrophy, microcephaly, migraines, Miller Fisher syndrome, mini-stroke, mitochondrial myopathy, mitochondrial DNA deletion syndrome, Moebius syndrome, monomelic muscular dystrophy, Molvan syndrome, motor neuron disease, smoke poisoning aerosol disease, mucolipidosis, mucopolysaccharidosis, multi-infarct dementia, multifocal motor neuropathy, multiple sclerosis, multisystem atrophy, multisystem atrophy with orthostatic hypotension, muscular dystrophy, myasthenia gravis, diffuse myelin-destructive sclerosis, myelitis, myositis cerebral infancy, myoclonic claudication, myoclonic seizures, myopathy, congenital myopathy, thyrotoxic myopathy, myotonia, myotonia congenita, narcolepsy, NARP (neuropathy, ataxia, and retinitis pigmentosa), neuroacanthocytosis, neuropathy with cerebral iron accumulation, neurodegenerative diseases, neurofibroma, neuroleptic malignancy, neurologic complications of AIDS, neurologic complications of Lyme disease, neurologic consequences of cytomegalovirus infection, neurologic manifestations of Pompe disease, neurologic sequelae of lupus, neuromyelitis optica, neuromyotonia, neurogenic cerebral lipofuscinosis, neuronal migration disorders, neuropathic pain, hereditary neuropathy, neuropathy , neurosarcoidosis, neurosyphilis, neurotoxicity, cavernous nevus, Niemann-Pick disease, O'Sullivan-McCrawl syndrome, occipital neuralgia, Ohtawara syndrome, olivopontine-cerebellar atrophy, strabismus, orthostatic hypotension, overuse syndrome, chronic pain, pantothenate kinase-related neuropathy, paraneoplastic syndrome, paresthesia, Parkinson's disease, choreoathetosis, hemiphagia, Parry-Lomborg disease, Pelitzowitz-Merzbacher disease, Pena-Schucker II syndrome, neuro Perimetrial cyst, Charcot-Marie-Tooth atrophy, periodic palsy, peripheral neuropathy, periventricular leukomalacia, persistent vegetative state, generalized developmental disability, Phelan-McCedar-Mead syndrome, phytanic acid storage disease, Pick's disease, nerve compression, piriformis syndrome, pituitary tumor, polymyositis, Pompe disease, cerebral perforation, post-poliomyelitis, postherpetic neuralgia, postinfectious encephalomyelitis, postural hypotension, postural orthostatic tachycardia syndrome, postural tachycardia syndrome, primary odontoid artery disease, primary hemiplegia sclerosis, primary progressive aphasia, prion disease, progressive bulbar palsy, progressive hemifacial atrophy, progressive ataxia, progressive multifocal leukoencephalopathy, progressive muscular atrophy, progressive sclerotic gray matter dystrophy, progressive supranuclear neuropathy, prosopagnosia, pseudobulbar palsy, pseudo-Torch syndrome, pseudo-toxoplasmosis, pseudotumor cerebri, psychogenic movement, Ramsey-Hunt syndrome I, Ramsey-Hunt syndrome II, Lamarck's encephalitis, reflex sympathetic dystrophy, Ralph's disease Sum's disease, infantile Refsume's disease, repetitive movement disorder, repetitive stress injury, restless legs syndrome, retrovirus-associated myelopathy, Rett syndrome, Reye's syndrome, rheumatic encephalitis, Reye-Dieter syndrome, sacral radiculocyst, St. Vitus' chorea, salivary gland disease, Sandhoff's disease, Sheldon's disease, schizencephaly, Setelberg's disease, epilepsy, semantic dementia, septal optic dysplasia, severe myotonic epilepsy of infancy (SMEI), shaken baby syndrome, herpes zoster, Shy-Dergren syndrome, Sjogren's syndrome, sleep apnea, sleeping sickness, Soto's syndrome, spasticity, spina bifida, spinal cord infarction, spinal cord injury, spinal cord tumor, spinal muscular atrophy, spinocerebellar ataxia, spinocerebellar atrophy, spinocerebellar degeneration, sporadic ataxia, Still-Richard-Olszewski syndrome, stiff-person syndrome, substantia nigra, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, short-lasting unilateral neuralgia (S UNCT) Headache, dysphagia, Sydenham's chorea, syncope, syphilitic spondylosclerosis, syringomyelia, syringomyelia, systemic lupus erythematosus, myeloma, delayed akinesia, Tarlov cyst, Tay-Sachs disease, temporal artery inflammation, thromboembolic syndrome, Thomson's myotonia, thoracic outlet syndrome, thyrotoxic myopathy, trigeminal neuralgia, Todd's palsy, Tourette syndrome, transient ischemic attack, infectious spongiform encephalopathy, transverse myelitis, traumatic brain injury, tremors, trigeminal Neuropathy, tropical spastic paraplegia, Troyer syndrome, tuberous sclerosis, angioedema, vasculitis of the central and peripheral nervous systems, vitamin B12 deficiency, von Eichner disease, Van Hippel-Lindau disease (VHL), von Recklinghausen disease, Wallenberg syndrome, Wildenig-Hoffmann disease, Wernicke-Korsakoff syndrome, Wester syndrome, cervical spondylosis, Whipple disease, Williams syndrome, Wilson disease, Wollman disease, and X-linked spinal or bulbar muscular atrophy. 1179. The method of embodiment 1177, wherein the disease or condition is acid lipase disease. 1180. The method of embodiment 1177, wherein the disease or condition is acid maltase deficiency. 1181. The method of embodiment 1177, wherein the disease or condition is acquired epileptic aphasia. 1182. The method of embodiment 1177, wherein the disease or condition is acute disseminated encephalomyelitis. 1183. The method of embodiment 1177, wherein the disease or condition is attention deficit hyperactivity disorder (ADHD). 1184. The method of embodiment 1177, wherein the disease or condition is Addison's pupil. 1185. The method of embodiment 1177, wherein the disease or condition is Addison's syndrome. 1186. The method of embodiment 1177, wherein the disease or condition is adrenoleukodystrophy. 1187. The method of embodiment 1177, wherein the disease or condition is agenesis of the corpus callosum. 1188. The method of embodiment 1177, wherein the disease or condition is agnosia. 1189. The method of embodiment 1177, wherein the disease or condition is Icardi syndrome. 1190. The method of embodiment 1177, wherein the disease or condition is Icardi-Guterres syndrome. 1191. The method of embodiment 1177, wherein the disease or condition is AIDS neurological complications. 1192. The method of embodiment 1177, wherein the disease or condition is Alexander's disease. 1193. The method of embodiment 1177, wherein the disease or condition is Alpers disease. 1194. The method of embodiment 1177, wherein the disease or condition is alternating hemiplegia. 1195. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease. 1196. The method of embodiment 1177, wherein the disease or condition is amyotrophic lateral sclerosis (ALS). 1197. The method of embodiment 1177, wherein the disease or condition is anencephaly. 1198. The method of embodiment 1177, wherein the disease or condition is aneurysm. 1199. The method of embodiment 1177, wherein the disease or condition is Angelman syndrome. 1200. The method of embodiment 1177, wherein the disease or condition is hemangiomatosis. 1201. The method of embodiment 1177, wherein the disease or condition is Angelman syndrome. 1202. The method of embodiment 1177, wherein the disease or condition is hypoxia. 1203. The method of embodiment 1177, wherein the disease or condition is antiphospholipid syndrome. 1204. The method of embodiment 1177, wherein the disease or condition is aphasia. 1205. The method of embodiment 1177, wherein the disease or condition is psychokinesia. 1206. The method of embodiment 1177, wherein the disease or condition is arachnoid cyst. 1207. The method of embodiment 1177, wherein the disease or condition is arachnoiditis. 1208. The method of embodiment 1177, wherein the disease or condition is Arnold-Chiari malformation. 1209. The method of embodiment 1177, wherein the disease or condition is arteriovenous malformation. 1210. The method of embodiment 1177, wherein the disease or condition is Asperger's syndrome. 1211. The method of embodiment 1177, wherein the disease or condition is ataxia. 1212. The method of embodiment 1177, wherein the disease or condition is ataxia telangiectasia. 1213. The method of embodiment 1177, wherein the disease or condition is ataxia and cerebellar or spinocerebellar degeneration. 1214. The method of embodiment 1177, wherein the disease or condition is atrial fibrillation and stroke. 1215. The method of embodiment 1177, wherein the disease or condition is attention deficit hyperactivity disorder. 1216. The method of embodiment 1177, wherein the disease or condition is autism spectrum disorder. 1217. The method of embodiment 1177, wherein the disease or condition is autonomic nervous system dysfunction. 1218. The method of embodiment 1177, wherein the disease or condition is back pain. 1219. The method of embodiment 1177, wherein the disease or condition is Barthel syndrome. 1220. The method of embodiment 1177, wherein the disease or condition is Batten's disease. 1221. The method of embodiment 1177, wherein the disease or condition is Becker's myotonia. 1222. The method of embodiment 1177, wherein the disease or condition is Behcet's disease. 1223. The method of embodiment 1177, wherein the disease or condition is Bernard's palsy. 1224. The method of embodiment 1177, wherein the disease or condition is benign idiopathic eye spasm. 1225. The method of embodiment 1177, wherein the disease or condition is benign focal muscular atrophy. 1226. The method of embodiment 1177, wherein the disease or condition is benign intracranial hypertension. 1227. The method of embodiment 1177, wherein the disease or condition is Bernhardt-Ross syndrome. 1228. The method of embodiment 1177, wherein the disease or condition is Bevacizumab's disease. 1229. The method of embodiment 1177, wherein the disease or condition is eyelid spasm. 1230. The method of embodiment 1177, wherein the disease or condition is Bloch-Sulzberg syndrome. 1231. The method of embodiment 1177, wherein the disease or condition is brachial nerve plexus injury. 1232. The method of embodiment 1177, wherein the disease or condition is brachial nerve plexus injury. 1233. The method of embodiment 1177, wherein the disease or condition is Bradbury-Eggleston syndrome. 1234. The method of embodiment 1177, wherein the disease or condition is a brain or spinal tumor (including but not limited to a tumor that has metastasized to the brain, such as metastatic breast cancer). 1235. The method of embodiment 1177, wherein the disease or condition is a cerebral aneurysm. 1236. The method of embodiment 1177, wherein the disease or condition is brain damage. 1237. The method of embodiment 1177, wherein the disease or condition is Brown-Strauss syndrome. 1238. The method of embodiment 1177, wherein the disease or condition is bulbar palsy. 1239. The method of embodiment 1177, wherein the disease or condition is bulbar muscle atrophy. 1240. The method of embodiment 1177, wherein the disease or condition is bulbar muscular dystrophy, cerebral somatic autosomal dominant arteriovenous lesions with subcortical infarcts and leukoencephalopathy (CADASIL). 1241. The method of embodiment 1177, wherein the disease or condition is Canavan disease. 1242. The method of embodiment 1177, wherein the disease or condition is carpal tunnel syndrome. 1243. The method of embodiment 1177, wherein the disease or condition is causalgia. 1244. The method of embodiment 1177, wherein the disease or condition is cavernous hemangioma. 1245. The method of embodiment 1177, wherein the disease or condition is cavernous hemangioma. 1246. The method of embodiment 1177, wherein the disease or condition is spongiosa. 1247. The method of embodiment 1177, wherein the disease or condition is central cervical cord syndrome. 1248. The method of embodiment 1177, wherein the disease or condition is central cord syndrome. 1249. The method of embodiment 1177, wherein the disease or condition is central pain syndrome. 1250. The method of embodiment 1177, wherein the disease or condition is central pontine myelolysis. 1251. The method of embodiment 1177, wherein the disease or condition is a head disorder. 1252. The method of embodiment 1177, wherein the disease or condition is neuramidase deficiency. 1253. The method of embodiment 1177, wherein the disease or condition is cerebellar degeneration. 1254. The method of embodiment 1177, wherein the disease or condition is cerebellar hypoplasia. 1255. The method of embodiment 1177, wherein the disease or condition is a cerebral aneurysm. 1256. The method of embodiment 1177, wherein the disease or condition is cerebral arteriosclerosis. 1257. The method of embodiment 1177, wherein the disease or condition is cerebral atrophy. 1258. The method of embodiment 1177, wherein the disease or condition is cerebral beriberi. 1259. The method of embodiment 1177, wherein the disease or condition is cerebrospinal fluid abnormality. 1260. The method of embodiment 1177, wherein the disease or condition is cerebral gigantism. 1261. The method of embodiment 1177, wherein the disease or condition is cerebral hypoxia. 1262. The method of embodiment 1177, wherein the disease or condition is cerebral palsy. 1263. The method of embodiment 1177, wherein the disease or condition is cerebro-oculofacial-skeletal syndrome (COFS). 1264. The method of embodiment 1177, wherein the disease or condition is Chuck-Murray-Duzumab disease. 1265. The method of embodiment 1177, wherein the disease or condition is Chiari malformation. 1266. The method of embodiment 1177, wherein the disease or condition is cholesterol storage disease. 1267. The method of embodiment 1177, wherein the disease or condition is chorea. 1268. The method of embodiment 1177, wherein the disease or condition is chorea acanthocytosis. 1269. The method of embodiment 1177, wherein the disease or condition is chronic inflammatory demyelinating polyneuropathy (CIDP). 1270. The method of embodiment 1177, wherein the disease or condition is chronic orthostatic intolerance. 1271. The method of embodiment 1177, wherein the disease or condition is chronic pain. 1272. The method of embodiment 1177, wherein the disease or condition is Caucasian syndrome type II. 1273. The method of embodiment 1177, wherein the disease or condition is Crohn's disease. 1274. The method of embodiment 1177, wherein the disease or condition is synovial disease. 1275. The method of embodiment 1177, wherein the disease or condition is coma. 1276. The method of embodiment 1177, wherein the disease or condition is complex regional pain syndrome. 1277. The method of embodiment 1177, wherein the disease or condition is concentric sclerosis (Barlow's sclerosis). 1278. The method of embodiment 1177, wherein the disease or condition is congenital bilateral facial paralysis. 1279. The method of embodiment 1177, wherein the disease or condition is congenital myasthenia. 1280. The method of embodiment 1177, wherein the disease or condition is congenital myopathy. 1281. The method of embodiment 1177, wherein the disease or condition is congenital vascular cavernous malformation. 1282. The method of embodiment 1177, wherein the disease or condition is corticobasal degeneration. 1283. The method of embodiment 1177, wherein the disease or condition is cranial arteritis. 1284. The method of embodiment 1177, wherein the disease or condition is craniosynostosis. 1285. The method of embodiment 1177, wherein the disease or condition is Crewe encephalitis. 1286. The method of embodiment 1177, wherein the disease or condition is Creutzfeldt-Jakob disease. 1287. The method of Example 1177, wherein the disease or condition is chronic progressive external ophthalmoplegia. 1288. The method of embodiment 1177, wherein the disease or condition is cumulative trauma disorder. 1289. The method of embodiment 1177, wherein the disease or condition is Cushing's syndrome. 1290. The method of embodiment 1177, wherein the disease or condition is giant cell inclusion disease. 1291. The method of embodiment 1177, wherein the disease or condition is a cellular giant virus infection. 1292. The method of embodiment 1177, wherein the disease or condition is dancing eyes-dancing feet syndrome. 1293. The method of embodiment 1177, wherein the disease or condition is Dandy-Walker syndrome. 1294. The method of embodiment 1177, wherein the disease or condition is Dawson's disease. 1295. The method of embodiment 1177, wherein the disease or condition is Demerol syndrome. 1296. The method of embodiment 1177, wherein the disease or condition is Dejerin-Kronmpke palsy. 1297. The method of embodiment 1177, wherein the disease or condition is dementia. 1298. The method of embodiment 1177, wherein the disease or condition is multi-infarct dementia. 1299. The method of embodiment 1177, wherein the disease or condition is semantic dementia. 1300. The method of embodiment 1177, wherein the disease or condition is subcortical dementia. 1301. The method of embodiment 1177, wherein the disease or condition is Lewy body dementia. 1302. The method of embodiment 1177, wherein the disease or condition is demyelination disease. 1303. The method of embodiment 1177, wherein the disease or condition is odontocerebellar ataxia. 1304. The method of embodiment 1177, wherein the disease or condition is odontoerythrodystrophy. 1305. The method of embodiment 1177, wherein the disease or condition is dermatomyositis. 1306. The method of embodiment 1177, wherein the disease or condition is developmental dyspraxia. 1307. The method of embodiment 1177, wherein the disease or condition is Deweker syndrome. 1308. The method of embodiment 1177, wherein the disease or condition is diabetic neuropathy. 1309. The method of embodiment 1177, wherein the disease or condition is diffuse sclerosis. 1310. The method of embodiment 1177, wherein the disease or condition is distal hereditary motor neuron disease. 1311. The method of embodiment 1177, wherein the disease or condition is Dravet syndrome. 1312. The method of embodiment 1177, wherein the disease or condition is autonomic nervous system dysfunction. 1313. The method of embodiment 1177, wherein the disease or condition is difficulty writing. 1314. The method of embodiment 1177, wherein the disease or condition is dyslexia. 1315. The method of embodiment 1177, wherein the disease or condition is difficulty swallowing. 1316. The method of embodiment 1177, wherein the disease or condition is dyspraxia. 1317. The method of embodiment 1177, wherein the disease or condition is myoclonic cerebellar coordination disorder. 1318. The method of embodiment 1177, wherein the disease or condition is progressive cerebellar dyssynergia. 1319. The method of embodiment 1177, wherein the disease or condition is a muscle tone disorder. 1320. The method of embodiment 1177, wherein the disease or condition is early infantile epileptic encephalopathy. 1321. The method of embodiment 1177, wherein the disease or condition is nullopterin syndrome. 1322. The method of embodiment 1177, wherein the disease or condition is encephalitis. 1323. The method of embodiment 1177, wherein the disease or condition is encephalitis lethargica. 1324. The method of embodiment 1177, wherein the disease or condition is encephalocele. 1325. The method of embodiment 1177, wherein the disease or condition is encephalomyelitis. 1326. The method of embodiment 1177, wherein the disease or condition is encephalopathy. 1327. The method of embodiment 1177, wherein the disease or condition is encephalopathy (familial infantile form). 1328. The method of embodiment 1177, wherein the disease or condition is cerebral trigeminal angiomatosis. 1329. The method of embodiment 1177, wherein the disease or condition is epilepsy. 1330. The method of embodiment 1177, wherein the disease or condition is epileptic hemiplegia. 1331. The method of embodiment 1177, wherein the disease or condition is intermittent ataxia. 1332. The method of embodiment 1177, wherein the disease or condition is Erb's palsy. 1333. The method of embodiment 1177, wherein the disease or condition is Erb-Duchenne palsy. 1334. The method of embodiment 1177, wherein the disease or condition is Dejerin-Kronmpke palsy. 1335. The method of embodiment 1177, wherein the disease or condition is essential tremor. 1336. The method of embodiment 1177, wherein the disease or condition is extrapontine myelinolysis. 1337. The method of embodiment 1177, wherein the disease or condition is Farber's disease. 1338. The method of embodiment 1177, wherein the disease or condition is Fabry disease. 1339. The method of embodiment 1177, wherein the disease or condition is Fall syndrome. 1340. The method of embodiment 1177, wherein the disease or condition is syncope. 1341. The method of embodiment 1177, wherein the disease or condition is familial autonomic nervous system disorder. 1342. The method of embodiment 1177, wherein the disease or condition is familial hemangioma. 1343. The method of embodiment 1177, wherein the disease or condition is familial idiopathic basal ganglia calcification. 1344. The method of embodiment 1177, wherein the disease or condition is familial recurrent palsy. 1345. The method of embodiment 1177, wherein the disease or condition is familial spastic paralysis. 1346. The method of embodiment 1177, wherein the disease or condition is Farber's disease. 1347. The method of embodiment 1177, wherein the disease or condition is febrile epilepsy. 1348. The method of embodiment 1177, wherein the disease or condition is fibromuscular dysplasia. 1349. The method of embodiment 1177, wherein the disease or condition is Fisher syndrome. 1350. The method of embodiment 1177, wherein the disease or condition is floppy baby syndrome. 1351. The method of embodiment 1177, wherein the disease or condition is foot drop. 1352. The method of embodiment 1177, wherein the disease or condition is fragile X disease. 1353. The method of embodiment 1177, wherein the disease or condition is Friedreich's ataxia. 1354. The method of embodiment 1177, wherein the disease or condition is frontotemporal dementia. 1355. The method of embodiment 1177, wherein the disease or condition is Gaucher disease. 1356. The method of embodiment 1177, wherein the disease or condition is systemic gangliosidosis (GM1, GM2). 1357. The method of embodiment 1177, wherein the disease or condition is Gerstmann syndrome. 1358. The method of embodiment 1177, wherein the disease or condition is Gerstmann-Stausler-Scheinker disease. 1359. The method of embodiment 1177, wherein the disease or condition is giant axonal neuropathy. 1360. The method of embodiment 1177, wherein the disease or condition is giant cell arteritis. 1361. The method of embodiment 1177, wherein the disease or condition is giant cell inclusion disease. 1362. The method of embodiment 1177, wherein the disease or condition is globular cell leukodystrophy. 1363. The method of embodiment 1177, wherein the disease or condition is glossopharyngeal neuralgia. 1364. The method of embodiment 1177, wherein the disease or condition is glycogen storage disease. 1365. The method of embodiment 1177, wherein the disease or condition is Guillain-Barré syndrome. 1366. The method of embodiment 1177, wherein the disease or condition is Holloway-Spatz disease. 1367. The method of embodiment 1177, wherein the disease or condition is head injury. 1368. The method of embodiment 1177, wherein the disease or condition is headache. 1369. The method of embodiment 1177, wherein the disease or condition is continuous hemicrania. 1370. The method of embodiment 1177, wherein the disease or condition is hemifacial spasticity. 1371. The method of embodiment 1177, wherein the disease or condition is alternating hemiplegia. 1372. The method of embodiment 1177, wherein the disease or condition is a hereditary neuropathy. 1373. The method of embodiment 1177, wherein the disease or condition is hereditary spastic posterior tibial paralysis. 1374. The method of embodiment 1177, wherein the disease or condition is polyneuritis-type hereditary ataxia. 1375. The method of embodiment 1177, wherein the disease or condition is herpes zoster. 1376. The method of embodiment 1177, wherein the disease or condition is herpes zoster oticus. 1377. The method of embodiment 1177, wherein the disease or condition is Hirayama syndrome. 1378. The method of embodiment 1177, wherein the disease or condition is Hodgkin's-Ellison syndrome. 1379. The method of embodiment 1177, wherein the disease or condition is holoprosencephaly. 1380. The method of embodiment 1177, wherein the disease or condition is HTLV-1 associated myelopathy. 1381. The method of embodiment 1177, wherein the disease or condition is Hughes syndrome. 1382. The method of embodiment 1177, wherein the disease or condition is Huntington's disease. 1383. The method of embodiment 1177, wherein the disease or condition is Hearle-Hauer syndrome. 1384. The method of embodiment 1177, wherein the disease or condition is hydrocephalus. 1385. The method of embodiment 1177, wherein the disease or condition is hydrocephalus. 1386. The method of embodiment 1177, wherein the disease or condition is normal pressure hydrocephalus. 1387. The method of embodiment 1177, wherein the disease or condition is hydromyelia. 1388. The method of embodiment 1177, wherein the disease or condition is hypercortisoneuria. 1389. The method of embodiment 1177, wherein the disease or condition is lethargy. 1390. The method of embodiment 1177, wherein the disease or condition is hypertonia. 1391. The method of embodiment 1177, wherein the disease or condition is hypotonia. 1392. The method of embodiment 1177, wherein the disease or condition is hypoxia. 1393. The method of embodiment 1177, wherein the disease or condition is immune-mediated encephalomyelitis. 1394. The method of embodiment 1177, wherein the disease or condition is inclusion body myositis. 1395. The method of embodiment 1177, wherein the disease or condition is incontinentia pigmenti. 1396. The method of embodiment 1177, wherein the disease or condition is juvenile hypotonia. 1397. The method of embodiment 1177, wherein the disease or condition is infantile neuroaxonal dystrophy. 1398. The method of embodiment 1177, wherein the disease or condition is juvenile phytanic acid storage disease. 1399. The method of embodiment 1177, wherein the disease or condition is juvenile Refsum's disease. 1400. The method of embodiment 1177, wherein the disease or condition is infantile seizures. 1401. The method of embodiment 1177, wherein the disease or condition is inflammatory myopathy. 1402. The method of embodiment 1177, wherein the disease or condition is occipital schistosomal malformation. 1403. The method of embodiment 1177, wherein the disease or condition is intestinal lipid malnutrition. 1404. The method of embodiment 1177, wherein the disease or condition is intracranial cyst. 1405. The method of embodiment 1177, wherein the disease or condition is intracranial hypertension. 1406. The method of embodiment 1177, wherein the disease or condition is Ithaca's syndrome. 1407. The method of embodiment 1177, wherein the disease or condition is Joubert syndrome. 1408. The method of embodiment 1177, wherein the disease or condition is Karns-Sayer syndrome. 1409. The method of embodiment 1177, wherein the disease or condition is Kennedy's disease. 1410. The method of embodiment 1177, wherein the disease or condition is Giannis Bromwich syndrome. 1411. The method of embodiment 1177, wherein the disease or condition is Klein-Levin syndrome. 1412. The method of embodiment 1177, wherein the disease or condition is Klebsiella pneumoniae syndrome. 1413. The method of embodiment 1177, wherein the disease or condition is Klippel-Trenrow syndrome (KTS). 1414. The method of embodiment 1177, wherein the disease or condition is Klure-Bucy syndrome. 1415. The method of embodiment 1177, wherein the disease or condition is Korsakoff's amnesia. 1416. The method of embodiment 1177, wherein the disease or condition is Clappavirus. 1417. The method of embodiment 1177, wherein the disease or condition is Kugelberg-Wiland disease. 1418. The method of embodiment 1177, wherein the disease or condition is kuru. 1419. The method of embodiment 1177, wherein the disease or condition is Lambert-Eaton myasthenia gravis. 1420. The method of embodiment 1177, wherein the disease or condition is Landau-Kleffner syndrome. 1421. The method of embodiment 1177, wherein the disease or condition is collateral femoral cutaneous nerve entrapment. 1422. The method of embodiment 1177, wherein the disease or condition is lateral cord medullary syndrome. 1423. The method of embodiment 1177, wherein the disease or condition is a learning disability. 1424. The method of embodiment 1177, wherein the disease or condition is Leydens disease. 1425. The method of embodiment 1177, wherein the disease or condition is Lennox-Castellos syndrome. 1426. The method of embodiment 1177, wherein the disease or condition is Reich-Nyhen syndrome. 1427. The method of embodiment 1177, wherein the disease or condition is cerebral white matter dystrophy. 1428. The method of embodiment 1177, wherein the disease or condition is Levine-Critchley syndrome. 1429. The method of embodiment 1177, wherein the disease or condition is Lewy body dementia. 1430. The method of embodiment 1177, wherein the disease or condition is Lischheimer's disease. 1431. The method of embodiment 1177, wherein the disease or condition is lipid storage disease. 1432. The method of embodiment 1177, wherein the disease or condition is lipoproteinemia. 1433. The method of embodiment 1177, wherein the disease or condition is lipolytic encephalopathy. 1434. The method of embodiment 1177, wherein the disease or condition is locked-in syndrome. 1435. The method of embodiment 1177, wherein the disease or condition is Lou Gehrig's disease. 1436. The method of embodiment 1177, wherein the disease or condition is lupus erythematosus. 1437. The method of embodiment 1177, wherein the disease or condition is Lyme disease-neurological complications. 1438. The method of embodiment 1177, wherein the disease or condition is a lysosomal storage disease. 1439. The method of embodiment 1177, wherein the disease or condition is Machado-Joseph disease. 1440. The method of embodiment 1177, wherein the disease or condition is megaloencephaly. 1441. The method of embodiment 1177, wherein the disease or condition is megalencephaly. 1442. The method of embodiment 1177, wherein the disease or condition is Melancholia-Rodriguez syndrome. 1443. The method of embodiment 1177, wherein the disease or condition is meningitis. 1444. The method of embodiment 1177, wherein the disease or condition is meningitis and encephalitis. 1445. The method of embodiment 1177, wherein the disease or condition is Menkes disease. 1446. The method of embodiment 1177, wherein the disease or condition is paresthesia. 1447. The method of embodiment 1177, wherein the disease or condition is metachromatic leukodystrophy. 1448. The method of embodiment 1177, wherein the disease or condition is microcephaly. 1449. The method of embodiment 1177, wherein the disease or condition is migraine. 1450. The method of embodiment 1177, wherein the disease or condition is Miller Fisher syndrome. 1451. The method of embodiment 1177, wherein the disease or condition is a mini-stroke. 1452. The method of embodiment 1177, wherein the disease or condition is mitochondrial myopathy. 1453. The method of embodiment 1177, wherein the disease or condition is mitochondrial DNA deletion syndrome. 1454. The method of embodiment 1177, wherein the disease or condition is Moebius syndrome. 1455. The method of embodiment 1177, wherein the disease or condition is unilateral limb muscle atrophy. 1456. The method of embodiment 1177, wherein the disease or condition is Molvain syndrome. 1457. The method of embodiment 1177, wherein the disease or condition is a motor neuron disease. 1458. The method of embodiment 1177, wherein the disease or condition is smoke sickness. 1459. The method of embodiment 1177, wherein the disease or condition is mucolipidosis. 1460. The method of embodiment 1177, wherein the disease or condition is mucopolysaccharidosis. 1461. The method of embodiment 1177, wherein the disease or condition is multi-infarct dementia. 1462. The method of embodiment 1177, wherein the disease or condition is multifocal motor neuropathy. 1463. The method of embodiment 1177, wherein the disease or condition is multiple sclerosis. 1464. The method of embodiment 1177, wherein the disease or condition is multisystem atrophy. 1465. The method of embodiment 1177, wherein the disease or condition is multisystem atrophy associated with orthostatic hypotension. 1466. The method of embodiment 1177, wherein the disease or condition is muscular dystrophy. 1467. The method of embodiment 1177, wherein the disease or condition is congenital myasthenia. 1468. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis. 1469. The method of embodiment 1177, wherein the disease or condition is diffuse myelin-destructive sclerosis. 1470. The method of embodiment 1177, wherein the disease or condition is myelitis. 1471. The method of embodiment 1177, wherein the disease or condition is infantile myoclonic encephalopathy. 1472. The method of embodiment 1177, wherein the disease or condition is myoclonus. 1473. The method of embodiment 1177, wherein the disease or condition is myoclonic seizure disorder. 1474. The method of embodiment 1177, wherein the disease or condition is myopathy. 1475. The method of embodiment 1177, wherein the disease or condition is congenital myopathy. 1476. The method of embodiment 1177, wherein the disease or condition is thyrotoxic myopathy. 1477. The method of embodiment 1177, wherein the disease or condition is myotonia. 1478. The method of embodiment 1177, wherein the disease or condition is myotonia congenita. 1479. The method of embodiment 1177, wherein the disease or condition is narcolepsy. 1480. The method of embodiment 1177, wherein the disease or condition is NARP (neuropathy, ataxia, and retinitis pigmentosa). 1481. The method of embodiment 1177, wherein the disease or condition is neuroacanthocytosis. 1482. The method of embodiment 1177, wherein the disease or condition is neurodegeneration associated with brain iron accumulation. 1483. The method of embodiment 1177, wherein the disease or condition is a neurodegenerative disease. 1484. The method of embodiment 1177, wherein the disease or condition is neurofibroma. 1485. The method of embodiment 1177, wherein the disease or condition is neuroleptic malignant syndrome. 1486. The method of embodiment 1177, wherein the disease or condition is a neurological complication of AIDS. 1487. The method of embodiment 1177, wherein the disease or condition is a neurological complication of Lyme disease. 1488. The method of embodiment 1177, wherein the disease or condition is a neurological consequence of a cytomegalovirus infection. 1489. The method of embodiment 1177, wherein the disease or condition is a neurological manifestation of Pompe disease. 1490. The method of embodiment 1177, wherein the disease or condition is a neurological sequelae of lupus. 1491. The method of embodiment 1177, wherein the disease or condition is neuromyelitis optica. 1492. The method of embodiment 1177, wherein the disease or condition is neuromyotonia. 1493. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis. 1494. The method of embodiment 1177, wherein the disease or condition is a neuronal migration disorder. 1495. The method of embodiment 1177, wherein the disease or condition is neuropathic pain. 1496. The method of embodiment 1177, wherein the disease or condition is a hereditary neuropathy. 1497. The method of embodiment 1177, wherein the disease or condition is a neuropathy. 1498. The method of embodiment 1177, wherein the disease or condition is neurosarcoidosis. 1499. The method of embodiment 1177, wherein the disease or condition is neurosyphilis. 1500. The method of embodiment 1177, wherein the disease or condition is neurotoxicity. 1501. The method of embodiment 1177, wherein the disease or condition is cavernous nevus. 1502. The method of embodiment 1177, wherein the disease or condition is Niemann-Pick disease. 1503. The method of embodiment 1177, wherein the disease or condition is O'Sullivan-McCrawl syndrome. 1504. The method of embodiment 1177, wherein the disease or condition is occipital neuralgia. 1505. The method of embodiment 1177, wherein the disease or condition is Ohtahara syndrome. 1506. The method of embodiment 1177, wherein the disease or condition is olivopontine-cerebellar atrophy. 1507. The method of embodiment 1177, wherein the disease or condition is strabismus nystagmus. 1508. The method of embodiment 1177, wherein the disease or condition is orthostatic hypotension. 1509. The method of embodiment 1177, wherein the disease or condition is overuse syndrome. 1510. The method of embodiment 1177, wherein the disease or condition is chronic pain. 1511. The method of embodiment 1177, wherein the disease or condition is pantothenate kinase-associated neurodegeneration. 1512. The method of embodiment 1177, wherein the disease or condition is paraneoplastic syndrome. 1513. The method of embodiment 1177, wherein the disease or condition is sensory abnormality. 1514. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease. 1515. The method of embodiment 1177, wherein the disease or condition is choreoathetosis. 1516. The method of embodiment 1177, wherein the disease or condition is hemicrania. 1517. The method of embodiment 1177, wherein the disease or condition is Parry-Lomborg disease. 1518. The method of embodiment 1177, wherein the disease or condition is Pelitzowitz-Merzbacher disease. 1519. The method of embodiment 1177, wherein the disease or condition is Penne-Schucker II syndrome. 1520. The method of embodiment 1177, wherein the disease or condition is perineurial cyst. 1521. The method of embodiment 1177, wherein the disease or condition is peroneal muscle atrophy. 1522. The method of embodiment 1177, wherein the disease or condition is periodic paralysis. 1523. The method of embodiment 1177, wherein the disease or condition is peripheral neuropathy. 1524. The method of embodiment 1177, wherein the disease or condition is periventricular leukomalacia. 1525. The method of embodiment 1177, wherein the disease or condition is a persistent vegetative state. 1526. The method of embodiment 1177, wherein the disease or condition is pervasive developmental disorder. 1527. The method of embodiment 1177, wherein the disease or condition is Phelan-McCedar-Mead syndrome. 1528. The method of embodiment 1177, wherein the disease or condition is phytanic acid storage disease. 1529. The method of embodiment 1177, wherein the disease or condition is Pick's disease. 1530. The method of embodiment 1177, wherein the disease or condition is nerve compression. 1531. The method of embodiment 1177, wherein the disease or condition is piriformis syndrome. 1532. The method of embodiment 1177, wherein the disease or condition is a pituitary tumor. 1533. The method of embodiment 1177, wherein the disease or condition is polymyositis. 1534. The method of embodiment 1177, wherein the disease or condition is Pompe disease. 1535. The method of embodiment 1177, wherein the disease or condition is pyreneesencephaly. 1536. The method of embodiment 1177, wherein the disease or condition is sequelae of poliomyelitis. 1537. The method of embodiment 1177, wherein the disease or condition is post-herpetic neuralgia. 1538. The method of embodiment 1177, wherein the disease or condition is post-infectious encephalomyelitis. 1539. The method of embodiment 1177, wherein the disease or condition is postural hypotension. 1540. The method of embodiment 1177, wherein the disease or condition is postural orthostatic tachycardia syndrome. 1541. The method of embodiment 1177, wherein the disease or condition is postural tachycardia syndrome. 1542. The method of embodiment 1177, wherein the disease or condition is primary odontoid atrophy. 1543. The method of embodiment 1177, wherein the disease or condition is primary lateral sclerosis. 1544. The method of embodiment 1177, wherein the disease or condition is primary progressive aphasia. 1545. The method of embodiment 1177, wherein the disease or condition is prion disease. 1546. The method of embodiment 1177, wherein the disease or condition is progressive bulbar palsy. 1547. The method of embodiment 1177, wherein the disease or condition is progressive hemifacial atrophy. 1548. The method of embodiment 1177, wherein the disease or condition is progressive ataxia. 1549. The method of embodiment 1177, wherein the disease or condition is progressive multifocal leukoencephalopathy. 1550. The method of embodiment 1177, wherein the disease or condition is progressive muscle atrophy. 1551. The method of embodiment 1177, wherein the disease or condition is progressive sclerotic gray matter dystrophy. 1552. The method of embodiment 1177, wherein the disease or condition is progressive supranuclear neuropathy. 1553. The method of embodiment 1177, wherein the disease or condition is prosopagnosia. 1554. The method of embodiment 1177, wherein the disease or condition is pseudobulbar palsy. 1555. The method of embodiment 1177, wherein the disease or condition is pseudo-Torch syndrome. 1556. The method of embodiment 1177, wherein the disease or condition is pseudotoxoplasmosis. 1557. The method of embodiment 1177, wherein the disease or condition is pseudotumor cerebri. 1558. The method of embodiment 1177, wherein the disease or condition is psychogenic movement. 1559. The method of embodiment 1177, wherein the disease or condition is Ramsey-Hunt Syndrome I. 1560. The method of embodiment 1177, wherein the disease or condition is Ramsey-Hunt syndrome II. 1561. The method of embodiment 1177, wherein the disease or condition is Lamarck's encephalitis. 1562. The method of embodiment 1177, wherein the disease or condition is reflex sympathetic dystrophy syndrome. 1563. The method of embodiment 1177, wherein the disease or condition is Refsum's disease. 1564. The method of embodiment 1177, wherein the disease or condition is juvenile Refsum's disease. 1565. The method of embodiment 1177, wherein the disease or condition is repetitive movement disorder. 1566. The method of embodiment 1177, wherein the disease or condition is repetitive stress injury. 1567. The method of embodiment 1177, wherein the disease or condition is restless legs syndrome. 1568. The method of embodiment 1177, wherein the disease or condition is retrovirus-associated myelopathy. 1569. The method of embodiment 1177, wherein the disease or condition is Rett syndrome. 1570. The method of embodiment 1177, wherein the disease or condition is Reye's syndrome. 1571. The method of embodiment 1177, wherein the disease or condition is rheumatic encephalitis. 1572. The method of embodiment 1177, wherein the disease or condition is Reye's-Davey syndrome. 1573. The method of embodiment 1177, wherein the disease or condition is sacral radicular cyst. 1574. The method of embodiment 1177, wherein the disease or condition is St. Vitus' chorea. 1575. The method of embodiment 1177, wherein the disease or condition is a salivary gland disease. 1576. The method of embodiment 1177, wherein the disease or condition is Sandhoff's disease. 1577. The method of embodiment 1177, wherein the disease or condition is Sheldon's disease. 1578. The method of embodiment 1177, wherein the disease or condition is schizencephaly. 1579. The method of embodiment 1177, wherein the disease or condition is Satterberg disease. 1580. The method of embodiment 1177, wherein the disease or condition is epilepsy. 1581. The method of embodiment 1177, wherein the disease or condition is semantic dementia. 1582. The method of embodiment 1177, wherein the disease or condition is septal dysplasia. 1583. The method of embodiment 1177, wherein the disease or condition is severe myotonic epilepsy of infancy (SMEI). 1584. The method of embodiment 1177, wherein the disease or condition is rocked baby syndrome. 1585. The method of embodiment 1177, wherein the disease or condition is herpes zoster. 1586. The method of embodiment 1177, wherein the disease or condition is Shy-Derger syndrome. 1587. The method of embodiment 1177, wherein the disease or condition is Sjögren's syndrome. 1588. The method of embodiment 1177, wherein the disease or condition is sleep apnea. 1589. The method of embodiment 1177, wherein the disease or condition is sleeping sickness. 1590. The method of embodiment 1177, wherein the disease or condition is Soto's syndrome. 1591. The method of embodiment 1177, wherein the disease or condition is seizure. 1592. The method of embodiment 1177, wherein the disease or condition is spina bifida. 1593. The method of embodiment 1177, wherein the disease or condition is spinal cord infarction. 1594. The method of embodiment 1177, wherein the disease or condition is spinal cord injury. 1595. The method of embodiment 1177, wherein the disease or condition is a spinal cord tumor. 1596. The method of embodiment 1177, wherein the disease or condition is spinal muscular atrophy. 1597. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia. 1598. The method of embodiment 1177, wherein the disease or condition is spinocerebellar atrophy. 1599. The method of embodiment 1177, wherein the disease or condition is spinocerebellar degeneration. 1600. The method of embodiment 1177, wherein the disease or condition is sporadic ataxia. 1601. The method of embodiment 1177, wherein the disease or condition is Still-Richard-Olszewski syndrome. 1602. The method of embodiment 1177, wherein the disease or condition is stiff-person syndrome. 1603. The method of embodiment 1177, wherein the disease or condition is substantia nigra. 1604. The method of embodiment 1177, wherein the disease or condition is stroke. 1605. The method of embodiment 1177, wherein the disease or condition is Sturge-Weber syndrome. 1606. The method of embodiment 1177, wherein the disease or condition is subacute sclerosing panencephalitis. 1607. The method of embodiment 1177, wherein the disease or condition is subcortical arteriosclerotic encephalopathy. 1608. The method of embodiment 1177, wherein the disease or condition is short-lasting unilateral neuropathic (SUNCT) headache. 1609. The method of embodiment 1177, wherein the disease or condition is dysphagia. 1610. The method of embodiment 1177, wherein the disease or condition is Sydenham's chorea. 1611. The method of embodiment 1177, wherein the disease or condition is syncope. 1612. The method of embodiment 1177, wherein the disease or condition is syphilitic spondylosclerosis. 1613. The method of embodiment 1177, wherein the disease or condition is syringomyelia. 1614. The method of embodiment 1177, wherein the disease or condition is syringomyelia. 1615. The method of embodiment 1177, wherein the disease or condition is systemic lupus erythematosus. 1616. The method of embodiment 1177, wherein the disease or condition is spinal cord leukemia. 1617. The method of embodiment 1177, wherein the disease or condition is delayed akinesia. 1618. The method of embodiment 1177, wherein the disease or condition is Tarlov cyst. 1619. The method of embodiment 1177, wherein the disease or condition is Tay-Sachs disease. 1620. The method of embodiment 1177, wherein the disease or condition is temporal artery inflammation. 1621. The method of embodiment 1177, wherein the disease or condition is thromboembolic syndrome. 1622. The method of Example 1177, wherein the disease or condition is Thompson's myotonia. 1623. The method of embodiment 1177, wherein the disease or condition is thoracic outlet syndrome. 1624. The method of embodiment 1177, wherein the disease or condition is thyrotoxic myopathy. 1625. The method of embodiment 1177, wherein the disease or condition is trigeminal neuralgia. 1626. The method of embodiment 1177, wherein the disease or condition is Todd's palsy. 1627. The method of embodiment 1177, wherein the disease or condition is Tourette syndrome. 1628. The method of embodiment 1177, wherein the disease or condition is a transient ischemic attack. 1629. The method of embodiment 1177, wherein the disease or condition is transmissible spongiform encephalopathy. 1630. The method of embodiment 1177, wherein the disease or condition is transverse myelitis. 1631. The method of embodiment 1177, wherein the disease or condition is traumatic brain injury. 1632. The method of embodiment 1177, wherein the disease or condition is tremor. 1633. The method of embodiment 1177, wherein the disease or condition is trigeminal neuralgia. 1634. The method of embodiment 1177, wherein the disease or condition is tropical spastic paraplegia. 1635. The method of embodiment 1177, wherein the disease or condition is Troye syndrome. 1636. The method of embodiment 1177, wherein the disease or condition is tuberous sclerosis. 1637. The method of embodiment 1177, wherein the disease or condition is angioedema. 1638. The method of embodiment 1177, wherein the disease or condition is a vasculitis syndrome of the central or peripheral nervous system. 1639. The method of embodiment 1177, wherein the disease or condition is vitamin B12 deficiency. 1640. The method of embodiment 1177, wherein the disease or condition is von Eichner's disease. 1641. The method of embodiment 1177, wherein the disease or condition is Van Hippel-Lindau disease (VHL). 1642. The method of embodiment 1177, wherein the disease or condition is von Recklinghausen's disease. 1643. The method of embodiment 1177, wherein the disease or condition is Wallenberg syndrome. 1644. The method of embodiment 1177, wherein the disease or condition is Wildnig-Hoffmann disease. 1645. The method of embodiment 1177, wherein the disease or condition is Wernicke-Korsakoff syndrome. 1646. The method of embodiment 1177, wherein the disease or condition is Wester syndrome. 1647. The method of embodiment 1177, wherein the disease or condition is cervical sprain. 1648. The method of embodiment 1177, wherein the disease or condition is Whipple's disease. 1649. The method of embodiment 1177, wherein the disease or condition is Williams syndrome. 1650. The method of embodiment 1177, wherein the disease or condition is Wilson's disease. 1651. The method of embodiment 1177, wherein the disease or condition is Wolman's disease. 1652. The method of embodiment 1177, wherein the disease or condition is X-linked spinal or bulbar muscular atrophy. 1653. The method of embodiment 1177, wherein the disease or condition is achromatopsia (color blindness), and/or wherein the heterologous nucleic acid sequence encodes cyclic nucleotide-gated cation channel alpha-3 (CNGA3) (e.g., a polypeptide represented by UniProt Accession No. Q16281 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1654. The method of embodiment 1177, wherein the disease or condition is achromatopsia (color blindness), and/or wherein the heterologous nucleic acid sequence encodes cyclic nucleotide-gated cation channel beta-3 (CNGB3) (e.g., a polypeptide represented by UniProt accession number Q9NQW8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1655. The method of embodiment 1177, wherein the disease or condition is achromatopsia (color blindness), and/or wherein the heterologous nucleic acid sequence encodes guanine nucleotide-binding protein G(t) subunit alpha-2 (GNAT2) (e.g., a polypeptide represented by UniProt Accession No. P19087 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1656. The method of embodiment 1177, wherein the disease or condition is achromatopsia (color blindness), and/or wherein the heterologous nucleic acid sequence encodes cone-shaped cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha (PDE6C) (e.g., a polypeptide represented by UniProt Accession No. P51160 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1657. The method of embodiment 1177, wherein the disease or condition is acute intermittent porphyria, and/or wherein the heterologous nucleic acid sequence encodes bilirubinogen deaminase (PBGD) HMBS (e.g., a polypeptide represented by UniProt Accession No. P08397 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1658. The method of embodiment 1177, wherein the disease or condition is Addison's syndrome (Addison's pupil), and/or wherein the heterologous nucleic acid sequence encodes MPZ (e.g., a polypeptide represented by UniProt Accession No. P25189 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1659. The method of embodiment 1177, wherein the disease or condition is age-related macular degeneration, and/or wherein the heterologous nucleic acid sequence encodes vascular endothelial growth factor receptor 1 (FLT1) (e.g., a polypeptide represented by UniProt Accession No. P17948 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1660. The method of embodiment 1177, wherein the disease or condition is age-related macular degeneration, and/or wherein the heterologous nucleic acid sequence encodes vascular endothelial growth factor A (VEGFA) (e.g., a polypeptide represented by UniProt Accession No. P15692 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1661. The method of embodiment 1177, wherein the disease or condition is agenesis of the corpus callosum (ACCPN), and/or wherein the heterologous nucleic acid sequence encodes SLC12A6 (e.g., a polypeptide represented by UniProt Accession No. Q9UHW9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1662. The method of embodiment 1177, wherein the disease or condition is Icardi-Guterres syndrome, and/or wherein the heterologous nucleic acid sequence encodes TREX1 (e.g., a polypeptide represented by UniProt Accession No. Q9NSU2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1663. The method of embodiment 1177, wherein the disease or condition is Alexander's disease, and/or wherein the heterologous nucleic acid sequence encodes GFAP (e.g., a polypeptide represented by UniProt Accession No. P14136 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1664. The method of embodiment 1177, wherein the disease or condition is Alpers syndrome, and/or wherein the heterologous nucleic acid sequence encodes POLG (e.g., a polypeptide represented by UniProt Accession No. P54098 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1665. The method of embodiment 1177, wherein the disease or condition is alternating hemiplegia, and/or wherein the heterologous nucleic acid sequence encodes ATP1A2 (e.g., a polypeptide represented by UniProt Accession No. P50993 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1666. The method of embodiment 1177, wherein the disease or condition is alternating hemiplegia, and/or wherein the heterologous nucleic acid sequence encodes ATP1A3 (e.g., a polypeptide represented by UniProt Accession No. P13637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1667. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes NGF (e.g., a polypeptide represented by UniProt Accession No. P01138 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1668. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes ApoE (e.g., a polypeptide represented by UniProt Accession No. P02649 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1669. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes presenilin (PSEN1) (e.g., a polypeptide represented by UniProt Accession No. A0A024R6A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1670. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes presenilin-2 (PSEN2) (e.g., a polypeptide represented by UniProt Accession No. P49810 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1671. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes amyloid-β proprotein (APP) (e.g., a polypeptide represented by UniProt Accession No. P05067 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1672. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes ADAM10 (e.g., a polypeptide represented by UniProt Accession No. 014672 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1673. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes MAPT (Tau) (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1674. The method of embodiment 1177, wherein the disease or condition is amyotrophic lateral sclerosis (ALS) (Lou Gehrig's disease), and/or wherein the heterologous nucleic acid sequence encodes superoxide dismutase-1 (SOD1) (e.g., a polypeptide represented by UniProt Accession No. P00441 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1675. The method of embodiment 1177, wherein the disease or condition is hereditary neuromuscular atrophy, and/or wherein the heterologous nucleic acid sequence encodes 45544 (e.g., a polypeptide represented by UniProt Accession No. Q9UHD8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1676. The method of embodiment 1177, wherein the disease or condition is Angelman syndrome, and/or wherein the heterologous nucleic acid sequence encodes ubiquitin protein ligase E3A (UBE3A) (e.g., a polypeptide represented by UniProt Accession No. Q05086 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1677. The method of embodiment 1177, wherein the disease or condition is aromatic L-amino acid decarboxylase deficiency (AADCD), and/or wherein the heterologous nucleic acid sequence encodes DDC (e.g., a polypeptide represented by UniProt Accession No. P20711 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1678. The method of embodiment 1177, wherein the disease or condition is ataxia, and/or wherein the heterologous nucleic acid sequence encodes APTX (e.g., a polypeptide represented by UniProt Accession No. Q7Z2E3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1679. The method of embodiment 1177, wherein the disease or condition is ataxia, and/or wherein the heterologous nucleic acid sequence encodes KCNA1 (e.g., a polypeptide represented by UniProt Accession No. Q09470 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1680. The method of embodiment 1177, wherein the disease or condition is ataxia, and/or wherein the heterologous nucleic acid sequence encodes CACNA1A (e.g., a polypeptide represented by UniProt Accession No. 000555 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1681. The method of embodiment 1177, wherein the disease or condition is ataxia telangiectasia (Louis-Barre syndrome), and/or wherein the heterologous nucleic acid sequence encodes serine protein kinase ATM (ATM) (e.g., a polypeptide represented by UniProt accession number Q13315 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1682. The method of embodiment 1177, wherein the disease or condition is attention deficit hyperactivity disorder (ADHD), and/or wherein the heterologous nucleic acid sequence encodes DRD4 (e.g., a polypeptide represented by UniProt Accession No. P21917 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1683. The method of embodiment 1177, wherein the disease or condition is attention deficit hyperactivity disorder (ADHD), and/or wherein the heterologous nucleic acid sequence encodes CDH2 (e.g., a polypeptide represented by UniProt Accession No. P19022 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1684. The method of embodiment 1177, wherein the disease or condition is Beck's muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes follistatin (FST) (e.g., a polypeptide represented by UniProt Accession No. P19883 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1685. The method of embodiment 1177, wherein the disease or condition is Beck's muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes DMD (e.g., a polypeptide represented by UniProt Accession No. P11532 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1686. The method of embodiment 1177, wherein the disease or condition is benign idiopathic eye spasm, and/or wherein the heterologous nucleic acid sequence encodes DRD5 (e.g., a polypeptide represented by UniProt Accession No. P21918 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1687. The method of embodiment 1177, wherein the disease or condition is Bradbury-Eggleston syndrome (pure autonomic nervous system failure), and/or wherein the heterologous nucleic acid sequence encodes COQ2 (e.g., a polypeptide represented by UniProt Accession No. Q96H96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1688. The method of embodiment 1177, wherein the disease or condition is bulbar palsy (BVVLS1), and/or wherein the heterologous nucleic acid sequence encodes SLC52A3 (e.g., a polypeptide represented by UniProt Accession No. Q9NQ40 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1689. The method of embodiment 1177, wherein the disease or condition is Canavan disease (aminoacylase 2 deficiency), and/or wherein the heterologous nucleic acid sequence encodes ASPA (e.g., a polypeptide represented by UniProt Accession No. P45381 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1690. The method of embodiment 1177, wherein the disease or condition is carpal tunnel syndrome, and/or wherein the heterologous nucleic acid sequence encodes TTR (e.g., a polypeptide represented by UniProt Accession No. P02766 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1691. The method of embodiment 1177, wherein the disease or condition is a cavernoma (spongioma, cavernous malformation), and/or wherein the heterologous nucleic acid sequence encodes KRIT1 (e.g., a polypeptide represented by UniProt Accession No. 000522 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1692. The method of embodiment 1177, wherein the disease or condition is cerebellar hypoplasia (CHEGDD), and/or wherein the heterologous nucleic acid sequence encodes OXR1 (e.g., a polypeptide represented by UniProt Accession No. Q8N573 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1693. The method of embodiment 1177, wherein the disease or condition is cerebellar ataxia (CAMRQ2), and/or wherein the heterologous nucleic acid sequence encodes WDR81 (e.g., a polypeptide represented by UniProt Accession No. Q562E7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1694. The method of embodiment 1177, wherein the disease or condition is cerebral arteriovenous disease associated with SCI and leukoencephalopathy (CADASIL), and/or wherein the heterologous nucleic acid sequence encodes NOTCH3 (e.g., a polypeptide represented by UniProt Accession No. Q9UM47 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1695. The method of embodiment 1177, wherein the disease or condition is cerebral gigantism (Soto's syndrome 1), and/or wherein the heterologous nucleic acid sequence encodes NSD1 (e.g., a polypeptide represented by UniProt accession number Q96L73 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1696. The method of embodiment 1177, wherein the disease or condition is cerebro-oculofacial-skeletal syndrome (COFS), and/or wherein the heterologous nucleic acid sequence encodes ERCC6 (e.g., a polypeptide represented by UniProt Accession No. Q03468 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1697. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN1 (PPT1) (e.g., a polypeptide represented by UniProt Accession No. P50897 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1698. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN2 (TPP1) (e.g., a polypeptide represented by UniProt Accession No. 014773 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1699. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Battenberg disease), and/or wherein the heterologous nucleic acid sequence encodes CLN3 (Battenberg disease protein) (e.g., a polypeptide represented by UniProt Accession No. Q13286 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1700. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN4 (e.g., a polypeptide represented by UniProt Accession No. Q9H3Z4 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1701. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN5 (e.g., a polypeptide represented by UniProt Accession No. 075503 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1702. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN6 (e.g., a polypeptide represented by UniProt Accession No. Q9NWW5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1703. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN7 (MFSD8) (e.g., a polypeptide represented by UniProt Accession No. Q8NHS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1704. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN8 (e.g., a polypeptide represented by UniProt Accession No. Q9UBY8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1705. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN10 (cathepsin D) (e.g., a polypeptide represented by UniProt Accession No. P07339 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1706. The method of embodiment 1177, wherein the disease or condition is clammy lipofuscinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN11 (granulin proprotein) (e.g., a polypeptide represented by UniProt Accession No. P28799 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1707. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN12 (ATP13A2) (e.g., a polypeptide represented by UniProt Accession No. Q9NQ11 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1708. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN13 (cathepsin F) (e.g., a polypeptide represented by UniProt Accession No. Q9UBX1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1709. The method of embodiment 1177, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN14 (KCTD7) (e.g., a polypeptide represented by UniProt Accession No. Q96MP8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1710. The method of embodiment 1177, wherein the disease or condition is Chuck-Murray-Dows disease, and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1711. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes MPZ (e.g., a polypeptide represented by UniProt Accession No. P25189 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1712. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes DNM2 (e.g., a polypeptide represented by UniProt Accession No. P50570 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1713. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes MFN2 (e.g., a polypeptide represented by UniProt Accession No. 095140 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1714. The method of embodiment 1177, wherein the disease or condition is Chuck-Murray-Dows disease, and/or wherein the heterologous nucleic acid sequence encodes KIF1B (e.g., a polypeptide represented by UniProt Accession No. 060333 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1715. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes SBF2 (e.g., a polypeptide represented by UniProt Accession No. Q86WG5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1716. The method of embodiment 1177, wherein the disease or condition is Chuck-Murray-Dows disease, and/or wherein the heterologous nucleic acid sequence encodes a PNKP (e.g., a polypeptide represented by UniProt Accession No. Q96T60 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1717. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes GDAP1 (e.g., a polypeptide represented by UniProt Accession No. Q8TB36 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1718. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes LMNA (e.g., a polypeptide represented by UniProt Accession No. P02545 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1719. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes FGD4 (e.g., a polypeptide represented by UniProt Accession No. Q96M96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1720. The method of embodiment 1177, wherein the disease or condition is Chuck-Marie-Dawley disease, and/or wherein the heterologous nucleic acid sequence encodes MTMR2 (e.g., a polypeptide represented by UniProt Accession No. Q13614 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1721. The method of embodiment 1177, wherein the disease or condition is chorea, and/or wherein the heterologous nucleic acid sequence encodes NKX2-1 (e.g., a polypeptide represented by UniProt Accession No. P43699 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1722. The method of embodiment 1177, wherein the disease or condition is chorea acanthocytosis, and/or wherein the heterologous nucleic acid sequence encodes VPS13A (e.g., a polypeptide represented by UniProt Accession No. Q96RL7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1723. The method of embodiment 1177, wherein the disease or condition is achoriocarcinoma, and/or wherein the heterologous nucleic acid sequence encodes Rab escort protein (Rep1) CHM (e.g., a polypeptide represented by UniProt Accession No. P24386 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1724. The method of embodiment 1177, wherein the disease or condition is Cockayne syndrome B (CSB), and/or wherein the heterologous nucleic acid sequence encodes ERCC6 (e.g., a polypeptide represented by UniProt Accession No. Q03468 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1725. The method of embodiment 1177, wherein the disease or condition is Crohn's disease, and/or wherein the heterologous nucleic acid sequence encodes RPS6KA3 (e.g., a polypeptide represented by UniProt Accession No. P51812 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1726. The method of embodiment 1177, wherein the disease or condition is craniosynostosis, and/or wherein the heterologous nucleic acid sequence encodes MSX2 (e.g., a polypeptide represented by UniProt Accession No. P35548 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1727. The method of embodiment 1177, wherein the disease or condition is craniosynostosis, and/or wherein the heterologous nucleic acid sequence encodes TWIST1 (e.g., a polypeptide represented by UniProt Accession No. Q15672 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1728. The method of embodiment 1177, wherein the disease or condition is craniosynostosis, and/or wherein the heterologous nucleic acid sequence encodes SKI (e.g., a polypeptide represented by UniProt Accession No. P12755 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1729. The method of embodiment 1177, wherein the disease or condition is craniosynostosis, and/or wherein the heterologous nucleic acid sequence encodes SMAD6 (e.g., a polypeptide represented by UniProt Accession No. 043541 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1730. The method of embodiment 1177, wherein the disease or condition is Creutzfeldt-Jakob disease, and/or wherein the heterologous nucleic acid sequence encodes a PRNP (e.g., a polypeptide represented by UniProt Accession No. P04156 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1731. The method of embodiment 1177, wherein the disease or condition is Creutzfeldt-Jakob disease, and/or wherein the heterologous nucleic acid sequence encodes HLA-DQB1 (e.g., a polypeptide represented by UniProt Accession No. P01920 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1732. The method of embodiment 1177, wherein the disease or condition is Kaplan-Meier syndrome (hyperbilirubinemia), and/or wherein the heterologous nucleic acid sequence encodes UDP-glucuronosyltransferase 1A1 (UGT1A1) (e.g., a polypeptide represented by UniProt Accession No. P22309 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1733. The method of embodiment 1177, wherein the disease or condition is Cushing's syndrome, and/or wherein the heterologous nucleic acid sequence encodes PRKACA (e.g., a polypeptide represented by UniProt Accession No. P17612 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1734. The method of embodiment 1177, wherein the disease or condition is dento-rubral atrophy (DRPLA), and/or wherein the heterologous nucleic acid sequence encodes ATN1 (e.g., a polypeptide represented by UniProt Accession No. P54259 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1735. The method of embodiment 1177, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes ARX (e.g., a polypeptide represented by UniProt Accession No. Q96QS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1736. The method of embodiment 1177, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes FGF12 (e.g., a polypeptide represented by UniProt Accession No. P61328 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1737. The method of embodiment 1177, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes a PIGP (e.g., a polypeptide represented by UniProt Accession No. P57054 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1738. The method of embodiment 1177, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes GABRB3 (e.g., a polypeptide represented by UniProt Accession No. P28472 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1739. The method of embodiment 1177, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes NECAP1 (e.g., a polypeptide represented by UniProt Accession No. Q8NC96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1740. The method of embodiment 1177, wherein the disease or condition is developmental dyspraxia (speech-language disorder 1 (SPCH1)), and/or wherein the heterologous nucleic acid sequence encodes FOXP2 (e.g., a polypeptide represented by UniProt Accession No. 015409 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1741. The method of embodiment 1177, wherein the disease or condition is Dravet syndrome, and/or wherein the heterologous nucleic acid sequence encodes sodium channel protein subunit alpha type 1 (SCN1A) (e.g., a polypeptide represented by UniProt accession number P35498 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1742. The method of embodiment 1177, wherein the disease or condition is Dravet syndrome, and/or wherein the heterologous nucleic acid sequence encodes SCN1B (e.g., a polypeptide represented by UniProt Accession No. Q07699 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1743. The method of embodiment 1177, wherein the disease or condition is Dravet syndrome, and/or wherein the heterologous nucleic acid sequence encodes SCN2A (e.g., a polypeptide represented by UniProt Accession No. Q99250 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1744. The method of embodiment 1177, wherein the disease or condition is Dravet syndrome, and/or wherein the heterologous nucleic acid sequence encodes GABA receptor subunit gamma-2 (GABRG2) (e.g., a polypeptide represented by UniProt Accession No. P18507 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1745. The method of embodiment 1177, wherein the disease or condition is autonomic nervous system disorder (Dye syndrome), and/or wherein the heterologous nucleic acid sequence encodes ELP1 (e.g., a polypeptide represented by UniProt accession number 095163 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1746. The method of embodiment 1177, wherein the disease or condition is dystonia, and/or wherein the heterologous nucleic acid sequence encodes GCH1 (e.g., a polypeptide represented by UniProt Accession No. P30793 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1747. The method of embodiment 1177, wherein the disease or condition is dystonia, and/or wherein the heterologous nucleic acid sequence encodes TOR1A (e.g., a polypeptide represented by UniProt Accession No. 014656 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1748. The method of embodiment 1177, wherein the disease or condition is dystonia, and/or wherein the heterologous nucleic acid sequence encodes SGCE (e.g., a polypeptide represented by UniProt Accession No. 043556 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1749. The method of embodiment 1177, wherein the disease or condition is dystonia, and/or wherein the heterologous nucleic acid sequence encodes TUBB4A (e.g., a polypeptide represented by UniProt Accession No. P04350 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1750. The method of embodiment 1177, wherein the disease or condition is encephalocele, and/or wherein the heterologous nucleic acid sequence encodes COL18A1 (e.g., a polypeptide represented by UniProt Accession No. P39060 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1751. The method of embodiment 1177, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes GRIN2A (e.g., a polypeptide represented by UniProt Accession No. Q12879 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1752. The method of embodiment 1177, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes CSTB (e.g., a polypeptide represented by UniProt Accession No. P04080 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1753. The method of embodiment 1177, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes STARD7 (e.g., a polypeptide represented by UniProt Accession No. Q9NQZ5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1754. The method of embodiment 1177, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes DEPDC5 (e.g., a polypeptide represented by UniProt Accession No. 075140 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1755. The method of embodiment 1177, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes PCDH19 (e.g., a polypeptide represented by UniProt Accession No. Q8TAB3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1756. The method of embodiment 1177, wherein the disease or condition is essential tremor, and/or wherein the heterologous nucleic acid sequence encodes DRD3 (e.g., a polypeptide represented by UniProt Accession No. P35462 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1757. The method of embodiment 1177, wherein the disease or condition is essential tremor, and/or wherein the heterologous nucleic acid sequence encodes NOTCH2NLC (e.g., a polypeptide represented by UniProt Accession No. P0DPK4 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1758. The method of embodiment 1177, wherein the disease or condition is essential tremor, and/or wherein the heterologous nucleic acid sequence encodes FUS (e.g., a polypeptide represented by UniProt Accession No. P35637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1759. The method of embodiment 1177, wherein the disease or condition is Fabry disease, and/or wherein the heterologous nucleic acid sequence encodes α-galactosidase A (GLA) (e.g., a polypeptide represented by UniProt Accession No. P06280 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1760. The method of embodiment 1177, wherein the disease or condition is Farber disease (neuramidase deficiency), and/or wherein the heterologous nucleic acid sequence encodes ASAH1 (e.g., a polypeptide represented by UniProt Accession No. Q13510 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1761. The method of embodiment 1177, wherein the disease or condition is Fahr's disease, and/or wherein the heterologous nucleic acid sequence encodes SLC20A2 (e.g., a polypeptide represented by UniProt Accession No. Q08357 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1762. The method of embodiment 1177, wherein the disease or condition is febrile epilepsy, and/or wherein the heterologous nucleic acid sequence encodes GABRG2 (e.g., a polypeptide represented by UniProt Accession No. P18507 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1763. The method of embodiment 1177, wherein the disease or condition is febrile epilepsy, and/or wherein the heterologous nucleic acid sequence encodes ADGRV1 (e.g., a polypeptide represented by UniProt Accession No. Q8WXG9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1764. The method of embodiment 1177, wherein the disease or condition is febrile epilepsy, and/or wherein the heterologous nucleic acid sequence encodes CPA6 (e.g., a polypeptide represented by UniProt Accession No. P11509 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1765. The method of embodiment 1177, wherein the disease or condition is febrile epilepsy, and/or wherein the heterologous nucleic acid sequence encodes SCN1A (e.g., a polypeptide represented by UniProt Accession No. P35498 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1766. The method of embodiment 1177, wherein the disease or condition is Friedreich's disease, and/or wherein the heterologous nucleic acid sequence encodes a protein called FXN (e.g., a polypeptide represented by UniProt Accession No. Q16595 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1767. The method of embodiment 1177, wherein the disease or condition is frontotemporal dementia, and/or wherein the heterologous nucleic acid sequence encodes a granulin precursor (GRN) (e.g., a polypeptide represented by UniProt Accession No. P28799 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1768. The method of embodiment 1177, wherein the disease or condition is frontotemporal dementia, and/or wherein the heterologous nucleic acid sequence encodes MAPT (tau) (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1769. The method of embodiment 1177, wherein the disease or condition is frontotemporal dementia, and/or wherein the heterologous nucleic acid sequence encodes PSEN1 (e.g., a polypeptide represented by UniProt Accession No. A0A024R6A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1770. The method of embodiment 1177, wherein the disease or condition is fucose deposition disease, and/or wherein the heterologous nucleic acid sequence encodes α-L-fucosidase (FUCA1) (e.g., a polypeptide represented by UniProt Accession No. P04066 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1771. The method of embodiment 1177, wherein the disease or condition is fundus alba, and/or wherein the heterologous nucleic acid sequence encodes RLBP1 (e.g., a polypeptide represented by UniProt Accession No. P12271 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1772. The method of embodiment 1177, wherein the disease or condition is Gaucher's disease (e.g., type I, II, or III), and/or wherein the heterologous nucleic acid sequence encodes glucocerebrosidase (GBA1) (e.g., a polypeptide represented by UniProt Accession No. P04062 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1773. The method of embodiment 1177, wherein the disease or condition is systemic gangliosidosis (e.g., GM1, GM2, or GM3), and/or wherein the heterologous nucleic acid sequence encodes GLB1 (e.g., a polypeptide represented by UniProt Accession No. P16278 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1774. The method of embodiment 1177, wherein the disease or condition is Gerstmann-Stausler-Scheinker disease, and/or wherein the heterologous nucleic acid sequence encodes a PRNP (e.g., a polypeptide represented by UniProt Accession No. P04156 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1775. The method of embodiment 1177, wherein the disease or condition is macroaxonal neuropathy, and/or wherein the heterologous nucleic acid sequence encodes a macroaxonal neuropathy protein (GAN) (e.g., a polypeptide represented by UniProt Accession No. Q9H2C0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1776. The method of embodiment 1177, wherein the disease or condition is glycogenostasis II (Pombe disease or acid maltase deficiency), and/or wherein the heterologous nucleic acid sequence encodes acid maltase (lysosomal α-glucosidase) (LYAG, GAA) (e.g., a polypeptide represented by UniProt Accession No. P10253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1777. The method of embodiment 1177, wherein the disease or condition is Guillain-Barré syndrome, and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1778. The method of embodiment 1177, wherein the disease or condition is chronic inflammatory demyelinating polyneuropathy (CIDP), and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1779. The method of embodiment 1177, wherein the disease or condition is Holloway-Spatz disease (PKAN or NBIA1), and/or wherein the heterologous nucleic acid sequence encodes PANK2 (e.g., a polypeptide represented by UniProt Accession No. Q9BZ23 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1780. The method of embodiment 1177, wherein the disease or condition is alternating hemiplegia, and/or wherein the heterologous nucleic acid sequence encodes ATP1A2 (e.g., a polypeptide represented by UniProt Accession No. P50993 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1781. The method of embodiment 1177, wherein the disease or condition is alternating hemiplegia, and/or wherein the heterologous nucleic acid sequence encodes ATP1A3 (e.g., a polypeptide represented by UniProt Accession No. P13637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1782. The method of embodiment 1177, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes WNK1 (e.g., a polypeptide represented by UniProt Accession No. Q9H4A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1783. The method of embodiment 1177, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes MFN2 (e.g., a polypeptide represented by UniProt Accession No. 095140 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1784. The method of embodiment 1177, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes HK1 (e.g., a polypeptide represented by UniProt Accession No. P19367 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1785. The method of embodiment 1177, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes TFG (e.g., a polypeptide represented by UniProt Accession No. Q92734 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1786. The method of embodiment 1177, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes SPTLC1 (e.g., a polypeptide represented by UniProt Accession No. 015269 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1787. The method of embodiment 1177, wherein the disease or condition is polyneuritis ataxia (Refsum's disease), and/or wherein the heterologous nucleic acid sequence encodes PHYH (e.g., a polypeptide represented by UniProt Accession No. 014832 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1788. The method of embodiment 1177, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes GLI2 (e.g., a polypeptide represented by UniProt Accession No. P10070 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1789. The method of embodiment 1177, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes TGIF1 (e.g., a polypeptide represented by UniProt Accession No. Q15583 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1790. The method of embodiment 1177, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes ZIC2 (e.g., a polypeptide represented by UniProt Accession No. 095409 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1791. The method of embodiment 1177, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes PTCH1 (e.g., a polypeptide represented by UniProt Accession No. Q13635 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1792. The method of embodiment 1177, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes SHH (e.g., a polypeptide represented by UniProt Accession No. Q15465 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1793. The method of embodiment 1177, wherein the disease or condition is Huntington's disease, and/or wherein the heterologous nucleic acid sequence encodes HTT (e.g., a polypeptide represented by UniProt Accession No. P42858 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1794. The method of embodiment 1177, wherein the disease or condition is hydrocephalus, and/or wherein the heterologous nucleic acid sequence encodes CCDC88C (e.g., a polypeptide represented by UniProt Accession No. Q9P219 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1795. The method of embodiment 1177, wherein the disease or condition is hydrocephalus, and/or wherein the heterologous nucleic acid sequence encodes WDR81 (e.g., a polypeptide represented by UniProt Accession No. Q562E7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1796. The method of embodiment 1177, wherein the disease or condition is hydrocephalus, and/or wherein the heterologous nucleic acid sequence encodes TRIM71 (e.g., a polypeptide represented by UniProt Accession No. Q2Q1W2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1797. The method of embodiment 1177, wherein the disease or condition is hydrocephalus, and/or wherein the heterologous nucleic acid sequence encodes MPDZ (e.g., a polypeptide represented by UniProt Accession No. 075970 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1798. The method of embodiment 1177, wherein the disease or condition is incontinentia pigmenti, and/or wherein the heterologous nucleic acid sequence encodes IKBKG (e.g., a polypeptide represented by UniProt Accession No. Q9Y6K9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1799. The method of embodiment 1177, wherein the disease or condition is juvenile hypotonia, and/or wherein the heterologous nucleic acid sequence encodes NALCN (e.g., a polypeptide represented by UniProt Accession No. Q8IZF0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1800. The method of embodiment 1177, wherein the disease or condition is juvenile hypotonia, and/or wherein the heterologous nucleic acid sequence encodes TBCK (e.g., a polypeptide represented by UniProt Accession No. Q8TEA7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1801. The method of embodiment 1177, wherein the disease or condition is juvenile hypotonia, and/or wherein the heterologous nucleic acid sequence encodes CCDC174 (e.g., a polypeptide represented by UniProt Accession No. Q6PII3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1802. The method of embodiment 1177, wherein the disease or condition is juvenile hypotonia, and/or wherein the heterologous nucleic acid sequence encodes UNC80 (e.g., a polypeptide represented by UniProt Accession No. Q8N2C7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1803. The method of embodiment 1177, wherein the disease or condition is childhood axonal dystrophy, and/or wherein the heterologous nucleic acid sequence encodes PLA2G6 (e.g., a polypeptide represented by UniProt Accession No. 060733 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1804. The method of embodiment 1177, wherein the disease or condition is juvenile phytanic acid storage disease (PBD1B), and/or wherein the heterologous nucleic acid sequence encodes PEX1 (e.g., a polypeptide represented by UniProt Accession No. 043933 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1805. The method of embodiment 1177, wherein the disease or condition is Joubert syndrome, and/or wherein the heterologous nucleic acid sequence encodes INPP5E (e.g., a polypeptide represented by UniProt Accession No. Q9NRR6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1806. The method of embodiment 1177, wherein the disease or condition is Kennedy's disease, and/or wherein the heterologous nucleic acid sequence encodes an androgen receptor (AR) (e.g., a polypeptide represented by UniProt Accession No. P10275 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1807. The method of embodiment 1177, wherein the disease or condition is KF syndrome, and/or wherein the heterologous nucleic acid sequence encodes GDF6 (e.g., a polypeptide represented by UniProt Accession No. Q6KF10 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1808. The method of embodiment 1177, wherein the disease or condition is Clappa disease (GALC deficiency), and/or wherein the heterologous nucleic acid sequence encodes GALC (e.g., a polypeptide represented by UniProt Accession No. P54803 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1809. The method of embodiment 1177, wherein the disease or condition is Lambert-Eaton myasthenia syndrome, and/or wherein the heterologous nucleic acid sequence encodes CACNA1A (e.g., a polypeptide represented by UniProt Accession No. 000555 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1810. The method of embodiment 1177, wherein the disease or condition is Lambert-Eaton myasthenia syndrome, and/or wherein the heterologous nucleic acid sequence encodes CACNB2 (e.g., a polypeptide represented by UniProt Accession No. Q13936 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1811. The method of embodiment 1177, wherein the disease or condition is Landau-Kleffner syndrome, and/or wherein the heterologous nucleic acid sequence encodes GRIN2A (e.g., a polypeptide represented by UniProt Accession No. Q12879 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1812. The method of embodiment 1177, wherein the disease or condition is late juvenile neuronal lipofuscinosis (CLN2), and/or wherein the heterologous nucleic acid sequence encodes TPP1 (e.g., a polypeptide represented by UniProt Accession No. 014773 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1813. The method of embodiment 1177, wherein the disease or condition is Reich-Nyhen syndrome, and/or wherein the heterologous nucleic acid sequence encodes HPRT1 (e.g., a polypeptide represented by UniProt Accession No. P00492 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1814. The method of embodiment 1177, wherein the disease or condition is Leber congenital amaurosis (retinal blindness), and/or wherein the heterologous nucleic acid sequence encodes retinal guanylate cyclase 1 (GUCY2D) (e.g., a polypeptide represented by UniProt Accession No. Q02846 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1815. The method of embodiment 1177, wherein the disease or condition is Leber congenital amaurosis (retinal blindness), and/or wherein the heterologous nucleic acid sequence encodes retinoid isosteric hydrolase (RPE65) (e.g., a polypeptide represented by UniProt Accession No. Q16518 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1816. The method of embodiment 1177, wherein the disease or condition is Leber congenital amaurosis (retinal blindness), and/or wherein the heterologous nucleic acid sequence encodes a 290 kDa centrosomal protein (CEP290) (e.g., a polypeptide represented by UniProt Accession No. 015078 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1817. The method of embodiment 1177, wherein the disease or condition is Leber congenital amaurosis (retinal blindness), and/or wherein the heterologous nucleic acid sequence encodes crumbs protein homolog 1 (CRB1) (e.g., a polypeptide represented by UniProt accession number P82279 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1818. The method of embodiment 1177, wherein the disease or condition is Leber's hereditary optic neuropathy, and/or wherein the heterologous nucleic acid sequence encodes NADH-ubiquinone oxidoreductase chain 4 (ND4) (e.g., a polypeptide represented by UniProt Accession No. P03905 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1819. The method of embodiment 1177, wherein the disease or condition is cerebral leukodystrophy, and/or wherein the heterologous nucleic acid sequence encodes ARSA (e.g., a polypeptide represented by UniProt Accession No. P15289 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1820. The method of embodiment 1177, wherein the disease or condition is Levine-Critchley syndrome (choreoacanthocytosis), and/or wherein the heterologous nucleic acid sequence encodes VPS13A (e.g., a polypeptide represented by UniProt Accession No. Q96RL7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1821. The method of embodiment 1177, wherein the disease or condition is dementia with Lewy bodies, and/or wherein the heterologous nucleic acid sequence encodes SNCA (e.g., a polypeptide represented by UniProt Accession No. P37840 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1822. The method of embodiment 1177, wherein the disease or condition is dementia with Lewy bodies, and/or wherein the heterologous nucleic acid sequence encodes SNCB (e.g., a polypeptide represented by UniProt Accession No. Q16143 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1823. The method of embodiment 1177, wherein the disease or condition is lipoproteinemia (Ulbach-Witt disease), and/or wherein the heterologous nucleic acid sequence encodes ECM1 (e.g., a polypeptide represented by UniProt Accession No. Q16610 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1824. The method of embodiment 1177, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes PAFAH1B1 (e.g., a polypeptide represented by UniProt Accession No. Q9PTR5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1825. The method of embodiment 1177, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes NDE1 (e.g., a polypeptide represented by UniProt Accession No. Q9NXR1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1826. The method of embodiment 1177, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes TUBA1A (e.g., a polypeptide represented by UniProt Accession No. Q71U36 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1827. The method of embodiment 1177, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes LAMB1 (e.g., a polypeptide represented by UniProt accession number LAMB1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1828. The method of embodiment 1177, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes KATNB1 (e.g., a polypeptide represented by UniProt Accession No. Q9BVA0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1829. The method of embodiment 1177, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes RELN (e.g., a polypeptide represented by UniProt Accession No. P78509 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1830. The method of embodiment 1177, wherein the disease or condition is macrocephaly/megalencephaly, and/or wherein the heterologous nucleic acid sequence encodes TBC1D7 (e.g., a polypeptide represented by UniProt Accession No. Q9P0N9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1831. The method of embodiment 1177, wherein the disease or condition is Menkes disease, and/or wherein the heterologous nucleic acid sequence encodes ATP7A (e.g., a polypeptide represented by UniProt Accession No. Q04656 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1832. The method of embodiment 1177, wherein the disease or condition is metachromatic leukodystrophy (MLD), and/or wherein the heterologous nucleic acid sequence encodes arylsulfatase A (ARSA) (e.g., a polypeptide represented by UniProt Accession No. P15289 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1833. The method of embodiment 1177, wherein the disease or condition is microcephaly, and/or wherein the heterologous nucleic acid sequence encodes KIF11 (e.g., a polypeptide represented by UniProt Accession No. P52732 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1834. The method of embodiment 1177, wherein the disease or condition is microcephaly, and/or wherein the heterologous nucleic acid sequence encodes MCPH1 (e.g., a polypeptide represented by UniProt Accession No. Q8NEM0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1835. The method of embodiment 1177, wherein the disease or condition is microcephaly, and/or wherein the heterologous nucleic acid sequence encodes SLC25A19 (e.g., a polypeptide represented by UniProt Accession No. Q9HC21 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1836. The method of embodiment 1177, wherein the disease or condition is familial hemicrania, and/or wherein the heterologous nucleic acid sequence encodes CACNA1A (e.g., a polypeptide represented by UniProt Accession No. 000555 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1837. The method of embodiment 1177, wherein the disease or condition is familial hemicrania, and/or wherein the heterologous nucleic acid sequence encodes ATP1A2 (e.g., a polypeptide represented by UniProt Accession No. P50993 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1838. The method of embodiment 1177, wherein the disease or condition is familial hemicrania, and/or wherein the heterologous nucleic acid sequence encodes SCN1A (e.g., a polypeptide represented by UniProt Accession No. P35498 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1839. The method of embodiment 1177, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes RRM2B (e.g., a polypeptide represented by UniProt Accession No. Q7LG56 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1840. The method of embodiment 1177, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes DGUOK (e.g., a polypeptide represented by UniProt Accession No. Q16854 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1841. The method of embodiment 1177, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes POLG (e.g., a polypeptide represented by UniProt Accession No. P54098 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1842. The method of embodiment 1177, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes TYMP (e.g., a polypeptide represented by UniProt Accession No. P19971 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1843. The method of embodiment 1177, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes TK2 (e.g., a polypeptide represented by UniProt Accession No. 000142 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1844. The method of embodiment 1177, wherein the disease or condition is Morvan's disease, and/or wherein the heterologous nucleic acid sequence encodes WNK1 (e.g., a polypeptide represented by UniProt Accession No. Q9H4A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1845. The method of embodiment 1177, wherein the disease or condition is mucolipidosis, and/or wherein the heterologous nucleic acid sequence encodes GNPTAB (e.g., a polypeptide represented by UniProt Accession No. Q3T906 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1846. The method of embodiment 1177, wherein the disease or condition is mucolipidosis, and/or wherein the heterologous nucleic acid sequence encodes MCOLN1 (e.g., a polypeptide represented by UniProt Accession No. Q9GZU1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1847. The method of embodiment 1177, wherein the disease or condition is mucopolysaccharidosis type I (MPS I) (Heller syndrome group), and/or wherein the heterologous nucleic acid sequence encodes α-L-iduronidase (IDUA) (e.g., a polypeptide represented by UniProt Accession No. P35475 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1848. The method of embodiment 1177, wherein the disease or condition is MPS II (Hunter syndrome), and/or wherein the heterologous nucleic acid sequence encodes iduronate-2-sulfatase (IDS) (e.g., a polypeptide represented by UniProt accession number P22304 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1849. The method of embodiment 1177, wherein the disease or condition is MPS IIIa (Sanfilippo syndrome type A), and/or wherein the heterologous nucleic acid sequence encodes heparan sulfate sulfatase (HSS) or N-sulfoglucosamine sulfohydrolase (SGSH) (e.g., a polypeptide represented by UniProt accession number P51688 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1850. The method of embodiment 1177, wherein the disease or condition is MPS IIIB (Sanfilippo syndrome type B), and/or wherein the heterologous nucleic acid sequence encodes N-acetyl-α-D-aminoglucosidase (NAGLU) (e.g., a polypeptide represented by UniProt accession number P54802 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1851. The method of embodiment 1177, wherein the disease or condition is MPS VI (Malot-Ramie syndrome), and/or wherein the heterologous nucleic acid sequence encodes arylsulfatase B (ARSB) (e.g., a polypeptide represented by UniProt Accession No. P15848 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1852. The method of embodiment 1177, wherein the disease or condition is MPS IV A (Morquet syndrome type A), and/or wherein the heterologous nucleic acid sequence encodes N-acetylgalactosamine-6-sulfatase (GALNS) (e.g., a polypeptide represented by UniProt accession number P34059 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1853. The method of embodiment 1177, wherein the disease or condition is MPS IV B (Morquet syndrome type B), and/or wherein the heterologous nucleic acid sequence encodes β-galactosidase 1 (GLB1) (e.g., a polypeptide represented by UniProt accession number P16278 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1854. The method of embodiment 1177, wherein the disease or condition is MPS VII (Steffen's syndrome), and/or wherein the heterologous nucleic acid sequence encodes a β-glucuronidase (e.g., a polypeptide represented by UniProt Accession No. P08236 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1855. The method of embodiment 1177, wherein the disease or condition is MPS VIII, and/or wherein the heterologous nucleic acid sequence encodes a glucosamine-6-sulfate sulfatase (e.g., a polypeptide represented by UniProt Accession No. P15586 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1856. The method of embodiment 1177, wherein the disease or condition is MPS IX, and/or wherein the heterologous nucleic acid sequence encodes hyaluronidase-1 (HYAL1) (e.g., a polypeptide represented by UniProt Accession No. Q12794 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1857. The method of embodiment 1177, wherein the disease or condition is multiple sclerosis, and/or wherein the heterologous nucleic acid sequence encodes PDCD1 (e.g., a polypeptide represented by UniProt Accession No. Q15116 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1858. The method of embodiment 1177, wherein the disease or condition is multisystem atrophy, and/or wherein the heterologous nucleic acid sequence encodes COQ2 (e.g., a polypeptide represented by UniProt Accession No. Q96H96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1859. The method of embodiment 1177, wherein the disease or condition is congenital presynaptic weakness, and/or wherein the heterologous nucleic acid sequence encodes CHAT (e.g., a polypeptide represented by UniProt Accession No. P28329 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1860. The method of embodiment 1177, wherein the disease or condition is myoclonus, and/or wherein the heterologous nucleic acid sequence encodes NOL3 (e.g., a polypeptide represented by UniProt Accession No. 060936 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1861. The method of embodiment 1177, wherein the disease or condition is myotonic spasticity and epilepsy (FAME2), and/or wherein the heterologous nucleic acid sequence encodes STARD7 (e.g., a polypeptide represented by UniProt Accession No. Q9NQZ5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1862. The method of embodiment 1177, wherein the disease or condition is narcolepsy, and/or wherein the heterologous nucleic acid sequence encodes HCRT (OX) (e.g., a polypeptide represented by UniProt Accession No. 043612 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1863. The method of embodiment 1177, wherein the disease or condition is narcolepsy, and/or wherein the heterologous nucleic acid sequence encodes MOG (e.g., a polypeptide represented by UniProt Accession No. Q16653 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1864. The method of embodiment 1177, wherein the disease or condition is neuroacanthocytosis (McCraw syndrome), and/or wherein the heterologous nucleic acid sequence encodes XK (e.g., a polypeptide represented by UniProt Accession No. P51811 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1865. The method of embodiment 1177, wherein the disease or condition is neurodevelopmental disorder with cerebral atrophy and facial dysmorphism (NEDCAFD), and/or wherein the heterologous nucleic acid sequence encodes TTC5 (e.g., a polypeptide represented by UniProt Accession No. Q8N0Z6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1866. The method of embodiment 1177, wherein the disease or condition is a neurodevelopmental disorder associated with infantile epileptic seizures, and/or wherein the heterologous nucleic acid sequence encodes NCDN (e.g., a polypeptide represented by UniProt Accession No. Q9UBB6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1867. The method of embodiment 1177, wherein the disease or condition is neurofibroma, and/or wherein the heterologous nucleic acid sequence encodes NF1 (e.g., a polypeptide represented by UniProt Accession No. P21359 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1868. The method of embodiment 1177, wherein the disease or condition is neuromyotonia, and/or wherein the heterologous nucleic acid sequence encodes HINT1 (e.g., a polypeptide represented by UniProt Accession No. P49773 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1869. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes PPT1 (e.g., a polypeptide represented by UniProt Accession No. P50897 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1870. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes TPP1 (e.g., a polypeptide represented by UniProt Accession No. 014773 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1871. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CLN5 (e.g., a polypeptide represented by UniProt Accession No. 075503 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1872. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CLN3 (e.g., a polypeptide represented by UniProt Accession No. Q13286 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1873. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CLN6 (e.g., a polypeptide represented by UniProt Accession No. Q9NWW5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1874. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CLN8 (e.g., a polypeptide represented by UniProt Accession No. Q9UBY8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1875. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes DNAJC5 (e.g., a polypeptide represented by UniProt Accession No. Q9H3Z4 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1876. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes MFSD8 (e.g., a polypeptide represented by UniProt Accession No. Q8NHS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1877. The method of embodiment 1177, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CTSD (e.g., a polypeptide represented by UniProt Accession No. P07339 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1878. The method of embodiment 1177, wherein the disease or condition is neuropathy, ataxia, and retinitis pigmentosa (NARP), and/or wherein the heterologous nucleic acid sequence encodes MTATP6 (e.g., a polypeptide represented by UniProt Accession No. P00846 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1879. The method of embodiment 1177, wherein the disease or condition is type II hereditary sensory and autonomic neuropathy, and/or wherein the heterologous nucleic acid sequence encodes WNK1 (e.g., a polypeptide represented by UniProt Accession No. Q9H4A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1880. The method of embodiment 1177, wherein the disease or condition is dysmyelinating congenital neuropathy 1, and/or wherein the heterologous nucleic acid sequence encodes EGR2 (e.g., a polypeptide represented by UniProt Accession No. P11161 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1881. The method of embodiment 1177, wherein the disease or condition is Niemann-Pick disease, and/or wherein the heterologous nucleic acid sequence encodes sphingomyelin phosphodiesterase 1 (SMPD1) (e.g., a polypeptide represented by UniProt Accession No. P17405 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1882. The method of embodiment 1177, wherein the disease or condition is Niemann-Pick disease, and/or wherein the heterologous nucleic acid sequence encodes NPC intracellular cholesterol transporter 1 (NPC1) (e.g., a polypeptide represented by UniProt Accession No. 015118 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1883. The method of embodiment 1177, wherein the disease or condition is Ohtahara syndrome (developmental and epileptic encephalopathy 1), and/or wherein the heterologous nucleic acid sequence encodes ARX (e.g., a polypeptide represented by UniProt accession number Q96QS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1884. The method of embodiment 1177, wherein the disease or condition is ornithine aminoformyl transferase deficiency, and/or wherein the heterologous nucleic acid sequence encodes OTC (e.g., a polypeptide represented by UniProt Accession No. P00480 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1885. The method of embodiment 1177, wherein the disease or condition is orthostatic intolerance, and/or wherein the heterologous nucleic acid sequence encodes SLC6A2 (e.g., a polypeptide represented by UniProt Accession No. P23975 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1886. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes glucocerebrosidase (GBA1) (e.g., a polypeptide represented by UniProt Accession No. P04062 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1887. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes dopamine decarboxylase (DDC) (e.g., a polypeptide represented by UniProt Accession No. P20711 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1888. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes a neurotrophin (e.g., a polypeptide represented by UniProt Accession No. Q99748 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1889. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes neuroglia-derived growth factor (GDGF) (e.g., a polypeptide represented by UniProt Accession No. P39905 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1890. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes tyrosine hydroxylase (TH) (tyrosine 3-monooxygenase) (e.g., a polypeptide represented by UniProt Accession No. P07101 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1891. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes glutamine decarboxylase (GAD) (e.g., a polypeptide represented by UniProt Accession No. Q99259 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1892. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes fibroblast growth factor 2 (FGF2) (e.g., a polypeptide represented by UniProt Accession No. P09038 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1893. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes brain-derived neurotrophic factor (BDNF) (e.g., a polypeptide represented by UniProt Accession No. P23560 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1894. The method of embodiment 1177, wherein the disease or condition is choreoathetosis, and/or wherein the heterologous nucleic acid sequence encodes PNKD (e.g., a polypeptide represented by UniProt Accession No. Q8N490 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1895. The method of embodiment 1177, wherein the disease or condition is Pelitzaus-Merzbacher disease, and/or wherein the heterologous nucleic acid sequence encodes PLP1 (e.g., a polypeptide represented by UniProt Accession No. P60201 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1896. The method of embodiment 1177, wherein the disease or condition is Pena-Schukel syndrome type II, and/or wherein the heterologous nucleic acid sequence encodes ERCC6 (e.g., a polypeptide represented by UniProt accession number Q03468 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1897. The method of embodiment 1177, wherein the disease or condition is periodic paralysis, and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1898. The method of embodiment 1177, wherein the disease or condition is Phelan-McCedar-Mead syndrome, and/or wherein the heterologous nucleic acid sequence encodes SH3 and multiple anchor protein repeat domains protein 3 (SHANK3) (e.g., a polypeptide represented by UniProt accession number Q9BYB0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1899. The method of embodiment 1177, wherein the disease or condition is phytanic acid storage disease (peroxisome biogenesis disorder 1B), and/or wherein the heterologous nucleic acid sequence encodes PEX1 (e.g., a polypeptide represented by UniProt Accession No. 043933 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1900. The method of embodiment 1177, wherein the disease or condition is Pick's disease, and/or wherein the heterologous nucleic acid sequence encodes PSEN1 (e.g., a polypeptide represented by UniProt Accession No. A0A024R6A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1901. The method of embodiment 1177, wherein the disease or condition is Pick's disease, and/or wherein the heterologous nucleic acid sequence encodes MAPT (tau) (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1902. The method of embodiment 1177, wherein the disease or condition is cerebral pyrenesia type 1, and/or wherein the heterologous nucleic acid sequence encodes COL4A1 (e.g., a polypeptide represented by UniProt Accession No. P02462 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1903. The method of embodiment 1177, wherein the disease or condition is juvenile primary lateral sclerosis, and/or wherein the heterologous nucleic acid sequence encodes ALS2 (e.g., a polypeptide represented by UniProt Accession No. Q96Q42 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1904. The method of embodiment 1177, wherein the disease or condition is primary progressive aphasia, and/or wherein the heterologous nucleic acid sequence encodes a GRN (e.g., a polypeptide represented by UniProt Accession No. P28799 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1905. The method of embodiment 1177, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes POLG (e.g., a polypeptide represented by UniProt Accession No. P54098 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1906. The method of embodiment 1177, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes POLG2 (e.g., a polypeptide represented by UniProt Accession No. Q9UHN1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1907. The method of embodiment 1177, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes SLC25A4 (e.g., a polypeptide represented by UniProt Accession No. P12235 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1908. The method of embodiment 1177, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes TWNK (e.g., a polypeptide represented by UniProt Accession No. Q96RR1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1909. The method of embodiment 1177, wherein the disease or condition is progressive bulbar palsy, and/or wherein the heterologous nucleic acid sequence encodes SLC52A3 (e.g., a polypeptide represented by UniProt Accession No. Q9NQ40 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1910. The method of embodiment 1177, wherein the disease or condition is progressive supranuclear neuropathy, and/or wherein the heterologous nucleic acid sequence encodes microtubule-associated protein tau (MAPT) Tau (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1911. The method of embodiment 1177, wherein the disease or condition is pseudo-Torch syndrome, and/or wherein the heterologous nucleic acid sequence encodes OCLN (e.g., a polypeptide represented by UniProt Accession No. Q16625 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1912. The method of embodiment 1177, wherein the disease or condition is pseudo-Torch syndrome, and/or wherein the heterologous nucleic acid sequence encodes STAT2 (e.g., a polypeptide represented by UniProt Accession No. P52630 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1913. The method of embodiment 1177, wherein the disease or condition is pseudo-Torch syndrome, and/or wherein the heterologous nucleic acid sequence encodes USP18 (e.g., a polypeptide represented by UniProt Accession No. Q9UMW8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1914. The method of embodiment 1177, wherein the disease or condition is Refsum's disease, and/or wherein the heterologous nucleic acid sequence encodes PHYH (e.g., a polypeptide represented by UniProt Accession No. 014832 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1915. The method of embodiment 1177, wherein the disease or condition is retinitis pigmentosa 38 (rod-cone dystrophy), and/or wherein the heterologous nucleic acid sequence encodes a tyrosine-protein kinase polymer (MERTK) (e.g., a polypeptide represented by UniProt Accession No. Q12866 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1916. The method of embodiment 1177, wherein the disease or condition is retinitis pigmentosa40, and/or wherein the heterologous nucleic acid sequence encodes PDE6B (e.g., a polypeptide represented by UniProt Accession No. P35913 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1917. The method of embodiment 1177, wherein the disease or condition is Rett syndrome, and/or wherein the heterologous nucleic acid sequence encodes methyl-CpG-binding protein 2 (MECP2) (e.g., a polypeptide represented by UniProt Accession No. P51608 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1918. The method of embodiment 1177, wherein the disease or condition is Sandhoff's disease, and/or wherein the heterologous nucleic acid sequence encodes β-hexosidase subunit alpha (HEXA) (e.g., a polypeptide represented by UniProt Accession No. P06865 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1919. The method of embodiment 1177, wherein the disease or condition is Sandhoff's disease, and/or wherein the heterologous nucleic acid sequence encodes β-hexosidase subunit β (HEXB) (e.g., a polypeptide represented by UniProt Accession No. P07686 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1920. The method of embodiment 1177, wherein the disease or condition is schizencephaly, and/or wherein the heterologous nucleic acid sequence encodes SIX3 (e.g., a polypeptide represented by UniProt Accession No. 095343 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1921. The method of embodiment 1177, wherein the disease or condition is schizencephaly, and/or wherein the heterologous nucleic acid sequence encodes EMX2 (e.g., a polypeptide represented by UniProt Accession No. Q04743 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1922. The method of embodiment 1177, wherein the disease or condition is schizencephaly, and/or wherein the heterologous nucleic acid sequence encodes SHH (e.g., a polypeptide represented by UniProt Accession No. Q15465 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1923. The method of embodiment 1177, wherein the disease or condition is Setelberg disease, and/or wherein the heterologous nucleic acid sequence encodes PLA2G6 (e.g., a polypeptide represented by UniProt Accession No. 060733 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1924. The method of embodiment 1177, wherein the disease or condition is septal optic dysplasia (Demersier syndrome), and/or wherein the heterologous nucleic acid sequence encodes HESX1 (e.g., a polypeptide represented by UniProt Accession No. Q9UBX0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1925. The method of embodiment 1177, wherein the disease or condition is Snydersbrock-Fisher syndrome, and/or wherein the heterologous nucleic acid sequence encodes POU3F3 (e.g., a polypeptide represented by UniProt Accession No. P20264 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1926. The method of embodiment 1177, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes SPG11 (e.g., a polypeptide represented by UniProt Accession No. Q96JI7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1927. The method of embodiment 1177, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes SPAST (e.g., a polypeptide represented by UniProt Accession No. Q9UBP0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1928. The method of embodiment 1177, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes KIF5A (e.g., a polypeptide represented by UniProt Accession No. Q12840 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1929. The method of embodiment 1177, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes NIPA1 (e.g., a polypeptide represented by UniProt Accession No. Q7RTP0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1930. The method of embodiment 1177, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes CYP7B1 (e.g., a polypeptide represented by UniProt Accession No. 075881 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1931. The method of embodiment 1177, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes ATL1 (e.g., a polypeptide represented by UniProt Accession No. Q8WXF7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1932. The method of embodiment 1177, wherein the disease or condition is spinal muscular atrophy (Kugelberg-Wiland disease), and/or wherein the heterologous nucleic acid sequence encodes the survival motor neuron protein (SMN) SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1933. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ataxin-1 (ATXN1) SCA1 (e.g., a polypeptide represented by UniProt Accession No. P54253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1934. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ataxin-2 (ATXN2) SCA2 (e.g., a polypeptide represented by UniProt Accession No. Q99700 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1935. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ataxin-3 (ATXN3) SCA3 (e.g., a polypeptide represented by UniProt Accession No. P54252 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1936. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ZFHX3 (e.g., a polypeptide represented by UniProt Accession No. Q15911 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1937. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes CACNA1A (e.g., a polypeptide represented by UniProt Accession No. 000555 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1938. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ATXN7 (SCA7) (e.g., a polypeptide represented by UniProt Accession No. 015265 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1939. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes TMEM240 (e.g., a polypeptide represented by UniProt Accession No. Q5SV17 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1940. The method of embodiment 1177, wherein the disease or condition is sporadic inclusion body myositis, and/or wherein the heterologous nucleic acid sequence encodes follistatin (FST) (e.g., a polypeptide represented by UniProt Accession No. P19883 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1941. The method of embodiment 1177, wherein the disease or condition is Still-Richard-Olszewski syndrome (Parkinson-Alzheimer's disease syndrome), and/or wherein the heterologous nucleic acid sequence encodes MAPT (Tau) (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1942. The method of embodiment 1177, wherein the disease or condition is congenital stiff-person syndrome, and/or wherein the heterologous nucleic acid sequence encodes GLRA1 (e.g., a polypeptide represented by UniProt Accession No. P23415 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1943. The method of embodiment 1177, wherein the disease or condition is congenital stiff-person syndrome, and/or wherein the heterologous nucleic acid sequence encodes GLRB (e.g., a polypeptide represented by UniProt Accession No. P48167 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1944. The method of embodiment 1177, wherein the disease or condition is substantia nigra, and/or wherein the heterologous nucleic acid sequence encodes NUP62 (e.g., a polypeptide represented by UniProt Accession No. P37198 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1945. The method of embodiment 1177, wherein the disease or condition is substantia nigra, and/or wherein the heterologous nucleic acid sequence encodes PDE8B (e.g., a polypeptide represented by UniProt Accession No. 095263 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1946. The method of embodiment 1177, wherein the disease or condition is substantia nigra, and/or wherein the heterologous nucleic acid sequence encodes MTATP6 (e.g., a polypeptide represented by UniProt Accession No. P00846 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1947. The method of embodiment 1177, wherein the disease or condition is substantia nigra, and/or wherein the heterologous nucleic acid sequence encodes VAC14 (e.g., a polypeptide represented by UniProt Accession No. Q08AM6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1948. The method of embodiment 1177, wherein the disease or condition is Sturge-Weber syndrome, and/or wherein the heterologous nucleic acid sequence encodes GNAQ (e.g., a polypeptide represented by UniProt Accession No. P50148 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1949. The method of embodiment 1177, wherein the disease or condition is subcortical vascular encephalopathy (cerebral arteriovenous disease), and/or wherein the heterologous nucleic acid sequence encodes HTRA1 (e.g., a polypeptide represented by UniProt Accession No. Q92743 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1950. The method of embodiment 1177, wherein the disease or condition is systemic lupus erythematosus, and/or wherein the heterologous nucleic acid sequence encodes DNASE1L3 (e.g., a polypeptide represented by UniProt Accession No. Q13609 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1951. The method of embodiment 1177, wherein the disease or condition is systemic lupus erythematosus, and/or wherein the heterologous nucleic acid sequence encodes TLR7 (e.g., a polypeptide represented by UniProt Accession No. Q9NYK1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1952. The method of embodiment 1177, wherein the disease or condition is delayed akinesia, and/or wherein the heterologous nucleic acid sequence encodes CYP2D6 (e.g., a polypeptide represented by UniProt Accession No. P10635 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1953. The method of embodiment 1177, wherein the disease or condition is Tay-Sachs disease, and/or wherein the heterologous nucleic acid sequence encodes β-hexosidase subunit alpha (HEXA) (e.g., a polypeptide represented by UniProt Accession No. P06865 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1954. The method of embodiment 1177, wherein the disease or condition is Tourette syndrome, and/or wherein the heterologous nucleic acid sequence encodes HDC (e.g., a polypeptide represented by UniProt Accession No. P19113 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1955. The method of embodiment 1177, wherein the disease or condition is Tourette syndrome, and/or wherein the heterologous nucleic acid sequence encodes SLITRK1 (e.g., a polypeptide represented by UniProt Accession No. Q96PX8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1956. The method of embodiment 1177, wherein the disease or condition is hereditary tremor type 1, and/or wherein the heterologous nucleic acid sequence encodes DRD3 (e.g., a polypeptide represented by UniProt Accession No. P35462 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1957. The method of embodiment 1177, wherein the disease or condition is Troye syndrome, and/or wherein the heterologous nucleic acid sequence encodes SPART (e.g., a polypeptide represented by UniProt Accession No. Q8N0X7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1958. The method of embodiment 1177, wherein the disease or condition is tuberous sclerosis, and/or wherein the heterologous nucleic acid sequence encodes TSC1 (e.g., a polypeptide represented by UniProt Accession No. Q92574 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1959. The method of embodiment 1177, wherein the disease or condition is tuberous sclerosis, and/or wherein the heterologous nucleic acid sequence encodes TSC2 (e.g., a polypeptide represented by UniProt Accession No. P49815 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1960. The method of embodiment 1177, wherein the disease or condition is tuberous sclerosis, and/or wherein the heterologous nucleic acid sequence encodes IFNG (e.g., a polypeptide represented by UniProt Accession No. P01579 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1961. The method of embodiment 1177, wherein the disease or condition is Van Hippel-Lindau disease, and/or wherein the heterologous nucleic acid sequence encodes VHL (e.g., a polypeptide represented by UniProt Accession No. P40337 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1962. The method of embodiment 1177, wherein the disease or condition is Van Hippel-Lindau disease, and/or wherein the heterologous nucleic acid sequence encodes CCND1 (e.g., a polypeptide represented by UniProt Accession No. P24385 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1963. The method of embodiment 1177, wherein the disease or condition is von Recklinghausen disease, and/or wherein the heterologous nucleic acid sequence encodes NF1 (e.g., a polypeptide represented by UniProt Accession No. P21359 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1964. The method of embodiment 1177, wherein the disease or condition is Wildnig-Hoffmann disease, and/or wherein the heterologous nucleic acid sequence encodes SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1965. The method of embodiment 1177, wherein the disease or condition is X-linked West syndrome, and/or wherein the heterologous nucleic acid sequence encodes ARX (e.g., a polypeptide represented by UniProt accession number Q96QS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1966. The method of embodiment 1177, wherein the disease or condition is Wilson's disease, and/or wherein the heterologous nucleic acid sequence encodes ATP7B (e.g., a polypeptide represented by UniProt Accession No. P35670 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1967. The method of embodiment 1177, wherein the disease or condition is Wolman's disease (acid lipase disease), and/or wherein the heterologous nucleic acid sequence encodes LIPA (e.g., a polypeptide represented by UniProt Accession No. P38571 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1968. The method of embodiment 1177, wherein the disease or condition is adrenoleukodystrophy X, and/or wherein the heterologous nucleic acid sequence encodes ATP-binding cassette family D member 1 (ABCD1) (e.g., a polypeptide represented by UniProt Accession No. P33897 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1969. The method of embodiment 1177, wherein the disease or condition is X-syndrome retinoschisis, and/or wherein the heterologous nucleic acid sequence encodes retinoschisis (RS1) (e.g., a polypeptide represented by UniProt Accession No. 015537 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1970. The method of embodiment 1177, wherein the disease or condition is X-linked retinitis pigmentosa, and/or wherein the heterologous nucleic acid sequence encodes X-linked retinitis pigmentosa GTPase regulator (RPGR) (e.g., a polypeptide represented by UniProt Accession No. Q92834 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1971. The method of embodiment 1177, wherein the disease or condition is X-linked spinal and bulbar muscular atrophy, and/or wherein the heterologous nucleic acid sequence encodes UBA1 (e.g., a polypeptide represented by UniProt Accession No. P22314 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1972. The method of embodiment 1177, wherein the disease or condition is advanced heart failure, and/or wherein the heterologous nucleic acid sequence encodes SERCA2a (ATP2A2) (e.g., a polypeptide represented by UniProt Accession No. P16615 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1973. The method of embodiment 1177, wherein the disease or condition is amyotrophic lateral sclerosis (ALS) (Lou Gehrig's disease), and/or wherein the heterologous nucleic acid sequence encodes superoxide dismutase-1 (SOD1) (e.g., a polypeptide represented by UniProt Accession No. P00441 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1974. The method of embodiment 1177, wherein the disease or condition is Anderson-Tavel syndrome, and/or wherein the heterologous nucleic acid sequence encodes KCNJ2 (e.g., a polypeptide represented by UniProt Accession No. P63252 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1975. The method of embodiment 1177, wherein the disease or condition is Barthel syndrome, and/or wherein the heterologous nucleic acid sequence encodes TAFAZZIN (e.g., a polypeptide represented by UniProt Accession No. Q16635 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1976. The method of embodiment 1177, wherein the disease or condition is Beck's muscular dystrophy (BMD), and/or wherein the heterologous nucleic acid sequence encodes DMD (e.g., a polypeptide represented by UniProt Accession No. P11532 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1977. The method of embodiment 1177, wherein the disease or condition is Beck's congenital myotonia, and/or wherein the heterologous nucleic acid sequence encodes CLCN1 (e.g., a polypeptide represented by UniProt Accession No. P35523 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1978. The method of embodiment 1177, wherein the disease or condition is Bethlem myopathy, and/or wherein the heterologous nucleic acid sequence encodes COL6A3 (e.g., a polypeptide represented by UniProt Accession No. P12111 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1979. The method of embodiment 1177, wherein the disease or condition is Bethlem myopathy, and/or wherein the heterologous nucleic acid sequence encodes COL6A2 (e.g., a polypeptide represented by UniProt Accession No. P12110 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1980. The method of embodiment 1177, wherein the disease or condition is Bethlem myopathy, and/or wherein the heterologous nucleic acid sequence encodes COL6A1 (e.g., a polypeptide represented by UniProt Accession No. P12109 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1981. The method of embodiment 1177, wherein the disease or condition is bulbar muscle atrophy, and/or wherein the heterologous nucleic acid sequence encodes AR (e.g., a polypeptide represented by UniProt Accession No. P10275 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1982. The method of embodiment 1177, wherein the disease or condition is systemic primary carnitine deficiency, and/or wherein the heterologous nucleic acid sequence encodes SLC22A5 (e.g., a polypeptide represented by UniProt Accession No. 076082 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1983. The method of embodiment 1177, wherein the disease or condition is carnitine acyltransferase deficiency type 1, and/or wherein the heterologous nucleic acid sequence encodes CPT1A (e.g., a polypeptide represented by UniProt Accession No. P50416 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1984. The method of embodiment 1177, wherein the disease or condition is carnitine acyltransferase deficiency type 2, and/or wherein the heterologous nucleic acid sequence encodes CPT2 (e.g., a polypeptide represented by UniProt Accession No. P23786 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1985. The method of embodiment 1177, wherein the disease or condition is catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2), and/or wherein the heterologous nucleic acid sequence encodes calcitonin-2 (CASQ2) (e.g., a polypeptide represented by UniProt Accession No. 014958 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1986. The method of embodiment 1177, wherein the disease or condition is central core disease (congenital myopathy type 1A), and/or wherein the heterologous nucleic acid sequence encodes RYR1 (e.g., a polypeptide represented by UniProt accession number P21817 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1987. The method of embodiment 1177, wherein the disease or condition is centronuclear myopathy type 1, and/or wherein the heterologous nucleic acid sequence encodes MTMR14 (e.g., a polypeptide represented by UniProt Accession No. Q8NCE2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1988. The method of embodiment 1177, wherein the disease or condition is centronuclear myopathy type 2, and/or wherein the heterologous nucleic acid sequence encodes DNM2 (e.g., a polypeptide represented by UniProt Accession No. 014717 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1989. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1990. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes MPZ (e.g., a polypeptide represented by UniProt Accession No. P25189 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1991. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes DNM2 (e.g., a polypeptide represented by UniProt Accession No. P50570 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1992. The method of embodiment 1177, wherein the disease or condition is Chuck-Marley-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes MFN2 (e.g., a polypeptide represented by UniProt Accession No. 095140 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1993. The method of embodiment 1177, wherein the disease or condition is Chuck-Murray-Dows disease, and/or wherein the heterologous nucleic acid sequence encodes KIF1B (e.g., a polypeptide represented by UniProt Accession No. 060333 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1994. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes SBF2 (e.g., a polypeptide represented by UniProt Accession No. Q86WG5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1995. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes a PNKP (e.g., a polypeptide represented by UniProt Accession No. Q96T60 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1996. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes GDAP1 (e.g., a polypeptide represented by UniProt Accession No. Q8TB36 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1997. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes LMNA (e.g., a polypeptide represented by UniProt Accession No. P02545 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1998. The method of embodiment 1177, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes FGD4 (e.g., a polypeptide represented by UniProt Accession No. Q96M96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 1999. The method of embodiment 1177, wherein the disease or condition is Chuck-Marie-Dawley disease, and/or wherein the heterologous nucleic acid sequence encodes MTMR2 (e.g., a polypeptide represented by UniProt Accession No. Q13614 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2000. The method of embodiment 1177, wherein the disease or condition is congenital muscular dystrophy (Ulrich's disease), and/or wherein the heterologous nucleic acid sequence encodes COL6A3 (e.g., a polypeptide represented by UniProt Accession No. P12111 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2001. The method of embodiment 1177, wherein the disease or condition is congenital muscular dystrophy (Ulrich's disease), and/or wherein the heterologous nucleic acid sequence encodes COL6A2 (e.g., a polypeptide represented by UniProt Accession No. P12110 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2002. The method of embodiment 1177, wherein the disease or condition is congenital muscular dystrophy (Ulrich's disease), and/or wherein the heterologous nucleic acid sequence encodes COL6A1 (e.g., a polypeptide represented by UniProt Accession No. P12109 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2003. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes COLQ (e.g., a polypeptide represented by UniProt Accession No. Q9Y215 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2004. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes AGRN (e.g., a polypeptide represented by UniProt Accession No. 000468 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2005. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes RAPSN (e.g., a polypeptide represented by UniProt Accession No. Q13702 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2006. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes GFPT1 (e.g., a polypeptide represented by UniProt Accession No. Q06210 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2007. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2008. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes ALG2 (e.g., a polypeptide represented by UniProt Accession No. Q9H553 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2009. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes ALG14 (e.g., a polypeptide represented by UniProt Accession No. Q96F25 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2010. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes DPAGT1 (e.g., a polypeptide represented by UniProt Accession No. Q9H3H5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2011. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes CHRNE (e.g., a polypeptide represented by UniProt Accession No. Q04844 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2012. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes CHRNA1 (e.g., a polypeptide represented by UniProt Accession No. P02708 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2013. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes DOK7 (e.g., a polypeptide represented by UniProt Accession No. Q18PE1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2014. The method of embodiment 1177, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes CHAT (e.g., a polypeptide represented by UniProt Accession No. P28329 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2015. The method of embodiment 1177, wherein the disease or condition is congenital myopathy, and/or wherein the heterologous nucleic acid sequence encodes ACTA1 (e.g., a polypeptide represented by UniProt Accession No. P68133 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2016. The method of embodiment 1177, wherein the disease or condition is congenital myopathy, and/or wherein the heterologous nucleic acid sequence encodes STAC3 (e.g., a polypeptide represented by UniProt Accession No. Q96MF2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2017. The method of embodiment 1177, wherein the disease or condition is congenital myopathy, and/or wherein the heterologous nucleic acid sequence encodes TPM3 (e.g., a polypeptide represented by UniProt Accession No. P06753 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2018. The method of embodiment 1177, wherein the disease or condition is myotonic dystrophy, and/or wherein the heterologous nucleic acid sequence encodes DMPK (e.g., a polypeptide represented by UniProt Accession No. Q09013 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2019. The method of embodiment 1177, wherein the disease or condition is Corey's disease (debranching enzyme deficiency or Forbes' disease), and/or wherein the heterologous nucleic acid sequence encodes AGL (e.g., a polypeptide represented by UniProt Accession No. P35573 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2020. The method of embodiment 1177, wherein the disease or condition is Danon disease, and/or wherein the heterologous nucleic acid sequence encodes LAMP2 (e.g., a polypeptide represented by UniProt Accession No. P13473 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2021. The method of embodiment 1177, wherein the disease or condition is Dezeen-Sotta disease, and/or wherein the heterologous nucleic acid sequence encodes MPZ (e.g., a polypeptide represented by UniProt Accession No. P25189 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2022. The method of embodiment 1177, wherein the disease or condition is Dezeen-Sotta disease, and/or wherein the heterologous nucleic acid sequence encodes EGR2 (e.g., a polypeptide represented by UniProt Accession No. P11161 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2023. The method of embodiment 1177, wherein the disease or condition is Dezeen-Sotta disease, and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2024. The method of embodiment 1177, wherein the disease or condition is Dezeen-Sotta disease, and/or wherein the heterologous nucleic acid sequence encodes PRX (e.g., a polypeptide represented by UniProt Accession No. Q9BXM0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2025. The method of embodiment 1177, wherein the disease or condition is Wieland's distal muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes TIA1 (e.g., a polypeptide represented by UniProt Accession No. P31483 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2026. The method of embodiment 1177, wherein the disease or condition is Miyoshi's distal muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes DYSF (e.g., a polypeptide represented by UniProt Accession No. 075923 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2027. The method of embodiment 1177, wherein the disease or condition is distal myopathy with anterior tibialis attack, and/or wherein the heterologous nucleic acid sequence encodes DYSF (e.g., a polypeptide represented by UniProt Accession No. 075923 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2028. The method of embodiment 1177, wherein the disease or condition is Duchenne muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes a muscular dystrophy protein (DMD) (e.g., a polypeptide represented by UniProt Accession No. P11532 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2029. The method of embodiment 1177, wherein the disease or condition is Duchenne muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes GALGT2 (B4GALNT2) (e.g., a polypeptide represented by UniProt Accession No. Q8NHY0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2030. The method of embodiment 1177, wherein the disease or condition is Dysforin disease, and/or wherein the heterologous nucleic acid sequence encodes a Dysforin protein (DYSF) (e.g., a polypeptide represented by UniProt Accession No. 075923 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2031. The method of embodiment 1177, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes EMD (e.g., a polypeptide represented by UniProt Accession No. P50402 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2032. The method of embodiment 1177, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes SYNE1 (e.g., a polypeptide represented by UniProt Accession No. Q8NF91 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2033. The method of embodiment 1177, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes SYNE2 (e.g., a polypeptide represented by UniProt Accession No. Q8WXH0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2034. The method of embodiment 1177, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes TMEM43 (e.g., a polypeptide represented by UniProt Accession No. Q9BTV4 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2035. The method of embodiment 1177, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes LMNA (e.g., a polypeptide represented by UniProt Accession No. P02545 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2036. The method of embodiment 1177, wherein the disease or condition is Ehrenberg disease (paramyotonia congenita), and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2037. The method of embodiment 1177, wherein the disease or condition is facioscapulohumeral muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes SMCHD1 (e.g., a polypeptide represented by UniProt Accession No. A6NHR9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2038. The method of embodiment 1177, wherein the disease or condition is facioscapulohumeral muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes LRIF1 (e.g., a polypeptide represented by UniProt Accession No. Q5T3J3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2039. The method of embodiment 1177, wherein the disease or condition is Friedreich's disease, and/or wherein the heterologous nucleic acid sequence encodes a protein called FXN (e.g., a polypeptide represented by UniProt Accession No. Q16595 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2040. The method of embodiment 1177, wherein the disease or condition is Fukuyama congenital muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes FKTN (e.g., a polypeptide represented by UniProt Accession No. 075072 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2041. The method of embodiment 1177, wherein the disease or condition is glycogenostasis II (Pombe disease or acid maltase deficiency), and/or wherein the heterologous nucleic acid sequence encodes GAA (e.g., a polypeptide represented by UniProt Accession No. P10253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2042. The method of embodiment 1177, wherein the disease or condition is type 10 glycogenopathies (glycogenopathies X), and/or wherein the heterologous nucleic acid sequence encodes PGAM2 (e.g., a polypeptide represented by UniProt Accession No. P15259 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2043. The method of embodiment 1177, wherein the disease or condition is type 11 glycogenopathies (glycogenopathies XI), and/or wherein the heterologous nucleic acid sequence encodes LDHA (e.g., a polypeptide represented by UniProt accession number P00338 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2044. The method of embodiment 1177, wherein the disease or condition is type 2 glycogenopathies (glycogenostasis II or Pompe disease or acid maltase deficiency), and/or wherein the heterologous nucleic acid sequence encodes GAA (e.g., a polypeptide represented by UniProt accession number P10253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2045. The method of embodiment 1177, wherein the disease or condition is type 3 glycogenopathies (glycogenostasis III), and/or wherein the heterologous nucleic acid sequence encodes AGL (e.g., a polypeptide represented by UniProt accession number P35573 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2046. The method of embodiment 1177, wherein the disease or condition is type 5 glycogenopathies (glycogenostasis V or McArdle's disease or myophosphokinase deficiency), and/or wherein the heterologous nucleic acid sequence encodes PYGM (e.g., a polypeptide represented by UniProt accession number P11217 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2047. The method of embodiment 1177, wherein the disease or condition is type 7 glycogenopathies (glycogenostasis VII or phosphofructokinase deficiency or Tay's disease), and/or wherein the heterologous nucleic acid sequence encodes PFKM (e.g., a polypeptide represented by UniProt Accession No. P08237 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2048. The method of embodiment 1177, wherein the disease or condition is type 9 glycogenopathies (glycogenostasis IX), and/or wherein the heterologous nucleic acid sequence encodes PHKB (e.g., a polypeptide represented by UniProt accession number Q93100 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2049. The method of embodiment 1177, wherein the disease or condition is type 9 glycogenopathies (glycogenopathies IX), and/or wherein the heterologous nucleic acid sequence encodes PHKA2 (e.g., a polypeptide represented by UniProt Accession No. P46019 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2050. The method of embodiment 1177, wherein the disease or condition is hereditary inclusion body myositis, and/or wherein the heterologous nucleic acid sequence encodes GNE (e.g., a polypeptide represented by UniProt Accession No. Q9Y223 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2051. The method of embodiment 1177, wherein the disease or condition is integrin-deficient congenital muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes ITGA7 (e.g., a polypeptide represented by UniProt Accession No. Q13683 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2052. The method of embodiment 1177, wherein the disease or condition is Kennedy's disease (spondylobular muscular atrophy), and/or wherein the heterologous nucleic acid sequence encodes an androgen receptor (AR) (e.g., a polypeptide represented by UniProt Accession No. P10275 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2053. The method of embodiment 1177, wherein the disease or condition is Kugelberg-Wiland disease, and/or wherein the heterologous nucleic acid sequence encodes SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2054. The method of embodiment 1177, wherein the disease or condition is lactate dehydrogenase A deficiency, and/or wherein the heterologous nucleic acid sequence encodes LDHA (e.g., a polypeptide represented by UniProt Accession No. P00338 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2055. The method of embodiment 1177, wherein the disease or condition is lactate dehydrogenase B deficiency, and/or wherein the heterologous nucleic acid sequence encodes LDHB (e.g., a polypeptide represented by UniProt Accession No. P07195 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2056. The method of embodiment 1177, wherein the disease or condition is Lambert-Eaton myasthenia syndrome, and/or wherein the heterologous nucleic acid sequence encodes CACNB2 (e.g., a polypeptide represented by UniProt Accession No. Q08289 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2057. The method of embodiment 1177, wherein the disease or condition is Ryan distal myopathy, and/or wherein the heterologous nucleic acid sequence encodes MYH7 (e.g., a polypeptide represented by UniProt Accession No. A7E2Y1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2058. The method of embodiment 1177, wherein the disease or condition is limb-girdle muscular dystrophy type 2C (LGMD-2C), and/or wherein the heterologous nucleic acid sequence encodes a γ-sarcoglycan (e.g., a polypeptide represented by UniProt accession number Q13326 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2059. The method of embodiment 1177, wherein the disease or condition is limb-girdle muscular dystrophy type 2D (LGMD-2D), and/or wherein the heterologous nucleic acid sequence encodes α-sarcoglycan (e.g., a polypeptide represented by UniProt Accession No. Q16586 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2060. The method of embodiment 1177, wherein the disease or condition is limb-girdle muscular dystrophy type 2E (LGMD-2E), and/or wherein the heterologous nucleic acid sequence encodes β-sarcoglycan (e.g., a polypeptide represented by UniProt accession number Q16585 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2061. The method of embodiment 1177, wherein the disease or condition is limb-girdle muscular dystrophy type 2F (LGMD-2F), and/or wherein the heterologous nucleic acid sequence encodes a delta-sarcoglycan (e.g., a polypeptide represented by UniProt Accession No. Q92629 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2062. The method of embodiment 1177, wherein the disease or condition is laminarin-deficient congenital muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes LAMA2 (e.g., a polypeptide represented by UniProt Accession No. P24043 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2063. The method of embodiment 1177, wherein the disease or condition is myo-o-encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes POMGNT1 (e.g., a polypeptide represented by UniProt Accession No. Q8WZA1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2064. The method of embodiment 1177, wherein the disease or condition is mitochondrial myopathy, and/or wherein the heterologous nucleic acid sequence encodes CHCHD10 (e.g., a polypeptide represented by UniProt Accession No. Q8WYQ3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2065. The method of embodiment 1177, wherein the disease or condition is Miyoshi myopathy, and/or wherein the heterologous nucleic acid sequence encodes DYSF (e.g., a polypeptide represented by UniProt Accession No. 075923 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2066. The method of embodiment 1177, wherein the disease or condition is myoadenylate deaminase deficiency, and/or wherein the heterologous nucleic acid sequence encodes AMPD1 (e.g., a polypeptide represented by UniProt Accession No. P23109 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2067. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 1, and/or wherein the heterologous nucleic acid sequence encodes DES (e.g., a polypeptide represented by UniProt Accession No. P17661 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2068. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 2, and/or wherein the heterologous nucleic acid sequence encodes CRYAB (e.g., a polypeptide represented by UniProt Accession No. P02511 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2069. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 3, and/or wherein the heterologous nucleic acid sequence encodes MYOT (e.g., a polypeptide represented by UniProt Accession No. Q9UBF9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2070. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 4 (ZASP-associated myopathy), and/or wherein the heterologous nucleic acid sequence encodes LDB3 (ZASP) (e.g., a polypeptide represented by UniProt Accession No. 075112 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2071. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 5, and/or wherein the heterologous nucleic acid sequence encodes FLNC (e.g., a polypeptide represented by UniProt Accession No. Q14315 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2072. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 6, and/or wherein the heterologous nucleic acid sequence encodes BAG3 (e.g., a polypeptide represented by UniProt Accession No. 095817 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2073. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 7, and/or wherein the heterologous nucleic acid sequence encodes KY (e.g., a polypeptide represented by UniProt Accession No. Q8NBH2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2074. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 8, and/or wherein the heterologous nucleic acid sequence encodes PYROXD1 (e.g., a polypeptide represented by UniProt Accession No. Q8WU10 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2075. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 9, and/or wherein the heterologous nucleic acid sequence encodes TTN (e.g., a polypeptide represented by UniProt Accession No. Q8WZ42 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2076. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 10, and/or wherein the heterologous nucleic acid sequence encodes SVIL (e.g., a polypeptide represented by UniProt Accession No. 095425 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2077. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 11, and/or wherein the heterologous nucleic acid sequence encodes UNC45B (e.g., a polypeptide represented by UniProt Accession No. Q8IWX7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2078. The method of embodiment 1177, wherein the disease or condition is myofibrillar myopathy 12, and/or wherein the heterologous nucleic acid sequence encodes MYL2 (e.g., a polypeptide represented by UniProt Accession No. Q99972 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2079. The method of embodiment 1177, wherein the disease or condition is myotonic dystrophy type 1 (Steinert disease), and/or wherein the heterologous nucleic acid sequence encodes a myotonic protein kinase (DMPK) (e.g., a polypeptide represented by UniProt Accession No. Q09013 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2080. The method of embodiment 1177, wherein the disease or condition is myotonic dystrophy type 2, and/or wherein the heterologous nucleic acid sequence encodes a CNBP (e.g., a polypeptide represented by UniProt Accession No. P62633 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2081. The method of embodiment 1177, wherein the disease or condition is myomicrotubular myopathy, and/or wherein the heterologous nucleic acid sequence encodes MTM1 (e.g., a polypeptide represented by UniProt Accession No. Q13496 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2082. The method of embodiment 1177, wherein the disease or condition is myopathy 1, and/or wherein the heterologous nucleic acid sequence encodes TPM3 (e.g., a polypeptide represented by UniProt Accession No. P06753 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2083. The method of embodiment 1177, wherein the disease or condition is myopathy 2, and/or wherein the heterologous nucleic acid sequence encodes NEB (e.g., a polypeptide represented by UniProt Accession No. P20929 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2084. The method of embodiment 1177, wherein the disease or condition is myopathy 5A, 5B, or 5C, and/or wherein the heterologous nucleic acid sequence encodes TNNT1 (e.g., a polypeptide represented by UniProt Accession No. P13805 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2085. The method of embodiment 1177, wherein the disease or condition is myopathy 3, and/or wherein the heterologous nucleic acid sequence encodes ACTA1 (e.g., a polypeptide represented by UniProt Accession No. P68133 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2086. The method of embodiment 1177, wherein the disease or condition is myopathy 6, and/or wherein the heterologous nucleic acid sequence encodes KBTBD13 (e.g., a polypeptide represented by UniProt Accession No. C9JR72 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2087. The method of embodiment 1177, wherein the disease or condition is myopathy 4, and/or wherein the heterologous nucleic acid sequence encodes TPM2 (e.g., a polypeptide represented by UniProt Accession No. P07951 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2088. The method of embodiment 1177, wherein the disease or condition is myopathy 7, and/or wherein the heterologous nucleic acid sequence encodes CFL2 (e.g., a polypeptide represented by UniProt Accession No. Q9Y281 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2089. The method of embodiment 1177, wherein the disease or condition is myopathy 8, and/or wherein the heterologous nucleic acid sequence encodes KLHL40 (e.g., a polypeptide represented by UniProt Accession No. Q2TBA0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2090. The method of embodiment 1177, wherein the disease or condition is myopathy 9, and/or wherein the heterologous nucleic acid sequence encodes KLHL41 (e.g., a polypeptide represented by UniProt Accession No. 060662 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2091. The method of embodiment 1177, wherein the disease or condition is myopathy 10, and/or wherein the heterologous nucleic acid sequence encodes LMOD3 (e.g., a polypeptide represented by UniProt Accession No. Q0VAK6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2092. The method of embodiment 1177, wherein the disease or condition is distal myopathy, and/or wherein the heterologous nucleic acid sequence encodes GNE (e.g., a polypeptide represented by UniProt Accession No. Q9Y223 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2093. The method of embodiment 1177, wherein the disease or condition is oculopharyngeal muscle atrophy, and/or wherein the heterologous nucleic acid sequence encodes PABPN1 (e.g., a polypeptide represented by UniProt Accession No. Q86U42 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2094. The method of embodiment 1177, wherein the disease or condition is ornithine aminoformyl transferase deficiency, and/or wherein the heterologous nucleic acid sequence encodes OTC (e.g., a polypeptide represented by UniProt Accession No. P00480 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2095. The method of embodiment 1177, wherein the disease or condition is myotonia congenita, and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2096. The method of embodiment 1177, wherein the disease or condition is hypokalemic periodic paralysis, and/or wherein the heterologous nucleic acid sequence encodes CACNA1S (e.g., a polypeptide represented by UniProt Accession No. Q13698 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2097. The method of embodiment 1177, wherein the disease or condition is hyperkalemic periodic paralysis, and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2098. The method of embodiment 1177, wherein the disease or condition is phosphoglycerate kinase deficiency, and/or wherein the heterologous nucleic acid sequence encodes PGK1 (e.g., a polypeptide represented by UniProt Accession No. P00558 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2099. The method of embodiment 1177, wherein the disease or condition is polymyositis, and/or wherein the heterologous nucleic acid sequence encodes PMSCL2 (e.g., a polypeptide represented by UniProt Accession No. Q01780 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2100. The method of embodiment 1177, wherein the disease or condition is polymyositis, and/or wherein the heterologous nucleic acid sequence encodes PMSCL1 (e.g., a polypeptide represented by UniProt Accession No. Q06265 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2101. The method of embodiment 1177, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes POLG (e.g., a polypeptide represented by UniProt Accession No. P54098 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2102. The method of embodiment 1177, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes POLG2 (e.g., a polypeptide represented by UniProt Accession No. Q9UHN1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2103. The method of embodiment 1177, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes SLC25A4 (e.g., a polypeptide represented by UniProt Accession No. P12235 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2104. The method of embodiment 1177, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes TWNK (e.g., a polypeptide represented by UniProt Accession No. Q96RR1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2105. The method of embodiment 1177, wherein the disease or condition is spinal muscular atrophy type 3 - Kugelberg-Wiland disease, and/or wherein the heterologous nucleic acid sequence encodes the survival motor neuron protein (SMN) SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2106. The method of embodiment 1177, wherein the disease or condition is Thompson's disease (myotonia congenita (somatic dominant)), and/or wherein the heterologous nucleic acid sequence encodes CLCN1 (e.g., a polypeptide represented by UniProt Accession No. P35523 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2107. The method of embodiment 1177, wherein the disease or condition is Walker-Warburg syndrome, and/or wherein the heterologous nucleic acid sequence encodes POMT1 (e.g., a polypeptide represented by UniProt Accession No. Q9Y6A1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2108. The method of embodiment 1177, wherein the disease or condition is X-linked microtubular myopathy, and/or wherein the heterologous nucleic acid sequence encodes myotubularin (MTM1) (e.g., a polypeptide represented by UniProt Accession No. Q13496 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2109. The method of embodiment 1177, wherein the disease or condition is Wednig-Hoffmann disease - spinal muscular atrophy type 1, and/or wherein the heterologous nucleic acid sequence encodes SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2110. The method of embodiment 1177, wherein the disease or condition is amyotrophic lateral sclerosis, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting superoxide dismutase 1 (SOD 1) (e.g., targeting RNA encoding a polypeptide represented by UniProt Accession No. P00441 or comprising an amino acid sequence having at least 95% sequence identity thereto). 2111. The method of embodiment 1177, wherein the disease or condition is amyotrophic lateral sclerosis, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting C9orf72 (e.g., targeting RNA encoding a polypeptide represented by UniProt Accession No. Q96LT7 or comprising an amino acid sequence having at least 95% sequence identity thereto). 2112. The method of embodiment 1177, wherein the disease or condition is Huntington's disease, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting Huntington's protein (HTT) (e.g., targeting RNA encoding a polypeptide represented by UniProt Accession No. P42858 or comprising an amino acid sequence having at least 95% sequence identity thereto). 2113. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting sortin-related receptor (SORL1) (e.g., targeting RNA encoding a polypeptide represented by UniProt Accession No. Q92673 or comprising an amino acid sequence having at least 95% sequence identity thereto). 2114. The method of embodiment 1177, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting neutral neurophospholipase (N-SMase; SMPD2) (e.g., targeting RNA encoding a polypeptide represented by UniProt Accession No. 060906 or comprising an amino acid sequence having at least 95% sequence identity thereto). 2115. The method of embodiment 1177, wherein the disease or condition is spinocerebellar ataxia type 2, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting ataxin-2 (ATXN2) (e.g., targeting RNA encoding a polypeptide represented by UniProt Accession No. Q99700 or comprising an amino acid sequence having at least 95% sequence identity thereto). 2116. The method of embodiment 1177, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting human SNCA (e.g., targeting RNA encoding a polypeptide represented by UniProt Accession No. P37840 or comprising an amino acid sequence having at least 95% sequence identity thereto). 2117. The method of embodiment 1176, wherein the disease or condition is a disease or condition of skeletal muscle. 2118. The method of Example 2117, wherein the disease or condition of skeletal muscle is acid maltase deficiency (AMD), amyotrophic lateral sclerosis (ALS), Anderson-Tawel syndrome, Barthel syndrome (TAZ), Beck muscular dystrophy (BMD), Beck congenital myotonia, Bethlem myopathy, bulbar muscular dystrophy (spondylobula), carnitine deficiency, carnitine palmitoyltransferase deficiency (CPT deficiency), central nuclear disease (CCD), central nuclear myopathy, Chuck-Marie-Duzin disease (CMT), congenital muscular dystrophy (CMD), congenital myotonic syndrome (CMS), congenital myotonic dystrophy, Corey's disease (debrachial enzyme deficiency), Danon's disease, debrachial enzyme deficiency, Dezeen- Duchenne muscular dystrophy (DSD), dermatomyositis (DM), distal muscular dystrophy (DD), distal myopathy with anterior tibial attacks, Duchenne muscular dystrophy (DMD), myotonic dystrophy (myotonic dystrophy), Emery-Dreyfus muscular dystrophy (EDMD), endocrine myopathy, Ehrenberg disease (congenital myotonia), facioscapulohumeral muscular dystrophy dystrophies (FSH or FSHD), Finnish distal myopathy, Forbes disease (debrachial myopathy), Friedreich's ataxia (FA), Fukuyama congenital muscular dystrophy, glycogenotype 10, glycogenotype 11, glycogenotype 2, glycogenotype 3, glycogenotype 5, glycogenotype 7, glycogenotype 9, Galls-Lane distal myopathy, Hauptmann-Tanhauser MD Emery-Dreyfus muscular dystrophy, hereditary inclusion body myositis, hereditary motor and sensory neuropathy (Chuck-Marley-Doucet disease), hyperthyroid myopathy, hypothyroid myopathy, inclusion body myositis (IBM), hereditary myopathies, integrin-deficient congenital muscular dystrophy, Kennedy disease (spondylobular atrophy), Kugelberg-Wieland disease (spinal muscular atrophy), lactate dehydrogenase deficiency, Lambert-Eaton myasthenia syndrome (LEMS), limb-girdle muscular dystrophy LGMD, Lou Gehrig's disease (muscular dystrophy), McArdle disease (phosphorylase deficiency), platelet-deficient congenital muscular dystrophy, muscle metabolic disease, mitochondrial myopathy, Miyoshi myopathy, Miyoshi distal myopathy, motor neuron disease, muscle-eye-encephalopathy, myasthenia gravis (MG), myoadenylate deaminase deficiency, myofibrillar myopathy, myophosphorylase deficiency, myotonia congenita (MC), myotonic muscular dystrophy (MMD), myotonic microtubular myopathy Myopathy (MTM or MM), myopathy, distal nonaka myopathy, oculopharyngeal muscle atrophy (OPMD), paramyotonia congenita, Pearson syndrome, periodic palsy, Charcot-Marie-Tooth disease (Chuck-Marie-Tooth disease), phosphofructokinase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, phosphorylase deficiency, phosphorylase deficiency, polymyositis (PM), Pompe disease (acid maltase deficiency), primary laminarin deficiency (LAMA2), progressive Patients with PEO, rod-like myopathy, spinal muscular atrophy (SMA), spondylobular muscular atrophy (SBMA), Steinert disease, Taret disease, myotonia congenita, Ulrich congenital muscular dystrophy, Walker-Warburg syndrome, Wieland distal myopathy, Wedniger-Hoffmann disease, or ZASP-related myopathy. 2119. The method of Example 2117, wherein the skeletal muscle disease or condition is acid maltase deficiency (AMD). 2120. The method of Example 2117, wherein the skeletal muscle disease or condition is amyotrophic lateral sclerosis (ALS). 2121. The method of embodiment 2117, wherein the skeletal muscle disease or condition is Anderson-Tavel syndrome. 2122. The method of embodiment 2117, wherein the skeletal muscle disease or condition is Barthel syndrome (TAZ). 2123. The method of embodiment 2117, wherein the skeletal muscle disease or condition is Beck's muscular dystrophy (BMD). 2124. The method of Example 2117, wherein the skeletal muscle disease or condition is Beck's congenital myotonia. 2125. The method of Example 2117, wherein the skeletal muscle disease or condition is Bethlem myopathy. 2126. The method of Example 2117, wherein the skeletal muscle disease or condition is bulbar muscle atrophy (spondylobular atrophy). 2127. The method of Example 2117, wherein the skeletal muscle disease or condition is carnitine deficiency. 2128. The method of Example 2117, wherein the skeletal muscle disease or condition is carnitine palmitoyltransferase deficiency (CPT deficiency). 2129. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is central core disease (CCD). 2130. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is centronuclear myopathy. 2131. The method of embodiment 2117, wherein the skeletal muscle disease or condition is Chuck-Malley-Dixie disease (CMT). 2132. The method of Example 2117, wherein the skeletal muscle disease or condition is congenital muscular dystrophy (CMD). 2133. The method of Example 2117, wherein the skeletal muscle disease or condition is congenital myasthenia gravis (CMS). 2134. The method of Example 2117, wherein the skeletal muscle disease or condition is myotonic dystrophy. 2135. The method of Example 2117, wherein the skeletal muscle disease or condition is Corey's disease (debrenning enzyme deficiency). 2136. The method of embodiment 2117, wherein the skeletal muscle disease or condition is Danon's disease. 2137. The method of Example 2117, wherein the disease or condition of skeletal muscle is debrenase deficiency. 2138. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is Dementia-Schönlein disease (DSD). 2139. The method of Example 2117, wherein the skeletal muscle disease or condition is dermatomyositis (DM). 2140. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is distal muscular dystrophy (DD). 2141. The method of Example 2117, wherein the skeletal muscle disease or condition is distal myopathy with anterior tibialis attacks. 2142. The method of Example 2117, wherein the skeletal muscle disease or condition is Duchenne muscular dystrophy (DMD). 2143. The method of Example 2117, wherein the skeletal muscle disease or condition is myotonic dystrophy. 2144. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is Emery-Dreyfus muscular dystrophy (EDMD). 2145. The method of Example 2117, wherein the skeletal muscle disease or condition is an endocrine myopathy. 2146. The method of Example 2117, wherein the skeletal muscle disease or condition is Ehrenberg disease (paramyotonia congenita). 2147. The method of Example 2117, wherein the skeletal muscle disease or condition is facioscapulohumeral muscular dystrophy (FSH or FSHD). 2148. The method of Example 2117, wherein the skeletal muscle disease or condition is Finnish distal tibia myopathy. 2149. The method of Example 2117, wherein the disease or condition of skeletal muscle is Forbes' disease (debrenning enzyme deficiency). 2150. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is Friedreich's ataxia (FA). 2151. The method of Example 2117, wherein the skeletal muscle disease or condition is Fukuyama congenital muscular dystrophy. 2152. The method of Example 2117, wherein the skeletal muscle disease or condition is type 10 glycogenosis. 2153. The method of Example 2117, wherein the skeletal muscle disease or condition is type 11 glycogenosis. 2154. The method of Example 2117, wherein the skeletal muscle disease or condition is type 2 glycogenosis. 2155. The method of Example 2117, wherein the skeletal muscle disease or condition is type 3 glycogenosis. 2156. The method of embodiment 2117, wherein the skeletal muscle disease or condition is type 5 glycogenosis. 2157. The method of Example 2117, wherein the skeletal muscle disease or condition is type 7 glycogenosis. 2158. The method of Example 2117, wherein the skeletal muscle disease or condition is type 9 glycogenosis. 2159. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is Gowers-Lyne distal myopathy. 2160. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is Hauptmann-Tanhauser MD (Emery-Dreyfus muscular dystrophy). 2161. The method of Example 2117, wherein the skeletal muscle disease or condition is hereditary inclusion body myositis. 2162. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is hereditary motor and sensory neuropathy (Chuck-Marie-Dew disease). 2163. The method of Example 2117, wherein the skeletal muscle disease or condition is hyperthyroidism myopathy. 2164. The method of Example 2117, wherein the skeletal muscle disease or condition is hypothyroidism myopathy. 2165. The method of Example 2117, wherein the skeletal muscle disease or condition is inclusion body myositis (IBM). 2166. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is a hereditary myopathy. 2167. The method of Example 2117, wherein the skeletal muscle disease or condition is integrin-deficient congenital muscular dystrophy. 2168. The method of Example 2117, wherein the skeletal muscle disease or condition is Kennedy's disease (spondylobular atrophy). 2169. The method of embodiment 2117, wherein the skeletal muscle disease or condition is Kugelberg-Wiland disease (spinal muscular atrophy). 2170. The method of Example 2117, wherein the disease or condition of skeletal muscle is lactate dehydrogenase deficiency. 2171. The method of embodiment 2117, wherein the skeletal muscle disease or condition is Lambert-Eaton myasthenia syndrome (LEMS). 2172. The method of embodiment 2117, wherein the skeletal muscle disease or condition is limb-girdle muscular dystrophy (LGMD). 2173. The method of Example 2117, wherein the skeletal muscle disease or condition is Lou Gehrig's disease (amyotrophic lateral sclerosis). 2174. The method of Example 2117, wherein the skeletal muscle disease or condition is McArdle's disease (phosphorylase deficiency). 2175. The method of Example 2117, wherein the skeletal muscle disease or condition is muscular dystrophy. 2176. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is a muscle metabolic disease. 2177. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is mitochondrial myopathy. 2178. The method of Example 2117, wherein the skeletal muscle disease or condition is Miyoshi myopathy. 2179. The method of Example 2117, wherein the skeletal muscle disease or condition is Miyoshi distal myopathy. 2180. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is a motor neuron disease. 2181. The method of Example 2117, wherein the skeletal muscle disease or condition is a muscle-eye-brain disease. 2182. The method of embodiment 2117, wherein the skeletal muscle disease or condition is myasthenia gravis (MG). 2183. The method of Example 2117, wherein the disease or condition of skeletal muscle is myoadenylate deaminase deficiency. 2184. The method of Example 2117, wherein the disease or condition of skeletal muscle is myofibrillar myopathy. 2185. The method of Example 2117, wherein the skeletal muscle disease or condition is muscle phosphorylase deficiency. 2186. The method of Example 2117, wherein the skeletal muscle disease or condition is myotonia congenita (MC). 2187. The method of Example 2117, wherein the skeletal muscle disease or condition is myotonic muscular dystrophy (MMD). 2188. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is myomicrotubular myopathy (MTM or MM). 2189. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is myopathy. 2190. The method of embodiment 2117, wherein the skeletal muscle disease or condition is distal myopathy. 2191. The method of Example 2117, wherein the skeletal muscle disease or condition is oculopharyngeal muscle atrophy (OPMD). 2192. The method of Example 2117, wherein the skeletal muscle disease or condition is paramyotonia congenita. 2193. The method of embodiment 2117, wherein the skeletal muscle disease or condition is Pearson syndrome. 2194. The method of Example 2117, wherein the skeletal muscle disease or condition is recurrent paralysis. 2195. The method of Example 2117, wherein the skeletal muscle disease or condition is Charcot-Marie-Tooth disease. 2196. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is phosphofructokinase deficiency. 2197. The method of Example 2117, wherein the skeletal muscle disease or condition is phosphoglycerate kinase deficiency. 2198. The method of embodiment 2117, wherein the skeletal muscle disease or condition is phosphoglycerate mutase deficiency. 2199. The method of Example 2117, wherein the disease or condition of skeletal muscle is phosphorylase deficiency. 2200. The method of Example 2117, wherein the skeletal muscle disease or condition is polymyositis (PM). 2201. The method of Example 2117, wherein the skeletal muscle disease or condition is Pompe disease (acid maltase deficiency). 2202. The method of Example 2117, wherein the skeletal muscle disease or condition is LAMA2 deficiency. 2203. The method of Example 2117, wherein the skeletal muscle disease or condition is progressive external ophthalmoplegia (PEO). 2204. The method of Example 2117, wherein the skeletal muscle disease or condition is nematode myopathy. 2205. The method of Example 2117, wherein the skeletal muscle disease or condition is muscular dystrophy (SMA). 2206. The method of Example 2117, wherein the skeletal muscle disease or condition is spondylobular muscular atrophy (SBMA). 2207. The method of Example 2117, wherein the skeletal muscle disease or condition is Steinert's disease (myotonic muscular dystrophy). 2208. The method of Example 2117, wherein the skeletal muscle disease or condition is Tayre's disease (phosphofructokinase deficiency). 2209. The method of Example 2117, wherein the skeletal muscle disease or condition is Thompson's disease (myotonia congenita). 2210. The method of Example 2117, wherein the skeletal muscle disease or condition is Ulrich congenital muscular dystrophy. 2211. The method of Example 2117, wherein the skeletal muscle disease or condition is Walker-Warburg syndrome (congenital muscular dystrophy). 2212. The method of embodiment 2117, wherein the disease or condition of skeletal muscle is Wieland distal myopathy. 2213. The method of Example 2117, wherein the skeletal muscle disease or condition is Wednig-Hoffmann disease (spinal muscular atrophy). 2214. The method of Example 2117, wherein the skeletal muscle disease or condition is ZASP-related myopathy. 2215. The method of embodiment 2117, wherein the disease or condition is achromatopsia (color blindness), and/or wherein the heterologous nucleic acid sequence encodes cyclic nucleotide-gated cation channel alpha-3 (CNGA3) (e.g., a polypeptide represented by UniProt Accession No. Q16281 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2216. The method of embodiment 2117, wherein the disease or condition is achromatopsia (color blindness), and/or wherein the heterologous nucleic acid sequence encodes cyclic nucleotide-gated cation channel beta-3 (CNGB3) (e.g., a polypeptide represented by UniProt Accession No. Q9NQW8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2217. The method of embodiment 2117, wherein the disease or condition is achromatopsia (color blindness), and/or wherein the heterologous nucleic acid sequence encodes guanine nucleotide-binding protein G(t) subunit alpha-2 (GNAT2) (e.g., a polypeptide represented by UniProt Accession No. P19087 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2218. The method of embodiment 2117, wherein the disease or condition is achromatopsia (color blindness), and/or wherein the heterologous nucleic acid sequence encodes cone-shaped cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha (PDE6C) (e.g., a polypeptide represented by UniProt Accession No. P51160 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2219. The method of embodiment 2117, wherein the disease or condition is acute intermittent porphyria, and/or wherein the heterologous nucleic acid sequence encodes bile chromogen deaminase (PBGD) HMBS (e.g., a polypeptide represented by UniProt Accession No. P08397 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2220. The method of embodiment 2117, wherein the disease or condition is Addison's syndrome (Addison's pupil), and/or wherein the heterologous nucleic acid sequence encodes MPZ (e.g., a polypeptide represented by UniProt Accession No. P25189 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2221. The method of embodiment 2117, wherein the disease or condition is age-related macular degeneration, and/or wherein the heterologous nucleic acid sequence encodes vascular endothelial growth factor receptor 1 (FLT1) (e.g., a polypeptide represented by UniProt Accession No. P17948 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2222. The method of embodiment 2117, wherein the disease or condition is age-related macular degeneration, and/or wherein the heterologous nucleic acid sequence encodes vascular endothelial growth factor A (VEGFA) (e.g., a polypeptide represented by UniProt Accession No. P15692 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2223. The method of embodiment 2117, wherein the disease or condition is agenesis of the corpus callosum (ACCPN), and/or wherein the heterologous nucleic acid sequence encodes SLC12A6 (e.g., a polypeptide represented by UniProt Accession No. Q9UHW9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2224. The method of embodiment 2117, wherein the disease or condition is Icardi-Guterres syndrome, and/or wherein the heterologous nucleic acid sequence encodes TREX1 (e.g., a polypeptide represented by UniProt Accession No. Q9NSU2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2225. The method of embodiment 2117, wherein the disease or condition is Alexander's disease, and/or wherein the heterologous nucleic acid sequence encodes GFAP (e.g., a polypeptide represented by UniProt Accession No. P14136 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2226. The method of embodiment 2117, wherein the disease or condition is Alpers syndrome, and/or wherein the heterologous nucleic acid sequence encodes POLG (e.g., a polypeptide represented by UniProt Accession No. P54098 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2227. The method of embodiment 2117, wherein the disease or condition is alternating hemiplegia, and/or wherein the heterologous nucleic acid sequence encodes ATP1A2 (e.g., a polypeptide represented by UniProt Accession No. P50993 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2228. The method of embodiment 2117, wherein the disease or condition is alternating hemiplegia, and/or wherein the heterologous nucleic acid sequence encodes ATP1A3 (e.g., a polypeptide represented by UniProt Accession No. P13637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2229. The method of embodiment 2117, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes NGF (e.g., a polypeptide represented by UniProt Accession No. P01138 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2230. The method of embodiment 2117, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes ApoE (e.g., a polypeptide represented by UniProt Accession No. P02649 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2231. The method of embodiment 2117, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes presenilin (PSEN1) (e.g., a polypeptide represented by UniProt Accession No. A0A024R6A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2232. The method of embodiment 2117, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes presenilin-2 (PSEN2) (e.g., a polypeptide represented by UniProt Accession No. P49810 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2233. The method of embodiment 2117, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes amyloid-β proprotein (APP) (e.g., a polypeptide represented by UniProt Accession No. P05067 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2234. The method of embodiment 2117, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes ADAM10 (e.g., a polypeptide represented by UniProt Accession No. 014672 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2235. The method of embodiment 2117, wherein the disease or condition is Alzheimer's disease, and/or wherein the heterologous nucleic acid sequence encodes MAPT (Tau) (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2236. The method of embodiment 2117, wherein the disease or condition is amyotrophic lateral sclerosis (ALS) (Lou Gehrig's disease), and/or wherein the heterologous nucleic acid sequence encodes superoxide dismutase-1 (SOD1) (e.g., a polypeptide represented by UniProt Accession No. P00441 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2237. The method of embodiment 2117, wherein the disease or condition is hereditary neuromuscular atrophy, and/or wherein the heterologous nucleic acid sequence encodes 45544 (e.g., a polypeptide represented by UniProt Accession No. Q9UHD8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2238. The method of embodiment 2117, wherein the disease or condition is Angelman syndrome, and/or wherein the heterologous nucleic acid sequence encodes ubiquitin protein ligase E3A (UBE3A) (e.g., a polypeptide represented by UniProt Accession No. Q05086 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2239. The method of embodiment 2117, wherein the disease or condition is aromatic L-amino acid decarboxylase deficiency (AADCD), and/or wherein the heterologous nucleic acid sequence encodes DDC (e.g., a polypeptide represented by UniProt Accession No. P20711 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2240. The method of embodiment 2117, wherein the disease or condition is ataxia, and/or wherein the heterologous nucleic acid sequence encodes APTX (e.g., a polypeptide represented by UniProt Accession No. Q7Z2E3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2241. The method of embodiment 2117, wherein the disease or condition is ataxia, and/or wherein the heterologous nucleic acid sequence encodes KCNA1 (e.g., a polypeptide represented by UniProt Accession No. Q09470 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2242. The method of embodiment 2117, wherein the disease or condition is ataxia, and/or wherein the heterologous nucleic acid sequence encodes CACNA1A (e.g., a polypeptide represented by UniProt Accession No. 000555 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2243. The method of embodiment 2117, wherein the disease or condition is ataxia telangiectasia (Louis-Barre syndrome), and/or wherein the heterologous nucleic acid sequence encodes a serine protein kinase ATM (ATM) (e.g., a polypeptide represented by UniProt accession number Q13315 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2244. The method of embodiment 2117, wherein the disease or condition is attention deficit hyperactivity disorder (ADHD), and/or wherein the heterologous nucleic acid sequence encodes DRD4 (e.g., a polypeptide represented by UniProt Accession No. P21917 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2245. The method of embodiment 2117, wherein the disease or condition is attention deficit hyperactivity disorder (ADHD), and/or wherein the heterologous nucleic acid sequence encodes CDH2 (e.g., a polypeptide represented by UniProt Accession No. P19022 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2246. The method of embodiment 2117, wherein the disease or condition is Beck's muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes follistatin (FST) (e.g., a polypeptide represented by UniProt Accession No. P19883 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2247. The method of embodiment 2117, wherein the disease or condition is Beck's muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes DMD (e.g., a polypeptide represented by UniProt Accession No. P11532 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2248. The method of embodiment 2117, wherein the disease or condition is benign idiopathic eye spasm, and/or wherein the heterologous nucleic acid sequence encodes DRD5 (e.g., a polypeptide represented by UniProt Accession No. P21918 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2249. The method of embodiment 2117, wherein the disease or condition is Bradbury-Eggleston syndrome (pure autonomic nervous system failure), and/or wherein the heterologous nucleic acid sequence encodes COQ2 (e.g., a polypeptide represented by UniProt accession number Q96H96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2250. The method of embodiment 2117, wherein the disease or condition is bulbar palsy (BVVLS1), and/or wherein the heterologous nucleic acid sequence encodes SLC52A3 (e.g., a polypeptide represented by UniProt Accession No. Q9NQ40 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2251. The method of embodiment 2117, wherein the disease or condition is Canavan disease (aminoacylase 2 deficiency), and/or wherein the heterologous nucleic acid sequence encodes ASPA (e.g., a polypeptide represented by UniProt Accession No. P45381 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2252. The method of embodiment 2117, wherein the disease or condition is carpal tunnel syndrome, and/or wherein the heterologous nucleic acid sequence encodes TTR (e.g., a polypeptide represented by UniProt Accession No. P02766 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2253. The method of embodiment 2117, wherein the disease or condition is a cavernoma (spongioma, cavernous malformation), and/or wherein the heterologous nucleic acid sequence encodes KRIT1 (e.g., a polypeptide represented by UniProt Accession No. 000522 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2254. The method of embodiment 2117, wherein the disease or condition is cerebellar hypoplasia (CHEGDD), and/or wherein the heterologous nucleic acid sequence encodes OXR1 (e.g., a polypeptide represented by UniProt Accession No. Q8N573 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2255. The method of embodiment 2117, wherein the disease or condition is cerebellar ataxia (CAMRQ2), and/or wherein the heterologous nucleic acid sequence encodes WDR81 (e.g., a polypeptide represented by UniProt Accession No. Q562E7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2256. The method of embodiment 2117, wherein the disease or condition is cerebral arteriovenous disease associated with SCI and leukoencephalopathy (CADASIL), and/or wherein the heterologous nucleic acid sequence encodes NOTCH3 (e.g., a polypeptide represented by UniProt Accession No. Q9UM47 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2257. The method of embodiment 2117, wherein the disease or condition is cerebral gigantism (Soto's syndrome 1), and/or wherein the heterologous nucleic acid sequence encodes NSD1 (e.g., a polypeptide represented by UniProt accession number Q96L73 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2258. The method of embodiment 2117, wherein the disease or condition is cerebro-oculofacial-skeletal syndrome (COFS), and/or wherein the heterologous nucleic acid sequence encodes ERCC6 (e.g., a polypeptide represented by UniProt Accession No. Q03468 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2259. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN1 (PPT1) (e.g., a polypeptide represented by UniProt Accession No. P50897 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2260. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN2 (TPP1) (e.g., a polypeptide represented by UniProt Accession No. 014773 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2261. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Battenberg disease), and/or wherein the heterologous nucleic acid sequence encodes CLN3 (Battenberg disease protein) (e.g., a polypeptide represented by UniProt accession number Q13286 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2262. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN4 (e.g., a polypeptide represented by UniProt Accession No. Q9H3Z4 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2263. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN5 (e.g., a polypeptide represented by UniProt Accession No. 075503 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2264. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN6 (e.g., a polypeptide represented by UniProt Accession No. Q9NWW5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2265. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN7 (MFSD8) (e.g., a polypeptide represented by UniProt Accession No. Q8NHS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2266. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN8 (e.g., a polypeptide represented by UniProt Accession No. Q9UBY8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2267. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN10 (cathepsin D) (e.g., a polypeptide represented by UniProt Accession No. P07339 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2268. The method of embodiment 2117, wherein the disease or condition is clammy lipofuscinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN11 (granulin proprotein) (e.g., a polypeptide represented by UniProt Accession No. P28799 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2269. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN12 (ATP13A2) (e.g., a polypeptide represented by UniProt Accession No. Q9NQ11 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2270. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN13 (cathepsin F) (e.g., a polypeptide represented by UniProt Accession No. Q9UBX1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2271. The method of embodiment 2117, wherein the disease or condition is ceratopsinosis (Baden's disease), and/or wherein the heterologous nucleic acid sequence encodes CLN14 (KCTD7) (e.g., a polypeptide represented by UniProt Accession No. Q96MP8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2272. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2273. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes MPZ (e.g., a polypeptide represented by UniProt Accession No. P25189 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2274. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes DNM2 (e.g., a polypeptide represented by UniProt Accession No. P50570 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2275. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes MFN2 (e.g., a polypeptide represented by UniProt Accession No. 095140 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2276. The method of embodiment 2117, wherein the disease or condition is Chuck-Murray-Dows disease, and/or wherein the heterologous nucleic acid sequence encodes KIF1B (e.g., a polypeptide represented by UniProt Accession No. 060333 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2277. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes SBF2 (e.g., a polypeptide represented by UniProt Accession No. Q86WG5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2278. The method of embodiment 2117, wherein the disease or condition is Chuck-Murray-Dows disease, and/or wherein the heterologous nucleic acid sequence encodes a PNKP (e.g., a polypeptide represented by UniProt Accession No. Q96T60 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2279. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes GDAP1 (e.g., a polypeptide represented by UniProt Accession No. Q8TB36 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2280. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes LMNA (e.g., a polypeptide represented by UniProt Accession No. P02545 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2281. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes FGD4 (e.g., a polypeptide represented by UniProt Accession No. Q96M96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2282. The method of embodiment 2117, wherein the disease or condition is Chuck-Marie-Dawley disease, and/or wherein the heterologous nucleic acid sequence encodes MTMR2 (e.g., a polypeptide represented by UniProt Accession No. Q13614 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2283. The method of embodiment 2117, wherein the disease or condition is chorea, and/or wherein the heterologous nucleic acid sequence encodes NKX2-1 (e.g., a polypeptide represented by UniProt Accession No. P43699 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2284. The method of embodiment 2117, wherein the disease or condition is chorea acanthocytosis, and/or wherein the heterologous nucleic acid sequence encodes VPS13A (e.g., a polypeptide represented by UniProt Accession No. Q96RL7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2285. The method of embodiment 2117, wherein the disease or condition is achoriocarcinoma, and/or wherein the heterologous nucleic acid sequence encodes Rab escort protein (Rep1) CHM (e.g., a polypeptide represented by UniProt Accession No. P24386 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2286. The method of embodiment 2117, wherein the disease or condition is Cockayne syndrome B (CSB), and/or wherein the heterologous nucleic acid sequence encodes ERCC6 (e.g., a polypeptide represented by UniProt accession number Q03468 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2287. The method of embodiment 2117, wherein the disease or condition is Crohn's disease, and/or wherein the heterologous nucleic acid sequence encodes RPS6KA3 (e.g., a polypeptide represented by UniProt Accession No. P51812 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2288. The method of embodiment 2117, wherein the disease or condition is craniosynostosis, and/or wherein the heterologous nucleic acid sequence encodes MSX2 (e.g., a polypeptide represented by UniProt Accession No. P35548 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2289. The method of embodiment 2117, wherein the disease or condition is craniosynostosis, and/or wherein the heterologous nucleic acid sequence encodes TWIST1 (e.g., a polypeptide represented by UniProt Accession No. Q15672 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2290. The method of embodiment 2117, wherein the disease or condition is craniosynostosis, and/or wherein the heterologous nucleic acid sequence encodes SKI (e.g., a polypeptide represented by UniProt Accession No. P12755 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2291. The method of embodiment 2117, wherein the disease or condition is craniosynostosis, and/or wherein the heterologous nucleic acid sequence encodes SMAD6 (e.g., a polypeptide represented by UniProt Accession No. 043541 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2292. The method of embodiment 2117, wherein the disease or condition is Creutzfeldt-Jakob disease, and/or wherein the heterologous nucleic acid sequence encodes a PRNP (e.g., a polypeptide represented by UniProt Accession No. P04156 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2293. The method of embodiment 2117, wherein the disease or condition is Creutzfeldt-Jakob disease, and/or wherein the heterologous nucleic acid sequence encodes HLA-DQB1 (e.g., a polypeptide represented by UniProt Accession No. P01920 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2294. The method of embodiment 2117, wherein the disease or condition is Kaplan-Meier syndrome (hyperbilirubinemia), and/or wherein the heterologous nucleic acid sequence encodes UDP-glucuronosyltransferase 1A1 (UGT1A1) (e.g., a polypeptide represented by UniProt Accession No. P22309 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2295. The method of embodiment 2117, wherein the disease or condition is Cushing's syndrome, and/or wherein the heterologous nucleic acid sequence encodes PRKACA (e.g., a polypeptide represented by UniProt Accession No. P17612 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2296. The method of embodiment 2117, wherein the disease or condition is dento-rubral atrophy (DRPLA), and/or wherein the heterologous nucleic acid sequence encodes ATN1 (e.g., a polypeptide represented by UniProt Accession No. P54259 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2297. The method of embodiment 2117, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes ARX (e.g., a polypeptide represented by UniProt Accession No. Q96QS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2298. The method of embodiment 2117, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes FGF12 (e.g., a polypeptide represented by UniProt Accession No. P61328 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2299. The method of embodiment 2117, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes a PIGP (e.g., a polypeptide represented by UniProt Accession No. P57054 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2300. The method of embodiment 2117, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes GABRB3 (e.g., a polypeptide represented by UniProt Accession No. P28472 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2301. The method of embodiment 2117, wherein the disease or condition is developmental and epileptic encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes NECAP1 (e.g., a polypeptide represented by UniProt Accession No. Q8NC96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2302. The method of embodiment 2117, wherein the disease or condition is developmental dyspraxia (speech-language disorder 1 (SPCH1)), and/or wherein the heterologous nucleic acid sequence encodes FOXP2 (e.g., a polypeptide represented by UniProt Accession No. 015409 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2303. The method of embodiment 2117, wherein the disease or condition is Dravet syndrome, and/or wherein the heterologous nucleic acid sequence encodes sodium channel protein subunit alpha type 1 (SCN1A) (e.g., a polypeptide represented by UniProt accession number P35498 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2304. The method of embodiment 2117, wherein the disease or condition is Dravet syndrome, and/or wherein the heterologous nucleic acid sequence encodes SCN1B (e.g., a polypeptide represented by UniProt Accession No. Q07699 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2305. The method of embodiment 2117, wherein the disease or condition is Dravet syndrome, and/or wherein the heterologous nucleic acid sequence encodes SCN2A (e.g., a polypeptide represented by UniProt Accession No. Q99250 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2306. The method of embodiment 2117, wherein the disease or condition is Dravet syndrome, and/or wherein the heterologous nucleic acid sequence encodes GABA receptor subunit gamma-2 (GABRG2) (e.g., a polypeptide represented by UniProt accession number P18507 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2307. The method of embodiment 2117, wherein the disease or condition is autonomic nervous system disorder (Dye syndrome), and/or wherein the heterologous nucleic acid sequence encodes ELP1 (e.g., a polypeptide represented by UniProt Accession No. 095163 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2308. The method of embodiment 2117, wherein the disease or condition is dystonia, and/or wherein the heterologous nucleic acid sequence encodes GCH1 (e.g., a polypeptide represented by UniProt Accession No. P30793 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2309. The method of embodiment 2117, wherein the disease or condition is dystonia, and/or wherein the heterologous nucleic acid sequence encodes TOR1A (e.g., a polypeptide represented by UniProt Accession No. 014656 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2310. The method of embodiment 2117, wherein the disease or condition is dystonia, and/or wherein the heterologous nucleic acid sequence encodes SGCE (e.g., a polypeptide represented by UniProt Accession No. 043556 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2311. The method of embodiment 2117, wherein the disease or condition is dystonia, and/or wherein the heterologous nucleic acid sequence encodes TUBB4A (e.g., a polypeptide represented by UniProt Accession No. P04350 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2312. The method of embodiment 2117, wherein the disease or condition is encephalocele, and/or wherein the heterologous nucleic acid sequence encodes COL18A1 (e.g., a polypeptide represented by UniProt Accession No. P39060 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2313. The method of embodiment 2117, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes GRIN2A (e.g., a polypeptide represented by UniProt Accession No. Q12879 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2314. The method of embodiment 2117, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes CSTB (e.g., a polypeptide represented by UniProt Accession No. P04080 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2315. The method of embodiment 2117, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes STARD7 (e.g., a polypeptide represented by UniProt Accession No. Q9NQZ5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2316. The method of embodiment 2117, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes DEPDC5 (e.g., a polypeptide represented by UniProt Accession No. 075140 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2317. The method of embodiment 2117, wherein the disease or condition is an epileptic disorder, and/or wherein the heterologous nucleic acid sequence encodes PCDH19 (e.g., a polypeptide represented by UniProt Accession No. Q8TAB3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2318. The method of embodiment 2117, wherein the disease or condition is essential tremor, and/or wherein the heterologous nucleic acid sequence encodes DRD3 (e.g., a polypeptide represented by UniProt Accession No. P35462 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2319. The method of embodiment 2117, wherein the disease or condition is essential tremor, and/or wherein the heterologous nucleic acid sequence encodes NOTCH2NLC (e.g., a polypeptide represented by UniProt Accession No. P0DPK4 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2320. The method of embodiment 2117, wherein the disease or condition is essential tremor, and/or wherein the heterologous nucleic acid sequence encodes FUS (e.g., a polypeptide represented by UniProt Accession No. P35637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2321. The method of embodiment 2117, wherein the disease or condition is Fabry disease, and/or wherein the heterologous nucleic acid sequence encodes α-galactosidase A (GLA) (e.g., a polypeptide represented by UniProt Accession No. P06280 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2322. The method of embodiment 2117, wherein the disease or condition is Farber disease (neuramidase deficiency), and/or wherein the heterologous nucleic acid sequence encodes ASAH1 (e.g., a polypeptide represented by UniProt Accession No. Q13510 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2323. The method of embodiment 2117, wherein the disease or condition is Fahr's disease, and/or wherein the heterologous nucleic acid sequence encodes SLC20A2 (e.g., a polypeptide represented by UniProt Accession No. Q08357 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2324. The method of embodiment 2117, wherein the disease or condition is febrile epilepsy, and/or wherein the heterologous nucleic acid sequence encodes GABRG2 (e.g., a polypeptide represented by UniProt Accession No. P18507 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2325. The method of embodiment 2117, wherein the disease or condition is febrile epilepsy, and/or wherein the heterologous nucleic acid sequence encodes ADGRV1 (e.g., a polypeptide represented by UniProt Accession No. Q8WXG9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2326. The method of embodiment 2117, wherein the disease or condition is febrile epilepsy, and/or wherein the heterologous nucleic acid sequence encodes CPA6 (e.g., a polypeptide represented by UniProt Accession No. P11509 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2327. The method of embodiment 2117, wherein the disease or condition is febrile epilepsy, and/or wherein the heterologous nucleic acid sequence encodes SCN1A (e.g., a polypeptide represented by UniProt Accession No. P35498 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2328. The method of embodiment 2117, wherein the disease or condition is Friedreich's disease, and/or wherein the heterologous nucleic acid sequence encodes a protein called FXN (e.g., a polypeptide represented by UniProt Accession No. Q16595 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2329. The method of embodiment 2117, wherein the disease or condition is frontotemporal dementia, and/or wherein the heterologous nucleic acid sequence encodes a granulin proprotein (GRN) (e.g., a polypeptide represented by UniProt Accession No. P28799 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2330. The method of embodiment 2117, wherein the disease or condition is frontotemporal dementia, and/or wherein the heterologous nucleic acid sequence encodes MAPT (tau) (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2331. The method of embodiment 2117, wherein the disease or condition is frontotemporal dementia, and/or wherein the heterologous nucleic acid sequence encodes PSEN1 (e.g., a polypeptide represented by UniProt Accession No. A0A024R6A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2332. The method of embodiment 2117, wherein the disease or condition is fucose deposition disease, and/or wherein the heterologous nucleic acid sequence encodes α-L-fucosidase (FUCA1) (e.g., a polypeptide represented by UniProt Accession No. P04066 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2333. The method of embodiment 2117, wherein the disease or condition is fundus alba, and/or wherein the heterologous nucleic acid sequence encodes RLBP1 (e.g., a polypeptide represented by UniProt Accession No. P12271 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2334. The method of embodiment 2117, wherein the disease or condition is Gaucher's disease (e.g., type I, II, or III), and/or wherein the heterologous nucleic acid sequence encodes glucocerebrosidase (GBA1) (e.g., a polypeptide represented by UniProt Accession No. P04062 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2335. The method of embodiment 2117, wherein the disease or condition is systemic gangliosidosis (e.g., GM1, GM2, or GM3), and/or wherein the heterologous nucleic acid sequence encodes GLB1 (e.g., a polypeptide represented by UniProt Accession No. P16278 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2336. The method of embodiment 2117, wherein the disease or condition is Gerstmann-Stausler-Scheinker disease, and/or wherein the heterologous nucleic acid sequence encodes PRNP (e.g., a polypeptide represented by UniProt Accession No. P04156 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2337. The method of embodiment 2117, wherein the disease or condition is macroaxonal neuropathy, and/or wherein the heterologous nucleic acid sequence encodes a macroaxonal neuropathy protein (GAN) (e.g., a polypeptide represented by UniProt Accession No. Q9H2C0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2338. The method of embodiment 2117, wherein the disease or condition is glycogenostasis II (Pombe disease or acid maltase deficiency), and/or wherein the heterologous nucleic acid sequence encodes acid maltase (lysosomal α-glucosidase) (LYAG, GAA) (e.g., a polypeptide represented by UniProt Accession No. P10253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2339. The method of embodiment 2117, wherein the disease or condition is Guillain-Barré syndrome, and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2340. The method of embodiment 2117, wherein the disease or condition is chronic inflammatory demyelinating polyneuropathy (CIDP), and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2341. The method of embodiment 2117, wherein the disease or condition is Holloway-Spatz disease (PKAN or NBIA1), and/or wherein the heterologous nucleic acid sequence encodes PANK2 (e.g., a polypeptide represented by UniProt Accession No. Q9BZ23 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2342. The method of embodiment 2117, wherein the disease or condition is alternating hemiplegia, and/or wherein the heterologous nucleic acid sequence encodes ATP1A2 (e.g., a polypeptide represented by UniProt Accession No. P50993 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2343. The method of embodiment 2117, wherein the disease or condition is alternating hemiplegia, and/or wherein the heterologous nucleic acid sequence encodes ATP1A3 (e.g., a polypeptide represented by UniProt Accession No. P13637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2344. The method of embodiment 2117, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes WNK1 (e.g., a polypeptide represented by UniProt Accession No. Q9H4A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2345. The method of embodiment 2117, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes MFN2 (e.g., a polypeptide represented by UniProt Accession No. 095140 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2346. The method of embodiment 2117, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes HK1 (e.g., a polypeptide represented by UniProt Accession No. P19367 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2347. The method of embodiment 2117, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes TFG (e.g., a polypeptide represented by UniProt Accession No. Q92734 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2348. The method of embodiment 2117, wherein the disease or condition is a hereditary neuropathy, and/or wherein the heterologous nucleic acid sequence encodes SPTLC1 (e.g., a polypeptide represented by UniProt Accession No. 015269 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2349. The method of embodiment 2117, wherein the disease or condition is polyneuritis ataxia (Refsum's disease), and/or wherein the heterologous nucleic acid sequence encodes PHYH (e.g., a polypeptide represented by UniProt Accession No. 014832 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2350. The method of embodiment 2117, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes GLI2 (e.g., a polypeptide represented by UniProt Accession No. P10070 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2351. The method of embodiment 2117, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes TGIF1 (e.g., a polypeptide represented by UniProt Accession No. Q15583 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2352. The method of embodiment 2117, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes ZIC2 (e.g., a polypeptide represented by UniProt Accession No. 095409 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2353. The method of embodiment 2117, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes PTCH1 (e.g., a polypeptide represented by UniProt Accession No. Q13635 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2354. The method of embodiment 2117, wherein the disease or condition is holoprosencephaly, and/or wherein the heterologous nucleic acid sequence encodes SHH (e.g., a polypeptide represented by UniProt Accession No. Q15465 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2355. The method of embodiment 2117, wherein the disease or condition is Huntington's disease, and/or wherein the heterologous nucleic acid sequence encodes HTT (e.g., a polypeptide represented by UniProt Accession No. P42858 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2356. The method of embodiment 2117, wherein the disease or condition is hydrocephalus, and/or wherein the heterologous nucleic acid sequence encodes CCDC88C (e.g., a polypeptide represented by UniProt Accession No. Q9P219 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2357. The method of embodiment 2117, wherein the disease or condition is hydrocephalus, and/or wherein the heterologous nucleic acid sequence encodes WDR81 (e.g., a polypeptide represented by UniProt Accession No. Q562E7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2358. The method of embodiment 2117, wherein the disease or condition is hydrocephalus, and/or wherein the heterologous nucleic acid sequence encodes TRIM71 (e.g., a polypeptide represented by UniProt Accession No. Q2Q1W2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2359. The method of embodiment 2117, wherein the disease or condition is hydrocephalus, and/or wherein the heterologous nucleic acid sequence encodes MPDZ (e.g., a polypeptide represented by UniProt Accession No. 075970 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2360. The method of embodiment 2117, wherein the disease or condition is incontinentia pigmenti, and/or wherein the heterologous nucleic acid sequence encodes IKBKG (e.g., a polypeptide represented by UniProt Accession No. Q9Y6K9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2361. The method of embodiment 2117, wherein the disease or condition is juvenile hypotonia, and/or wherein the heterologous nucleic acid sequence encodes NALCN (e.g., a polypeptide represented by UniProt Accession No. Q8IZF0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2362. The method of embodiment 2117, wherein the disease or condition is juvenile hypotonia, and/or wherein the heterologous nucleic acid sequence encodes TBCK (e.g., a polypeptide represented by UniProt Accession No. Q8TEA7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2363. The method of embodiment 2117, wherein the disease or condition is juvenile hypotonia, and/or wherein the heterologous nucleic acid sequence encodes CCDC174 (e.g., a polypeptide represented by UniProt Accession No. Q6PII3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2364. The method of embodiment 2117, wherein the disease or condition is juvenile hypotonia, and/or wherein the heterologous nucleic acid sequence encodes UNC80 (e.g., a polypeptide represented by UniProt Accession No. Q8N2C7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2365. The method of embodiment 2117, wherein the disease or condition is childhood axonal dystrophy, and/or wherein the heterologous nucleic acid sequence encodes PLA2G6 (e.g., a polypeptide represented by UniProt Accession No. 060733 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2366. The method of embodiment 2117, wherein the disease or condition is juvenile phytanic acid storage disease (PBD1B), and/or wherein the heterologous nucleic acid sequence encodes PEX1 (e.g., a polypeptide represented by UniProt Accession No. 043933 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2367. The method of embodiment 2117, wherein the disease or condition is Joubert syndrome, and/or wherein the heterologous nucleic acid sequence encodes INPP5E (e.g., a polypeptide represented by UniProt Accession No. Q9NRR6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2368. The method of embodiment 2117, wherein the disease or condition is Kennedy's disease, and/or wherein the heterologous nucleic acid sequence encodes an androgen receptor (AR) (e.g., a polypeptide represented by UniProt Accession No. P10275 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2369. The method of embodiment 2117, wherein the disease or condition is KF syndrome, and/or wherein the heterologous nucleic acid sequence encodes GDF6 (e.g., a polypeptide represented by UniProt Accession No. Q6KF10 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2370. The method of embodiment 2117, wherein the disease or condition is Clappa disease (GALC deficiency), and/or wherein the heterologous nucleic acid sequence encodes GALC (e.g., a polypeptide represented by UniProt Accession No. P54803 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2371. The method of embodiment 2117, wherein the disease or condition is Lambert-Eaton myasthenia syndrome, and/or wherein the heterologous nucleic acid sequence encodes CACNA1A (e.g., a polypeptide represented by UniProt Accession No. 000555 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2372. The method of embodiment 2117, wherein the disease or condition is Lambert-Eaton myasthenia syndrome, and/or wherein the heterologous nucleic acid sequence encodes CACNB2 (e.g., a polypeptide represented by UniProt Accession No. Q13936 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2373. The method of embodiment 2117, wherein the disease or condition is Landau-Kleffner syndrome, and/or wherein the heterologous nucleic acid sequence encodes GRIN2A (e.g., a polypeptide represented by UniProt Accession No. Q12879 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2374. The method of embodiment 2117, wherein the disease or condition is late juvenile neuronal lipofuscinosis (CLN2), and/or wherein the heterologous nucleic acid sequence encodes TPP1 (e.g., a polypeptide represented by UniProt Accession No. 014773 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2375. The method of embodiment 2117, wherein the disease or condition is Reich-Nyhen syndrome, and/or wherein the heterologous nucleic acid sequence encodes HPRT1 (e.g., a polypeptide represented by UniProt Accession No. P00492 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2376. The method of embodiment 2117, wherein the disease or condition is Leber congenital amaurosis (retinal blindness), and/or wherein the heterologous nucleic acid sequence encodes retinal guanylate cyclase 1 (GUCY2D) (e.g., a polypeptide represented by UniProt Accession No. Q02846 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2377. The method of embodiment 2117, wherein the disease or condition is Leber congenital amaurosis (retinal blindness), and/or wherein the heterologous nucleic acid sequence encodes a retinoid isosteric hydrolase (RPE65) (e.g., a polypeptide represented by UniProt Accession No. Q16518 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2378. The method of embodiment 2117, wherein the disease or condition is Leber congenital amaurosis (retinal blindness), and/or wherein the heterologous nucleic acid sequence encodes a 290 kDa centrosomal protein (CEP290) (e.g., a polypeptide represented by UniProt Accession No. 015078 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2379. The method of embodiment 2117, wherein the disease or condition is Leber congenital amaurosis (retinal blindness), and/or wherein the heterologous nucleic acid sequence encodes crumbs protein homolog 1 (CRB1) (e.g., a polypeptide represented by UniProt accession number P82279 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2380. The method of embodiment 2117, wherein the disease or condition is Leber's hereditary optic neuropathy, and/or wherein the heterologous nucleic acid sequence encodes NADH-ubiquinone oxidoreductase chain 4 (ND4) (e.g., a polypeptide represented by UniProt Accession No. P03905 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2381. The method of embodiment 2117, wherein the disease or condition is cerebral leukodystrophy, and/or wherein the heterologous nucleic acid sequence encodes ARSA (e.g., a polypeptide represented by UniProt Accession No. P15289 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2382. The method of embodiment 2117, wherein the disease or condition is Levine-Critchley syndrome (choreoacanthocytosis), and/or wherein the heterologous nucleic acid sequence encodes VPS13A (e.g., a polypeptide represented by UniProt Accession No. Q96RL7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2383. The method of embodiment 2117, wherein the disease or condition is dementia with Lewy bodies, and/or wherein the heterologous nucleic acid sequence encodes SNCA (e.g., a polypeptide represented by UniProt Accession No. P37840 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2384. The method of embodiment 2117, wherein the disease or condition is dementia with Lewy bodies, and/or wherein the heterologous nucleic acid sequence encodes SNCB (e.g., a polypeptide represented by UniProt Accession No. Q16143 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2385. The method of embodiment 2117, wherein the disease or condition is lipoproteinemia (Ulbach-Witt disease), and/or wherein the heterologous nucleic acid sequence encodes ECM1 (e.g., a polypeptide represented by UniProt Accession No. Q16610 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2386. The method of embodiment 2117, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes PAFAH1B1 (e.g., a polypeptide represented by UniProt Accession No. Q9PTR5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2387. The method of embodiment 2117, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes NDE1 (e.g., a polypeptide represented by UniProt Accession No. Q9NXR1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2388. The method of embodiment 2117, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes TUBA1A (e.g., a polypeptide represented by UniProt Accession No. Q71U36 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2389. The method of embodiment 2117, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes LAMB1 (e.g., a polypeptide represented by UniProt accession number LAMB1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2390. The method of embodiment 2117, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes KATNB1 (e.g., a polypeptide represented by UniProt Accession No. Q9BVA0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2391. The method of embodiment 2117, wherein the disease or condition is lithospermia, and/or wherein the heterologous nucleic acid sequence encodes RELN (e.g., a polypeptide represented by UniProt Accession No. P78509 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2392. The method of embodiment 2117, wherein the disease or condition is macrocephaly/megalencephaly, and/or wherein the heterologous nucleic acid sequence encodes TBC1D7 (e.g., a polypeptide represented by UniProt Accession No. Q9P0N9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2393. The method of embodiment 2117, wherein the disease or condition is Menkes disease, and/or wherein the heterologous nucleic acid sequence encodes ATP7A (e.g., a polypeptide represented by UniProt Accession No. Q04656 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2394. The method of embodiment 2117, wherein the disease or condition is metachromatic leukodystrophy (MLD), and/or wherein the heterologous nucleic acid sequence encodes arylsulfatase A (ARSA) (e.g., a polypeptide represented by UniProt Accession No. P15289 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2395. The method of embodiment 2117, wherein the disease or condition is microcephaly, and/or wherein the heterologous nucleic acid sequence encodes KIF11 (e.g., a polypeptide represented by UniProt Accession No. P52732 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2396. The method of embodiment 2117, wherein the disease or condition is microcephaly, and/or wherein the heterologous nucleic acid sequence encodes MCPH1 (e.g., a polypeptide represented by UniProt Accession No. Q8NEM0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2397. The method of embodiment 2117, wherein the disease or condition is microcephaly, and/or wherein the heterologous nucleic acid sequence encodes SLC25A19 (e.g., a polypeptide represented by UniProt Accession No. Q9HC21 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2398. The method of embodiment 2117, wherein the disease or condition is familial hemicrania, and/or wherein the heterologous nucleic acid sequence encodes CACNA1A (e.g., a polypeptide represented by UniProt Accession No. 000555 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2399. The method of embodiment 2117, wherein the disease or condition is familial hemicrania, and/or wherein the heterologous nucleic acid sequence encodes ATP1A2 (e.g., a polypeptide represented by UniProt Accession No. P50993 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2400. The method of embodiment 2117, wherein the disease or condition is familial hemicrania, and/or wherein the heterologous nucleic acid sequence encodes SCN1A (e.g., a polypeptide represented by UniProt Accession No. P35498 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2401. The method of embodiment 2117, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes RRM2B (e.g., a polypeptide represented by UniProt Accession No. Q7LG56 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2402. The method of embodiment 2117, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes DGUOK (e.g., a polypeptide represented by UniProt Accession No. Q16854 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2403. The method of embodiment 2117, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes POLG (e.g., a polypeptide represented by UniProt Accession No. P54098 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2404. The method of embodiment 2117, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes TYMP (e.g., a polypeptide represented by UniProt Accession No. P19971 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2405. The method of embodiment 2117, wherein the disease or condition is mitochondrial DNA deletion syndrome, and/or wherein the heterologous nucleic acid sequence encodes TK2 (e.g., a polypeptide represented by UniProt Accession No. 000142 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2406. The method of embodiment 2117, wherein the disease or condition is Morvan's disease, and/or wherein the heterologous nucleic acid sequence encodes WNK1 (e.g., a polypeptide represented by UniProt Accession No. Q9H4A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2407. The method of embodiment 2117, wherein the disease or condition is mucolipidosis, and/or wherein the heterologous nucleic acid sequence encodes GNPTAB (e.g., a polypeptide represented by UniProt Accession No. Q3T906 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2408. The method of embodiment 2117, wherein the disease or condition is mucolipidosis, and/or wherein the heterologous nucleic acid sequence encodes MCOLN1 (e.g., a polypeptide represented by UniProt Accession No. Q9GZU1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2409. The method of embodiment 2117, wherein the disease or condition is mucopolysaccharidosis type I (MPS I) (Heller syndrome group), and/or wherein the heterologous nucleic acid sequence encodes α-L-iduronidase (IDUA) (e.g., a polypeptide represented by UniProt Accession No. P35475 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2410. The method of embodiment 2117, wherein the disease or condition is MPS II (Hunter syndrome), and/or wherein the heterologous nucleic acid sequence encodes iduronate-2-sulfatase (IDS) (e.g., a polypeptide represented by UniProt accession number P22304 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2411. The method of embodiment 2117, wherein the disease or condition is MPS IIIa (Sanfilippo syndrome type A), and/or wherein the heterologous nucleic acid sequence encodes heparan sulfate sulfatase (HSS) or N-sulfoglucosamine sulfohydrolase (SGSH) (e.g., a polypeptide represented by UniProt accession number P51688 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2412. The method of embodiment 2117, wherein the disease or condition is MPS IIIB (Sanfilippo syndrome type B), and/or wherein the heterologous nucleic acid sequence encodes N-acetyl-α-D-aminoglucosidase (NAGLU) (e.g., a polypeptide represented by UniProt accession number P54802 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2413. The method of embodiment 2117, wherein the disease or condition is MPS VI (Malot-Ramie syndrome), and/or wherein the heterologous nucleic acid sequence encodes arylsulfatase B (ARSB) (e.g., a polypeptide represented by UniProt Accession No. P15848 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2414. The method of embodiment 2117, wherein the disease or condition is MPS IV A (Morquet syndrome type A), and/or wherein the heterologous nucleic acid sequence encodes N-acetylgalactosamine-6-sulfatase (GALNS) (e.g., a polypeptide represented by UniProt accession number P34059 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2415. The method of embodiment 2117, wherein the disease or condition is MPS IV B (Morquet syndrome type B), and/or wherein the heterologous nucleic acid sequence encodes β-galactosidase 1 (GLB1) (e.g., a polypeptide represented by UniProt accession number P16278 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2416. The method of embodiment 2117, wherein the disease or condition is MPS VII (Steffen's syndrome), and/or wherein the heterologous nucleic acid sequence encodes a β-glucuronidase (e.g., a polypeptide represented by UniProt Accession No. P08236 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2417. The method of embodiment 2117, wherein the disease or condition is MPS VIII, and/or wherein the heterologous nucleic acid sequence encodes a glucosamine-6-sulfate sulfatase (e.g., a polypeptide represented by UniProt Accession No. P15586 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2418. The method of embodiment 2117, wherein the disease or condition is MPS IX, and/or wherein the heterologous nucleic acid sequence encodes hyaluronidase-1 (HYAL1) (e.g., a polypeptide represented by UniProt Accession No. Q12794 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2419. The method of embodiment 2117, wherein the disease or condition is multiple sclerosis, and/or wherein the heterologous nucleic acid sequence encodes PDCD1 (e.g., a polypeptide represented by UniProt Accession No. Q15116 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2420. The method of embodiment 2117, wherein the disease or condition is multisystem atrophy, and/or wherein the heterologous nucleic acid sequence encodes COQ2 (e.g., a polypeptide represented by UniProt Accession No. Q96H96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2421. The method of embodiment 2117, wherein the disease or condition is congenital presynaptic weakness, and/or wherein the heterologous nucleic acid sequence encodes CHAT (e.g., a polypeptide represented by UniProt Accession No. P28329 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2422. The method of embodiment 2117, wherein the disease or condition is myoclonus, and/or wherein the heterologous nucleic acid sequence encodes NOL3 (e.g., a polypeptide represented by UniProt Accession No. 060936 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2423. The method of embodiment 2117, wherein the disease or condition is myotonic spasticity and epilepsy (FAME2), and/or wherein the heterologous nucleic acid sequence encodes STARD7 (e.g., a polypeptide represented by UniProt Accession No. Q9NQZ5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2424. The method of embodiment 2117, wherein the disease or condition is narcolepsy, and/or wherein the heterologous nucleic acid sequence encodes HCRT (OX) (e.g., a polypeptide represented by UniProt Accession No. 043612 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2425. The method of embodiment 2117, wherein the disease or condition is narcolepsy, and/or wherein the heterologous nucleic acid sequence encodes MOG (e.g., a polypeptide represented by UniProt Accession No. Q16653 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2426. The method of embodiment 2117, wherein the disease or condition is neuroacanthocytosis (McCraw syndrome), and/or wherein the heterologous nucleic acid sequence encodes XK (e.g., a polypeptide represented by UniProt Accession No. P51811 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2427. The method of embodiment 2117, wherein the disease or condition is neurodevelopmental disorder with cerebral atrophy and facial dysmorphism (NEDCAFD), and/or wherein the heterologous nucleic acid sequence encodes TTC5 (e.g., a polypeptide represented by UniProt Accession No. Q8N0Z6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2428. The method of embodiment 2117, wherein the disease or condition is a neurodevelopmental disorder associated with infantile epileptic seizures, and/or wherein the heterologous nucleic acid sequence encodes NCDN (e.g., a polypeptide represented by UniProt Accession No. Q9UBB6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2429. The method of embodiment 2117, wherein the disease or condition is neurofibroma, and/or wherein the heterologous nucleic acid sequence encodes NF1 (e.g., a polypeptide represented by UniProt Accession No. P21359 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2430. The method of embodiment 2117, wherein the disease or condition is neuromyotonia, and/or wherein the heterologous nucleic acid sequence encodes HINT1 (e.g., a polypeptide represented by UniProt Accession No. P49773 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2431. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes PPT1 (e.g., a polypeptide represented by UniProt Accession No. P50897 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2432. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes TPP1 (e.g., a polypeptide represented by UniProt Accession No. 014773 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2433. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CLN5 (e.g., a polypeptide represented by UniProt Accession No. 075503 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2434. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CLN3 (e.g., a polypeptide represented by UniProt Accession No. Q13286 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2435. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CLN6 (e.g., a polypeptide represented by UniProt Accession No. Q9NWW5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2436. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CLN8 (e.g., a polypeptide represented by UniProt Accession No. Q9UBY8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2437. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes DNAJC5 (e.g., a polypeptide represented by UniProt Accession No. Q9H3Z4 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2438. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes MFSD8 (e.g., a polypeptide represented by UniProt Accession No. Q8NHS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2439. The method of embodiment 2117, wherein the disease or condition is neuronal ceramide lipofuscinosis, and/or wherein the heterologous nucleic acid sequence encodes CTSD (e.g., a polypeptide represented by UniProt Accession No. P07339 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2440. The method of embodiment 2117, wherein the disease or condition is neuropathy, ataxia, and retinitis pigmentosa (NARP), and/or wherein the heterologous nucleic acid sequence encodes MTATP6 (e.g., a polypeptide represented by UniProt Accession No. P00846 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2441. The method of embodiment 2117, wherein the disease or condition is type II hereditary sensory and autonomic neuropathy, and/or wherein the heterologous nucleic acid sequence encodes WNK1 (e.g., a polypeptide represented by UniProt Accession No. Q9H4A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2442. The method of embodiment 2117, wherein the disease or condition is dysmyelinating congenital neuropathy 1, and/or wherein the heterologous nucleic acid sequence encodes EGR2 (e.g., a polypeptide represented by UniProt Accession No. P11161 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2443. The method of embodiment 2117, wherein the disease or condition is Niemann-Pick disease, and/or wherein the heterologous nucleic acid sequence encodes sphingomyelin phosphodiesterase 1 (SMPD1) (e.g., a polypeptide represented by UniProt Accession No. P17405 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2444. The method of embodiment 2117, wherein the disease or condition is Niemann-Pick disease, and/or wherein the heterologous nucleic acid sequence encodes NPC intracellular cholesterol transporter 1 (NPC1) (e.g., a polypeptide represented by UniProt Accession No. 015118 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2445. The method of embodiment 2117, wherein the disease or condition is Ohtahara syndrome (developmental and epileptic encephalopathy 1), and/or wherein the heterologous nucleic acid sequence encodes ARX (e.g., a polypeptide represented by UniProt accession number Q96QS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2446. The method of embodiment 2117, wherein the disease or condition is ornithine aminoformyl transferase deficiency, and/or wherein the heterologous nucleic acid sequence encodes OTC (e.g., a polypeptide represented by UniProt Accession No. P00480 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2447. The method of embodiment 2117, wherein the disease or condition is orthostatic intolerance, and/or wherein the heterologous nucleic acid sequence encodes SLC6A2 (e.g., a polypeptide represented by UniProt Accession No. P23975 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2448. The method of embodiment 2117, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes glucocerebrosidase (GBA1) (e.g., a polypeptide represented by UniProt Accession No. P04062 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2449. The method of embodiment 2117, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes dopamine decarboxylase (DDC) (e.g., a polypeptide represented by UniProt Accession No. P20711 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2450. The method of embodiment 2117, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes a neurotrophin (e.g., a polypeptide represented by UniProt Accession No. Q99748 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2451. The method of embodiment 2117, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes neuroglia-derived growth factor (GDGF) (e.g., a polypeptide represented by UniProt Accession No. P39905 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2452. The method of embodiment 2117, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes tyrosine hydroxylase (TH) (tyrosine 3-monooxygenase) (e.g., a polypeptide represented by UniProt Accession No. P07101 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2453. The method of embodiment 2117, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes glutamine decarboxylase (GAD) (e.g., a polypeptide represented by UniProt Accession No. Q99259 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2454. The method of embodiment 2117, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes fibroblast growth factor 2 (FGF2) (e.g., a polypeptide represented by UniProt Accession No. P09038 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2455. The method of embodiment 2117, wherein the disease or condition is Parkinson's disease, and/or wherein the heterologous nucleic acid sequence encodes brain-derived neurotrophic factor (BDNF) (e.g., a polypeptide represented by UniProt Accession No. P23560 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2456. The method of embodiment 2117, wherein the disease or condition is choreoathetosis, and/or wherein the heterologous nucleic acid sequence encodes PNKD (e.g., a polypeptide represented by UniProt Accession No. Q8N490 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2457. The method of embodiment 2117, wherein the disease or condition is Pelitzaus-Merzbacher disease, and/or wherein the heterologous nucleic acid sequence encodes PLP1 (e.g., a polypeptide represented by UniProt Accession No. P60201 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2458. The method of embodiment 2117, wherein the disease or condition is Pena-Schukel syndrome type II, and/or wherein the heterologous nucleic acid sequence encodes ERCC6 (e.g., a polypeptide represented by UniProt accession number Q03468 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2459. The method of embodiment 2117, wherein the disease or condition is periodic paralysis, and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2460. The method of embodiment 2117, wherein the disease or condition is Phelan-McCedar-Mead syndrome, and/or wherein the heterologous nucleic acid sequence encodes SH3 and multiple anchor protein repeat domains protein 3 (SHANK3) (e.g., a polypeptide represented by UniProt accession number Q9BYB0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2461. The method of embodiment 2117, wherein the disease or condition is phytanic acid storage disease (peroxisome biogenesis disorder 1B), and/or wherein the heterologous nucleic acid sequence encodes PEX1 (e.g., a polypeptide represented by UniProt Accession No. 043933 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2462. The method of embodiment 2117, wherein the disease or condition is Pick's disease, and/or wherein the heterologous nucleic acid sequence encodes PSEN1 (e.g., a polypeptide represented by UniProt Accession No. A0A024R6A3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2463. The method of embodiment 2117, wherein the disease or condition is Pick's disease, and/or wherein the heterologous nucleic acid sequence encodes MAPT (tau) (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2464. The method of embodiment 2117, wherein the disease or condition is cerebral pyrenesia type 1, and/or wherein the heterologous nucleic acid sequence encodes COL4A1 (e.g., a polypeptide represented by UniProt Accession No. P02462 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2465. The method of embodiment 2117, wherein the disease or condition is juvenile primary lateral sclerosis, and/or wherein the heterologous nucleic acid sequence encodes ALS2 (e.g., a polypeptide represented by UniProt Accession No. Q96Q42 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2466. The method of embodiment 2117, wherein the disease or condition is primary progressive aphasia, and/or wherein the heterologous nucleic acid sequence encodes a GRN (e.g., a polypeptide represented by UniProt Accession No. P28799 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2467. The method of embodiment 2117, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes POLG (e.g., a polypeptide represented by UniProt Accession No. P54098 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2468. The method of embodiment 2117, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes POLG2 (e.g., a polypeptide represented by UniProt Accession No. Q9UHN1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2469. The method of embodiment 2117, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes SLC25A4 (e.g., a polypeptide represented by UniProt Accession No. P12235 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2470. The method of embodiment 2117, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes TWNK (e.g., a polypeptide represented by UniProt Accession No. Q96RR1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2471. The method of embodiment 2117, wherein the disease or condition is progressive bulbar palsy, and/or wherein the heterologous nucleic acid sequence encodes SLC52A3 (e.g., a polypeptide represented by UniProt Accession No. Q9NQ40 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2472. The method of embodiment 2117, wherein the disease or condition is progressive supranuclear neuropathy, and/or wherein the heterologous nucleic acid sequence encodes microtubule-associated protein tau (MAPT) Tau (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2473. The method of embodiment 2117, wherein the disease or condition is pseudo-Torch syndrome, and/or wherein the heterologous nucleic acid sequence encodes OCLN (e.g., a polypeptide represented by UniProt Accession No. Q16625 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2474. The method of embodiment 2117, wherein the disease or condition is pseudo-Torch syndrome, and/or wherein the heterologous nucleic acid sequence encodes STAT2 (e.g., a polypeptide represented by UniProt Accession No. P52630 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2475. The method of embodiment 2117, wherein the disease or condition is pseudo-Torch syndrome, and/or wherein the heterologous nucleic acid sequence encodes USP18 (e.g., a polypeptide represented by UniProt Accession No. Q9UMW8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2476. The method of embodiment 2117, wherein the disease or condition is Refsum's disease, and/or wherein the heterologous nucleic acid sequence encodes PHYH (e.g., a polypeptide represented by UniProt Accession No. 014832 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2477. The method of embodiment 2117, wherein the disease or condition is retinitis pigmentosa 38 (rod-cone dystrophy), and/or wherein the heterologous nucleic acid sequence encodes a tyrosine-protein kinase polymer (MERTK) (e.g., a polypeptide represented by UniProt Accession No. Q12866 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2478. The method of embodiment 2117, wherein the disease or condition is retinitis pigmentosa40, and/or wherein the heterologous nucleic acid sequence encodes PDE6B (e.g., a polypeptide represented by UniProt Accession No. P35913 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2479. The method of embodiment 2117, wherein the disease or condition is Rett syndrome, and/or wherein the heterologous nucleic acid sequence encodes methyl-CpG-binding protein 2 (MECP2) (e.g., a polypeptide represented by UniProt accession number P51608 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2480. The method of embodiment 2117, wherein the disease or condition is Sandhoff's disease, and/or wherein the heterologous nucleic acid sequence encodes β-hexosidase subunit alpha (HEXA) (e.g., a polypeptide represented by UniProt Accession No. P06865 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2481. The method of embodiment 2117, wherein the disease or condition is Sandhoff's disease, and/or wherein the heterologous nucleic acid sequence encodes β-hexosidase subunit β (HEXB) (e.g., a polypeptide represented by UniProt Accession No. P07686 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2482. The method of embodiment 2117, wherein the disease or condition is schizencephaly, and/or wherein the heterologous nucleic acid sequence encodes SIX3 (e.g., a polypeptide represented by UniProt Accession No. 095343 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2483. The method of embodiment 2117, wherein the disease or condition is schizencephaly, and/or wherein the heterologous nucleic acid sequence encodes EMX2 (e.g., a polypeptide represented by UniProt Accession No. Q04743 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2484. The method of embodiment 2117, wherein the disease or condition is schizencephaly, and/or wherein the heterologous nucleic acid sequence encodes SHH (e.g., a polypeptide represented by UniProt Accession No. Q15465 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2485. The method of embodiment 2117, wherein the disease or condition is Setelberg disease, and/or wherein the heterologous nucleic acid sequence encodes PLA2G6 (e.g., a polypeptide represented by UniProt Accession No. 060733 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2486. The method of embodiment 2117, wherein the disease or condition is septal optic dysplasia (Demersier syndrome), and/or wherein the heterologous nucleic acid sequence encodes HESX1 (e.g., a polypeptide represented by UniProt Accession No. Q9UBX0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2487. The method of embodiment 2117, wherein the disease or condition is Snydersbrock-Fisher syndrome, and/or wherein the heterologous nucleic acid sequence encodes POU3F3 (e.g., a polypeptide represented by UniProt Accession No. P20264 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2488. The method of embodiment 2117, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes SPG11 (e.g., a polypeptide represented by UniProt Accession No. Q96JI7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2489. The method of embodiment 2117, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes SPAST (e.g., a polypeptide represented by UniProt Accession No. Q9UBP0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2490. The method of embodiment 2117, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes KIF5A (e.g., a polypeptide represented by UniProt Accession No. Q12840 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2491. The method of embodiment 2117, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes NIPA1 (e.g., a polypeptide represented by UniProt Accession No. Q7RTP0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2492. The method of embodiment 2117, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes CYP7B1 (e.g., a polypeptide represented by UniProt Accession No. 075881 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2493. The method of embodiment 2117, wherein the disease or condition is spastic paralysis, and/or wherein the heterologous nucleic acid sequence encodes ATL1 (e.g., a polypeptide represented by UniProt Accession No. Q8WXF7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2494. The method of embodiment 2117, wherein the disease or condition is spinal muscular atrophy (Kugelberg-Wiland disease), and/or wherein the heterologous nucleic acid sequence encodes the survival motor neuron protein (SMN) SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2495. The method of embodiment 2117, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ataxin-1 (ATXN1) SCA1 (e.g., a polypeptide represented by UniProt Accession No. P54253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2496. The method of embodiment 2117, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ataxin-2 (ATXN2) SCA2 (e.g., a polypeptide represented by UniProt Accession No. Q99700 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2497. The method of embodiment 2117, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ataxin-3 (ATXN3) SCA3 (e.g., a polypeptide represented by UniProt Accession No. P54252 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2498. The method of embodiment 2117, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ZFHX3 (e.g., a polypeptide represented by UniProt Accession No. Q15911 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2499. The method of embodiment 2117, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes CACNA1A (e.g., a polypeptide represented by UniProt Accession No. 000555 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2500. The method of embodiment 2117, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes ATXN7 (SCA7) (e.g., a polypeptide represented by UniProt Accession No. 015265 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2501. The method of embodiment 2117, wherein the disease or condition is spinocerebellar ataxia, and/or wherein the heterologous nucleic acid sequence encodes TMEM240 (e.g., a polypeptide represented by UniProt Accession No. Q5SV17 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2502. The method of embodiment 2117, wherein the disease or condition is sporadic inclusion body myositis, and/or wherein the heterologous nucleic acid sequence encodes follistatin (FST) (e.g., a polypeptide represented by UniProt Accession No. P19883 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2503. The method of embodiment 2117, wherein the disease or condition is Still-Richard-Olszewski syndrome (Parkinson-Alzheimer's disease), and/or wherein the heterologous nucleic acid sequence encodes MAPT (Tau) (e.g., a polypeptide represented by UniProt Accession No. P10636 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2504. The method of embodiment 2117, wherein the disease or condition is congenital stiff-person syndrome, and/or wherein the heterologous nucleic acid sequence encodes GLRA1 (e.g., a polypeptide represented by UniProt Accession No. P23415 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2505. The method of embodiment 2117, wherein the disease or condition is congenital stiff-person syndrome, and/or wherein the heterologous nucleic acid sequence encodes GLRB (e.g., a polypeptide represented by UniProt Accession No. P48167 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2506. The method of embodiment 2117, wherein the disease or condition is substantia nigra, and/or wherein the heterologous nucleic acid sequence encodes NUP62 (e.g., a polypeptide represented by UniProt Accession No. P37198 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2507. The method of embodiment 2117, wherein the disease or condition is substantia nigra, and/or wherein the heterologous nucleic acid sequence encodes PDE8B (e.g., a polypeptide represented by UniProt Accession No. 095263 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2508. The method of embodiment 2117, wherein the disease or condition is substantia nigra, and/or wherein the heterologous nucleic acid sequence encodes MTATP6 (e.g., a polypeptide represented by UniProt Accession No. P00846 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2509. The method of embodiment 2117, wherein the disease or condition is substantia nigra, and/or wherein the heterologous nucleic acid sequence encodes VAC14 (e.g., a polypeptide represented by UniProt Accession No. Q08AM6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2510. The method of embodiment 2117, wherein the disease or condition is Sturge-Weber syndrome, and/or wherein the heterologous nucleic acid sequence encodes GNAQ (e.g., a polypeptide represented by UniProt Accession No. P50148 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2511. The method of embodiment 2117, wherein the disease or condition is subcortical vascular encephalopathy (cerebral arteriovenous encephalopathy), and/or wherein the heterologous nucleic acid sequence encodes HTRA1 (e.g., a polypeptide represented by UniProt Accession No. Q92743 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2512. The method of embodiment 2117, wherein the disease or condition is systemic lupus erythematosus, and/or wherein the heterologous nucleic acid sequence encodes DNASE1L3 (e.g., a polypeptide represented by UniProt Accession No. Q13609 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2513. The method of embodiment 2117, wherein the disease or condition is systemic lupus erythematosus, and/or wherein the heterologous nucleic acid sequence encodes TLR7 (e.g., a polypeptide represented by UniProt Accession No. Q9NYK1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2514. The method of embodiment 2117, wherein the disease or condition is delayed akinesia, and/or wherein the heterologous nucleic acid sequence encodes CYP2D6 (e.g., a polypeptide represented by UniProt Accession No. P10635 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2515. The method of embodiment 2117, wherein the disease or condition is Tay-Sachs disease, and/or wherein the heterologous nucleic acid sequence encodes β-hexosidase subunit alpha (HEXA) (e.g., a polypeptide represented by UniProt Accession No. P06865 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2516. The method of embodiment 2117, wherein the disease or condition is Tourette syndrome, and/or wherein the heterologous nucleic acid sequence encodes HDC (e.g., a polypeptide represented by UniProt Accession No. P19113 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2517. The method of embodiment 2117, wherein the disease or condition is Tourette syndrome, and/or wherein the heterologous nucleic acid sequence encodes SLITRK1 (e.g., a polypeptide represented by UniProt Accession No. Q96PX8 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2518. The method of embodiment 2117, wherein the disease or condition is hereditary tremor type 1, and/or wherein the heterologous nucleic acid sequence encodes DRD3 (e.g., a polypeptide represented by UniProt Accession No. P35462 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2519. The method of embodiment 2117, wherein the disease or condition is Troye syndrome, and/or wherein the heterologous nucleic acid sequence encodes SPART (e.g., a polypeptide represented by UniProt Accession No. Q8N0X7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2520. The method of embodiment 2117, wherein the disease or condition is tuberous sclerosis, and/or wherein the heterologous nucleic acid sequence encodes TSC1 (e.g., a polypeptide represented by UniProt Accession No. Q92574 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2521. The method of embodiment 2117, wherein the disease or condition is tuberous sclerosis, and/or wherein the heterologous nucleic acid sequence encodes TSC2 (e.g., a polypeptide represented by UniProt Accession No. P49815 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2522. The method of embodiment 2117, wherein the disease or condition is tuberous sclerosis, and/or wherein the heterologous nucleic acid sequence encodes IFNG (e.g., a polypeptide represented by UniProt Accession No. P01579 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2523. The method of embodiment 2117, wherein the disease or condition is Van Hippel-Lindau disease, and/or wherein the heterologous nucleic acid sequence encodes VHL (e.g., a polypeptide represented by UniProt Accession No. P40337 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2524. The method of embodiment 2117, wherein the disease or condition is Van Hippel-Lindau disease, and/or wherein the heterologous nucleic acid sequence encodes CCND1 (e.g., a polypeptide represented by UniProt Accession No. P24385 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2525. The method of embodiment 2117, wherein the disease or condition is von Recklinghausen disease, and/or wherein the heterologous nucleic acid sequence encodes NF1 (e.g., a polypeptide represented by UniProt Accession No. P21359 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2526. The method of embodiment 2117, wherein the disease or condition is Wildnig-Hoffmann disease, and/or wherein the heterologous nucleic acid sequence encodes SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2527. The method of embodiment 2117, wherein the disease or condition is X-linked West syndrome, and/or wherein the heterologous nucleic acid sequence encodes ARX (e.g., a polypeptide represented by UniProt accession number Q96QS3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2528. The method of embodiment 2117, wherein the disease or condition is Wilson's disease, and/or wherein the heterologous nucleic acid sequence encodes ATP7B (e.g., a polypeptide represented by UniProt Accession No. P35670 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2529. The method of embodiment 2117, wherein the disease or condition is Wolman's disease (acid lipase disease), and/or wherein the heterologous nucleic acid sequence encodes LIPA (e.g., a polypeptide represented by UniProt Accession No. P38571 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2530. The method of embodiment 2117, wherein the disease or condition is adrenoleukodystrophy X, and/or wherein the heterologous nucleic acid sequence encodes ATP-binding cassette family D member 1 (ABCD1) (e.g., a polypeptide represented by UniProt accession number P33897 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2531. The method of embodiment 2117, wherein the disease or condition is X-syndrome retinoschisis, and/or wherein the heterologous nucleic acid sequence encodes retinoschisis (RS1) (e.g., a polypeptide represented by UniProt Accession No. 015537 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2532. The method of embodiment 2117, wherein the disease or condition is X-linked retinitis pigmentosa, and/or wherein the heterologous nucleic acid sequence encodes an X-linked retinitis pigmentosa GTPase regulator (RPGR) (e.g., a polypeptide represented by UniProt Accession No. Q92834 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2533. The method of embodiment 2117, wherein the disease or condition is X-linked spinal and bulbar muscular atrophy, and/or wherein the heterologous nucleic acid sequence encodes UBA1 (e.g., a polypeptide represented by UniProt Accession No. P22314 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2534. The method of embodiment 2117, wherein the disease or condition is advanced heart failure, and/or wherein the heterologous nucleic acid sequence encodes SERCA2a (ATP2A2) (e.g., a polypeptide represented by UniProt Accession No. P16615 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2535. The method of embodiment 2117, wherein the disease or condition is amyotrophic lateral sclerosis (ALS) (Lou Gehrig's disease), and/or wherein the heterologous nucleic acid sequence encodes superoxide dismutase-1 (SOD1) (e.g., a polypeptide represented by UniProt Accession No. P00441 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2536. The method of embodiment 2117, wherein the disease or condition is Anderson-Tavel syndrome, and/or wherein the heterologous nucleic acid sequence encodes KCNJ2 (e.g., a polypeptide represented by UniProt Accession No. P63252 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2537. The method of embodiment 2117, wherein the disease or condition is Barthel syndrome, and/or wherein the heterologous nucleic acid sequence encodes TAFAZZIN (e.g., a polypeptide represented by UniProt Accession No. Q16635 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2538. The method of embodiment 2117, wherein the disease or condition is Beck's muscular dystrophy (BMD), and/or wherein the heterologous nucleic acid sequence encodes DMD (e.g., a polypeptide represented by UniProt Accession No. P11532 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2539. The method of embodiment 2117, wherein the disease or condition is Beck's congenital myotonia, and/or wherein the heterologous nucleic acid sequence encodes CLCN1 (e.g., a polypeptide represented by UniProt Accession No. P35523 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2540. The method of embodiment 2117, wherein the disease or condition is Bethlem myopathy, and/or wherein the heterologous nucleic acid sequence encodes COL6A3 (e.g., a polypeptide represented by UniProt Accession No. P12111 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2541. The method of embodiment 2117, wherein the disease or condition is Bethlem myopathy, and/or wherein the heterologous nucleic acid sequence encodes COL6A2 (e.g., a polypeptide represented by UniProt Accession No. P12110 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2542. The method of embodiment 2117, wherein the disease or condition is Bethlem myopathy, and/or wherein the heterologous nucleic acid sequence encodes COL6A1 (e.g., a polypeptide represented by UniProt Accession No. P12109 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2543. The method of embodiment 2117, wherein the disease or condition is bulbar muscle atrophy, and/or wherein the heterologous nucleic acid sequence encodes AR (e.g., a polypeptide represented by UniProt Accession No. P10275 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2544. The method of embodiment 2117, wherein the disease or condition is systemic primary carnitine deficiency, and/or wherein the heterologous nucleic acid sequence encodes SLC22A5 (e.g., a polypeptide represented by UniProt Accession No. 076082 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2545. The method of embodiment 2117, wherein the disease or condition is carnitine acyltransferase deficiency type 1, and/or wherein the heterologous nucleic acid sequence encodes CPT1A (e.g., a polypeptide represented by UniProt Accession No. P50416 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2546. The method of embodiment 2117, wherein the disease or condition is carnitine acyltransferase deficiency type 2, and/or wherein the heterologous nucleic acid sequence encodes CPT2 (e.g., a polypeptide represented by UniProt Accession No. P23786 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2547. The method of embodiment 2117, wherein the disease or condition is catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2), and/or wherein the heterologous nucleic acid sequence encodes calcitonin-2 (CASQ2) (e.g., a polypeptide represented by UniProt Accession No. 014958 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2548. The method of embodiment 2117, wherein the disease or condition is central core disease (congenital myopathy type 1A), and/or wherein the heterologous nucleic acid sequence encodes RYR1 (e.g., a polypeptide represented by UniProt accession number P21817 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2549. The method of embodiment 2117, wherein the disease or condition is centronuclear myopathy type 1, and/or wherein the heterologous nucleic acid sequence encodes MTMR14 (e.g., a polypeptide represented by UniProt Accession No. Q8NCE2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2550. The method of embodiment 2117, wherein the disease or condition is centronuclear myopathy type 2, and/or wherein the heterologous nucleic acid sequence encodes DNM2 (e.g., a polypeptide represented by UniProt Accession No. 014717 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2551. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2552. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes MPZ (e.g., a polypeptide represented by UniProt Accession No. P25189 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2553. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes DNM2 (e.g., a polypeptide represented by UniProt Accession No. P50570 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2554. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes MFN2 (e.g., a polypeptide represented by UniProt Accession No. 095140 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2555. The method of embodiment 2117, wherein the disease or condition is Chuck-Murray-Dows disease, and/or wherein the heterologous nucleic acid sequence encodes KIF1B (e.g., a polypeptide represented by UniProt Accession No. 060333 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2556. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes SBF2 (e.g., a polypeptide represented by UniProt Accession No. Q86WG5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2557. The method of embodiment 2117, wherein the disease or condition is Chuck-Murray-Dows disease, and/or wherein the heterologous nucleic acid sequence encodes a PNKP (e.g., a polypeptide represented by UniProt Accession No. Q96T60 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2558. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes GDAP1 (e.g., a polypeptide represented by UniProt Accession No. Q8TB36 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2559. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes LMNA (e.g., a polypeptide represented by UniProt Accession No. P02545 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2560. The method of embodiment 2117, wherein the disease or condition is Chuck-Mary-Dew disease, and/or wherein the heterologous nucleic acid sequence encodes FGD4 (e.g., a polypeptide represented by UniProt Accession No. Q96M96 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2561. The method of embodiment 2117, wherein the disease or condition is Chuck-Marie-Dawley disease, and/or wherein the heterologous nucleic acid sequence encodes MTMR2 (e.g., a polypeptide represented by UniProt Accession No. Q13614 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2562. The method of embodiment 2117, wherein the disease or condition is congenital muscular dystrophy (Ulrich's disease), and/or wherein the heterologous nucleic acid sequence encodes COL6A3 (e.g., a polypeptide represented by UniProt Accession No. P12111 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2563. The method of embodiment 2117, wherein the disease or condition is congenital muscular dystrophy (Ulrich's disease), and/or wherein the heterologous nucleic acid sequence encodes COL6A2 (e.g., a polypeptide represented by UniProt Accession No. P12110 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2564. The method of embodiment 2117, wherein the disease or condition is congenital muscular dystrophy (Ulrich's disease), and/or wherein the heterologous nucleic acid sequence encodes COL6A1 (e.g., a polypeptide represented by UniProt Accession No. P12109 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2565. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes COLQ (e.g., a polypeptide represented by UniProt Accession No. Q9Y215 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2566. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes AGRN (e.g., a polypeptide represented by UniProt Accession No. 000468 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2567. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes RAPSN (e.g., a polypeptide represented by UniProt Accession No. Q13702 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2568. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes GFPT1 (e.g., a polypeptide represented by UniProt Accession No. Q06210 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2569. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2570. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes ALG2 (e.g., a polypeptide represented by UniProt Accession No. Q9H553 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2571. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes ALG14 (e.g., a polypeptide represented by UniProt Accession No. Q96F25 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2572. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes DPAGT1 (e.g., a polypeptide represented by UniProt Accession No. Q9H3H5 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2573. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes CHRNE (e.g., a polypeptide represented by UniProt Accession No. Q04844 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2574. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes CHRNA1 (e.g., a polypeptide represented by UniProt Accession No. P02708 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2575. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes DOK7 (e.g., a polypeptide represented by UniProt Accession No. Q18PE1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2576. The method of embodiment 2117, wherein the disease or condition is myasthenia gravis, and/or wherein the heterologous nucleic acid sequence encodes CHAT (e.g., a polypeptide represented by UniProt Accession No. P28329 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2577. The method of embodiment 2117, wherein the disease or condition is congenital myopathy, and/or wherein the heterologous nucleic acid sequence encodes ACTA1 (e.g., a polypeptide represented by UniProt Accession No. P68133 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2578. The method of embodiment 2117, wherein the disease or condition is congenital myopathy, and/or wherein the heterologous nucleic acid sequence encodes STAC3 (e.g., a polypeptide represented by UniProt Accession No. Q96MF2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2579. The method of embodiment 2117, wherein the disease or condition is congenital myopathy, and/or wherein the heterologous nucleic acid sequence encodes TPM3 (e.g., a polypeptide represented by UniProt Accession No. P06753 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2580. The method of embodiment 2117, wherein the disease or condition is myotonic dystrophy, and/or wherein the heterologous nucleic acid sequence encodes DMPK (e.g., a polypeptide represented by UniProt Accession No. Q09013 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2581. The method of embodiment 2117, wherein the disease or condition is Corey's disease (debranching enzyme deficiency or Forbes' disease), and/or wherein the heterologous nucleic acid sequence encodes AGL (e.g., a polypeptide represented by UniProt Accession No. P35573 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2582. The method of embodiment 2117, wherein the disease or condition is Danon disease, and/or wherein the heterologous nucleic acid sequence encodes LAMP2 (e.g., a polypeptide represented by UniProt Accession No. P13473 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2583. The method of embodiment 2117, wherein the disease or condition is Dezeen-Sortie disease, and/or wherein the heterologous nucleic acid sequence encodes MPZ (e.g., a polypeptide represented by UniProt Accession No. P25189 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2584. The method of embodiment 2117, wherein the disease or condition is Dezeen-Sortie disease, and/or wherein the heterologous nucleic acid sequence encodes EGR2 (e.g., a polypeptide represented by UniProt Accession No. P11161 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2585. The method of embodiment 2117, wherein the disease or condition is Dezeen-Sotta disease, and/or wherein the heterologous nucleic acid sequence encodes PMP22 (e.g., a polypeptide represented by UniProt Accession No. Q01453 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2586. The method of embodiment 2117, wherein the disease or condition is Dezeen-Sortie disease, and/or wherein the heterologous nucleic acid sequence encodes PRX (e.g., a polypeptide represented by UniProt Accession No. Q9BXM0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2587. The method of embodiment 2117, wherein the disease or condition is Wieland's distal muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes TIA1 (e.g., a polypeptide represented by UniProt Accession No. P31483 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2588. The method of embodiment 2117, wherein the disease or condition is Miyoshi's distal muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes DYSF (e.g., a polypeptide represented by UniProt Accession No. 075923 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2589. The method of embodiment 2117, wherein the disease or condition is distal myopathy with anterior tibialis dysplasia, and/or wherein the heterologous nucleic acid sequence encodes DYSF (e.g., a polypeptide represented by UniProt Accession No. 075923 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2590. The method of embodiment 2117, wherein the disease or condition is Duchenne muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes a muscular dystrophy protein (DMD) (e.g., a polypeptide represented by UniProt Accession No. P11532 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2591. The method of embodiment 2117, wherein the disease or condition is Duchenne muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes GALGT2 (B4GALNT2) (e.g., a polypeptide represented by UniProt Accession No. Q8NHY0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2592. The method of embodiment 2117, wherein the disease or condition is Dysforin disease, and/or wherein the heterologous nucleic acid sequence encodes a Dysforin protein (DYSF) (e.g., a polypeptide represented by UniProt Accession No. 075923 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2593. The method of embodiment 2117, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes EMD (e.g., a polypeptide represented by UniProt Accession No. P50402 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2594. The method of embodiment 2117, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes SYNE1 (e.g., a polypeptide represented by UniProt Accession No. Q8NF91 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2595. The method of embodiment 2117, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes SYNE2 (e.g., a polypeptide represented by UniProt Accession No. Q8WXH0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2596. The method of embodiment 2117, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes TMEM43 (e.g., a polypeptide represented by UniProt Accession No. Q9BTV4 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2597. The method of embodiment 2117, wherein the disease or condition is Emory-Dreyfus muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes LMNA (e.g., a polypeptide represented by UniProt Accession No. P02545 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2598. The method of embodiment 2117, wherein the disease or condition is Ehrenberg disease (paramyotonia congenita), and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2599. The method of embodiment 2117, wherein the disease or condition is facioscapulohumeral muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes SMCHD1 (e.g., a polypeptide represented by UniProt Accession No. A6NHR9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2600. The method of embodiment 2117, wherein the disease or condition is facioscapulohumeral muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes LRIF1 (e.g., a polypeptide represented by UniProt Accession No. Q5T3J3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2601. The method of embodiment 2117, wherein the disease or condition is Friedreich's disease, and/or wherein the heterologous nucleic acid sequence encodes a protein called FXN (e.g., a polypeptide represented by UniProt Accession No. Q16595 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2602. The method of embodiment 2117, wherein the disease or condition is Fukuyama congenital muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes FKTN (e.g., a polypeptide represented by UniProt Accession No. 075072 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2603. The method of embodiment 2117, wherein the disease or condition is glycogenostasis II (Pombe disease or acid maltase deficiency), and/or wherein the heterologous nucleic acid sequence encodes GAA (e.g., a polypeptide represented by UniProt Accession No. P10253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2604. The method of embodiment 2117, wherein the disease or condition is type 10 glycogenopathies (glycogenopathies X), and/or wherein the heterologous nucleic acid sequence encodes PGAM2 (e.g., a polypeptide represented by UniProt accession number P15259 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2605. The method of embodiment 2117, wherein the disease or condition is type 11 glycogenopathies (glycogenopathies XI), and/or wherein the heterologous nucleic acid sequence encodes LDHA (e.g., a polypeptide represented by UniProt accession number P00338 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2606. The method of embodiment 2117, wherein the disease or condition is type 2 glycogenopathies (glycogenostasis II, Pompe disease, or acid maltase deficiency), and/or wherein the heterologous nucleic acid sequence encodes GAA (e.g., a polypeptide represented by UniProt accession number P10253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2607. The method of embodiment 2117, wherein the disease or condition is type 3 glycogenopathies (glycogenostasis III), and/or wherein the heterologous nucleic acid sequence encodes AGL (e.g., a polypeptide represented by UniProt accession number P35573 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2608. The method of embodiment 2117, wherein the disease or condition is type 5 glycogenopathies (glycogenostasis V or McArdle's disease or myophosphokinase deficiency), and/or wherein the heterologous nucleic acid sequence encodes PYGM (e.g., a polypeptide represented by UniProt accession number P11217 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2609. The method of embodiment 2117, wherein the disease or condition is type 7 glycogenopathies (glycogenostasis VII or phosphofructokinase deficiency or Tay's disease), and/or wherein the heterologous nucleic acid sequence encodes PFKM (e.g., a polypeptide represented by UniProt Accession No. P08237 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2610. The method of embodiment 2117, wherein the disease or condition is type 9 glycogenopathies (glycogenostasis IX), and/or wherein the heterologous nucleic acid sequence encodes PHKB (e.g., a polypeptide represented by UniProt accession number Q93100 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2611. The method of embodiment 2117, wherein the disease or condition is glycogenopathies type 9 (glycogenopathies IX), and/or wherein the heterologous nucleic acid sequence encodes PHKA2 (e.g., a polypeptide represented by UniProt accession number P46019 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2612. The method of embodiment 2117, wherein the disease or condition is hereditary inclusion body myositis, and/or wherein the heterologous nucleic acid sequence encodes GNE (e.g., a polypeptide represented by UniProt Accession No. Q9Y223 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2613. The method of embodiment 2117, wherein the disease or condition is integrin-deficient congenital muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes ITGA7 (e.g., a polypeptide represented by UniProt Accession No. Q13683 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2614. The method of embodiment 2117, wherein the disease or condition is Kennedy's disease (spondylobular muscular atrophy), and/or wherein the heterologous nucleic acid sequence encodes an androgen receptor (AR) (e.g., a polypeptide represented by UniProt Accession No. P10275 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2615. The method of embodiment 2117, wherein the disease or condition is Kugelberg-Wiland disease, and/or wherein the heterologous nucleic acid sequence encodes SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2616. The method of embodiment 2117, wherein the disease or condition is lactate dehydrogenase A deficiency, and/or wherein the heterologous nucleic acid sequence encodes LDHA (e.g., a polypeptide represented by UniProt Accession No. P00338 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2617. The method of embodiment 2117, wherein the disease or condition is lactate dehydrogenase B deficiency, and/or wherein the heterologous nucleic acid sequence encodes LDHB (e.g., a polypeptide represented by UniProt Accession No. P07195 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2618. The method of embodiment 2117, wherein the disease or condition is Lambert-Eaton myasthenia syndrome, and/or wherein the heterologous nucleic acid sequence encodes CACNB2 (e.g., a polypeptide represented by UniProt Accession No. Q08289 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2619. The method of embodiment 2117, wherein the disease or condition is Ryan distal myopathy, and/or wherein the heterologous nucleic acid sequence encodes MYH7 (e.g., a polypeptide represented by UniProt Accession No. A7E2Y1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2620. The method of embodiment 2117, wherein the disease or condition is limb-girdle muscular dystrophy type 2C (LGMD-2C), and/or wherein the heterologous nucleic acid sequence encodes γ-sarcoglycan (e.g., a polypeptide represented by UniProt accession number Q13326 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2621. The method of embodiment 2117, wherein the disease or condition is limb-girdle muscular dystrophy type 2D (LGMD-2D), and/or wherein the heterologous nucleic acid sequence encodes α-sarcoglycan (e.g., a polypeptide represented by UniProt Accession No. Q16586 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2622. The method of embodiment 2117, wherein the disease or condition is limb-girdle muscular dystrophy type 2E (LGMD-2E), and/or wherein the heterologous nucleic acid sequence encodes β-sarcoglycan (e.g., a polypeptide represented by UniProt accession number Q16585 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2623. The method of embodiment 2117, wherein the disease or condition is limb-girdle muscular dystrophy type 2F (LGMD-2F), and/or wherein the heterologous nucleic acid sequence encodes a delta-sarcoglycan (e.g., a polypeptide represented by UniProt Accession No. Q92629 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2624. The method of embodiment 2117, wherein the disease or condition is laminarin-deficient congenital muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes LAMA2 (e.g., a polypeptide represented by UniProt Accession No. P24043 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2625. The method of embodiment 2117, wherein the disease or condition is myo-o-encephalopathy, and/or wherein the heterologous nucleic acid sequence encodes POMGNT1 (e.g., a polypeptide represented by UniProt Accession No. Q8WZA1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2626. The method of embodiment 2117, wherein the disease or condition is mitochondrial myopathy, and/or wherein the heterologous nucleic acid sequence encodes CHCHD10 (e.g., a polypeptide represented by UniProt Accession No. Q8WYQ3 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2627. The method of embodiment 2117, wherein the disease or condition is Miyoshi myopathy, and/or wherein the heterologous nucleic acid sequence encodes DYSF (e.g., a polypeptide represented by UniProt Accession No. 075923 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2628. The method of embodiment 2117, wherein the disease or condition is myoadenylate deaminase deficiency, and/or wherein the heterologous nucleic acid sequence encodes AMPD1 (e.g., a polypeptide represented by UniProt Accession No. P23109 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2629. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 1, and/or wherein the heterologous nucleic acid sequence encodes DES (e.g., a polypeptide represented by UniProt Accession No. P17661 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2630. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 2, and/or wherein the heterologous nucleic acid sequence encodes CRYAB (e.g., a polypeptide represented by UniProt Accession No. P02511 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2631. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 3, and/or wherein the heterologous nucleic acid sequence encodes MYOT (e.g., a polypeptide represented by UniProt Accession No. Q9UBF9 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2632. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 4 (ZASP-associated myopathy), and/or wherein the heterologous nucleic acid sequence encodes LDB3 (ZASP) (e.g., a polypeptide represented by UniProt Accession No. 075112 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2633. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 5, and/or wherein the heterologous nucleic acid sequence encodes FLNC (e.g., a polypeptide represented by UniProt Accession No. Q14315 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2634. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 6, and/or wherein the heterologous nucleic acid sequence encodes BAG3 (e.g., a polypeptide represented by UniProt Accession No. 095817 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2635. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 7, and/or wherein the heterologous nucleic acid sequence encodes KY (e.g., a polypeptide represented by UniProt Accession No. Q8NBH2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2636. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 8, and/or wherein the heterologous nucleic acid sequence encodes PYROXD1 (e.g., a polypeptide represented by UniProt Accession No. Q8WU10 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2637. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 9, and/or wherein the heterologous nucleic acid sequence encodes TTN (e.g., a polypeptide represented by UniProt Accession No. Q8WZ42 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2638. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 10, and/or wherein the heterologous nucleic acid sequence encodes SVIL (e.g., a polypeptide represented by UniProt Accession No. 095425 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2639. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 11, and/or wherein the heterologous nucleic acid sequence encodes UNC45B (e.g., a polypeptide represented by UniProt Accession No. Q8IWX7 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2640. The method of embodiment 2117, wherein the disease or condition is myofibrillar myopathy 12, and/or wherein the heterologous nucleic acid sequence encodes MYL2 (e.g., a polypeptide represented by UniProt Accession No. Q99972 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2641. The method of embodiment 2117, wherein the disease or condition is myotonic dystrophy type 1 (Steinert disease), and/or wherein the heterologous nucleic acid sequence encodes a myotonic protein kinase (DMPK) (e.g., a polypeptide represented by UniProt Accession No. Q09013 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2642. The method of embodiment 2117, wherein the disease or condition is myotonic dystrophy type 2, and/or wherein the heterologous nucleic acid sequence encodes a CNBP (e.g., a polypeptide represented by UniProt Accession No. P62633 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2643. The method of embodiment 2117, wherein the disease or condition is myotubular myopathy, and/or wherein the heterologous nucleic acid sequence encodes MTM1 (e.g., a polypeptide represented by UniProt Accession No. Q13496 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2644. The method of embodiment 2117, wherein the disease or condition is myopathy 1, and/or wherein the heterologous nucleic acid sequence encodes TPM3 (e.g., a polypeptide represented by UniProt Accession No. P06753 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2645. The method of embodiment 2117, wherein the disease or condition is myopathy 2, and/or wherein the heterologous nucleic acid sequence encodes NEB (e.g., a polypeptide represented by UniProt Accession No. P20929 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2646. The method of embodiment 2117, wherein the disease or condition is myopathy 5A, 5B, or 5C, and/or wherein the heterologous nucleic acid sequence encodes TNNT1 (e.g., a polypeptide represented by UniProt Accession No. P13805 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2647. The method of embodiment 2117, wherein the disease or condition is myopathy 3, and/or wherein the heterologous nucleic acid sequence encodes ACTA1 (e.g., a polypeptide represented by UniProt Accession No. P68133 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2648. The method of embodiment 2117, wherein the disease or condition is myopathy 6, and/or wherein the heterologous nucleic acid sequence encodes KBTBD13 (e.g., a polypeptide represented by UniProt Accession No. C9JR72 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2649. The method of embodiment 2117, wherein the disease or condition is myopathy 4, and/or wherein the heterologous nucleic acid sequence encodes TPM2 (e.g., a polypeptide represented by UniProt Accession No. P07951 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2650. The method of embodiment 2117, wherein the disease or condition is myopathy 7, and/or wherein the heterologous nucleic acid sequence encodes CFL2 (e.g., a polypeptide represented by UniProt Accession No. Q9Y281 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2651. The method of embodiment 2117, wherein the disease or condition is myopathy 8, and/or wherein the heterologous nucleic acid sequence encodes KLHL40 (e.g., a polypeptide represented by UniProt Accession No. Q2TBA0 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2652. The method of embodiment 2117, wherein the disease or condition is myopathy 9, and/or wherein the heterologous nucleic acid sequence encodes KLHL41 (e.g., a polypeptide represented by UniProt Accession No. 060662 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2653. The method of embodiment 2117, wherein the disease or condition is myopathy 10, and/or wherein the heterologous nucleic acid sequence encodes LMOD3 (e.g., a polypeptide represented by UniProt Accession No. Q0VAK6 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2654. The method of embodiment 2117, wherein the disease or condition is distal myopathy, and/or wherein the heterologous nucleic acid sequence encodes GNE (e.g., a polypeptide represented by UniProt Accession No. Q9Y223 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2655. The method of embodiment 2117, wherein the disease or condition is oculopharyngeal muscle atrophy, and/or wherein the heterologous nucleic acid sequence encodes PABPN1 (e.g., a polypeptide represented by UniProt Accession No. Q86U42 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2656. The method of embodiment 2117, wherein the disease or condition is ornithine aminoformyl transferase deficiency, and/or wherein the heterologous nucleic acid sequence encodes OTC (e.g., a polypeptide represented by UniProt Accession No. P00480 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2657. The method of embodiment 2117, wherein the disease or condition is myotonia congenita, and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2658. The method of embodiment 2117, wherein the disease or condition is hypokalemic periodic paralysis, and/or wherein the heterologous nucleic acid sequence encodes CACNA1S (e.g., a polypeptide represented by UniProt Accession No. Q13698 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2659. The method of embodiment 2117, wherein the disease or condition is hyperkalemic periodic paralysis, and/or wherein the heterologous nucleic acid sequence encodes SCN4A (e.g., a polypeptide represented by UniProt Accession No. P35499 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2660. The method of embodiment 2117, wherein the disease or condition is phosphoglycerate kinase deficiency, and/or wherein the heterologous nucleic acid sequence encodes PGK1 (e.g., a polypeptide represented by UniProt Accession No. P00558 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2661. The method of embodiment 2117, wherein the disease or condition is polymyositis, and/or wherein the heterologous nucleic acid sequence encodes PMSCL2 (e.g., a polypeptide represented by UniProt Accession No. Q01780 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2662. The method of embodiment 2117, wherein the disease or condition is polymyositis, and/or wherein the heterologous nucleic acid sequence encodes PMSCL1 (e.g., a polypeptide represented by UniProt Accession No. Q06265 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2663. The method of embodiment 2117, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes POLG (e.g., a polypeptide represented by UniProt Accession No. P54098 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2664. The method of embodiment 2117, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes POLG2 (e.g., a polypeptide represented by UniProt Accession No. Q9UHN1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2665. The method of embodiment 2117, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes SLC25A4 (e.g., a polypeptide represented by UniProt Accession No. P12235 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2666. The method of embodiment 2117, wherein the disease or condition is progressive external ophthalmoplegia, and/or wherein the heterologous nucleic acid sequence encodes TWNK (e.g., a polypeptide represented by UniProt Accession No. Q96RR1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2667. The method of embodiment 2117, wherein the disease or condition is spinal muscular atrophy type 3 - Kugelberg-Wiland disease, and/or wherein the heterologous nucleic acid sequence encodes the survival motor neuron protein (SMN) SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2668. The method of embodiment 2117, wherein the disease or condition is Thompson's disease (myotonia congenita (somatic dominant)), and/or wherein the heterologous nucleic acid sequence encodes CLCN1 (e.g., a polypeptide represented by UniProt Accession No. P35523 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2669. The method of embodiment 2117, wherein the disease or condition is Walker-Warburg syndrome, and/or wherein the heterologous nucleic acid sequence encodes POMT1 (e.g., a polypeptide represented by UniProt Accession No. Q9Y6A1 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2670. The method of embodiment 2117, wherein the disease or condition is X-linked microtubular myopathy, and/or wherein the heterologous nucleic acid sequence encodes myotubularin (MTM1) (e.g., a polypeptide represented by UniProt Accession No. Q13496 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2671. The method of embodiment 2117, wherein the disease or condition is Hutchinson-Gilford Progeria Syndrome (HGPS), and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting human laminin A (LMNA) (e.g., a polypeptide represented by UniProt Accession No. P02545 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2672. The method of embodiment 2117, wherein the disease or condition is spinal muscular atrophy (SMA), and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide that targets a human survival motor neuron (SMN) (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2673. The method of embodiment 2117, wherein the disease or condition is Pompe disease, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting human acid α-glucosidase (GAA) (e.g., a polypeptide represented by UniProt Accession No. P10253 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2674. The method of embodiment 2117, wherein the disease or condition is Duchenne muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting human muscular dystrophy protein (DMD) (e.g., a polypeptide represented by UniProt Accession No. P11532 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2675. The method of embodiment 2117, wherein the disease or condition is myotonic dystrophy type 1-Steinert disease, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting human myotonic dystrophy-protein kinase (DMPK) (e.g., a polypeptide represented by UniProt Accession No. Q09013 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2676. The method of embodiment 2117, wherein the disease or condition is muscle atrophy, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting human myostatin (MSTN) (e.g., a polypeptide represented by UniProt Accession No. 014793 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2677. The method of embodiment 2117, wherein the disease or condition is facioscapulohumeral muscular dystrophy, and/or wherein the heterologous nucleic acid sequence encodes an antisense oligonucleotide targeting human double homeobox 4 (DUX4) (e.g., a polypeptide represented by UniProt Accession No. Q9UBX2 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2678. The method of embodiment 2117, wherein the disease or condition is Wednig-Hoffmann disease - spinal muscular atrophy type 1, and/or wherein the heterologous nucleic acid sequence encodes SMN1 (e.g., a polypeptide represented by UniProt Accession No. Q16637 or a polypeptide comprising an amino acid sequence having at least 95% sequence identity thereto). 2679. The method of any one of embodiments 1176 to 2678, wherein the subject is a mammal, such as a human. 2680. A cell, cell-free system, or other translation system comprising a capsid polypeptide according to any one of Examples 1 to 986, a nucleic acid molecule according to any one of Examples 987 to 1006, or a viral particle according to any one of Examples 1007 to 1165. 2681. A method for preparing a virus (e.g., a small, dependent virus particle, such as an adeno-associated virus (AAV) particle), comprising: (a) providing a cell, a cell-free system, or other translation system comprising a nucleic acid according to any one of Examples 987 to 1006; and (b) culturing the cell, cell-free system, or other translation system under conditions suitable for producing the virus particle, (c) thereby preparing the virus particle. 2682. The method of embodiment 2681, wherein the cell, cell-free system, or other translation system comprises a second nucleic acid molecule, and at least a portion of the second nucleic acid molecule is encapsulated in the dependent virus particle. 2683. The method of embodiment 2682, wherein the second nucleic acid comprises a payload, such as a heterologous nucleic acid sequence encoding a therapeutic product, such as described herein. 2684. The method of any one of embodiments 2681 to 2683, wherein the nucleic acid molecule of any one of embodiments 987 to 1006 mediates the production of viral particles, wherein the viral particles do not comprise the nucleic acid of any one of embodiments 987 to 1006 or a fragment thereof. 2685. The method of any one of embodiments 2681 to 2684, wherein the nucleic acid molecule of any one of embodiments 987 to 1006 mediates production of viral particles at a level similar to or at least 10% greater than the level of production mediated by a nucleic acid comprising SEQ ID NO: 2 in an otherwise similar production system. 2686. A composition, such as a pharmaceutical composition, comprising the viral particles of any one of Examples 1007 to 1165 or the viral particles produced by the method of any one of Examples 2681 to 2685 and a pharmaceutically acceptable carrier or excipient. 2687. A capsid polypeptide according to any one of Examples 1 to 986, a nucleic acid molecule according to any one of Examples 987 to 1006, a viral particle according to any one of Examples 1007 to 1165, or a composition according to Example 2686 for use in treating a disease or condition in a subject, wherein (a) the subject is as defined in Example 2215 and/or (b) the disease or condition is as defined in any one of Examples 1176 to 2678. 2688. A capsid polypeptide according to any one of Examples 1 to 986, a nucleic acid molecule according to any one of Examples 987 to 1006, a viral particle according to any one of Examples 1007 to 1165, or a composition according to Example 2686, for use in the production of a medicament for treating a disease or condition in a subject, wherein (a) the subject is as defined in Example 2215 and/or (b) the disease or condition is as defined in any one of Examples 1176 to 2678. 8. Example

The present invention is further illustrated by the following examples, which are provided for illustrative purposes only and should not be construed as limiting the scope or content of the present invention in any way.

Unless otherwise indicated, biodistribution, transduction, and/or productivity are presented as fold improvement compared to the ratio exhibited by viral particles comprising the capsid polypeptide of SEQ ID NO: 1. In some cases, the ratio is presented in log ₂ notation. 8.1. Example 1: Evaluation of High-Throughput AAV9 Library No. 1 in the CNS 8.1.1. Materials and Methods 8.1.1.1. Creation of Library No. 1

Using a machine learning algorithm trained on data from hundreds of thousands of capsid variants across multiple serotypes, including AAV particle production efficiency, transduction in multiple tissues, and biodistribution, a library of 1E5 capsid variants of wild-type AAV9 ("Library 1") was designed with the goal of generating capsids that would be encapsidated into AAV particles and efficiently transduce central nervous system tissues after intravenous injection, while de-targeting the liver and other tissue types. The designed capsid polypeptides were cloned into plasmids to create a library of plasmids encoding the capsid variants. A library of AAV variant genomes encoding each variant capsid and a unique capsid variant barcode identifier was cloned into two previously described ITR plasmid backbones (Ogden et al., 2019, Science 366(6469):1139-1143; Digital Object Identifier: 10.1126/science.aaw2900, hereby incorporated by reference in its entirety), one with capsid gene expression under the control of the neuron-specific hSyn promoter and the other with capsid gene expression under the control of the ubiquitous CBh promoter, both of which are expressed in the CNS and other tissues. Each plasmid backbone contains a unique genomic identifier ("backbone tag") that enables analysis of the biological distribution and transduction efficiency of each capsid variant via each of two promoters. Each capsid polypeptide variant is combined with 1-500 unique genomic identifiers ("barcodes") to enable measurement of the biological replicates of each virus containing a unique capsid polypeptide. A library of AAV capsid variants, each containing a genome encoding a variant capsid polypeptide, was generated by transient triple transfection of adherent HEK293T cells. Transfection was accomplished using a 1:1:1/150 ratio of Helper, Rep, and VAR/ITR plasmids, optimized for limiting cross-encapsulation. Cells were harvested, lysed, and purified by a series of steps: (1) filtration, (2) tangential flow filtration (TFF), (3) iodixanol gradient purification, and (4) buffer exchange. The resulting virus was subjected to appropriate sterility and endotoxin tests and titer analysis by ddPCR. 8.1.1.2. In vitro evaluation of library 1

Data were prepared as described below. To measure the packaging efficiency (or "production") of each variant, barcodes of vector genomes from both the plasmid library and the generated AAV library were prepared using two rounds of PCR for Illumina sequencing. The production efficiency of each of the generated AAV particle variants was normalized to its abundance in the input plasmid library and calculated by comparing the barcode sequencing levels of each variant in the generated AAV particle vector pool with the barcode sequence levels of each variant in the input plasmid library used to generate the AAV vector pool. The measurement of variant frequency in the AAV vector library also enables downstream normalization of biodistribution and transduction measurements using variant frequency in the input vector library. 8.1.1.3. In vivo evaluation of libraries in non - human primates ( NHPs)

All NHP experiments were conducted according to institutional policy and NIH guidelines. Two female cynomolgus macaques weighing 2.5 and 2.6 kg, serologically negative for neutralizing antibodies against AAV9 (serum NAb titers <1:4 based on in vitro NAb assays), were selected for the study. Animals were treated with methylprednisolone (40 or 80 mg IM) on day -8 and weekly for the duration of the study. Blood samples were collected prior to test article administration. Animals received an intravenous injection of a cocktail of promoter vectors (total combined dose per animal: 8.64 e13 vg/kg). During the survival period, animals were monitored according to the animal institution's standard operating procedures. Serum samples were collected 2, 4, and 7 days after injection and weekly. Animals were sacrificed 4 weeks after injection, and coronal brain sections and other tissues were collected for biodistribution and transduction analysis. The collected tissues are shown in Table 6A. All samples were collected in RNAlater® (Sigma-Aldrich) and incubated overnight at 4°C, after which the RNAlater® was drained and the samples were frozen at -80°C or maintained in RNAlater® at 4°C (a small number of samples). In addition, serum and cerebrospinal fluid samples were collected at necropsy and stored at -80°C. Table 6A : List of collected organizations organization adrenal glands Adipose tissue aorta Coronal section of the brain carotid artery Dorsal root ganglion (cervical spine) Dorsal root ganglion (thoracic spine) Dorsal root ganglion (lumbar spine) Dorsal root ganglion (sacrum) gonads (ovaries) Heart base apex of the heart ventricles kidneys liver lung cervical lymph nodes optic nerve sciatic nerve skeletal muscle gastrocnemius muscle skeletal muscle quadriceps Skeletal muscle diaphragm Spinal cord (cervical vertebrae) Spinal cord (cranial thoracic vertebrae) Spinal cord (caudal thoracic vertebrae) Spinal cord (lumbar vertebrae) spleen

Brain sections were dissected to isolate regions including, but not limited to, the frontal cortex, temporal cortex, motor cortex, hippocampus, basal ganglia, midbrain, brainstem, and cerebellum. For all biodistribution and transduction analyses, total DNA and RNA were extracted from tissue samples by Trizol/chloroform and isopropanol precipitation. Reverse transcription was performed using primers specific for the vector transgene and containing a unique molecular identifier (UMI) with Protoscript II Reverse Transcriptase (NEB). A control reaction lacking reverse transcriptase (-RT control) was also prepared. Biodistribution (based on viral DNA quantification) and transduction (based on viral transcript RNA quantification) were quantified using Luna Universal Probe qPCR Master Mix (NEB) using primers and probes specific for the transgene construct. Finally, samples were prepared for next-generation sequencing by amplifying the transgenic barcode region using primers compatible with the Illumina NGS platform and sequenced using the NextSeq 550 (Illumina).

After sequencing, barcode tags are extracted from reads with the expected amplicon structure, and the abundance of each barcode (number of reads or UMIs) is recorded. This is measured by sequencing variant regions of the input plastid sample individually, limiting the analysis to the set of barcodes present in the input plastid sample.

To pool packaging replicates, read counts from duplicate virus production samples were summed. To pool biodistribution samples, read counts from samples from the same tissue were summed. To pool transduction samples, the number of transduction events (measured by detected unique ID tags) from samples from the same tissue was summed.

Viral packaging was calculated by normalizing total production copies to input plasmid abundance. Tissue biodistribution and transduction were calculated by normalizing total biodistribution or transduction samples to input virus abundance. Output is reported as fold change relative to WT AAV9. 8.1.2. Results

Analysis of production, transduction, and biodistribution results from CBh-driven and hSyn-driven constructs in multiple brain regions (including pooled reads from all brain regions collected) identified over 1,000 unique capsid sequences that exhibited better transduction of pooled brain tissue samples compared to WT AAV9 and contained at least two of the mutations Q592V, T593S, and G594M, including variants designated V1-V60 and V62-146.

The production, biodistribution, and transduction results of variants V1-V60 and V62-146 from this library experiment are summarized in Table 7A (production), Tables 7B-1 and 7B-2 (brain tissue biodistribution), Table 7C (peripheral tissue biodistribution), Tables 7D-1 and 7D-2 (brain tissue transduction), and Table 7E (peripheral tissue transduction). Table 7A : Production efficiency of variant viral particles relative to that of WT AAV9 viral particles in HEK293 cells in vitro. Variant number Fold change relative to wtAAV9 Variant number Fold change relative to wtAAV9 V1 0.38 V75 0.39 V2 0.42 V76 0.51 V3 0.44 V77 0.86 V4 0.46 V78 0.44 V5 0.59 V79 0.50 V6 0.47 V80 0.57 V7 0.32 V81 0.71 V8 0.13 V82 0.79 V9 0.33 V83 0.49 V10 0.62 V84 0.55 V11 0.43 V85 0.53 V12 0.43 V86 0.38 V13 0.66 V87 0.66 V14 0.34 V88 0.69 V15 0.46 V89 0.38 V16 0.62 V90 0.54 V17 0.55 V91 0.83 V18 0.31 V92 0.71 V19 0.52 V93 0.59 V20 0.48 V94 0.48 V21 0.45 V95 0.47 V22 0.69 V96 0.38 V23 0.36 V97 0.05 V24 0.92 V98 0.19 V25 0.92 V99 0.59 V26 0.62 V100 0.68 V27 0.75 V101 0.66 V28 0.65 V102 0.46 V29 0.27 V103 0.44 V30 0.62 V104 0.51 V31 0.51 V105 0.53 V32 0.87 V106 0.31 V33 0.95 V107 0.40 V34 0.48 V108 0.45 V35 0.86 V109 0.63 V36 0.40 V110 0.48 V37 0.77 V111 0.33 V38 0.28 V112 0.56 V39 0.33 V113 0.42 V40 0.58 V114 0.56 V41 0.72 V115 0.42 V42 0.49 V116 0.32 V43 0.76 V117 0.36 V44 0.56 V118 0.40 V45 0.79 V119 0.43 V46 0.56 V120 0.48 V47 0.53 V121 0.52 V48 0.62 V122 0.81 V49 0.79 V123 0.25 V50 0.53 V124 0.46 V51 0.46 V125 0.35 V52 0.73 V126 0.45 V53 0.67 V127 0.62 V54 0.92 V128 0.32 V55 0.52 V129 0.45 V56 0.22 V130 0.41 V57 0.97 V131 0.48 V58 1.08 V132 0.50 V59 0.42 V133 0.47 V60 0.46 V134 0.67 V62 0.11 V135 0.51 V63 0.94 V136 0.46 V64 0.49 V137 0.75 V65 0.58 V138 0.59 V66 0.32 V139 0.51 V67 0.64 V140 0.52 V68 0.70 V141 0.43 V69 0.63 V142 0.41 V70 0.71 V143 0.69 V71 0.41 V144 0.49 V72 0.81 V145 0.59 V73 0.65 V146 0.52 V74 1.00 Table 7B - 1 . Fold change in the biodistribution of virions containing the indicated variant capsid polypeptides relative to the biodistribution of virions containing WT AAV9 for brain regions. "Summary" is the average of all other measured regions. CBh indicates measurements from virions containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates virions containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that the variant was not detected in the indicated sample. organ brain brain brain brain brain brain brain brain brain brain brain brain organization Summary Summary Summary basal ganglia basal ganglia basal ganglia brain stem brain stem brain stem Cerebellum Cerebellum Cerebellum Starter Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Variant number V1 33.66 40.40 31.65 42.38 52.09 40.76 11.86 15.06 12.91 53.70 59.36 42.14 V2 32.24 34.78 27.10 43.85 43.66 30.77 11.76 14.47 13.32 37.75 48.01 41.56 V3 32.27 32.70 31.91 42.50 40.39 34.00 7.05 6.61 5.29 56.33 60.82 66.02 V4 28.31 28.99 21.18 34.22 33.07 22.31 14.75 14.12 9.83 37.81 43.44 34.32 V5 23.82 25.45 20.94 27.81 31.84 27.92 9.02 9.30 7.57 36.73 34.33 22.99 V6 29.61 24.72 13.12 32.63 24.94 6.29 18.28 15.07 6.28 49.17 36.97 8.86 V7 18.58 21.30 16.77 10.44 19.16 19.30 11.46 10.27 6.44 36.85 40.80 30.09 V8 0 12.49 12.08 0 20.60 17.60 0 6.95 6.26 0 6.71 8.81 V9 21.84 19.69 13.70 37.27 27.11 6.72 9.40 8.35 5.44 20.98 24.88 28.17 V10 24.08 21.69 15.50 39.11 30.70 12.28 11.39 10.45 7.77 27.48 25.32 19.63 V11 14.99 15.38 12.27 12.00 16.72 17.91 5.00 4.60 3.13 24.13 23.20 16.51 V12 25.52 26.73 30.05 36.59 34.42 29.82 8.45 14.02 29.14 41.52 39.71 36.26 V13 24.02 19.82 10.51 35.30 29.06 15.33 9.66 8.04 4.35 34.56 25.60 10.10 V14 21.33 25.57 23.87 28.34 30.35 24.82 7.43 9.34 9.53 32.88 41.87 39.79 V15 21.12 19.68 16.62 19.80 19.56 19.59 11.08 9.68 6.04 33.74 29.27 19.87 V16 17.56 15.69 11.53 20.86 18.52 13.51 8.24 7.41 5.32 24.68 23.24 20.83 V17 28.85 28.81 21.46 33.76 36.53 29.71 11.30 9.74 5.74 44.97 45.12 33.02 V18 27.35 28.89 25.00 38.87 35.75 24.41 11.74 13.14 12.69 32.14 32.83 26.51 V19 23.38 24.04 18.36 30.61 30.35 21.89 11.54 10.36 6.63 37.84 39.23 29.45 V20 28.72 26.60 20.31 39.87 36.15 26.16 10.05 9.34 7.14 37.28 36.56 32.03 V21 19.31 20.14 16.94 20.13 19.78 15.06 6.95 6.23 4.04 33.77 35.72 29.91 V22 18.54 17.47 24.67 26.58 24.41 31.02 5.57 6.00 13.67 25.70 24.22 36.37 V23 15.97 17.11 15.87 22.78 24.64 22.97 4.95 5.51 5.58 21.19 21.33 17.66 V24 21.33 20.98 16.81 27.87 26.46 19.74 9.71 9.75 8.26 26.42 25.84 20.23 V25 22.43 20.79 13.84 32.09 26.00 13.25 10.55 10.30 7.63 31.28 30.30 21.11 V26 11.78 10.33 6.51 9.53 8.99 6.77 6.14 4.90 2.10 15.73 14.32 9.96 V27 19.53 20.22 14.39 26.98 24.67 15.16 10.30 10.54 7.73 25.10 26.96 19.15 V28 24.16 23.46 19.34 27.32 24.73 17.31 9.98 10.85 11.25 32.31 31.30 25.55 V29 12.72 12.05 8.62 15.97 13.95 8.47 5.67 5.45 4.09 16.32 15.42 10.83 V30 15.77 13.37 7.53 20.69 16.24 7.85 7.59 6.70 4.12 20.39 17.03 September 20 V31 18.05 17.99 13.44 21.24 20.44 14.39 11.12 9.70 5.88 24.02 24.52 18.47 V32 16.40 14.84 9.69 22.52 18.90 10.45 7.27 6.52 4.23 20.08 18.88 13.06 V33 22.98 21.23 18.56 21.24 24.53 37.00 8.50 7.66 5.73 36.42 32.39 25.44 V34 7.73 7.75 5.26 8.41 8.56 5.81 5.53 4.99 3.14 7.44 9.34 7.25 V35 22.13 18.68 10.47 27.45 22.85 12.37 8.09 7.10 4.41 28.80 22.96 10.99 V36 21.74 22.06 16.02 24.36 25.18 18.43 13.71 11.13 5.84 27.15 33.70 28.46 V37 27.93 25.37 21.56 39.74 35.37 28.05 10.08 9.17 7.38 41.23 37.58 33.82 V38 26.37 29.07 22.36 26.50 31.83 25.88 16.88 12.26 5.01 39.29 47.16 37.47 V39 10.82 12.11 11.49 13.88 14.45 12.29 3.69 5.14 6.36 16.28 14.71 9.75 V40 19.81 20.65 14.69 23.03 27.23 21.12 7.79 8.13 6.04 41.68 32.26 15.42 V41 15.24 14.97 11.00 16.79 16.82 12.58 10.71 11.30 9.45 19.33 16.84 9.98 V42 17.87 17.79 13.31 19.02 20.40 16.61 8.60 9.24 7.91 27.49 23.06 12.69 V43 22.62 21.30 15.79 24.66 23.33 17.43 12.70 12.18 9.47 32.05 29.35 20.45 V44 11.28 10.48 6.84 17.81 15.56 9.17 4.49 5.76 5.51 12.02 13.31 10.36 V45 13.73 11.11 5.56 16.57 13.99 7.84 6.73 6.04 3.91 22.69 15.45 3.93 V46 12.38 11.42 7.36 17.10 13.24 6.18 5.96 5.82 4.19 15.37 14.13 8.87 V47 9.90 9.82 8.39 12.24 11.97 9.93 7.76 7.18 5.27 13.52 13.28 11.05 V48 22.51 23.81 18.51 26.68 27.23 20.07 10.31 12.37 11.39 30.06 33.50 26.63 V49 19.66 18.70 13.59 28.25 27.78 21.25 7.32 6.80 4.80 21.33 21.87 17.60 V50 26.23 28.15 26.21 35.95 35.18 27.99 13.70 14.19 12.82 36.10 40.65 39.43 V51 18.64 19.24 16.80 25.04 24.78 20.02 8.66 9.39 9.08 25.28 24.75 19.49 V52 14.73 13.05 7.98 19.95 16.85 9.38 5.86 5.09 3.06 25.01 21.53 12.35 V53 14.06 14.24 9.03 19.93 18.96 11.35 7.75 7.24 4.58 14.34 15.08 9.37 V54 14.83 13.80 8.79 16.30 15.85 10.50 7.27 8.36 6.89 21.29 17.38 9.04 V55 23.82 21.22 13.02 27.30 23.02 12.76 9.47 10.23 8.39 41.41 31.96 14.76 V56 11.74 9.26 4.22 14.26 12.31 7.31 7.21 6.58 4.46 16.26 11.41 3.29 V57 13.17 November 17 6.43 16.25 13.63 7.64 4.72 4.72 4.50 15.97 12.91 6.34 V58 11.32 September 20 4.47 14.02 11.15 5.06 5.60 4.58 2.17 13.73 10.84 4.91 V59 16.72 15.18 10.52 19.97 18.15 12.65 8.97 7.21 3.16 30.21 27.19 18.57 V60 21.30 19.36 12.99 26.72 25.07 17.89 10.96 9.36 5.36 26.82 24.59 16.72 V62 0 6.30 8.01 0 8.64 11.54 0 5.09 5.79 0 6.78 9.00 V63 15.03 14.60 10.88 16.18 16.22 12.61 7.87 7.25 4.99 19.37 18.93 14.03 V64 12.60 11.67 7.36 October 24th 12.51 10.01 8.00 6.36 3.28 14.28 13.54 8.52 V65 18.05 4.88 13.44 21.24 6.08 14.39 11.12 1.94 5.88 24.02 7.27 18.47 V66 5.06 4.56 3.99 6.59 6.80 4.47 1.93 0.63 1.74 8.29 2.96 4.71 V67 4.48 3.60 4.60 4.41 6.53 11.64 0.82 1.93 0.17 3.52 3.84 1.72 V68 3.09 3.58 3.58 7.01 3.85 4.61 0.80 2.51 3.24 2.14 5.74 5.12 V69 3.42 6.66 3.00 3.41 9.06 3.52 2.67 4.02 1.80 5.44 6.82 4.74 V70 7.73 2.58 4.12 9.60 2.95 7.59 5.63 2.02 0.05 6.98 2.85 6.24 V71 2.88 0.61 1.64 3.46 2.07 1.68 2.29 0.27 1.25 3.44 0.33 1.53 V72 0.16 1.62 1.39 0.10 1.96 5.47 0.15 0.51 0.50 0.24 1.77 0.46 V73 2.07 1.27 0.63 2.63 0.33 0.58 0.35 2.36 0.77 2.70 2.05 0.02 V74 1.52 0.67 0.70 0.20 0.33 0.33 2.29 0.79 1.79 3.94 1.01 0.02 V75 0.85 0.52 0.30 0.39 0.17 0.19 0.96 0.95 0.39 1.24 0.92 0.52 V76 0.40 1.10 0.46 0.16 0.62 0.12 0.81 0.81 0.80 0.02 1.96 1.24 V77 5.29 5.15 4.06 6.49 6.77 5.97 4.65 3.52 1.17 7.54 7.61 6.29 V78 0.70 0.69 0.66 0.05 0.04 0.02 0.91 0.65 0.02 0.29 0.19 0.02 V79 1.26 1.35 1.41 0.57 1.36 2.69 0.86 0.73 0.39 2.22 1.95 1.29 V80 0.63 0.54 0.31 1.25 1.11 0.68 0.76 0.50 0.13 0.02 0.02 0.02 V81 0.94 0.99 0.86 2.38 1.59 0.29 0.17 0.37 0.59 0.13 1.31 2.41 V82 0.81 0.58 0.24 0.42 0.23 0.03 2.04 1.30 0.39 0.39 0.45 0.33 V83 0.68 0.61 0.40 0.32 0.20 0.02 1.10 0.71 0.02 0.98 0.60 0.02 V84 1.06 0.95 0.59 0.60 0.63 0.48 0.34 1.35 2.02 0.34 0.19 0.02 V85 1.54 1.41 1.01 0.44 0.29 0.02 0.80 0.58 0.13 2.83 2.34 1.26 V86 0.72 0.87 0.88 0.54 1.08 1.52 0.67 1.07 1.44 0.25 0.57 0.82 V87 1.22 0.85 0.09 0.19 0.13 0.02 0.38 0.30 0.11 4.15 2.69 0.02 V88 0.92 1.14 1.19 0.28 1.60 2.89 0.12 0.63 1.25 2.01 1.25 0.08 V89 1.20 0.90 0.34 0.31 0.26 0.14 2.84 2.01 0.46 2.09 1.54 0.56 V90 0.63 0.58 0.39 0.24 0.15 0.02 0.84 0.64 0.24 1.42 0.85 0.02 V91 0.62 0.76 0.61 0.19 0.58 0.64 0.38 0.30 0.15 1.36 1.72 1.36 V92 0.66 0.68 0.56 0.70 0.68 0.51 1.07 0.74 0.14 0.28 0.77 1.17 V93 1.01 1.50 1.37 0.50 1.38 1.52 0.90 0.97 0.74 0.47 2.25 2.65 V94 0.93 0.81 0.47 0.67 0.48 0.20 0.05 0.23 0.27 0.02 0.02 0.02 V95 0.82 0.63 0.25 1.20 0.75 0.02 0.46 0.35 0.12 1.47 1.03 0.27 V96 1.57 1.55 1.39 0.92 0.97 1.00 0.45 0.54 0.71 1.30 1.48 1.68 V97 0 0.78 0 0 0.30 0 0 1.79 0 0 0.02 0 V98 0.51 0.52 0.50 0.02 0.02 0.02 0.58 0.47 0.18 0.82 0.55 0.02 V99 0.38 0.52 0.59 1.23 2.03 2.55 0.02 0.33 0.72 0.02 0.02 0.02 V100 1.39 2.42 2.71 0.99 7.42 11.03 0.58 0.33 0.02 3.06 2.01 0.53 V101 0.54 0.67 0.54 0.84 0.76 0.45 0.59 0.73 0.62 0.08 0.37 0.42 V102 0.50 0.75 0.82 0.19 0.14 0.07 0.92 0.78 0.45 0.02 0.16 0.26 V103 1.30 1.04 0.49 1.52 1.11 0.37 1.23 0.88 0.21 1.44 1.19 0.65 V104 0.19 0.45 0.63 0.28 1.07 1.68 0.09 0.05 0.02 0.13 0.16 0.16 V105 0.69 0.91 0.91 0.76 1.24 1.41 0.36 0.78 1.10 0.82 1.11 1.11 V106 1.61 1.35 0.75 6.60 3.82 0.15 0.58 0.53 0.34 0.41 0.90 1.09 V107 0.71 0.66 0.53 0.80 0.66 0.35 0.40 0.61 1.06 0.94 0.63 0.02 V108 0.60 0.91 1.17 0.33 0.22 0.03 0.55 0.62 0.63 0.72 1.91 3.09 V109 1.43 1.17 0 2.34 1.89 0 0.96 0.81 0 0.70 0.56 0 V110 1.19 1.50 1.08 0.12 2.13 2.15 1.17 1.31 0.94 2.55 0.99 0.02 V111 1.34 1.00 0.35 1.03 0.82 0.38 0.74 0.70 0.52 1.69 1.09 0.16 V112 0.90 1.07 1.11 1.44 1.79 1.92 1.40 1.63 1.70 0.60 0.37 0.02 V113 0.80 1.10 1.43 1.54 1.27 0.68 1.97 1.36 0.09 0.19 0.95 1.95 V114 1.50 1.27 0.71 3.39 2.11 0.37 0.83 1.62 2.07 0.43 0.24 0.02 V115 0.56 0.59 0.44 0.30 0.37 0.31 0.68 0.53 0.27 0.02 0.02 0.02 V116 1.05 0.88 0.47 0.45 0.57 0.70 0.37 0.64 1.10 1.63 1.06 0.02 V117 0.63 0.85 1.20 1.15 2.84 5.63 0.23 0.16 0.02 0.60 0.39 0.02 V118 0.93 0.84 0.57 0.78 0.71 0.49 0.80 0.68 0.38 1.51 1.17 0.50 V119 0.68 0.71 0.50 0.46 0.38 0.20 1.54 1.29 0.73 0.02 0.79 0.97 V120 1.08 1.07 0.92 3.05 1.98 0.02 0.26 0.27 0.27 0.19 0.17 0.11 V121 0.97 1.17 1.41 1.05 2.43 4.63 0.88 1.05 1.31 0.68 0.62 0.46 V122 0.61 0.95 1.16 0.43 0.99 1.44 0.49 1.04 1.59 0.37 0.84 1.19 V123 0.63 0.63 0.58 0.15 0.10 0.02 0.58 1.58 3.41 0.02 0.02 0.02 V124 0.43 0.36 0.20 0.91 0.56 0.05 0.41 0.44 0.38 0.02 0.02 0.02 V125 0.70 0.74 0.62 0.41 0.90 1.30 1.46 0.94 0.03 1.30 0.78 0.02 V126 0.40 0.48 0.60 0.02 0.31 0.82 0.15 0.18 0.22 0.38 0.56 0.79 V127 1.17 1.06 0.64 1.99 2.05 1.40 0.37 0.41 0.32 2.57 1.95 0.91 V128 0.46 0.90 1.28 0.16 0.86 1.53 0.76 1.23 1.65 0.02 1.13 2.21 V129 0.39 0.50 0.56 0.07 0.23 0.39 1.03 0.85 0.44 0.02 0.67 1.31 V130 1.08 0.86 0.43 3.52 2.06 0.20 0.48 0.62 0.61 0.65 0.56 0.32 V131 0.64 0.50 0.22 0.02 0.20 0.35 1.25 0.76 0.02 0.02 0.08 0.14 V132 0.57 0.39 0.07 0.28 0.17 0.02 0.55 0.35 0.02 1.05 0.64 0.02 V133 1.02 1.32 1.22 1.94 3.27 3.49 1.06 0.95 0.59 0.02 0.37 0.55 V134 0.74 0.82 0.69 1.30 1.34 1.02 0.33 0.46 0.49 0.29 0.16 0.02 V135 0.59 0.87 0.90 0.02 0.59 0.96 0.43 1.05 1.43 0.02 0.38 0.61 V136 0.31 0.26 0.15 0.02 0.16 0.56 0.37 0.27 0.02 0.02 0.02 0.02 V137 0.70 0.56 0.26 1.05 0.78 0.21 0.27 0.36 0.51 0.97 0.69 0.13 V138 6.15 5.79 4.08 9.07 7.27 3.54 3.83 3.51 2.40 7.89 8.48 7.13 V139 0.84 0.81 0.54 1.55 1.23 0.61 0.87 0.53 0.10 1.98 1.39 0.53 V140 1.05 0.93 0.60 1.79 1.87 1.77 0.13 0.39 0.84 0.21 0.13 0.02 V141 0.73 1.08 1.06 0.78 1.07 1 0.45 1.09 1.42 0.77 0.54 0.20 V142 0.64 0.64 0.48 0.74 0.69 0.47 0.17 0.49 0.74 0.58 0.41 0.14 V143 0.23 0.53 0.60 0.45 0.74 0.72 0.29 0.46 0.47 0.11 0.71 0.90 V144 1.06 0.91 0.53 0.36 0.28 0.13 0.87 0.70 0.35 1.31 0.88 0.26 V145 0.52 0.52 0.53 0.49 0.46 0.39 0.63 0.51 0.18 0.64 0.62 0.58 V146 0.88 1.13 1.39 0.83 0.76 0.54 2.13 1.67 0.62 0.49 0.67 0.84 Table 7B-2. Fold change in the biodistribution of virions containing the indicated variant capsid polypeptides relative to the biodistribution of virions containing WT AAV9 for brain regions. "Summary" is the average of all other measured regions. CBh indicates measurements from virions containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates virions containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that the variant was not detected in the indicated sample. organ brain brain brain brain brain brain brain brain brain brain brain brain organization forebrain forebrain forebrain hippocampus hippocampus hippocampus midbrain midbrain midbrain Temporal cortex Temporal cortex Temporal cortex Starter Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Variant number V1 37.21 41.91 31.66 9.59 16.58 14.84 21.82 29.21 24.48 33.33 42.25 35.17 V2 42.35 41.79 29.66 19.79 22.95 18.36 11.09 17.00 17.23 38.48 35.36 22.96 V3 29.20 29.04 27.20 17.45 17.32 16.10 19.79 21.79 24.80 33.33 31.28 25.28 V4 33.54 31.05 20.14 12.28 11.04 6.66 25.13 18.76 8.07 26.73 30.78 25.79 V5 27.90 31.24 27.32 15.14 15.42 11.59 18.88 18.75 14.00 21.51 25.41 23.77 V6 26.18 21.96 11.72 8.46 15.54 35.03 25.05 24.33 24.45 27.30 25.59 22.70 V7 18.72 21.34 16.87 16.82 17.68 12.37 14.00 14.79 10.81 16.40 16.09 11.12 V8 0 16.38 14.94 0 27.59 36.73 0 October 17th 12.59 0 9.41 5.15 V9 33.16 31.46 24.92 5.06 3.27 0.03 5.64 4.63 2.33 20.65 17.60 10.09 V10 24.23 23.97 22.00 8.97 7.99 5.67 22.10 22.86 22.97 22.76 20.79 15.37 V11 17.14 15.27 9.64 2019.19 11.16 0.12 19.26 23.91 23.63 13.61 13.81 11.00 V12 24.75 29.22 40.68 12.49 15.42 22.09 25.84 22.25 13.88 18.16 19.39 22.77 V13 23.32 19.72 11.07 27.57 18.98 5.63 19.99 18.91 13.16 16.94 16.19 11.60 V14 24.09 29.91 29.08 2.97 2.48 1.36 8.31 8.75 7.08 23.61 27.97 26.33 V15 23.98 21.14 14.48 17.71 14.58 7.94 20.71 22.13 26.33 17.49 18.11 20.24 V16 14.80 13.41 10.30 14.53 11.90 6.32 23.57 19.51 9.91 16.85 14.07 7.13 V17 32.62 31.45 22.41 19.60 16.42 8.98 24.19 22.02 14.23 25.22 25.33 19.28 V18 32.94 36.16 33.15 16.61 20.07 19.67 20.37 22.13 19.88 27.11 31.99 32.32 V19 21.20 21.26 15.84 17.40 14.57 7.94 October 18 10.20 7.52 21.25 24.93 22.39 V20 26.65 25.55 21.32 18.60 14.47 6.01 23.19 19.44 10.66 34.20 30.17 19.67 V21 20.56 22.17 19.63 13.61 11.89 7.25 11.99 9.79 5.00 18.76 21.72 21.19 V22 17.71 16.75 23.68 13.97 12.73 16.50 12.00 10.69 10.69 20.55 19.01 23.17 V23 18.64 17.55 13.02 3.25 2.11 0.22 9.33 11.63 13.01 18.45 22.36 24.75 V24 24.01 23.34 18.35 17.73 16.11 10.96 14.05 15.40 14.60 22.63 22.73 19.05 V25 26.15 23.96 15.71 13.40 12.29 7.89 11.38 October 19th 6.39 18.58 19.02 14.84 V26 17.06 13.61 6.14 13.38 10.31 4.30 12.61 11.26 7.45 10.04 9.35 6.86 V27 22.15 25.10 19.51 11.94 10.86 6.49 12.89 13.59 9.82 17.69 18.63 13.74 V28 25.31 25.70 23.23 25.57 31.51 36.36 19.81 16.55 8.98 27.15 24.67 17.33 V29 14.65 13.12 8.44 6.82 6.32 4.29 12.62 12.01 8.65 12.66 13.65 12.04 V30 15.99 13.21 7.11 16.76 11.97 4.64 October 16 9.02 5.45 15.93 15.40 10.67 V31 21.28 21.07 15.70 14.49 11.35 5.34 12.04 11.54 8.14 15.86 18.13 16.28 V32 17.12 17.00 13.11 18.01 12.02 2.76 15.15 11.58 4.81 14.98 14.63 11.07 V33 27.36 23.82 15.85 9.81 10.39 13.29 23.53 18.20 4.53 24.39 20.82 12.02 V34 8.43 7.61 4.65 2.62 2.20 1.18 20.70 13.96 5.07 5.04 6.97 6.14 V35 30.28 25.99 15.26 10.22 8.97 5.64 16.34 12.06 3.87 22.10 20.06 13.63 V36 24.76 24.88 17.98 15.65 12.22 5.81 10.57 9.54 5.94 24.94 22.00 13.37 V37 30.91 26.41 15.94 10.96 12.78 20.85 24.54 22.72 20.90 22.83 21.05 18.60 V38 32.89 35.49 27.00 24.83 23.67 15.14 18.20 18.11 12.57 19.61 22.75 18.69 V39 8.78 11.90 13.86 3.22 3.68 3.47 14.16 20.14 24.15 11.58 13.06 12.69 V40 16.68 20.53 16.82 10.54 11.04 7.56 7.41 13.66 13.58 15.18 18.90 15.83 V41 18.80 17.76 12.35 15.33 14.38 9.64 7.66 9.55 September 18 13.70 14.53 12.03 V42 21.11 21.59 16.86 10.07 10.39 7.92 14.77 13.47 8.77 16.12 18.15 16.10 V43 26.89 23.33 14.14 19.77 18.52 13.51 15.06 16.02 14.75 20.40 20.37 17.05 V44 15.02 12.59 6.96 20.59 12.17 1.84 8.78 7.50 4.29 5.90 5.47 3.60 V45 14.95 11.64 5.13 7.72 7.63 5.70 8.88 7.65 4.49 10.61 October 21 7.52 V46 15.41 14.92 10.35 9.83 7.58 3.51 6.74 7.09 5.39 11.16 11.81 September 21 V47 8.69 9.53 9.71 7.21 6.70 5.00 6.25 8.02 9.87 9.01 8.11 5.54 V48 23.49 24.46 18.82 7.29 7.11 4.86 23.97 19.90 10.75 25.23 26.56 20.90 V49 20.72 18.40 11.67 14.86 13.84 9.55 13.63 13.22 9.93 24.73 21.64 13.26 V50 28.83 31.46 30.16 13.91 13.43 10.34 16.51 20.23 22.22 23.26 25.04 23.73 V51 22.48 23.41 20.84 5.73 7.60 8.64 19.41 20.76 19.14 14.70 15.93 15.17 V52 11.56 12.35 9.86 11.70 6.75 0.58 16.29 11.05 3.17 October 24th 10.70 8.42 V53 13.59 18.29 13.53 4.06 2.95 1.37 18.35 14.25 7.33 15.67 14.95 9.34 V54 17.52 15.62 9.47 7.24 7.71 5.44 13.01 13.03 9.01 14.41 13.46 8.75 V55 22.51 21.66 14.98 17.42 14.47 7.76 18.12 18.90 14.32 20.96 20.73 14.99 V56 14.61 9.97 2.00 5.23 8.47 October 21 9.86 6.38 0.70 8.73 7.04 3.41 V57 16.03 12.96 5.78 16.14 14.12 9.52 6.99 6.66 5.66 14.87 12.63 7.12 V58 10.03 9.31 6.91 6.97 7.34 6.85 14.78 10.96 3.21 12.81 9.70 3.06 V59 16.18 15.94 13.30 4.64 4.03 2.52 8.22 6.62 3.12 13.73 12.35 8.34 V60 21.34 17.91 9.85 30.27 19.66 2.85 19.80 2019.17 14.55 18.58 18.92 15.83 V62 0 4.46 5.22 0 20.45 26.89 0 4.40 5.12 0 2.98 2.93 V63 19.32 18.21 12.95 3.72 5.84 6.76 16.35 14.69 9.48 15.15 14.57 10.78 V64 15.10 12.45 6.72 12.49 8.95 3.67 10.97 9.28 5.18 16.46 15.21 9.72 V65 4.33 5.38 6.55 1.18 1.18 1.18 1.18 1.18 1.18 1.18 1.18 1.18 V66 4.66 4.50 4.01 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V67 2.80 4.52 5.98 6.22 6.22 6.22 6.22 6.22 6.22 6.22 6.22 6.22 V68 2.31 2.72 2.65 3.66 3.66 3.66 3.66 3.66 3.66 3.66 3.66 3.66 V69 7.06 6.07 3.68 4.10 4.10 4.10 4.10 4.10 4.10 4.10 4.10 4.10 V70 3.94 3.66 2.49 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 V71 0.14 0.15 0.16 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V72 1.65 1.33 0.60 2.72 2.72 2.72 2.72 2.72 2.72 2.72 2.72 2.72 V73 0.65 1.40 1.62 2.71 2.71 2.71 2.71 2.71 2.71 2.71 2.71 2.71 V74 0.86 0.58 0.06 0.49 0.49 0.49 0.49 0.49 0.49 0.49 0.49 0.49 V75 0.52 0.30 0.05 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46 1.46 V76 0.06 0.66 0.87 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V77 3.71 4.02 3.79 September 19 7.05 2.95 3.95 3.21 1.58 3.16 3.58 3.62 V78 0.23 1.46 4.25 0.04 0.03 0.02 4.67 3.25 0.02 0.56 0.40 0.02 V79 0.36 0.84 1.70 0.02 0.02 0.02 1.08 1.65 2.59 2.57 2.03 0.81 V80 0.13 0.14 0.11 1.71 1.67 1.13 1.70 1.19 0.42 0.27 0.36 0.35 V81 0.36 0.29 0.14 0.77 0.86 0.77 3.51 2.16 0.02 0.69 0.83 0.85 V82 0.73 0.64 0.38 1.99 0.95 0.02 0.44 0.26 0.06 0.33 0.35 0.26 V83 0.87 1.09 1.18 0.02 0.02 0.02 0.02 0.45 0.96 0.59 0.76 0.87 V84 3.51 1.99 0.06 0.02 0.02 0.02 0.60 0.90 0.91 1.32 1.10 0.60 V85 3.64 2.67 0.73 0.02 0.02 0.02 0.58 0.39 0.04 0.89 2.09 3.72 V86 1.06 0.74 0.18 0.02 0.02 0.02 0.55 0.34 0.02 1.41 1.35 1.00 V87 0.39 0.38 0.31 0.02 0.02 0.02 0.31 0.29 0.22 1.37 0.94 0.06 V88 0.69 0.63 0.42 1.08 0.65 0.02 0.32 0.31 0.24 1.61 2.00 2.13 V89 0.64 0.47 0.16 0.02 0.14 0.28 0.18 0.48 0.77 0.66 0.49 0.16 V90 0.22 0.38 0.52 0.30 0.18 0.02 0.02 0.02 0.02 0.65 1.18 1.66 V91 0.16 0.22 0.18 1.16 0.71 0.19 0.49 0.50 0.35 0.86 0.96 0.74 V92 0.70 0.64 0.44 1.48 0.88 0.02 0.42 0.36 0.20 0.48 0.63 0.71 V93 1.04 1.22 0.97 1.61 1.35 0.73 3.68 1.94 0.12 0.99 1.43 1.32 V94 1.11 1.44 1.16 4.70 2.26 0.15 2.65 1.24 0.02 1.26 1.57 1.26 V95 0.70 0.64 0.43 0.22 0.13 0.02 0.80 0.50 0.02 0.33 0.51 0.66 V96 1.37 1.51 1.70 0.02 1.85 5.01 9.35 6.36 0.02 1.14 1.23 1.33 V97 0 2.62 0 0 0.02 0 0 0.02 0 0 0.02 0 V98 0.43 1.28 3.00 0.02 0.02 0.02 0.02 0.02 0.02 1.02 0.73 0.06 V99 0.35 0.21 0.02 0.02 0.02 0.02 1.44 0.88 0.02 0.02 0.02 0.02 V100 0.12 0.72 1.09 0.90 3.20 4.17 0.78 1.59 1.90 2.33 1.43 0.19 V101 1.10 0.82 0.38 0.02 0.85 1.07 0.02 0.52 0.69 0.54 0.72 0.62 V102 1.10 2.94 4.09 2.08 1.16 0.02 0.28 0.16 0.02 0.02 0.17 0.29 V103 1.20 0.77 0.04 0.71 0.43 0.02 1.74 1.45 0.78 1.06 1.19 1.15 V104 0.06 0.99 1.83 0.02 0.02 0.02 0.37 0.22 0.02 0.37 0.23 0.02 V105 1.04 0.75 0.26 0.02 0.51 0.86 0.03 0.12 0.18 0.98 1.03 0.84 V106 0.81 1.87 2.47 0.12 0.06 0.02 0.68 0.39 0.02 0.32 0.38 0.35 V107 0.11 0.08 0.04 3.39 3.35 3.10 0.32 0.27 0.17 0.67 0.68 0.67 V108 0.98 0.87 0.56 1.18 1.03 0.63 0.06 0.09 0.12 0.51 1.10 1.79 V109 1.27 1.05 0 7.95 6.30 0 0.02 0.02 0 0.76 0.63 0 V110 0.36 1.92 1.90 0.02 0.06 0.06 0.66 0.62 0.37 2.12 1.98 1.23 V111 1.18 0.85 0.26 2.13 1.27 0.02 0.99 0.61 0.02 2.01 1.60 0.74 V112 0.09 0.70 1.45 0.02 0.60 1.22 0.92 1.36 1.71 1.12 0.90 0.41 V113 0.40 1.92 4.17 0.02 0.35 0.81 0.02 0.54 1.34 0.38 0.50 0.62 V114 0.75 0.91 0.83 4.14 2.28 0.02 0.16 0.56 0.78 1.94 1.53 0.73 V115 2.23 1.21 0.08 0.02 3.14 4.17 0.38 0.20 0.02 0.02 0.46 0.68 V116 1.79 1.34 0.37 0.02 0.02 0.02 1.49 1.23 0.64 1.18 0.91 0.32 V117 0.72 0.49 0.02 0.02 0.02 0.02 0.14 0.10 0.02 0.83 0.89 0.93 V118 0.83 1.17 1.52 0.02 0.17 0.38 0.47 0.35 0.10 1.10 0.86 0.33 V119 0.02 0.35 0.46 0.02 0.50 0.61 1.16 0.56 0.02 1.36 0.84 0.23 V120 1.38 2.26 3.44 0.02 0.98 2.29 0.89 1.03 1.12 0.95 0.93 0.77 V121 1.16 0.86 0.20 2.88 1.90 0.07 1.23 0.82 0.02 0.53 0.80 1.24 V122 1.02 1.12 1.01 1.85 1.13 0.06 0.26 0.22 0.12 0.64 1.03 1.32 V123 0.58 0.42 0.08 8.26 5.34 0.02 0.02 0.02 0.02 0.09 0.08 0.04 V124 0.09 0.05 0.02 0.02 0.02 0.02 0.02 0.89 1.70 1.05 0.65 0.03 V125 0.47 0.82 1.10 0.32 0.44 0.48 0.02 0.24 0.50 0.15 0.51 0.89 V126 0.39 0.39 0.36 0.02 0.62 1.58 0.60 0.65 0.69 1.10 0.88 0.38 V127 0.99 0.69 0.27 0.02 0.02 0.02 0.02 0.54 0.72 0.58 0.49 0.28 V128 0.34 0.56 0.73 0.96 0.58 0.02 0.81 0.97 0.98 0.78 0.70 0.46 V129 1.00 0.93 0.65 0.02 0.02 0.02 0.02 0.02 0.02 0.15 0.20 0.23 V130 0.30 0.57 0.67 0.02 0.24 0.35 0.82 0.61 0.26 0.73 0.71 0.50 V131 0.81 0.52 0.07 0.02 0.02 0.02 0.97 0.67 0.18 1.27 1.08 0.62 V132 0.98 0.63 0.04 0.02 0.02 0.02 0.48 0.68 0.83 0.19 0.14 0.04 V133 1.56 1.19 0.53 1.97 1.06 0.02 0.11 0.73 1.07 0.74 1.14 1.22 V134 0.75 0.84 0.71 1.96 2.97 3.01 0.07 0.71 1.14 1.01 0.84 0.47 V135 0.93 0.85 0.55 0.02 0.24 0.38 0.70 0.73 0.56 1.81 1.80 1.32 V136 1.37 1.06 0.28 0.02 0.02 0.02 0.02 0.02 0.02 0.14 0.10 0.02 V137 1.05 0.79 0.20 0.02 0.02 0.02 0.86 0.88 0.85 0.26 0.22 0.10 V138 7.97 6.86 4.03 2.65 1.59 0.06 4.20 4.34 3.55 3.69 4.25 4.07 V139 0.17 0.84 1.10 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.51 0.77 V140 0.77 0.53 0.06 0.98 0.63 0.02 4.00 2.65 0.02 1.28 1.14 0.75 V141 1.20 1.27 0.97 0.74 0.78 0.58 0.02 0.02 0.02 0.83 2.04 2.56 V142 0.48 0.55 0.49 0.03 0.02 0.02 1.50 1.04 0.30 1.07 1.10 0.86 V143 0.11 0.35 0.43 0.02 0.32 0.44 0.23 0.16 0.07 0.25 0.59 0.68 V144 1.31 2.06 2.21 3.04 1.64 0.02 0.05 0.11 0.14 1.34 0.90 0.24 V145 0.22 0.57 1.46 0.97 0.67 0.02 0.08 0.06 0.02 0.65 0.61 0.51 V146 0.68 0.75 0.76 0.64 2.45 4.79 0.54 3.67 8.30 0.42 0.42 0.37 Table 7C . Fold change in the biodistribution of virions containing the indicated variant capsid polypeptides relative to the biodistribution of virions containing WT AAV9 in non-brain regions. CBh indicates measurements from virions containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates virions containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that the variant was not detected in the indicated sample. organ dorsal root ganglion dorsal root ganglion dorsal root ganglion liver liver liver skeletal muscle skeletal muscle skeletal muscle spinal cord spinal cord spinal cord spleen spleen spleen organization Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Starter Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Variant number V1 11.01 11.97 September 19 0.31 0.34 0.27 7.63 9.43 7.80 27.57 30.06 20.81 1.93 2.20 1.68 V2 15.12 14.43 10.10 0.31 0.28 0.19 9.23 9.33 6.94 15.40 19.56 16.66 1.90 1.79 1.19 V3 11.09 10.80 9.62 0.22 0.21 0.18 10.58 9.48 6.57 23.93 21.46 15.65 1.38 1.62 2.04 V4 9.47 9.45 6.99 0.20 0.20 0.16 9.64 9.09 6.13 7.72 9.77 8.19 1.16 1.64 1.57 V5 October 13th 10.37 8.37 0.17 0.19 0.18 8.16 9.24 8.35 18.04 20.19 16.80 1.12 1.22 1.04 V6 9.28 9.16 9.47 0.31 0.28 0.19 7.67 6.56 3.78 27.57 24.42 18.89 1.38 1.27 1.05 V7 10.42 10.85 8.22 0.13 0.13 0.10 3.68 2.85 1.38 14.05 12.83 7.72 0.59 0.96 0.94 V8 0 7.70 2.89 0 0.26 0.20 0 2.21 0.99 0 7.79 October 13th 0 1.19 0.62 V9 7.56 6.38 3.42 0.36 0.37 0.34 6.81 4.95 0.93 13.81 23.03 34.59 0.94 1.03 1.08 V10 7.12 8.00 9.54 0.31 0.28 0.20 6.77 7.50 8.64 19.31 18.40 15.53 1.49 1.32 0.91 V11 10.61 8.39 3.83 0.45 0.39 0.24 6.66 8.14 8.18 7.27 6.40 3.90 2.22 1.83 0.96 V12 11.91 11.46 10.36 0.20 0.18 0.14 8.60 8.37 7.87 11.44 11.98 13.31 1.57 1.47 1.24 V13 October 16 8.11 3.87 0.24 0.30 0.32 7.75 6.15 2.91 20.20 17.70 10.62 1.32 1.21 0.81 V14 4.04 7.43 9.85 0.17 0.18 0.15 4.28 5.03 4.75 35.95 34.43 23.79 2.97 3.76 3.71 V15 6.80 7.54 9.82 0.18 0.17 0.17 6.83 6.24 4.83 8.99 11.48 17.41 1.32 1.25 1.11 V16 8.26 9.45 13.21 0.22 0.22 0.23 3.12 2.89 2.36 10.82 9.16 5.78 2.43 2.48 2.70 V17 8.91 9.25 7.53 0.39 0.36 0.25 9.50 9.38 7.01 20.43 15.58 6.87 1.90 1.60 0.90 V18 12.38 12.24 9.83 0.12 0.13 0.13 14.37 14.48 11.86 33.61 33.83 26.55 1.50 1.69 1.60 V19 9.49 9.31 6.93 0.29 0.31 0.26 6.98 6.20 3.88 15.81 17.52 13.94 1.40 1.21 0.71 V20 10.72 9.61 6.52 0.35 0.32 0.22 10.47 September 18 5.84 13.98 14.10 13.00 1.53 1.60 1.60 V21 7.29 8.76 9.14 0.17 0.17 0.16 5.47 5.42 4.28 15.72 15.97 12.55 1.58 1.71 1.52 V22 9.02 8.40 10.01 0.17 0.15 0.15 9.15 8.13 7.13 8.53 7.04 4.50 0.98 0.97 1.65 V23 6.79 7.06 6.42 0.17 0.17 0.15 7.48 6.29 3.45 11.14 10.88 8.53 1.18 1.32 1.30 V24 8.80 8.24 6.07 0.13 0.12 0.07 6.43 6.07 4.53 18.96 18.75 14.87 0.99 0.96 0.76 V25 9.56 9.54 7.34 0.16 0.16 0.11 September 21 7.99 4.76 21.00 15.66 6.51 1.51 1.45 1.02 V26 7.43 5.14 0.48 0.08 0.08 0.07 6.20 4.65 1.42 14.52 11.69 5.85 1.14 0.94 0.48 V27 6.50 5.67 3.43 0.19 0.18 0.12 9.00 8.64 5.84 17.20 18.30 12.71 1.39 1.38 0.95 V28 13.46 12.70 9.86 0.34 0.33 0.26 7.31 7.46 6.86 17.57 16.52 12.67 1.81 1.69 1.29 V29 5.31 4.53 2.59 0.11 0.10 0.08 6.60 5.07 2.06 13.60 October 13th 4.01 0.89 0.78 0.49 V30 3.55 2.71 1.23 0.07 0.07 0.05 6.80 5.69 3.16 17.28 12.24 4.65 0.81 0.80 0.57 V31 6.86 6.92 5.45 0.37 0.35 0.26 4.78 4.70 3.50 9.54 9.08 6.18 1.36 1.28 0.89 V32 8.84 7.86 4.99 0.26 0.24 0.17 5.83 4.90 2.71 9.67 10.74 September 21 0.93 0.93 0.73 V33 8.48 8.55 9.69 0.32 0.28 0.17 7.60 7.39 7.57 20.83 16.21 6.08 1.37 1.14 0.59 V34 3.16 3.50 2.74 0.12 0.11 0.07 2.91 2.75 1.80 5.79 4.96 2.73 0.56 0.49 0.28 V35 6.44 6.34 5.17 0.16 0.14 0.07 7.82 6.36 3.09 23.24 19.27 10.51 1.61 1.40 0.86 V36 4.74 7.61 8.37 0.19 0.18 0.13 5.13 6.13 5.39 19.41 15.52 7.73 1.22 1.37 1.11 V37 10.79 9.33 5.43 0.37 0.37 0.41 9.22 8.07 5.39 12.73 10.62 6.53 1.18 1.07 0.87 V38 11.05 8.53 4.06 0.21 0.19 0.13 2.90 4.41 4.39 10.62 12.85 10.12 1.33 1.41 1.05 V39 8.14 7.34 4.88 0.11 0.11 0.08 4.73 3.96 2.15 8.32 10.76 11.36 0.76 0.79 0.68 V40 10.07 9.47 6.32 0.47 0.47 0.35 5.84 5.58 3.72 13.99 9.52 3.50 2.12 1.85 1.08 V41 4.18 5.48 5.81 0.44 0.40 0.27 5.99 8.44 9.25 10.00 9.66 6.74 1.48 1.35 0.88 V42 7.95 7.11 4.56 0.20 0.18 0.12 5.43 5.22 3.77 12.13 12.56 9.55 1.06 0.97 0.64 V43 8.24 7.40 4.89 0.39 0.36 0.26 8.17 7.33 4.86 10.90 10.55 8.15 1.81 1.67 1.20 V44 7.14 5.66 2.79 0.27 0.26 0.20 3.80 3.52 2.33 3.22 3.55 2.71 0.71 0.67 0.46 V45 5.48 5.66 4.77 0.19 0.17 0.12 5.04 5.00 3.90 5.80 7.56 7.54 0.86 0.75 0.46 V46 6.44 5.97 4.01 0.08 0.08 0.05 5.86 5.10 3.04 13.71 9.71 3.63 1.38 1.34 0.92 V47 4.75 4.88 4.55 0.35 0.34 0.30 2.25 2.37 2.29 4.03 2.95 0.93 0.99 0.97 0.82 V48 13.20 11.68 7.27 0.59 0.58 0.43 5.89 7.54 7.23 9.42 14.85 14.83 1.68 2.19 2.07 V49 6.32 5.92 4.25 0.39 0.37 0.26 6.77 6.43 4.71 13.36 13.54 10.64 1.42 1.32 0.93 V50 11.82 November 24 8.60 0.72 0.75 0.70 11.63 12.42 11.68 13.07 18.45 22.01 2.11 2.33 2.26 V51 14.20 12.70 8.32 0.61 0.60 0.50 3.10 4.66 6.32 10.55 11.89 11.38 1.74 1.78 1.53 V52 7.03 5.73 2.98 0.21 0.18 0.11 3.41 3.07 1.96 18.67 13.55 5.28 0.79 0.77 0.55 V53 8.43 7.08 4.13 0.38 0.33 0.21 5.58 4.31 2.27 3.32 11.23 9.45 1.26 1.53 1.08 V54 8.55 7.30 4.26 0.16 0.14 0.08 7.78 6.77 4.03 17.32 11.93 4.42 1.49 1.28 0.74 V55 7.58 6.52 3.84 0.28 0.24 0.15 9.70 7.64 3.70 18.11 16.00 9.46 1.51 1.28 0.72 V56 1.94 1.86 1.40 0.10 0.09 0.06 6.52 4.49 0.90 10.75 7.93 2.98 2.55 2.06 1.02 V57 7.00 7.42 8.07 0.09 0.08 0.06 7.97 6.87 4.08 16.03 13.61 8.36 0.92 0.81 0.55 V58 9.64 9.12 7.07 0.33 0.28 0.15 8.32 6.65 2.86 9.37 8.00 4.82 0.94 0.82 0.51 V59 6.06 6.63 6.78 0.44 0.42 0.31 5.75 6.11 5.91 13.28 21.06 28.73 1.41 1.36 1.08 V60 7.30 7.93 7.47 0.51 0.47 0.34 4.20 4.05 3.09 13.71 13.74 10.80 1.60 1.45 0.96 V62 0 0.62 0.90 0 0.11 0.09 0 0.50 0.74 0 1.79 1.28 0 0.44 0.51 V63 5.89 6.69 6.46 0.16 0.14 0.10 8.86 7.62 4.46 17.69 15.10 8.71 1.39 1.37 1.05 V64 6.21 4.80 2.35 0.10 0.09 0.06 5.04 4.29 2.47 5.19 7.27 6.07 1.10 1.03 0.67 V65 5.29 5.76 6.01 0.56 0.53 0.42 2.22 2.54 2.81 2.09 1.71 0.90 1.20 1.21 1.08 V66 2.58 2.72 2.96 0.43 0.43 0.42 1.10 1.74 3.18 7.06 4.91 0.55 0.92 1.21 1.82 V67 3.92 2.97 1.04 0.33 0.30 0.20 1.27 0.94 0.30 1.61 1.21 0.47 0.49 0.50 0.42 V68 3.74 3.19 1.81 0.71 0.65 0.45 1.87 2.45 2.70 2.54 1.77 0.52 1.00 0.98 0.76 V69 2.51 2.69 3.02 0.48 0.43 0.31 1.90 1.52 0.60 2.35 1.57 0.02 0.76 0.70 0.56 V70 1.82 2.06 1.92 0.63 0.61 0.45 1.87 1.68 1.09 1.92 1.97 1.50 0.93 0.80 0.47 V71 0.69 0.63 0.45 0.20 0.19 0.16 0.79 0.72 0.52 0.17 0.11 0.02 0.90 0.84 0.64 V72 1.13 0.93 0.45 0.52 0.46 0.31 0.98 0.91 0.69 1.22 0.90 0.28 0.49 0.43 0.26 V73 1.06 0.80 0.35 0.60 0.59 0.43 0.81 0.61 0.27 1.62 1.63 1.11 0.48 0.51 0.39 V74 0.64 0.51 0.21 0.50 0.46 0.32 1.04 1.20 1.26 1.03 0.88 0.53 0.52 0.47 0.32 V75 1.40 1.33 0.90 0.38 0.38 0.29 0.52 0.47 0.30 0.78 0.39 0.02 0.88 0.86 0.59 V76 0.53 0.48 0.31 0.81 0.82 0.61 1.00 1.72 1.73 0.10 0.79 0.95 0.71 0.75 0.55 V77 3.45 3.97 4.20 0.51 0.48 0.36 2.04 1.89 1.34 2.43 3.10 3.37 0.84 0.84 0.68 V78 0.54 0.48 0.30 0.32 0.30 0.26 0.02 0.25 0.82 0.25 0.69 1.53 0.59 0.87 1.48 V79 1.48 1.06 0.08 0.46 0.43 0.35 1.34 1.20 0.82 0.86 0.56 0.02 0.72 1.01 1.47 V80 1.49 0.88 0.07 0.71 0.65 0.42 0.25 0.34 0.34 1.09 0.67 0.14 1.10 1.00 0.63 V81 1.80 1.47 0.75 0.49 0.44 0.28 0.88 0.61 0.13 0.76 0.70 0.47 0.65 0.72 0.67 V82 1.15 0.69 0.15 0.44 0.40 0.26 0.34 0.33 0.22 1.12 0.89 0.44 0.54 0.41 0.20 V83 0.35 0.22 0.02 0.49 0.44 0.29 0.62 0.58 0.42 0.11 0.07 0.02 0.61 0.62 0.52 V84 0.27 0.50 0.60 0.40 0.40 0.31 0.64 0.69 0.56 0.33 0.61 0.65 0.81 1.13 1.12 V85 0.69 0.46 0.02 0.46 0.49 0.48 0.02 0.36 0.90 0.10 0.15 0.21 0.80 0.78 0.63 V86 0.34 0.34 0.27 0.23 0.23 0.20 1.01 1.58 2.07 3.62 2.20 0.08 0.68 0.72 0.63 V87 1.05 0.79 0.20 0.39 0.36 0.27 0.49 0.50 0.47 0.75 0.49 0.02 0.66 0.58 0.37 V88 0.96 0.78 0.38 0.49 0.49 0.40 1.43 0.97 0.16 0.42 0.46 0.40 0.72 0.65 0.44 V89 0.02 0.44 1.01 0.39 0.41 0.38 0.60 1.30 2.04 2.13 1.69 0.81 0.87 0.88 0.72 V90 1.44 1.53 1.38 0.42 0.43 0.39 0.15 0.10 0.02 1.73 1.08 0.10 0.86 0.80 0.58 V91 0.63 0.57 0.35 0.51 0.49 0.34 0.09 0.19 0.20 1.17 0.60 0.04 0.60 0.56 0.37 V92 0.31 0.23 0.07 0.63 0.57 0.39 0.50 0.89 1.25 1.08 0.73 0.17 0.67 0.64 0.46 V93 0.53 0.78 0.76 0.77 0.73 0.50 0.93 0.88 0.58 0.24 0.47 0.45 0.84 0.89 0.65 V94 0.39 1.12 1.26 0.35 0.35 0.26 1.03 0.72 0.30 1.17 1.33 0.93 0.75 0.71 0.45 V95 0.65 0.67 0.59 0.32 0.29 0.19 0.48 0.51 0.46 0.26 0.16 0.02 0.49 0.60 0.63 V96 0.23 0.60 1.40 0.62 0.60 0.53 1.00 0.86 0.52 0.44 0.63 0.91 0.53 0.76 1.15 V97 0 0.02 0 0 0.89 0 0 1.94 0 0 2.37 0 0 2.02 0 V98 0.45 0.48 0.52 0.28 0.27 0.23 0.02 0.02 0.02 0.02 0.02 0.02 1.79 1.55 0.95 V99 0.26 1.07 1.98 0.45 0.41 0.28 0.84 0.74 0.47 0.02 0.02 0.02 1.11 1.09 0.84 V100 0.72 0.42 0.02 0.44 0.45 0.36 0.09 0.31 0.45 3.57 2.46 0.82 0.70 0.71 0.52 V101 0.76 0.72 0.47 0.53 0.55 0.42 1.49 1.04 0.40 0.37 0.69 0.63 0.60 0.72 0.58 V102 1.95 2.10 1.80 0.70 0.68 0.51 2.54 2.27 1.44 0.37 1.25 1.68 1.38 1.28 0.86 V103 0.82 0.73 0.48 0.32 0.31 0.23 0.36 0.23 0.02 0.71 1.01 1.15 1.06 1.15 1.06 V104 0.55 0.55 0.44 0.40 0.44 0.41 1.30 1.71 1.82 1.03 0.62 0.04 0.75 0.69 0.46 V105 1.09 0.76 0.20 0.71 0.75 0.65 0.59 0.49 0.26 0.56 1.24 1.54 0.98 0.91 0.60 V106 3.50 2.14 0.13 0.74 0.82 0.73 1.27 1.12 0.69 0.13 0.14 0.10 0.76 1.01 1.00 V107 0.29 0.38 0.57 0.32 0.31 0.29 0.92 0.74 0.29 0.97 1.81 3.26 0.80 0.83 0.86 V108 1.22 0.89 0.24 0.36 0.33 0.25 0.13 0.23 0.33 0.58 0.76 0.83 0.96 0.93 0.72 V109 2.43 2.05 0 0.78 0.71 0 2.55 2.44 0 0.09 0.07 0 1.23 1.01 0 V110 1.39 1.87 1.48 0.86 0.96 0.71 1.20 1.52 1.14 0.33 0.44 0.31 1.15 1.39 0.99 V111 1.10 0.70 0.02 0.41 0.45 0.43 0.97 0.81 0.45 3.32 1.97 0.02 0.89 1.13 1.22 V112 2.87 2.15 0.68 0.84 0.86 0.76 0.70 0.59 0.32 0.02 4.05 8.20 0.80 1.01 1.13 V113 0.19 0.46 0.91 0.70 0.72 0.67 0.46 0.42 0.30 0.85 0.58 0.10 2.28 2.37 2.19 V114 0.84 0.74 0.45 0.65 0.69 0.58 0.99 0.91 0.61 0.49 0.31 0.07 1.08 1.23 1.04 V115 0.76 0.57 0.26 0.61 0.58 0.40 0.16 0.70 0.91 0.32 0.25 0.12 0.59 0.90 0.85 V116 0.20 1.37 3.57 0.36 0.38 0.38 0.48 0.73 1.12 1.48 0.96 0.04 2.25 2.55 2.82 V117 0.87 1.25 1.95 0.78 0.69 0.46 0.53 0.67 0.88 0.31 0.20 0.02 0.63 0.47 0.13 V118 0.86 2.53 4.98 0.45 0.48 0.46 0.93 0.88 0.66 0.24 0.19 0.08 0.85 1.03 1.16 V119 0.62 1.56 1.76 0.46 0.52 0.42 1.07 1.20 0.91 0.02 0.80 0.96 0.74 0.85 0.64 V120 1.43 1.01 0.13 0.35 0.33 0.25 0.78 0.52 0.02 0.02 0.28 0.65 0.90 0.93 0.87 V121 0.57 0.55 0.45 0.67 0.68 0.66 2.00 1.70 0.95 0.78 0.80 0.74 1.13 1.17 1.12 V122 0.97 1.03 0.91 0.67 0.63 0.46 0.71 0.82 0.80 0.99 1.19 1.13 0.62 0.60 0.44 V123 0.14 0.99 2.60 0.24 0.23 0.20 1.36 0.93 0.02 0.02 0.02 0.02 0.87 0.75 0.47 V124 0.93 0.76 0.39 0.29 0.32 0.29 0.92 1.01 0.90 0.04 4.31 7.53 2.26 2.24 1.71 V125 0.40 0.69 0.97 0.20 0.22 0.21 0.27 0.27 0.23 0.07 0.06 0.04 0.49 0.56 0.53 V126 0.94 1.13 1.42 0.26 0.26 0.22 0.94 0.81 0.48 0.31 2.74 6.40 0.89 0.84 0.66 V127 1.07 1.33 1.13 0.21 0.25 0.21 0.67 0.87 0.74 0.02 0.07 0.09 0.47 0.39 0.21 V128 0.67 0.81 0.86 0.21 0.20 0.15 0.02 0.12 0.25 1.91 1.14 0.02 0.54 0.50 0.35 V129 0.22 0.31 0.39 0.22 0.23 0.21 0.34 0.36 0.33 0.29 0.60 0.84 0.55 0.63 0.60 V130 0.68 0.85 0.80 0.50 0.50 0.39 0.91 0.69 0.30 0.45 0.27 0.05 0.87 0.92 0.71 V131 0.24 0.23 0.17 0.27 0.27 0.20 0.18 0.70 1.16 0.53 0.48 0.31 0.49 0.55 0.49 V132 0.27 0.54 0.84 0.61 0.64 0.58 2.18 1.63 0.56 0.02 0.14 0.28 1.09 1.14 0.99 V133 0.27 1.15 1.76 0.84 0.86 0.69 0.83 1.19 1.22 0.52 1.02 1.12 0.84 0.98 0.84 V134 0.29 0.39 0.41 0.56 0.51 0.35 0.10 0.60 0.97 0.48 0.48 0.34 0.54 0.60 0.51 V135 0.32 0.39 0.37 0.52 0.54 0.44 0.61 0.41 0.11 1.15 5.21 7.10 0.73 0.89 0.81 V136 0.50 0.40 0.12 0.85 0.85 0.86 0.35 1.26 3.74 0.03 0.02 0.02 0.63 0.73 1.02 V137 0.56 0.58 0.59 0.63 0.59 0.46 0.24 0.53 1.05 0.11 0.17 0.26 0.77 0.80 0.79 V138 3.76 3.26 1.94 0.22 0.21 0.14 2.65 2.64 2.07 3.29 3.56 2.99 0.68 0.60 0.37 V139 2.86 2.11 0.91 0.13 0.11 0.07 1.25 0.66 0.02 0.35 0.17 0.02 0.80 0.84 0.61 V140 2.66 2.58 2.15 0.21 0.19 0.13 0.48 0.55 0.62 0.22 0.15 0.02 0.37 0.38 0.35 V141 0.40 0.82 1.00 0.43 0.45 0.36 1.66 1.14 0.37 0.06 0.29 0.38 0.63 0.91 0.88 V142 1.23 0.92 0.36 0.34 0.34 0.27 0.68 0.59 0.35 0.10 0.08 0.05 0.64 0.81 0.78 V143 1.06 0.77 0.31 0.27 0.25 0.16 0.51 0.57 0.46 0.60 0.44 0.19 0.33 0.32 0.21 V144 1.89 2.08 1.76 0.41 0.43 0.36 0.24 0.85 1.23 0.17 1.01 1.40 0.88 0.75 0.42 V145 0.62 0.64 0.70 0.52 0.52 0.54 0.23 0.36 0.73 1.94 1.32 0.02 2.38 2.52 2.93 V146 0.62 0.55 0.35 0.75 0.72 0.58 0.80 0.74 0.55 1.53 1.04 0.18 0.86 0.88 0.78 Table 7D-1 : Fold change in transduction of virions containing the indicated variant capsid polypeptides relative to transduction of virions containing wild-type AAV9 in brain tissue. CBh indicates measurements from virions containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates measurements from virions containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that no variant transduction was detected in the indicated sample. organ brain brain brain brain brain brain brain brain brain brain brain brain organization Summary Summary Summary basal ganglia basal ganglia basal ganglia brain stem brain stem brain stem Cerebellum Cerebellum Cerebellum Starter Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Variant number V1 74.31 80.80 53.33 75.41 95.92 78.41 23.76 27.53 18.06 116.92 125.37 107.87 V2 72.23 79.18 57.52 149.42 137.76 88.93 14.71 21.42 17.88 85.80 83.49 65.91 V3 67.12 61.11 47.40 139.74 147.53 156.23 7.34 11.97 17.99 101.64 80.74 15.92 V4 52.69 58.27 42.15 87.25 89.47 65.68 11.45 8.78 4.03 90.18 103.72 101.14 V5 52.51 50.49 34.21 109.21 88.54 44.91 3.31 4.01 3.31 106.12 92.87 58.58 V6 53.02 49.30 46.00 80.71 70.04 45.80 8.48 10.89 16.88 120.50 95.50 0.02 V7 38.06 48.54 37.16 119.74 97.08 50.74 4.49 8.23 7.01 39.29 49.99 51.70 V8 0 47.84 25.93 0 69.59 77.46 0 0.02 0.02 0 76.64 63.14 V9 46.65 47.15 41.58 20.01 53.34 106.44 10.51 12.44 13.08 114.92 83.92 0.02 V10 41.23 46.40 51.40 88.94 114.30 159.21 11.68 15.99 20.96 44.69 52.75 74.17 V11 66.46 46.31 15.51 101.17 84.63 46.31 5.31 5.64 4.27 139.42 106.53 37.75 V12 41.23 46.04 56.09 50.44 66.24 105.81 17.03 15.45 13.00 45.51 48.10 57.51 V13 63.43 45.88 17.75 104.43 73.76 22.72 10.97 7.64 2.79 87.94 67.05 24.69 V14 42.70 45.43 34.73 98.51 68.33 19.30 7.05 7.35 5.33 97.70 115.77 125.85 V15 52.08 45.39 33.57 55.50 67.63 100.26 16.65 14.45 11.09 81.94 81.57 81.73 V16 43.16 45.11 51.23 111.69 98.42 68.00 10.35 9.84 9.40 64.13 76.69 124.73 V17 47.55 45.03 29.56 56.10 64.84 57.49 12.63 9.72 4.54 64.43 61.21 46.87 V18 47.12 44.87 31.86 54.08 55.72 46.60 17.35 13.86 7.16 69.01 51.43 12.66 V19 46.28 44.03 28.69 94.95 86.43 55.58 14.96 13.86 8.54 59.97 74.79 83.07 V20 48.15 43.05 31.05 69.92 65.16 50.59 11.47 11.05 9.32 80.29 74.56 54.99 V21 43.36 42.08 30.38 107.04 81.05 31.56 4.96 8.10 8.72 79.54 70.45 45.03 V22 55.13 41.94 12.23 86.72 68.33 0.02 18.97 13.28 0.02 74.69 68.09 39.70 V23 39.51 40.82 34.23 38.25 48.89 56.40 15.06 11.40 5.20 76.86 84.62 91.95 V24 41.11 40.43 31.31 62.22 58.14 42.14 17.30 15.18 9.71 58.85 57.08 47.24 V25 41.88 40.34 26.99 110.15 108.27 78.95 11.91 8.71 3.64 66.97 68.14 59.00 V26 44.07 40.03 27.81 35.65 23.07 0.02 28.08 23.31 13.60 68.23 72.59 75.23 V27 50.29 39.54 18.96 91.74 60.69 19.82 19.90 13.68 5.22 75.58 67.47 46.16 V28 39.41 38.71 32.08 57.22 66.21 73.40 13.77 13.23 10.52 73.92 67.46 46.54 V29 42.68 38.60 24.77 53.93 46.24 26.90 16.66 13.03 6.37 61.93 54.56 34.46 V30 37.78 36.15 22.76 60.27 51.42 29.28 11.87 11.36 6.94 77.86 66.43 40.93 V31 37.95 35.47 23.01 67.38 59.84 37.14 7.45 7.22 4.79 52.95 54.54 48.45 V32 41.47 34.48 18.87 105.00 83.45 39.44 5.01 6.04 5.19 76.74 68.82 45.94 V33 40.11 33.63 22.93 38.34 38.43 43.25 12.58 8.15 0.02 63.29 63.76 70.51 V34 35.95 33.16 2019.12 34.80 34.19 22.84 6.85 8.97 6.31 79.94 56.49 23.28 V35 41.84 33.07 16.27 81.69 57.56 12.96 16.68 12.75 5.97 75.57 61.59 26.41 V36 31.15 32.78 22.83 98.00 82.22 45.45 7.02 9.02 6.98 30.69 36.53 37.05 V37 34.21 32.16 33.72 64.57 47.75 0.02 9.69 9.54 11.42 63.56 68.68 101.05 V38 28.92 31.95 22.45 75.82 63.48 34.99 7.96 3.70 0.02 43.54 34.95 19.02 V39 35.45 31.62 20.35 69.70 52.21 18.70 10.98 12.17 10.34 64.04 65.72 60.98 V40 29.15 31.59 21.15 49.37 49.48 34.01 9.26 7.42 3.58 44.55 37.81 23.76 V41 29.16 31.19 23.86 42.34 53.62 52.51 7.41 6.73 4.15 44.57 59.70 73.38 V42 37.42 31.06 16.71 96.32 72.63 29.74 14.75 11.47 5.48 55.31 47.18 27.71 V43 34.80 30.32 2019.10 46.19 49.27 45.64 4.04 6.13 7.01 76.61 66.14 37.21 V44 31.93 30.20 19.02 43.05 42.57 30.29 6.78 6.62 4.19 39.55 47.63 49.39 V45 36.91 29.89 15.46 73.34 63.64 38.04 6.02 5.81 4.01 65.80 53.98 26.58 V46 31.39 29.64 18.58 24.69 20.27 10.74 10.80 8.40 3.96 44.90 46.78 40.87 V47 31.15 29.46 22.67 55.38 53.26 42.76 November 18 9.81 6.57 39.14 44.11 52.28 V48 31.26 29.13 18.23 39.34 32.96 18.15 7.75 5.12 1.67 101.64 93.33 66.59 V49 34.19 29.07 16.82 62.86 54.05 31.73 6.60 6.60 4.87 84.22 74.51 47.42 V50 31.53 28.94 20.17 35.01 41.03 43.03 10.72 6.96 1.59 70.35 65.72 49.11 V51 25.04 28.85 27.41 59.08 60.26 51.70 7.76 8.78 7.94 30.53 33.19 35.13 V52 36.66 28.59 13.54 90.74 67.19 26.96 5.96 5.22 2.98 35.82 34.23 26.38 V53 21.45 28.57 18.35 47.64 55.40 38.12 3.13 6.46 4.39 27.35 34.87 31.08 V54 29.16 28.30 17.52 40.14 35.29 20.93 10.54 8.91 4.63 62.56 59.22 44.37 V55 31.45 27.85 16.20 43.29 34.17 16.59 8.12 8.76 6.11 60.36 60.21 49.59 V56 40.00 27.83 8.86 83.89 68.70 35.29 11.01 6.01 0.02 72.25 48.64 0.02 V57 30.86 27.34 19.87 56.37 53.95 46.15 6.58 5.53 3.64 50.35 46.17 32.24 V58 32.13 26.72 15.44 55.14 48.37 30.74 7.24 7.05 5.66 58.04 49.47 25.06 V59 26.38 26.57 22.30 35.57 30.92 19.03 12.45 7.21 0.02 34.04 43.78 62.06 V60 28.44 26.50 18.34 51.62 44.98 27.38 8.13 8.99 7.57 53.36 52.57 44.64 V62 0 25.76 25.66 0 15.43 21.89 0 28.78 28.24 0 9.71 17.85 V63 26.53 25.56 18.07 44.52 40.56 26.98 13.15 11.82 7.46 38.34 40.42 38.50 V64 31.73 25.30 12.38 33.90 25.76 11.99 7.42 7.34 4.42 61.64 50.43 29.33 V65 6.07 10.10 14.09 0.02 10.83 28.06 4.30 3.79 2.59 4.70 10.22 22.88 V66 8.62 7.77 6.01 0.02 0.02 0.02 17.09 10.55 0.02 0.02 7.12 29.27 V67 5.20 5.42 4.41 4.91 3.07 0.02 3.87 2.14 0.02 11.28 13.50 16.11 V68 5.87 4.97 2.84 7.91 4.82 0.02 5.19 3.37 0.89 4.54 7.58 11.85 V69 5.45 4.20 1.87 10.29 14.26 22.36 2.70 1.66 0.02 11.81 8.97 0.02 V70 2.72 3.73 3.56 0.02 0.02 0.02 0.02 1.77 2.61 4.92 6.38 7.71 V71 1.31 2.87 4.93 6.18 8.36 11.77 0.02 0.02 0.02 3.55 5.26 9.59 V72 3.29 2.63 1.37 4.43 2.98 0.02 2.33 2.08 1.51 5.09 5.62 6.68 V73 4.72 2.34 0.02 0.02 0.02 0.02 4.68 2.22 0.02 5.11 3.00 0.02 V74 1.15 2.25 3.06 0.02 4.59 10.43 1.89 2.14 1.92 0.02 0.02 0.02 V75 1.16 2.22 2.04 0.02 0.02 0.02 0.02 1.32 1.50 0.02 0.02 0.02 V76 0.02 2.03 2.39 0.02 0.02 0.02 0.02 2.41 2.64 0.02 0.02 0.02 V77 11.28 8.62 3.81 12.52 7.98 0.02 7.40 4.19 0.02 8.99 8.79 7.43 V78 3.66 5.53 8.71 0.02 0.02 0.02 3.03 3.75 4.79 0.02 10.12 42.42 V79 6.04 4.42 1.52 9.51 6.43 0.02 4.99 4.50 3.34 5.46 4.05 0.02 V80 3.55 4.19 3.24 11.16 6.10 0.02 2.93 4.27 3.56 0.02 0.02 0.02 V81 2.50 3.22 3.18 5.90 3.65 0.02 0.02 0.85 1.40 0.02 2.29 6.20 V82 1.92 2.92 2.33 12.09 5.94 0.02 0.02 3.46 3.66 0.02 0.02 0.02 V83 2.40 2.78 2.56 0.02 0.02 0.02 5.95 6.61 5.64 0.02 0.02 0.02 V84 3.86 2.78 1.10 0.02 0.02 0.02 7.65 5.65 2.43 0.02 0.02 0.02 V85 1.81 2.72 3.34 8.54 5.53 0.02 2.24 2.58 2.45 0.02 0.02 0.02 V86 3.15 2.71 1.62 0.02 4.60 9.67 5.85 3.22 0.02 0.02 0.02 0.02 V87 3.46 2.56 0.97 0.02 0.02 0.02 5.14 3.04 0.02 0.02 0.02 0.02 V88 2.19 2.51 2.24 0.02 3.20 6.69 2.72 2.98 2.47 2.97 2.01 0.02 V89 3.19 2.45 1.11 0.02 0.02 0.02 2.64 2.91 2.44 5.77 3.93 0.02 V90 2.79 2.40 1.43 13.17 16.29 17.06 3.46 1.90 0.02 0.02 0.02 0.02 V91 2.42 2.24 1.30 4.57 4.55 3.10 1.20 1.06 0.57 7.87 4.30 0.02 V92 2.31 2.19 1.53 3.63 4.45 4.57 1.90 2.08 1.68 4.16 2.80 0.02 V93 3.87 2.18 0.43 0.02 0.02 0.02 5.75 2.59 0.02 0.02 2.33 4.21 V94 2.50 2.17 1.16 11.78 5.52 0.02 3.09 3.86 2.56 0.02 0.02 0.02 V95 2.65 2.16 1.14 5.01 3.14 0.02 0.02 0.73 1.26 2.88 1.98 0.02 V96 11.42 7.94 1.80 21.56 14.71 0.02 19.81 13.72 3.96 19.81 13.72 3.96 V97 0 6.89 0 0 0.02 0 0 0.02 0 0 0.02 0 V98 2.97 6.62 12.22 0.02 0.02 0.02 0.02 6.74 16.14 0.02 6.74 16.14 V99 9.76 5.54 0.02 30.70 18.80 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V100 4.44 5.36 4.32 0.02 7.80 12.92 3.66 3.64 2.38 3.66 3.64 2.38 V101 6.18 5.35 2.90 6.48 3.21 0.02 10.20 8.23 3.99 10.20 8.23 3.99 V102 4.28 5.33 4.56 0.02 0.02 0.02 3.53 3.61 2.51 3.53 3.61 2.51 V103 6.62 4.98 2.10 0.02 0.02 0.02 6.57 5.46 3.09 6.57 5.46 3.09 V104 8.94 4.95 0.02 33.76 20.15 0.02 4.43 2.35 0.02 4.43 2.35 0.02 V105 6.81 4.94 1.93 21.42 12.56 0.02 5.62 2.93 0.02 5.62 2.93 0.02 V106 6.61 4.91 2.08 0.02 0.02 0.02 3.28 5.00 4.58 3.28 5.00 4.58 V107 5.43 4.63 3.02 0.02 0.02 0.02 7.48 5.50 2.22 7.48 5.50 2.22 V108 4.72 4.61 3.52 0.02 0.02 0.02 7.79 6.57 3.87 7.79 6.57 3.87 V109 6.07 4.61 0 0.02 0.02 0 5.01 3.65 0 5.01 3.65 0 V110 4.10 4.57 2.76 0.02 0.02 0.02 October 17th 7.24 3.04 October 17th 7.24 3.04 V111 1.96 4.48 5.92 0.02 5.70 11.80 0.02 3.99 6.52 0.02 3.99 6.52 V112 5.11 4.48 2.81 8.03 October 13th November 21 4.22 3.54 2.07 4.22 3.54 2.07 V113 7.17 4.36 0.02 11.29 7.39 0.02 8.89 5.17 0.02 8.89 5.17 0.02 V114 3.25 4.26 3.69 23.01 13.01 0.02 2.01 2.02 1.35 2.01 2.02 1.35 V115 2.96 4.24 3.45 0.02 0.02 0.02 3.67 5.03 3.79 3.67 5.03 3.79 V116 3.39 4.19 4.79 0.02 0.02 0.02 6.71 5.97 4.22 6.71 5.97 4.22 V117 4.47 4.19 3.33 21.07 14.23 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V118 5.19 4.13 2.07 0.02 0.02 0.02 7.71 4.41 0.02 7.71 4.41 0.02 V119 3.65 4.08 2.72 0.02 0.02 0.02 4.52 3.87 1.99 4.52 3.87 1.99 V120 3.35 4.07 4.37 10.54 6.91 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V121 4.64 4.05 2.72 8.76 5.89 0.02 0.02 1.37 2.99 0.02 1.37 2.99 V122 1.35 4.03 5.65 6.38 3.91 0.02 0.84 2.28 2.93 0.84 2.28 2.93 V123 4.32 4.02 3.09 0.02 0.02 0.02 5.35 3.18 0.02 5.35 3.18 0.02 V124 1.46 5.68 7.95 0.02 8.26 15.83 0.02 3.85 5.83 0.02 5.20 12.91 V125 1.83 5.23 7.40 0.02 10.65 22.10 2.27 1.24 0.02 4.96 3.35 0.02 V126 6.02 4.37 1.46 0.02 0.02 0.02 4.97 2.97 0.02 0.02 4.00 14.25 V127 1.72 2.74 2.22 0.02 0.02 0.02 2.13 0.93 0.02 0.02 2.51 4.33 V128 3.69 2.11 0.02 13.92 8.59 0.02 3.65 2.00 0.02 0.02 0.02 0.02 V129 4.11 4.15 3.24 4.84 6.03 6.45 2.54 4.22 4.75 0.02 0.02 0.02 V130 2.92 3.92 3.37 0.02 6.14 10.07 2.90 2.15 0.93 3.17 9.66 16.42 V131 2.23 2.45 1.95 0.02 0.02 0.02 1.84 1.94 1.43 8.06 7.84 6.33 V132 2.75 3.97 4.35 0.02 0.02 0.02 0.02 3.77 6.38 0.02 0.02 0.02 V133 5.61 3.61 1.00 19.85 11.02 0.02 3.47 2.57 1.10 3.80 2.31 0.02 V134 2.50 3.29 2.89 5.89 6.71 5.76 0.02 1.56 2.12 10.15 8.44 4.69 V135 1.85 2.59 2.33 0.02 3.29 5.57 1.53 2.30 2.05 3.35 2.07 0.02 V136 3.59 2.37 0.02 16.94 12.06 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V137 1.87 2.34 2.80 0.02 0.02 0.02 3.48 4.17 4.62 0.02 0.02 0.02 V138 20.33 18.66 12.25 38.38 27.15 7.70 5.04 3.62 1.42 18.36 19.53 18.84 V139 3.90 6.87 6.17 12.26 12.72 9.22 0.02 1.48 1.70 14.08 20.01 22.55 V140 5.65 5.65 4.89 0.02 4.43 11.67 6.99 5.16 2.15 0.02 5.57 19.03 V141 5.55 5.20 3.22 0.02 0.02 0.02 7.86 6.65 3.54 0.02 0.02 0.02 V142 2.94 3.69 3.21 0.02 0.02 0.02 6.07 5.63 3.53 0.02 0.02 0.02 V143 2.14 3.57 3.16 2.89 3.03 2.22 0.76 2.12 2.05 3.32 3.81 3.63 V144 2.66 3.22 2.59 0.02 0.02 0.02 6.60 4.37 1.43 0.02 0.02 0.02 V145 4.02 3.97 3.99 12.64 8.98 0.02 3.32 3.14 2.93 3.63 5.65 12.94 V146 4.84 3.68 1.59 0.02 0.02 0.02 10.49 6.12 0.02 0.02 0.02 0.02 Table 7D-2 : Fold change in transduction of virions containing the indicated variant capsid polypeptides relative to transduction of virions containing wild-type AAV9 in brain tissue. CBh indicates measurements from virions containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates measurements from virions containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that no variant transduction was detected in the indicated sample. organ brain brain brain brain brain brain brain brain brain brain brain brain organization forebrain forebrain forebrain hippocampus hippocampus hippocampus midbrain midbrain midbrain Temporal cortex Temporal cortex Temporal cortex Starter Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Variant number V1 115.72 118.52 66.98 0.02 0.02 0.02 15.25 52.27 59.60 191.77 194.45 122.52 V2 120.38 148.55 104.83 0.02 86.06 121.27 113.34 113.60 81.94 105.54 114.29 82.68 V3 102.93 90.16 68.44 0.02 0.02 0.02 18.84 25.97 39.58 157.93 135.24 88.76 V4 64.26 99.28 76.73 0.02 0.02 0.02 35.30 38.12 29.59 123.26 111.69 66.34 V5 85.08 92.60 66.11 0.02 0.02 0.02 16.99 29.87 36.42 59.34 81.02 76.55 V6 59.45 70.31 96.30 0.02 0.02 0.02 65.30 70.88 92.83 68.41 76.90 104.09 V7 84.00 119.62 84.47 0.02 0.02 0.02 34.60 17.86 0.02 0.02 46.52 57.66 V8 0 104.80 45.24 0 0.02 0.02 0 105.64 0.02 0 45.85 29.34 V9 85.99 80.33 62.17 0.02 0.02 0.02 40.48 53.98 71.92 28.27 70.29 120.95 V10 75.06 80.33 79.71 0.02 0.02 0.02 67.46 46.27 0.02 31.41 30.12 25.85 V11 62.10 36.41 8.12 360.16 203.92 0.02 40.93 24.47 0.02 171.51 127.45 52.63 V12 70.77 86.96 111.25 128.26 85.94 0.02 58.30 41.25 0.02 61.08 80.57 120.24 V13 128.19 86.39 31.85 0.02 0.02 0.02 28.16 41.47 46.05 108.18 80.99 34.42 V14 21.99 44.85 43.96 0.02 0.02 0.02 0.02 10.64 19.56 101.21 110.81 87.71 V15 111.93 79.21 35.14 141.13 95.05 0.02 16.04 11.41 0.02 44.80 44.56 45.57 V16 56.46 65.87 83.42 0.02 0.02 0.02 26.58 37.94 68.92 55.69 61.75 77.28 V17 98.39 95.33 60.44 0.02 0.02 0.02 48.64 28.12 0.02 67.94 67.13 46.66 V18 66.39 82.05 70.78 0.02 0.02 0.02 60.78 52.63 31.49 93.38 93.00 70.61 V19 75.77 59.65 29.22 0.02 0.02 0.02 19.21 43.73 56.33 67.07 56.94 31.58 V20 80.46 68.39 47.28 155.56 99.91 0.02 17.68 35.97 68.36 74.08 62.44 38.32 V21 46.38 52.31 41.48 0.02 0.02 0.02 25.47 31.25 31.99 80.05 106.81 107.59 V22 115.33 77.17 17.07 0.02 0.02 0.02 14.62 11.52 0.02 51.05 45.02 55.34 V23 35.21 55.22 59.30 170.20 103.08 0.02 19.34 24.74 28.58 94.55 72.48 32.04 V24 60.66 66.55 55.39 0.02 0.02 0.02 37.02 42.37 42.71 56.88 58.23 47.89 V25 55.68 59.97 41.51 0.02 0.02 0.02 0.02 22.67 40.01 45.77 34.44 14.95 V26 65.64 50.18 25.87 0.02 0.02 0.02 0.02 15.56 37.41 67.15 81.06 83.90 V27 58.76 49.76 24.81 71.00 34.12 0.02 56.48 45.04 22.95 67.62 69.30 45.04 V28 35.12 47.48 51.45 84.87 53.18 0.02 48.22 51.05 49.59 67.36 54.01 27.80 V29 68.14 70.60 51.18 56.46 32.49 0.02 12.83 19.50 23.37 80.66 68.54 39.31 V30 61.65 61.14 36.65 0.02 0.02 0.02 0.02 5.48 8.48 21.28 49.93 52.29 V31 65.30 64.22 41.66 0.02 0.02 0.02 50.22 37.59 15.06 55.11 48.94 29.55 V32 52.73 39.00 17.77 0.02 48.54 84.52 19.31 34.95 45.69 53.94 45.50 25.61 V33 70.60 54.37 35.37 85.31 58.92 0.02 38.78 28.28 0.02 60.93 55.24 49.15 V34 58.75 64.36 38.02 0.02 72.09 85.65 35.20 34.60 23.15 36.88 33.79 19.47 V35 47.36 40.45 24.98 0.02 0.02 0.02 0.02 11.65 26.27 57.70 53.10 36.82 V36 49.22 53.41 34.51 0.02 0.02 0.02 18.02 29.37 30.71 37.76 44.61 34.43 V37 33.97 37.66 54.30 164.20 115.05 0.02 37.32 55.22 125.63 39.10 26.96 0.02 V38 37.23 63.73 49.05 0.02 0.02 0.02 30.67 32.12 23.64 21.42 62.73 66.27 V39 59.90 52.42 32.77 0.02 0.02 0.02 0.02 0.02 0.02 19.69 11.47 0.02 V40 43.29 60.32 40.86 125.55 59.61 0.02 28.53 35.77 29.54 29.89 51.23 44.17 V41 34.65 37.27 26.29 0.02 0.02 0.02 28.54 25.04 15.21 79.74 70.65 42.62 V42 41.88 43.51 29.78 71.44 118.54 127.45 24.35 23.71 17.22 28.35 18.52 4.83 V43 59.85 46.16 23.99 0.02 0.02 0.02 41.52 33.24 15.42 21.75 25.97 25.93 V44 36.99 40.36 26.54 0.02 0.02 0.02 69.66 57.44 30.70 97.30 68.56 25.82 V45 45.02 38.89 22.85 0.02 0.02 0.02 37.09 28.00 11.01 64.76 51.04 24.70 V46 60.62 56.53 32.63 0.02 0.02 0.02 0.02 9.12 14.52 75.58 71.23 44.76 V47 44.45 43.62 34.96 0.02 0.02 0.02 43.09 39.72 28.89 48.15 36.94 16.20 V48 18.11 27.57 22.27 0.02 0.02 0.02 19.89 33.35 36.80 13.89 28.95 30.94 V49 28.30 29.72 22.24 0.02 0.02 0.02 25.43 15.63 0.02 41.44 37.31 24.03 V50 32.23 28.08 18.10 0.02 62.91 129.10 47.21 52.84 52.34 32.97 44.23 48.90 V51 39.89 47.27 42.28 0.02 0.02 0.02 0.02 15.25 34.94 41.73 54.59 58.75 V52 55.70 43.36 20.79 100.95 53.96 0.02 22.94 25.90 21.86 88.13 59.02 18.38 V53 36.55 53.31 30.06 0.02 0.02 0.02 48.18 28.03 9.66 16.83 42.59 32.49 V54 28.16 38.38 26.41 0.02 0.02 0.02 34.79 23.81 8.49 32.40 42.62 33.30 V55 49.34 36.02 15.50 0.02 0.02 0.02 0.02 20.75 33.63 52.41 45.02 25.13 V56 60.07 43.11 18.55 0.02 0.02 0.02 0.02 0.02 0.02 39.50 33.95 20.05 V57 44.21 42.25 36.97 0.02 0.02 0.02 31.67 26.21 13.36 48.67 39.81 22.47 V58 50.76 42.49 26.93 0.02 0.02 0.02 0.02 12.24 31.16 51.93 31.87 0.02 V59 21.83 34.92 40.02 0.02 0.02 0.02 47.96 78.23 115.73 66.99 40.74 0.02 V60 31.69 32.25 23.99 0.02 0.02 0.02 0.02 0.02 0.02 58.34 50.80 31.11 V62 0 30.98 30.69 0 0.02 0.02 0 31.23 0.02 0 40.67 24.88 V63 23.91 27.15 21.28 0.02 0.02 0.02 45.02 47.89 41.02 39.31 35.63 23.00 V64 55.49 45.97 22.41 0.02 0.02 0.02 0.02 0.02 0.02 55.88 37.71 13.63 V65 15.07 21.74 24.59 0.02 0.02 0.02 0.02 21.91 56.89 11.56 7.13 0.02 V66 9.99 11.35 12.58 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V67 6.03 7.69 6.93 0.02 0.02 0.02 0.02 0.02 0.02 0.02 8.08 14.97 V68 7.29 6.05 3.40 0.02 0.02 0.02 16.01 14.64 9.82 0.02 0.02 0.02 V69 6.31 3.58 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V70 10.52 8.90 4.97 0.02 0.02 0.02 0.02 0.02 0.02 0.02 3.34 5.37 V71 0.02 2.10 4.12 0.02 0.02 0.02 0.02 0.02 0.02 0.02 11.01 26.75 V72 2.72 1.50 0.02 0.02 0.02 0.02 0.02 0.02 0.02 6.26 3.92 0.02 V73 10.93 4.79 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V74 2.21 3.45 3.66 0.02 0.02 0.02 0.02 4.64 10.57 0.02 0.02 0.02 V75 0.02 0.02 0.02 0.02 0.02 0.02 0.02 11.45 16.45 15.50 14.91 9.22 V76 0.02 2.60 2.51 0.02 0.02 0.02 0.02 0.02 0.02 0.02 6.82 8.13 V77 19.21 17.02 November 17 0.02 0.02 0.02 18.99 12.11 0.02 13.27 10.51 5.18 V78 7.07 8.07 9.12 0.02 0.02 0.02 0.02 0.02 0.02 16.28 10.60 0.02 V79 5.84 3.23 0.02 0.02 0.02 0.02 19.23 13.01 0.02 0.02 0.02 0.02 V80 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 15.76 24.11 21.98 V81 0.02 5.49 8.00 0.02 0.02 0.02 35.83 22.14 0.02 0.02 0.02 0.02 V82 0.02 1.49 1.39 0.02 0.02 0.02 0.02 0.02 0.02 8.54 7.83 4.52 V83 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V84 4.47 2.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V85 0.02 5.55 9.33 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V86 0.02 2.31 3.39 0.02 0.02 0.02 0.02 0.02 0.02 10.49 6.06 0.02 V87 4.01 2.18 0.02 0.02 0.02 0.02 13.21 8.81 0.02 0.02 5.73 13.16 V88 0.02 1.61 2.34 0.02 0.02 0.02 0.02 0.02 0.02 7.31 4.22 0.02 V89 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 14.20 8.23 0.02 V90 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V91 0.02 1.14 1.09 0.02 0.02 0.02 0.02 4.61 6.29 0.02 3.00 3.53 V92 2.23 2.23 1.60 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V93 8.96 3.71 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V94 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V95 6.15 3.15 0.02 0.02 0.02 0.02 October 13th 6.36 0.02 0.02 4.14 7.77 V96 6.62 3.69 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V97 0 35.19 0 0 0.02 0 0 0.02 0 0 0.02 00 V98 8.59 14.50 20.47 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V99 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V100 0.02 3.92 4.53 0.02 0.02 0.02 56.45 31.58 0.02 0.02 10.28 14.68 V101 3.98 4.83 3.04 0.02 0.02 0.02 13.10 6.49 0.02 0.02 0.02 0.02 V102 16.52 15.56 9.55 0.02 0.02 0.02 0.02 0.02 0.02 0.02 October 21 15.49 V103 15.35 7.83 0.02 0.02 0.02 0.02 0.02 7.90 16.97 0.02 0.02 0.02 V104 10.36 5.06 0.02 0.02 0.02 0.02 34.14 20.39 0.02 0.02 0.02 0.02 V105 8.77 8.41 5.38 0.02 70.63 115.11 0.02 0.02 0.02 10.09 5.52 0.02 V106 15.31 7.17 0.02 0.02 0.02 0.02 25.23 14.46 0.02 0.02 0.02 0.02 V107 3.50 1.97 0.02 0.02 0.02 0.02 0.02 0.02 0.02 8.05 10.35 13.67 V108 0.02 4.71 7.36 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V109 11.72 7.85 0 0.02 0.02 0 38.64 31.65 0 0.02 0.02 0 V110 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 13.63 12.50 V111 5.68 8.58 8.27 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V112 4.93 2.54 0.02 0.02 0.02 0.02 16.24 10.25 0.02 0.02 6.67 12.73 V113 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V114 0.02 2.18 2.57 0.02 0.02 0.02 0.02 0.02 0.02 0.02 11.43 16.69 V115 0.02 7.22 7.22 0.02 0.02 0.02 28.26 14.55 0.02 0.02 0.02 0.02 V116 3.92 4.28 4.01 0.02 71.98 171.66 0.02 0.02 0.02 0.02 5.62 13.00 V117 12.93 7.14 0.02 0.02 0.02 0.02 0.02 28.79 80.74 0.02 0.02 0.02 V118 4.01 5.27 5.21 0.02 0.02 0.02 13.21 8.50 0.02 0.02 0.02 0.02 V119 0.02 4.17 3.79 0.02 0.02 0.02 0.02 0.02 0.02 0.02 10.94 12.29 V120 0.02 6.94 12.18 0.02 0.02 0.02 21.31 27.98 35.24 14.88 September 11th 0.02 V121 5.38 2.96 0.02 0.02 0.02 0.02 0.02 11.92 32.92 12.37 7.76 0.02 V122 1.96 7.84 9.75 0.02 0.02 0.02 0.02 7.91 16.11 0.02 2.57 4.51 V123 12.51 13.69 12.93 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V124 0.02 8.29 11.10 0.02 0.02 0.02 0.02 0.02 0.02 19.53 10.89 0.02 V125 0.02 13.36 19.36 0.02 0.02 0.02 0.02 10.78 22.40 0.02 0.02 0.02 V126 17.43 9.58 0.02 0.02 0.02 0.02 19.15 12.87 0.02 0.02 0.02 0.02 V127 0.02 6.00 5.59 0.02 0.02 0.02 16.40 8.06 0.02 0.02 5.25 6.04 V128 4.27 2.16 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V129 5.95 4.54 2.26 0.02 0.02 0.02 19.59 12.21 0.02 6.84 3.98 0.02 V130 3.39 1.54 0.02 0.02 0.02 0.02 November 17 6.22 0.02 0.02 4.05 5.72 V131 0.02 2.08 2.72 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V132 0.02 0.02 0.02 0.02 0.02 0.02 26.24 32.74 35.10 18.32 10.66 0.02 V133 4.06 3.69 2.10 0.02 0.02 0.02 13.39 7.43 0.02 0.02 0.02 0.02 V134 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 8.84 13.08 V135 3.58 3.31 1.95 0.02 0.02 0.02 0.02 0.02 0.02 0.02 4.34 6.33 V136 10.40 6.05 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V137 2.71 2.99 2.93 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V138 43.18 40.88 27.00 0.02 0.02 0.02 12.94 7.85 0.02 36.14 40.88 35.02 V139 0.02 6.38 6.46 0.02 0.02 0.02 0.02 0.02 0.02 0.02 8.38 10.48 V140 12.26 8.89 4.09 0.02 0.02 0.02 0.02 0.02 0.02 9.41 5.83 0.02 V141 13.78 12.27 6.74 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V142 2.84 5.39 5.04 0.02 0.02 0.02 0.02 0.02 0.02 0.02 3.54 5.45 V143 5.32 5.32 3.12 0.02 0.02 0.02 0.02 September 18 13.52 0.02 3.99 5.05 V144 0.02 4.70 5.42 0.02 0.02 0.02 0.02 0.02 0.02 0.02 6.17 8.79 V145 3.88 2.25 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 5.91 18.04 V146 3.50 5.65 6.64 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 Table 7E. Fold change in transduction of viral particles containing the indicated variant capsid polypeptides relative to transduction of viral particles containing wild-type AAV9 in non-brain tissues. CBh indicates measurements from viral particles containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates viral particles containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that no variant transduction was detected in the indicated sample. organ dorsal root ganglion dorsal root ganglion dorsal root ganglion liver liver liver skeletal muscle skeletal muscle skeletal muscle spinal cord spinal cord spinal cord spleen spleen spleen organization Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Summary Starter Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Cb Summary hSyn Variant number V1 0.02 0.02 0.02 0.38 0.54 0.63 2.41 1.85 1.36 41.52 54.29 40.05 0.02 0.02 0.02 V2 6.18 5.45 2.96 0.21 0.27 0.32 2.75 1.92 0.02 57.12 46.21 23.32 18.47 10.58 0.02 V3 0.02 0.02 0.02 0.12 0.16 0.29 2.29 2.02 0.02 45.59 43.57 37.55 0.02 6.65 22.88 V4 0.02 2.51 2.67 0.19 0.17 0.11 1.29 1.04 0.68 5.34 10.66 10.53 0.02 4.88 8.55 V5 2.78 2.63 1.64 0.14 0.17 0.21 1.86 1.70 1.66 12.85 15.31 12.96 0.02 0.02 0.02 V6 0.02 0.02 0.02 0.29 0.29 0.33 1.19 1.47 4.24 19.75 26.43 44.04 0.02 0.02 0.02 V7 0.02 4.71 4.64 0.11 0.13 0.14 1.68 1.11 0.02 10.46 5.00 0.02 0.02 0.02 0.02 V8 0 9.29 0.02 0 0.39 0.47 0 2.19 2.39 0 9.85 12.41 0 0.02 0.02 V9 0.02 0.02 0.02 0.62 0.57 0.39 3.93 4.19 6.57 36.73 30.19 17.06 0.02 0.02 0.02 V10 0.02 0.02 0.02 0.69 0.65 0.50 1.37 1.20 0.02 27.20 17.25 0.02 0.02 0.02 0.02 V11 0.02 0.02 0.02 0.81 0.85 0.85 2.49 1.90 0.02 12.38 6.84 0.02 0.02 0.02 0.02 V12 0.02 0.02 0.02 0.19 0.22 0.32 0.53 0.64 1.63 8.82 5.77 0.02 0.02 0.02 0.02 V13 0.02 0.02 0.02 0.19 0.26 0.36 1.03 0.77 0.02 25.55 25.51 18.20 0.02 0.02 0.02 V14 0.02 2.81 3.53 0.18 0.14 0.07 1.32 0.99 0.02 43.82 41.65 27.83 0.02 0.02 0.02 V15 0.02 0.02 0.02 0.18 0.16 0.07 0.39 0.35 0.02 14.55 12.76 9.64 0.02 0.02 0.02 V16 0.02 0.02 0.02 0.19 0.19 0.19 2.10 1.91 0.02 0.02 13.26 40.87 0.02 0.02 0.02 V17 0.02 0.02 0.02 0.55 0.55 0.48 1.77 1.46 0.76 34.32 26.21 11.85 15.85 9.60 0.02 V18 0.02 0.02 0.02 0.08 0.07 0.06 2.22 1.75 0.02 44.11 29.43 7.47 0.02 0.02 0.02 V19 6.28 2.88 0.02 0.29 0.34 0.37 1.40 1.36 1.72 23.23 21.40 13.36 9.39 5.60 0.02 V20 0.02 0.02 0.02 0.23 0.33 0.62 0.86 1.12 3.12 42.77 33.53 16.21 0.02 0.02 0.02 V21 0.02 2.06 2.89 0.17 0.18 0.20 1.86 1.58 0.73 0.02 4.37 7.59 0.02 0.02 0.02 V22 0.02 0.02 0.02 0.08 0.09 0.18 2.31 2.33 0.02 26.52 19.34 0.02 0.02 0.02 0.02 V23 0.02 0.02 0.02 0.06 0.09 0.15 0.94 0.77 0.02 46.79 34.59 13.56 0.02 0.02 0.02 V24 0.02 0.02 0.02 0.14 0.14 0.13 1.35 1.10 0.02 35.82 27.64 12.66 3.62 7.23 12.35 V25 0.02 1.99 2.41 0.14 0.17 0.19 0.80 0.82 1.22 15.85 16.91 12.65 0.02 3.87 7.71 V26 0.02 0.02 0.02 0.05 0.06 0.07 1.46 1.21 0.02 21.81 26.11 26.62 0.02 0.02 0.02 V27 0.02 2.16 2.07 0.10 0.17 0.23 0.98 0.76 0.52 43.92 37.78 20.42 7.89 4.20 0.02 V28 6.31 5.05 2.98 0.39 0.39 0.36 2.11 1.78 0.02 23.33 24.98 23.53 0.02 0.02 0.02 V29 2.10 2.06 1.41 0.11 0.11 0.10 0.94 0.79 0.36 17.46 14.18 7.39 0.02 2.00 4.50 V30 0.02 0.02 0.02 0.09 0.07 0.03 0.49 0.34 0.02 15.36 15.32 10.06 0.02 0.02 0.02 V31 0.02 3.30 4.08 0.32 0.35 0.37 1.48 1.10 0.02 21.69 17.52 8.93 10.52 6.42 0.02 V32 0.02 0.02 0.02 0.37 0.32 0.21 1.17 0.99 0.52 17.52 21.17 18.96 4.72 2.98 0.02 V33 0.02 0.02 0.02 0.22 0.23 0.26 0.82 0.88 1.33 20.52 17.80 13.86 4.74 3.62 0.02 V34 0.02 6.84 6.27 0.04 0.05 0.06 0.86 0.67 0.53 26.61 16.93 5.49 0.02 0.02 0.02 V35 3.00 3.07 2.37 0.14 0.14 0.12 2.12 1.81 0.60 19.43 16.29 9.35 0.02 0.02 0.02 V36 0.02 0.02 0.02 0.14 0.16 0.17 0.88 0.76 0.70 5.45 8.21 7.28 0.02 0.02 0.02 V37 0.02 0.02 0.02 0.29 0.31 0.45 0.45 0.43 0.02 16.93 15.44 14.90 9.12 7.07 0.02 V38 0.02 0.02 0.02 0.07 0.06 0.04 0.02 0.02 0.02 0.02 8.98 November 21 0.02 0.02 0.02 V39 0.02 0.02 0.02 0.09 0.11 0.14 0.69 0.55 0.02 8.53 9.85 8.99 0.02 0.02 0.02 V40 0.02 0.02 0.02 0.25 0.31 0.34 2.43 1.78 0.90 0.02 6.00 7.01 0.02 0.02 0.02 V41 0.02 0.02 0.02 0.70 0.67 0.55 1.91 1.81 2.08 30.21 28.01 18.03 0.02 0.02 0.02 V42 2.66 1.25 0.02 0.19 0.21 0.23 0.99 0.74 0.02 4.91 5.30 4.08 0.02 2.43 4.98 V43 0.02 0.02 0.02 0.26 0.26 0.25 1.39 1.24 0.70 9.42 7.44 3.66 0.02 0.02 0.02 V44 0.02 2.52 2.77 0.29 0.38 0.47 1.27 1.04 0.70 0.02 5.35 7.28 8.51 4.90 0.02 V45 0.02 0.02 0.02 0.18 0.17 0.14 1.58 1.39 1.01 11.22 7.83 2.61 0.02 0.02 0.02 V46 0.02 0.02 0.02 0.13 0.11 0.08 1.01 0.85 0.66 7.55 7.65 5.16 4.07 2.34 0.02 V47 8.46 4.49 0.02 0.26 0.37 0.62 1.15 1.14 1.32 7.82 6.35 3.43 0.02 0.02 0.02 V48 0.02 2.93 3.32 0.72 0.66 0.50 1.21 0.86 0.02 6.02 9.33 8.73 0.02 0.02 0.02 V49 0.02 1.37 1.93 0.37 0.43 0.50 1.03 1.05 1.47 20.51 13.11 2.54 0.02 0.02 0.02 V50 0.02 1.99 3.15 0.58 0.62 0.66 2.29 1.99 0.80 14.28 12.67 8.28 0.02 0.02 0.02 V51 7.82 4.02 0.02 0.42 0.55 0.82 1.31 1.18 0.80 18.07 17.05 12.43 0.02 0.02 0.02 V52 3.75 1.71 0.02 0.28 0.27 0.24 0.98 0.80 0.50 17.35 18.11 12.96 0.02 0.02 0.02 V53 0.02 7.39 5.23 0.29 0.42 0.43 2.93 1.45 0.02 14.57 7.84 2.29 0.02 0.02 0.02 V54 3.79 3.14 1.53 0.08 0.09 0.09 0.85 0.74 0.78 21.04 13.32 4.03 5.67 3.05 0.02 V55 0.02 0.02 0.02 0.37 0.38 0.34 0.91 0.64 0.02 18.91 15.47 7.98 0.02 0.02 0.02 V56 0.02 0.02 0.02 0.09 0.09 0.06 0.02 0.02 0.02 8.55 4.86 0.02 0.02 0.02 0.02 V57 0.02 0.02 0.02 0.08 0.06 0.02 1.08 1.02 0.61 5.75 6.11 6.34 3.10 2.24 0.02 V58 0.02 0.02 0.02 0.31 0.26 0.11 1.58 1.52 1.42 28.10 17.11 0.02 0.02 0.02 0.02 V59 0.02 0.02 0.02 0.42 0.43 0.42 1.75 1.46 0.02 14.50 13.13 9.15 11.72 8.02 0.02 V60 0.02 3.43 5.01 0.41 0.45 0.50 1.78 1.41 0.02 6.32 7.27 6.58 October 21 6.66 0.02 V62 0 0.02 0.02 0 0.31 0.48 0 0.02 0.02 0 17.47 10.53 0 0.02 0.02 V63 3.68 1.80 0.02 0.11 0.16 0.25 1.09 0.96 0.62 3.40 3.83 3.24 0.02 0.02 0.02 V64 0.02 1.53 1.46 0.08 0.10 0.12 0.56 0.45 0.37 6.91 14.58 13.45 5.59 5.93 4.68 V65 0.02 0.02 0.02 0.89 0.95 1.08 2.01 1.70 0.02 5.00 September 19 13.49 0.02 0.02 0.02 V66 0.02 0.02 0.02 0.76 0.88 1.31 2.00 1.78 0.02 9.96 6.40 0.02 0.02 0.02 0.02 V67 0.02 0.02 0.02 0.37 0.38 0.38 0.02 0.10 0.61 3.00 3.47 3.17 0.02 6.36 15.44 V68 0.02 1.29 1.77 0.73 0.79 0.85 1.17 1.14 1.35 7.26 4.09 0.02 3.91 2.50 0.02 V69 0.02 0.02 0.02 0.57 0.63 0.82 1.77 1.57 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V70 2.84 1.35 0.02 1.64 1.50 1.09 0.42 0.40 0.44 0.02 2.87 4.55 4.24 2.63 0.02 V71 0.02 0.02 0.02 0.30 0.34 0.43 1.06 1.05 1.09 0.02 0.02 0.02 0.02 0.02 0.02 V72 5.86 4.77 3.00 0.35 0.36 0.36 0.65 0.56 0.02 5.42 3.37 0.02 0.02 0.02 0.02 V73 5.89 2.55 0.02 0.69 0.81 0.88 0.66 0.75 1.35 0.02 0.02 0.02 0.02 0.02 0.02 V74 0.02 0.02 0.02 0.38 0.41 0.44 0.62 0.65 0.97 0.02 2.60 5.02 3.56 2.38 0.02 V75 0.02 0.02 0.02 0.36 0.50 0.59 0.81 0.71 0.75 0.02 0.02 0.02 0.02 0.02 0.02 V76 0.02 0.02 0.02 0.71 0.70 0.60 0.51 0.65 1.32 0.02 0.02 0.02 October 18 5.37 0.02 V77 0.02 0.02 0.02 0.53 0.54 0.52 1.08 1.07 1.27 11.49 6.77 0.02 June 19 4.14 0.02 V78 0.02 0.02 0.02 0.31 0.32 0.38 0.28 0.51 2.41 0.02 0.02 0.02 0.02 0.02 0.02 V79 0.02 3.43 6.63 0.48 0.68 1.26 0.47 0.40 0.02 0.02 3.64 8.72 0.02 0.02 0.02 V80 7.38 9.77 7.07 0.67 0.75 0.78 2.19 1.53 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V81 0.02 1.95 2.78 0.44 0.45 0.42 1.31 1.15 0.70 7.22 4.13 0.02 0.02 0.02 0.02 V82 0.02 0.02 0.02 0.52 0.60 0.61 0.74 0.56 0.37 0.02 0.02 0.02 0.02 0.02 0.02 V83 0.02 0.02 0.02 0.85 0.78 0.56 1.11 0.89 0.02 13.87 8.02 0.02 0.02 0.02 0.02 V84 4.82 4.31 2.41 0.40 0.43 0.41 0.72 0.63 0.61 0.02 0.02 0.02 0.02 0.02 0.02 V85 5.65 5.90 4.87 0.44 0.60 0.97 1.26 1.22 1.23 0.02 0.02 0.02 0.02 0.02 0.02 V86 0.02 0.02 0.02 0.13 0.17 0.25 1.10 0.87 0.02 4.54 2.60 0.02 0.02 0.02 0.02 V87 0.02 0.02 0.02 0.33 0.38 0.51 1.28 1.37 2.14 0.02 2.46 5.57 0.02 0.02 0.02 V88 3.43 1.71 0.02 0.52 0.60 0.73 1.02 0.90 0.62 0.02 0.02 0.02 0.02 0.02 0.02 V89 0.02 0.02 0.02 0.47 0.52 0.58 1.48 1.18 0.02 6.15 3.53 0.02 9.94 6.47 0.02 V90 0.02 0.02 0.02 0.23 0.39 0.69 0.97 0.77 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V91 0.02 0.02 0.02 0.49 0.45 0.35 0.67 0.50 0.29 0.02 0.02 0.02 0.02 0.02 0.02 V92 0.02 0.02 0.02 0.55 0.53 0.45 1.16 0.91 0.02 2.22 1.26 0.02 0.02 0.02 0.02 V93 0.02 1.97 1.89 0.44 0.44 0.40 1.26 1.04 0.96 0.02 2.09 2.48 7.22 3.83 0.02 V94 0.02 2.95 2.54 0.34 0.26 0.15 1.16 0.69 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V95 3.31 3.35 2.50 0.41 0.46 0.52 1.11 0.89 0.02 0.02 1.78 3.29 4.95 3.26 0.02 V96 0.02 0.02 0.02 0.76 0.79 0.86 0.79 0.92 1.99 19.78 12.49 0.02 0.02 0.02 0.02 V97 0 37.42 0 0 0.88 0 0 2.20 0 0 0.02 0 0 0.02 0 V98 0.02 0.02 0.02 0.43 0.48 0.64 0.69 0.91 2.70 8.56 5.45 0.02 0.02 0.02 0.02 V99 0.02 10.03 14.01 1.02 0.85 0.42 0.75 1.18 3.55 0.02 0.02 0.02 0.02 0.02 0.02 V100 0.02 0.02 0.02 0.68 0.72 0.71 0.69 0.49 0.02 0.02 0.02 0.02 13.80 8.09 0.02 V101 0.02 3.42 3.17 0.43 0.50 0.51 1.27 1.21 1.60 0.02 0.02 0.02 0.02 0.02 0.02 V102 8.91 4.14 0.02 0.57 0.85 1.24 0.99 0.73 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V103 0.02 0.02 0.02 0.36 0.45 0.61 1.23 1.10 0.78 3.82 2.21 0.02 0.02 0.02 0.02 V104 0.02 0.02 0.02 0.41 0.38 0.28 1.66 1.27 0.02 10.32 5.70 0.02 0.02 0.02 0.02 V105 0.02 0.02 0.02 0.89 0.88 0.78 1.75 1.58 1.42 0.02 0.02 0.02 0.02 0.02 0.02 V106 0.02 0.02 0.02 0.75 0.84 0.91 1.23 0.90 0.02 7.63 4.04 0.02 0.02 0.02 0.02 V107 0.02 0.02 0.02 0.15 0.23 0.48 1.26 1.11 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V108 0.02 0.02 0.02 0.38 0.44 0.54 1.28 1.48 2.92 4.54 2.66 0.02 0.02 0.02 0.02 V109 0.02 0.02 0 0.76 0.75 0 0.94 0.98 0 0.02 0.02 0 0.02 0.02 0 V110 0.02 2.76 2.01 0.83 0.88 0.78 0.63 0.81 1.53 0.02 5.86 5.29 0.02 0.02 0.02 V111 0.02 3.04 4.32 0.29 0.40 0.60 1.14 1.07 1.09 5.66 3.23 0.02 9.15 5.91 0.02 V112 0.02 0.02 0.02 0.80 0.90 1.06 0.59 0.80 2.08 4.91 2.87 0.02 0.02 5.25 13.13 V113 0.02 0.02 0.02 0.75 0.80 0.88 1.11 1.16 1.71 0.02 0.02 0.02 11.16 7.67 0.02 V114 0.02 0.02 0.02 0.88 0.94 0.91 0.57 0.55 0.68 4.69 2.45 0.02 0.02 0.02 0.02 V115 0.02 0.02 0.02 0.43 0.59 0.71 0.34 0.45 0.95 0.02 0.02 0.02 0.02 0.02 0.02 V116 0.02 0.02 0.02 0.31 0.45 0.84 0.79 0.67 0.02 3.91 2.42 0.02 0.02 0.02 0.02 V117 0.02 7.59 14.57 0.75 0.75 0.73 1.55 1.34 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V118 0.02 1.12 1.81 0.48 0.64 0.99 1.20 1.32 2.29 2.00 3.57 4.77 0.02 0.02 0.02 V119 0.02 0.02 0.02 0.65 0.71 0.67 1.27 1.04 1.00 0.02 0.02 0.02 0.02 0.02 0.02 V120 0.02 0.02 0.02 0.28 0.28 0.25 1.29 1.30 1.61 0.02 0.02 0.02 0.02 0.02 0.02 V121 5.80 3.14 0.02 0.85 0.92 1.07 1.29 1.11 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V122 2.11 1.04 0.02 0.60 0.65 0.68 1.10 1.04 1.10 0.02 3.32 5.73 0.02 0.02 0.02 V123 0.02 7.28 13.49 0.27 0.34 0.54 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V124 0.02 0.02 0.02 0.28 0.31 0.35 3.06 2.60 1.47 0.02 0.02 0.02 0.02 0.02 0.02 V125 0.02 0.02 0.02 0.15 0.16 0.16 1.27 1.00 0.02 10.57 6.03 0.02 0.02 0.02 0.02 V126 0.02 0.02 0.02 0.29 0.30 0.32 1.63 1.40 0.02 5.79 3.60 0.02 0.02 0.02 0.02 V127 0.02 2.12 1.94 0.20 0.27 0.31 1.20 0.88 0.49 4.96 2.25 0.02 0.02 0.02 0.02 V128 0.02 0.02 0.02 0.28 0.30 0.33 0.51 0.40 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V129 0.02 4.83 7.07 0.21 0.21 0.19 0.60 0.66 1.19 0.02 0.02 0.02 0.02 0.02 0.02 V130 7.31 3.28 0.02 0.46 0.51 0.51 1.76 1.64 1.86 3.38 1.74 0.02 0.02 0.02 0.02 V131 0.02 0.02 0.02 0.22 0.23 0.23 0.69 0.91 2.16 0.02 0.02 0.02 0.02 4.31 9.10 V132 0.02 0.02 0.02 0.69 0.73 0.76 1.91 1.52 0.02 7.93 4.58 0.02 0.02 0.02 0.02 V133 0.02 3.92 4.39 0.92 1.04 1.09 0.81 0.81 1.11 0.02 0.02 0.02 0.02 0.02 0.02 V134 0.02 3.58 4.21 0.59 0.53 0.38 1.16 0.84 0.02 0.02 0.02 0.02 0.02 0.02 0.02 V135 3.86 3.52 2.04 0.39 0.53 0.69 1.15 1.03 1.03 0.02 0.02 0.02 5.77 3.42 0.02 V136 0.02 0.02 0.02 0.75 0.85 1.26 2.08 1.89 0.02 10.36 13.65 20.78 0.02 0.02 0.02 V137 2.92 3.18 3.06 0.50 0.61 0.92 1.95 1.87 1.55 5.40 3.37 0.02 4.37 3.09 0.02 V138 0.02 0.02 0.02 0.13 0.12 0.08 0.94 0.85 0.71 11.74 6.59 0.02 0.02 0.02 0.02 V139 0.02 0.02 0.02 0.08 0.16 0.24 0.30 0.40 0.85 7.50 3.60 0.02 0.02 0.02 0.02 V140 4.41 7.09 8.54 0.30 0.28 0.21 0.98 0.83 0.02 0.02 2.51 5.61 0.02 0.02 0.02 V141 0.02 0.02 0.02 0.41 0.47 0.49 1.10 1.15 1.78 0.02 0.02 0.02 7.40 4.22 0.02 V142 0.02 1.43 1.75 0.32 0.42 0.54 0.57 0.42 0.02 0.02 0.02 0.02 4.58 2.78 0.02 V143 0.02 0.02 0.02 0.16 0.16 0.15 0.50 0.43 0.41 0.02 0.86 1.07 0.02 0.02 0.02 V144 16.64 7.50 0.02 0.26 0.32 0.37 0.41 0.59 1.43 10.26 5.30 0.02 8.29 4.86 0.02 V145 4.18 2.40 0.02 0.38 0.50 0.99 1.40 1.41 1.47 3.87 2.54 0.02 0.02 0.02 0.02 V146 0.02 0.02 0.02 1.06 1.13 1.25 0.70 0.71 0.88 3.49 2.12 0.02 0.02 0.02 0.02 8.2. Example 2: In vivo Evaluation of Medium Flux Library 2 in Non-human Primates 8.2.1. Methods 8.2.1.1. Variant selection

A library of variants (library 2) was created using a combination of design and selection strategies. The primary goal was to develop capsids that could be efficiently encapsulated in AAV particles, effectively transduce central nervous system tissues after intravenous administration, and target the liver and other tissue types. The first set of variants was selected from an in-house dataset obtained from other non-human primate (NHP) experiments using either: (1) an algorithm that optimizes capsid potency while balancing sequence diversity and measurement uncertainty; (2) reproducibility of capsid potency across brain regions; or (3) manual curation by examining individual phenotypic potency and sequence diversity. The second set of variants were novel designs using machine learning algorithms trained on extensive data from hundreds of thousands of capsid variants, focusing on optimizing capsid performance while maintaining distribution with respect to the original training set and leveraging methods that exploit additivity observed in fitness landscapes. The study also included variants containing stop codons in VP1 and VP2 as transduction-negative controls (expected to produce virus but not transduce cells) and a VP3 stop codon as a production-negative control (expected not to produce virus). The study also included variants with the WT-AAV9 capsid polypeptide as a control. 8.2.1.2. Library Creation

The viral particles used in this study, including those containing a series of variant capsids provided in Table 1, were individually generated by transient triple transfection of adherent HEK293T cells, followed by co-purification via iodixanol gradients. Each variant capsid contained within the viral particle contained a genome with a unique set of eight identifying barcodes and a different random sequence ID for quantification, thus providing a measure of biological replicates in this study. Each genome further contained sequence encoding a fluorescent reporter gene under the control of the ubiquitous Cbh promoter.

The presentation of each individual variant within the virus pool was measured by NGS using a unique barcode pool associated with each variant. Variants identified as having low initial productivity were individually produced again in different production rounds and combined with virus from previous production to balance the presentation of each variant so that it was within a 10-fold range in the final test. The final test included each variant in an IV test at 9e10-3e11 vg/kg, measured by ddPCR for final titer and by NGS analysis for variant presentation. The production efficiency of individual variants was calculated by NGS relative to the production efficiency of wild-type AAV9 in each round of production. For variants produced in multiple rounds, the productivity was calculated as the average of the productivity across multiple rounds. These ratios are provided in Table 8-B. 8.2.1.3. In vivo evaluation of reservoirs in NHPs

All NHP experiments were conducted in accordance with institutional policies and NIH guidelines. One young adult male and one adult female cynomolgus macaque ( Macaca fascicularis ) weighing 2.2-2.9 kg and seronegative for anti-AAV9 neutralizing antibodies (NAbs) were selected for the study (seronegative status based on serum NAb titers <1:4 in an in vitro NAb assay). Blood samples were collected prior to test article administration. Animals were anesthetized orally with ketamine and xylazine and received intravenous injections (doses: 1.22e13 vg/kg and 1.27e13 vg/kg). During the survival period, animals were monitored for signs of inflammation and treated with weekly intramuscular injections of steroids (methylprednisolone, 8 mg/kg) and dexamethasone, as needed, according to the animal institution's SOP and the advice of the veterinarian. Serum samples were collected 1, 12, 24, and 48 hours after injection, as well as weekly. Four weeks after injection, animals were sacrificed and tissues were collected for biodistribution and transduction analyses. The non-brain tissues collected are shown in Table 8A-1, and the brain tissues collected are shown in Table 8A-2. Peripheral tissue samples were collected in ^RNA later® (Sigma-Aldrich) and incubated overnight at 4°C, after which ^the RNA later® was drained and the samples were frozen at -80°C. The whole brain was cut into 4 mm coronal slabs using refrigerated species-specific brain matrix. The slabs were arranged sequentially (rostral to caudal). Each slab was divided equally along the sagittal midline into the left and right hemispheres. The slabs from the right hemisphere were immersed in RNAlater as previously described, drained, and frozen. For subregions of the brain, the left hemisphere slab was subcutaneously excised, placed in a cryotube, and immediately frozen on dry ice. Table 8A-1 : List of non-brain tissues collected Adipose tissue (abdomen, subcutaneous) aorta Femoral bone marrow Carotid artery (left side) Dorsal root ganglia: cervical vertebrae (bilateral) Dorsal root ganglia: thoracic vertebrae (bilateral) Dorsal root ganglia: lumbar spine (bilateral) Dorsal root ganglia: sacrum (bilateral) adrenal glands Gonads: testicles or ovaries Atrium (right side) apex of the heart Ventricle (left) kidneys Right lobe of the liver Left lobe of the liver Anterior lobe (bilateral) cervical lymph nodes Sciatic nerve (right) Skeletal muscle biceps brachii (bilateral) Skeletal muscle diaphragm skeletal muscle gastrocnemius muscle Skeletal muscle quadriceps (bilateral) cervical spinal cord Table 8A-2 : List of brain tissues collected Basal ganglia (caudate nucleus, globus alba, putamen) Brain stem (medulla, cerebral bridges) Cerebellum Forebrain (frontal cortex, motor cortex) hippocampus midbrain parietal cortex substantia nigra Temporal cortex thalamus Basal ganglia (caudate nucleus, globus alba, putamen) Brain stem (medulla, cerebral bridges) Cerebellum Forebrain (frontal cortex, motor cortex) 8.2.1.4. Batch Sequencing NGS Library Preparation

Brain sections were dissected to isolate various regions, including, but not limited to, the frontal cortex, temporal cortex, motor cortex, hippocampus, basal ganglia, midbrain, brain stem, and cerebellum. For all biodistribution and transduction analyses, total DNA and RNA were extracted from tissue samples using the DNeasy Blood and Tissue Kit (Qiagen) and the RNeasy Kit using Trizol/chloroform, respectively. RNA was extracted from the upper aqueous phase using the RNeasy (QIAGEN) kit according to the manufacturer's recommendations and further treated with Turbo™ DNase (Thermo Fisher Scientific) to remove any vector DNA contamination from the RNA sample. Reverse transcription was performed using primers specific for the vector transgene and containing a unique molecular identifier (UMI) using Protoscript II reverse transcriptase (New England Biolabs). A control reaction lacking reverse transcriptase (-RT control) was also prepared. Finally, samples were prepared for next-generation sequencing by amplifying the transgenic barcode region using primers compatible with the Illumina NGS platform and sequenced using the NextSeq 550 (Illumina). 8.2.1.5. Bulk Tissue NGS Sample Analysis and Analysis

After sequencing, barcode tags are extracted from reads with the expected amplicon structure, and the abundance of each barcode (number of reads, number of UMIs, or number of unique ID tags) is recorded. Analysis is limited to the set of barcodes present in the input virus sample, as measured by individual sequencing analysis of the input virus sample. To aggregate biodistributed samples, read counts are summed across samples from the same tissue. To aggregate brain transduction samples, the number of transduction events (measured by detected unique ID tags) is summed across samples from the same tissue. To aggregate all other transduction samples, the number of UMIs is summed across samples from the same tissue.

Tissue biodistribution and transduction were calculated by normalizing total biodistribution or transduction counts by input virus abundance. Transduction and biodistribution rates were calculated as fold change relative to wild-type (WT) AAV9. Measurements were reported as mean and standard deviation of barcode replicates (n = 8-16). 8.2.1.6. Single-cell nuclear RNA sequencing data analysis

Tissue Processing : All CNS tissue blocks were cut into four approximately 25 mg blocks on a cryostat and weighed. Each 25 mg tissue sample was placed in a tube on ice and 200 μl of EZ Lysis Buffer + RNase Inhibitor was added. The tissue was triturated with a pair of microscissors for approximately 1 min and transferred to a 7 ml dounce homogenizer using a wide-bore pipette. Each approximately 25 mg tissue block was homogenized in a separate 7 ml dounce homogenizer. EZ Lysis Buffer + RNase Inhibitor was added to the sample in the dounce homogenizer for a total volume of 7 ml. The sample was homogenized with a dounce using a loose-fitting pestle (Pestle A) at steady strokes (approximately 1 stroke/s) followed by a tight-fitting pestle (Pestle B).

Filtration and Cleaning : After Dounce homogenization, stack a 70 μm filter on top of a 40 μm filter in a 50 mL conical centrifuge tube pre-coated with 1× PBS + 2% BSA + 0.2 U/μl mouse RNase inhibitor. Using a funnel, pour the sample (7 ml) through the filter. Next, rinse by passing 7 ml of 1× PBS + 20% BSA + 0.2 U/μl mouse RNase inhibitor through the funnel and filter. Repeat the trituration, Dounce homogenization, and filtration for a second 25 mg tissue block, allowing the two tissue blocks to be combined during the filtration step. Transfer a small (10 μl) aliquot of the filtered sample to a 0.5 ml protein lobind tube containing 1 μl of propidium iodide for counting. Divide the filtered sample into four pre-coated 15 ml conical centrifuge tubes, each containing 7 ml of sample. Centrifuge the tubes at 200 RCF for 10 min at 4°C. Discard the supernatant and resuspend the pellet in an appropriate volume of 1x PBS + 5% BSA + RNase inhibitor to obtain approximately 3 million nuclei/ml. Transfer a small (5 μl) aliquot of the sample to a 0.5 ml protein lobind tube containing 15 μl of 1× PBS + 5% BSA + 0.2 U/μl mouse RNase inhibitor + 1:100 propidium iodide for counting. Stain the remaining sample with 1:100 Draq7.

FACS cleanup : Nuclei were sorted on a Sony MA900 cell sorter by gating for intact nuclei that stained positive for Draq7 and discarding any doublets. Intact nuclei were further gated for GFP positivity, and extensive gating for sorting was applied to maximize capture of even faintly GFP-positive nuclei. FACS-cleared nuclei were centrifuged at 200 RCF for 10 min at 4°C with a final concentration of 10% BSA. The pellet was resuspended in 1× PBS + 2% BSA + RNase inhibitor and counted. The final nuclei concentration was adjusted as needed for 10× encapsulation.

10x Encapsulation and Library Preparation : Single cells were encapsulated using the 10X Chromium X platform (10x Genomics) according to the manufacturer's standard instructions. Reverse transcription was performed according to the 10X protocol. cDNA was amplified using the 10X cDNA Amplification Kit, which allows amplification of oligo-dT-captured transcripts. Viral transcript-specific primers were added during cDNA amplification to enable early amplification and purification of viral transcripts. Following cDNA amplification, a portion of the cDNA library was used to generate gene expression libraries according to the 10x standard protocol, and the libraries were quality controlled and sequenced according to the standard 10X protocol. A small portion of the cDNA library was used to generate targeted libraries by PCR amplification of the Dyno barcode region. To target amplification of viral transcripts captured by oligo-dT, a combination of primers conjugated to the TruSeq Handle and viral transcript-specific primers was used. Once the targeted product was amplified, PCR was pre-indexed and indexed, and the library was sequenced using an Illumina NextSeq 2000 sequencer.

Gene expression data processing : 10X gene expression libraries were sequenced at a depth of 5000 reads per nucleus. Gene expression sequencing data were demultiplexed using Illumina bcl-convert with default settings, then aligned to the cynomolgus macaque reference genome (v6.0, assembly GCA_011100615.1) and quantified using the active intron pattern using the CellRanger pipeline v7.1.0. Duplex detection and filtering were performed using the Scrublet suite v0.2.3. Dimensionality reduction, batch effect removal, clustering, and identification of marker genes were performed using Scanpy v1.9.3.

Cell type annotation : 10X gene expression RNA transcript data were plotted on UMAP plots (Leiden clustering) to display cell clusters. Cell type identification was performed using an in-house algorithm that inferred cell type markers from a reference dataset compiled from the published literature (Siletti et al., 2023, Science, 382(6667):eadd7046, which is incorporated herein by reference in its entirety). This allowed us to annotate the major cell types in CNS tissues, including neurons, oligodendrocytes, oligodendrocyte progenitors, astrocytes, microneurons, and vascular cells. To validate the annotations, curated cell type-specific markers from the literature were used (Khrameeva et al., 2020, Genome Res. 30(5):776-789; Han et al., 2022, Nature 604(7907):723-731; He et al., 2021, Current Biology 31(24):5473-5486.e6; Agarwal et al., 2020, Nature Comms. 11:4183, each of which is incorporated herein by reference in its entirety), and these markers were confirmed to follow the expected expression pattern in the data.

Targeted library data processing : Targeted libraries were processed using an in-house pipeline to obtain transduced variant identity and 10X signature barcodes. To completely remove chimeric molecules, transcript/transcript (TPT) filtering was performed with a threshold of 0.5 for the forward and 0.02 for the reverse molecules, respectively (Dixit, 2021, bioRxiv 093237, which is incorporated herein by reference in its entirety). Targeted libraries were then filtered against a gene expression library to correlate cell type information and the analysis was restricted to valid cell barcodes. Data were further filtered with a cutoff of 250–1000 reads per molecule to remove any remaining sequencing artifacts. Finally, nuclei with more than three observed transduction events (which may represent clumping artifacts) were excluded from downstream analysis.

Determination of transduction efficiency : To calculate the normalized transduction efficiency of variant 'i' in cell type 'j', the number of transduction events observed for variant 'i' in cell type 'j' was divided by the population count of cell type 'j'. To generate the data shown in Figures 2A-2B, this value was further normalized by multiplying the amount of administered vector genome (vg) (defined as the fraction of reads (RNAseq) belonging to variant 'i' in the test article) by the total vg administered to the brain [Transduction efficiency of variant 'i' in cell type 'j' = (number of transduction events 'i' / number of cells 'j') / number of administered vector genomes for variant 'i']. 8.2.2. Results

The production, biodistribution, and transduction results of the selected variants are summarized in Table 8B (production), Table 8C (spinal cord and peripheral biodistribution), Tables 8D-1 and 8D-2 (CNS transduction), and Table 8E (spinal cord and peripheral transduction). Among the selected variants, variants V1, V5, V11, V27, and V30 were included in Pool 1, while V61 and V147 were new variants in Pool 2. Table 8B : Production efficiency of variant viral particles relative to that of WT AAV9 viral particles in HEK293 cells in vitro. Variant number Fold change relative to wtAAV9 V1 0.86 V5 1.03 V11 0.76 V27 0.98 V30 0.53 V61 1.26 V147 1.19

Nearly all variant capsids evaluated in this assessment increased biodistribution in all skeletal muscle tissue samples compared to the capsid polypeptide of SEQ ID NO: 1. None of the variant capsids increased biodistribution in the liver or spleen compared to the capsid polypeptide of SEQ ID NO: 1. The results of this analysis are summarized in Table 8C.

All capsids increased transduction in all brain samples compared to the capsid polypeptide of SEQ ID NO: 1. The results of this analysis are summarized in Tables 8D-1 and 8D-2. The variant capsids evaluated in this assessment also increased transduction in muscle samples, but not in other tissues, although these increases in transduction were not as great as those in brain samples (Table 8E). Table 8C. Fold changes in the biodistribution of virions containing the indicated variant capsid polypeptides relative to the biodistribution of virions containing WT AAV9 in non-brain tissues, with standard deviations indicated in parentheses after each value. "Summary" for a tissue is the mean of all measured areas in the indicated organ. organ dorsal root ganglion liver skeletal muscle skeletal muscle skeletal muscle skeletal muscle spinal cord spleen organization Summary Summary Summary biceps gastrocnemius muscle Quadriceps Summary Summary Variant number V1 2.82 (1.2) 0.51 (1.03) 3.81 (1.14) 3.66 (1.27) 4.19 (1.13) 3.48 (1.17) 4.06 (2.69) 1.33 (1.06) V5 2.27 (1.21) 0.24 (1.08) 3.59 (1.13) 4.14 (1.13) 3.64 (1.18) 3.13 (1.17) 2.9 (2.43) 0.79 (1.06) V11 0.8 (1.2) 0.38 (1.06) 1.24 (1.16) 1.34 (1.12) 1.33 (1.29) 1.06 (1.16) 0.45 (1.47) 0.66 (1.06) V27 3 (1.26) 0.33 (1.07) 5.3 (1.07) 5.55 (1.13) 5.38 (1.08) 5.03 (1.1) 2.46 (1.55) 0.87 (1.04) V30 2.45 (1.26) 0.11 (1.12) 3.73 (1.18) 3.87 (1.24) 3.85 (1.16) 3.43 (1.32) 1.5 (2.16) 0.79 (1.08) V61 1.02 (1.3) 0.3 (1.04) 1.33 (1.11) 1.31 (1.32) 1.35 (1.31) 1.24 (1.12) 0.77 (2.84) 0.59 (1.04) V147 3.96 (1.09) 0.18 (1.04) 6.97 (1.07) 6.78 (1.2) 7.37 (1.04) 6.63 (1.12) 6.17 (2.09) 0.93 (1.1) Table 8D-1 . Fold changes in transduction by viral particles containing the indicated variant capsid polypeptides relative to the biodistribution of viral particles containing WT AAV9 in brain tissue, with standard deviations indicated in parentheses after each value. "Summary" for a tissue is the mean of all measured areas in the indicated organ. organ brain brain brain brain brain brain brain brain Region Summary basal ganglia basal ganglia basal ganglia basal ganglia brain stem Cerebellum forebrain organization Summary Summary caudate nucleus Pale Ball Putamen Summary Summary Summary Variant number V1 33.51 (1.11) 34.91 (1.09) 35.09 (1.19) 27.7 (1.24) 37.83 (1.18) 14.23 (1.1) 43.44 (1.15) 48.89 (1.15) V5 24.06 (1.06) 21.39 (1.07) 20.97 (1.06) 16.43 (1.21) 24.94 (1.12) 9.44 (1.14) 34.87 (1.05) 39.4 (1.09) V11 4.28 (1.27) 5.49 (1.29) 5.65 (1.28) 4.55 (1.43) 5.69 (1.35) 2.22 (1.42) 5.57 (1.27) 5.08 (1.43) V27 33.6 (1.09) 35.68 (1.08) 35.56 (1.09) 31.95 (1.12) 37.81 (1.16) 17.8 (1.11) 48.85 (1.1) 43.91 (1.1) V30 25.54 (1.06) 27.38 (1.06) 26.63 (1.13) 23.42 (1.14) 30.5 (1.17) 12.08 (1.14) 35.68 (1.11) 38.11 (1.08) V61 10.39 (1.22) 10.35 (1.17) 10.3 (1.21) 8.39 (1.41) 11.19 (1.26) 4.48 (1.22) 12.39 (1.16) 17.41 (1.28) V147 55.29 (1.1) 52.25 (1.11) 52.98 (1.13) 36.13 (1.19) 60.8 (1.08) 18.66 (1.08) 64.87 (1.09) 101.22 (1.11) Table 8D-2 . Fold change in transduction of viral particles containing the indicated variant capsid polypeptides relative to the biodistribution of viral particles containing WT AAV9 in brain tissue, with standard deviations indicated in parentheses after each value. "Summary" for a tissue is the mean of all measured areas in the indicated organ. organ brain brain brain brain brain brain brain brain Region forebrain forebrain hippocampus midbrain parietal cortex substantia nigra Temporal cortex thalamus organization frontal cortex Sports leather Summary Summary Summary Summary Summary Summary Variant number V1 35.38 (1.22) 53.17 (1.15) 37.05 (1.28) 23.46 (1.16) 55.15 (1.21) 13.95 (1.3) 76.97 (1.16) 52.23 (1.22) V5 24.11 (1.24) 44.26 (1.08) 30.44 (1.2) 15.86 (1.13) 44.4 (1.1) 8.12 1.28) 52.85 (1.1) 34.5 (1.1) V11 3.53 (1.64) 5.48 (1.46) 4.82 (1.28) 3.02 (1.24) 5.79 (1.3) 1.93 (1.62) 6.83 (1.47) 6.66 (1.4) V27 32.16 (1.12) 47.62 (1.12) 38.32 (1.23) 25.28 (1.13) 52.85 (1.11) 15.85 (1.19) 65.84 (1.1) 44.35 (1.13) V30 28.05 (1.13) 41.24 (1.11) 32.86 (1.09) 15.46 (1.12) 41.96 (1.1) 7.36 (1.26) 62.24 (1.09) 34.95 (1.09) V61 10.23 (1.48) 19.54 (1.29) 11.52 (1.38) 6.63 (1.25) 17.55 (1.26) 3.58 (1.61) 20.94 (1.31) 15.62 (1.5) V147 74.01 (1.12) 110 (1.11) 71.44 (1.15) 28.07 (1.11) 112.36 (1.14) 15.63 (1.23) 148.13 (1.13) 85.23 (1.14) Table 8E . Fold changes in transduction by viral particles containing the indicated variant capsid polypeptides relative to the biodistribution of viral particles containing WT AAV9 in non-brain tissues, with standard deviations indicated in parentheses after each value. "Summary" for a tissue is the mean of all measured areas in the indicated organ. organ dorsal root ganglion liver skeletal muscle skeletal muscle skeletal muscle skeletal muscle spinal cord spleen organization Summary Summary Summary biceps gastrocnemius muscle Quadriceps Summary Summary Variant number V1 2.77 (1.79) 0.49 (1.12) 4.12 (1.11) 3.97 (1.13) 4.23 (1.11) 4.03 (1.13) 18.9 (1.48) 1.21 (1.33) V5 1.54 (1.43) 0.21 (1.16) 5.41 (1.08) 5.07 (1.09) 5.73 (1.08) 5.03 (1.09) 12.63 (1.27) 0.8 (1.38) V11 0.61 (1.59) 0.4 (1.1) 0.94 (1.16) 0.84 (1.18) 1 (1.14) 0.91 (1.25) 3.04 (1.7) 0.81 (1.39) V27 2.13 (1.69) 0.32 (1.06) 4.96 (1.09) 4.5 (1.09) 5.3 (1.1) 4.68 (1.11) 23.47 (1.32) 1.04 (1.26) V30 1.21 (1.66) 0.11 (1.08) 2.68 (1.13) 2.33 (1.14) 2.91 (1.16) 2.49 (1.11) 12.8 (1.26) 0.69 (1.41) V61 1.7 (1.31) 0.28 (1.1) 1.27 (1.1) 1.23 (1.15) 1.32 (1.09) 1.2 (1.12) 6.2 (1.51) 0.54 (1.4) V147 3.5 (1.59) 0.18 (1.08) 6.58 (1.18) 6.08 (1.19) 6.94 (1.18) 6.3 (1.16) 33.54 (1.08) 0.8 (1.68)

The cell type-specific tropism of AAV capsid variants V1, V5, V27, V30, V61, and V147 in the cerebral cortex and basal ganglia of cynomolgus macaques was investigated by single-cell nuclear RNA sequencing and analysis. This analysis identified all major central nervous system (CNS) cell types, including therapeutically relevant cells such as neurons, excitatory neurons, intermediate neurons, medium spiny neurons, and astrocytes.

Results of single-cell nuclear RNA sequencing, providing cell type-specific transduction efficiency of AAV capsid variants V1, V5, V27, V30, V61, and V147, are shown in Figure 2A (basal ganglia) and Figure 2B (cerebral cortex).

Without wishing to be bound by theory, these data support the discovery that incorporation of the variant capsid polypeptides disclosed herein into viral particles results in, for example, increased transduction and expression of a heterologous transgene included in the viral particle, relative to otherwise similar viral particles comprising a wild-type AAV9 capsid polypeptide (e.g., the capsid polypeptide of SEQ ID NO: 1). These data demonstrate that viral particles comprising a capsid polypeptide containing any of the mutations or motifs described herein have unexpectedly significant improvements, including improvements in transduction of heterologous transgenes encapsulated in viral particles in skeletal muscle cells and in central nervous system ("CNS") cells (e.g., cells in the spinal cord and brain), compared to otherwise similar viral particles comprising a capsid composed of a wild-type AAV9 capsid polypeptide. These capsid polypeptides are contemplated for use in gene therapy, such as in viral particles and compositions containing the same, for treating subjects in need thereof, such as humans, for example, for treating CNS and skeletal muscle disorders. 8.3. Example 3: In vivo evaluation of library 1 in mice 8.3.1. Materials and Methods 8.3.1.1. Animal Studies

All mouse experiments were performed in accordance with institutional policy, federal regulations, and approval from the Institutional Animal Care and Use Committee. Three wild-type C57BL/6J male mice and three wild-type BALB/C male mice, all approximately two months of age, received an intravenous injection (via the tail vein) of 100 μL of pool 1 at 8.0 e ¹³ vg/kg. Animals were monitored throughout the study and sacrificed 3 weeks after injection. The tissues collected are shown in Table 9. Samples were immersed in ^RNA later® (Sigma-Aldrich) at 4°C for 24 hours. ^The RNA later® was then drained and the samples stored at -80°C. Table 9. List of tissues collected and number of samples used for biodistribution and transduction analysis organization Number of samples used for transduction analysis Number of samples used for biodistribution analysis brain 12 12 liver 6 6

The details of the tissue processing and NGS analysis workflow for batch tissue samples are described below. 8.3.1.2. Tissue dissection, homogenization, and nucleic acid extraction

One hemisphere of brain tissue was further bisected into head and tail sections using clean disposable scalpels in a cryostat (-20°C) cold room. Dissected brain and liver tissues were homogenized individually in Trizol using a TissueLyser II (QIAGEN) with stainless steel beads (5 mm) according to the manufacturer's recommendations. Chloroform was added to each homogenized sample, and the samples were vortexed and centrifuged to achieve phase separation. DNA was extracted from the organic layer using the DNeasy® Blood and Tissue Kit (QIAGEN), and RNA was extracted from the upper aqueous phase using the RNeasy Blood and Tissue Kit (QIAGEN) according to the manufacturer's recommendations. Reverse transcription is performed using specific RT primers that ligate to the vector transcript to generate a targeted cDNA library. 8.3.1.3. NGS library preparation

Each cDNA and DNA sample was amplified using pre-indexed primers specific for the target region, which contained a barcode and ID, with Illumina handles (R1 and R2) as pendants. Each sample amplification was tracked in real time by qPCR and terminated once the sample's Rn reached an inflection point. The pre-indexed samples were indexed using custom Illumina indexing primers to index each tissue sample. These indexed libraries were then sequenced using the Illumina NextSeq200 sequencer. 8.3.1.4. Batch NGS Sequencing Data Analysis

After sequencing, barcode tags are extracted from reads with the expected amplicon structure, and the abundance (number of reads, number of UMIs, or number of unique ID tags) is recorded. To aggregate biodistribution samples, read counts are summed for samples from the same tissue or organ. To aggregate transduction samples, the number of transduction events (measured by the number of detected unique barcode and ID tag combinations) is summed for samples from the same tissue or organ.

Transduction and biodistribution rates were calculated by normalizing the aggregate transduction or biodistribution counts by input virus abundance. Rates are relative to AAV9 reporter. 8.3.2. Results

The biodistribution and transduction results of selected AAV capsid variants evaluated in this assessment are summarized in Table 10A (brain biodistribution), Table 10B (brain transduction), and Table 10C (liver transduction).

A large number of AAV capsid variants evaluated in this assessment showed increased biodistribution in brain samples in a similar manner relative to AAV9 in both mouse strains (summarized in Table 10A). In general, AAV capsid variants that showed increased brain biodistribution were also associated with increased brain transduction (summarized in Table 10B). None of the AAV capsid variants evaluated in this assessment were associated with increased transduction in liver tissue (summarized in Table 10C). Table 10A. Changes in the biodistribution of virions containing the indicated variant capsid polypeptides relative to the biodistribution of virions containing WT AAV9 in brain tissue. CBh indicates measurements from virions containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates virions containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that the variant was not detected in the indicated sample. Mouse strains Balb/c C57bl/6 Starter hSyn Cb hSyn Cb Variant number V1 31.72 39.71 27.86 25.10 V2 16.33 22.55 16.14 16.67 V3 58.47 25.80 9.85 24.32 V4 25.46 28.63 19.14 31.32 V5 19.03 21.96 16.40 23.77 V6 19.48 24.71 53.15 26.43 V7 21.29 18.61 27.21 30.02 V8 4.59 6.13 14.07 22.37 V9 19.85 31.41 16.65 15.30 V10 27.31 36.86 16.92 19.91 V11 3.95 0.24 29.43 13.32 V12 43.38 57.66 60.29 55.18 V13 12.11 29.78 9.88 26.49 V14 19.41 23.67 14.89 17.69 V15 23.90 19.36 31.68 27.63 V16 13.42 33.51 18.63 21.64 V17 16.18 26.75 19.98 27.53 V18 4.36 9.93 8.39 7.92 V19 18.45 33.02 19.37 22.64 V20 25.74 29.19 12.93 33.41 V21 23.62 39.99 26.70 25.34 V22 39.72 19.52 25.04 17.12 V23 25.63 26.20 18.13 23.25 V24 19.09 13.16 9.09 11.14 V25 8.18 16.51 4.97 14.67 V26 0 2.26 0.59 7.59 V27 10.88 11.99 7.20 11.05 V28 20.98 23.17 19.80 21.04 V29 1.90 3.61 5.79 3.09 V30 2.54 8.39 4.58 11.23 V31 13.82 25.24 18.56 19.85 V32 11.43 16.24 10.66 8.75 V33 6.11 24.76 13.32 20.78 V34 6.76 5.38 7.81 10.36 V35 6.64 7.96 5.31 11.59 V36 19.54 25.08 17.94 21.85 V37 10.15 22.03 20.72 32.37 V38 39.25 69.54 34.32 31.36 V39 18.51 14.55 9.71 10.10 V40 23.21 24.70 14.47 25.09 V41 3.75 0.41 10.03 10.58 V42 18.16 23.73 19.50 23.43 V43 5.22 10.45 10.65 15.11 V44 3.51 12.82 6.94 11.72 V45 1.06 5.70 3.72 6.95 V46 1.27 5.76 1.75 5.43 V47 29.12 17.50 15.97 12.46 V48 27.68 28.20 23.85 34.01 V49 13.41 22.41 11.55 20.69 V50 26.89 43.28 27.68 27.66 V51 34.89 24.02 32.55 23.79 V52 11.12 13.81 9.12 17.65 V53 0 1.92 7.23 16.14 V54 2.09 4.52 2.43 4.01 V55 3.59 12.93 5.31 12.60 V56 0 2.35 0.17 11.64 V57 1.53 7.89 7.01 8.43 V58 1.69 7.47 4.72 11.84 V59 10.75 26.15 10.55 15.13 V60 16.15 22.20 13.09 25.16 V62 0 0 0.18 0 V63 1.99 1.00 6.46 3.70 V64 1.42 6.44 0.96 2.55 V65 4.60 8.37 4.87 November 18 V66 37.86 11.01 10.50 27.83 V67 0 0.03 0.24 3.47 V68 3.52 4.92 2.38 4.48 V69 5.34 5.33 1.90 9.03 V70 1.31 2.44 0.74 1.74 V71 0 1.19 0.09 0.33 V72 0.90 1.15 0.20 1.76 V73 0 0 0 0.16 V74 0.13 0.67 0.24 0.81 V75 0 0.43 0.52 0.09 V76 0.07 0.60 0.98 0.07 V77 7.81 18.58 5.55 11.99 V78 0 1.81 0 1.18 V79 0.54 0.95 3.76 0.81 V80 0 0.02 1.60 0.66 V81 0 0.89 0.75 1.07 V82 0.06 0.85 0.08 0.36 V83 0 8.73 0.74 0 V84 0.59 0.85 1.14 0.77 V85 0 1.37 0 1.64 V86 1.79 0.74 0.44 0.14 V87 0 0.39 0 0.75 V88 0.53 0.62 0.77 0.28 V89 0 0.23 0.70 1.33 V90 0 0 0.33 0 V91 0 0.09 0.14 0.69 V92 0 0.12 0.12 0.72 V93 0.34 0.22 1.35 0.13 V94 0.93 0 1.20 0.24 V95 0 0.53 0.05 1.32 V96 0 0 1.50 0.37 V97 0 0 1.96 0 V98 1.53 1.66 1.64 0.63 V99 3.87 1.24 0 0.28 V100 2.16 0.40 1.00 4.15 V101 0.76 0.46 0.40 0.58 V102 0 0.87 0.07 1.03 V103 0 0 1.83 0.27 V104 0 0.07 3.12 0.16 V105 0.98 0.56 1.13 0.61 V106 0.87 0.62 0.34 1.54 V107 0 0.10 0 1.36 V108 0 1.05 0.78 0.22 V109 0 2.37 0 0.28 V110 0.44 2.61 0.86 0.24 V111 2.28 0 0.30 2.37 V112 0 2.14 4.05 0.41 V113 4.00 0.85 0.59 0.75 V114 0 0 1.30 3.06 V115 0 1.40 1.03 1.12 V116 0 0.17 3.27 1.12 V117 0 0.03 0 0 V118 0.02 0.24 0.79 0.98 V119 0 1.33 0.61 0.09 V120 0 0.06 0.22 0.19 V121 0.03 0 0.42 0.16 V122 0.26 0.64 0.58 0.58 V123 0 0 0 0 V124 1.32 0.29 3.43 0.11 V125 2.68 1.35 0.50 1.58 V126 0.12 0.06 0 8.33 V127 0.50 3.26 1.80 3.39 V128 0 0.11 0.28 0.49 V129 0.08 0.24 0.22 0.33 V130 0.73 0.33 1.36 0.41 V131 0.42 0.03 0.09 0.19 V132 0 0.22 0.56 0.24 V133 0.23 1.47 0.70 0.30 V134 0 0.93 0.58 1.29 V135 0.17 0 1.12 0.56 V136 0 0 0.07 0.61 V137 0 0.91 0.11 0.80 V138 9.57 13.23 7.07 14.79 V139 0.79 0.56 2.70 1.54 V140 3.64 2.75 3.20 1.76 V141 0.28 0.71 1.31 0.25 V142 0.02 0.47 0.26 1.42 V143 0 0 1.99 0.10 V144 0 0.13 0.47 0.71 V145 0.03 0.87 0 0.78 V146 1.95 1.51 1.42 0.56 Table 10B. Changes in transduction of brain tissue by virions containing the indicated variant capsid polypeptides compared to transduction by virions containing WT AAV9. CBh indicates measurements from virions containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates measurements from virions containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that the variant was not detected in the indicated sample. Mouse strains Balb/c C57bl/6 Starter hSyn Cb hSyn Cb Variant number V1 20.80 39.02 16.00 33.21 V2 16.98 31.86 15.73 25.05 V3 27.92 35.71 23.06 27.80 V4 17.93 30.73 13.18 26.46 V5 15.73 27.23 13.39 21.74 V6 12.38 39.09 11.23 25.76 V7 15.87 27.67 11.46 27.65 V8 12.69 9.27 21.52 23.07 V9 15.85 38.96 13.56 28.61 V10 25.41 34.30 17.38 25.69 V11 2.07 6.36 8.04 18.17 V12 29.86 34.05 21.99 26.82 V13 11.33 42.07 November 18 24.41 V14 19.40 22.82 14.75 13.27 V15 26.88 50.41 21.59 34.73 V16 27.35 37.84 15.94 27.63 V17 12.38 31.53 9.02 25.54 V18 7.63 14.23 9.71 12.00 V19 16.11 38.17 13.17 31.99 V20 18.84 35.10 14.64 25.62 V21 24.21 43.18 22.10 34.10 V22 26.11 31.30 21.99 20.72 V23 20.79 37.55 18.12 26.69 V24 10.12 14.79 6.22 12.38 V25 7.64 19.59 5.94 13.88 V26 5.77 8.02 4.49 8.55 V27 7.59 16.66 5.90 12.10 V28 16.76 32.39 13.88 29.61 V29 7.38 10.58 6.14 9.01 V30 10.47 17.62 6.54 13.73 V31 14.37 36.63 11.57 22.82 V32 9.06 28.11 6.07 19.64 V33 10.95 25.99 8.51 19.38 V34 11.99 28.22 9.72 23.89 V35 6.95 13.86 3.60 11.14 V36 13.54 37.00 12.89 25.32 V37 11.08 29.90 13.99 26.42 V38 21.89 32.70 11.75 27.51 V39 16.71 34.33 18.84 26.17 V40 11.29 26.38 9.45 19.86 V41 0 0.88 6.25 12.06 V42 17.27 34.17 12.99 26.97 V43 8.16 20.88 10.04 23.17 V44 13.53 28.71 7.37 20.93 V45 8.98 27.83 6.42 17.13 V46 4.80 9.49 3.48 7.43 V47 13.81 22.83 11.73 17.63 V48 15.41 36.34 11.66 29.02 V49 9.68 28.85 7.53 21.77 V50 17.43 37.39 15.05 30.56 V51 24.29 38.80 17.03 24.40 V52 9.64 24.75 6.74 20.61 V53 2.35 1.52 6.66 13.20 V54 4.86 8.42 2.62 5.94 V55 12.11 21.35 6.72 2019.18 V56 11.04 16.99 7.97 11.10 V57 4.90 11.44 3.41 7.37 V58 8.24 32.36 October 14th 22.34 V59 21.26 33.96 13.22 26.22 V60 24.47 38.61 14.27 32.55 V62 0 0 0 0 V63 1.81 7.13 1.64 4.03 V64 5.00 8.10 3.61 5.85 V65 12.54 16.32 8.29 13.39 V66 16.04 13.19 13.72 15.67 V67 0 0.15 3.43 3.82 V68 4.63 7.94 5.14 5.25 V69 7.99 2:30 PM 4.66 9.89 V70 2.53 4.81 1.81 3.92 V71 0 0.19 0 0.89 V72 2.20 1.69 1.14 2.07 V73 0.65 0.28 0.51 0.87 V74 0.72 0.90 0.56 0.52 V75 0.72 1.02 1.12 1.05 V76 0.96 1.94 0.99 0.50 V77 8.99 20.93 7.16 14.95 V78 1.16 1.12 0.90 0.57 V79 1.62 1.49 0.63 0.86 V80 0.46 0 1.44 2.45 V81 1.36 2.97 1.58 2.44 V82 0.71 0.76 0.83 1.32 V83 0 0.71 0 0.55 V84 0.59 0.92 1.60 0.54 V85 0.70 0.54 1.64 0.83 V86 2.59 0.23 0.34 0.72 V87 0 1.02 0 1.10 V88 0.32 0.65 0.50 0.37 V89 0.59 0.64 1.84 1.73 V90 1.52 1.20 2.96 0.62 V91 0.56 0.59 0 0.57 V92 0.41 1.13 0.63 0.79 V93 1.40 1.84 0.91 0.53 V94 0.93 0.75 0 2.61 V95 2.51 1.08 0.65 0.60 V96 4.62 0.76 0 0.29 V97 0 0 2.23 0 V98 0 0.44 1.01 0 V99 0 0.96 2.66 1.48 V100 1.73 2.17 0 1.34 V101 0.77 1.21 1.20 2.34 V102 0 0.83 1.42 0.32 V103 0.75 0.80 0 0.31 V104 0 0 2.01 0.42 V105 0.34 0.67 1.33 1.20 V106 0.55 0.40 0.43 1.24 V107 0 1.08 0.42 0.70 V108 1.42 0.95 1.47 0.74 V109 0 0.60 0 0.92 V110 0.98 0.40 0.38 0.93 V111 2.11 0.87 0 0.22 V112 1.50 0.26 0 1.62 V113 2.48 0.70 1.28 1.09 V114 0.66 1.21 0 1.50 V115 1.38 0 0.36 0.34 V116 0.51 1.00 1.59 0.62 V117 0 0 1.38 2.54 V118 1.55 0.91 1.55 0.94 V119 0.48 0.54 2.25 1.24 V120 2.33 0.99 2.42 1.27 V121 1.45 0.82 3.95 1.48 V122 0.18 0.40 0.69 0.69 V123 1.65 0 0 0 V124 0.71 0.87 0.55 0.67 V125 2.96 2.70 2.30 2.08 V126 0 0.59 0.61 0.92 V127 3.09 5.66 2.58 2.38 V128 0 0.72 0.97 0.56 V129 0 1.23 0.90 1.07 V130 1.19 1.61 1.11 1.24 V131 0.35 0.44 0.27 0.34 V132 1.55 0.40 0.60 0.94 V133 1.07 0.64 0.62 0.66 V134 0.51 0 0.60 0.56 V135 0.75 0.18 0.77 0.99 V136 1.93 0.53 0 2.04 V137 0 1.54 0.58 0.65 V138 12.39 21.85 8.03 14.53 V139 2.88 4.34 3.84 5.78 V140 1.57 5.14 3.66 6.29 V141 0.80 0.69 0.83 1.07 V142 0.64 1.01 1.83 0.78 V143 0.41 0.37 0.32 0.42 V144 0 0.78 0.81 0.40 V145 1.42 0.99 1.65 0.46 V146 0 1.08 1.32 1.81 Table 10C. Changes in transduction of liver tissue by virions containing the indicated variant capsid polypeptides compared to transduction by virions containing WT AAV9. CBh indicates measurements from virions containing genomes with the cap gene under the control of the CBh promoter. hSyn indicates measurements from virions containing genomes with the cap gene under the control of the hSyn promoter. A value of "0" indicates that the variant was not detected in the indicated sample. Mouse strains Balb/c C57bl/6 Starter hSyn Cb hSyn Cb Variant number V1 0.31 0.12 0.33 0.29 V2 0 0.10 0.13 0.18 V3 0.61 0.15 0.65 0.06 V4 0.11 0.05 0.12 0 V5 0.07 0.11 0.08 0.11 V6 0 0.09 0.77 0.44 V7 0.20 0 0 0.11 V8 0 0 0 0.22 V9 0 0.11 0 0.27 V10 0 0.06 0.38 0.58 V11 0.36 0 0 0.27 V12 0 0.31 0.29 0.28 V13 0 0.19 0.16 0.32 V14 0 0.15 0 0.12 V15 0.31 0.13 0.67 0.10 V16 0.26 0.28 0.57 0.17 V17 0.27 0.18 0.58 0.22 V18 0 0.19 0 0.12 V19 0.29 0.10 0.15 0.19 V20 0.53 0.19 0.28 0.40 V21 0.12 0.10 0.39 0.16 V22 0 0.12 0 0.19 V23 0 0.10 0.23 0.06 V24 0 0.10 0 0.12 V25 0.20 0.10 0.22 0.04 V26 0 0.07 0 0 V27 0.04 0.11 0 0.13 V28 0.25 0.21 0.41 0.22 V29 0 0.09 0 0.06 V30 0.07 0.08 0 0.03 V31 0.06 0.37 0.25 0.28 V32 0.09 0.10 0.09 0.16 V33 0 0.26 0 0.28 V34 0 0.05 0.19 0 V35 0 0.05 0.22 0.09 V36 0 0.10 0.38 0.12 V37 0 0.30 0 0.36 V38 0 0.08 0.19 0.20 V39 0 0.08 0 0.46 V40 0.61 0.38 0.16 0.41 V41 0 0.08 0.12 0.28 V42 0 0.09 0.07 0.19 V43 0.12 0.20 0.13 0.20 V44 0.24 0.19 0.25 0.06 V45 0 0.05 0 0.06 V46 0.06 0.07 0 0.08 V47 0.22 0.12 0.36 0.14 V48 0.28 0.43 0.60 0.65 V49 0.25 0.32 0.18 0.14 V50 0.81 0.44 0.29 0.61 V51 0.28 0.45 0.30 0.46 V52 0 0.12 0.09 0.15 V53 0.15 0.26 0.32 0.24 V54 0.07 0.06 0.07 0.11 V55 0 0.07 0.09 0.24 V56 0 0.08 0 0 V57 0.09 0.05 0.10 0 V58 0.24 0 0 0.18 V59 0.59 0.13 0 0.39 V60 0.21 0.33 0.46 0.20 V62 0 0 0 0 V63 0 0.03 0.22 0.036 V64 0 0.06 0.07 0 V65 0.22 0.53 0.70 0.27 V66 0 0.18 1.19 0.53 V67 0 0.05 0.33 0.32 V68 0.38 0.35 0.66 0.87 V69 0 0.21 0.37 0.44 V70 0.52 0.53 0.79 0.64 V71 0.18 0.10 0.20 0.12 V72 0.13 0.32 0.14 0.38 V73 0.45 0.54 0.49 0.71 V74 0.08 0.10 0.18 0.43 V75 0.38 0.12 0.80 0.14 V76 0.11 0.67 0.36 0.88 V77 0.61 0.54 0.41 0.62 V78 0 0.32 0.43 0.31 V79 0.28 0.45 0.30 0.31 V80 0.64 0.21 0.52 0.58 V81 0.59 0.38 0.38 0.47 V82 0.43 0.46 0.26 0.44 V83 0.48 0.24 1.02 0.44 V84 0.51 0.20 0.11 0.24 V85 0.49 0.19 1.04 0.34 V86 0.45 0.08 0.64 0.19 V87 0 0.56 0.19 0.21 V88 0.56 0.19 0.48 0.40 V89 0.62 0.28 0.22 0.27 V90 0 0.55 1.14 0.25 V91 0.19 0.28 0.21 0.40 V92 0.28 0.37 0.61 0.76 V93 0.24 0.44 0.35 0.29 V94 0 0.26 0 0.08 V95 0.39 0.19 0.52 0.26 V96 1.61 0.20 0 0.40 V97 0 0 0 0 V98 0 0.30 0 0.46 V99 0 0.66 0 0.60 V100 1.01 0.08 0.21 0.36 V101 0.40 0.31 0.36 0.42 V102 0 0.50 0.68 0.35 V103 0.26 0.14 0 0.29 V104 0.30 0.28 0 0.57 V105 0.72 0.27 0.38 0.70 V106 0.58 0.56 0.62 0.42 V107 0 0.12 0.40 0.23 V108 0.17 0.33 0.53 0.50 V109 4.76 0.51 0 0.87 V110 0.94 0.76 0.82 0.76 V111 0.18 0.30 0.39 0.24 V112 0.87 0.36 0.56 0.71 V113 0.58 0.24 0.92 0.59 V114 0.11 0.29 1.10 0.25 V115 0.16 0.08 0 0.28 V116 0.71 0.31 0.38 0.21 V117 0 0.45 0 0.96 V118 0.23 0.21 0.33 0.40 V119 0.67 0.09 0.36 0.22 V120 0 0.23 0 0 V121 0.51 0.57 0 0.34 V122 0.25 0.57 0.59 0.48 V123 0 0.22 0.61 0 V124 0.25 0.07 0 0.54 V125 0.17 0.05 0 0.06 V126 0 0.15 0.58 0.06 V127 0.17 0.09 0.62 0.27 V128 0 0.21 0.31 0.30 V129 0.30 0.32 0.32 0.45 V130 0.42 0.19 0.27 0.49 V131 0.36 0.15 0 0.18 V132 0 0.49 1.44 0.42 V133 0.28 0.22 0.30 0.67 V134 0.09 0.31 0.96 0.42 V135 0.09 0.25 0.65 0.31 V136 0 0.46 1.44 0.55 V137 0.65 0.24 0.56 0.47 V138 0 0.17 0.13 0.17 V139 0 0.07 0 0.08 V140 0 0.04 0.19 0.18 V141 0.19 0.32 0.40 0.43 V142 0.07 0.17 0.16 0.30 V143 0 0.17 0.19 0.06 V144 0.36 0.32 0.51 0.16 V145 0.74 0.24 0.26 0.45 V146 0 0.43 0.79 0.71 8.4. Example 4: In vivo evaluation of library 2 in mice 8.4.1. Materials and methods 8.4.1.1. Animal studies

All mouse experiments were performed in accordance with institutional policy, federal regulations, and approval from the Institutional Animal Care and Use Committee. Five wild-type C57BL/6J male mice, aged 8-10 weeks, each received an intravenous injection (via the tail vein) of 100 μL of the vector library (including some of the variants described herein). Two mice received a low dose of 6.6e ¹² vg/kg to 6.9e ¹² vg/kg, and the remaining three mice received a high dose of 3.4e ¹³ vg/kg to 3.7e ¹³ vg/kg. Animals were monitored throughout the study and sacrificed 4 weeks after injection. The tissues collected are shown in Table 11. After collection, samples were immediately flash-frozen in liquid nitrogen (or ethanol-dry ice) and stored at -80°C. Table 11. List of tissues collected for biodistribution and transduction analysis. organization Notes brain •Left ventral side•Left dorsal side•Right ventral side•Right dorsal side•Left cerebellum•Right cerebellum. liver Divide into three

The details of the tissue processing and NGS analysis workflow for batch tissue samples are described below. 8.4.1.2. Tissue Homogenization and Nucleic Acid Extraction

For all biodistribution analyses, total DNA was extracted from tissue samples using the MagMAX DNA Multi-Sample Ultra 2.0 Kit (Thermofisher). Samples were first homogenized in the provided lysis buffer and then incubated with proteinase K at 65°C. Lysates were then added to plates for automated extraction using a KingFisher Apex instrument (Thermofisher). For all transduction analyses, total RNA was extracted using the MagMAX™ mirVana™ Total RNA Isolation Kit (Thermofisher) according to the manufacturer's recommendations and further treated with DNase I-XT (New England Biolabs) to remove any vector DNA contamination from the RNA samples. Reverse transcription was performed using primers specific for the vector transgene and containing a unique molecular identifier (UMI) using Protoscript II reverse transcriptase (New England Biolabs). A control reaction lacking reverse transcriptase (-RT control) was also prepared. Transduction and biodistribution samples were prepared for next-generation sequencing by amplifying the transgene barcode region using primers compatible with the Illumina NGS platform and sequenced using the NextSeq 2000 (Illumina). 8.4.1.3. Bulk NGS Sequencing Data Analysis

After sequencing, barcode tags are extracted from reads with the expected amplicon structure, and the abundance (number of reads, number of UMIs, or number of unique ID tags) is recorded. To aggregate biodistribution samples, read counts are summed for samples from the same tissue or organ. To aggregate transduction samples, the number of transduction events (measured by the number of detected unique barcode and ID tag combinations) is summed for samples from the same tissue or organ.

Transduction and biodistribution rates were calculated by normalizing the aggregate transduction or biodistribution counts by input virus abundance. Ratios were calculated relative to V27. Ratios were then linearly shifted based on measurements from independent experiments and reported relative to AAV9. 8.4.2. Results

The biodistribution and transduction results of the AAV capsid variants evaluated in this assessment are summarized in Table 12A (brain biodistribution), Table 12B (liver biodistribution), Table 12C (brain transduction), and Table 12D (liver transduction).

Nearly all AAV capsid variants evaluated in this assessment increased biodistribution in brain samples (summarized in Table 12A). Similarly, the AAV capsid variants evaluated were also associated with increased brain transduction (summarized in Table 12C). All AAV capsid variants evaluated in this assessment were associated with decreased biodistribution and transduction in liver tissue (summarized in Tables 12B and 12D, respectively). Table 12A. Changes in brain biodistribution of virions containing the indicated variant capsid polypeptides under the control of the CBh promoter. Ratios were calculated relative to V27 based on measurements from independent experiments, with linear shifts reported relative to wild-type AAV9. A value of "0" indicates that the variant was not detected in the indicated sample. Variant number Brain biodistribution Variant number Brain biodistribution Variant number Brain biodistribution V1 11.98 V31 4.58 V61 4.19 V2 9.48 V32 4.22 V62 0.00 V3 17.01 V33 6.09 V63 3.80 V4 5.02 V34 2.41 V64 2.58 V5 7.78 V35 6.56 V133 0.39 V6 5.11 V36 6.20 V138 1.37 V7 3.00 V37 3.78 V147 5.34 V8 1.86 V38 5.95 V9 3.26 V39 7.66 V10 4.98 V40 2.70 V11 3.68 V41 2.23 V12 7.08 V42 4.02 V13 4.99 V43 6.87 V14 8.14 V44 2.47 V15 4.52 V45 4.22 V16 4.02 V46 4.93 V17 7.00 V47 1.96 V18 6.98 V48 4.14 V19 4.51 V49 4.88 V20 4.82 V50 5.14 V21 4.34 V51 2.20 V22 5.10 V52 2.71 V23 4.43 V53 2.11 V24 6.24 V54 3.04 V25 6.29 V55 8.41 V26 5.16 V56 5.05 V27 5.45 V57 3.01 V28 4.87 V58 2.99 V29 2.95 V59 2.25 V30 5.83 V60 4.43 Table 12B. Alterations in the liver biodistribution of virions containing the indicated variant capsid polypeptides under the control of the CBh promoter. Ratios were calculated relative to V27 based on measurements from independent experiments, with linear shifts reported relative to wild-type AAV9. A value of "0" indicates that the variant was not detected in the indicated sample. Variant number Liver biodistribution Variant number Liver biodistribution Variant number Liver biodistribution V1 0.05 V31 0.07 V61 0.03 V2 0.03 V32 0.02 V62 0.00 V3 0.06 V33 0.05 V63 0.02 V4 0.02 V34 0.01 V64 0.00 V5 0.01 V35 0.01 V133 0.05 V6 0.04 V36 0.02 V138 0.03 V7 0.06 V37 0.06 V147 0.00 V8 0.01 V38 0.02 V9 0.05 V39 0.03 V10 0.03 V40 0.03 V11 0.04 V41 0.03 V12 0.03 V42 0.02 V13 0.03 V43 0.09 V14 0.02 V44 0.03 V15 0.02 V45 0.03 V16 0.02 V46 0.00 V17 0.07 V47 0.07 V18 0.02 V48 0.04 V19 0.02 V49 0.04 V20 0.04 V50 0.11 V21 0.01 V51 0.05 V22 0.01 V52 0.03 V23 0.07 V53 0.02 V24 0.01 V54 0.01 V25 0.03 V55 0.05 V26 0.01 V56 0.02 V27 0.02 V57 0.00 V28 0.05 V58 0.06 V29 0.01 V59 0.06 V30 0.01 V60 0.10 Table 12C. Variation in brain transduction of viral particles containing the indicated variant capsid polypeptides under the control of the CBh promoter. Ratios were calculated relative to V27 based on measurements from independent experiments, linear shifts were reported relative to wild-type AAV9. A value of "0" indicates that the variant was not detected in the indicated sample. Variant number Brain transduction Variant number Brain transduction Variant number Brain transduction V1 16.74 V31 4.95 V61 8.11 V2 13.86 V32 7.91 V62 0.00 V3 12.46 V33 10.51 V63 4.98 V4 9.78 V34 4.47 V64 3.61 V5 9.84 V35 11.62 V133 1.72 V6 11.67 V36 7.04 V138 1.37 V7 4.45 V37 6.36 V147 9.91 V8 3.33 V38 4.18 V9 4.32 V39 6.97 V10 8.09 V40 7.04 V11 4.86 V41 4.47 V12 8.31 V42 6.88 V13 9.96 V43 8.29 V14 11.79 V44 3.47 V15 8.21 V45 5.94 V16 6.00 V46 4.04 V17 6.92 V47 2.62 V18 5.11 V48 9.61 V19 8.61 V49 11.49 V20 6.81 V50 7.80 V21 7.76 V51 5.24 V22 7.28 V52 3.86 V23 6.27 V53 3.51 V24 10.71 V54 7.05 V25 10.22 V55 11.80 V26 6.66 V56 8.70 V27 9.04 V57 5.68 V28 7.93 V58 4.32 V29 8.54 V59 4.85 V30 8.59 V60 7.05 Table 12D. Variation in liver transduction of viral particles containing the indicated variant capsid polypeptides under the control of the CBh promoter. Ratios were calculated relative to V27 based on measurements from independent experiments, linear shifts were reported relative to wild-type AAV9. A value of "0" indicates that the variant was not detected in the indicated sample. Variant number Liver transduction Variant number Liver transduction Variant number Liver transduction V1 0.09 V31 0.12 V61 0.06 V2 0.07 V32 0.11 V62 0.00 V3 0.04 V33 0.18 V63 0.05 V4 0.07 V34 0.03 V64 0.00 V5 0.03 V35 0.05 V133 0.30 V6 0.10 V36 0.06 V138 0.02 V7 0.04 V37 0.14 V147 0.02 V8 0.04 V38 0.05 V9 0.07 V39 0.02 V10 0.12 V40 0.15 V11 0.11 V41 0.10 V12 0.03 V42 0.08 V13 0.13 V43 0.11 V14 0.03 V44 0.06 V15 0.05 V45 0.03 V16 0.03 V46 0.02 V17 0.11 V47 0.11 V18 0.00 V48 0.15 V19 0.12 V49 0.16 V20 0.10 V50 0.27 V21 0.05 V51 0.17 V22 0.04 V52 0.06 V23 0.04 V53 0.07 V24 0.02 V54 0.01 V25 0.06 V55 0.09 V26 0.01 V56 0.02 V27 0.05 V57 0.02 V28 0.17 V58 0.14 V29 0.01 V59 0.16 V30 0.02 V60 0.15 8.5. Example 5: In vivo evaluation of Bank 1 in marmosets 8.5.1. Materials and methods 8.5.1.1. Animal studies

All NHP experiments were conducted in accordance with institutional policy, federal regulations, and approval from the Institutional Animal Care and Use Committee. Three female common marmoset ( Callitrhix jacchus ) primates weighing 0.26 kg, 0.28 kg, and 0.23 kg were selected for study based on negative AAV neutralizing antibody serum titers. These animals received intravenous injections of 8.23e ¹³ vg/kg, 7.64e ¹³ vg/kg, or 9.3e ¹³ vg/kg of vector (including Bank 1). During the survival period, animals were monitored according to the institution's standard operating procedures, and blood was sampled at regular intervals for hematology and clinical chemistry. Animals were treated with methylprednisolone (10 mg/1 g IM) on day -7, day 0, and weekly throughout the study.

Four weeks after injection, animals were sacrificed and tissues were collected for biodistribution and transduction analysis. The collected tissues are shown in Table 13. Samples were quickly frozen in liquid nitrogen or collected into RNAlater® (Sigma-Aldrich) and incubated overnight at 4°C, after which the RNAlater® was drained and the samples were frozen at -80°C. Table 13. List of tissues collected and number of samples used for biodistribution and transduction analysis. organization Number of samples used for transduction analysis Number of samples used for biodistribution analysis brain twenty three twenty four liver 6 6 skeletal muscle 6 6 heart 6 6 spleen 6 6 8.5.1.2. Batch Sequencing NGS Library Preparation

For all biodistribution and transduction analyses, total DNA was extracted from tissue samples using the MagMAX DNA Multi-Sample Ultra 2.0 Kit (Thermofisher). Samples were first homogenized in the provided lysis buffer and then incubated with proteinase K at 65°C. Lysates were then added to plates for automated extraction using a KingFisher Apex instrument (Thermofisher). RNA was extracted using the MagMAX™ mirVana™ Total RNA Isolation Kit (Thermofisher) and further treated with DNase I-XT (New England Biolabs) to remove any vector DNA contamination from the RNA sample. Reverse transcription was performed using primers specific for the vector transgene and containing a unique molecular identifier (UMI) using Protoscript II Reverse Transcriptase (New England Biolabs). A control reaction lacking reverse transcriptase (-RT control) was also prepared. Finally, samples were prepared for next-generation sequencing by amplifying the transgenic barcode region using primers compatible with the Illumina NGS platform and sequenced using the NextSeq 2000 (Illumina). 8.5.1.3. Bulk Tissue NGS Sample Analysis and Analysis

After sequencing, barcode tags are extracted from reads with the expected amplicon structure, and the abundance (number of reads, number of UMIs, or number of unique ID tags) is recorded. To aggregate biodistribution samples, read counts are summed for samples from the same tissue or organ. To aggregate transduction samples, the number of transduction events (measured by the number of detected unique barcode and ID tag combinations) is summed for samples from the same tissue or organ.

Transduction and biodistribution rates were calculated by normalizing the aggregate transduction or biodistribution counts by input virus abundance. Rates are relative to AAV9 reporter. 8.5.2. Results

The biodistribution and transduction results of selected AAV capsid variants are summarized in Table 14A (brain biodistribution), Table 14B (liver biodistribution), Table 14C (brain transduction), and Table 14D (liver transduction).

AAV capsid variants were associated with increased biodistribution and transduction in brain samples relative to wild-type AAV9 (summarized in Tables 14A and 14C, respectively). None of the AAV capsid variants evaluated in this assessment were associated with increased biodistribution or transduction in liver tissue (summarized in Tables 14B and 14D, respectively), with the vast majority demonstrating significantly reduced biodistribution and transduction relative to wild-type AAV9. Table 14A . Changes in the biodistribution of virions containing the indicated variant capsid polypeptides relative to the biodistribution of virions containing WT AAV9 in brain tissue. Variant number Brain biodistribution Variant number Brain biodistribution Variant number Brain biodistribution V1 24.79 V33 12.20 V65 4.59 V2 15.50 V34 1.46 V67 1.14 V3 21.62 V35 16.70 V68 0.75 V4 4.97 V36 15.90 V69 2.78 V5 19.13 V37 16.13 V75 0.34 V7 7.43 V38 12.02 V76 1.77 V8 11.80 V39 7.89 V77 1.21 V9 7.40 V40 7.91 V82 0.99 V10 6.69 V41 7.48 V84 0.50 V11 9.12 V42 6.69 V85 0.08 V13 12.28 V43 17.13 V94 0.03 V14 15.36 V44 5.05 V101 0.07 V15 8.65 V45 5.16 V103 0.10 V16 4.78 V46 10.07 V105 0.91 V17 12.26 V47 5.45 V114 0.27 V18 20.32 V48 11.54 V118 2.02 V19 6.08 V49 10.95 V122 0.12 V20 6.66 V50 16.31 V125 0.03 V21 10.91 V51 7.96 V127 1.22 V22 30.15 V52 6.07 V133 0.09 V23 7.41 V53 11.07 V138 1.92 V24 13.47 V54 8.86 V139 1.38 V25 15.55 V55 9.89 V141 0.23 V26 7.74 V56 7.54 V142 0.55 V27 13.35 V57 9.82 V143 0.57 V28 7.26 V58 5.40 V29 6.85 V59 3.72 V30 8.71 V60 8.56 V31 9.41 V63 11.23 V32 5.87 V64 October 13th Table 14B . Changes in transduction of brain tissue by viral particles containing the indicated variant capsid polypeptides relative to transduction by viral particles containing WT AAV9. Variant number Brain transduction Variant number Brain transduction Variant number Brain transduction V1 118.16 V33 14.23 V65 9.99 V2 66.03 V34 4.03 V67 5.49 V3 53.88 V35 19.84 V68 2.28 V4 25.77 V36 21.65 V69 5.71 V5 62.59 V37 21.83 V75 14.45 V7 40.28 V38 16.65 V76 5.07 V8 18.26 V39 20.16 V77 2.08 V9 40.36 V40 6.57 V82 2.91 V10 15.15 V41 40.81 V84 8.51 V11 11.29 V42 32.34 V85 5.75 V13 16.63 V43 2019.18 V94 11.12 V14 55.54 V44 25.26 V101 3.26 V15 43.56 V45 27.68 V103 3.59 V16 73.25 V46 40.65 V105 3.76 V17 33.44 V47 11.30 V114 3.93 V18 59.75 V48 25.43 V118 1.87 V19 37.47 V49 20.69 V122 1.75 V20 27.55 V50 15.76 V125 4.87 V21 44.30 V51 24.55 V127 3.78 V22 40.09 V52 15.33 V133 3.47 V23 38.78 V53 20.22 V138 7.76 V24 60.53 V54 31.23 V139 5.20 V25 42.57 V55 33.62 V141 3.72 V26 49.39 V56 31.03 V142 7.77 V27 44.94 V57 32.10 V143 1.55 V28 26.92 V58 12.55 V29 38.23 V59 26.02 V30 31.84 V60 33.78 V31 28.73 V63 17.50 V32 14.11 V64 36.29 Table 14C . Changes in the biodistribution of virions containing the indicated variant capsid polypeptides relative to the biodistribution of virions containing WT AAV9 in liver tissue. Variant number Liver biodistribution Variant number Liver biodistribution Variant number Liver biodistribution V1 0.49 V33 0.37 V65 0.60 V2 0.39 V34 0.36 V67 0.34 V3 0.60 V35 0.14 V68 0.46 V4 0.25 V36 0.39 V69 0.44 V5 0.22 V37 0.46 V75 0.18 V7 0.14 V38 0.41 V76 0.42 V8 0.31 V39 0.23 V77 0.61 V9 0.46 V40 0.52 V82 0.40 V10 0.52 V41 0.28 V84 0.33 V11 0.92 V42 0.36 V85 0.28 V13 0.36 V43 0.25 V94 0.42 V14 0.17 V44 0.22 V101 0.47 V15 0.30 V45 0.22 V103 0.18 V16 0.14 V46 0.20 V105 0.43 V17 0.52 V47 0.23 V114 0.51 V18 0.14 V48 0.29 V118 0.49 V19 0.28 V49 0.31 V122 0.45 V20 0.34 V50 0.86 V125 0.37 V21 0.26 V51 0.41 V127 0.41 V22 0.41 V52 0.15 V133 0.45 V23 0.47 V53 0.39 V138 0.12 V24 0.31 V54 0.17 V139 0.08 V25 0.40 V55 0.26 V141 0.47 V26 0.16 V56 0.27 V142 0.31 V27 0.30 V57 0.05 V143 0.27 V28 0.30 V58 0.28 V29 0.12 V59 0.45 V30 0.05 V60 0.26 V31 0.35 V63 0.00 V32 0.18 V64 0.20 Table 14D . Changes in the biodistribution of viral particles containing the indicated variant capsid polypeptides relative to WT AAV9 transduction in liver tissue. A value of "0" indicates that the variant was not detected in the indicated sample. Variant number Liver transduction Variant number Liver transduction Variant number Liver transduction V1 0.61 V33 0.93 V65 0.00 V2 0.48 V34 0.00 V67 0.00 V3 0.47 V35 0.00 V68 0.60 V4 0.38 V36 0.38 V69 0.00 V5 1.31 V37 0.00 V75 0.00 V7 0.00 V38 0.00 V76 0.89 V8 0.00 V39 3.53 V77 0.36 V9 0.00 V40 1.44 V82 0.00 V10 0.00 V41 0.36 V84 0.37 V11 0.00 V42 0.20 V85 1.01 V13 0.00 V43 0.00 V94 0.97 V14 0.00 V44 0.00 V101 0.00 V15 0.48 V45 0.00 V103 0.63 V16 0.00 V46 0.40 V105 0.00 V17 1.67 V47 0.99 V114 1.03 V18 0.00 V48 0.89 V118 1.31 V19 0.94 V49 0.00 V122 0.00 V20 0.00 V50 0.00 V125 0.00 V21 0.32 V51 0.00 V127 0.00 V22 0.00 V52 0.00 V133 0.61 V23 0.00 V53 0.71 V138 0.00 V24 0.61 V54 0.00 V139 0.45 V25 0.68 V55 0.27 V141 0.00 V26 0.00 V56 0.00 V142 0.00 V27 0.34 V57 0.00 V143 0.81 V28 0.52 V58 0.55 V29 0.00 V59 1.14 V30 0.00 V60 0.49 V31 0.84 V63 0.31 V32 0.25 V64 0.00 9. Sequence Listing

Exemplary sequences herein are provided in Table 15 below, where SEQ = SEQ ID NO. Table 15 describe sequence SEQ AAV9 VP1 wild-type reference sequence (amino acids) MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 1 AAV9 VP1 wild-type reference sequence (nucleotides) ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGACCGGCTGGGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 2 AAV2 VP1 wild-type reference sequence (amino acids) MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPPKPAERHKDDSRGLVLPGYKYLGPFNGLDKGEPVNEADAAALEHDKAYDRQLDSGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRVLEPLGLVEEPVKTAPGKKRPVEHSPVEPDSSSSGTGKAGQQPARKRLNFGQTGDADSVP DPQPLGQPPAAPSGLGTNTMATGSGAPMADNNEGADGVGNSSGNWHCDSTWMGDRVITTSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPA DVFMVPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTNTPSGTTTQSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHLNGRDSLVNPGPAMASHKDDEEKFFPQSGVLIFGKQGSEKTN VDIEKVMITDEEEIRTTNPVATEQYGSVSTNLQRGNRQAATADVNTQGVLPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTTFSAAKFASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSVNVDFTVDTNGVYSEPRPIGTRYLTRNL 3 AAV2 VP1 wild-type reference sequence (nucleotides) ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACACTCTCTCTGAAGGAATAAGACAGTGGTGGAAGCTCAAACCTGGCCCACCACCACCAAAGCCCGCAGAGCGGCATAAGGACGACAGCAGGGGTCTTGTG CTTCCTGGGTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGAGAGCCGGTCAACGAGGCAGACGCCGCGGCCCTCGAGCACGACAAAGCCTACGACCGGCAGCTCGACAGCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCGGAGTTTCAGGAGCGCCTTAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGACGAGCAGTCTTCCAGGCGAAAAAGAGGGTTCTTGAACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACG GCTCCGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAGCCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCAGCCTGCAAGAAAAAGATTGAATTTTGGTCAGACTGGAGACGCAGACTCAGTACCTGAC CCCCAGCCTCTCGGACAGCCACCAGCAGCCCCCTCTGGTCTGGGAACTAATACGATGGCTACAGGCAGTGGCGCACCAATGGCAGACAATAACGAGGGCGCCGACGGAGTGGGTAATTCCTCGGGAAATTGGCATTGC GATTCCACATGGATGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAACCACCTCTACAAACAAATTTCCAGCCAATCAGGAGCCTCGAACGACAATCACTACTTTGGCTACAGC ACCCCTTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAAAGACTCATCAACAACAACTGGGGATTCCGACCCAAGAGACTCAACTTCAAGCTCTTTAACATTCAAGTCAAAGAG GTCACGCAGAATGACGGTACGACGACGATTGCCAATAACCTTACCAGCACGGTTCAGGTGTTTACTGACTCGGAGTACCAGCTCCCGTACGTCCTCGGCTCGGCGCATCAAGGATGCCTCCCGCCGTTCCCAGCAGAC GTCTTCATGGTGCCACAGTATGGATACCTCACCCTGAACAACGGGAGTCAGGCAGTAGGACGCTCTTCATTTTACTGCCTGGAGTACTTTCCTTCTCAGATGCTGCGTACCGGAAACAACTTTACCTTCAGCTACACT TTTGAGGACGTTCCTTTCCACAGCAGCTACGCTCACAGCCAGAGTCTGGACCGTCTCATGAATCCTCTCATCGACCAGTACCTGTATTACTTGAGCAGAACAAACACTCCAAGTGGAACCACCACGCAGTCAAGGCTT CAGTTTTCTCAGGCCGGAGCGAGTGACATTCGGGACCAGTCTAGGAACTGGCTTCCTGGACCCTGTTACCGCCAGCAGCGAGTATCAAAGACATCTGCGGATAACAACAACAGTGAATACTCGTGGACTGGAGCTACC AAGTACCACCTCAATGGCAGAGACTCTCTGGTGAATCCGGGCCCGGCCATGGCAAGCCACAAGGACGATGAAGAAAAGTTTTTTCCTCAGAGCGGGGTTCTCATCTTTGGGAAGCAAGGCTCAGAGAAAACAAATGTG GACATTGAAAAGGTCATGATTACAGACGAAGAGGAAATCAGGACAACCAATCCCGTGGCTACGGAGCAGTATGGTTCTGTATCTACCAACCTCCAGAGAGGCAACAGACAAGCAGCTACCGCAGATGTCAACACACAA GGCGTTCTTCCAGGCATGGTCTGCAGGACAGAGATGTGTACCTTCAGGGGCCCATCTGGGCAAAGATTCCACACACGGACGGACATTTTCACCCCTCTCCCCTCCATGGGTGGATTCGGACTTAAACACCCTCCTCCA CAGATTCTCATCAAGAACACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGTGCGGCAAAGTTTGCTTCCTTCATCACACAGTACTCCACGGGACAGGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAAC AGCAAACGCTGGAATCCCGAAATTCAGTACACTTCCAACTACAACAAGTCTGTTAATGTGGACTTTACTGTGGACACTAATGGCGTGTATTCAGAGCCTCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 4 AAV5 VP1 wild-type reference sequence (amino acids) MSFVDHPPDWLEEVGEGLREFLGLEAGPPKPKPNQQHQDQARGLVLPGYNYLGPGNGLDRGEPVNRADEVAREHDISYNEQLEAGDNPYLKYNHADAEFQEKLADDTSFGGNLGKAVFQAKKRVLEPFGLVEEGAKTAPTGKRIDDHFPKRKKARTEEDSKPSTSSDAEAGPSGSQQLQIP AQPASSLGADTMSAGGGGPLGDNNQGADGVGNASGDWHCDSTWMGDRVVTKSTRTWVLPSYNNHQYREIKSGSVDGSNANAYFGYSTPWGYFDFNRFHSHWSPRDWQRLINNYWGFRPRSLRVKIFNIQVKEVTVQDSTTTIANNLTSTVQVFTDDDYQLPYVVGNGTEGCLPAFPPQVFT LPQYGYATLNRDNTENPTERSSFCLEYFPSKMLRTGNNFEFTYNFEEVPFHSSFAPSQNLFKLANPLVDQYLYRFVSTNNTGGVQFNKNLAGRYANTYKNWFPGPMGRTQGWNLGSGVNRASVSAFATTNRMELEGASYQVPPQPNGMTNNLQGSNTYALENTMIFNSQPANPGTTATYL EGNMLITSESETQPVNRVAYNVGGQMATNNQSSTTAPATGTYNLQEIVPGSVWMERDVYLQGPIWAKIPETGAHFHPSPAMGGFGLKHPPPMMLIKNTPVPGNITSFSDVPVSSFITQYSTGQVTVEMEWELKKENSKRWNPEIQYTNNYNDPQFVDFAPDSTGEYRTTRPIGTRYLTRPL 5 AAV5 VP1 wild-type reference sequence (nucleotides) ATGTCTTTTGTTGATCACCCTCCAGATTGGTTGGAAGAAGTTGGTGAAGGTCTTCGCGAGTTTTTGGGCCTTGAAGCGGGCCCACCGAAACCAAAACCCAATCAGCAGCATCAAGATCAAGCCCGTGGTCTTGTG CTGCCTGGTTATAACTATCTCGGACCCGGAAACGGGCTCGATCGAGGAGAGCCTGTCAACAGGGCAGACGAGGTCGCGCGAGAGCACGACATCTCGTACAACGAGCAGCTTGAGGCGGGAGACAACCCCTACCTCA AGTACAACCACGCGGACGCCGAGTTTCAGGAGAAGCTCGCCGACGACACATCCTTCGGGGGAAACCTCGGAAAGGCAGTCTTTCAGGCCAAGAAAAGGGTTCTCGAACCTTTTGGCCTGGTTGAAGAGGGTGCTAA GACGGCCCCTACCGGAAAGCGGATAGACGACCACTTTCCAAAAAGAAAGAAGGCTCGGACCGAAGAGGACTCCAAGCCTTCCACCTCGTCAGACGCCGAAGCTGGACCCAGCGGATCCCAGCAGCTGCAAATCCCA GCCCAACCAGCCTCAAGTTTGGGAGCTGATACAATGTCTGCGGGAGGTGGCGGCCCATTGGGCGACAATAACCAAGGTGCCGATGGAGTGGGCAATGCCTCGGGAGATTGGCATTGCGATTCCACGTGGATGGGGG ACAGAGTCGTCACCAAGTCCACCGAACCTGGGTGCTGCCCAGCTACAACAACCACCAGTACCGAGAGATCAAAAGCGGCTCCGTCGACGGAAGCAACGCCAACGCCTACTTTGGATACAGCACCCCCTGGGGGTA CTTTGACTTTAACCGCTTCCACAGCCACTGGAGCCCCCGAGACTGGCAAAGACTCATCAACAACTACTGGGGCTTCAGACCCCGGTCCCTCAGAGTCAAAATCTTCAACATTCAAGTCAAAGAGGTCACGGTGCAG GACTCCACCACCACCATCGCCAACAACCTCACCTCCACCGTCCAAGTGTTTACGGACGACGACTACCAGCTGCCCTACGTCGTCGGCAACGGGACCGAGGGATGCCTGCCGGCCTTCCCTCCGCAGGTCTTTACGC TGCCGCAGTACGGTTACGCGACGCTGAACCGCGACAACAGAAATCCCACCGAGAGGAGCAGCTTCTTCTGCCTAGAGTACTTTCCCAGCAAGATGCTGAGAACGGGCAACAACTTTGAGTTTACCTACAACTT TGAGGAGGTGCCCTTCCACTCCAGCTTCGCTCCCAGTCAGAACCTGTTCAAGCTGGCCAACCCGCTGGTGGACCAGTACTTGTACCGCTTCGTGAGCACAAATAACACTGGCGGAGTCCAGTTCAACAAGAACCTG GCCGGGAGATACGCCAACACCTACAAAAACTGGTTCCCGGGGCCCATGGGCCGAACCCAGGGCTGGAACCTGGGCTCCGGGGTCAACCGCGCCAGTGTCAGCGCCTTCGCCACGACCAATAGGATGGAGCTCGAGG GCGCGAGTTACCAGGTGCCCCCGCAGCCGAACGGCATGACCAACAACCTCCAGGGCAGCAACACCTATGCCCTGGAGAACACTATGATCTTCAACAGCCAGCCGGCGAACCCGGGCACCACCGCCACGTACCTCGA GGGCAACATGCTCATCACCAGCGAGAGCGAGACGCAGCCGGTGAACCGCGTGGCGTACAACGTCGGCGGGCAGATGGCCACCAACAACCAGAGCTCCACCACTGCCCCCGCGACCGGCACGTACAACCTCCAGGAA ATCGTGCCCGGCAGCGTGTGGATGGAGAGGGACGTGTACCTCCAAGGACCCATCTGGGCCAAGATCCCAGAGACGGGGGCGCACTTTCACCCCTCTCCGGCCATGGGCGGATTCGGACTCAAACACCCACCGCCCA TGATGCTCATCAAGAACACGCCTGTGCCCGGAAATATCACCAGCTTCTCGGACGTGCCCGTCAGCAGCTTCATCACCCAGTACAGCACCGGGCAGGTCACCGTGGAGATGGAGTGGGAGCTCAAGAAGGAAAACTC CAAGAGGTGGAACCCAGAGATCCAGTACACAAACAACTACAACGACCCCCAGTTTGTGGACTTTGCCCCGGACAGCACCGGGGAATACAGAACCACCAGACCTATCGGAACCCGATACCTTACCCGACCCCTTTAA 6 AAV8 VP1 wild-type reference sequence (amino acids) MAADGYLPDWLEDNLSEGIREWWALKPGAPPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEPSPQRSPDSSTGIGKKGQQPARKRLNFGQTGDSESVP DPQPLGEPPAAPSGVGPNTMAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGATNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLSFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFP ADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFQFTYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTGGTANTQTLGFSQGGPNTMANQAKNWLPGPCYRQQRVSTTTGQNNNSNFAWTAGTKYHLNGRNSLANPGIAMATHKDDEERFFPSNGILIFGKQNAARD NADYSDVMLTSEEEIKTTNPVATEEYGIVADNLQQQNTAPQIGTVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQSKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTSVDFAVNTEGVYSEPRPIGTRYLTRNL 7 AAV8 VP1 wild-type reference sequence (nucleotides) ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTGGGCGCTGAAACCTGGAGCCCCGAAGCCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGGTG CTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGGCGGCGGACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTGCAGGCGGGTGACAATCCGTACCTGCGGT ATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCTAAGACGG CTCCTGGAAAGAAGAGACCGGTAGAGCCATCACCCCAGCGTTCTCCAGACTCCTCTACGGGCATCGGCAAGAAAGGCCAACAGCCCGCCAGAAAAAGACTCAATTTTGGTCAGACTGGCGACTCAGAGTCAGTTCCAGA CCCTCAACCTCTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTGGGACCTAATACAATGGCTGCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCGGGAAATTGGCATTG CGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAACCTCTACAAGCAAATCTCCAACGGGACATCGGGAGGAGCCACCAACGACAACACCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCAGCTTCAAGCTCTTCAACATCCAGGTC AAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTCACCAGCACCATCCAGGTGTTTACGGACTCGGAGTACCAGCTGCCGTACGTTCTCGGCTCTGCCCACCAGGGCTGCCTGCCTCCGTTCCCGG CGGACGTGTTCATGATTCCCCAGTACGGCTACCTAACACTCAACAACGGTAGTCAGGCCGTGGGACGCTCCTCCTTCTACTGCCTGGAATACTTTCCTTCGCAGATGCTGAGAACCGGCAACAACTTCCAGTTTACTT ACACCTTCGAGGACGTGCCTTTCCACAGCAGCTACGCCCACAGCCAGAGCTTGGACCGGCTGATGAATCCTCTGATTGACCAGTACCTGTACTACTTGTCTCGGACTCAAACAACAGGAGGCACGGCAAATACGCAGAC TCTGGGCTTCAGCCAAGGTGGGCCTAATACAATGGCCAATCAGGCAAAGAACTGGCTGCCAGGACCCTGTTACCGCCAACAACGCGTCTCAACGACAACCGGGCAAAACAACAATAGCAACTTTGCCTGGACTGCTGG GACCAAATACCATCTGAATGGAAGAAATTCATTGGCTAATCCTGGCATCGCTATGGCAACACACAAAGACGACGAGGAGCGTTTTTTTCCCAGTAACGGGATCCTGATTTTTGGCAAACAAAATGCTGCCAGAGACAAT GCGGATTACAGCGATGTCATGCTCACCAGCGAGGAAGAAATCAAAACCACTAACCCTGTGGCTACAGAGGAATACGGTATCGTGGCAGATAACTTGCAGCAGCAAAACACGGCTCCTCAAATTGGAACTGTCAACAGC CAGGGGGCCTTACCCGGTATGGTCTGGCAGAACCGGGACGGTACCTGCAGGGTCCCATCTGGGCCAAGATTCCTCACACGGACGGCAACTTCCACCCGTCTCCGCTGATGGGCGGCTTTGGCCTGAAACATCCTCCGC CTCAGATCCTGATCAAGAACACGCCTGTACCTGCGGATCCTCCGACCACCTTCAACCAGTCAAAGCTGAACTCTTTCATCACGCAATACAGCACCGGACAGGTCAGCGTGGAAATTGAATGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCCGAGATCCAGTACACCTCCAACTACTACAAATCTACAAGTGTGGACTTTGCTGTTAATACAGAAGGCGTGTACTCTGAACCCCGCCCCATTGGCACCCGTTACCTCACCCGTAATCTGTAA 8 AAVrh74 VP1 wild-type reference sequence (amino acids) MAADGYLPDWLEDNLSEGIREWWDLKPGAPPKPKANQQKQDNGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVESPVKTAPGKKRPVEPSPQRSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVP DPQPIGEPPAGPSGLGSGTMAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFP ADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEERFFPSSGVLMFGKQGAGKD NVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNAAPIVGAVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQAKLASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLTRNL 9 AAVrh74 VP1 wild-type reference sequence (nucleotides) ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTGGGACCTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACAACGGCCGGGGTCTGGTG CTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGGCGGCGGACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCCAAGCGGGTGACAATCCGTACCTGCGGT ATAATCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGCGCAGTCTTCCAGGCCAAAAAGCGGGTTCTCGAACCTCTGGGCCTGGTTGAATCGCCGGTTAAGACGG CTCCTGGAAAGAAGAGGCCGGTAGAGCCATCACCCCAGCGCTCTCCAGACTCCTCTACGGGCATCGGCAAGAAAGGCCAGCAGCCCGCAAAAAAGAGACTCAATTTTGGGCAGACTGGCGACTCAGAGTCAGTCCCCGA CCCTCAACCAATCGGAGAACCACCAGCAGGCCCCTCTGGTCTGGGATCTGGTACAAATGGCTGCAGGCGGTGGCGCTCCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCAGGAAATTGGCATTG CGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGCACCTGGGCCCTGCCCACCTACAACAACCTCTACAAGCAAATCTCCAACGGGACCTCGGGAGGAAGCACCAACGACAACACCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGGCTCAACTTCAAGCTCTTCAACATCCAAGTC AAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTTACCAGCACGATTCAGGTCTTTACGGACTCGGAATACCAGCTCCCGTACGTGCTCGGCTCGGCGCACCAGGGCTGCCTGCCTCCGTTCCCGG CGGACGTCTTCATGATTCCTCAGTACGGGTACCTGACTCTGAACAATGGCAGTCAGGCTGTGGGCCGGTCGTCCTTCTACTGCCTGGAGTACTTTCCTTCTCAAATGCTGAGAACGGGCAACAACTTTGAATTCAGCT ACAACTTCGAGGACGTGCCCTTCCACAGCAGCTACGCGCACAGCCAGAGCCTGGACCGGCTGATGAACCCTCTCATCGACCAGTACTTGTACTACCTGTCCCGGACTCAAAGCACGGGCGGTACTGCAGGAACTCAGCA GTTGCTATTTTCTCAGGCCGGGCCTAACAACATGTCGGCTCAGGCCAAGAACTGGCTACCCGGTCCCTGCTACCGGCAGCAACGTGTCTCCACGACACTGTCGCAGAACAACAGCAACTTTGCCTGGACGGGTGC CACCAAGTATCATCTGAATGGCAGAGACTCTCTGGTGAATCCTGGCGTTGCCATGGCTACCCACAAGGACGACGAAGAGCGATTTTTCCATCCAGCGGAGTCTTAATGTTTGGGAAACAGGGAGCTGGAAAAGACAAC GTGGACTATAGCAGCGTGATGCTAACCAGCGAGGAAGAAATAAAGACCACCAACCCAGTGGCCACAGAACAGTACGGCGTGGTGGCCGATAACCTGCAACAGCAAAACGCCGCTCCTATTGTAGGGGCCGTCAATAGT CAAGGAGCCTTACCTGGCATGGTGTGGCAGAACCGGGACGGTACCTGCAGGGTCCCATCTGGGCCAAGATTCCTCATACGGACGGCAACTTTCATCCCTCGCCGCTGATGGGAGGCTTTGGACTGAAGCATCCGCCTC CTCAGATCCTGATTAAAAACACACCTGTTCCCGCGGATCCTCCGACCACCTTCAATCAGGCCAAGCTGGCTTCTTTCATCACGCAGTACAGTACCGGCCAGGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAGAA CAGCAAACGCTGGAACCCAGAGATTCAGTACACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTCAATACTGAGGGTACTTATTCCGAGCCTCGCCCCATTGGCACCCGTTACCTCACCCGTAATCTGTAA 10 AAVrh74 VP1 wild-type alternative reference sequence (amino acids) 11 V1 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNAQSAQAQAVSMQIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 12 V2 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNTQSIQAQAVSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 13 V3 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVAITNEEEIKTTNPVATESYGQVATNLQSAQAQAVSMQIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 14 V4 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMNNQSILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 15 V5 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEPYGSVAVNHQSTQAQAVSMSNQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 16 V6 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTVNPVATESYGQVATNHQSAQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 17 V7 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGLVSTNHQSAQAQAVSMQIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 18 V8 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITVEEEIKTTNPVATESYGQVATNTQSAQAQAVSMIIQAQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 19 v9 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTKRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 20 V10 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL twenty one V11 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVAITNEEEIKTTNPVATEPYGQVATNHQSAQAQAVSMTWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL twenty two V12 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADNVMITNEEEIKTTNPVATESYGQVATNTQSAQAQAVSMKIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL twenty three V13 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEMYGQVATNHQSAQAQAVSMQQQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL twenty four V14 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEPYGYVATNHQSTQAQAVSMSLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 25 V15 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVCITNEEEIKTTNPVATESYGQVATSTQSAQAQAVSMKIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 26 V16 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVIITNEEEIKTTNPVATESYGQVATSTQSAQAQAVSMKIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 27 V17 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSTQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 28 V18 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTNRDN VDADKVNITNEEEIKTTNPVATESYGQVAVNHQSAQAQAVSMAIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 29 V19 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMQNQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 30 V20 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSNQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 31 V21 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQVQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 32 V22 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATSTQSAVTQAVSMKIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 33 V23 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGVDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 34 V24 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVAVNHQSAQAQAVSMSGQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 35 V25 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSANTQAVSMQWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 36 V26 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGGDN VDADKVMITNEEEIKTTNPVATESYGQVATNLQSAQAQAVSMQWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 37 V27 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAVSMTMLNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 38 V28 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSPQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 39 V29 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTHRDD VDADKVMITNEEEIKTTNPVATESYGQCATNNQSAQAQAVSMKWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 40 V30 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADNVFITNEEEIKTTNPVATESYGQVATSHQSAQAQAVSMQWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 41 V31 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVAMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 42 V32 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNNQSAQAQAVSMTMQNVGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 43 V33 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNTQSAQAQAVSMTMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 44 V34 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGCVATNIQSAQAQAVSMKWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 45 V35 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNTQSAQAQAVSMMMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 46 V36 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVNITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 47 V37 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDH VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 48 V38 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADLVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 49 V39 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVCITNEEEIKTTNPVATESWGQVATNLQSAQAQAVSMKLQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 50 V40 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSTQSQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 51 V41 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGKDN VDADKVMITNEEEIKTTNPVATEPYGQVATNHQSAQAQAVSMTWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 52 V42 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN ADADKVMITTEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 53 V43 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATSAQSAQAQAVSMMIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 54 V44 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQNQNLGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 55 V45 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATSHQSAQAQAVSMQQQNCGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 56 V46 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVYITNEEEIKTTNPVATESWGNVATNTQSAQAQAVSMMMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 57 V47 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAVSMQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 58 V48 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEPYGQVATNMQSTQAQAVSMSLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 59 V49 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNFQSAQAQAVSMTLQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 60 V50 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEPYGQVATNAQSTQAQAVSMSLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 61 V51 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 62 V52 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSMQGTNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 63 V53 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGGDN VDADKVMITNEEEIKTTNPVATEPYGQVATNHQSAQAQAVSMTWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 64 V54 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNNQSAQAQAVSMQWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 65 V55 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVAITNEEEIKTTNPVATESYGQVATSAQSAQAQAVSMQIQNCGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 66 V56 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADNVVITNEEEIKTTNPVATESYGQVATSHQSAQAQAVSMQWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 67 V57 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGGDN VDADKVMITNEEEIKTTNPVATESYGQVATNNQSAQAQAVSMQWQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 68 V58 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNMQSAQAQAVSMVMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 69 V59 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNIQSAQAQAVSMTVQNLGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 70 V60 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVAITNEEEIKTTNPVATESYGQVATSTQSAQAQAVSMFVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 71 V61 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGTVATNHQSAQAQAVSMQWQTQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 72 V62 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNTEEIKTTNPVATESYGQVATSLQSAQAQAVSMKVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 73 V63 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVAVSHQSAQNQAVSMTLQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 74 V64 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVCITNEEEIKTTNPVATESYGQVATNMQSAQAQAVSMKWQNQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPP PQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 75 V65 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVAMTIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 76 V66 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVAMQVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 77 V67 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTDRDN VDADKVMITNEEEIKTTNPVATESYGQVATSHQSAQAQAVAMTMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 78 V68 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVAMTMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 79 V69 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATSHQSAQAQAVAMTLQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 80 V70 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAVAMTMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 81 V71 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGMVATNHQSAQAQAVAMNAQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 82 V72 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEWYGQVATNHQSAQAQAVAMTMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 83 V73 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAVAMSMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 84 V74 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNHQSAQAQAVAMNMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 85 V75 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQQQSVAMNVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 86 V76 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQQTQTQAVAMNVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 87 V77 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNTQSAQAQAVSTQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 88 V78 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSTQNNNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 89 V79 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAVSTQMQAQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 90 V80 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSTQAQAVSTTAQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 91 V81 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNNQSAQAQAVSTQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 92 V82 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNMQSAQTQAVSTSMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 93 V83 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAVSTQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 94 V84 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSANTQAVSTTNNSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 95 V85 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNNQSAQAQAVSTGVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 96 V86 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAVSTQNNNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 97 V87 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNLQSAQAQAVSTGIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 98 V88 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSSTTQAVSTQHQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 99 V89 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAVSTQIQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 100 V90 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNLQSAQAQAVSTGVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 101 V91 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATSHQSAQAQAVSTEMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 102 V92 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSTSMQNQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 103 V93 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSTQAQAVSTQMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 104 V94 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAGTQAVSTQMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 105 V95 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSTQNQNQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 106 V96 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVNITNEEEIKTTNPVATESYGSVATNHQSTQSQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 107 V97 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESMGSVATSHQSTQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 108 V98 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGLDN VDADKVSITNEEEIKTTNPVATESYGSVATNHQSAQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 109 V99 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNHQQAQAQSMTMNSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 110 V100 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNHQSANAQAQSMNNQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 111 V101 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNHQSAQAQAQSMTNQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 112 V102 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTVRDN VDADKVMITNEEEIKTTNPVATESYGVVATNHQSTQAQAQSMALQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 113 V103 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGSDN VDADKVMITNEEEIKTTNPVATESYGSVCTNHQSIQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 114 V104 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQSMQGQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 115 V105 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGNVATNHQSSQAQAQSMNMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 116 V106 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTMRDN VDADKVSITNEEEIKTTNPVATESYGQVATNHQSAQAQAQSMNMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 117 V107 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDIDKVSITNEEEIKTTNPVATESYGSVATNHQSAQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 118 V108 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESFGSVATNHQSAQAQAQSMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 119 V109 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAQSMNMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 120 V110 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAQSMVMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 121 V111 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVSITNEEEIKTTNPVATESYGSVATNHQSAQAQAQSMQMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 122 V112 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTQAQSMSMQAQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 123 V113 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVYITNEEEIKTTNPVATESYGSVATNHQSTQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 124 V114 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTSRDN VDADKVMITNEEEIKTTNPVATESYGSVAQNHQSIQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 125 V115 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVCMNHQSIQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 126 V116 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGADN VDADKVYITNEEEIKTTNPVATESYGSVATNHQSIQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 127 V117 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMISNEEEIKTTNPVATESYGSVCTNNQSIQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 128 V118 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVSITNEEEIKTTNPVATESYGTVATNHQSAQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 129 V119 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSSNAQAQSMQNQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 130 V120 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVFITNEEEIKTTNPVATESYGSVATNHQSAQAQAQSMNMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 131 V121 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDL VDADKVSITNEEEIKTTNPVATESYGSVATNHQSAQAQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 132 V122 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEQYGSVATNHQSAQAQAQSMTMQTQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 133 V123 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTDRDN VDADKVMITNEEEIKTTNPVATESYGSVATNHQSAQAQAQSMQMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 134 V124 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSTNAQAVQMAMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 135 V125 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVQMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 136 V126 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSTQAQAVQMAMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 137 V127 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNTQSAQAQAVQMAMQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 138 V128 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEWYGQVATNHQSAQAQAVQMTIQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 139 V129 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSGKVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 140 V130 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAVSGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 141 V131 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATSHQSAQAQAVSGKVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 142 V132 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGTVATNHQSAQAQAVTMSMQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 143 V133 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNHQQAQTQAVTMNVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 144 V134 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQSVTMNNQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 145 V135 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGTVATNHQSAQAQAVTMNNQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 146 V136 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGTVATNHQSAQAQAVTMNLQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 147 V137 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGSVATNHQSAQAQAVTMNNQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 148 V138 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESWGNVATNAQSTQTQAVSMKLQNQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPP PQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 149 V139 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGGDN VDADKVMITNEEEIKTTNPVATESWGNVATNNQSTQTQAVSMKLQNQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPP PQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 150 V140 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESWGNVATNNQSTQTQAVSMKLQNQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPP PQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 151 V141 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEELKTTNPVATEPYGSVATNHQSTQAQAVSMSNQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 152 V142 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGREN VDADKVMITNEEEIKTTNPVATEPYGSVATNHQSTQAQAVSMSNQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 153 V143 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEQYGSVSTNHQSGQAQAVSMSMQNQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 154 V144 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATEPYGSVATNHQSTGAQAVSMSNQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 155 V145 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVTITNEEEIKTTNPVATESYGSVATNHQSTQSQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 156 V146 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVSITNEEEIKTTNPVATESYGSVATNHQSTQSQAQSMTLQSQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 157 V147 (amino acid) sequence MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGTVATNNQSAQAQAVSMMLQSQGVLPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL 158 V1 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACGCTCAGAGTGCCCAAGCACAGGCGGTAAGTATGCAGATCCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 159 V2 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGTGTGGCCACAAACACCCAGAGTATACAAGCACAGGCGGTCAGTATGACACTACAATCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 160 V3 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCGCGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACTTACAGAGTGCCCAAGCACAGGCGGTGTCAATGCAAATACAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 161 V4 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTCAGCATGCAGATGAATAACCA AAGCATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 162 V5 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCCTATGGAAGCGTGGCCGTAAACCACCAGAGTACCCAAGCACAGGCGGTGTCAATGTCTAACCAATCTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 163 V6 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTGTGAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTATCCATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 164 V7 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATTAGTGAGCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGTCAATGCAAATACAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 165 V8 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCGTGGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACACGCAGAGTGCCCAAGCACAGGCGGTGTCTATGATCATCCAAGCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 166 v9 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTAAGAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTAAGCATGCAAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 167 V10 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGTCGATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 168 V11 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCGCGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTAAGCATGACGTGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 169 V12 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAACGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACACTCAGAGTGCCCAAGCACAGGCGGTTAGTATGAAAATCCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 170 V13 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGATGTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGAGCATGCAACAACAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 171 V14 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCATATGGATACGTGGCCACAAACCACCAGAGTACTCAAGCACAGGCGGTAAGTATGTCCCTTCAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 172 V15 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCTGTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACATCGACCCAGAGTGCCCAAGCACAGGCGGTGTCAATGAAGATACAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 173 V16 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACATCGACGCAGAGTGCCCAAGCACAGGCGGTGTCAATGAAGATTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 174 V17 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTACGCAAGCACAGGCGGTATCGATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 175 V18 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTAACAGAGACAACGT GGATGCGGACAAAGTCAATATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCGTGAACCACCAGAGTGCCCAAGCACAGCCGGTTAGCATGGCCATCCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 176 V19 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTTAGTATGCAGATGCAAAACCA AGGAGTTCTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 177 V20 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTAATCAAGCACAGGCGGTGAGTATGCAAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 178 V21 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGTGCAGGCGGTGAGCATGCAAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 179 V22 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACATCGACCCAGAGTGCCGTAACGCAGGCGGTATCCATGAAAATACAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 180 V23 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAGTGGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGCGGTGAGCATGCAAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 181 V24 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCGTCAACCACCAGAGTGCCCAAGCACAGGCGGTCAGCATGTCAGGACAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 182 V25 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCAATACACAGGCGGTTAGTATGCAGTGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 183 V26 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAGGCGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACTTGCAGAGTGCCCAAGCACAGGCGGTCAGCATGCAGTGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 184 V27 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACCCAGGCGGTCAGTATGACTATGTTAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 185 V28 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTCCACAAGCACAGGCGGTATCGATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 186 V29 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTCACAGGGACGATGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAATGTGCCACAAACAATCAGAGTGCCCAAGCACAGGCTGTCTCGATGAAATGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 187 V30 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAATGTCTTTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAGCCACCAGAGTGCCCAAGCACAGCGGTGAGCATGCAGTGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 188 V31 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTAGCCATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 189 V32 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAACAACCAGAGTGCCCAAGCACAGGCGGTATCGATGACAATGCAAAACGT GGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 190 V33 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACACAGAGTGCCCAAGCACAGGCGGTATCAATGACTATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 191 V34 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATGTGTGGCCACAAAACATCCAGAGTGCCCAAGCACAGGCGGTGTCAATGAAATGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 192 V35 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACACAGAGTGCCCAAGCACAGGCGGTATCAATGATGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 193 V36 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCAACATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGTCTATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 194 V37 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGACGTGACCACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTTTCGATGCAAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 195 V38 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACCTGGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTAAGTATGCAAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 196 V39 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCTGTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTGGGGACAAGTGGCCACAAACCTTCAGAGTGCCCAAGCACAGGCGGTCAGCATGAAACTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 197 V40 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTACACAATCGCAGGCGGTAAGTATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 198 V41 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAAAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGTCGATGACCTGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 199 V42 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGC AGATGCGGACAAAGTCATGATAACCACTGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTCAGTATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 200 V43 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACATCTGCACAGAGTGCCCAAGCACAGGCGGTGTCAATGATGATCCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 201 V44 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCTGTCTCTATGCAGAACCAAAACCT GGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 202 V45 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACATCGCACCAGAGTGCCCAAGCACAGGCGGTTTCTATGCAGCAACAAAACTG TGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 203 V46 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCTATATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTGGGGAAACGTGGCCACAAACACCCAGAGTGCCCAAGCACAGGCGGTATCTATGATGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 204 V47 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACACAGGCGGTGTCGATGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 205 V48 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCTTATGGACAAGTGGCCACAAAACATGCAGAGTACTCAAGCACAGGCGGTGAGCATGTCATTGCAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 206 V49 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACTTCCAGAGTGCCCAAGCACAGGCGGTTAGTATGACACTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 207 V50 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCTTATGGACAAGTGGCCACAAACGCCCAGAGTACTCAAGCACAGGCGGTGTCCATGTCTCTCCAATCTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 208 V51 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTCAGCATGACCTTACAATCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 209 V52 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGAGCATGCAAGGTACAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 210 V53 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAGGTGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCGTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGTGTCTATGACTTGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 211 V54 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAACAACCAGAGTGCCCAAGCACAGGCGGTATCGATGCAGTGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 212 V55 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCGCAATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAGTGCCCAGAGTGCCCAAGCACAGCGGTTAGCATGCAAATACAAAACTG CGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 213 V56 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAACGTCGTAATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAGTCACCAGAGTGCCCAAGCACAGGCGGTTTCAATGCAATGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 214 V57 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAGGTGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAACAACCAGAGTGCCCAAGCACAGGCTGTCTCCATGCAATGGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 215 V58 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACATGCAGAGTGCCCAAGCACAGGCGGTAAGCATGGTAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 216 V59 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACATCCAGAGTGCCCAAGCACAGGCGGTATCAATGACGGTTCAAAACTT AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 217 V60 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCGCTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAGCACCCAGAGTGCCCAAGCACAGGCGGTTTCTATGTTCGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 218 V61 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAACAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTATCAATGCAGTGGCAAACCCA AGGAGTTCTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 219 V62 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACACCGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACATCTCTCCAGAGTGCCCAAGCACAGGCGGTATCAATGAAAGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 220 V63 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCGTGAGCCACCAGAGTGCCCAAAATCAGGCGGTTTCGATGACGCTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 221 V64 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCTGTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACATGCAGAGTGCCCAAGCACAGGCGGTATCGATGAAGTGGCAAAACCA AGGAGTCCTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 222 V65 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTCGCCATGACATTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 223 V66 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTTGCAATGCAAGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 224 V67 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGACAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACATCCCACCAGAGTGCCCAAGCACAGGCGGTAGCGATGACCATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 225 V68 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTCGCGATGACCATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 226 V69 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACATCTCACCAGAGTGCCCAAGCACAGGCGGTCGCCATGACCCTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 227 V70 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACGCAGGCGGTTGCGATGACAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 228 V71 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAATGGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTTGCTATGAATGCACAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 229 V72 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTGGTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGGCTATGACCATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 230 V73 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACACAGGCGGTCGCTATGTCAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 231 V74 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCTGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGGCTATGAACATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 232 V75 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAACAGCAGTCGGTTGCCATGAACGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 233 V76 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGCAGACGCAAACTCAGGCGGTGGCCATGAATGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 234 V77 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACACGCAGAGTGCCCAAGCACAGGCGGTGAGTACGCAAATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 235 V78 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGTGTCTACCCAAAATAACAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 236 V79 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACCCAGGCGGTTTCAACACAGATGCAAGCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 237 V80 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTACGCAAGCACAGGCGGTAAGTACAACGGCCCAATCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 238 V81 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAACAACCAGAGTGCCCAAGCACAGGCGGTGTCCACCCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 239 V82 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACATGCAGAGTGCCCAAACGCAGGCGGTCAGCACTTCTATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 240 V83 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACACAGGCGGTGAGCACGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 241 V84 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCAATACTCAGGCGGTGAGTACTACGAACAACAGCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 242 V85 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGCGTGGGCCACAAACAATCAGAGTGCCCAAGCACAGGCGGTGAGTACGGGTGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 243 V86 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACGCAGGCGGTTAGTACGCAGAATAATAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 244 V87 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCGGTGGCCACAAACCTCCAGAGTGCCCAAGCACAGGCGGTTTCAACTGGTATACAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 245 V88 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTTCGACGACCCAGGCGGTGAGCACGCAACATCAAAGCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 246 V89 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACCCAGGCGGTTAGCACCCAGATCCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 247 V90 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCAGTGGCCACAAACTTGCAGAGTGCCCAAGCACAGGCGGTGTCCACCGGTGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 248 V91 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAGCCACCAGAGTGCCCAAGCACAGGCGGTGAGTACAGAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 249 V92 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGTCCACTAGCATGCAAAACCA AGGAGTTCTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 250 V93 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTACTCAAGCACAGGCGGTTTCAACGCAGATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 251 V94 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCGGTACCCAGGCGGTTAGCACCCAAATGCAATCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 252 V95 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGTCAACCCAGAACCAAAACCA AGGAGTCCTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 253 V96 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCAACATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGCGTGGCCACAAACCACCAGAGTACACAATCGCAGGCGCAGAGCATGACACTGCAATCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 254 V97 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCATGGGAAGTGTGGCCACATCTCACCAGAGTACGCAAGCACAGGCGCAGTCAATGACACTGCAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 255 V98 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGACTTGACAACGT GGATGCGGACAAAGTCTCCATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCTGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGTCAATGACACTACAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 256 V99 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCGGTGGCCACAAACCACCAGCAGGCCCAAGCACAGGCGCAGAGCATGACAATGAATTCTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 257 V100 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCGGTGGCCACAAACCACCAGAGTGCCAACGCACAGGCGCAGAGCATGAACAATCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 258 V101 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCGGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGTCAATGACCAACCAATCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 259 V102 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGTAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAGTTGTGGCCACAAACCACCAGAGTACCCAAGCACAGGCGCAGTCAATGGCACTGCAATCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 260 V103 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGATCAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGCGTGTGCACAAACCACCAGAGTATTCAAGCACAGGCGCAGTCTATGACTCTGCAATCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 261 V104 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGAGCATGCAAGGTCAATCTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 262 V105 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAATGTGGCCACAAACCACCAGAGTTCACAAGCACAGGCGCAGAGTATGAATATGCAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 263 V106 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTATGAGAGACAACGT GGATGCGGACAAAGTCTCAATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGTCGATGAACATGCAATCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 264 V107 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGACATCGACAAAGTCTCCATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGAGTATGACCCTGCAATCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 265 V108 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTTCGGATCGGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGTCCATGCAGATGCAATCGCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 266 V109 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACGCAGGCGCAGTCCATGAACATGCAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 267 V110 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACACAGGCGCAGTCGATGGTCATGCAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 268 V111 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCTCGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCTGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGAGTATGCAGATGCAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 269 V112 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAACGCAGGCGCAGTCCATGTCGATGCAAGCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 270 V113 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCTACATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGCGTGGCCACAAACCACCAGAGTACTCAAGCACAGGCGCAGAGCATGACGTTGCAATCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 271 V114 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTAGCAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCGGTGGCCCAGAACCACCAGAGTATACAAGCACAGGCGCAGTCCATGACACTGCAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 272 V115 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGCGTGTGCATGAACCACCAGAGTATACAAGCACAGGCGCAGTCAATGACACTCCAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 273 V116 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAGCAGACAACGT GGATGCGGACAAAGTCTATATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGTTCCGTGGCCACAAACCACCAGAGTATACAAGCACAGGCGCAGAGTATGACCTTACAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 274 V117 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAAGTAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCTGTGTGTACAAACAACCAGAGTATACAAGCACAGGCGCAGAGCATGACCCTCCAATCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 275 V118 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCAGCATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAACCGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGAGCATGACGTTACAATCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 276 V119 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTTCTAACGCACAGGCGCAGTCCATGCAGAACCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 277 V120 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCTTCATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCTGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGTCAATGAACATGCAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 278 V121 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACTTGGT GGATGCGGACAAAGTCAGTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGCGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGTCAATGACGCTACAATCACA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 279 V122 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCAGTATGGAAGCGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGAGTATGACTATGCAAACCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 280 V123 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGATAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGTGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGAGCATGCAGATGCAAAGCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 281 V124 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTACAAACGCACAGGCGGTACAGATGGCTATGCAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 282 V125 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGCAAATGACACTACAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 283 V126 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTACCCAAGCACAGGCGGTCCAAATGGCAATGCAATCTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 284 V127 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACACGCAGAGTGCCCAAGCACAGGCGGTACAGATGGCCATGCAATCTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 285 V128 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTGGTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTGCAAATGACAATCCAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 286 V129 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTTAGCGGCAAAGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 287 V130 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTTTCGGGCTGGGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 288 V131 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAGTCACCAGAGTGCCCAAGCACAGGCGGTGAGTGGCAAAGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 289 V132 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAACCGTGGCCACAAACCACCAGAGTGCCCAAGCACAGCCGGTGACCATGTCTATGCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 290 V133 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGATCTGTGGCCACAAACCACCAGCAGGCCCAAACACAGGCGGTTACCATGAATGTTCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 291 V134 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGTCGGTTACCATGAACAACCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 292 V135 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAACTGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTCACCATGAACAACCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 293 V136 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAACCGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTAACCATGAACCTACAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 294 V137 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGCGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGGTAACCATGAATAACCAAAACCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 295 V138 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTGGGGAAACGTGGCCACAAACGCCCAGAGTACTCAAACACAGGCGGTATCCATGAAATTACAAAACCA AGGAGTCCTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 296 V139 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAGGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTGGGGAAATGTGGCCACAAACAATCAGAGTACACAAACGCAGGCGGTATCGATGAAACTGCAAAACCA AGGAGTTCTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 297 V140 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTGGGGAAATGTGGCCACAAACAATCAGAGTACTCAAACGCAGGCGGTATCTATGAAGCTACAAAACCA AGGAGTCCTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 298 V141 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAACTAAAAACTACTAACCCGGTAGCAACGGAGCCTTATGGATCAGTGGCCACAAACCACCAGAGTACTCAAGCACAGGCGGTTTCAATGAGCAATCAAAGCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 299 V142 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGAGAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCGTATGGAAGTGTGGCCACAAACCACCAGAGTACGCAAGCACAGCCGGTTAGCATGTCAAACCAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 300 V143 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCAATATGGATCGGTGTCCACAAACCACCAGAGTGGACAAGCACAGGCGGTTTCAATGTCGATGCAAAACCA AGGATGCTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 301 V144 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGCCTTATGGAAGCGTGGCCACAAACCACCAGAGTACTGGTGCACAGGCGGTGAGCATGTCCAACCAAAGCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 302 V145 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCACTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGTGTGGCCACAAACCACCAGAGTACACAAAGTCAGGCGCAGTCTATGACACTACAATCCCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 303 V146 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCAGTATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAAGTGTGGCCACAAACCACCAGAGTACACAAAGCCAGGCGCAGTCGATGACTTTACAAAGTCA AGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 304 V147 (nucleotide) sequence ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTG CTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAG TACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACG GCTCCTGGAAAGAAGAGGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGAC CCTCAACCAATCGGAGAACCTCCCGCAGCCCTCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGC GATTCCCAATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGC TACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTC AAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCCAG CGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCT ACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGC TAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTT CTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGT GGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGAACCGTGGCCACAAACAATCAGAGTGCCCAAGCACAGGCGGTCTCGATGATGCTACAATCGCA AGGATGCTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGGAATGAAGCACCCGCCTCC TCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAA CAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAA 305 CBh promoter CCAACCTGAAAAAAAGTGATTTCAGGCAGGTGCTCCAGGTAATTAAACATTAATACCCCACCAACCAACCATCCCTTAAACCCTTACCTCTTGCTCAGCTAATTACAGCCCGGAGGAGAAGGGCCGTCCCGCCCGCTCACCTGTGGGAGTAACGCGGTCAGTCAGAGCCGGGGCGGGCGGCGCGAGGCGGCGGCGGAGC GGGGCACGGGGCGAAGGCAGCGCAGCGACTCCCGCCCGCCGCGCGCTTCGCTTTTTTATAGGGCCGCCGCCGCCGCCGCCTCGCCATAAAAGGAAACTTTCGGAGCGCGCCGCTCTGATTGGCTGCCGCCGCACCTCTCCGCCTCGCCCCGCCCCGCCCCTCGCCCCGCCCCGCCCCGCCTGGCGCGCCCCCCCCCC CCCCCCGCCCCCATCGCTGCACAAAATAATTAAAAAAATAAATAAATACAAAATTGGGGGTGGGGAGGGGGGGGAGATGGGGAGAGTGAAGCAGAACGTGGGGCTCACCTCGACCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCACAATGCCAGGCGG GCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACG 306 hSYN promoter AGTGCAAGTGGGTTTTAGGACCAGGATGAGGCGGGGTGGGGGTGCCTACCTGACGACCGACCCCGACCCACTGGACAAGCACCCAACCCCCATTCCCCAAATTGCGCATCCCCTATCAGAGAGGGGGAGGGGAAACAGGATGCGGCGAGGCGCGTGCGCACTGCCAGCTTCAGCACCGCGGACAGTGCCTTCGCCCCCGCCTGGCGGCGCGCGCCACCGCCGCC TCAGCACTGAAGGCGCGCTGACGTCACTCGCCGGTCCCCCGCAAACTCCCCTCCGGCCACCTTGGTCGCGTCCGCGCCGCCGCCGGCCCAGCCGGACCGCACCACGCGAGGCGCGAGATAGGGGGGCACGGGCGCGACCATCTGCGCTGCGGCGCCGGCGACTCAGCGCTGCCTCAGTCTGCGGTGGGCAGCGGAGGAGTCGTGTCGTGCCTGAGAGCGCAG 307 Targeting peptides PLNGAVHLY 308 Targeting peptides IVMNSLK 309 Targeting peptides RDSPKGW 310 Targeting peptides YSTDVRM 311 Targeting peptides RESPRGL 312 Targeting peptides GNNTRSV 313 Targeting peptides GNNTRDT 314 Targeting peptides TNSTRPV 315 Targeting peptides ASSLNIA 316 Targeting peptides SLEEEWAQVECEVYGRGCPSGSLDESFYDWFERQL 317 Targeting peptides TPFYPVGYTVKQPGTCGDGVLQPGEECDDGNPDVSDGCIDCHRAYCGDGYRHQGVEDCDGSDFGYLTCETYLPGSYGDLRCTQYCSIDSTPCRYFT 318 Targeting peptides RGDY 319 Targeting peptides RGDF 320 Targeting peptides " _RGDX1X2X3X4 ( _SEQ ID NO: ₃₂₁ ), wherein each of _X1 to _X4 is any amino acid. In various categories of SEQ ID NO: ₃₂₁ , _X1 , _X2 , and _X3 are each independently selected from L, G, V, and A, and/or _X4 is S, V, A, G, or L. In some embodiments, at least one of _X2 and _X3 is G." 321 Targeting peptides RGDLGLS 322 Targeting peptides RGDLSTP 323 Targeting peptides SNSRGDYNSL 324 Targeting peptides ENRRGDFNNT 325 Targeting peptides SRGDYNSL 326 Targeting peptides RGDYNSL 327 Targeting peptides RGDLST 328 Targeting peptides RGDYVGL 329 Targeting peptides RGDAVGV 330 connector GGGS 331 10. Citation of References

All publications, patent applications, patents, and other publications and references cited herein (e.g., sequence database element symbols) are incorporated by reference in their entirety. For example, all GenBank, Unigene, and Entrez sequences mentioned herein (e.g., in any Table herein) are incorporated by reference. Unless otherwise specified, sequence accession numbers designated herein (including in any Table herein) refer to database entries as of August 21, 2020. When a gene or protein is referenced by multiple sequence accession numbers, all sequence variants are encompassed.

Figures 1A - 1C . Illustration of exemplary AAV serotype alignments. Amino acids present only in the VP1 polypeptide are in normal text; amino acids present only in the VP1 and VP2 polypeptides are bolded; amino acids present in the VP1, VP2, and VP3 polypeptides are underlined. In order of appearance, the figure shows SEQ ID NOs: 5, 3, 1, 7, and 9, respectively.

Figure 2A - 2B . Transduction rates of AAV capsid variants V1, V5, V27, V30, V61, and V147 in different cell types in the basal ganglia ( Figure 2A ) and cerebral cortex ( Figure 2B ) obtained by single-cell nuclear RNA sequencing and analysis.

TW202528335A_113132954_SEQL.xml

Claims (35)

A variant adeno-associated virus (AAV) capsid polypeptide comprising an amino acid sequence having at least 95% sequence identity to the VP1 capsid polypeptide of SEQ ID NO:1 or to the VP2 or VP3 portion thereof, wherein the variant AAV capsid polypeptide comprises: (a) valine at a position corresponding to Q592 compared to SEQ ID NO:1; (b) serine at a position corresponding to T593 compared to SEQ ID NO:1; and (c) methionine at a position corresponding to G594 compared to SEQ ID NO:1. The variant AAV capsid polypeptide of claim 1, further comprising: (a) methionine at a position corresponding to W595 compared to SEQ ID NO:1; and (b) leucine at a position corresponding to V596 compared to SEQ ID NO:1. The variant AAV capsid polypeptide of claim 1 or claim 2, further comprising: (a) asparagine at a position corresponding to H584 compared to SEQ ID NO:1; (b) threonine at a position corresponding to Q579 compared to SEQ ID NO:1; (c) serine at a position corresponding to N598 compared to SEQ ID NO:1; and (d) valine at a position corresponding to I601 compared to SEQ ID NO:1. The variant AAV capsid polypeptide of any one of claims 1 to 3, wherein the amino acid sequence has at least 95% sequence identity to the VP1 capsid polypeptide of SEQ ID NO: 158 or to the VP2 or VP3 portion thereof. The variant AAV capsid polypeptide of any one of claims 1 to 3, wherein the amino acid sequence has at least 98% sequence identity to the VP1 capsid polypeptide of SEQ ID NO: 158 or to the VP2 or VP3 portion thereof. The variant AAV capsid polypeptide of any one of claims 1 to 3, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 158 or the amino acid sequence of the VP2 or VP3 portion of SEQ ID NO: 158. The variant AAV capsid polypeptide of claim 1, further comprising: (a) glutamine at a position corresponding to W595 compared to SEQ ID NO:1; and (b) isoleucine at a position corresponding to V596 compared to SEQ ID NO:1. The variant AAV capsid polypeptide of claim 1 or claim 7, further comprising alanine at a position corresponding to H584 compared to SEQ ID NO: 1. The variant AAV capsid polypeptide of any one of claims 1, 7, and 8, wherein the amino acid sequence has at least 95% sequence identity to the VP1 capsid polypeptide of SEQ ID NO: 12 or to the VP2 or VP3 portion thereof. The variant AAV capsid polypeptide of any one of claims 1, 7, and 8, wherein the amino acid sequence has at least 98% sequence identity to the VP1 capsid polypeptide of SEQ ID NO: 12 or to the VP2 or VP3 portion thereof. The variant AAV capsid polypeptide of any one of claims 1, 7, and 8, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 12 or the amino acid sequence of the VP2 or VP3 portion of SEQ ID NO: 12. The variant AAV capsid polypeptide of claim 1, further comprising: (a) threonine at a position corresponding to W595 compared to SEQ ID NO:1 and (b) methionine at a position corresponding to V596 compared to SEQ ID NO:1. The variant AAV capsid polypeptide of claim 1 or claim 12, further comprising leucine at a position corresponding to Q597 compared to SEQ ID NO: 1. The variant AAV capsid polypeptide of any one of claims 1, 12, and 13, further comprising a threonine at a position corresponding to A589 compared to SEQ ID NO: 1. The variant AAV capsid polypeptide of any one of claims 1 and 12 to 14, wherein the amino acid sequence has at least 95% sequence identity to the VP1 capsid polypeptide of SEQ ID NO: 38 or to the VP2 or VP3 portion thereof. The variant AAV capsid polypeptide of any one of claims 1 and 12 to 14, wherein the amino acid sequence has at least 98% sequence identity to the VP1 capsid polypeptide of SEQ ID NO: 38 or to the VP2 or VP3 portion thereof. The variant AAV capsid polypeptide of any one of claims 1 and 12 to 14, comprising the amino acid sequence of the VP1 capsid polypeptide of SEQ ID NO: 38 or the amino acid sequence of the VP2 or VP3 portion of SEQ ID NO: 38. A nucleic acid molecule encoding the variant AAV capsid polypeptide of any one of claims 1 to 17. The nucleic acid molecule of claim 18, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 305. The nucleic acid molecule of claim 18, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 159. The nucleic acid molecule of claim 18, wherein the nucleic acid molecule comprises a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence of SEQ ID NO: 185. A recombinant AAV viral particle comprising the variant AAV capsid polypeptide of any one of claims 1 to 17. The recombinant AAV viral particle of claim 22, comprising a minigene having AAV inverted terminal repeats and a transgene encoding a payload. The recombinant AAV viral particle of claim 23, wherein the transgene is operably linked to a regulatory sequence that directs expression of the transgene in a host cell. An isolated host cell comprising the variant AAV capsid polypeptide of any one of claims 1 to 21. An isolated host cell comprising the recombinant AAV viral particle of any one of claims 22 to 24. The isolated host cell of claim 26, comprising a heterologous nucleic acid comprising a nucleotide sequence encoding the variant AAV capsid polypeptide. The isolated host cell of claim 27, wherein the heterologous nucleic acid further comprises a nucleotide sequence encoding a rep polypeptide. The isolated host cell of claim 27, further comprising a heterologous nucleic acid comprising a nucleotide sequence encoding a rep polypeptide. The isolated host cell of any one of claims 27 to 29, further comprising a heterologous nucleic acid comprising one or more nucleotide sequences encoding an accessory protein. The isolated host cell of any one of claims 25 to 30, which is a mammalian cell or an insect cell. A method for delivering a transgene to a cell, the method comprising contacting the cell with the recombinant AAV viral particle of claim 23 or claim 24. A method for delivering a transgene to the CNS of an individual, comprising administering to the individual the recombinant AAV viral particle of claim 23 or claim 24. A method for delivering a transgene to muscle of an individual, the method comprising administering to the individual the recombinant AAV viral particle of claim 23 or claim 24. The method of claim 33 or claim 34, wherein the recombinant AAV particles are administered systemically.